UPDATE_TYPE,INITIAL_POSTING_DATE,PACKAGE_NDC,GENERIC_NAME,CONTACT_INFO,AVAILABILITY,RELATED_INFO,UPDATE_DATE,THERAPEUTIC_CATEGORY,DOSAGE_FORM,PRESENTATION,COMPANY_NAME,SHORTAGE_REASON,STATUS,OPENFDA_APPLICATION_NUMBER,OPENFDA_BRAND_NAME,OPENFDA_GENERIC_NAME,OPENFDA_MANUFACTURER_NAME,OPENFDA_PRODUCT_NDC,OPENFDA_PRODUCT_TYPE,OPENFDA_ROUTE,OPENFDA_SUBSTANCE_NAME,OPENFDA_RXCUI,OPENFDA_SPL_ID,OPENFDA_SPL_SET_ID,OPENFDA_PACKAGE_NDC,OPENFDA_UNII,OPENFDA_NUI,OPENFDA_PHARM_CLASS_EPC,OPENFDA_PHARM_CLASS_PE,DISCONTINUED_DATE,RELATED_INFO_LINK,OPENFDA_PHARM_CLASS_CS,CHANGE_DATE,OPENFDA_PHARM_CLASS_MOA,RESOLVED_NOTE
Revised,10/31/2017,76045-009-11,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['DILAUDID'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['76045-009', '76045-010', '76045-121']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1872265', '1872269', '1872752', '2277368', '2277370']",['97bfcafb-2037-47dc-a0ae-f7b8007c47df'],['9eebd88a-5632-460f-b7b6-26c8a180540d'],"['76045-009-96', '76045-009-06', '76045-009-01', '76045-009-11', '76045-010-01', '76045-010-11', '76045-121-01', '76045-121-11']",['L960UP2KRW'],,,,,,,,,
Reverified,04/10/2020,44567-603-24,Dexmedetomidine Hydrochloride Injection,WG Critical Care 888-493-0861,Available,Marketed by WG Critical Care,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)",HQ Specialty Pharma,,Current,['NDA206628'],['DEXMEDETOMIDINE IN DEXTROSE'],['DEXMEDETOMIDINE'],"['WG Critical Care, LLC']","['44567-603', '44567-600', '44567-601', '44567-602']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909', '1788947']",['e6fa3e27-b374-49b6-a678-a5954f5beae8'],['0d2710f2-ee47-4114-ab5c-8dca74cdcb8d'],"['44567-600-04', '44567-601-04', '44567-602-24', '44567-603-24']",['1018WH7F9I'],,,,,,,,,
Reverified,01/01/2020,16729-483-03,Atropine Sulfate Injection,"866-941-7875, option 2",Unavailable,Discontinuation of the manufacture of the drug,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)",Accord Healthcare Inc.,Discontinuation of the manufacture of the drug,Current,['ANDA212868'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Accord Healthcare, Inc.,']","['16729-483', '16729-484']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['4082a1cf-1e1b-6f40-e063-6294a90aec06'],['c82cb295-ffce-47d6-97ad-a8aa723f4e4f'],"['16729-483-03', '16729-483-31', '16729-484-90', '16729-484-31', '16729-484-45', '16729-484-03']",['03J5ZE7KA5'],,,,,,,,,
Reverified,07/26/2023,13811-709-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Limited Availability,Allocation to current contracted customers,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)","Trigen Laboratories, LLC",Demand increase for the drug,Current,['ANDA205327'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Trigen Laboratories, LLC']","['13811-709', '13811-706', '13811-707', '13811-708', '13811-710']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461']",['54f7316b-8a84-4145-aecf-f380afbf261b'],['c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f'],"['13811-709-10', '13811-706-10', '13811-707-10', '13811-708-10', '13811-710-10', '13811-710-30']",['4B3SC438HI'],,,,,,,,,
Revised,03/26/2018,0409-3795-01,Ketorolac Tromethamine Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA074802'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Hospira, Inc.']","['0409-3795', '0409-3793', '0409-3796']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['60f4ed51-f1c1-45d4-b43a-969678901bdd'],['8accbb78-fc64-45d5-69b0-35c23a1d2a2e'],"['0409-3793-19', '0409-3793-01', '0409-3793-25', '0409-3795-19', '0409-3795-01', '0409-3795-25', '0409-3796-19', '0409-3796-01', '0409-3796-25']",['4EVE5946BQ'],,,,,,,,,
Revised,04/28/2023,60505-6282-6,Carboplatin Injection,Apotex Inc.: 800-706-5575,"Limited Availability, Replenishment is expected 12/1/25",Wholesaler & Distributor through Marketing partner (Apotex Inc.),11/05/2025,['Oncology'],Injection,"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)",Teyro Labs,Demand increase for the drug,Current,['ANDA077861'],['CARBOPLATIN'],['CARBOPLATIN'],['Apotex Corp.'],['60505-6282'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0e68e276-b0df-4f03-e063-6394a90a22b9'],['1c275825-0275-4c73-b650-e4c1519f13b8'],"['60505-6282-1', '60505-6282-3', '60505-6282-6', '60505-6282-7']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,01/01/2020,16729-484-90,Atropine Sulfate Injection,"866-941-7875, option 2",Unavailable,Discontinuation of the manufacture of the drug,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)",Accord Healthcare Inc.,Discontinuation of the manufacture of the drug,Current,['ANDA212868'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Accord Healthcare, Inc.,']","['16729-484', '16729-483']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['4082a1cf-1e1b-6f40-e063-6294a90aec06'],['c82cb295-ffce-47d6-97ad-a8aa723f4e4f'],"['16729-483-03', '16729-483-31', '16729-484-90', '16729-484-31', '16729-484-45', '16729-484-03']",['03J5ZE7KA5'],,,,,,,,,
Reverified,04/02/2020,63323-411-12,Midazolam Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)","Fresenius Kabi USA, LLC",,Current,['ANDA075154'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-411', '63323-412']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['9814447b-a93e-42ad-b57e-5db0a5b7f552'],['a91ce254-14a3-4cbf-8ab8-5da252aa3fdc'],"['63323-411-22', '63323-411-27', '63323-411-15', '63323-411-12', '63323-411-18', '63323-411-25', '63323-411-13', '63323-411-10', '63323-412-18', '63323-412-25', '63323-412-03', '63323-412-02', '63323-412-06', '63323-412-05', '63323-412-13', '63323-412-10']",['W7TTW573JJ'],,,,,,,,,
Revised,04/07/2020,36000-284-25,Furosemide Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)",Baxter Healthcare,,Current,['ANDA202747'],['FUROSEMIDE'],['FUROSEMIDE'],['Baxter Healthcare Corporation'],"['36000-284', '36000-063', '36000-064', '36000-065', '36000-282', '36000-283']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53'],['c71371a7-75c5-45b8-b762-8d782d4c71bc'],"['36000-063-05', '36000-064-05', '36000-065-05', '36000-282-25', '36000-283-25', '36000-284-25']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,12/05/2024,63304-693-05,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-05)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-693', '63304-692']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
Reverified,01/26/2024,70726-0305-1,Riluzole Oral Suspension,610-937-6172,Available,,11/03/2025,['Neurology'],Oral Suspension,"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)","EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",,Current,,['TEGLUTIK'],['RILUZOLE'],['EDW PHARMA'],['70726-0305'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RILUZOLE'],"['2058147', '2675565']",['125fdd67-c898-437b-e063-6394a90a3543'],['125fdd37-02f7-a610-e063-6294a90a009d'],['70726-0305-1'],['7LJ087RS6F'],"['N0000175740', 'M0483511']",['Benzothiazole [EPC]'],,,https://www.fda.gov/media/177206/download,['Benzothiazoles [CS]'],,,
Reverified,03/17/2023,0054-0389-25,Methamphetamine Hydrochloride Tablet,800-631-2174,Available,,10/24/2025,['Psychiatry'],Tablet,"Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 0054-0389-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA203846'],['METHAMPHETAMINE HYDROCHLORIDE'],['METHAMPHETAMINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],['0054-0389'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHAMPHETAMINE HYDROCHLORIDE'],['977860'],['9f3c9287-0615-4d2e-823d-673b33586e06'],['90c02ac6-e5e2-4c97-8c68-81e4e389a195'],['0054-0389-25'],['997F43Z9CV'],,,,,,,,,
Reverified,04/07/2020,25021-311-04,Furosemide Injection,866-625-1618,Available,,08/26/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Sagent Pharmaceuticals,,Current,['ANDA213902'],['FUROSEMIDE'],['FUROSEMIDE'],['Sagent Pharmaceuticals'],['25021-311'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['222ce48f-2856-4be2-b16f-6fca38c0dceb'],['d63c1277-dd7e-4d21-9e80-68143f55e2dc'],"['25021-311-02', '25021-311-04', '25021-311-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,02/20/2018,55150-170-30,Bupivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)",Eugia US LLC,,Current,['ANDA203895'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-170', '55150-167', '55150-168', '55150-169', '55150-171', '55150-172', '55150-249', '55150-250']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
Revised,02/15/2023,63323-426-10,Rocuronium Bromide Injection,888-386-1300,Available,Check wholesalers for inventory.,11/05/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['ANDA078651'],['ROCURONIUM'],['ROCURONIUM BROMIDE'],"['Fresenius Kabi USA, LLC']",['63323-426'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],"['d6e2ff8d-838d-4c27-8e73-230548b09d63', '3f4d5e11-2c14-4406-8954-04dba2fc65ff']","['f1933332-1ae0-4dc1-be4c-694849e6c9f9', 'fb9524b2-c353-4747-8954-7ca2529eabb2']","['63323-426-02', '63323-426-05', '63323-426-01', '63323-426-10', '63323-426-12', '63323-426-15']",['I65MW4OFHZ'],,,,,,,,,
Reverified,10/12/2022,0406-8893-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-325-8888,Available,,11/05/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)",SpecGx LLC,,Current,['ANDA040440'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['SpecGx LLC'],"['0406-8893', '0406-8891', '0406-8884', '0406-8892', '0406-8885', '0406-8894']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['b25a2f3f-ee3a-44c0-a475-f371025c767b'],['72ddd1c9-ddbd-4c95-acd9-003189a353a3'],"['0406-8891-01', '0406-8884-01', '0406-8892-01', '0406-8885-01', '0406-8893-01', '0406-8894-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/10/2025,0093-8036-01,Glyburide Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/10/2025,['Endocrinology/Metabolism'],Tablet,"Glyburide (Micronized), Tablet, 6 mg (NDC 0093-8036-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA074686'],['GLYBURIDE'],['GLYBURIDE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-8036', '0093-8034', '0093-8035']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLYBURIDE'],"['310536', '310539', '314000']",['00e55b1b-81b5-4df1-8a6d-4d54ac403e76'],['e84c0dfc-a4e9-4c89-b6ea-45732eb412f5'],"['0093-8034-01', '0093-8035-01', '0093-8035-05', '0093-8036-01']",['SX6K58TVWC'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,06/10/2025,,['Sulfonylurea Compounds [CS]'],,,
Reverified,03/21/2023,25021-115-06,Clindamycin Phosphate Injection,866-625-1618,Available,,08/26/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)",Sagent Pharmaceuticals,,Current,['ANDA090108'],['CLINDAMYCIN'],['CLINDAMYCIN PHOSPHATE'],['Sagent Pharmaceuticals'],['25021-115'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['1737244', '1737578', '1737581']",['4662502b-ce7c-4278-854d-cf8632ac9b83'],['7a6967b3-5563-4bed-9eee-d400f800e799'],"['25021-115-02', '25021-115-04', '25021-115-06']",['EH6D7113I8'],,,,,,,,,
Reverified,02/15/2023,55150-225-05,Rocuronium Bromide Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)",Eugia US LLC,,Current,['ANDA206206'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Eugia US LLC'],"['55150-225', '55150-226']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['256e0877-720b-40a2-be71-d503e8b860ab'],['116385ea-69fc-4f44-b463-6210291032df'],"['55150-225-05', '55150-226-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,07/26/2023,68025-098-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Unavailable,Estimated recovery: TBD,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)","Vertical Pharmaceuticals, LLC",Other,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-098', '68025-088', '68025-089', '68025-095', '68025-096', '68025-097', '68025-084']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
New,02/06/2025,0591-0844-10,"Glipizide Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue manufacture of the drug.,02/06/2025,['Endocrinology/Metabolism'],Tablet,"Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076467'],['GLIPIZIDE ER'],['GLIPIZIDE'],"['Actavis Pharma, Inc.']","['0591-0844', '0591-0900', '0591-0845']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLIPIZIDE'],"['310489', '314006', '315107']",['90e0de65-ed5f-460a-a96f-77d4d76ceedd'],['a430577c-f233-40a7-bfd8-3d2bc6f98aa2'],"['0591-0900-30', '0591-0844-01', '0591-0844-10', '0591-0845-01', '0591-0845-10']",['X7WDT95N5C'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,02/06/2025,,['Sulfonylurea Compounds [CS]'],,,
Reverified,02/20/2018,0409-1752-50,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE WITH EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Hospira, Inc.']","['0409-1752', '0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,03/23/2018,63323-288-21,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-288', '63323-286', '63323-287', '63323-285']",['HUMAN PRESCRIPTION DRUG'],['EPIDURAL'],['ROPIVACAINE HYDROCHLORIDE'],"['905189', '905191', '1734084', '1734086', '1734090', '1734091', '1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484']","['cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c', '75465ceb-e894-487d-aa80-671fa0841fce']","['23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6', '56dfabf7-f7a8-4601-b17a-cb16fb995b0f']","['63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95', '63323-288-25', '63323-288-27']",['V910P86109'],,,,,,,,,
Reverified,07/26/2023,68025-089-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Available,,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)","Vertical Pharmaceuticals, LLC",,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-089', '68025-088', '68025-095', '68025-096', '68025-097', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
Revised,11/01/2017,0641-6254-01,Hydromorphone Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA217812'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],['0641-6254'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],['897745'],['ba25ec4f-3b81-4960-bf74-6a1e4c6be45c'],['c729424e-e483-4bf8-b86c-ce56636dcffa'],['0641-6254-01'],['L960UP2KRW'],,,,,,,,,
Reverified,03/12/2021,69918-501-05,Desmopressin Acetate Spray,888-337-7464,Unavailable,,09/17/2025,['Hematology'],Spray,"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)",Ferring,Requirements related to complying with good manufacturing practices,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,03/23/2018,63323-287-21,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Backordered. Next release November 2025. Check wholesalers for inventory.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-287', '63323-286', '63323-288', '63323-285']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '905191', '1734084', '1734086', '1734090', '1734091', '1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484']",['cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9'],['23d2d448-a744-4877-9f2d-7e57c198da89'],"['63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63']",['V910P86109'],,,,,,,,,
Reverified,07/26/2023,62175-312-37,"Methylphenidate Hydrochloride Tablet, Extended Release",844-834-0530,Unavailable,Unavailable,11/03/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA091695'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Lannett Company, Inc.']","['62175-312', '62175-310', '62175-311', '62175-313']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2001564', '2001565', '2001566', '2001568']",['fd0e4ddf-c516-4464-aeca-eb1d3bd24667'],['3d1f5aff-5d39-496c-b5ed-7f3c70ec641c'],"['62175-310-37', '62175-311-37', '62175-312-37', '62175-313-37']",['4B3SC438HI'],,,,,,,,,
Reverified,10/31/2017,0409-2634-05,Hydromorphone Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA078591'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']",['0409-2634'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['1724338', '1724340', '1724341']",['f0c8c83c-fb41-4571-a72e-6542311351dd'],['3832ede8-d3fc-455d-ecab-3b77be5869f5'],"['0409-2634-10', '0409-2634-01', '0409-2634-25', '0409-2634-05', '0409-2634-50']",['L960UP2KRW'],,,,,,,01/02/2025,,
New,06/10/2025,0093-0109-10,Carbamazepine Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/10/2025,['Neurology'],Tablet,"Epitol, Tablet, 200 mg (NDC 0093-0109-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA070541'],['CARBAMAZEPINE'],['CARBAMAZEPINE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-0109', '0093-0778']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CARBAMAZEPINE'],"['308973', '308979']",['042aa2c6-95ff-410a-abcf-a8ee79fa96d8'],['bfd63965-56e6-4af7-b7ef-45a5105d4d35'],"['0093-0109-01', '0093-0109-10', '0093-0778-01']",['33CM23913M'],"['N0000008486', 'N0000175751', 'N0000185506', 'N0000191266', 'N0000187064', 'N0000185507', 'N0000185607']",['Mood Stabilizer [EPC]'],['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],06/10/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]']",
Revised,07/24/2017,51754-5011-4,Sodium Bicarbonate Injection,828-758-5474 ext. 154,Unavailable,Next batch release expected in 1 week.,11/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)","Exela Pharma Sciences, LLC",Demand increase for the drug,Current,['ANDA211091'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Exela Pharma Sciences, LLC']","['51754-5011', '51754-5001', '51754-5002', '51754-5012']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],"['807284', '1868486', '1923484', '2198792']",['4da0ba66-756d-4b4d-8018-81ca16578ef1'],['e9698a4f-1a95-4f28-a945-e8009d1d6dd4'],"['51754-5001-5', '51754-5001-4', '51754-5011-4', '51754-5002-5', '51754-5012-4']",['8MDF5V39QO'],,,,,,,,,
New,06/03/2025,65862-064-39,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-39)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-064', '65862-062', '65862-063']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
Revised,04/02/2020,0641-6057-25,Midazolam Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA075243'],['MIDAZOLAM'],['MIDAZOLAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6057', '0641-6059', '0641-6056', '0641-6061', '0641-6063', '0641-6060']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['559c03fb-24ea-4b7b-8afd-e33cb3a2340a'],['575d8bf0-7af7-427c-a231-966e2a5e070d'],"['0641-6057-01', '0641-6057-10', '0641-6057-25', '0641-6059-01', '0641-6059-10', '0641-6056-01', '0641-6056-10', '0641-6061-01', '0641-6061-10', '0641-6061-25', '0641-6063-01', '0641-6063-10', '0641-6063-25', '0641-6060-01', '0641-6060-10']",['W7TTW573JJ'],,,,,,,,,
Reverified,06/06/2018,0338-0072-25,Ketorolac Tromethamine Injection,888-229-0001,Available,,10/22/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)",Baxter Healthcare,,Current,['ANDA209900'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Baxter Healthcare Corporation'],"['0338-0072', '0338-0069', '0338-0076']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['2da4dd8a-1b18-481d-b733-9c031d9ea7e3'],['4b58836d-9d58-4539-9691-9e11c505ef2a'],"['0338-0069-10', '0338-0072-25', '0338-0076-10']",['4EVE5946BQ'],,,,,,,,,
Reverified,03/10/2023,43547-407-50,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-407', '43547-406', '43547-408']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,03/23/2018,63323-285-13,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,07/26/2023,13811-711-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Limited Availability,Allocation to current contracted customers,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)","Trigen Laboratories, LLC",Demand increase for the drug,Current,['NDA216117'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Trigen Laboratories, LLC']","['13811-711', '13811-700']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2605796', '2605798']",['ba649db4-df0d-4587-8370-3f866e66e54b'],['dd8d7b6e-c23d-4e16-bb53-959e9127ebc6'],"['13811-711-30', '13811-700-30']",['4B3SC438HI'],,,,,,,,,
Revised,11/01/2017,0703-0110-03,Hydromorphone Hydrochloride Injection,800-545-8800,Available,,11/06/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA078591'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Teva Parenteral Medicines, Inc.']","['0703-0110', '0703-0113', '0703-0018']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['1724338', '1724340', '1724341']",['c32108cc-7b73-4921-9f9e-54b3d60c1c6e'],['f0b78db9-a38c-41bb-8233-5e93f7f18c5c'],"['0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01']",['L960UP2KRW'],,,,,,,,,
New,12/05/2024,0074-7269-50,Cyclosporine Oral Solution,800-633-9110,,"Abbvie has made a business decision to permanently discontinue GENGRAF Oral Solution (cyclosporine oral solution, USP) 100 mg/mL .",12/05/2024,['Transplant'],Oral Solution,"Gengraf, Oral Solution, 100 mg/ml (NDC 0074-7269-50)",AbbVie Inc.,,To Be Discontinued,['ANDA065025'],['GENGRAF'],['CYCLOSPORINE'],['AbbVie Inc.'],['0074-7269'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CYCLOSPORINE'],"['835886', '835892']",['e7317e31-31d8-4af8-b92d-cd58d8a44a1f'],['29891f95-9079-4880-7abc-194e49767dd5'],['0074-7269-50'],['83HN0GTJ6D'],"['N0000175457', 'N0000175458', 'N0000182141', 'N0000185503']",['Calcineurin Inhibitor Immunosuppressant [EPC]'],,12/05/2024,,,,"['Calcineurin Inhibitors [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",
Revised,12/08/2021,63323-924-30,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-30)","Fresenius Kabi USA, LLC",,Resolved,['ANDA088911'],['BACTERIOSTATIC SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-924'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],['313002'],['d83b23bf-9f14-4e45-a569-b227cbb08e88'],['e5e325d1-0d58-40c9-9645-3ae402ff9d92'],"['63323-924-01', '63323-924-10', '63323-924-03', '63323-924-30']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,05/30/2025,0409-1178-30,Meperidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Analgesia/Addiction'],Injection,"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA021171'],['DEMEROL'],['MEPERIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1178', '0409-1181', '0409-1176', '0409-1179', '0409-1180', '0409-1362', '0409-1418']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['860792', '861463', '861473', '861493', '861494', '861522', '861529', '861617', '1242106', '1242503', '2539186', '2539188', '2539191', '2539192']",['1271f15f-ccda-4892-8fb0-9bb2d38ded4a'],['b31d1308-28c3-43f4-e0a6-2f3ed76b8975'],"['0409-1181-30', '0409-1176-03', '0409-1176-30', '0409-1178-03', '0409-1178-30', '0409-1179-03', '0409-1179-30', '0409-1180-59', '0409-1180-69', '0409-1362-11', '0409-1362-01', '0409-1418-11', '0409-1418-01']",['N8E7F7Q170'],,,,,,,,,
Reverified,10/12/2022,0527-1505-37,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)","Lannett Company, Inc.",,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,03/10/2023,59651-722-99,Clonazepam Tablet,866-850-2876,Available,,10/15/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)",Aurobindo Pharma USA,,Current,['ANDA075150'],['CLONAZEPAM'],['CLONAZEPAM'],['Aurobindo Pharma Limited'],"['59651-722', '59651-723', '59651-724']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['b1582eb7-af35-45d5-a52e-0e380d08527d'],['b1582eb7-af35-45d5-a52e-0e380d08527d'],"['59651-722-01', '59651-722-99', '59651-723-01', '59651-723-99', '59651-724-01', '59651-724-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,01/19/2023,62135-668-90,Quinapril/Hydrochlorothiazide Tablet,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,Available,,08/19/2025,['Cardiovascular'],Tablet,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA076374'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],"['Chartwell RX, LLC']","['62135-668', '62135-667', '62135-669']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809']",['0c3f4504-d57e-aa79-e063-6294a90ad5b8'],['2eae533f-d0af-47e8-a1f2-94bc8cc89b5a'],"['62135-667-90', '62135-668-90', '62135-669-90']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],,,['Thiazides [CS]'],,,
New,11/21/2024,0591-3870-60,Memantine Hydrochloride Tablet,800-545-8800,,,11/21/2024,['Neurology'],Tablet,"Namenda, Tablet, 5 mg (NDC 0591-3870-60)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA021487'],['MEMANTINE HYDROCHLORIDE'],['MEMANTINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0591-3870', '0591-3875', '0591-3900']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEMANTINE HYDROCHLORIDE'],"['996561', '996571', '996572']",['985e1190-b8a0-4775-9a20-ad1924b14fb2'],['72973b46-f307-4a9e-8fb1-ad2cbccfd736'],"['0591-3870-60', '0591-3870-45', '0591-3870-44', '0591-3875-60', '0591-3875-45', '0591-3875-44', '0591-3900-87']",['JY0WD0UA60'],,,,11/21/2024,,,,,
New,07/16/2025,0008-4117-01,Ethionamide Tablet,844-646-4398,,"Discontinuation of the manufacture of the drug.
Supply expected to exhaust September 2025",07/16/2025,['Anti-Infective'],Tablet,"Trecator, Tablet, 250 mg (NDC 0008-4117-01)",Pfizer Inc.,,To Be Discontinued,['NDA013026'],['TRECATOR'],['ETHIONAMIDE'],"['Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.']",['0008-4117'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ETHIONAMIDE'],"['197681', '835721']",['24a0b78d-6cf2-4539-a3de-b3b077383da0'],['04a413fe-95f4-47a7-42ac-283a9e78297d'],['0008-4117-01'],['OAY8ORS3CQ'],['N0000175483'],['Antimycobacterial [EPC]'],,07/16/2025,,,,,
New,01/06/2025,0703-2056-03,Cisatracurium Besylate Injection,800-545-8800,,,01/06/2025,['Anesthesia'],Injection,"Injection, 20 mg/10 mL (NDC 0703-2056-03)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/06/2025,,,,,
New,01/22/2025,71093-130-01,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-130', '71093-129', '71093-131']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Reverified,07/26/2023,0406-1445-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-325-8888,Limited Availability,Allocation to all customers.,11/05/2025,['Psychiatry'],Tablet,"Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA075629'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],['SpecGx LLC'],"['0406-1445', '0406-1473']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091145', '1091225']",['7bfd27d5-70ed-440b-949a-140aa3304d4a'],['ed004cf0-eb23-43d2-96dc-20c4ad63824f'],"['0406-1445-01', '0406-1473-01']",['4B3SC438HI'],,,,,,,,,
Reverified,11/01/2017,0409-1805-01,Hydromorphone Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)","Hospira, Inc., a Pfizer Company",,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1805', '0409-1283', '0409-1312', '0409-1380', '0409-4264']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1724383', '1724644', '1872271', '2675350']",['53b6867a-0ae3-48ff-b257-9e58cc76de9c'],['f9ca2ef5-46d8-475a-a26e-f7c8becd6db7'],"['0409-1283-17', '0409-1283-37', '0409-1312-16', '0409-1312-36', '0409-1380-11', '0409-1380-01', '0409-4264-11', '0409-4264-01', '0409-1805-10', '0409-1805-01']",['L960UP2KRW'],,,,,,,,,
Reverified,12/08/2020,0338-0644-06,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)",Baxter Healthcare,,Current,['NDA018931'],['TRAVASOL'],"['LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE']",['Baxter Healthcare Corporation'],['0338-0644'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE HYDROCHLORIDE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['801644', '801648']",['e0279078-016d-48fd-8de1-c894422b33ff'],['8543b5be-0f43-4891-9e56-d7c39fe839b5'],"['0338-0644-03', '0338-0644-04', '0338-0644-06']","['OF5P57N2ZX', '94ZLA3W45F', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'JNJ23Q2COM', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Reverified,02/17/2021,0068-0597-01,Rifampin Injection,800-633-1610,Available,,09/17/2025,['Anti-Infective'],Injection,"Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)",Sanofi-Aventis U.S. LLC,,Current,['NDA050627'],['RIFADIN IV'],['RIFAMPIN'],['Sanofi-Aventis U.S. LLC'],['0068-0597'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['RIFAMPIN'],"['207436', '312821']",['d5ee3f24-779e-4fd0-ba26-e870acbd1111'],['036ab68e-5085-4edc-bd83-784b43d64eab'],['0068-0597-01'],['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,07/26/2023,68025-088-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Available,,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)","Vertical Pharmaceuticals, LLC",,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-088', '68025-089', '68025-095', '68025-096', '68025-097', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
New,01/06/2025,45963-566-08,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-08)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/06/2025,,,,,
Reverified,03/10/2023,16729-137-00,Clonazepam Tablet,"866-941-7875, option 2",Available,,11/04/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)",Accord Healthcare Inc.,,Current,['ANDA077147'],['CLONAZEPAM'],['CLONAZEPAM'],['Accord Healthcare Inc.'],"['16729-137', '16729-136', '16729-138']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['0e1e7f41-f78b-27cf-e063-6394a90a1ae0'],['ebc11109-e7bf-452d-b675-4b3236d54164'],"['16729-136-00', '16729-136-16', '16729-137-00', '16729-137-16', '16729-138-00', '16729-138-16']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,03/01/2017,0409-5534-14,Sodium Bicarbonate Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d,,,,
Revised,07/26/2023,57664-606-88,"Methylphenidate Hydrochloride Tablet, Extended Release",800-818-4555,Unavailable,Currently not marketed,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)","Sun Pharmaceutical Industries, Inc.",Discontinuation of the manufacture of the drug,Current,['ANDA205135'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-606', '57664-607', '57664-608', '57664-609']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['0da4b745-d498-8823-e063-6394a90a4524'],['d048e52d-7406-4fc1-9a72-c073bafc7439'],"['57664-606-88', '57664-607-88', '57664-608-88', '57664-609-88']",['4B3SC438HI'],,,,,,,,,
New,07/21/2025,73070-403-15,Insulin Degludec Injection,609-987-5800,,"Unbranded Insulin Degludec 3 mL U-100 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injection,"Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch® (NDC 73070-403-15)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA203314'],['INSULIN DEGLUDEC'],['INSULIN DEGLUDEC'],"['Novo Nordisk Pharma, Inc.']","['73070-403', '73070-503', '73070-400']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN DEGLUDEC'],"['1670011', '1670021', '2107520']",['c1be283d-4b1d-4996-b2a7-4488dbff3037'],['c1be283d-4b1d-4996-b2a7-4488dbff3037'],"['73070-403-15', '73070-503-15', '73070-400-11']",['54Q18076QB'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
Reverified,03/10/2023,16729-136-00,Clonazepam Tablet,"866-941-7875, option 2",Available,,11/04/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)",Accord Healthcare Inc.,,Current,['ANDA077147'],['CLONAZEPAM'],['CLONAZEPAM'],['Accord Healthcare Inc.'],"['16729-136', '16729-137', '16729-138']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['0e1e7f41-f78b-27cf-e063-6394a90a1ae0'],['ebc11109-e7bf-452d-b675-4b3236d54164'],"['16729-136-00', '16729-136-16', '16729-137-00', '16729-137-16', '16729-138-00', '16729-138-16']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,03/23/2018,55150-200-10,Ropivacaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)",Eugia US LLC,Demand increase for the drug,Current,['ANDA205612'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-200', '55150-195', '55150-196', '55150-197', '55150-198', '55150-199', '55150-201']",['HUMAN PRESCRIPTION DRUG'],['EPIDURAL'],['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734207', '1734347', '1734475', '1734483']",['34725b26-d6e9-4d1b-95a0-da03764cc102'],['3763b7b6-da49-4658-b93d-28f5da24d09e'],"['55150-195-20', '55150-196-99', '55150-197-20', '55150-198-30', '55150-199-20', '55150-200-10', '55150-201-20']",['V910P86109'],,,,,,,,,
Reverified,07/26/2023,62175-311-37,"Methylphenidate Hydrochloride Tablet, Extended Release",844-834-0530,Unavailable,Unavailable,11/03/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA091695'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Lannett Company, Inc.']","['62175-311', '62175-310', '62175-312', '62175-313']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2001564', '2001565', '2001566', '2001568']",['fd0e4ddf-c516-4464-aeca-eb1d3bd24667'],['3d1f5aff-5d39-496c-b5ed-7f3c70ec641c'],"['62175-310-37', '62175-311-37', '62175-312-37', '62175-313-37']",['4B3SC438HI'],,,,,,,,,
Reverified,04/07/2020,16729-501-43,Furosemide Injection,866-941-7875,Unavailable,Unavailable,11/04/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA070017'],['FUROSEMIDE'],['FUROSEMIDE'],"['Accord Healthcare, Inc.']","['16729-501', '16729-500', '16729-502']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['1cfab300-d796-6a68-e063-6394a90a73f9'],['f6f64972-714c-4ee9-8a5e-9ffcab41a73b'],"['16729-500-30', '16729-500-08', '16729-501-64', '16729-501-43', '16729-502-03', '16729-502-43']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/10/2023,43547-408-50,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-408', '43547-406', '43547-407']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,12/10/2021,0338-0049-11,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-11)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,10/12/2022,72516-014-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",855-257-0292,Available,,10/24/2025,['Psychiatry'],Tablet,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)",Oryza Pharmaceuticals Inc.,,Current,['ANDA210293'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Oryza Pharmaceuticals Inc.'],"['72516-014', '72516-016', '72516-015', '72516-013', '72516-012', '72516-011']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['39fb17a2-617d-37dc-e063-6394a90a1be3'],['acd27181-a3f3-4c38-85d8-029a4a82e7c2'],"['72516-016-01', '72516-015-01', '72516-014-01', '72516-013-01', '72516-012-01', '72516-011-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/22/2012,63323-492-37,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487', '63323-493', '63323-496']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029', '1737636', '1737637', '1737640', '1737641', '1737763', '1737764']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33', 'fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74', 'd5e0d06f-ba1e-44d4-aa89-39d6c146dc23']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26', '63323-492-08', '63323-492-97', '63323-493-03', '63323-493-97', '63323-493-01', '63323-493-91', '63323-496-03', '63323-496-97']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,03/04/2025,65862-583-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-05)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-583', '65862-582', '65862-584', '65862-585', '65862-586', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
Revised,01/06/2023,0013-2655-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 1.4 mg preservative free (NDC 0013-2655-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2655', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Reverified,10/31/2017,76045-005-11,Morphine Sulfate Injection,888-386-1300,Unavailable,Backordered. Next release Q1-2026. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)","Fresenius Kabi USA, LLC",Other,Current,['NDA204223'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Fresenius Kabi, USA LLC', 'Fresenius Kabi USA, LLC']","['76045-005', '76045-004', '76045-006', '76045-007', '76045-008']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['894912', '894914', '998212', '998213', '1442790']","['286bce70-23cd-4d5b-989b-230d6cdd5a91', 'e064585d-2d2d-41cd-a0f1-43494ce4775b']","['1f53de80-efc8-4930-b3e3-fba0d026af05', 'b62ee1ef-db55-417a-a02e-b103890f9c4b']","['76045-004-01', '76045-004-11', '76045-005-01', '76045-005-11', '76045-006-01', '76045-006-11', '76045-007-01', '76045-007-11', '76045-008-01', '76045-008-11', '76045-004-02', '76045-004-12', '76045-005-02', '76045-005-12', '76045-006-02', '76045-006-12', '76045-007-00', '76045-007-10', '76045-008-00', '76045-008-10']",['X3P646A2J0'],,,,,,,,,
Reverified,03/23/2018,63323-162-02,Ketorolac Tromethamine Injection,888-386-1300,Available,Check wholesaler inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)","Fresenius Kabi USA, LLC",,Current,['ANDA075784'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Fresenius Kabi USA, LLC']","['63323-162', '63323-161']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']","['2b1c6066-d9e0-40a0-ade5-776fc35a3626', '55ed7afb-db66-4b28-939b-db45b55bf058', 'ab476c4c-2c72-47b1-bf42-7a89703b0dd4']","['ccf905ca-e164-4779-9485-2d139c821bad', '950b7295-3f68-4027-ac2b-2f7d0f5f8ef9', 'd1920335-8e45-4960-b6e9-e6f1f9e6820c']","['63323-161-41', '63323-161-16', '63323-162-43', '63323-162-16', '63323-162-45', '63323-162-26', '63323-161-21', '63323-161-12', '63323-162-23', '63323-162-12', '63323-162-25', '63323-162-14', '63323-161-00', '63323-161-01', '63323-162-11', '63323-162-51', '63323-162-00', '63323-162-01', '63323-162-03', '63323-162-02']",['4EVE5946BQ'],,,,,,,,,
New,03/04/2025,65862-584-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-05)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-584', '65862-582', '65862-583', '65862-585', '65862-586', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
Revised,05/03/2022,17478-050-01,Sufentanil Citrate Injection,800-631-2174,Unavailable,Not currently manufactured,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)","Hikma Pharmaceuticals USA, Inc.",Other,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,04/02/2020,47781-589-91,Midazolam Hydrochloride Injection,Athenex: 855-273-0154; Alvogen: 973-532-7840,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-91)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,01/01/2012,0143-9554-01,Leucovorin Calcium Injection,800-631-2174,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 0143-9554-01)","Hikma Pharmaceuticals USA, Inc.",,Resolved,['ANDA089717'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9554', '0143-9555', '0143-9553', '0143-9552']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['e2d1484b-2920-45ab-9207-4caa5285fef4'],['cc52077f-5663-4f79-a273-0aecf655e038'],"['0143-9555-01', '0143-9554-01', '0143-9553-01', '0143-9552-01']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Revised,11/03/2023,81665-104-96,Cromolyn Sodium Concentrate,Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com,Available,Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195,08/15/2025,['Pulmonary/Allergy'],Concentrate,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)",Ailex Pharmaceuticals,,Current,['ANDA209264'],['CROMOLYN SODIUM'],['CROMOLYN SODIUM'],['Omnivium Pharmaceuticals LLC'],['81665-104'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CROMOLYN SODIUM'],['831261'],['3df4d7be-4e96-4e6d-ba6e-b9c93acd76e2'],['a742664b-265e-49f9-9744-d04e1fb620ae'],['81665-104-96'],['Q2WXR1I0PK'],,,,,,,,,
Reverified,02/03/2016,0409-3299-25,Sodium Acetate Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)","Hospira, Inc., a Pfizer Company",,Current,['NDA018893'],['SODIUM ACETATE'],['SODIUM ACETATE'],"['Hospira, Inc.']",['0409-3299'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE ANHYDROUS'],['237371'],"['eadea22b-c475-4596-8c15-e738af5a711d', '99255488-8958-49ab-965c-083119f5ba3c']","['abc41ed1-9512-4bea-9295-1a9ca134b6c2', 'c3be2468-45e8-4ecc-a30b-e966743a563f']","['0409-3299-15', '0409-3299-05', '0409-3299-16', '0409-3299-06', '0409-3299-45', '0409-3299-25', '0409-3299-46', '0409-3299-26']",['NVG71ZZ7P0'],,,,,,,,,
Reverified,12/15/2021,25021-820-05,Methylprednisolone Acetate Injection,866-625-1618,Available,,08/26/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)",Sagent Pharmaceuticals,,Current,['ANDA201835'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Sagent Pharmaceuticals'],"['25021-820', '25021-821']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358610', '1358617']",['13e1ca54-4fc4-4e93-a52d-c9320865e3cb'],['f98314ea-a4e4-4f78-987b-3e9b45a08bb4'],"['25021-820-05', '25021-820-10', '25021-821-05']",['43502P7F0P'],,,,,,,,,
Reverified,10/12/2022,0527-0766-37,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)","Lannett Company, Inc.",,Current,['ANDA215565'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Lannett Company, Inc.']","['0527-0766', '0527-0760', '0527-0761', '0527-0762', '0527-0763', '0527-0764', '0527-0765']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['e0804f43-4685-4017-b839-3212d1167362'],['f92497b5-baea-4760-b615-45a0b6184402'],"['0527-0760-37', '0527-0761-37', '0527-0762-37', '0527-0763-37', '0527-0764-37', '0527-0765-37', '0527-0766-37']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/10/2020,42023-187-10,Dexmedetomidine Hydrochloride Injection,800-828-9393,Available,Please check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)","Par Pharmaceutical, Inc.",,Current,['ANDA208266'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['ENDO USA, Inc.']","['42023-187', '42023-146', '42023-186']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['309710', '1718906', '1718909']",['d518b2d2-b39c-47ac-b45f-8c6a045a8dae'],['1ee59985-4c1d-48f7-b8f9-5584c2d55e08'],"['42023-146-25', '42023-186-20', '42023-187-10']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,79672-613-05,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, 1000 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Nextgen Pharmaceuticals LLC'],['79672-613'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['3c545b9f-67e4-489d-bb60-c39c990d7dda'],['28f79c75-82d2-4912-81fc-a723b5ccf4c1'],"['79672-613-01', '79672-613-10', '79672-613-02', '79672-613-20', '79672-613-03', '79672-613-30', '79672-613-04', '79672-613-40', '79672-613-05', '79672-613-50']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,10/09/2025,0781-2234-01,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-01)",Sandoz Inc.,,To Be Discontinued,['ANDA076515'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],['0781-2234'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],['200329'],['a7952460-51d0-4188-b3e0-ec8e81e19585'],['5a09ce48-7139-4fc7-9b6e-439459c8e866'],"['0781-2234-10', '0781-2234-01', '0781-2234-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
New,07/10/2025,72305-088-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 88 ug (NDC 72305-088-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-088', '72305-025', '72305-050', '72305-075', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,04/10/2020,43598-975-58,Dexmedetomidine Hydrochloride Injection,Distributed by DRL,Available,Distributed by DRL,09/29/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)",Gland Pharma Limited,,Current,['ANDA209307'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"[""Dr.Reddy's Laboratories Inc""]","['43598-975', '43598-976']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['5785a11f-7784-4ae0-8029-f50b782eaf4a'],['d174c19d-56f1-4ef4-087c-23c26db8e40b'],"['43598-976-11', '43598-976-58', '43598-975-11', '43598-975-58']",['1018WH7F9I'],,,,,,,,,
Revised,06/21/2018,65282-1505-1,Sodium Chloride 0.9% Injection,978-657-0889,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1505-1)","Spectra Medical Devices, LLC",,Resolved,['ANDA206171'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Spectra Medical Deviecs, LLC']","['65282-1505', '65282-1510']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807637', '1807646']",['0e649488-3951-382e-e063-6294a90a55c1'],['7e316d21-d6ad-4976-bd90-268fd7e51361'],"['65282-1510-1', '65282-1505-1']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,63323-411-10,Midazolam Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['ANDA075154'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-411', '63323-412']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['9814447b-a93e-42ad-b57e-5db0a5b7f552'],['a91ce254-14a3-4cbf-8ab8-5da252aa3fdc'],"['63323-411-22', '63323-411-27', '63323-411-15', '63323-411-12', '63323-411-18', '63323-411-25', '63323-411-13', '63323-411-10', '63323-412-18', '63323-412-25', '63323-412-03', '63323-412-02', '63323-412-06', '63323-412-05', '63323-412-13', '63323-412-10']",['W7TTW573JJ'],,,,,,,,,
New,07/21/2025,73070-503-15,Insulin Degludec Injection,609-987-5800,,"Unbranded Insulin Degludec 3 mL U-200 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injection,"Insulin Degludec, Injection, 3 mL Insulin Degludec 200 units/mL (U-200) FlexTouch® (NDC 73070-503-15)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA203314'],['INSULIN DEGLUDEC'],['INSULIN DEGLUDEC'],"['Novo Nordisk Pharma, Inc.']","['73070-503', '73070-403', '73070-400']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN DEGLUDEC'],"['1670011', '1670021', '2107520']",['c1be283d-4b1d-4996-b2a7-4488dbff3037'],['c1be283d-4b1d-4996-b2a7-4488dbff3037'],"['73070-403-15', '73070-503-15', '73070-400-11']",['54Q18076QB'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
Reverified,04/10/2020,63323-671-20,Dexmedetomidine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)","Fresenius Kabi USA, LLC",Other,Current,['ANDA208129'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-671'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['27411591-44a1-44c4-89c3-dd8c2687f0e2'],['4d5d2294-89a0-4b6f-aa00-d39a0393b6a8'],"['63323-671-02', '63323-671-20', '63323-671-05', '63323-671-50', '63323-671-01', '63323-671-00']",['1018WH7F9I'],,,,,,,,,
Revised,12/22/2020,68001-313-56,Azacitidine Injection,800-545-8800,Unavailable,Estimated availability: TBD,11/06/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg (NDC 68001-313-56)","Teva Pharmaceuticals USA, Inc.",Other,Current,['NDA208216'],['AZACITIDINE'],['AZACITIDINE'],['BluePoint Laboratories'],['68001-313'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['36080e4e-a0fe-ba15-e063-6394a90aed5c'],['5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a'],['68001-313-56'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
New,04/22/2025,50742-405-10,Oxaliplatin Injection,866-321-5031 (Ingenus Pharmaceuticals),,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,04/22/2025,['Oncology'],Injection,"Oxaliplatin, Injection, 50 mg/10 mL (NDC 50742-405-10)",Novast Labs,,To Be Discontinued,['ANDA207562'],['OXALIPLATIN'],['OXALIPLATIN'],"['Ingenus Pharmaceuticals, LLC']","['50742-405', '50742-406']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['OXALIPLATIN'],"['1736776', '1736781']",['91b1d13f-6401-496f-a2e5-76e84775efd0'],['9613ae3d-72e2-40f7-8151-b43e915a6f1c'],"['50742-405-10', '50742-406-20']",['04ZR38536J'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,04/22/2025,,,,,
Revised,02/20/2018,55150-160-72,Lidocaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-160-72)",Eugia US LLC,Demand increase for the drug,Current,['ANDA203040'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-160', '55150-158', '55150-159']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737566', '1737568', '1737757']",['e2600451-756c-4986-9e8e-26ce1d865afd'],['5524cbfd-d6e6-42eb-aaa5-22495e0a86b6'],"['55150-158-72', '55150-159-74', '55150-160-72']",['V13007Z41A'],,,,,,,,,
Reverified,04/10/2020,0409-1596-10,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1596', '0409-1660', '0409-1638', '0409-1434', '0409-7838', '0409-7853', '0409-7875']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['284397', '309710', '1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['231f50fe-2c91-44b9-946e-33b836c07b94'],['548a88c0-afda-427e-75ac-5af0cfa2224c'],"['0409-1660-55', '0409-1660-50', '0409-1660-35', '0409-1660-10', '0409-1660-22', '0409-1660-20', '0409-1638-32', '0409-1638-02', '0409-1434-01', '0409-1596-01', '0409-1596-10', '0409-7838-01', '0409-7838-24', '0409-7853-01', '0409-7853-24', '0409-7875-01', '0409-7875-12']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,76297-001-41,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-41)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['LABORATORIOS GRIFOLS SA'],['76297-001'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['ff5ef1ef-2a0d-476d-8483-ffd7cd47c635'],['eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf'],"['76297-001-12', '76297-001-11', '76297-001-22', '76297-001-21', '76297-001-32', '76297-001-31', '76297-001-02', '76297-001-01', '76297-001-42', '76297-001-41', '76297-001-52', '76297-001-51', '76297-001-62', '76297-001-61', '76297-001-72', '76297-001-71', '76297-001-82', '76297-001-81', '76297-001-92', '76297-001-91']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,0409-2308-01,Midazolam Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA075857'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2308', '0409-2305', '0409-0001']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['1666800', '1666814', '1666823', '1666798']","['b303a281-6633-47d5-bf29-5e9055e26da6', '8c3cf34b-901d-407a-946d-a1556bb24551']","['b95415fa-17c2-42ab-a6b0-e628d01c94ed', '1abda8b8-48a8-4995-af86-39220d1aa240']","['0409-2305-55', '0409-2305-50', '0409-2308-69', '0409-2308-49', '0409-2308-70', '0409-2308-50', '0409-2305-16', '0409-2305-17', '0409-2305-04', '0409-2305-05', '0409-2308-21', '0409-2308-01', '0409-2308-22', '0409-2308-02', '0409-0001-01', '0409-0001-25']",['W7TTW573JJ'],,,,,,,,,
Reverified,03/23/2018,76045-107-10,Ketorolac Tromethamine Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)","Fresenius Kabi USA, LLC",Other,Current,['ANDA203242'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Fresenius Kabi USA, LLC']","['76045-107', '76045-104', '76045-105', '76045-209']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860113', '860114', '860115']",['0dab642d-7fcf-4301-8ac9-10e64a040c6b'],['3d88cbe6-5230-47aa-80af-0c41283d1f00'],"['76045-104-10', '76045-105-20', '76045-107-10', '76045-209-00', '76045-209-10']",['4EVE5946BQ'],,,,,,,,,
Reverified,04/10/2020,71225-126-05,Dexmedetomidine Hydrochloride Injection,844-566-2505,Available,,09/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)",Slayback Pharma,,Current,['ANDA212791'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Slayback Pharma LLC'],['71225-126'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['027725dc-e468-446c-b702-ab0f8a9e3be5'],['e5d28ed8-e427-4850-81aa-98702d3b6a5d'],"['71225-126-02', '71225-126-05', '71225-126-03', '71225-126-06', '71225-126-01', '71225-126-04']",['1018WH7F9I'],,,,,,,,,
Revised,12/03/2021,0409-3977-03,Sterile Water Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,10/23/2025,['Other'],Injection,"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['NDA018802'],['BACTERIOSTATIC WATER'],['BACTERIOSTATIC WATER'],"['Hospira, Inc.']","['0409-3977', '0409-1093']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['e421caa9-6011-4cdf-a16c-6fe96d8b958a'],['87d6e9dc-fe3b-4593-ac9a-d7493d1959c7'],"['0409-3977-01', '0409-3977-03', '0409-1093-14', '0409-1093-04']",['059QF0KO0R'],,,,,,,,,
Revised,01/01/2012,0409-1630-10,Atropine Sulfate Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: December 2026,11/07/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA021146'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Hospira, Inc.']","['0409-1630', '0409-9630', '0409-4910', '0409-4911']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['9211a9e9-35d0-457d-ac95-4ad43ea6bf28'],['ad8916e7-206e-409e-2582-30d072845dd4'],"['0409-1630-15', '0409-1630-10', '0409-9630-15', '0409-9630-05', '0409-4910-11', '0409-4910-34', '0409-4911-11', '0409-4911-34']",['03J5ZE7KA5'],,,,,,,,,
Reverified,07/14/2023,59417-116-01,"Lisdexamfetamine Dimesylate Tablet, Chewable",877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],"Tablet, Chewable","Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA208510'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-116', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Reverified,10/05/2022,72485-508-10,Etomidate Injection,908-803-2586,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",11/04/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)","Caplin Steriles, Ltd.",,Current,['ANDA215028'],['ETOMIDATE'],['ETOMIDATE'],['Armas Pharmaceuticals Inc.'],"['72485-508', '72485-509']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['7444860b-36c1-459d-94ba-d7301d9dc2ca'],['75467058-da52-48fa-8d4e-e1025ec7d461'],"['72485-508-01', '72485-508-10', '72485-509-01', '72485-509-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
New,07/23/2025,0832-1015-00,Amantadine Hydrochloride Capsule,763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Antiviral', 'Neurology']",Capsule,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-00)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA070589'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-1015'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849389'],['398493aa-8a67-10e2-e063-6394a90aef8d'],['5232b933-1df9-43b4-8ac2-61bfa4855e68'],"['0832-1015-00', '0832-1015-50']",['M6Q1EO9TD0'],,,,07/23/2025,,,,,
Reverified,01/19/2023,62135-667-90,Quinapril/Hydrochlorothiazide Tablet,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,Available,,08/19/2025,['Cardiovascular'],Tablet,"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA076374'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],"['Chartwell RX, LLC']","['62135-667', '62135-668', '62135-669']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809']",['0c3f4504-d57e-aa79-e063-6294a90ad5b8'],['2eae533f-d0af-47e8-a1f2-94bc8cc89b5a'],"['62135-667-90', '62135-668-90', '62135-669-90']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],,,['Thiazides [CS]'],,,
Revised,02/22/2012,0409-4277-01,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088327'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4277', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
Reverified,02/22/2012,0409-3182-01,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089646'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3182', '0409-1209', '0409-3177', '0409-3178', '0409-3181', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Reverified,02/20/2018,71288-723-52,Bupivacaine Hydrochloride Injection,844-824-8426,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,08/19/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)",Kindos Pharmaceuticals Co. Ltd.,,Current,['ANDA216039'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Meitheal Pharmaceuticals Inc'],"['71288-723', '71288-726']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404']",['0949c302-51ce-4fc9-8b99-1df94e693718'],['fe340f98-a0f3-446e-b281-47fd91c1e537'],"['71288-723-52', '71288-726-52']",['7TQO7W3VT8'],,,,,,,,,
New,07/23/2025,0245-5316-01,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['KLOR-CON'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0245-5316', '0245-5315']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953', '628958', '832718']",['39e77e07-bdc8-28e9-e063-6394a90a120c'],['1ff53330-065c-4213-9c0c-ac498621d09d'],"['0245-5315-11', '0245-5315-15', '0245-5315-89', '0245-5315-01', '0245-5316-11', '0245-5316-15', '0245-5316-89', '0245-5316-01']",['660YQ98I10'],,,,07/23/2025,,,,,
Reverified,07/18/2023,0480-3667-20,Liraglutide Injection,833-493-4689,Available,Distributed by Teva,11/04/2025,['Endocrinology/Metabolism'],Injection,"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)","Novo Nordisk, Inc.",,Current,['NDA022341'],['LIRAGLUTIDE'],['LIRAGLUTIDE'],"['Teva Pharmaceuticals USA, Inc.']",['0480-3667'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],['897122'],['b56c797c-a46a-4dbf-a367-9d7f26c7d29d'],['14bf9812-14ee-46ce-93b1-686e4906cbbc'],"['0480-3667-19', '0480-3667-22', '0480-3667-20']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
Reverified,02/14/2022,0338-0017-38,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
New,12/09/2024,62756-224-88,Tiagabine Hydrochloride Tablet,800-818-4555,,Discontinuing for business reasons,12/09/2024,['Neurology'],Tablet,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-88)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077555'],['TIAGABINE HYDROCHLORIDE'],['TIAGABINE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['62756-224', '62756-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TIAGABINE HYDROCHLORIDE'],"['1299911', '1299917']",['57975e74-e45b-4fd9-9718-bfc9690acae5'],['7eeb2d81-c5d7-46a0-aa5c-149b55df71bd'],"['62756-200-83', '62756-200-18', '62756-224-83', '62756-224-88', '62756-224-08', '62756-224-18']",['DQH6T6D8OY'],,,,12/09/2024,,,,,
New,10/09/2025,0781-2868-01,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-01)",Sandoz Inc.,,To Be Discontinued,['ANDA075757'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],"['0781-2868', '0781-2859']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],"['198051', '199119']",['6a54ba13-eeb3-4c8c-800b-dc9aaf961c3f'],['516170d4-4913-4577-a2d2-f5c52d1e79c6'],"['0781-2859-10', '0781-2859-01', '0781-2859-92', '0781-2859-31', '0781-2868-10', '0781-2868-01', '0781-2868-92', '0781-2868-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Revised,01/01/2012,0143-9553-01,Leucovorin Calcium Injection,800-631-2174,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 0143-9553-01)","Hikma Pharmaceuticals USA, Inc.",,Resolved,['ANDA040056'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9553', '0143-9555', '0143-9554', '0143-9552']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['e2d1484b-2920-45ab-9207-4caa5285fef4'],['cc52077f-5663-4f79-a273-0aecf655e038'],"['0143-9555-01', '0143-9554-01', '0143-9553-01', '0143-9552-01']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,02/14/2022,0338-9143-30,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9143-30)",Baxter Healthcare,,Current,['NDA020179'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Company'],"['0338-9143', '0338-9147']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795616']",['539f43d0-ac05-4261-a87d-8b34b07e0dd7'],['0bfb32b2-d034-4219-a055-3448f0c424f7'],"['0338-9147-30', '0338-9143-30']",['LX22YL083G'],,,,,,,,,
New,12/09/2024,63323-960-10,Tigecycline Injection,888-386-1300,,Check wholesalers for inventory.,12/09/2024,['Anti-Infective'],Injection,"Injection, 50 mg/5 mL (NDC 63323-960-10)","Fresenius Kabi USA, LLC",,To Be Discontinued,['NDA205645'],['TIGECYCLINE'],['TIGECYCLINE'],"['Fresenius Kabi USA, LLC']",['63323-960'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['TIGECYCLINE'],['581531'],['0a2a6def-f494-41f8-8125-4296924b1753'],['acf5dbe5-ca75-4300-816f-b3f4625f6e7d'],"['63323-960-01', '63323-960-10']",['70JE2N95KR'],"['N0000175938', 'M0021223']",['Tetracycline-class Antibacterial [EPC]'],,12/09/2024,,['Tetracyclines [CS]'],,,
New,06/13/2025,0480-7270-10,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077793'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals, Inc.']",['0480-7270'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],['904481'],['95e8c960-5096-43a9-8807-89cdf404a214'],['f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8'],"['0480-7270-98', '0480-7270-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
Reverified,07/14/2023,59417-104-10,Lisdexamfetamine Dimesylate Capsule,877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],Capsule,"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA021977'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-104', '59417-101', '59417-102', '59417-103', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Revised,12/15/2022,0002-1434-80,Dulaglutide Injection,800-545-5979,,,06/13/2025,['Endocrinology/Metabolism'],Injection,"Trulicity, Injection, 1.5 mg/.5 mL (NDC 0002-1434-80)",Eli Lilly and Co.,,Resolved,['BLA125469'],['TRULICITY'],['DULAGLUTIDE'],['Eli Lilly and Company'],"['0002-1434', '0002-1433', '0002-2236', '0002-3182']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['DULAGLUTIDE'],"['1551295', '1551300', '1551304', '1551306', '2395777', '2395779', '2395783', '2395785']",['2a046089-7cd3-43d3-9f7f-27e3e4b49f0d'],['463050bd-2b1c-40f5-b3c3-0a04bb433309'],"['0002-1433-01', '0002-1433-80', '0002-1433-61', '0002-1434-01', '0002-1434-80', '0002-1434-61', '0002-2236-01', '0002-2236-80', '0002-2236-61', '0002-3182-01', '0002-3182-80', '0002-3182-61']",['WTT295HSY5'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],06/13/2025,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],Available
New,03/28/2025,0591-3005-01,Ursodiol Tablet,800-545-8800,,A business decision was made to discontinue manufacture of the drug.,03/28/2025,['Other'],Tablet,"Ursodiol, Tablet, 500 mg (NDC 0591-3005-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA020675'],['URSODIOL'],['URSODIOL'],"['Actavis Pharma, Inc.']","['0591-3005', '0591-2998']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['URSODIOL'],"['858733', '858751']",['3ca902a9-d8c3-4c4b-a49f-efc62cf2028a'],['0a7c1ae6-4878-43e7-9026-073f74af64c0'],"['0591-2998-01', '0591-3005-01']",['724L30Y2QR'],"['N0000175802', 'M0002475']",['Bile Acid [EPC]'],,03/28/2025,,['Bile Acids and Salts [CS]'],,,
New,10/27/2025,0310-6615-02,Pramlintide Acetate Injection,800-236-9933,,Discontinuation of the manufacture of the drug.,10/27/2025,['Endocrinology/Metabolism'],Injection,"SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02)",AstraZeneca AB,,To Be Discontinued,['NDA021332'],['SYMLINPEN'],['PRAMLINTIDE ACETATE'],['AstraZeneca Pharmaceuticals LP'],"['0310-6615', '0310-6627']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PRAMLINTIDE ACETATE'],"['861042', '861043', '861044', '861045']",['a84753f1-6ac5-4a47-a382-29972938ccaa'],['4aea30ff-eb0d-45c1-b114-3127966328ff'],"['0310-6615-02', '0310-6627-02']",['726I6TE06G'],,,,10/27/2025,,,,,
New,07/10/2025,72305-088-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 88 ug (NDC 72305-088-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-088', '72305-025', '72305-050', '72305-075', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,02/14/2022,0990-7922-55,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7922', '0990-7923', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
New,10/16/2025,0049-3190-01,Voriconazole Injection,844-646-4398,,Discontinuation of the manufacture of the drug,10/16/2025,['Antiviral'],Injection,"Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01)",Pfizer Inc.,,To Be Discontinued,['NDA021267'],['VFEND'],['VORICONAZOLE'],['Roerig'],"['0049-3190', '0049-3170', '0049-3180', '0049-3160']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['VORICONAZOLE'],"['351209', '352220', '349434', '349435', '352218', '352219', '465355', '546624']","['090a37ad-7e2c-4a77-8afd-96e3725d8622', 'c73f8708-e113-451e-a49b-ed5da19e60db']","['dac26bcd-7a59-401f-9f66-a0649767cece', 'ce3ef5cf-3087-4d92-9d94-9eb8287228db']","['0049-3190-01', '0049-3170-30', '0049-3180-30', '0049-3190-28', '0049-3160-44']",['JFU09I87TR'],"['N0000175487', 'M0002083', 'N0000182141', 'N0000182140', 'N0000185504']",['Azole Antifungal [EPC]'],,10/16/2025,,['Azoles [CS]'],,"['Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]', 'Cytochrome P450 2C9 Inhibitors [MoA]']",
Revised,06/28/2022,72078-035-02,Remifentanil Hydrochloride Injection,800-796-9526,Available,,11/06/2025,['Analgesia/Addiction'],Injection,"Ultiva, Injection, 2 mg (NDC 72078-035-02)","Mylan Institutional, a Viatris Company",,Current,['NDA020630'],['ULTIVA'],['REMIFENTANIL HYDROCHLORIDE'],['Mylan Institutional LLC'],"['72078-035', '72078-034', '72078-036']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729581', '1729584', '1729586', '1729710', '1729712']",['c10cf43f-066a-43ff-9166-242cbb7754af'],['8b4c8696-e23e-4c51-a4d2-babab5bd945a'],"['72078-034-00', '72078-034-01', '72078-035-00', '72078-035-02', '72078-036-00', '72078-036-05']",['5V444H5WIC'],,,,,,,,,
Reverified,07/14/2023,64850-552-01,Lisdexamfetamine Dimesylate Capsule,888-852-6657,Limited Availability,Limited Availability,11/04/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA218604'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Elite Laboratories, Inc.']","['64850-552', '64850-550', '64850-551', '64850-553', '64850-554', '64850-555', '64850-556']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['e414bb2e-d404-44ea-931c-5998b0a4c87e'],['0e024b69-567c-4b40-9c3e-a2daec34256c'],"['64850-550-01', '64850-551-01', '64850-552-01', '64850-553-01', '64850-554-01', '64850-555-01', '64850-556-01']",['SJT761GEGS'],,,,,,,,,
Reverified,02/22/2012,0409-1209-01,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088571'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-1209', '0409-3177', '0409-3178', '0409-3181', '0409-3182', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],['EPIDURAL'],"['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Reverified,02/20/2018,63323-466-31,Bupivacaine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,"['ANDA070553', 'NDA018304']",['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-466', '63323-464', '63323-462', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL', 'INFILTRATION']",['BUPIVACAINE HYDROCHLORIDE'],"['1724880', '1724881', '1725078', '1725175', '1724884', '1724885', '1725082', '1725177', '1672917', '1672919', '1673296', '1673298', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['b41b5dbd-7aff-4d97-ac97-f4355393ee4e', 'd3ba9fb9-63c8-4597-bb0a-cd01d31a24b6', '13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['e700eb7b-8b14-49c9-96b2-331f18776e45', 'b6bfc04a-1868-4630-9ca1-8c027af97ce3', 'dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-464-01', '63323-464-17', '63323-466-03', '63323-466-17', '63323-464-08', '63323-464-38', '63323-466-08', '63323-466-38', '63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,06/04/2025,0003-3622-12,Atazanavir Sulfate Capsule,1-800-332-2056; for Medical Inquiries (1-800-321-1335),,Permanent discontinuation,06/04/2025,['Antiviral'],Capsule,"Reyataz, Capsule, 300 mg (NDC 0003-3622-12)",Bristol Myers Squibb Co.,,To Be Discontinued,['NDA021567'],['REYATAZ'],['ATAZANAVIR'],"['E.R. Squibb & Sons, L.L.C.']","['0003-3622', '0003-3624', '0003-3631', '0003-3638']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ATAZANAVIR SULFATE'],"['402093', '402094', '402246', '402247', '664741', '664743', '1598985', '1598989']",['510c2d51-4943-401c-a008-ea22f61c6938'],['165cff62-b284-4a27-a65d-9ec8a5bfcdd8'],"['0003-3624-12', '0003-3631-12', '0003-3622-12', '0003-3638-10']",['4MT4VIE29P'],,,,06/04/2025,,,,,
New,07/10/2025,72305-137-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 137 ug (NDC 72305-137-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-137', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Revised,12/15/2022,0002-3182-80,Dulaglutide Injection,800-545-5979,,,06/13/2025,['Endocrinology/Metabolism'],Injection,"Trulicity, Injection, 4.5 mg/.5 mL (NDC 0002-3182-80)",Eli Lilly and Co.,,Resolved,['BLA125469'],['TRULICITY'],['DULAGLUTIDE'],['Eli Lilly and Company'],"['0002-3182', '0002-1433', '0002-1434', '0002-2236']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['DULAGLUTIDE'],"['1551295', '1551300', '1551304', '1551306', '2395777', '2395779', '2395783', '2395785']",['2a046089-7cd3-43d3-9f7f-27e3e4b49f0d'],['463050bd-2b1c-40f5-b3c3-0a04bb433309'],"['0002-1433-01', '0002-1433-80', '0002-1433-61', '0002-1434-01', '0002-1434-80', '0002-1434-61', '0002-2236-01', '0002-2236-80', '0002-2236-61', '0002-3182-01', '0002-3182-80', '0002-3182-61']",['WTT295HSY5'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],06/13/2025,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],Available
Reverified,02/20/2018,0409-1162-01,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070584'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1162', '0409-1159', '0409-1160', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/03/2016,0409-3299-05,Sodium Acetate Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)","Hospira, Inc., a Pfizer Company",,Current,['NDA018893'],['SODIUM ACETATE'],['SODIUM ACETATE'],"['Hospira, Inc.']",['0409-3299'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE ANHYDROUS'],['237371'],"['eadea22b-c475-4596-8c15-e738af5a711d', '99255488-8958-49ab-965c-083119f5ba3c']","['abc41ed1-9512-4bea-9295-1a9ca134b6c2', 'c3be2468-45e8-4ecc-a30b-e966743a563f']","['0409-3299-15', '0409-3299-05', '0409-3299-16', '0409-3299-06', '0409-3299-45', '0409-3299-25', '0409-3299-46', '0409-3299-26']",['NVG71ZZ7P0'],,,,,,,,,
Reverified,07/26/2023,43598-439-01,"Methylphenidate Hydrochloride Tablet, Extended Release",866-732-3952,Unavailable,Estimated availability TBD,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 43598-439-01)","Dr. Reddy's Laboratories, Inc.",Other,Current,,,,,,,,,,,,,,,,,,,,,,
New,04/07/2025,10147-0922-5,Haloperidol Decanoate Injection,800-526-7736,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 10/31/2025,04/07/2025,['Psychiatry'],Injection,"Haloperidol Decanoate, Injection, 100 mg/1 mL (NDC 10147-0922-5)",Janssen Pharmaceuticals,,To Be Discontinued,['NDA018701'],['HALOPERIDOL DECANOATE'],['HALOPERIDOL DECANOATE'],['Patriot Pharmaceuticals LLC'],"['10147-0922', '10147-0921']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['HALOPERIDOL DECANOATE'],"['1719803', '1719862']",['2e815b50-b5db-72e4-e063-6294a90afd55'],['9f0f42a8-5f7c-4be7-93ef-3ec225502cc6'],"['10147-0921-3', '10147-0922-5']",['AC20PJ4101'],,,,04/07/2025,,,,,
Reverified,03/10/2023,59651-724-01,Clonazepam Tablet,866-850-2876,Available,,10/15/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)",Aurobindo Pharma USA,,Current,['ANDA075150'],['CLONAZEPAM'],['CLONAZEPAM'],['Aurobindo Pharma Limited'],"['59651-724', '59651-722', '59651-723']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['b1582eb7-af35-45d5-a52e-0e380d08527d'],['b1582eb7-af35-45d5-a52e-0e380d08527d'],"['59651-722-01', '59651-722-99', '59651-723-01', '59651-723-99', '59651-724-01', '59651-724-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,03/23/2018,63323-285-23,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,05/30/2025,0641-6053-25,Meperidine Hydrochloride Injection,800-631-2174,Unavailable,Additional lots scheduled to be available in the October-November 2025 timeframe.,10/24/2025,['Analgesia/Addiction'],Injection,"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA080445'],['MEPERIDINE HYDROCHLORIDE'],['MEPERIDINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6053', '0641-6054', '0641-6052']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['861476', '1665685', '1665697']",['9566d54d-7343-4695-94ff-8b5f2d384c81'],['e0e998da-f056-4fce-be8e-ed60cf3b461b'],"['0641-6053-01', '0641-6053-25', '0641-6054-01', '0641-6054-25', '0641-6052-01', '0641-6052-25']",['N8E7F7Q170'],,,,,,,,,
New,04/07/2025,50458-254-14,Haloperidol Decanoate Injection,800-526-7736,,Last batch expiration date 8/31/2025,04/07/2025,['Psychiatry'],Injection,"Haldol, Injection, 100 mg/1 mL (NDC 50458-254-14)",Janssen Pharmaceuticals,,To Be Discontinued,['NDA018701'],['HALDOL DECANOATE'],['HALOPERIDOL DECANOATE'],"['Janssen Pharmaceuticals, Inc.']","['50458-254', '50458-253']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['HALOPERIDOL DECANOATE'],"['1719803', '1719847', '1719862', '1720026']",['2cf0430f-e455-8d17-e063-6394a90a5cd3'],['af0159a8-dff5-449a-aa2b-a0c430081e21'],"['50458-253-01', '50458-253-03', '50458-254-14']",['AC20PJ4101'],,,,04/07/2025,,,,,
New,03/03/2025,0310-6770-30,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,800-236-9933,,,03/03/2025,['Endocrinology/Metabolism'],Tablet,"Qtern, Tablet, 5 mg; 5 mg (NDC 0310-6770-30)",AstraZeneca AB,,To Be Discontinued,['NDA209091'],['QTERN'],['DAPAGLIFLOZIN AND SAXAGLIPTIN'],['AstraZeneca Pharmaceuticals LP'],"['0310-6770', '0310-6780']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['DAPAGLIFLOZIN', 'SAXAGLIPTIN HYDROCHLORIDE']","['1925498', '1925504', '2169274', '2169276']",['d675ddaa-3a40-4323-9edd-b04f13f10a03'],['423c489c-085b-4320-b892-7868ebd6dc6b'],"['0310-6780-30', '0310-6780-95', '0310-6770-30', '0310-6770-95']","['1ULL0QJ8UC', 'Z8J84YIX6L']","['N0000187059', 'N0000187058']",['Sodium-Glucose Cotransporter 2 Inhibitor [EPC]'],,,,,,['Sodium-Glucose Transporter 2 Inhibitors [MoA]'],
Reverified,02/15/2023,65219-065-05,Rocuronium Bromide Injection,888-386-1300,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,11/05/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['ANDA078651'],['ROCURONIUM'],['ROCURONIUM BROMIDE'],"['Fresenius Kabi USA, LLC']",['65219-065'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['68f8f5e7-46a8-47f9-a622-6339df1a3d1b'],['209a654d-f92d-4242-bfef-2dcc90a30d3f'],"['65219-065-02', '65219-065-05']",['I65MW4OFHZ'],,,,,,,,,
Revised,07/14/2023,72205-135-91,"Lisdexamfetamine Dimesylate Tablet, Chewable",(855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)",Novadoz Pharmaceuticals LLC,Shortage of an active ingredient,Current,['ANDA218306'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Novadoz Pharmaceuticals LLC'],"['72205-135', '72205-132', '72205-133', '72205-134', '72205-136', '72205-137']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],"['72205-132-91', '72205-133-91', '72205-134-91', '72205-135-91', '72205-136-91', '72205-137-91']",['SJT761GEGS'],,,,,,,,,
New,01/22/2025,64764-677-30,Febuxostat Tablet,855-268-1825,,Anticipate continued distribution to wholesalers until March 2026,01/22/2025,['Other'],Tablet,"Uloric, Tablet, 80 mg (NDC 64764-677-30)",Takeda Pharmaceuticals USA Inc.,,To Be Discontinued,['NDA021856'],['ULORIC'],['FEBUXOSTAT'],"['Takeda Pharmaceuticals America, Inc.']","['64764-677', '64764-918']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FEBUXOSTAT'],"['834235', '834239', '834241', '834243']",['fecf6101-9a35-4781-bea4-e7b92b4afb81'],['54de10ef-fe5f-4930-b91d-6bbb04c664bd'],"['64764-918-30', '64764-918-90', '64764-918-18', '64764-918-11', '64764-677-30', '64764-677-13', '64764-677-19', '64764-677-11']",['101V0R1N2E'],"['N0000175698', 'N0000000206']",['Xanthine Oxidase Inhibitor [EPC]'],,01/22/2025,,,,['Xanthine Oxidase Inhibitors [MoA]'],
Reverified,02/20/2018,63323-462-31,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA018304'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-462', '63323-464', '63323-466', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1672917', '1672919', '1673296', '1673298', '1724880', '1724881', '1724884', '1724885', '1725078', '1725082', '1725175', '1725177', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/17/2021,67457-445-60,Rifampin Injection,800-796-9526,Available,,11/06/2025,['Anti-Infective'],Injection,"Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)","Mylan Institutional, a Viatris Company",,Current,['ANDA065421'],['RIFAMPIN'],['RIFAMPIN'],['Mylan Institutional LLC'],['67457-445'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['RIFAMPIN'],['312821'],['f1107e3c-754b-407d-9d66-23f545c0c692'],['8be91604-d7cd-4f2b-997d-e3364e4092e5'],['67457-445-60'],['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Revised,07/14/2023,57664-046-88,Lisdexamfetamine Dimesylate Capsule,800-818-4555,Limited Availability,Additional supply anticipated in Q3 2025 followed by early 2026,10/21/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['ANDA214484'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-046', '57664-047', '57664-048', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
Revised,01/01/2012,63323-806-20,Fentanyl Citrate Injection,888-386-1300,Unavailable,Next release not available at this time. Check wholesalers for inventory.,11/05/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)","Fresenius Kabi USA, LLC",Other,Current,['ANDA210762'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Fresenius Kabi USA, LLC']",['63323-806'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270']",['341b092a-1f6f-40f1-98f2-9346bf2e1242'],['38d0c14a-a0c1-44cc-a939-0304eb8037d6'],"['63323-806-11', '63323-806-01', '63323-806-12', '63323-806-02', '63323-806-13', '63323-806-05', '63323-806-14', '63323-806-20', '63323-806-50']",['MUN5LYG46H'],,,,,,,,,
Revised,02/17/2015,0143-9933-25,"Cefotaxime Sodium Powder, for Solution",800-631-2174,Unavailable,Shortage duration is unknown at this time.,10/24/2025,"['Anti-Infective', 'Pediatric']","Powder, For Solution","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA065072'],['CEFOTAXIME'],['CEFOTAXIME'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9933', '0143-9931', '0143-9930']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CEFOTAXIME SODIUM'],"['309068', '1656313', '1656318']",['7e0897ec-2275-4438-9cc5-4c951e52ad97'],['ed23b6bc-32c7-4c50-a53d-313ae78e5623'],"['0143-9931-01', '0143-9931-25', '0143-9933-01', '0143-9933-25', '0143-9930-01', '0143-9930-10']",['258J72S7TZ'],,,,,,,,,
Reverified,03/23/2018,63323-285-63,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,03/13/2023,61703-124-40,Methotrexate Sodium Injection,844-646-4398,Available,,10/23/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)","Hospira, Inc., a Pfizer Company",,Current,['NDA011719'],['METHOTREXATE'],['METHOTREXATE'],"['Hospira, Inc.']","['61703-124', '61703-161']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS', 'SUBCUTANEOUS']",['METHOTREXATE SODIUM'],"['1655956', '1946772']",['6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910'],['bd287e89-32f9-4396-95fa-4b562869f476'],"['61703-124-40', '61703-161-02', '61703-161-05']",['3IG1E710ZN'],,,,,,,,,
Revised,12/20/2023,0641-6024-10,Fentanyl Citrate Injection,800-631-2174,Unavailable,Inventory available in vial presentations.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6024', '0641-6027', '0641-6025', '0641-6028', '0641-6026', '0641-6029', '0641-6030', '0641-6247', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
Revised,04/28/2023,61703-360-18,Carboplatin Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA076517'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']","['61703-360', '61703-150', '61703-262', '61703-600']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5aa72c15-8033-4559-b257-373371b18958'],['47677091-fd20-49af-933c-c9dd2be21de9'],"['61703-360-18', '61703-150-05', '61703-262-05', '61703-600-05']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,02/15/2023,0143-9250-10,Rocuronium Bromide Injection,800-631-2174,Available,Additional lots will be available.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA204679'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9250', '0143-9251']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['1b6667a4-f267-483a-ae9f-2a514db8a21d'],['d3a172a5-01ab-47d8-92ac-a8539b1d4dc4'],"['0143-9250-01', '0143-9250-10', '0143-9251-01', '0143-9251-10']",['I65MW4OFHZ'],,,,,,,,,
Revised,07/14/2023,0480-3564-01,Lisdexamfetamine Dimesylate Capsule,800-545-8800,Limited Availability,Estimated availability: December 2025,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Teva Pharmaceuticals, Inc.']","['0480-3564', '0480-3565', '0480-3566', '0480-3567', '0480-3568', '0480-3569', '0480-3570']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['6cfe6c98-51b1-45a4-831c-33624ab129cb'],['c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc'],"['0480-3565-01', '0480-3566-01', '0480-3567-01', '0480-3568-01', '0480-3569-01', '0480-3570-01', '0480-3564-01']",['SJT761GEGS'],,,,,,,,,
Revised,12/20/2023,0641-6026-05,Fentanyl Citrate Injection,800-631-2174,Unavailable,Inventory available in vial presentations.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6026', '0641-6024', '0641-6027', '0641-6025', '0641-6028', '0641-6029', '0641-6030', '0641-6247', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
New,12/05/2024,63304-692-01,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-01)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-692', '63304-693']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
Reverified,03/23/2018,65219-632-20,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)","Fresenius Kabi USA, LLC",,Current,['ANDA212808'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['FRESENIUS KABI USA, LLC']",['65219-632'],['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],,['7203f32f-2e48-4924-b882-d4f3863ae952'],['da4a7675-97bf-4d2a-9fdc-c1b4b2999126'],"['65219-632-02', '65219-632-10', '65219-632-04', '65219-632-20']",['V910P86109'],,,,,,,,,
Reverified,02/28/2025,0378-8261-93,"Methylphenidate Film, Extended Release",800-796-9526,Available,,11/06/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 15mg/9hrs (NDC 0378-8261-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA206497'],['METHYLPHENIDATE'],['METHYLPHENIDATE'],['Mylan Pharmaceuticals Inc.'],"['0378-8261', '0378-8260', '0378-8262', '0378-8263']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['435703f5-35b9-4d50-a12a-89546888c61a'],['1643b6a5-80da-4d4f-8c5f-feb907875702'],"['0378-8260-16', '0378-8260-93', '0378-8261-16', '0378-8261-93', '0378-8262-16', '0378-8262-93', '0378-8263-16', '0378-8263-93']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
Reverified,04/07/2020,36000-283-25,Furosemide Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)",Baxter Healthcare,,Current,['ANDA202747'],['FUROSEMIDE'],['FUROSEMIDE'],['Baxter Healthcare Corporation'],"['36000-283', '36000-063', '36000-064', '36000-065', '36000-282', '36000-284']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53'],['c71371a7-75c5-45b8-b762-8d782d4c71bc'],"['36000-063-05', '36000-064-05', '36000-065-05', '36000-282-25', '36000-283-25', '36000-284-25']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,03/21/2023,0338-3612-50,Clindamycin Phosphate Injection,888-229-0001,Limited Availability,Estimated recovery: December 2025,10/22/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)",Baxter Healthcare,Demand increase for the drug,Current,['ANDA208084'],['CLINDAMYCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Baxter Healthcare Company'],"['0338-3612', '0338-3410', '0338-3814']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN PHOSPHATE'],"['309335', '309336', '309339']",['9373fc85-1d70-4907-842a-ae9e2a3958b3'],['78832ac6-04c5-45e0-ae4d-f56d7920dda9'],"['0338-3410-50', '0338-3410-24', '0338-3612-50', '0338-3612-24', '0338-3814-50', '0338-3814-24']",['EH6D7113I8'],,,,,,,,,
Revised,03/23/2018,55150-201-20,Ropivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)",Eugia US LLC,,Current,['ANDA205612'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-201', '55150-195', '55150-196', '55150-197', '55150-198', '55150-199', '55150-200']",['HUMAN PRESCRIPTION DRUG'],['EPIDURAL'],['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734207', '1734347', '1734475', '1734483']",['34725b26-d6e9-4d1b-95a0-da03764cc102'],['3763b7b6-da49-4658-b93d-28f5da24d09e'],"['55150-195-20', '55150-196-99', '55150-197-20', '55150-198-30', '55150-199-20', '55150-200-10', '55150-201-20']",['V910P86109'],,,,,,,,,
Revised,09/05/2018,0641-6002-10,Lorazepam Injection,800-631-2174,Unavailable,Unavailable,10/24/2025,['Neurology'],Injection,"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)","Hikma Pharmaceuticals USA, Inc.",Regulatory delay,Current,['NDA018140'],['ATIVAN'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6002', '0641-6003', '0641-6001', '0641-6000']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['206819', '206820', '238100', '238101', '1665188', '1665190', '1665326', '1665327']",['209b0091-c890-4f69-a693-d0594c2606fe'],['5fc0e987-61c9-40c4-b0d5-fcea07c8733e'],"['0641-6003-01', '0641-6003-25', '0641-6002-01', '0641-6002-10', '0641-6001-01', '0641-6001-25', '0641-6000-01', '0641-6000-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,04/07/2020,23155-473-42,Furosemide Injection,855-228-9470,Available,,11/03/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)","Avet Pharmaceuticals, Inc.",,Current,['ANDA203428'],['FUROSEMIDE'],['FUROSEMIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],['23155-473'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['936eaafa-5088-4ebc-85bc-685ffb85c81f'],['1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec'],"['23155-473-31', '23155-473-41', '23155-473-32', '23155-473-42', '23155-473-43', '23155-473-33', '23155-473-44', '23155-473-45']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/10/2023,16729-137-16,Clonazepam Tablet,"866-941-7875, option 2",Available,,11/04/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)",Accord Healthcare Inc.,,Current,['ANDA077147'],['CLONAZEPAM'],['CLONAZEPAM'],['Accord Healthcare Inc.'],"['16729-137', '16729-136', '16729-138']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['0e1e7f41-f78b-27cf-e063-6394a90a1ae0'],['ebc11109-e7bf-452d-b675-4b3236d54164'],"['16729-136-00', '16729-136-16', '16729-137-00', '16729-137-16', '16729-138-00', '16729-138-16']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,01/06/2023,0013-2650-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 0.4 mg preservative free (NDC 0013-2650-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2650', '0013-2626', '0013-2646', '0013-2649', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Revised,02/29/2024,47335-326-08,Naltrexone Hydrochloride Tablet,800-818-4555,Unavailable,Currently not marketed,10/21/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-08)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA090356'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']",['47335-326'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['b0c2b60a-dc96-483b-933e-2fed58b64372'],['0f30f885-d0cd-4fa6-a8e0-142f08a56792'],"['47335-326-83', '47335-326-88', '47335-326-08', '47335-326-18']",['Z6375YW9SF'],,,,,,,,,
New,07/10/2025,72305-125-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 125 ug (NDC 72305-125-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-125', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,02/08/2019,70069-021-25,Dexamethasone Sodium Phosphate Injection,732-554-1019,Available,,08/19/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)","Somerset Therapeutics, LLC",,Current,['ANDA207442'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Somerset Therapeutics, LLC']",['70069-021'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],['1812079'],['73618326-ff56-4a30-9d6d-6b019b61c2cd'],['799028e2-c0e4-494f-89ff-1b786babc34a'],"['70069-021-01', '70069-021-25']",['AI9376Y64P'],,,,,,,,,
New,12/09/2024,62756-224-08,Tiagabine Hydrochloride Tablet,800-818-4555,,Discontinuing for business reasons,12/09/2024,['Neurology'],Tablet,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-08)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077555'],['TIAGABINE HYDROCHLORIDE'],['TIAGABINE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['62756-224', '62756-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TIAGABINE HYDROCHLORIDE'],"['1299911', '1299917']",['57975e74-e45b-4fd9-9718-bfc9690acae5'],['7eeb2d81-c5d7-46a0-aa5c-149b55df71bd'],"['62756-200-83', '62756-200-18', '62756-224-83', '62756-224-88', '62756-224-08', '62756-224-18']",['DQH6T6D8OY'],,,,12/09/2024,,,,,
Reverified,04/02/2020,63323-412-10,Midazolam Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,"['ANDA075154', 'ANDA208878']",['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-412', '63323-411']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']","['9814447b-a93e-42ad-b57e-5db0a5b7f552', 'c2aaa2df-aa73-4ea7-96be-528010260e25']","['a91ce254-14a3-4cbf-8ab8-5da252aa3fdc', '09daf48f-1d44-4b7b-bb53-bd5635b93ca6']","['63323-411-22', '63323-411-27', '63323-411-15', '63323-411-12', '63323-411-18', '63323-411-25', '63323-411-13', '63323-411-10', '63323-412-18', '63323-412-25', '63323-412-03', '63323-412-02', '63323-412-06', '63323-412-05', '63323-412-13', '63323-412-10', '63323-412-00']",['W7TTW573JJ'],,,,,,,,,
Revised,01/01/2012,71288-161-20,Leucovorin Calcium Injection,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 71288-161-20)",Kindos Pharmaceuticals Co. Ltd.,,Resolved,['ANDA216590'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Meitheal Pharmaceuticals Inc.'],"['71288-161', '71288-160', '71288-162', '71288-163', '71288-164']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['077a459b-e884-4452-aed3-0857a38ce26f'],['9df20901-6980-4d4e-89ec-40f3c1f91852'],"['71288-160-10', '71288-161-20', '71288-162-30', '71288-163-30', '71288-164-50']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
New,03/04/2025,65862-585-01,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-585', '65862-582', '65862-583', '65862-584', '65862-586', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
Revised,12/10/2021,0409-7101-67,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-67)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA019465'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']","['0409-7101', '0409-7132']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807547', '1807631', '1807632', '1807633']",['9d75502b-257f-4a37-9a85-b98c4278c474'],['a2a964f7-c3ec-4dfb-e3a0-6d8136a80397'],"['0409-7101-68', '0409-7101-66', '0409-7101-69', '0409-7101-67', '0409-7101-04', '0409-7101-02', '0409-7132-68', '0409-7132-66', '0409-7132-69', '0409-7132-67', '0409-7132-04', '0409-7132-02']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,12/15/2021,0009-3475-01,Methylprednisolone Acetate Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)",Pfizer Inc.,Other,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-3475', '0009-3073']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743781', '1743855', '1743856']",['befd723e-d1e2-41b9-83f1-17bca0c2a941'],['9a7b3837-e038-48bf-97e9-78ad463760dc'],"['0009-3073-01', '0009-3073-03', '0009-3475-01', '0009-3475-03']",['43502P7F0P'],,,,,,,,,
Reverified,11/01/2017,76045-010-11,Hydromorphone Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)","Fresenius Kabi USA, LLC",,Current,['NDA019034'],['DILAUDID'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['76045-010', '76045-009', '76045-121']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1872265', '1872269', '1872752', '2277368', '2277370']",['97bfcafb-2037-47dc-a0ae-f7b8007c47df'],['9eebd88a-5632-460f-b7b6-26c8a180540d'],"['76045-009-96', '76045-009-06', '76045-009-01', '76045-009-11', '76045-010-01', '76045-010-11', '76045-121-01', '76045-121-11']",['L960UP2KRW'],,,,,,,,,
Reverified,12/08/2020,0338-1130-03,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)",Baxter Healthcare,,Current,['ANDA075880'],['PREMASOL - SULFITE-FREE (AMINO ACID)'],"['LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE']",['Baxter Healthcare Company'],"['0338-1130', '0338-1131']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'CYSTEINE HYDROCHLORIDE', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'TAURINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['801395', '801398', '801403', '801405']",['4083b5c8-ad5f-43f6-ab19-3c87acb2883f'],['9afdcc3e-0d06-47f4-86ca-40da48b2b02b'],"['0338-1130-03', '0338-1130-04', '0338-1130-06', '0338-1131-03']","['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', 'ZT934N0X4W', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '1EQV5MLY3D', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Reverified,02/03/2016,0409-3299-26,Sodium Acetate Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)","Hospira, Inc., a Pfizer Company",,Current,['NDA018893'],['SODIUM ACETATE'],['SODIUM ACETATE'],"['Hospira, Inc.']",['0409-3299'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE ANHYDROUS'],['237371'],"['eadea22b-c475-4596-8c15-e738af5a711d', '99255488-8958-49ab-965c-083119f5ba3c']","['abc41ed1-9512-4bea-9295-1a9ca134b6c2', 'c3be2468-45e8-4ecc-a30b-e966743a563f']","['0409-3299-15', '0409-3299-05', '0409-3299-16', '0409-3299-06', '0409-3299-45', '0409-3299-25', '0409-3299-46', '0409-3299-26']",['NVG71ZZ7P0'],,,,,,,,,
Revised,02/28/2025,0574-2420-65,"Methylphenidate Film, Extended Release",800-455-8070,Available,Available. Distributed by Padagis US LLC,10/02/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)","Noven Pharmaceuticals, Inc.",,Current,['NDA021514'],['METHYLPHENIDATE TRANSDERMAL SYSTEM'],['METHYLPHENIDATE'],['PADAGIS US LLC'],"['0574-2420', '0574-2410', '0574-2415', '0574-2430']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['b743ef45-2fc0-4086-8a02-6078e6a09eaa'],['7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb'],"['0574-2410-65', '0574-2415-65', '0574-2420-65', '0574-2430-65']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
Revised,05/01/2020,24208-800-60,Hydroxypropyl Cellulose (1600000 Wamw) Insert,800-553-5340,Unavailable,Discontinuation of the manufacture of the drug,09/17/2025,['Ophthalmology'],Insert,"Lacrisert, Insert, 5 mg (NDC 24208-800-60)",Bausch & Lomb Incorporated,Discontinuation of the manufacture of the drug,Current,['NDA018771'],['LACRISERT'],['HYDROXYPROPYL CELLULOSE'],['Bausch & Lomb Incorporated'],['24208-800'],['HUMAN PRESCRIPTION DRUG'],['OPHTHALMIC'],['HYDROXYPROPYL CELLULOSE (1600000 WAMW)'],"['476707', '754512']",['1e1a2eb7-408a-9cae-e063-6394a90a544b'],['cc7a6a52-0b77-4df7-8403-dd21c1334f6c'],"['24208-800-60', '24208-800-10']",['RFW2ET671P'],,,,,,,,,
Reverified,04/10/2020,67457-924-50,Dexmedetomidine Hydrochloride Injection,800-796-9526,Available,,11/06/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)","Mylan Institutional, a Viatris Company",,Current,['ANDA212571'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Mylan Institutional LLC'],"['67457-924', '67457-925']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['b51a1fb0-fcee-4a76-9eaf-91c35813c242'],['f140de5a-f13d-46b4-a742-049c63e474f5'],"['67457-924-00', '67457-924-50', '67457-925-00', '67457-925-10']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0338-0049-31,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-31)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,42806-339-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(718) 276-8600 ext. 3,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)","Epic Pharma, LLC",,Current,['ANDA040444'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Epic Pharma, LLC']","['42806-339', '42806-341', '42806-343', '42806-344', '42806-345']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961']",['f11301e2-3b5d-468d-b44c-45839e7e5dfb'],['1757e132-061d-4773-89ed-fdc77f69008f'],"['42806-339-01', '42806-341-01', '42806-343-01', '42806-344-01', '42806-345-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,10/11/2024,0338-0117-03,Lactated Ringers Injection,888-229-0001,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 500 mL bag, 24 count (NDC 0338-0117-03)",Baxter Healthcare,,Resolved,['NDA016682'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE']",['Baxter Healthcare Company'],['0338-0117'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847630'],['a3c6770a-d279-4ea9-b8ed-5484be18121e'],['dad7735c-709b-40ea-ab7a-15577e24a966'],"['0338-0117-02', '0338-0117-03', '0338-0117-04']","['M4I0D6VV5M', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Reverified,03/10/2023,0093-0832-01,Clonazepam Tablet,800-545-8800,Available,,10/16/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA074569'],['CLONAZEPAM'],['CLONAZEPAM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-0832', '0093-3212', '0093-3213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['d6abe4e3-7699-4ead-95f4-739a961b23ad'],['8069b1a0-7c06-4252-b44e-e2eef065d9b8'],"['0093-0832-01', '0093-0832-05', '0093-3212-01', '0093-3212-05', '0093-3213-01', '0093-3213-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,12/10/2021,76297-001-11,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-11)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['LABORATORIOS GRIFOLS SA'],['76297-001'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['ff5ef1ef-2a0d-476d-8483-ffd7cd47c635'],['eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf'],"['76297-001-12', '76297-001-11', '76297-001-22', '76297-001-21', '76297-001-32', '76297-001-31', '76297-001-02', '76297-001-01', '76297-001-42', '76297-001-41', '76297-001-52', '76297-001-51', '76297-001-62', '76297-001-61', '76297-001-72', '76297-001-71', '76297-001-82', '76297-001-81', '76297-001-92', '76297-001-91']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/26/2023,68025-096-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Available,,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)","Vertical Pharmaceuticals, LLC",,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-096', '68025-088', '68025-089', '68025-095', '68025-097', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
Revised,08/23/2024,70100-424-02,Indocyanine Green Injection,888-393-3767,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Indocyanine Green, Injection, 25 mg (NDC 70100-424-02)",Renew Pharmaceuticals Limited,,Resolved,['ANDA040811'],['INDOCYANINE GREEN'],['INDOCYANINE GREEN AND WATER'],['Renew Pharmaceuticals Limited'],['70100-424'],['HUMAN PRESCRIPTION DRUG'],,,,['3abdfd10-c4e6-472e-b4eb-d4953f029132'],['a6f24787-c243-445a-9c55-7c7479b292d9'],"['70100-424-02', '0409-4887-17']",,,,,,,,08/26/2025,,Available
Reverified,04/10/2020,63323-671-50,Dexmedetomidine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['ANDA208129'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-671'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['27411591-44a1-44c4-89c3-dd8c2687f0e2'],['4d5d2294-89a0-4b6f-aa00-d39a0393b6a8'],"['63323-671-02', '63323-671-20', '63323-671-05', '63323-671-50', '63323-671-01', '63323-671-00']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0990-7983-55,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-55)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7983', '0990-7730', '0990-7984', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,01/13/2022,25021-131-82,Metronidazole Injection,866-625-1618,Available,Labeler: Sagent Pharmaceuticals,09/22/2025,['Anti-Infective'],Injection,"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)",InfoRLife SA,,Current,['ANDA206191'],['METRONIDAZOLE'],['METRONIDAZOLE'],['Sagent Pharmaceuticals'],['25021-131'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['METRONIDAZOLE'],['311683'],['cad111bb-2009-422a-b16e-87d75ade4e4c'],['d46870f5-e2b1-46bd-8413-4a0a8bcf3175'],['25021-131-82'],['140QMO216E'],"['N0000175435', 'M0014907']",['Nitroimidazole Antimicrobial [EPC]'],,,,['Nitroimidazoles [CS]'],,,
Revised,01/01/2012,70436-119-80,Leucovorin Calcium Injection,888-447-0095,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 350 mg (NDC 70436-119-80)",Slate Run Pharmaceuticals,,Resolved,['ANDA217021'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Slate Run Pharmaceuticals, LLC']","['70436-119', '70436-116', '70436-117', '70436-118', '70436-120']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['2a4aaed3-885e-bc10-e063-6294a90a61af'],['d8bdd60c-9a1c-4ef4-ba6b-b911849128f1'],"['70436-116-80', '70436-116-82', '70436-117-80', '70436-118-80', '70436-120-80', '70436-119-80']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
New,05/28/2025,0472-0804-60,Desonide Cream,800-545-8800,,,05/28/2025,['Dermatology'],Cream,"Desowen, Cream, .5 mg/1 g (NDC 0472-0804-60)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA019048'],['DESONIDE'],['DESONIDE'],"['Actavis Pharma, Inc.']","['0472-0804', '0472-0803']",['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['DESONIDE'],"['197572', '349351']",['f3953b9e-138f-4d86-8eea-0fc03c3c2747'],['ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99'],"['0472-0804-15', '0472-0804-60', '0472-0803-02', '0472-0803-04']",['J280872D1O'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,05/28/2025,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
Revised,01/06/2023,0013-2656-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 1.6 mg preservative free (NDC 0013-2656-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2656', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Reverified,07/26/2023,50458-588-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,Available,,11/04/2025,['Psychiatry'],Tablet,"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)",Janssen Pharmaceuticals,,Current,['NDA021121'],['CONCERTA'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Janssen Pharmaceuticals, Inc.']","['50458-588', '50458-585', '50458-586', '50458-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],,['4035a366-ebde-a1aa-e063-6294a90af4c4'],['1a88218c-5b18-4220-8f56-526de1a276cd'],"['50458-585-01', '50458-588-01', '50458-586-01', '50458-587-01']",['4B3SC438HI'],,,,,,,,,
Revised,10/11/2024,0338-0125-03,Lactated Ringers Injection,888-229-0001,,Discontinuation of the manufacture of the drug.,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-03)",Baxter Healthcare,,To Be Discontinued,['NDA016679'],['LACTATED RINGERS AND DEXTROSE'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE AND DEXTROSE MONOHYDRATE']",['Baxter Healthcare Corporation'],['0338-0125'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'DEXTROSE MONOHYDRATE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847627'],['8fc5f645-fb02-4ecf-9c07-5d515b96d7ca'],['6acc9f96-7088-45a7-b48f-1a861e3467ab'],"['0338-0125-03', '0338-0125-04']","['M4I0D6VV5M', 'LX22YL083G', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,10/03/2025,,,10/03/2025,,
Reverified,04/10/2020,71225-126-06,Dexmedetomidine Hydrochloride Injection,844-566-2505,Available,,09/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)",Slayback Pharma,,Current,['ANDA212791'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Slayback Pharma LLC'],['71225-126'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['027725dc-e468-446c-b702-ab0f8a9e3be5'],['e5d28ed8-e427-4850-81aa-98702d3b6a5d'],"['71225-126-02', '71225-126-05', '71225-126-03', '71225-126-06', '71225-126-01', '71225-126-04']",['1018WH7F9I'],,,,,,,,,
Revised,02/20/2018,55150-249-50,Bupivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)",Eugia US LLC,,Current,['ANDA207183'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-249', '55150-167', '55150-168', '55150-169', '55150-170', '55150-171', '55150-172', '55150-250']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
New,10/01/2025,0071-0535-23,Quinapril Hydrochloride Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,10/01/2025,['Cardiovascular'],Tablet,"Accupril, Tablet, 40 mg (NDC 0071-0535-23)",Pfizer Inc.,,To Be Discontinued,['NDA019885'],['ACCUPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Parke-Davis Div of Pfizer Inc'],"['0071-0535', '0071-0527', '0071-0530', '0071-0532', '0071-1205', '0071-1410', '0071-1620', '0071-1840']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['207891', '207892', '207893', '207895', '312748', '312749', '312750', '314203']",['ee20d3b1-a5c8-4510-a931-3872df7b77f4'],['63cf5651-d52c-4d27-9fd4-ed9cd9724dff'],"['0071-0527-23', '0071-0530-23', '0071-0530-40', '0071-0532-23', '0071-0532-40', '0071-0535-23', '0071-1205-23', '0071-1410-23', '0071-1620-23', '0071-1840-23']",['33067B3N2M'],,,,10/01/2025,,,,,
Reverified,02/22/2012,63323-495-27,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-495', '63323-492', '63323-491', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,06/26/2025,0093-5538-01,Eszopiclone Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/26/2025,['Neurology'],Tablet,"Eszopiclone, Tablet, 2 mg (NDC 0093-5538-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA091169'],['ESZOPICLONE'],['ESZOPICLONE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-5538', '0093-5537', '0093-5539']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ESZOPICLONE'],"['485440', '485442', '485465']",['b7cc855f-8510-4cb2-a941-18d3c4472236'],['2435e2f1-bc52-488f-80e9-f1758e354aae'],"['0093-5537-56', '0093-5538-01', '0093-5539-01']",['UZX80K71OE'],,,,06/26/2025,,,,,
New,07/23/2025,0832-1015-50,Amantadine Hydrochloride Capsule,763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Antiviral', 'Neurology']",Capsule,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-50)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA070589'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-1015'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849389'],['398493aa-8a67-10e2-e063-6394a90aef8d'],['5232b933-1df9-43b4-8ac2-61bfa4855e68'],"['0832-1015-00', '0832-1015-50']",['M6Q1EO9TD0'],,,,07/23/2025,,,,,
New,07/23/2025,0245-5315-01,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['KLOR-CON'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0245-5315', '0245-5316']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953', '628958', '832718']",['39e77e07-bdc8-28e9-e063-6394a90a120c'],['1ff53330-065c-4213-9c0c-ac498621d09d'],"['0245-5315-11', '0245-5315-15', '0245-5315-89', '0245-5315-01', '0245-5316-11', '0245-5316-15', '0245-5316-89', '0245-5316-01']",['660YQ98I10'],,,,07/23/2025,,,,,
Revised,12/08/2023,0054-0548-44,Lidocaine Hydrochloride Solution,800-631-2174,,,08/29/2025,['Anesthesia'],Solution,"Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-0548-44)","Hikma Pharmaceuticals USA, Inc.",,Resolved,,,,,,,,,,,,,,,,,,,,08/29/2025,,Available
Reverified,09/24/2019,48102-053-05,Echothiophate Iodide Ophthalmic Solution,516-277-1449,Available,Available through limited distribution by Walgreens Specialty Pharmacy.,09/17/2025,['Ophthalmology'],Ophthalmic Solution,"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)",Fera Pharmaceuticals,,Current,['NDA011963'],['PHOSPHOLINE IODIDE'],['ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION'],"['Fera Pharmaceuticals, LLC']",['48102-053'],['HUMAN PRESCRIPTION DRUG'],['OPHTHALMIC'],,"['205739', '310049']",['66abcfcf-b16e-4181-b1db-96bfba0ab95e'],['8afc8951-db76-4f27-8752-7c0d6aa47244'],"['48102-053-05', '48102-054-05', '48102-055-05']",,,,,,,,,,
Reverified,11/23/2021,0409-4887-99,Sterile Water Injection,844-646-4398,Available,,10/23/2025,['Other'],Injection,"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)","Hospira, Inc., a Pfizer Company",,Current,['NDA018801'],['STERILE WATER'],['WATER'],"['Hospira, Inc.']",['0409-4887'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['900859c0-a075-4fb1-98ce-0e329acc009a'],['2b9ea23a-f9e9-48a8-25b7-519e3bbd6828'],"['0409-4887-25', '0409-4887-99', '0409-4887-31', '0409-4887-05', '0409-4887-17', '0409-4887-10', '0409-4887-32', '0409-4887-34', '0409-4887-23', '0409-4887-20', '0409-4887-24', '0409-4887-50']",['059QF0KO0R'],,,,,,,,,
New,10/10/2025,0781-3519-90,Pemetrexed Disodium Injection,800-525-8747,,Discontinuation of the manufacture of the drug,10/10/2025,['Oncology'],Injection,"Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90)",Sandoz Inc.,,To Be Discontinued,['NDA214657'],['PEMETREXED'],['PEMETREXED DISODIUM'],['Sandoz Inc.'],"['0781-3519', '0781-3518', '0781-3520']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PEMETREXED DISODIUM'],"['2602363', '2602365', '2602366']",['770c3cd5-b229-4666-b004-ca43e69fbade'],['7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3'],"['0781-3518-76', '0781-3519-90', '0781-3520-91']",['2PKU919BA9'],,,,10/10/2025,,,,,
New,11/03/2025,60951-602-85,Acetaminophen; Oxycodone Hydrochloride Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,11/03/2025,['Analgesia/Addiction'],Tablet,"Percocet, Tablet, 325 mg; 5 mg (NDC 60951-602-85)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA040330'],['ENDOCET'],['OXYCODONE AND ACETAMINOPHEN'],"['ENDO USA, Inc.']","['60951-602', '60951-700', '60951-712', '60951-701']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ACETAMINOPHEN', 'OXYCODONE HYDROCHLORIDE']","['1049214', '1049216', '1049221', '1049223', '1049225', '1049227', '1049635', '1487288']",['2a088d17-73b2-457f-99f6-efcd32f648a5'],['944d3e60-7eee-11de-a413-0002a5d5c51b'],"['60951-602-70', '60951-602-85', '60951-700-70', '60951-712-70', '60951-701-70']","['C1ENJ2TE6C', '362O9ITL9D']",,,,11/03/2025,,,,,
Reverified,02/14/2022,0990-7923-13,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7923', '0990-7922', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Revised,12/30/2020,0143-9785-10,Valproate Sodium Injection,800-631-2174,Available,Additional lots will be available.  Product will be made available as it is released.,10/24/2025,['Neurology'],Injection,"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA078523'],['VALPROATE SODIUM'],['VALPROATE SODIUM'],['Hikma Pharmaceuticals USA Inc.'],['0143-9785'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['VALPROATE SODIUM'],['1099648'],['0610e50d-6447-4a0e-bc36-dc0bffa95c7d'],['bcf57b31-4811-4104-82b3-46fb91a53ee0'],"['0143-9785-01', '0143-9785-10']",['5VOM6GYJ0D'],,,,,,,,,
New,04/28/2025,0832-0465-60,Nystatin Topical Powder,800-654-2299,,,04/28/2025,"['Anti-Infective', 'Dermatology']",Topical Powder,"Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-60)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA065183'],['NYAMYC'],['NYSTATIN'],"['Upsher-Smith Laboratories, LLC']",['0832-0465'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['NYSTATIN'],"['584414', '646456']",['3984f88f-d61f-1fa9-e063-6394a90acb11'],['01b44f91-9b68-464a-9693-b5d3e793bf3c'],"['0832-0465-15', '0832-0465-30', '0832-0465-60']",['BDF1O1C72E'],"['N0000175498', 'M0017172']",['Polyene Antifungal [EPC]'],,04/28/2025,,['Polyenes [CS]'],,,
Reverified,06/13/2018,0143-9595-25,Lidocaine Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA084625'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9595', '0143-9594']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737566', '1737761']",['94a2c3cf-9d57-4185-884d-e52af6c139c8'],['1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1'],"['0143-9595-01', '0143-9595-25', '0143-9594-01', '0143-9594-25']",['V13007Z41A'],,,,,,,,,
Reverified,02/14/2022,0338-9147-30,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9147-30)",Baxter Healthcare,,Current,['NDA020179'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Company'],"['0338-9147', '0338-9143']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795616']",['539f43d0-ac05-4261-a87d-8b34b07e0dd7'],['0bfb32b2-d034-4219-a055-3448f0c424f7'],"['0338-9147-30', '0338-9143-30']",['LX22YL083G'],,,,,,,,,
New,01/23/2025,0591-2880-01,"Verapamil Hydrochloride Capsule, Extended Release",800-545-8800,,,01/23/2025,['Cardiovascular'],"Capsule, Extended Release","Verelan, Capsule, Extended Release, 120 mg (NDC 0591-2880-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA019614'],['VERAPAMIL HYDROCHLORIDE'],['VERAPAMIL HYDROCHLORIDE'],['Teva Pharmaceuticals Inc'],"['0591-2880', '0591-2882', '0591-2884', '0591-2886']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VERAPAMIL HYDROCHLORIDE'],['897624'],['319554df-fc0d-428a-9799-a352100f1ce9'],['0742cf97-601b-4c13-a6c3-1a6a616ed292'],"['0591-2880-01', '0591-2882-01', '0591-2884-01', '0591-2886-01']",['V3888OEY5R'],,,,01/23/2025,,,,,
New,02/05/2025,50242-121-01,Pirfenidone Capsule,800-551-2231,,,02/05/2025,['Pulmonary/Allergy'],Capsule,"Esbriet, Capsule, 267 mg (NDC 50242-121-01)","Genentech, Inc",,To Be Discontinued,['NDA022535'],['ESBRIET'],['PIRFENIDONE'],"['Genentech, Inc.']","['50242-121', '50242-122', '50242-123']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PIRFENIDONE'],"['1592279', '1592285', '1868014', '1868016', '1868018', '1868020']",['98714ede-f5d3-4338-aa0f-bbadaf339b85'],['2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e'],"['50242-121-01', '50242-122-86', '50242-122-06', '50242-123-01']",['D7NLD2JX7U'],"['N0000191420', 'M0018236']",['Pyridone [EPC]'],,02/05/2025,,['Pyridones [CS]'],,,
Revised,06/13/2018,55150-254-10,Lidocaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)",Eugia US LLC,Demand increase for the drug,Current,['ANDA207182'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-254', '55150-251', '55150-252', '55150-255', '55150-253', '55150-256']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', '0b1f03c2-db2f-4f90-acc0-d73abd731bf6']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', 'ef782e5e-e2d7-465a-99c6-b12611f3158c']","['55150-251-24', '55150-252-24', '55150-254-24', '55150-255-24', '55150-251-10', '55150-252-20', '55150-253-50', '55150-254-10', '55150-255-20', '55150-256-50']",['V13007Z41A'],,,,,,,,,
Reverified,11/06/2017,0338-1075-02,Dobutamine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)",Baxter Healthcare,,Current,['NDA020255'],['DOBUTAMINE HYDROCHLORIDE IN DEXTROSE'],['DOBUTAMINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-1075', '0338-1073', '0338-1077']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],"['309985', '309986', '309987']",['2ac85da3-8337-4b3b-8cda-d9399780542f'],['6b17b98b-e06d-42ed-925f-69aa2699dead'],"['0338-1073-02', '0338-1075-02', '0338-1077-02']",['0WR771DJXV'],,,,,,,,,
New,07/28/2025,0049-3170-30,Voriconazole Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,07/28/2025,['Anti-Infective'],Tablet,"Vfend, Tablet, 50 mg (NDC 0049-3170-30)",Pfizer Inc.,,To Be Discontinued,['NDA021266'],['VFEND'],['VORICONAZOLE'],['Roerig'],"['0049-3170', '0049-3180', '0049-3190', '0049-3160']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VORICONAZOLE'],"['349434', '349435', '351209', '352218', '352219', '352220', '465355', '546624']",['c73f8708-e113-451e-a49b-ed5da19e60db'],['ce3ef5cf-3087-4d92-9d94-9eb8287228db'],"['0049-3170-30', '0049-3180-30', '0049-3190-28', '0049-3160-44']",['JFU09I87TR'],"['N0000175487', 'M0002083', 'N0000182141', 'N0000182140', 'N0000185504']",['Azole Antifungal [EPC]'],,07/28/2025,,['Azoles [CS]'],,"['Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]', 'Cytochrome P450 2C9 Inhibitors [MoA]']",
Reverified,10/12/2022,11534-195-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",732-382-6085 Monday to Friday 9 am to 3:45 pm,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)","Sunrise Pharmaceutical, Inc.",,Current,['ANDA209799'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['SUNRISE PHARMACEUTICAL, INC.']","['11534-195', '11534-190', '11534-191', '11534-192', '11534-193', '11534-194', '11534-196']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['86a00bec-51eb-4d73-a945-b1937970b29a'],['ac102599-3a5b-4154-899e-6ff262be7ff7'],"['11534-190-01', '11534-190-03', '11534-191-01', '11534-191-03', '11534-192-01', '11534-192-03', '11534-193-01', '11534-193-03', '11534-194-01', '11534-194-03', '11534-195-01', '11534-195-03', '11534-196-01', '11534-196-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,10/12/2022,64850-502-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",888-852-6657,Limited Availability,3 months,11/04/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA211352'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Elite Laboratories, Inc.']","['64850-502', '64850-500', '64850-501', '64850-503', '64850-504', '64850-505', '64850-506']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['b65e0266-7172-4730-8f93-eb42e08fb7b8'],['e677690f-790f-4626-ad78-097cdb6ea540'],"['64850-500-01', '64850-500-05', '64850-500-30', '64850-501-01', '64850-501-05', '64850-501-30', '64850-502-01', '64850-502-05', '64850-502-30', '64850-503-01', '64850-503-05', '64850-503-30', '64850-504-01', '64850-504-05', '64850-504-30', '64850-505-01', '64850-505-05', '64850-505-30', '64850-506-01', '64850-506-05', '64850-506-30']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/14/2022,0990-7922-09,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7922', '0990-7923', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Reverified,02/20/2018,63323-464-17,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)","Fresenius Kabi USA, LLC",,Current,"['ANDA070552', 'NDA018304']",['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-464', '63323-466', '63323-462', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1724880', '1724881', '1725078', '1725175', '1724884', '1724885', '1725082', '1725177', '1672917', '1672919', '1673296', '1673298', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['b41b5dbd-7aff-4d97-ac97-f4355393ee4e', 'd3ba9fb9-63c8-4597-bb0a-cd01d31a24b6', '13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['e700eb7b-8b14-49c9-96b2-331f18776e45', 'b6bfc04a-1868-4630-9ca1-8c027af97ce3', 'dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-464-01', '63323-464-17', '63323-466-03', '63323-466-17', '63323-464-08', '63323-464-38', '63323-466-08', '63323-466-38', '63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,01/19/2023,43547-411-09,Quinapril Hydrochloride Tablet,866-931-9829,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,11/05/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA205823'],['QUINAPRIL'],['QUINAPRIL'],"['Solco Healthcare US, LLC']","['43547-411', '43547-410', '43547-412', '43547-413']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['b8f1731a-cbac-4f64-a8d4-320b80b335e1'],['cd46691d-5593-4a9f-a937-999c6803e312'],"['43547-410-09', '43547-411-09', '43547-412-09', '43547-413-09']",['33067B3N2M'],,,,,,,,,
Reverified,10/12/2022,64850-500-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",888-852-6657,Limited Availability,3 months,11/04/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA211352'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Elite Laboratories, Inc.']","['64850-500', '64850-501', '64850-502', '64850-503', '64850-504', '64850-505', '64850-506']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['b65e0266-7172-4730-8f93-eb42e08fb7b8'],['e677690f-790f-4626-ad78-097cdb6ea540'],"['64850-500-01', '64850-500-05', '64850-500-30', '64850-501-01', '64850-501-05', '64850-501-30', '64850-502-01', '64850-502-05', '64850-502-30', '64850-503-01', '64850-503-05', '64850-503-30', '64850-504-01', '64850-504-05', '64850-504-30', '64850-505-01', '64850-505-05', '64850-505-30', '64850-506-01', '64850-506-05', '64850-506-30']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,11/06/2017,0143-9254-25,Dopamine Hydrochloride Injection,800-631-2174,Unavailable,Additional lots will be available in the December 2025 timeframe.  Product will be made available as it is released.,10/24/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA207707'],['DOPAMINE HYDROCHLORIDE'],['DOPAMINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9254', '0143-9252', '0143-9253', '0143-9255']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1743938', '1743941', '1743950', '1743953']",['67349236-e8e3-45ec-a76d-2a0a150d8d59'],['0e499952-46c7-4172-8c70-186312e240a3'],"['0143-9252-01', '0143-9252-25', '0143-9253-01', '0143-9253-25', '0143-9254-01', '0143-9254-25', '0143-9255-01', '0143-9255-25']",['7L3E358N9L'],,,,,,,,,
Reverified,02/20/2018,63323-472-17,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)","Fresenius Kabi USA, LLC",,Current,['ANDA070554'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-472', '63323-463', '63323-461', '63323-468']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012413', '1012417', '1724786', '1724787', '1724809', '1724810', '1867594', '1867596', '1867618', '1867620']",['cc1f6507-eb3e-4398-a1d3-0c56a2099e6b'],['bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb'],"['63323-472-03', '63323-472-17', '63323-472-01', '63323-472-37', '63323-463-01', '63323-463-57', '63323-461-01', '63323-461-57', '63323-468-02', '63323-468-37', '63323-468-01', '63323-468-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,10/11/2024,0941-0679-05,Peritoneal Dialysis Solution,888-229-0001,,,07/07/2025,['Renal'],Solution,"Peritoneal Dialysis, Solution, Various NDCs (NDC 0941-0679-05)",Baxter Healthcare,,Resolved,['NDA021321'],['EXTRANEAL'],"['ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE']",['Vantive US Healthcare LLC'],['0941-0679'],['HUMAN PRESCRIPTION DRUG'],['INTRAPERITONEAL'],"['CALCIUM CHLORIDE', 'ICODEXTRIN', 'MAGNESIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']","['1100742', '1100746']",['3005f010-638d-670e-e063-6294a90af468'],['d5b85158-b0d6-4855-9d07-8d1b3ad9ab71'],"['0941-0679-52', '0941-0679-53', '0941-0679-06', '0941-0679-05']","['M4I0D6VV5M', '2NX48Z0A9G', '02F3473H9O', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,07/07/2025,,Available
Reverified,02/22/2012,63323-496-97,Lidocaine Hydrochloride Injection,888-386-1300,Unavailable,Next release date not available at this time.,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-496', '63323-492', '63323-493']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737636', '1737637', '1737640', '1737641', '1737763', '1737764']",['fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df'],['d5e0d06f-ba1e-44d4-aa89-39d6c146dc23'],"['63323-492-08', '63323-492-97', '63323-493-03', '63323-493-97', '63323-493-01', '63323-493-91', '63323-496-03', '63323-496-97']",['EC2CNF7XFP'],,,,,,,,,
Revised,11/06/2017,0409-2346-32,Dobutamine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: April 2026; Estimated Recovery: June 2026,10/23/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA020201'],['DOBUTAMINE IN DEXTROSE'],['DOBUTAMINE IN DEXTROSE'],"['Hospira, Inc.']","['0409-2346', '0409-2347', '0409-3724']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],"['309985', '309986', '309987']",['2cd41f69-c1ea-44a0-9b56-b6f9d963f6a5'],['9943a961-3b50-4847-8a84-d8414ce38daa'],"['0409-2347-31', '0409-2347-32', '0409-2346-31', '0409-2346-32', '0409-3724-11', '0409-3724-32']",['0WR771DJXV'],,,,,,,,,
Reverified,03/10/2023,72888-153-00,Clonazepam Tablet,sales@advagenpharma.com,Information pending,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-153', '72888-152', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,06/21/2018,0409-4888-50,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-50)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018803'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']","['0409-4888', '0409-1918']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807628', '1807631', '1807637', '1807638']",['9ee88abb-024a-4a3b-9776-1777eaf2f760'],['8eb172da-dcd4-4660-4a8f-ad44a14b4af7'],"['0409-4888-02', '0409-4888-10', '0409-4888-03', '0409-4888-20', '0409-4888-06', '0409-4888-50', '0409-4888-01', '0409-4888-12', '0409-4888-90', '0409-1918-42', '0409-1918-32', '0409-1918-43', '0409-1918-33', '0409-1918-45', '0409-1918-35']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,11/21/2024,0591-3900-87,Memantine Hydrochloride Tablet,800-545-8800,,,11/21/2024,['Neurology'],Tablet,"Namenda, Tablet, Kit (NDC 0591-3900-87)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA021487'],['MEMANTINE HYDROCHLORIDE'],['MEMANTINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0591-3900', '0591-3870', '0591-3875']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],,"['996561', '996571', '996572']",['985e1190-b8a0-4775-9a20-ad1924b14fb2'],['72973b46-f307-4a9e-8fb1-ad2cbccfd736'],"['0591-3870-60', '0591-3870-45', '0591-3870-44', '0591-3875-60', '0591-3875-45', '0591-3875-44', '0591-3900-87']",['JY0WD0UA60'],,,,11/21/2024,,,,,
New,09/29/2025,0781-3443-95,Fondaparinux Sodium Injection,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,09/29/2025,['Hematology'],Injection,"Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95)","Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,To Be Discontinued,['ANDA206812'],['FONDAPARINUX SODIUM'],['FONDAPARINUX SODIUM'],['Sandoz Inc.'],"['0781-3443', '0781-3454', '0781-3465', '0781-3476']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['FONDAPARINUX SODIUM'],"['861356', '861360', '861363', '861365']",['3d5a4b69-462b-7e51-e063-6294a90a0721'],['baa50757-a927-4d56-a933-5d7798fe6ab0'],"['0781-3443-94', '0781-3443-12', '0781-3443-95', '0781-3454-94', '0781-3454-12', '0781-3454-95', '0781-3465-94', '0781-3465-12', '0781-3465-95', '0781-3476-94', '0781-3476-12', '0781-3476-95']",['X0Q6N9USOZ'],,,,09/29/2025,,,,,
Reverified,03/21/2023,0338-3814-50,Clindamycin Phosphate Injection,888-229-0001,Available,,10/22/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)",Baxter Healthcare,,Current,['ANDA208084'],['CLINDAMYCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Baxter Healthcare Company'],"['0338-3814', '0338-3410', '0338-3612']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN PHOSPHATE'],"['309335', '309336', '309339']",['9373fc85-1d70-4907-842a-ae9e2a3958b3'],['78832ac6-04c5-45e0-ae4d-f56d7920dda9'],"['0338-3410-50', '0338-3410-24', '0338-3612-50', '0338-3612-24', '0338-3814-50', '0338-3814-24']",['EH6D7113I8'],,,,,,,,,
Reverified,12/22/2021,42806-799-30,Rifampin Capsule,(718) 276-8600 ext. 3,Unavailable,Discontinuation of the manufacture of the drug.,10/15/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 300 mg (NDC 42806-799-30)","Epic Pharma, LLC",Discontinuation of the manufacture of the drug,Current,['ANDA064150'],['RIFAMPIN'],['RIFAMPIN'],"['EPIC PHARMA, LLC']","['42806-799', '42806-801']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['a4ac02e8-68ac-4e79-8ca5-0939dd002c87'],['0391f1e1-70d4-4b15-8b58-055bb6a385b8'],"['42806-801-30', '42806-801-01', '42806-799-30', '42806-799-60', '42806-799-01', '42806-799-05']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Revised,10/12/2022,13107-070-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(866) 850-2876 or CustomerService@AurobindoUSA.com,Unavailable,Estimated availability February 2026,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)",Aurobindo Pharma USA,Shortage of an active ingredient,Current,['ANDA202424'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Aurolife Pharma, LLC']","['13107-070', '13107-068', '13107-069', '13107-071', '13107-072', '13107-073', '13107-074']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['95842af2-8d9d-4eb1-ba39-86cdbd829a79'],['a582d57f-d191-4ca5-b105-585b2d8a0e3e'],"['13107-068-50', '13107-068-01', '13107-068-25', '13107-068-05', '13107-068-99', '13107-069-50', '13107-069-01', '13107-069-25', '13107-069-05', '13107-069-99', '13107-070-50', '13107-070-01', '13107-070-25', '13107-070-05', '13107-070-99', '13107-071-50', '13107-071-01', '13107-071-25', '13107-071-05', '13107-071-99', '13107-072-50', '13107-072-01', '13107-072-25', '13107-072-05', '13107-072-99', '13107-073-50', '13107-073-01', '13107-073-25', '13107-073-05', '13107-073-99', '13107-074-50', '13107-074-01', '13107-074-25', '13107-074-05', '13107-074-99']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,04/29/2025,0409-1402-12,Heparin Sodium Injection,844-646-4398,,Discontinuation of the manufacture of the drug.,04/29/2025,['Hematology'],Injection,"Heparin Sodium, Injection, 5000 [USP'U]/1 mL (NDC 0409-1402-12)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA088100'],['HEPARIN SODIUM'],['HEPARIN SODIUM'],"['Hospira, Inc.']","['0409-1402', '0409-1316']",['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['HEPARIN SODIUM'],"['1361853', '1659260']",['d77ce65b-d238-4187-aef4-593bc074d335'],['c8c4edd2-ee9e-4558-6b8c-b83adc242a0a'],"['0409-1402-27', '0409-1402-12', '0409-1316-11', '0409-1316-32']",['ZZ45AB24CA'],,,,04/29/2025,,,,,
Revised,04/28/2023,16729-295-33,Carboplatin Injection,"866-941-7875, option 2",Unavailable,Discontinuation of the manufacture of the drug,11/04/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA206775'],['CARBOPLATIN'],['CARBOPLATIN'],"['Accord Healthcare, Inc.']",['16729-295'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['35cf6068-f31a-211b-e063-6294a90a6b53'],['48aa7ef3-9f44-2a08-e054-00144ff88e88'],"['16729-295-31', '16729-295-33', '16729-295-34', '16729-295-12', '16729-295-38']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,12/22/2021,42806-799-05,Rifampin Capsule,(718) 276-8600 ext. 3,Unavailable,Discontinuation of the manufacture of the drug.,10/15/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 300 mg (NDC 42806-799-05)","Epic Pharma, LLC",Discontinuation of the manufacture of the drug,Current,['ANDA064150'],['RIFAMPIN'],['RIFAMPIN'],"['EPIC PHARMA, LLC']","['42806-799', '42806-801']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['a4ac02e8-68ac-4e79-8ca5-0939dd002c87'],['0391f1e1-70d4-4b15-8b58-055bb6a385b8'],"['42806-801-30', '42806-801-01', '42806-799-30', '42806-799-60', '42806-799-01', '42806-799-05']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,02/22/2012,83090-007-10,Lidocaine Hydrochloride Injection,"844-425-3131, SinteticaCS@eversana.com",Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 4% 10X5ML)  is Preservative free.",08/19/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)",Sintetica US,,Current,['ANDA214269'],['NA'],['LIDOCAINE HYDROCHLORIDE'],['Sintetica US LLC'],['83090-007'],['HUMAN PRESCRIPTION DRUG'],['RETROBULBAR'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],['1010844'],['eff2e41b-a181-2c76-e053-2995a90aa8b0'],['a7529e5b-47b1-4148-98dd-65aecc33a8c3'],"['83090-007-01', '83090-007-10']",['EC2CNF7XFP'],,,,,,,,,
Reverified,10/05/2022,55150-222-20,Etomidate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)",Eugia US LLC,Demand increase for the drug,Current,['ANDA206126'],['ETOMIDATE'],['ETOMIDATE'],['Eugia US LLC'],"['55150-222', '55150-221']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['278b160e-cdc4-451e-9405-cb001f443680'],['0820f15a-046b-4185-a2b3-2e4051ee3d82'],"['55150-221-10', '55150-222-20']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Reverified,02/20/2018,63323-460-37,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)","Fresenius Kabi USA, LLC",,Current,['NDA018304'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-460', '63323-465', '63323-467', '63323-464', '63323-466', '63323-462']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012391', '1012396', '1012404', '1012421', '1012455', '1012457', '1672917', '1672919', '1673296', '1673298', '1724880', '1724881', '1724884', '1724885', '1725078', '1725082', '1725175', '1725177']",['2b1a1f80-cb29-4ac1-9e72-20225ed45715'],['eb6d8fee-def4-4c96-9972-695e8cea8ea8'],"['63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,06/13/2025,0093-7201-98,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-98)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076056'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-7201', '0093-0771', '0093-7202']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],"['904458', '904467', '904475']",['72579e23-23ef-4ab7-ad64-24d5ea7997eb'],['99e0e848-f8f3-4b42-b880-8fbc42633948'],"['0093-0771-98', '0093-0771-10', '0093-7201-98', '0093-7201-10', '0093-7202-98', '0093-7202-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
Reverified,07/14/2023,47781-565-01,Lisdexamfetamine Dimesylate Capsule,844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)",Alvogen,,Current,['ANDA214547'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Alvogen Inc.'],"['47781-565', '47781-562', '47781-563', '47781-564', '47781-566', '47781-567', '47781-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['567bb281-4098-07f8-9503-92299dc1c4c6'],['7f2dd6ee-3363-c87c-9693-ed838942556c'],"['47781-562-01', '47781-563-01', '47781-564-01', '47781-565-01', '47781-566-01', '47781-567-01', '47781-568-01']",['SJT761GEGS'],,,,,,,,,
Reverified,02/22/2012,0409-3182-02,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089646'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3182', '0409-1209', '0409-3177', '0409-3178', '0409-3181', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],12/19/2024,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Revised,04/28/2023,0703-4248-01,Carboplatin Injection,800-545-8800,Limited Availability,Limited Availability,10/16/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)","Teva Pharmaceuticals USA, Inc.",Other,Current,['ANDA077269'],['CARBOPLATIN'],['CARBOPLATIN'],"['Teva Parenteral Medicines, Inc.']","['0703-4248', '0703-4244', '0703-4246', '0703-4239']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],"['bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df', 'b943761e-6a46-45a0-bdb4-1fec1e101f8c']","['f330f5a2-2cad-402f-bcbb-26245a753276', 'e176b6ef-2ff6-498b-a9d8-7a634d147f37']","['0703-4244-01', '0703-4246-01', '0703-4248-01', '0703-4239-01', '0703-4244-81', '0703-4246-81', '0703-4248-81', '0703-4239-81']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,03/27/2018,25021-671-66,Ropivacaine Hydrochloride Injection,Sagent: 866-625-1618,Available,Marketed by Sagent Pharmaceuticals,08/26/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)",InfoRLife SA,,Current,['ANDA206166'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Sagent Pharmaceuticals'],"['25021-671', '25021-652']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734347', '1734355', '1734479', '1734481']","['04d1b1c6-1963-4b42-8479-dbf787b6de17', '2eb59cb8-dab8-43f4-ad73-672446e104ca']","['8c5c762f-d266-4b1a-809e-f11bfc89bc2d', '9572b3de-684c-4028-a577-5aa69ba6b02d']","['25021-671-82', '25021-671-87', '25021-652-82', '25021-652-87', '25021-671-66', '25021-671-67']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,0406-5116-01,Lisdexamfetamine Dimesylate Capsule,800-325-8888,Limited Availability,Allocation to all customers. Backorder expected in November with next release in December 2025.,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA211840'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['SpecGx LLC'],"['0406-5116', '0406-5111', '0406-5112', '0406-5113', '0406-5114', '0406-5115', '0406-5117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['3ffc0695-83f7-4898-9fd7-451c0989cfe0'],['806a1c15-0842-4787-b2ad-09a21fd96b37'],"['0406-5111-01', '0406-5112-01', '0406-5113-01', '0406-5114-01', '0406-5115-01', '0406-5116-01', '0406-5117-01']",['SJT761GEGS'],,,,,,,,,
New,06/27/2025,0591-3713-05,Ezetimibe Tablet,800-545-8800,,A business decision was made to discontinue manufacture of the product,06/27/2025,['Cardiovascular'],Tablet,"Ezetimibe, Tablet, 10 mg (NDC 0591-3713-05)","Actavis Pharma, Inc.",,To Be Discontinued,['ANDA200831'],['EZETIMIBE'],['EZETIMIBE'],"['Actavis Pharma, Inc.']",['0591-3713'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['EZETIMIBE'],['349556'],['24aaf5ca-08e0-4db8-9734-cf2a606f8e57'],['f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba'],"['0591-3713-30', '0591-3713-19', '0591-3713-05']",['EOR26LQQ24'],"['N0000008553', 'N0000175911']",['Dietary Cholesterol Absorption Inhibitor [EPC]'],['Decreased Cholesterol Absorption [PE]'],06/27/2025,,,,,
Reverified,04/28/2023,61703-339-22,Carboplatin Injection,844-646-4398,Available,,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)","Hospira, Inc., a Pfizer Company",,Current,['ANDA076517'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']",['61703-339'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0ddf4411-7138-412a-908a-fadf22bdfb79'],['c3ae9880-44bb-4f4e-93d8-8a5e21708a30'],"['61703-339-18', '61703-339-22', '61703-339-50', '61703-339-56']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,10/01/2025,0071-0527-23,Quinapril Hydrochloride Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,10/01/2025,['Cardiovascular'],Tablet,"Accupril, Tablet, 5 mg (NDC 0071-0527-23)",Pfizer Inc.,,To Be Discontinued,['NDA019885'],['ACCUPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Parke-Davis Div of Pfizer Inc'],"['0071-0527', '0071-0530', '0071-0532', '0071-0535', '0071-1205', '0071-1410', '0071-1620', '0071-1840']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['207891', '207892', '207893', '207895', '312748', '312749', '312750', '314203']",['ee20d3b1-a5c8-4510-a931-3872df7b77f4'],['63cf5651-d52c-4d27-9fd4-ed9cd9724dff'],"['0071-0527-23', '0071-0530-23', '0071-0530-40', '0071-0532-23', '0071-0532-40', '0071-0535-23', '0071-1205-23', '0071-1410-23', '0071-1620-23', '0071-1840-23']",['33067B3N2M'],,,,10/01/2025,,,,,
Reverified,07/14/2023,0054-0370-25,Lisdexamfetamine Dimesylate Capsule,800-631-2174,Limited Availability,Available on allocation,10/24/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202827'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-0370', '0054-0660', '0054-0371', '0054-0372', '0054-0373', '0054-0374', '0054-0375']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['5d119550-4386-4bfa-a5d0-bb18e66191b7'],['6740a621-9bec-4178-a4fc-a3fc89f34e0a'],"['0054-0660-25', '0054-0370-25', '0054-0371-25', '0054-0372-25', '0054-0373-25', '0054-0374-25', '0054-0375-25']",['SJT761GEGS'],,,,,,,,,
Revised,12/20/2023,0641-6027-25,Fentanyl Citrate Injection,800-631-2174,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6027', '0641-6024', '0641-6025', '0641-6028', '0641-6026', '0641-6029', '0641-6030', '0641-6247', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
Revised,12/08/2020,0338-0644-03,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)",Baxter Healthcare,,Current,['NDA018931'],['TRAVASOL'],"['LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE']",['Baxter Healthcare Corporation'],['0338-0644'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE HYDROCHLORIDE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['801644', '801648']",['e0279078-016d-48fd-8de1-c894422b33ff'],['8543b5be-0f43-4891-9e56-d7c39fe839b5'],"['0338-0644-03', '0338-0644-04', '0338-0644-06']","['OF5P57N2ZX', '94ZLA3W45F', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'JNJ23Q2COM', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Revised,03/23/2018,55150-195-20,Ropivacaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)",Eugia US LLC,Demand increase for the drug,Current,['ANDA205612'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-195', '55150-196', '55150-197', '55150-198', '55150-199', '55150-200', '55150-201']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734207', '1734347', '1734475', '1734483']",['34725b26-d6e9-4d1b-95a0-da03764cc102'],['3763b7b6-da49-4658-b93d-28f5da24d09e'],"['55150-195-20', '55150-196-99', '55150-197-20', '55150-198-30', '55150-199-20', '55150-200-10', '55150-201-20']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,0527-4667-37,Lisdexamfetamine Dimesylate Capsule,844-834-0530,Unavailable,Unavailable,11/03/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA215802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Lannett Company, Inc.']","['0527-4667', '0527-4661', '0527-4662', '0527-4663', '0527-4664', '0527-4665', '0527-4666']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7ac942a6-689a-420b-87bf-dc59003400dc'],['2cedb4c2-1e40-4bc4-b9f4-127150c4afbd'],"['0527-4661-37', '0527-4662-37', '0527-4663-37', '0527-4664-37', '0527-4665-37', '0527-4666-37', '0527-4667-37']",['SJT761GEGS'],,,,,,,,,
Reverified,01/01/2012,63323-806-50,Fentanyl Citrate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)","Fresenius Kabi USA, LLC",Other,Current,['ANDA210762'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Fresenius Kabi USA, LLC']",['63323-806'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270']",['341b092a-1f6f-40f1-98f2-9346bf2e1242'],['38d0c14a-a0c1-44cc-a939-0304eb8037d6'],"['63323-806-11', '63323-806-01', '63323-806-12', '63323-806-02', '63323-806-13', '63323-806-05', '63323-806-14', '63323-806-20', '63323-806-50']",['MUN5LYG46H'],,,,,,,,,
Revised,02/17/2015,0143-9935-01,"Cefotaxime Sodium Powder, for Solution",800-631-2174,Unavailable,Shortage duration is unknown at this time.,10/24/2025,"['Anti-Infective', 'Pediatric']","Powder, For Solution","Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA065071'],['CEFOTAXIME'],['CEFOTAXIME'],['Hikma Pharmaceuticals USA Inc.'],['0143-9935'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CEFOTAXIME SODIUM'],['309065'],['e25af43f-54cb-4526-a8a5-6bef0a7939c7'],['ef1a6dc6-bc3d-4f09-8f92-7ff328f56561'],['0143-9935-01'],['258J72S7TZ'],,,,,,,,,
New,01/08/2025,72162-2169-3,Ramelteon Tablet,866-732-3952,,,01/08/2025,['Other'],Tablet,"Tablet, 8 mg (NDC 72162-2169-3)","Dr. Reddy's Laboratories, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/08/2025,,,,,
Reverified,07/14/2023,65162-024-09,Lisdexamfetamine Dimesylate Capsule,866-525-7270,Unavailable,Shortage of an active ingredient,11/07/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)",Amneal Pharmaceuticals,Shortage of an active ingredient,Current,['ANDA202830'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Amneal Pharmaceuticals LLC'],"['65162-024', '65162-023', '65162-025', '65162-026', '65162-027', '65162-028']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850']",['5fde01e6-09ba-4a92-bd47-aad0d7c518e4'],['c11cb3b6-3dff-477b-a249-b4c3118edc5f'],"['65162-023-09', '65162-024-09', '65162-025-09', '65162-026-09', '65162-027-09', '65162-028-09']",['SJT761GEGS'],,,,,,,,,
Reverified,04/07/2020,23155-473-44,Furosemide Injection,855-228-9470,Available,,11/03/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)","Avet Pharmaceuticals, Inc.",,Current,['ANDA203428'],['FUROSEMIDE'],['FUROSEMIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],['23155-473'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['936eaafa-5088-4ebc-85bc-685ffb85c81f'],['1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec'],"['23155-473-31', '23155-473-41', '23155-473-32', '23155-473-42', '23155-473-43', '23155-473-33', '23155-473-44', '23155-473-45']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,04/10/2020,0143-9532-25,Dexmedetomidine Hydrochloride Injection,800-631-2174,Unavailable,Additional lots will be available in the January 2026 timeframe.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA205046'],['DEXMEDETOMIDINE HCL'],['DEXMEDETOMIDINE HCL'],['Hikma Pharmaceuticals USA Inc.'],['0143-9532'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['309710'],['27ff2cf4-825d-4e29-bd8d-ffccffa13c74'],['de6f01a2-9f2d-4c68-9c02-06643704acb1'],"['0143-9532-01', '0143-9532-25']",['1018WH7F9I'],,,,,,,,,
New,01/13/2025,0069-0296-30,Talazoparib Tosylate Capsule,800-533-4535,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0353-30",01/13/2025,['Oncology'],Capsule,"Talzenna, Capsule, .25 mg (NDC 0069-0296-30)",Pfizer Inc.,,To Be Discontinued,['NDA211651'],['TALZENNA'],['TALAZOPARIB'],['Pfizer Laboratories Div Pfizer Inc'],"['0069-0296', '0069-1195', '0069-1501', '0069-1751', '0069-1031', '0069-1235']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TALAZOPARIB TOSYLATE'],"['2099946', '2099952', '2099954', '2099956', '2591510', '2591512', '2591520', '2591521', '2639960', '2639962', '2639964', '2639966']",['2cb65f61-9a14-46d9-85a3-a7eea76160c5'],['f2423edd-6d24-495c-aec1-c2f457f08d9a'],"['0069-0296-30', '0069-1195-30', '0069-1501-30', '0069-1751-30', '0069-1031-30', '0069-1235-30']",['02WK9U5NZC'],,,,01/13/2025,,,,,
Revised,12/15/2021,55150-314-01,Methylprednisolone Acetate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)",Eugia US LLC,Demand increase for the drug,Current,['ANDA211930'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Eugia US LLC'],"['55150-314', '55150-313']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358610', '1358617']",['a0cbcdb5-f657-49f7-8f86-cc5959d69db0'],['a0cbcdb5-f657-49f7-8f86-cc5959d69db0'],"['55150-313-25', '55150-313-01', '55150-314-25', '55150-314-01']",['43502P7F0P'],,,,,,,,,
Reverified,03/26/2018,0409-3793-01,Ketorolac Tromethamine Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA074802'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Hospira, Inc.']","['0409-3793', '0409-3795', '0409-3796']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['60f4ed51-f1c1-45d4-b43a-969678901bdd'],['8accbb78-fc64-45d5-69b0-35c23a1d2a2e'],"['0409-3793-19', '0409-3793-01', '0409-3793-25', '0409-3795-19', '0409-3795-01', '0409-3795-25', '0409-3796-19', '0409-3796-01', '0409-3796-25']",['4EVE5946BQ'],,,,,,,,,
Reverified,02/08/2019,63323-165-05,Dexamethasone Sodium Phosphate Injection,888-386-1300,Available,Check wholesalers for inventory.,11/05/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)","Fresenius Kabi USA, LLC",,Current,['ANDA084916'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Fresenius Kabi USA, LLC']",['63323-165'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['1116927', '1812194']","['a832bff9-0bb3-4350-abb5-d57b9417070c', '9dd90418-e564-4bc5-9077-506a1c2c1bce']","['2b626a48-c7aa-4443-9164-a08ff069ccd1', '4fedef4f-ec96-4f36-b2f0-01e243e3b89e']","['63323-165-11', '63323-165-51', '63323-165-13', '63323-165-53', '63323-165-02', '63323-165-01', '63323-165-03', '63323-165-05', '63323-165-30', '63323-165-16', '63323-165-26']",['AI9376Y64P'],,,,,,,,,
Revised,12/10/2021,0264-1800-31,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-31)",B. Braun Medical Inc.,,Resolved,['NDA017464'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],['0264-1800'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807630', '1807631', '1807632']",['7d4ee37f-5016-422c-9f66-e675ae22c46a'],['cc14fafd-3dcd-4fc8-bdbd-6f355c375768'],"['0264-1800-36', '0264-1800-31', '0264-1800-32']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,70860-601-10,Midazolam Hydrochloride Injection,Athenex: 855-273-0154; Alvogen: 973-532-7840,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-10)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,10/11/2024,0264-7750-00,Lactated Ringers Injection,800-227-2862,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-00)",B. Braun Medical Inc.,,Resolved,['NDA019632'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['B. Braun Medical Inc.'],['0264-7750'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847630'],"['f67c6808-1eeb-4299-a0b7-694863bcad5a', 'ed789cd7-83ae-4ec1-a696-e87c1569da49']","['d3d29c8f-c326-4097-814a-7f4e08c67068', 'f6d82772-638c-4584-b9d3-8833669f5963']","['0264-7750-00', '0264-7750-10', '0264-7750-20', '0264-7750-07']","['M4I0D6VV5M', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Reverified,03/10/2023,72888-154-01,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-154', '72888-152', '72888-153']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,12/10/2021,0990-7983-09,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-09)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7983', '0990-7730', '0990-7984', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,08/29/2025,82497-012-04,Methotrexate Injection,224-441-6390,,Discontinuation of the manufacture of the drug,08/29/2025,['Rheumatology'],Injection,"Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)","Assertio Specialty Pharmaceuticals, LLC",,To Be Discontinued,['NDA204824'],['OTREXUP'],['METHOTREXATE'],"['Otter Pharmaceuticals, LLC']","['82497-012', '82497-010', '82497-015', '82497-017', '82497-020', '82497-022', '82497-025']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['METHOTREXATE'],"['1441402', '1441407', '1441411', '1441413', '1441416', '1441418', '1441422', '1441424', '1747179', '1747181', '1747185', '1747187', '1747192', '1747194']",['9aaba145-f343-4498-b754-fb7c78181bd7'],['7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f'],"['82497-010-02', '82497-010-04', '82497-012-02', '82497-012-04', '82497-015-02', '82497-015-04', '82497-017-02', '82497-017-04', '82497-020-02', '82497-020-04', '82497-022-02', '82497-022-04', '82497-025-02', '82497-025-04']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,08/29/2025,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
Reverified,04/07/2020,25021-311-02,Furosemide Injection,866-625-1618,Available,,08/26/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Sagent Pharmaceuticals,,Current,['ANDA213902'],['FUROSEMIDE'],['FUROSEMIDE'],['Sagent Pharmaceuticals'],['25021-311'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['222ce48f-2856-4be2-b16f-6fca38c0dceb'],['d63c1277-dd7e-4d21-9e80-68143f55e2dc'],"['25021-311-02', '25021-311-04', '25021-311-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/10/2023,59651-724-05,Clonazepam Tablet,866-850-2876,Available,,10/15/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)",Aurobindo Pharma USA,,Current,['ANDA075150'],['CLONAZEPAM'],['CLONAZEPAM'],['Aurobindo Pharma Limited'],"['59651-724', '59651-722', '59651-723']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['b1582eb7-af35-45d5-a52e-0e380d08527d'],['b1582eb7-af35-45d5-a52e-0e380d08527d'],"['59651-722-01', '59651-722-99', '59651-723-01', '59651-723-99', '59651-724-01', '59651-724-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,01/26/2024,70726-0304-1,Riluzole Oral Suspension,610-937-6172,Available,,11/03/2025,['Neurology'],Oral Suspension,"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)","EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",,Current,,['TEGLUTIK'],['RILUZOLE'],"['EDW PHARMA, INC']",['70726-0304'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RILUZOLE'],"['2058147', '2675565']",['10e69e6c-1158-96e0-e063-6294a90ac44d'],['0f2b5cfc-a23d-699a-e063-6394a90a67d1'],['70726-0304-1'],['7LJ087RS6F'],"['N0000175740', 'M0483511']",['Benzothiazole [EPC]'],,,https://www.fda.gov/media/185611/download?attachment,['Benzothiazoles [CS]'],,,
New,08/29/2025,82497-017-04,Methotrexate Injection,224-441-6390,,Discontinuation of the manufacture of the drug,08/29/2025,['Rheumatology'],Injection,"Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)","Assertio Specialty Pharmaceuticals, LLC",,To Be Discontinued,['NDA204824'],['OTREXUP'],['METHOTREXATE'],"['Otter Pharmaceuticals, LLC']","['82497-017', '82497-010', '82497-012', '82497-015', '82497-020', '82497-022', '82497-025']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['METHOTREXATE'],"['1441402', '1441407', '1441411', '1441413', '1441416', '1441418', '1441422', '1441424', '1747179', '1747181', '1747185', '1747187', '1747192', '1747194']",['9aaba145-f343-4498-b754-fb7c78181bd7'],['7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f'],"['82497-010-02', '82497-010-04', '82497-012-02', '82497-012-04', '82497-015-02', '82497-015-04', '82497-017-02', '82497-017-04', '82497-020-02', '82497-020-04', '82497-022-02', '82497-022-04', '82497-025-02', '82497-025-04']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,08/29/2025,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
New,03/05/2025,67457-524-33,Ibandronate Sodium Injection,888-282-0125,,,03/05/2025,['Endocrinology/Metabolism'],Injection,"Ibandronate Sodium, Injection, 3 mg/3 mL (NDC 67457-524-33)",Norvium Bioscience LLC,,To Be Discontinued,['ANDA202671'],['IBANDRONATE SODIUM'],['IBANDRONATE SODIUM'],['Mylan Institutional LLC'],['67457-524'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['IBANDRONATE SODIUM'],['904952'],['270c89b1-757a-41ef-8067-d9034a4bdc9e'],['a70566e1-cbe5-472a-85ae-08a14117552a'],['67457-524-33'],['J12U072QL0'],,,,03/05/2025,,,,,
Reverified,03/10/2023,43547-407-10,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-407', '43547-406', '43547-408']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,01/01/2020,0409-1141-02,Sodium Chloride 23.4% Injection,844-646-4398,,,07/02/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Chloride, Injection, 400 mEq/100 mL (4 mEq/mL) (NDC 0409-1141-02)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018897'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']",['0409-1141'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],['313016'],['eb5856a5-e97c-4990-9ef1-97c8f221a59a'],['af6aebad-ef03-4d19-9a40-18e5a278b812'],"['0409-1141-12', '0409-1141-02']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Revised,07/26/2023,62037-725-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 18 mg (NDC 62037-725-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA076772'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['62037-725', '62037-734', '62037-726', '62037-727']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['89caac38-0ada-4326-8b3e-65f0d23cbb1b'],['85ef422d-af27-4126-9841-6892af1871d6'],"['62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01']",['4B3SC438HI'],,,,,,,,,
New,02/06/2025,0591-0844-01,"Glipizide Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue manufacture of the drug.,02/06/2025,['Endocrinology/Metabolism'],Tablet,"Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076467'],['GLIPIZIDE ER'],['GLIPIZIDE'],"['Actavis Pharma, Inc.']","['0591-0844', '0591-0900', '0591-0845']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLIPIZIDE'],"['310489', '314006', '315107']",['90e0de65-ed5f-460a-a96f-77d4d76ceedd'],['a430577c-f233-40a7-bfd8-3d2bc6f98aa2'],"['0591-0900-30', '0591-0844-01', '0591-0844-10', '0591-0845-01', '0591-0845-10']",['X7WDT95N5C'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,02/06/2025,,['Sulfonylurea Compounds [CS]'],,,
Reverified,03/10/2023,0093-0832-05,Clonazepam Tablet,800-545-8800,Available,,10/16/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA074569'],['CLONAZEPAM'],['CLONAZEPAM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-0832', '0093-3212', '0093-3213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['d6abe4e3-7699-4ead-95f4-739a961b23ad'],['8069b1a0-7c06-4252-b44e-e2eef065d9b8'],"['0093-0832-01', '0093-0832-05', '0093-3212-01', '0093-3212-05', '0093-3213-01', '0093-3213-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,03/23/2018,63323-288-10,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-288', '63323-286', '63323-287', '63323-285']",['HUMAN PRESCRIPTION DRUG'],['EPIDURAL'],['ROPIVACAINE HYDROCHLORIDE'],"['905189', '905191', '1734084', '1734086', '1734090', '1734091', '1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484']","['cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c', '75465ceb-e894-487d-aa80-671fa0841fce']","['23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6', '56dfabf7-f7a8-4601-b17a-cb16fb995b0f']","['63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95', '63323-288-25', '63323-288-27']",['V910P86109'],,,,,,,,,
Revised,07/26/2023,62037-726-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-545-8800,Limited Availability,Estimated availability: TBD,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 36 mg (NDC 62037-726-01)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA076772'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['62037-726', '62037-725', '62037-734', '62037-727']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['89caac38-0ada-4326-8b3e-65f0d23cbb1b'],['85ef422d-af27-4126-9841-6892af1871d6'],"['62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01']",['4B3SC438HI'],,,,,,,,,
Revised,08/23/2024,66259-936-15,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-15)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
Reverified,02/08/2019,67457-421-30,Dexamethasone Sodium Phosphate Injection,800-796-9526,Available,,11/06/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)","Mylan Institutional, a Viatris Company",,Current,['ANDA040803'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Mylan Institutional LLC'],"['67457-421', '67457-423', '67457-422', '67457-420']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1116927', '1812194']",['dd5c82b6-a194-462c-9626-34a9b410cfea'],['dff598e8-e662-411f-978d-4ba3fb8ef7db'],"['67457-423-00', '67457-423-12', '67457-422-00', '67457-422-54', '67457-421-00', '67457-421-30', '67457-420-00', '67457-420-10']",['AI9376Y64P'],,,,,,,,,
Reverified,03/03/2025,0574-4022-35,Bacitracin Ophthalmic Ointment,866-634-9120,Unavailable,Shortage is estimated for 18 months,09/17/2025,"['Anti-Infective', 'Ophthalmology']",Ophthalmic Ointment,"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)",Padagis US LLC,Discontinuation of the manufacture of the drug,Current,['ANDA061212'],['BACITRACIN'],['BACITRACIN'],['Padagis US LLC'],['0574-4022'],['HUMAN PRESCRIPTION DRUG'],['OPHTHALMIC'],['BACITRACIN'],['308508'],['cad3576e-8534-4132-ac3b-13919e15dc01'],['6ed2f2bd-9d2f-46af-a44c-95a02ca034de'],"['0574-4022-11', '0574-4022-01', '0574-4022-13', '0574-4022-35']",['58H6RWO52I'],['N0000008479'],,['Decreased Cell Wall Synthesis & Repair [PE]'],,,,,,
Reverified,07/26/2023,13811-710-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Limited Availability,Allocation to current contracted customers,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)","Trigen Laboratories, LLC",Demand increase for the drug,Current,['ANDA205327'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Trigen Laboratories, LLC']","['13811-710', '13811-709', '13811-706', '13811-707', '13811-708']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461']",['54f7316b-8a84-4145-aecf-f380afbf261b'],['c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f'],"['13811-709-10', '13811-706-10', '13811-707-10', '13811-708-10', '13811-710-10', '13811-710-30']",['4B3SC438HI'],,,,,,,,,
Reverified,10/31/2017,0409-2634-01,Hydromorphone Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA078591'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']",['0409-2634'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['1724338', '1724340', '1724341']",['f0c8c83c-fb41-4571-a72e-6542311351dd'],['3832ede8-d3fc-455d-ecab-3b77be5869f5'],"['0409-2634-10', '0409-2634-01', '0409-2634-25', '0409-2634-05', '0409-2634-50']",['L960UP2KRW'],,,,,,,01/02/2025,,
Reverified,12/08/2020,0338-1130-04,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)",Baxter Healthcare,,Current,['ANDA075880'],['PREMASOL - SULFITE-FREE (AMINO ACID)'],"['LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE']",['Baxter Healthcare Company'],"['0338-1130', '0338-1131']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'CYSTEINE HYDROCHLORIDE', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'TAURINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['801395', '801398', '801403', '801405']",['4083b5c8-ad5f-43f6-ab19-3c87acb2883f'],['9afdcc3e-0d06-47f4-86ca-40da48b2b02b'],"['0338-1130-03', '0338-1130-04', '0338-1130-06', '0338-1131-03']","['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', 'ZT934N0X4W', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '1EQV5MLY3D', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
New,02/20/2025,0023-6147-30,Silodosin Capsule,800-633-9110,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,02/20/2025,['Urology'],Capsule,"Rapaflo, Capsule, 4 mg (NDC 0023-6147-30)",AbbVie Inc.,,To Be Discontinued,['NDA022206'],['RAPAFLO'],['SILODOSIN'],"['Allergan, Inc.']","['0023-6147', '0023-6142']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SILODOSIN'],"['809477', '809481', '826612', '826614']",['34eec0b8-ef99-4d69-bd3f-da1373da2e49'],['da0314f6-b1d6-44ee-8b1e-f763dbb8613f'],"['0023-6142-90', '0023-6142-30', '0023-6147-30']",['CUZ39LUY82'],"['N0000000099', 'N0000175553']",['alpha-Adrenergic Blocker [EPC]'],,02/20/2025,,,,['Adrenergic alpha-Antagonists [MoA]'],
Revised,12/15/2021,70121-1573-5,Methylprednisolone Acetate Injection,866-525-7270,Available,Next supply: week of 11/24/2025,11/07/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)",Amneal Pharmaceuticals,Other,Current,['ANDA210043'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Amneal Pharmaceuticals LLC'],"['70121-1573', '70121-1574']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743855']",['0bdaa3cf-cf32-4959-b87a-65215ac4648d'],['d944240d-2c19-46ba-ad4f-3fbee7b8629c'],"['70121-1573-1', '70121-1573-5', '70121-1574-1', '70121-1574-5']",['43502P7F0P'],,,,,,,,,
New,11/21/2024,0555-0071-01,Isoniazid Tablet,800-545-8800,,Product available through 12/03/2024,11/21/2024,['Anti-Infective'],Tablet,"Tablet, 300 mg (NDC 0555-0071-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA080937'],['ISONIAZID'],['ISONIAZID'],"['Teva Pharmaceuticals USA, Inc.']","['0555-0071', '0555-0066']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ISONIAZID'],"['197832', '311166']",['ead93989-8a7e-4483-917e-388152515e1d'],['9499f1cf-2f46-4047-8b71-90aee7dee854'],"['0555-0066-02', '0555-0071-01', '0555-0071-02']",['V83O1VOZ8L'],['N0000175483'],['Antimycobacterial [EPC]'],,11/21/2024,,,,,
Reverified,02/14/2022,0338-0017-48,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Reverified,12/13/2017,72205-101-07,Bumetanide Injection,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)",MSN Laboratories Private Limited,,Current,['ANDA215364'],['BUMETANIDE'],['BUMETANIDE'],['Novadoz Pharmaceuticals LLC'],"['72205-101', '72205-102']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],"['72205-101-01', '72205-101-07', '72205-102-01', '72205-102-07']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,10/09/2025,0781-2868-92,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-92)",Sandoz Inc.,,To Be Discontinued,['ANDA075757'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],"['0781-2868', '0781-2859']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],"['198051', '199119']",['6a54ba13-eeb3-4c8c-800b-dc9aaf961c3f'],['516170d4-4913-4577-a2d2-f5c52d1e79c6'],"['0781-2859-10', '0781-2859-01', '0781-2859-92', '0781-2859-31', '0781-2868-10', '0781-2868-01', '0781-2868-92', '0781-2868-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Revised,10/12/2022,0555-0974-02,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['0555-0974', '0555-0971', '0555-0775', '0555-0972', '0555-0776', '0555-0777', '0555-0973']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['88468f3d-7d03-4cee-aabf-3abc8c9b5e38'],['cffbbb15-d776-41ae-a8a6-687f2c07bfa4'],"['0555-0971-02', '0555-0775-02', '0555-0972-02', '0555-0776-02', '0555-0777-02', '0555-0973-02', '0555-0974-02']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,12/05/2024,70510-2171-2,Edaravone Injection,855-457-6968,,"A business decision was made to discontinue manufacture of this product. Distribution will end as early as April 1, 2025. The discontinuation of Radicava (edaravone) injection will not impact the commercial availability of Radicava ORS (edaravone) oral suspension.",12/05/2024,['Neurology'],Injection,"Radicava, Injection, 30 mg/100 mL (NDC 70510-2171-2)","Mitsubishi Tanabe Pharma America, Inc.",,To Be Discontinued,['NDA209176'],['RADICAVA'],['EDARAVONE'],"['Mitsubishi Tanabe Pharma America, Inc.']","['70510-2171', '70510-2321', '70510-2322']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['EDARAVONE'],"['1924316', '1924317', '2602117', '2602122']",['abe2c188-af45-49b9-a914-2d9bc12a726f'],['0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11'],"['70510-2171-1', '70510-2171-2', '70510-2321-1', '70510-2321-2', '70510-2323-1', '70510-2322-1', '70510-2324-1']",['S798V6YJRP'],,,,12/05/2024,,,,,
New,07/29/2025,60505-3947-3,Adefovir Dipivoxil Tablet,800-706-5575,,Discontinuation of the manufacture of the drug,07/29/2025,['Antiviral'],Tablet,"Adefovir Dipivoxil, Tablet, 10 mg (NDC 60505-3947-3)",Apotex Corp.,,To Be Discontinued,['ANDA205459'],['ADEFOVIR DIPIVOXIL'],['ADEFOVIR DIPIVOXIL'],['Apotex Corp.'],['60505-3947'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ADEFOVIR DIPIVOXIL'],['881341'],['bd0233d0-e141-a321-66a5-4afd09dbabfe'],['08e07fae-3191-b6a3-c894-d3a8cc53923f'],['60505-3947-3'],['U6Q8Z01514'],,,,07/29/2025,,,,,
New,07/08/2025,0004-0802-85,Oseltamivir Phosphate Capsule,800-551-2231,,Discontinuation of the manufacture of the drug,07/08/2025,['Antiviral'],Capsule,"Tamiflu, Capsule, 30 mg (NDC 0004-0802-85)","Genentech, Inc",,To Be Discontinued,['NDA021087'],['TAMIFLU'],['OSELTAMIVIR PHOSPHATE'],"['Genentech, Inc.']","['0004-0802', '0004-0801', '0004-0800', '0004-0822']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OSELTAMIVIR PHOSPHATE'],"['261315', '312122', '728109', '728111', '728113', '728115', '1115698', '1115700']",['7ab9f8e7-2dd7-4e79-b837-10582f2249ce'],['ee3c9555-60f2-4f82-a760-11983c86e97b'],"['0004-0802-85', '0004-0801-85', '0004-0800-85', '0004-0800-07', '0004-0800-08', '0004-0822-05']",['4A3O49NGEZ'],,,,07/08/2025,,,,,
Reverified,11/01/2023,60505-4743-1,Lisdexamfetamine Dimesylate Capsule,800-706-5575,Available,Product currently available,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)",Apotex Corp.,,Current,['ANDA216944'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Apotex Corp.'],"['60505-4743', '60505-4739', '60505-4740', '60505-4741', '60505-4742', '60505-4744', '60505-4745']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7a3783a0-bb54-a95b-99f4-9d3aa9788649'],['ecad4442-a644-18e3-6ff2-fdbac45eec47'],"['60505-4739-1', '60505-4740-1', '60505-4741-1', '60505-4742-1', '60505-4743-1', '60505-4744-1', '60505-4745-1']",['SJT761GEGS'],,,,,,,,,
New,03/04/2025,65862-582-01,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 2.5 mg; 10 mg (NDC 65862-582-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-582', '65862-583', '65862-584', '65862-585', '65862-586', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
New,01/28/2025,60505-4478-3,Teriflunomide Tablet,800-706-5575,,,01/28/2025,['Neurology'],Tablet,"Teriflunomide, Tablet, 14 mg (NDC 60505-4478-3)",Apotex Corp.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/28/2025,,,,,
Reverified,04/02/2020,0409-2596-03,Midazolam Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)","Hospira, Inc., a Pfizer Company",,Current,['ANDA075293'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2596', '0409-2587']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['923cfac2-557d-40b4-9ee0-3e933685a5fc'],['affecd4d-1f78-4bbe-5a8d-86849bbdc520'],"['0409-2587-04', '0409-2587-05', '0409-2596-13', '0409-2596-03', '0409-2596-15', '0409-2596-05']",['W7TTW573JJ'],,,,,,,,,
Revised,10/12/2022,57844-130-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],['ADDERALL'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['57844-130', '57844-105', '57844-117', '57844-110', '57844-112', '57844-115', '57844-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541365', '541878', '541879', '541892', '541894', '577957', '577960', '577961', '577962', '687043', '687045', '1009145', '1009147']",['79af1dc6-c7cf-41b1-a750-e9b47c2187ff'],['f22635fe-821d-4cde-aa12-419f8b53db81'],"['57844-105-01', '57844-117-01', '57844-110-01', '57844-112-01', '57844-115-01', '57844-120-01', '57844-130-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/14/2022,0990-7923-20,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7923', '0990-7922', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Revised,01/06/2023,0013-2626-81,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 5 mg/mL, w/ preservative (NDC 0013-2626-81)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
New,01/22/2025,64380-154-01,Minocycline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Antiviral'],Tablet,"Minocycline Hydrochloride, Tablet, 50 mg (NDC 64380-154-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA065131'],['MINOCYCLINE HYDROCHLORIDE'],['MINOCYCLINE HYDROCHLORIDE'],['Strides Pharma Science Limited'],"['64380-154', '64380-155', '64380-156']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MINOCYCLINE HYDROCHLORIDE'],"['207362', '207364', '403840']",['73a30dc4-352b-4307-b902-07ffefc99a99'],['d6e136ba-c9b1-4846-ae2a-98a29cb4504d'],"['64380-154-01', '64380-155-01', '64380-156-01']",['0020414E5U'],,,,01/22/2025,,,,,
Revised,01/01/2012,71288-162-30,Leucovorin Calcium Injection,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 71288-162-30)",Kindos Pharmaceuticals Co. Ltd.,,Resolved,['ANDA216590'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Meitheal Pharmaceuticals Inc.'],"['71288-162', '71288-160', '71288-161', '71288-163', '71288-164']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['077a459b-e884-4452-aed3-0857a38ce26f'],['9df20901-6980-4d4e-89ec-40f3c1f91852'],"['71288-160-10', '71288-161-20', '71288-162-30', '71288-163-30', '71288-164-50']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,04/10/2020,0409-1660-20,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1660', '0409-1638', '0409-1434', '0409-1596', '0409-7838', '0409-7853', '0409-7875']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['284397', '309710', '1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['231f50fe-2c91-44b9-946e-33b836c07b94'],['548a88c0-afda-427e-75ac-5af0cfa2224c'],"['0409-1660-55', '0409-1660-50', '0409-1660-35', '0409-1660-10', '0409-1660-22', '0409-1660-20', '0409-1638-32', '0409-1638-02', '0409-1434-01', '0409-1596-01', '0409-1596-10', '0409-7838-01', '0409-7838-24', '0409-7853-01', '0409-7853-24', '0409-7875-01', '0409-7875-12']",['1018WH7F9I'],,,,,,,,,
New,02/26/2025,58151-103-93,"Tolterodine Tartrate Capsule, Extended Release",800-796-9526,,,02/26/2025,['Urology'],"Capsule, Extended Release","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA021228'],['DETROL LA'],['TOLTERODINE TARTRATE'],['Viatris Specialty LLC'],"['58151-103', '58151-104']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOLTERODINE TARTRATE'],"['855182', '855184', '855189', '855191']",['a1e49744-9302-47ee-92af-8b19aa0b2fc1'],['d7274947-4f88-47ee-a39f-bd5ac46fcf8d'],"['58151-103-93', '58151-103-77', '58151-103-05', '58151-104-93', '58151-104-77', '58151-104-05']",['5T619TQR3R'],,,,02/26/2025,,,,,
New,04/28/2025,55154-5623-0,Midodrine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Cardiovascular'],Tablet,"Orvaten, Tablet, 5 mg (NDC 55154-5623-0)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,,,,,,,,,,,,,,,,,04/28/2025,,,,,
New,07/10/2025,72305-050-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 50 ug (NDC 72305-050-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-050', '72305-025', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,11/06/2017,0338-1077-02,Dobutamine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)",Baxter Healthcare,,Current,['NDA020255'],['DOBUTAMINE HYDROCHLORIDE IN DEXTROSE'],['DOBUTAMINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-1077', '0338-1073', '0338-1075']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],"['309985', '309986', '309987']",['2ac85da3-8337-4b3b-8cda-d9399780542f'],['6b17b98b-e06d-42ed-925f-69aa2699dead'],"['0338-1073-02', '0338-1075-02', '0338-1077-02']",['0WR771DJXV'],,,,,,,,,
Reverified,11/23/2021,0409-4887-10,Sterile Water Injection,844-646-4398,Available,,10/23/2025,['Other'],Injection,"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA018801'],['STERILE WATER'],['WATER'],"['Hospira, Inc.']",['0409-4887'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['900859c0-a075-4fb1-98ce-0e329acc009a'],['2b9ea23a-f9e9-48a8-25b7-519e3bbd6828'],"['0409-4887-25', '0409-4887-99', '0409-4887-31', '0409-4887-05', '0409-4887-17', '0409-4887-10', '0409-4887-32', '0409-4887-34', '0409-4887-23', '0409-4887-20', '0409-4887-24', '0409-4887-50']",['059QF0KO0R'],,,,,,,,,
Reverified,10/31/2017,63323-451-01,Morphine Sulfate Injection,888-386-1300,Unavailable,Backordered. Next release November 2025. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)","Fresenius Kabi USA, LLC",Other,Current,['NDA204223'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Fresenius Kabi USA, LLC']","['63323-451', '63323-452', '63323-454', '63323-455', '63323-458']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['1731993', '1732006', '1732011', '1732136', '2003714']",['dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc'],['582f42e5-444e-4246-af8c-e7e28097c69a'],"['63323-452-00', '63323-452-01', '63323-454-00', '63323-454-01', '63323-455-00', '63323-455-01', '63323-458-00', '63323-458-01', '63323-451-00', '63323-451-01']",['X3P646A2J0'],,,,,,,,,
Reverified,02/22/2012,63323-201-02,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)","Fresenius Kabi USA, LLC",,Current,['ANDA088586'],['LIDOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-201', '63323-202']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1737757']",['d19c26f4-1214-40f7-9680-43c885613306'],['cddb2b22-fce3-8967-6e54-dca3df5ac4b3'],"['63323-201-01', '63323-201-02', '63323-201-03', '63323-201-10', '63323-202-01', '63323-202-02']",['V13007Z41A'],,,,,,,,,
Reverified,02/14/2022,65219-460-20,Dextrose Monohydrate 5% Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)","Fresenius Kabi USA, LLC",,Current,['ANDA207449'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['FRESENIUS KABI USA, LLC']","['65219-460', '65219-456', '65219-464', '65219-458', '65219-462']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['efc3b0c9-518a-47db-bb3e-ebdfd4646e9b'],['576a22d8-5f2f-497e-80ad-1842ca74bb53'],"['65219-456-05', '65219-456-60', '65219-464-05', '65219-464-50', '65219-458-05', '65219-458-30', '65219-460-05', '65219-460-20', '65219-462-05', '65219-462-10']",['LX22YL083G'],,,,,,,,,
New,02/04/2025,0472-0117-45,Tretinoin Cream,800-796-9526,,,02/04/2025,['Dermatology'],Cream,"Avita, Cream, .25 mg/1 g (NDC 0472-0117-45)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA020404'],['TRETINOIN'],['TRETINOIN'],"['Actavis Pharma, Inc.']",['0472-0117'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['TRETINOIN'],['106302'],['b99bedbe-3d36-47dd-b84c-05f8bb394b83'],['b5e385a2-f6f9-41cb-8a33-eedba397043f'],"['0472-0117-20', '0472-0117-45']",['5688UTC01R'],"['N0000175607', 'M0018962']",['Retinoid [EPC]'],,02/04/2025,,['Retinoids [CS]'],,,
Revised,10/31/2017,63323-454-01,Morphine Sulfate Injection,888-386-1300,Unavailable,Backordered. Next release December 2025. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)","Fresenius Kabi USA, LLC",Other,Current,['NDA204223'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Fresenius Kabi USA, LLC']","['63323-454', '63323-452', '63323-455', '63323-458', '63323-451']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['1731993', '1732006', '1732011', '1732136', '2003714']",['dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc'],['582f42e5-444e-4246-af8c-e7e28097c69a'],"['63323-452-00', '63323-452-01', '63323-454-00', '63323-454-01', '63323-455-00', '63323-455-01', '63323-458-00', '63323-458-01', '63323-451-00', '63323-451-01']",['X3P646A2J0'],,,,,,,,,
Revised,06/13/2018,55150-251-10,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)",Eugia US LLC,,Current,['ANDA207182'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-251', '55150-252', '55150-254', '55150-255', '55150-253', '55150-256']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', '0b1f03c2-db2f-4f90-acc0-d73abd731bf6']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', 'ef782e5e-e2d7-465a-99c6-b12611f3158c']","['55150-251-24', '55150-252-24', '55150-254-24', '55150-255-24', '55150-251-10', '55150-252-20', '55150-253-50', '55150-254-10', '55150-255-20', '55150-256-50']",['V13007Z41A'],,,,,,,,,
Reverified,11/06/2017,0338-1005-03,Dopamine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)",Baxter Healthcare,,Current,['NDA019615'],['DOPAMINE HYDROCHLORIDE AND DEXTROSE'],['DOPAMINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-1005', '0338-1007', '0338-1009']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743869', '1743871', '1743877', '1743879']",['1b91b75f-c6e4-4425-bea8-023458ecf8f9'],['cb97d4a0-89ed-407c-a763-209386b6f75c'],"['0338-1005-02', '0338-1005-03', '0338-1007-02', '0338-1007-03', '0338-1009-02']",['7L3E358N9L'],,,,,,,,,
Revised,12/27/2023,45567-0060-1,Technetium TC-99M Pyrophosphate Kit Injection,800-818-4555,Limited Availability,Additional supply anticipated early 2026,10/21/2025,['Medical Imaging'],Injection,"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['NDA019039'],['KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE'],['TECHNETIUM TC99M PYROPHOSPHATE'],"['Sun Pharmaceutical Industries, Inc.']",['45567-0060'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['TECHNETIUM TC-99M PYROPHOSPHATE'],,['3010b45e-eed1-a5d0-e063-6294a90a40cf'],['1f0cbd23-2fb3-43b7-b8af-7de246151149'],"['45567-0060-1', '45567-0060-2']",['5L76I61H2B'],"['N0000177914', 'N0000000205']",['Radioactive Diagnostic Agent [EPC]'],,,,,,['Radiopharmaceutical Activity [MoA]'],
Revised,10/31/2017,66794-160-02,Morphine Sulfate Injection,800-414-1901,Available,,11/04/2025,['Analgesia/Addiction'],Injection,"Mitigo (Morphine Sulfate Injection, USP), Injection, 200 mg/20 mL (NDC 66794-160-02)",Piramal Critical Care Inc.,,Current,['ANDA204393'],['MITIGO'],['MORPHINE SULFATE'],"['Piramal Critical Care, Inc.']","['66794-160', '66794-162']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL']",['MORPHINE SULFATE'],"['1731522', '1731998', '2055307', '2055311']",['3f72fcc3-7855-bdf8-e063-6294a90a20b2'],['728f3d83-9a63-0c1f-e053-2a91aa0ac7db'],"['66794-160-02', '66794-162-02']",['X3P646A2J0'],,,,,,,,,
Revised,02/22/2012,0409-4904-34,Lidocaine Hydrochloride Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,['ANDA083158'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4904', '0409-4903', '0409-1323', '0409-9137']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1012066', '1012068']",['477abea3-c873-4265-82e8-5508ef54399f'],['ad1ef0a8-88db-4648-c098-d009eaeb4e5b'],"['0409-4903-11', '0409-4903-34', '0409-4904-11', '0409-4904-34', '0409-1323-15', '0409-1323-05', '0409-9137-11', '0409-9137-05']",['V13007Z41A'],,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d,,12/19/2024,,
Reverified,04/07/2020,70860-302-10,Furosemide Injection,866-625-1618,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-10,08/26/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-10)",Sagent Pharmaceuticals,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,04/28/2023,16729-295-34,Carboplatin Injection,"866-941-7875, option 2",Limited Availability,non-Exempt status from FDA,11/04/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA206775'],['CARBOPLATIN'],['CARBOPLATIN'],"['Accord Healthcare, Inc.']",['16729-295'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['35cf6068-f31a-211b-e063-6294a90a6b53'],['48aa7ef3-9f44-2a08-e054-00144ff88e88'],"['16729-295-31', '16729-295-33', '16729-295-34', '16729-295-12', '16729-295-38']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,11/07/2025,0409-4910-34,Atropine Sulfate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)""","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA021146'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Hospira, Inc.']","['0409-4910', '0409-1630', '0409-9630', '0409-4911']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['9211a9e9-35d0-457d-ac95-4ad43ea6bf28'],['ad8916e7-206e-409e-2582-30d072845dd4'],"['0409-1630-15', '0409-1630-10', '0409-9630-15', '0409-9630-05', '0409-4910-11', '0409-4910-34', '0409-4911-11', '0409-4911-34']",['03J5ZE7KA5'],,,,11/07/2025,,,,,
New,11/21/2024,0591-3875-44,Memantine Hydrochloride Tablet,800-545-8800,,,11/21/2024,['Neurology'],Tablet,"Namenda, Tablet, 10 mg (NDC 0591-3875-44)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA021487'],['MEMANTINE HYDROCHLORIDE'],['MEMANTINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0591-3875', '0591-3870', '0591-3900']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEMANTINE HYDROCHLORIDE'],"['996561', '996571', '996572']",['985e1190-b8a0-4775-9a20-ad1924b14fb2'],['72973b46-f307-4a9e-8fb1-ad2cbccfd736'],"['0591-3870-60', '0591-3870-45', '0591-3870-44', '0591-3875-60', '0591-3875-45', '0591-3875-44', '0591-3900-87']",['JY0WD0UA60'],,,,11/21/2024,,,,,
Revised,01/01/2012,63323-806-01,Fentanyl Citrate Injection,888-386-1300,Unavailable,Next release December 2025. Check wholesalers for inventory.,11/05/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)","Fresenius Kabi USA, LLC",Other,Current,['ANDA210762'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Fresenius Kabi USA, LLC']",['63323-806'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270']",['341b092a-1f6f-40f1-98f2-9346bf2e1242'],['38d0c14a-a0c1-44cc-a939-0304eb8037d6'],"['63323-806-11', '63323-806-01', '63323-806-12', '63323-806-02', '63323-806-13', '63323-806-05', '63323-806-14', '63323-806-20', '63323-806-50']",['MUN5LYG46H'],,,,,,,,,
New,01/10/2025,0409-1610-50,Bupivacaine Hydrochloride Injection,844-646-4398,,"Discontinuation of the manufacture of the drug.
Replaced with NDC 0409-0525-01",01/10/2025,['Anesthesia'],Injection,"Marcaine, Injection, 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1610-50)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1610', '0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,01/10/2025,,,,,
Reverified,01/01/2012,64253-400-91,Atropine Sulfate Injection,630-682-4600,Available,,11/03/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 64253-400-91)","Medefil, Inc.",,Current,['ANDA214970'],['ATROPINE SULFATE'],['ATROPINE SULFATE INJECTION'],"['Medefil, Inc.']",['64253-400'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],['1190546'],['fbfdf718-beff-ad22-e053-6294a90a3715'],['fbfdf718-befe-ad22-e053-6294a90a3715'],"['64253-400-30', '64253-400-91']",['03J5ZE7KA5'],,,,,,,,,
Reverified,02/28/2025,68968-5555-3,"Methylphenidate Film, Extended Release",800-455-8070,Unavailable,Estimated availability TBD,10/02/2025,['Psychiatry'],"Film, Extended Release","Daytrana, Film, Extended Release, 30 mg (NDC 68968-5555-3)","Noven Pharmaceuticals, Inc.",Shortage of an active ingredient,Current,['NDA021514'],['DAYTRANA'],['METHYLPHENIDATE'],"['Noven Therapeutics, LLC']","['68968-5555', '68968-5552', '68968-5553', '68968-5554']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443']",['55f4b5f4-6d3c-4677-a94c-d47ffb59a91a'],['2c312c31-3198-4775-91ab-294e0b4b9e7f'],"['68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
New,05/02/2025,0555-9131-67,Drospirenone; Ethinyl Estradiol Tablet,800-545-8800,,,05/02/2025,['Reproductive'],Tablet,"Ocella, Tablet, Kit (NDC 0555-9131-67)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA021098'],['OCELLA'],['DROSPIRENONE AND ETHINYL ESTRADIOL'],"['TEVA PHARMACEUTICALS USA, INC.']",['0555-9131'],['HUMAN PRESCRIPTION DRUG'],,,"['284207', '748797', '748800', '801185']",['16f205ad-cc9e-4879-9f7c-9cc3577d48fb'],['0d729f4d-2fa3-47f6-8a1f-d8cfea4cff37'],"['0555-9131-79', '0555-9131-67']",,,,,05/02/2025,,,,,
Reverified,10/25/2022,0487-9901-30,Albuterol Sulfate Solution,800-443-4313,Available,"Albuterol 0.5% is in stock, though demand remains high; additional supply can be produced as needed.",10/24/2025,"['Pulmonary/Allergy', 'Pediatric']",Solution,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)",Nephron Pharmaceuticals Corporation,Other,Current,['ANDA075664'],['ALBUTEROL SULFATE'],['ALBUTEROL SULFATE'],['Nephron Pharmaceuticals Corporation'],['0487-9901'],['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],['ALBUTEROL SULFATE'],['245314'],['30dbae21-c906-0624-e063-6394a90a299c'],['ecc00500-58b8-491f-80df-dc6c89a08cae'],"['0487-9901-30', '0487-9901-02']",['021SEF3731'],,,,,,,,,
New,05/14/2025,0832-0038-50,Oxybutynin Chloride Tablet,800-654-2299,,,05/14/2025,['Renal'],Tablet,"Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-50)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074625'],['OXYBUTYNIN CHLORIDE'],['OXYBUTYNIN CHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-0038'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXYBUTYNIN CHLORIDE'],['863664'],['2f3b30f0-e463-2de1-e063-6394a90a1b69'],['3ee6835a-7a7d-49a9-8460-2f1dd270ead3'],"['0832-0038-00', '0832-0038-50', '0832-0038-10', '0832-0038-89', '0832-0038-01']",['L9F3D9RENQ'],,,,05/14/2025,,,,,
Reverified,02/22/2012,63323-486-27,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-486', '63323-492', '63323-491', '63323-495', '63323-485', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,06/26/2025,0093-5539-01,Eszopiclone Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/26/2025,['Neurology'],Tablet,"Eszopiclone, Tablet, 3 mg (NDC 0093-5539-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA091169'],['ESZOPICLONE'],['ESZOPICLONE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-5539', '0093-5537', '0093-5538']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ESZOPICLONE'],"['485440', '485442', '485465']",['b7cc855f-8510-4cb2-a941-18d3c4472236'],['2435e2f1-bc52-488f-80e9-f1758e354aae'],"['0093-5537-56', '0093-5538-01', '0093-5539-01']",['UZX80K71OE'],,,,06/26/2025,,,,,
New,03/18/2025,0781-6185-56,Travoprost Solution/Drops,800-525-8747,,Business related decision to discontinue the product,03/18/2025,['Ophthalmology'],Solution/Drops,"Travatan Z, Solution/Drops, 2.5 mL (NDC 0781-6185-56)",Sandoz Inc.,,To Be Discontinued,['NDA021994'],['TRAVOPROST OPHTHALMIC SOLUTION'],['TRAVOPROST'],['Sandoz Inc'],['0781-6185'],['HUMAN PRESCRIPTION DRUG'],['OPHTHALMIC'],['TRAVOPROST'],['284008'],['c9120f44-4d13-49f1-924f-34e36f35da10'],['c17aa704-1ec6-4610-a448-4964bdb1cba1'],"['0781-6185-56', '0781-6185-75']",['WJ68R08KX9'],"['N0000175454', 'M0017805']",['Prostaglandin Analog [EPC]'],,03/18/2025,,['Prostaglandins [CS]'],,,
New,08/13/2025,66658-230-01,Palivizumab Injection,866-773-5274,,Discontinuation of the manufacture of the drug,08/13/2025,['Antiviral'],Injection,"Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)",Swedish Orphan Biovitrum AB,,To Be Discontinued,['BLA103770'],['SYNAGIS'],['PALIVIZUMAB'],['Swedish Orphan Biovitrum AB (publ)'],"['66658-230', '66658-231']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PALIVIZUMAB'],"['1657341', '1657343', '1657361', '1657362']",['825a4b3c-e419-457c-8862-fd7b74a171ed'],['3a0096c7-8139-44cd-bba4-520ab05c2cb2'],"['66658-231-01', '66658-230-01']",['DQ448MW7KS'],"['M0001357', 'N0000175615', 'N0000175623']",['Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]'],,08/13/2025,,"['Antibodies, Monoclonal [CS]']",,['Fusion Protein Inhibitors [MoA]'],
Reverified,07/14/2023,0378-6858-77,Lisdexamfetamine Dimesylate Capsule,800-796-9526,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA202835'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Mylan Pharmaceuticals Inc.'],"['0378-6858', '0378-6854', '0378-6855', '0378-6856', '0378-6857', '0378-6859', '0378-6860']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['63cd6f7c-f976-440e-a35f-e71a9f2fd1bb'],['efbde0f6-b848-4664-b741-c6c630e66108'],"['0378-6854-77', '0378-6855-77', '0378-6856-77', '0378-6857-77', '0378-6858-77', '0378-6859-77', '0378-6860-77']",['SJT761GEGS'],,,,,,,,,
Reverified,10/05/2022,72572-161-10,Etomidate Injection,800-631-2174,Available,Distributed by Civica,10/24/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA202354'],['ETOMIDATE'],['ETOMIDATE'],"['Civica, Inc.']","['72572-161', '72572-160']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['380f0c88-03f8-4cfa-8823-4766c2f7700c'],['98002094-f065-4b5f-963f-2c34b5241316'],"['72572-160-01', '72572-160-10', '72572-161-01', '72572-161-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Reverified,02/20/2018,70069-753-25,Bupivacaine Hydrochloride Injection,732-554-1037,Available,,08/19/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)","Somerset Therapeutics, LLC",,Current,['ANDA217792'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-753', '70069-752']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404']",['2b24af95-6f20-4945-bf8c-742f1d6f2721'],['bcaab86f-20f0-4482-8d73-e29b36dced58'],"['70069-752-25', '70069-752-10', '70069-752-01', '70069-753-25', '70069-753-01', '70069-753-10']",['7TQO7W3VT8'],,,,,,,,,
New,06/13/2025,0093-0771-98,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-98)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076056'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-0771', '0093-7201', '0093-7202']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],"['904458', '904467', '904475']",['72579e23-23ef-4ab7-ad64-24d5ea7997eb'],['99e0e848-f8f3-4b42-b880-8fbc42633948'],"['0093-0771-98', '0093-0771-10', '0093-7201-98', '0093-7201-10', '0093-7202-98', '0093-7202-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
Reverified,07/14/2023,0406-5114-01,Lisdexamfetamine Dimesylate Capsule,800-325-8888,Limited Availability,Allocation to all customers. Backorder expected in November with next release in December 2025.,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA211840'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['SpecGx LLC'],"['0406-5114', '0406-5111', '0406-5112', '0406-5113', '0406-5115', '0406-5116', '0406-5117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['3ffc0695-83f7-4898-9fd7-451c0989cfe0'],['806a1c15-0842-4787-b2ad-09a21fd96b37'],"['0406-5111-01', '0406-5112-01', '0406-5113-01', '0406-5114-01', '0406-5115-01', '0406-5116-01', '0406-5117-01']",['SJT761GEGS'],,,,,,,,,
Reverified,10/05/2022,72266-146-10,Etomidate Injection,833-291-9645,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",09/29/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)",Gland Pharma Limited,,Current,['ANDA209058'],['ETOMIDATE'],['ETOMIDATE INJECTION'],['Fosun Pharma USA Inc'],"['72266-146', '72266-147']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['2b365133-b609-3285-e063-6394a90a69a6'],['8b6c54d8-3f3f-4290-841c-976bea01086f'],"['72266-146-01', '72266-146-10', '72266-147-01', '72266-147-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
New,02/06/2025,0378-5090-73,Varenicline Tartrate Tablet,800-796-9526,,Permanent discontinuation in the manufacturing of the drug,02/06/2025,['Analgesia/Addiction'],Tablet,"Varenicline Tartrate, Tablet, 1 mg (NDC 0378-5090-73)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['ANDA202019'],['VARENICLINE'],['VARENICLINE'],['Mylan Pharmaceuticals Inc.'],"['0378-5090', '0378-5089', '0378-5091']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VARENICLINE TARTRATE'],"['636671', '636676', '749289']",['5b7b6e3b-f427-4000-b252-968f3adbaa3b'],['4233fb78-ac6c-49f3-aad8-7e4bee18cac6'],"['0378-5089-73', '0378-5090-73', '0378-5091-85', '0378-5089-46', '0378-5090-23']",['82269ASB48'],,,,02/06/2025,,,,,
New,10/31/2025,0603-5165-32,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5165', '0603-5166', '0603-5167', '0603-5168']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
Revised,07/14/2023,0480-3568-01,Lisdexamfetamine Dimesylate Capsule,800-545-8800,Limited Availability,Estimated availability: November 2025,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)","Teva Pharmaceuticals USA, Inc.",Other,Current,['ANDA202802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Teva Pharmaceuticals, Inc.']","['0480-3568', '0480-3565', '0480-3566', '0480-3567', '0480-3569', '0480-3570', '0480-3564']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['6cfe6c98-51b1-45a4-831c-33624ab129cb'],['c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc'],"['0480-3565-01', '0480-3566-01', '0480-3567-01', '0480-3568-01', '0480-3569-01', '0480-3570-01', '0480-3564-01']",['SJT761GEGS'],,,,,,,,,
New,01/06/2025,45963-568-08,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-08)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA202968'],['EZETIMIBE AND SIMVASTATIN'],['EZETIMIBE AND SIMVASTATIN'],"['Actavis Pharma, Inc.']","['45963-568', '45963-565', '45963-566', '45963-567']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['EZETIMIBE', 'SIMVASTATIN']","['476345', '476349', '476350', '476351']",['bd64aee1-c95f-4767-8d31-af93dd0ab692'],['00680bea-d2fb-4362-ba67-e866b732e9ed'],"['45963-565-30', '45963-565-08', '45963-566-30', '45963-566-08', '45963-567-30', '45963-567-08', '45963-568-30', '45963-568-08']","['AGG2FN16EV', 'EOR26LQQ24']","['N0000175589', 'N0000000121', 'N0000008553', 'N0000175911']","['HMG-CoA Reductase Inhibitor [EPC]', 'Dietary Cholesterol Absorption Inhibitor [EPC]']",['Decreased Cholesterol Absorption [PE]'],01/06/2025,,,,['Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]'],
Reverified,02/20/2018,63323-463-57,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Available,Check wholesaler for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)","Fresenius Kabi USA, LLC",,Current,['ANDA070968'],['SENSORCAINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-463', '63323-472', '63323-461', '63323-468']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],"['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012413', '1012417', '1724786', '1724787', '1724809', '1724810', '1867594', '1867596', '1867618', '1867620']",['cc1f6507-eb3e-4398-a1d3-0c56a2099e6b'],['bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb'],"['63323-472-03', '63323-472-17', '63323-472-01', '63323-472-37', '63323-463-01', '63323-463-57', '63323-461-01', '63323-461-57', '63323-468-02', '63323-468-37', '63323-468-01', '63323-468-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,11/21/2023,0641-1495-35,Promethazine Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA083312'],['PROMETHAZINE HYDROCHLORIDE'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-1495', '0641-1496']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992858']",['80a400d2-d293-4180-bfa7-7a8ce0734bc5'],['13d9e59d-eadb-41d5-9f47-9c11a6efb31c'],"['0641-1495-31', '0641-1495-35', '0641-1496-31', '0641-1496-35']",['R61ZEH7I1I'],,,,,,,,,
Revised,07/14/2023,57664-085-88,"Lisdexamfetamine Dimesylate Tablet, Chewable",800-818-4555,Limited Availability,Available Q4 2025,10/21/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA214134'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-085', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
New,06/27/2025,0591-3713-19,Ezetimibe Tablet,800-545-8800,,A business decision was made to discontinue manufacture of the product,06/27/2025,['Cardiovascular'],Tablet,"Ezetimibe, Tablet, 10 mg (NDC 0591-3713-19)","Actavis Pharma, Inc.",,To Be Discontinued,['ANDA200831'],['EZETIMIBE'],['EZETIMIBE'],"['Actavis Pharma, Inc.']",['0591-3713'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['EZETIMIBE'],['349556'],['24aaf5ca-08e0-4db8-9734-cf2a606f8e57'],['f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba'],"['0591-3713-30', '0591-3713-19', '0591-3713-05']",['EOR26LQQ24'],"['N0000008553', 'N0000175911']",['Dietary Cholesterol Absorption Inhibitor [EPC]'],['Decreased Cholesterol Absorption [PE]'],06/27/2025,,,,,
New,04/23/2025,50090-6868-3,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 50090-6868-3)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,,,,,,,,,,,,,,,,,04/23/2025,,,,,
Revised,11/21/2023,0641-6084-25,Promethazine Hydrochloride Injection,800-631-2174,Unavailable,This presentation is temporarily on backorder.,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['ANDA083312'],['PHENERGAN'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6084', '0641-6085']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992462', '992858', '992876']",['7d6e64fc-bbf2-4ea9-b866-8115c448e687'],['481866da-a712-48a5-853f-8e84aacaab6d'],"['0641-6084-01', '0641-6084-25', '0641-6085-01', '0641-6085-25']",['R61ZEH7I1I'],,,,,,,,,
Revised,09/05/2018,0641-6001-25,Lorazepam Injection,800-631-2174,Limited Availability,Lots are being manufactured to meet demand,10/24/2025,['Neurology'],Injection,"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['NDA018140'],['ATIVAN'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6001', '0641-6003', '0641-6002', '0641-6000']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['206819', '206820', '238100', '238101', '1665188', '1665190', '1665326', '1665327']",['209b0091-c890-4f69-a693-d0594c2606fe'],['5fc0e987-61c9-40c4-b0d5-fcea07c8733e'],"['0641-6003-01', '0641-6003-25', '0641-6002-01', '0641-6002-10', '0641-6001-01', '0641-6001-25', '0641-6000-01', '0641-6000-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,07/14/2023,0054-0372-25,Lisdexamfetamine Dimesylate Capsule,800-631-2174,Limited Availability,Available on allocation,10/24/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202827'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-0372', '0054-0660', '0054-0370', '0054-0371', '0054-0373', '0054-0374', '0054-0375']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['5d119550-4386-4bfa-a5d0-bb18e66191b7'],['6740a621-9bec-4178-a4fc-a3fc89f34e0a'],"['0054-0660-25', '0054-0370-25', '0054-0371-25', '0054-0372-25', '0054-0373-25', '0054-0374-25', '0054-0375-25']",['SJT761GEGS'],,,,,,,,,
Reverified,10/05/2022,0409-6695-01,Etomidate Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)","Hospira, Inc., a Pfizer Company",,Current,['NDA018227'],['AMIDATE'],['ETOMIDATE'],"['Hospira, Inc.']",['0409-6695'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008', '1654009', '1654011']",['b59f4852-2843-4a8f-a597-306ebddb259a'],['b7ed5bf8-ba75-44dc-8f81-96b4ad5766be'],"['0409-6695-11', '0409-6695-01', '0409-6695-12', '0409-6695-02']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
New,11/03/2025,60951-701-70,Acetaminophen; Oxycodone Hydrochloride Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,11/03/2025,['Analgesia/Addiction'],Tablet,"Percocet, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA040330'],['ENDOCET'],['OXYCODONE AND ACETAMINOPHEN'],"['ENDO USA, Inc.']","['60951-701', '60951-602', '60951-700', '60951-712']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ACETAMINOPHEN', 'OXYCODONE HYDROCHLORIDE']","['1049214', '1049216', '1049221', '1049223', '1049225', '1049227', '1049635', '1487288']",['2a088d17-73b2-457f-99f6-efcd32f648a5'],['944d3e60-7eee-11de-a413-0002a5d5c51b'],"['60951-602-70', '60951-602-85', '60951-700-70', '60951-712-70', '60951-701-70']","['C1ENJ2TE6C', '362O9ITL9D']",,,,11/03/2025,,,,,
Reverified,02/20/2018,0409-1165-02,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070585'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1165', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,01/08/2025,43598-741-01,Ramelteon Tablet,866-732-3952,,,01/08/2025,['Other'],Tablet,"Tablet, 8 mg (NDC 43598-741-01)","Dr. Reddy's Laboratories, Inc.",,To Be Discontinued,['ANDA091693'],['RAMELTEON'],['RAMELTEON'],['Dr.Reddys Laboratories Inc'],['43598-741'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RAMELTEON'],['577348'],['54220029-c5df-b277-af7e-2786da03bbed'],['b71cd925-1bae-5a6a-072b-941ad6d3ce65'],"['43598-741-30', '43598-741-01', '43598-741-10']",['901AS54I69'],"['N0000175743', 'N0000000250']",['Melatonin Receptor Agonist [EPC]'],,01/08/2025,,,,['Melatonin Receptor Agonists [MoA]'],
Reverified,07/14/2023,65162-028-09,Lisdexamfetamine Dimesylate Capsule,866-525-7270,Unavailable,Shortage of an active ingredient,11/07/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)",Amneal Pharmaceuticals,Shortage of an active ingredient,Current,['ANDA202830'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Amneal Pharmaceuticals LLC'],"['65162-028', '65162-023', '65162-024', '65162-025', '65162-026', '65162-027']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850']",['5fde01e6-09ba-4a92-bd47-aad0d7c518e4'],['c11cb3b6-3dff-477b-a249-b4c3118edc5f'],"['65162-023-09', '65162-024-09', '65162-025-09', '65162-026-09', '65162-027-09', '65162-028-09']",['SJT761GEGS'],,,,,,,,,
New,04/28/2025,0832-7123-11,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7123', '0832-7122', '0832-7124']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
New,01/08/2025,43598-741-10,Ramelteon Tablet,866-732-3952,,,01/08/2025,['Other'],Tablet,"Tablet, 8 mg (NDC 43598-741-10)","Dr. Reddy's Laboratories, Inc.",,To Be Discontinued,['ANDA091693'],['RAMELTEON'],['RAMELTEON'],['Dr.Reddys Laboratories Inc'],['43598-741'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RAMELTEON'],['577348'],['54220029-c5df-b277-af7e-2786da03bbed'],['b71cd925-1bae-5a6a-072b-941ad6d3ce65'],"['43598-741-30', '43598-741-01', '43598-741-10']",['901AS54I69'],"['N0000175743', 'N0000000250']",['Melatonin Receptor Agonist [EPC]'],,01/08/2025,,,,['Melatonin Receptor Agonists [MoA]'],
Revised,02/22/2012,0409-4283-01,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088295'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']",['0409-4283'],['HUMAN PRESCRIPTION DRUG'],"['RETROBULBAR', 'TOPICAL']",['LIDOCAINE HYDROCHLORIDE'],['1010844'],['499e9cfa-ea8d-487c-a8b3-fd7e1917d25f'],['89a4bd73-89f4-4fd7-2c9f-921e1da8f96b'],"['0409-4283-11', '0409-4283-25', '0409-4283-01']",['V13007Z41A'],,,,,,,,,
Revised,11/06/2017,0409-7810-22,Dopamine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,10/23/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018826'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],"['Hospira, Inc.']","['0409-7810', '0409-7809']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743877', '1743879']",['3b4d4d9d-5e19-420f-a447-1ad8346844d9'],['08f23f6e-150d-45ea-098e-f2edf64c21a1'],"['0409-7809-11', '0409-7809-22', '0409-7809-31', '0409-7809-24', '0409-7810-11', '0409-7810-22']",['7L3E358N9L'],,,,,,,,,
Revised,04/28/2023,0338-0004-02,Sterile Water Irrigant,888-229-0001,Available,,10/22/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)",Baxter Healthcare,,Current,['NDA017428'],['STERILE WATER'],['WATER'],['Baxter Healthcare Corporation'],"['0338-0004', '0338-0003']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['43dc7530-ed0a-4976-af2a-0d39a2532fb7'],['ef3e79c5-3f58-4b36-a296-64b7d9a651c1'],"['0338-0003-44', '0338-0003-46', '0338-0003-47', '0338-0004-02', '0338-0004-03', '0338-0004-04', '0338-0004-05']",['059QF0KO0R'],,,,,,,,,
Reverified,04/28/2023,0990-7139-09,Sterile Water Irrigant,1-866-829-9025 or ProductAvailability@icumed.com,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)",Otsuka ICU Medical LLC,Other,Current,['NDA017513'],['STERILE WATER'],['WATER'],['ICU Medical Inc.'],"['0990-7139', '0990-6139', '0990-7973']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['514c37b1-817a-4dae-a2de-3d938ea76e4e'],['e3484bc6-ed7f-43ef-9d49-c131a8dff2dd'],"['0990-6139-22', '0990-6139-03', '0990-7139-09', '0990-7139-36', '0990-7973-05', '0990-7973-07', '0990-7973-08']",['059QF0KO0R'],,,,,https://www.fda.gov/media/182619/download?attachment,,,,
New,10/27/2025,0310-6627-02,Pramlintide Acetate Injection,800-236-9933,,Discontinuation of the manufacture of the drug.,10/27/2025,['Endocrinology/Metabolism'],Injection,"SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02)",AstraZeneca AB,,To Be Discontinued,['NDA021332'],['SYMLINPEN'],['PRAMLINTIDE ACETATE'],['AstraZeneca Pharmaceuticals LP'],"['0310-6627', '0310-6615']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PRAMLINTIDE ACETATE'],"['861042', '861043', '861044', '861045']",['a84753f1-6ac5-4a47-a382-29972938ccaa'],['4aea30ff-eb0d-45c1-b114-3127966328ff'],"['0310-6615-02', '0310-6627-02']",['726I6TE06G'],,,,10/27/2025,,,,,
Revised,02/20/2018,55150-164-02,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)",Eugia US LLC,,Current,['ANDA203082'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-164', '55150-161', '55150-162', '55150-163', '55150-165']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737562', '1737566', '1737568', '1737757', '1737761']","['9916b09d-a116-469d-92d5-60e50ea9782b', '9b60bc92-6093-49f9-a6ba-075104ff7bb5']","['9916b09d-a116-469d-92d5-60e50ea9782b', '89701fac-7536-4f16-87fb-f4cc121e74ee']","['55150-161-09', '55150-162-09', '55150-163-00', '55150-164-09', '55150-165-09', '55150-161-02', '55150-162-05', '55150-163-30', '55150-164-02', '55150-165-05']",['V13007Z41A'],,,,,,,,,
Revised,02/08/2019,55150-305-10,Dexamethasone Sodium Phosphate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 100 mg/10 mL (NDC 55150-305-10)",Eugia US LLC,Demand increase for the drug,Current,['ANDA210967'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Eugia US LLC'],['55150-305'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],['309696'],['46f657ae-77ec-4eca-a1eb-df540d94eded'],['224c34c9-cadc-40cb-a9b7-a9772fd0208e'],"['55150-305-01', '55150-305-10']",['AI9376Y64P'],,,,,,,,,
New,06/13/2025,57844-140-56,Phentermine Hydrochloride Tablet,800-545-8800,,,06/13/2025,['Other'],Tablet,"Adipex-P, Tablet, 37.5 mg (NDC 57844-140-56)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Revised,02/22/2012,0409-4278-01,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088328'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4278', '0409-4713', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'INTRAVENOUS']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
Reverified,10/14/2016,63323-483-27,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-483', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,02/07/2025,65862-117-01,Benazepril Hydrochloride Tablet,866-850-2876,,,02/07/2025,['Cardiovascular'],Tablet,"Benazepril Hydrochloride, Tablet, 20 mg (NDC 65862-117-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA078212'],['BENAZEPRIL HYDROCHLORIDE'],['BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-117', '65862-116', '65862-118']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BENAZEPRIL HYDROCHLORIDE'],"['898687', '898690', '898719']",['65334c7f-e49f-44d9-a6c1-6c1ce6e88fbe'],['09e383a8-e912-4cf7-8fb3-05545af80dd0'],"['65862-116-90', '65862-116-01', '65862-117-90', '65862-117-01', '65862-118-90', '65862-118-01']",['N1SN99T69T'],,,,02/07/2025,,,,,
New,09/09/2025,0409-6535-01,Vancomycin Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,09/09/2025,['Anti-Infective'],Injection,"Vancomycin Hydrochloride, Injection, 1 g Single Dose ADD-Vantage® Glass Vial (NDC 0409-6535-01)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA062933'],['VANCOMYCIN HYDROCHLORIDE'],['VANCOMYCIN HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-6535', '0409-6531', '0409-6534']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['VANCOMYCIN HYDROCHLORIDE'],"['1807513', '1807516', '1807518']",['771a44e0-5858-449c-be36-438a9ff52e67'],['2fd9de3f-a95f-451c-a687-d2e1306e53bf'],"['0409-6531-11', '0409-6531-01', '0409-6535-11', '0409-6535-01', '0409-6534-11', '0409-6534-01']",['71WO621TJD'],,,,09/09/2025,,,,,
New,06/04/2025,0003-3638-10,Atazanavir Sulfate Oral Powder,1-800-332-2056; for Medical Inquiries (1-800-321-1335),,Permanent discontinuation,06/04/2025,['Antiviral'],Oral Powder,"Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)",Bristol Myers Squibb Co.,,To Be Discontinued,['NDA206352'],['REYATAZ'],['ATAZANAVIR'],"['E.R. Squibb & Sons, L.L.C.']","['0003-3638', '0003-3624', '0003-3631', '0003-3622']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ATAZANAVIR SULFATE'],"['402093', '402094', '402246', '402247', '664741', '664743', '1598985', '1598989']",['510c2d51-4943-401c-a008-ea22f61c6938'],['165cff62-b284-4a27-a65d-9ec8a5bfcdd8'],"['0003-3624-12', '0003-3631-12', '0003-3622-12', '0003-3638-10']",['4MT4VIE29P'],,,,06/04/2025,,,,,
Revised,12/08/2023,0121-0950-03,Lidocaine Hydrochloride Solution,800-845-8210,,,08/29/2025,['Anesthesia'],Solution,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-0950-03)",PAI Pharma,,Resolved,['ANDA218138'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['PAI Holdings, LLC dba PAI Pharma']","['0121-0950', '0121-4950']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LIDOCAINE HYDROCHLORIDE'],['1010739'],['8bd8bb07-066a-4c8c-ac5b-76f746318a49'],['d5e23ede-957c-4a32-b1c6-268acb773c31'],"['0121-0950-03', '0121-4950-15', '0121-4950-40']",['V13007Z41A'],,,,,,,08/29/2025,,Available
Reverified,02/14/2022,0409-7100-02,Dextrose Monohydrate 5% Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 12.5 g/250mL (5%) (NDC 0409-7100-02)","Hospira, Inc., a Pfizer Company",,Current,['NDA019466'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Hospira, Inc.']",['0409-7100'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795610', '1795616']",['477c216c-7446-473a-892d-918faf1dc877'],['10e98cb0-31a5-4ad1-3eaa-aa4af387a42d'],"['0409-7100-68', '0409-7100-66', '0409-7100-69', '0409-7100-67', '0409-7100-04', '0409-7100-02']",['LX22YL083G'],,,,,,,,,
New,07/23/2025,0832-5322-10,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-10)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-5322', '0832-5323']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953']",['39e726b1-eab8-fcf4-e063-6394a90a950a'],['616f0de7-8843-44a1-8fa6-274d889286aa'],"['0832-5322-11', '0832-5322-10', '0832-5323-11', '0832-5323-10']",['660YQ98I10'],,,,07/23/2025,,,,,
Revised,07/14/2023,57664-048-88,Lisdexamfetamine Dimesylate Capsule,800-818-4555,Limited Availability,Additional supply anticipated in Q4 2025 followed by early 2026,10/21/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['ANDA214484'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-048', '57664-047', '57664-046', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
New,07/29/2025,61570-072-01,Esterified Estrogens Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,07/29/2025,['Endocrinology/Metabolism'],Tablet,"Menest, Tablet, .3 mg (NDC 61570-072-01)",Pfizer Inc.,,To Be Discontinued,['ANDA084951'],['MENEST'],['ESTERIFIED ESTROGENS'],['Pfizer Laboratories Div Pfizer Inc'],"['61570-072', '61570-073', '61570-074', '61570-075']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ESTROGENS, ESTERIFIED']","['197666', '197667', '197668', '197669', '212039', '212232', '212373', '212464']",['78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb'],['e0141598-0bb2-4cf0-c9b8-6867b34bbb17'],"['61570-072-01', '61570-073-01', '61570-074-01', '61570-075-50']",['3ASP8Q3768'],,,,07/29/2025,,,,,
Reverified,02/20/2018,0409-1559-10,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,02/20/2018,55150-168-30,Bupivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)",Eugia US LLC,,Current,['ANDA203895'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-168', '55150-167', '55150-169', '55150-170', '55150-171', '55150-172', '55150-249', '55150-250']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
Revised,11/21/2023,0641-0928-25,Promethazine Hydrochloride Injection,800-631-2174,Unavailable,This presentation is temporarily on backorder.  Recovery expected in the November - December 2025 timeframe,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['ANDA083312'],['PROMETHAZINE HYDROCHLORIDE'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-0928', '0641-0929']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992858']",['9f14d3f5-ad01-44b5-a2b7-16ed5f501f87'],['4bf3912c-8339-401e-9711-dad6acf15f11'],"['0641-0928-21', '0641-0928-25', '0641-0929-21', '0641-0929-25']",['R61ZEH7I1I'],,,,,,,,,
Revised,11/01/2023,60505-4739-1,Lisdexamfetamine Dimesylate Capsule,800-706-5575,Available,Product currently available,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)",Apotex Corp.,,Current,['ANDA216944'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Apotex Corp.'],"['60505-4739', '60505-4740', '60505-4741', '60505-4742', '60505-4743', '60505-4744', '60505-4745']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7a3783a0-bb54-a95b-99f4-9d3aa9788649'],['ecad4442-a644-18e3-6ff2-fdbac45eec47'],"['60505-4739-1', '60505-4740-1', '60505-4741-1', '60505-4742-1', '60505-4743-1', '60505-4744-1', '60505-4745-1']",['SJT761GEGS'],,,,,,,,,
Reverified,02/14/2022,0338-0017-41,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Reverified,01/19/2023,65862-618-90,Quinapril Hydrochloride Tablet,866-850-2876,Unavailable,Discontinuation of the manufacture of the drug,10/15/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Aurobindo Pharma USA,Discontinuation of the manufacture of the drug,Current,['ANDA202725'],['QUINAPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-618', '65862-617', '65862-619', '65862-620']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['5263abd5-ce46-4918-9bb0-9632861bcbc9'],['93e6e668-5306-4f26-81d8-cbc3a7a5e787'],"['65862-617-30', '65862-617-90', '65862-617-99', '65862-617-55', '65862-617-10', '65862-617-78', '65862-618-30', '65862-618-90', '65862-618-99', '65862-618-55', '65862-618-10', '65862-618-78', '65862-619-30', '65862-619-90', '65862-619-99', '65862-619-19', '65862-619-10', '65862-619-78', '65862-620-30', '65862-620-90', '65862-620-99', '65862-620-39', '65862-620-10', '65862-620-78']",['33067B3N2M'],,,,,,,,,
Reverified,07/26/2023,50458-587-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,Available,,11/04/2025,['Psychiatry'],Tablet,"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)",Janssen Pharmaceuticals,,Current,['NDA021121'],['CONCERTA'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Janssen Pharmaceuticals, Inc.']","['50458-587', '50458-585', '50458-588', '50458-586']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],,['4035a366-ebde-a1aa-e063-6294a90af4c4'],['1a88218c-5b18-4220-8f56-526de1a276cd'],"['50458-585-01', '50458-588-01', '50458-586-01', '50458-587-01']",['4B3SC438HI'],,,,,,,,,
Revised,08/23/2024,66259-937-16,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-16)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
New,11/21/2024,0173-0906-13,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-13)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0906', '0173-0897', '0173-0903', '0173-0911', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Reverified,03/10/2023,0093-3213-01,Clonazepam Tablet,800-545-8800,Available,,10/16/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA074569'],['CLONAZEPAM'],['CLONAZEPAM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-3213', '0093-0832', '0093-3212']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['d6abe4e3-7699-4ead-95f4-739a961b23ad'],['8069b1a0-7c06-4252-b44e-e2eef065d9b8'],"['0093-0832-01', '0093-0832-05', '0093-3212-01', '0093-3212-05', '0093-3213-01', '0093-3213-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,02/03/2016,0409-7299-25,Sodium Acetate Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)","Hospira, Inc., a Pfizer Company",,Current,['NDA018893'],['SODIUM ACETATE'],['SODIUM ACETATE'],"['Hospira, Inc.']",['0409-7299'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE ANHYDROUS'],['1859490'],"['7ed61ab6-b7ad-45ae-b660-0ed685661bc7', 'c434d6ad-d2f5-43eb-81d5-b6165b652aa7']","['ce9a7469-c4ba-4f60-8f7a-47ef0974316e', 'c91ede49-c7cc-47b7-0f93-e6841dd5916a']","['0409-7299-45', '0409-7299-25', '0409-7299-83', '0409-7299-73']",['NVG71ZZ7P0'],,,,,,,,,
New,01/08/2025,61703-161-05,Methotrexate Sodium Injection,844-646-4398,,Discontinuation of the manufacture of the drug,01/08/2025,"['Oncology', 'Rheumatology']",Injection,"Injection, 25 mg/1 mL (NDC 61703-161-05)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA011719'],['METHOTREXATE'],['METHOTREXATE'],"['Hospira, Inc.']","['61703-161', '61703-124']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS', 'SUBCUTANEOUS']",['METHOTREXATE SODIUM'],"['1655956', '1946772']",['6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910'],['bd287e89-32f9-4396-95fa-4b562869f476'],"['61703-124-40', '61703-161-02', '61703-161-05']",['3IG1E710ZN'],,,,01/08/2025,,,,,
New,01/06/2025,45963-566-30,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-30)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/06/2025,,,,,
Reverified,03/23/2018,63323-285-20,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Revised,09/05/2018,0641-6046-10,Lorazepam Injection,800-631-2174,Unavailable,Unavailable,10/24/2025,['Neurology'],Injection,"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)","Hikma Pharmaceuticals USA, Inc.",Regulatory delay,Current,['NDA018140'],['LORAZEPAM'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6046', '0641-6044', '0641-6045', '0641-6047']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['238100', '238101', '1665188', '1665326']",['7c73dbc6-2623-4443-9b05-97dec7a0be2e'],['e9b54e42-04cf-4c62-90e1-36f7b31a4e81'],"['0641-6044-01', '0641-6044-25', '0641-6046-01', '0641-6046-10', '0641-6045-01', '0641-6045-25', '0641-6047-01', '0641-6047-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,06/13/2025,13668-386-90,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-90)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
New,08/15/2025,0591-3984-05,Celecoxib Capsule,800-545-8800,,Discontinuation of the manufacture of the drug,08/15/2025,['Analgesia/Addiction'],Capsule,"Celecoxib, Capsule, 200 mg (NDC 0591-3984-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA200562'],['CELECOXIB'],['CELECOXIB'],"['Actavis Pharma, Inc.']","['0591-3984', '0591-3982', '0591-3983', '0591-3985']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CELECOXIB'],"['205322', '205323', '349514', '686379']",['64c601bc-9b67-400f-9e30-e26de56f2f8b'],['05224473-27dc-4f6d-a52a-c40a7af2f2f4'],"['0591-3982-60', '0591-3983-01', '0591-3983-05', '0591-3984-01', '0591-3984-05', '0591-3985-60']",['JCX84Q7J1L'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,08/15/2025,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Reverified,04/28/2023,61703-262-05,Carboplatin Injection,844-646-4398,Available,,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA076517'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']","['61703-262', '61703-360', '61703-150', '61703-600']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5aa72c15-8033-4559-b257-373371b18958'],['47677091-fd20-49af-933c-c9dd2be21de9'],"['61703-360-18', '61703-150-05', '61703-262-05', '61703-600-05']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,03/25/2020,0088-2102-24,"Rifapentine Tablet, Film Coated",800-633-1610 Option 7,Available,,09/17/2025,['Anti-Infective'],Tablet,"Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)",Sanofi-Aventis U.S. LLC,,Current,['NDA021024'],['PRIFTIN'],['RIFAPENTINE'],['sanofi-aventis U.S. LLC'],['0088-2102'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAPENTINE'],"['242671', '261101']",['ec69d365-607b-45bd-9cc8-5fea540f8b23'],['3a64fb70-b85e-43d9-8bcd-7e893f568ae1'],"['0088-2102-01', '0088-2102-24']",['XJM390A33U'],"['N0000175501', 'M0019113']",['Rifamycin Antimycobacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,07/14/2023,64850-556-01,Lisdexamfetamine Dimesylate Capsule,888-852-6657,Limited Availability,Limited Availability,11/04/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA218604'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Elite Laboratories, Inc.']","['64850-556', '64850-550', '64850-551', '64850-552', '64850-553', '64850-554', '64850-555']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['e414bb2e-d404-44ea-931c-5998b0a4c87e'],['0e024b69-567c-4b40-9c3e-a2daec34256c'],"['64850-550-01', '64850-551-01', '64850-552-01', '64850-553-01', '64850-554-01', '64850-555-01', '64850-556-01']",['SJT761GEGS'],,,,,,,,,
New,08/27/2025,0409-7809-24,Dopamine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,08/27/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA018826'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],"['Hospira, Inc.']","['0409-7809', '0409-7810']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743877', '1743879']",['3b4d4d9d-5e19-420f-a447-1ad8346844d9'],['08f23f6e-150d-45ea-098e-f2edf64c21a1'],"['0409-7809-11', '0409-7809-22', '0409-7809-31', '0409-7809-24', '0409-7810-11', '0409-7810-22']",['7L3E358N9L'],,,,,,,,,
New,01/06/2025,0597-0545-44,Adalimumab-adbm Injection,800-243-0127,,,01/06/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0545-44)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['ADALIMUMAB-ADBM'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0545', '0597-0595', '0597-0555', '0597-0585', '0597-0575', '0597-0565']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640891', '2640893', '2640895', '2640900', '2640902', '2680743', '2680748', '2680756', '2680759']",['d6ed9087-bc5c-4c0e-843b-90b0400b0ed1'],['62f39a7c-00df-4519-a8d4-39bbd0a649ed'],"['0597-0595-20', '0597-0590-26', '0597-0555-80', '0597-0550-06', '0597-0585-89', '0597-0580-37', '0597-0545-22', '0597-0545-44', '0597-0545-66', '0597-0540-10', '0597-0575-50', '0597-0575-40', '0597-0575-60', '0597-0570-32', '0597-0565-20', '0597-0560-12']",,,,,01/06/2025,,,,,
Revised,05/30/2025,0409-1176-30,Meperidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Analgesia/Addiction'],Injection,"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['NDA021171'],['DEMEROL'],['MEPERIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1176', '0409-1181', '0409-1178', '0409-1179', '0409-1180', '0409-1362', '0409-1418']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['860792', '861463', '861473', '861493', '861494', '861522', '861529', '861617', '1242106', '1242503', '2539186', '2539188', '2539191', '2539192']",['1271f15f-ccda-4892-8fb0-9bb2d38ded4a'],['b31d1308-28c3-43f4-e0a6-2f3ed76b8975'],"['0409-1181-30', '0409-1176-03', '0409-1176-30', '0409-1178-03', '0409-1178-30', '0409-1179-03', '0409-1179-30', '0409-1180-59', '0409-1180-69', '0409-1362-11', '0409-1362-01', '0409-1418-11', '0409-1418-01']",['N8E7F7Q170'],,,,,,,,,
New,06/13/2025,59310-812-06,Fluticasone Propionate; Salmeterol Xinafoate Powder,800-545-8800,,,06/13/2025,['Pulmonary/Allergy'],Powder,"AirDuo RespiClick, Powder, 113 ug; 14 ug (NDC 59310-812-06)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA208799'],['AIRDUO RESPICLICK'],['FLUTICASONE PROPIONATE AND SALMETEROL'],"['Teva Respiratory, LLC']","['59310-812', '59310-805', '59310-822']",['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],"['FLUTICASONE PROPIONATE', 'SALMETEROL XINAFOATE']","['1918194', '1918199', '1918203', '1918205', '1918209', '1918211']",['b597bc2d-bf1e-4f9b-826a-b3e39ed56545'],['9c122b91-a11f-49ca-80bb-3eec5112db87'],"['59310-805-06', '59310-805-08', '59310-812-06', '59310-812-08', '59310-822-06', '59310-822-08']","['6EW8Q962A5', 'O2GMZ0LF5W']",,,,06/13/2025,,,,,
Reverified,03/27/2023,72888-153-01,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-153', '72888-152', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,08/15/2025,0591-3983-05,Celecoxib Capsule,800-545-8800,,Discontinuation of the manufacture of the drug,08/15/2025,['Analgesia/Addiction'],Capsule,"Celecoxib, Capsule, 100 mg (NDC 0591-3983-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA200562'],['CELECOXIB'],['CELECOXIB'],"['Actavis Pharma, Inc.']","['0591-3983', '0591-3982', '0591-3984', '0591-3985']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CELECOXIB'],"['205322', '205323', '349514', '686379']",['64c601bc-9b67-400f-9e30-e26de56f2f8b'],['05224473-27dc-4f6d-a52a-c40a7af2f2f4'],"['0591-3982-60', '0591-3983-01', '0591-3983-05', '0591-3984-01', '0591-3984-05', '0591-3985-60']",['JCX84Q7J1L'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,08/15/2025,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Revised,02/15/2023,0143-9251-10,Rocuronium Bromide Injection,800-631-2174,Available,Additional lots will be available.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA204679'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9251', '0143-9250']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['1b6667a4-f267-483a-ae9f-2a514db8a21d'],['d3a172a5-01ab-47d8-92ac-a8539b1d4dc4'],"['0143-9250-01', '0143-9250-10', '0143-9251-01', '0143-9251-10']",['I65MW4OFHZ'],,,,,,,,,
New,01/06/2025,0597-0495-40,Adalimumab-adbm Injection,800-243-0127,,,01/06/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0495-40)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['CYLTEZO'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0495', '0597-0370', '0597-0405', '0597-0400', '0597-0375', '0597-0485']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640889', '2640891', '2640892', '2640893', '2640894', '2640895', '2640898', '2640900', '2640901', '2640902', '2640903', '2680743', '2680746', '2680748', '2680750', '2680756', '2680757', '2680759', '2680760']",['0abec80c-8b06-4e08-bb5a-dd42ef508aa6'],['115ea79b-7209-7f19-b35d-36ec0828fbf5'],"['0597-0370-82', '0597-0370-72', '0597-0370-45', '0597-0405-80', '0597-0405-10', '0597-0400-89', '0597-0375-48', '0597-0375-97', '0597-0375-23', '0597-0375-16', '0597-0375-53', '0597-0485-46', '0597-0485-20', '0597-0480-12', '0597-0495-47', '0597-0495-50', '0597-0495-40', '0597-0495-60', '0597-0490-32']",,,,,01/06/2025,,,,,
New,06/13/2025,0591-5553-05,Doxycycline Hyclate Tablet,800-545-8800,,,06/13/2025,['Anti-Infective'],Tablet,"Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA062421'],['DOXYCYCLINE HYCLATE'],['DOXYCYCLINE HYCLATE'],"['Actavis Pharma, Inc.']",['0591-5553'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DOXYCYCLINE HYCLATE'],['1650143'],['0fb9a3f8-9ebb-4c21-8a73-9f082b39039c'],['a569ba80-ffea-40b2-9fbe-a42810b1fccb'],"['0591-5553-50', '0591-5553-05']",['19XTS3T51U'],,,,06/13/2025,,,,,
Reverified,06/28/2022,72078-034-01,Remifentanil Hydrochloride Injection,800-796-9526,Available,,11/06/2025,['Analgesia/Addiction'],Injection,"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)","Mylan Institutional, a Viatris Company",,Current,['NDA020630'],['ULTIVA'],['REMIFENTANIL HYDROCHLORIDE'],['Mylan Institutional LLC'],"['72078-034', '72078-035', '72078-036']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729581', '1729584', '1729586', '1729710', '1729712']",['c10cf43f-066a-43ff-9166-242cbb7754af'],['8b4c8696-e23e-4c51-a4d2-babab5bd945a'],"['72078-034-00', '72078-034-01', '72078-035-00', '72078-035-02', '72078-036-00', '72078-036-05']",['5V444H5WIC'],,,,,,,,,
Reverified,07/26/2023,68025-098-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Available,,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)","Vertical Pharmaceuticals, LLC",,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-098', '68025-088', '68025-089', '68025-095', '68025-096', '68025-097', '68025-084']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
Reverified,03/24/2023,0009-0011-03,Hydrocortisone Sodium Succinate Injection,844-646-4398,Available,,10/23/2025,"['Pulmonary/Allergy', 'Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Renal', 'Rheumatology']",Injection,"Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)","Hospira, Inc., a Pfizer Company",,Current,['NDA009866'],['SOLU-CORTEF'],['HYDROCORTISONE SODIUM SUCCINATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0011', '0009-0825', '0009-0013', '0009-0016', '0009-0005']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],"['105398', '238755', '1738586', '1738589', '1738590', '1738592', '1738594', '1738596']",['8512044a-4a54-4634-bb97-9e20126adc61'],['65eefd58-b166-4d71-ade6-45c8fdf86922'],"['0009-0825-01', '0009-0011-03', '0009-0011-04', '0009-0013-05', '0009-0013-06', '0009-0016-12', '0009-0005-01']",['50LQB69S1Z'],,,,,https://cdernexus.fda.gov/suite/sites/dsm/page/home,,12/19/2024,,
New,10/07/2025,61958-1401-1,Cobicistat Tablet,800-445-3235,,Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.,10/07/2025,['Antiviral'],Tablet,"Tybost, Tablet, 150 mg (NDC 61958-1401-1)","Gilead Sciences, Inc.",,To Be Discontinued,['NDA203094'],['TYBOST'],['COBICISTAT'],"['Gilead Sciences, Inc.']","['61958-1401', '61958-1402']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['COBICISTAT'],"['1551993', '1551999', '2719618', '2719620']",['1590e99d-baf0-426e-8405-ab7d3aa3698e'],['3784c35c-e87f-410c-900b-8fd6313c6010'],"['61958-1401-1', '61958-1402-1']",['LW2E03M5PG'],"['N0000190114', 'N0000191001', 'N0000185503', 'N0000182137', 'N0000190107', 'N0000190108', 'N0000190113', 'N0000191423']",['Cytochrome P450 3A Inhibitor [EPC]'],,10/07/2025,,,,"['Cytochrome P450 3A Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]', 'Cytochrome P450 2D6 Inhibitors [MoA]', 'Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]', 'Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]', 'Breast Cancer Resistance Protein Inhibitors [MoA]', 'Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]']",
Reverified,03/10/2023,72888-152-05,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-152', '72888-153', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,03/23/2018,63323-286-35,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-286', '63323-285', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,10/12/2022,0406-8884-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-325-8888,Unavailable,Next release expected November 2025,11/05/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)",SpecGx LLC,Other,Current,['ANDA040440'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['SpecGx LLC'],"['0406-8884', '0406-8891', '0406-8892', '0406-8885', '0406-8893', '0406-8894']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['b25a2f3f-ee3a-44c0-a475-f371025c767b'],['72ddd1c9-ddbd-4c95-acd9-003189a353a3'],"['0406-8891-01', '0406-8884-01', '0406-8892-01', '0406-8885-01', '0406-8893-01', '0406-8894-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,10/05/2022,65219-445-10,Etomidate Injection,800-551-7176,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,11/04/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 65219-445-10)","Caplin Steriles, Ltd.",,Current,['ANDA215028'],['ETOMIDATE'],['ETOMIDATE'],"['Fresenius Kabi USA, LLC']","['65219-445', '65219-447']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']","['446487f1-002e-41d3-846a-67570e797171', '30488a7e-ea9e-4a27-95a9-a07149c50282']","['f38fad46-f2dd-4692-a2a9-a13d0a717bf8', 'd07efb9e-5264-461d-96d8-e11fa71c5751']","['65219-445-12', '65219-445-22', '65219-445-01', '65219-445-10', '65219-447-02', '65219-447-20']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Reverified,12/22/2020,43066-015-10,Ropivacaine Hydrochloride Injection,888-229-0001,Limited Availability,Check wholesalers for inventory; Marketed by Baxter,11/04/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)","Caplin Steriles, Ltd.",Other,Current,['ANDA212808'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['43066-015', '43066-019', '43066-023', '43066-027']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734084', '1734207', '1734475', '1734483']",['ef624077-2197-426c-9521-8f966f49240b'],['781d4b7f-7556-4695-8d48-7772d7a0d8e9'],"['43066-015-01', '43066-015-10', '43066-019-01', '43066-019-10', '43066-023-01', '43066-023-10', '43066-027-01', '43066-027-10']",['V910P86109'],,,,,,,,,
New,10/20/2025,0781-3317-80,Oxaliplatin Injection,800-525-8747,,Discontinuation of the manufacture of the drug,10/20/2025,['Oncology'],Injection,"Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80)",Sandoz Inc.,,To Be Discontinued,['ANDA078817'],['OXALIPLATIN'],['OXALIPLATIN'],['Sandoz Inc'],"['0781-3317', '0781-3315']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['OXALIPLATIN'],"['1736776', '1736781']",['f3766495-fce3-461c-8c95-e890f5e3383f'],['ab162009-6f84-4d56-ab56-5e84409ec814'],"['0781-3315-70', '0781-3317-80']",['04ZR38536J'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,10/20/2025,,,,,
Revised,01/01/2012,67457-528-10,Leucovorin Calcium Injection,800-796-9526,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium Preservative Free, Injection, 100 mg/10 mL (NDC 67457-528-10)","Mylan Institutional, a Viatris Company",,Resolved,['ANDA203800'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Mylan Institutional LLC'],"['67457-528', '67457-529', '67457-530']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803932', '1803937']",['2890b03c-dbef-4db8-8b07-c042d7765677'],['1cb701ca-2478-4268-9d69-80293965d59d'],"['67457-528-10', '67457-529-20', '67457-530-35']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,04/10/2020,0409-0155-02,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-0155', '0409-4596']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718907', '1718909', '1718910']",['1fdb4815-2990-4926-ba76-25241810489e'],['92b7ddaa-e45a-4b64-a802-bb5df8771dd6'],"['0409-4596-01', '0409-4596-20', '0409-0155-01', '0409-0155-02']",['1018WH7F9I'],,,,,,,,,
Reverified,02/14/2022,0990-7923-37,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7923', '0990-7922', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
New,12/09/2024,62756-224-18,Tiagabine Hydrochloride Tablet,800-818-4555,,Discontinuing for business reasons,12/09/2024,['Neurology'],Tablet,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-18)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077555'],['TIAGABINE HYDROCHLORIDE'],['TIAGABINE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['62756-224', '62756-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TIAGABINE HYDROCHLORIDE'],"['1299911', '1299917']",['57975e74-e45b-4fd9-9718-bfc9690acae5'],['7eeb2d81-c5d7-46a0-aa5c-149b55df71bd'],"['62756-200-83', '62756-200-18', '62756-224-83', '62756-224-88', '62756-224-08', '62756-224-18']",['DQH6T6D8OY'],,,,12/09/2024,,,,,
New,03/24/2025,78206-171-01,Montelukast Sodium Granule,844-674-3200,,,03/24/2025,['Pulmonary/Allergy'],Granule,"Singulair, Granule, 4 mg (NDC 78206-171-01)",Organon,,To Be Discontinued,['NDA021409'],['SINGULAIR'],['MONTELUKAST SODIUM'],['Organon LLC'],"['78206-171', '78206-170', '78206-173', '78206-172']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MONTELUKAST SODIUM'],"['153892', '153893', '200224', '242438', '261367', '311759', '351246', '404406']",['57a12189-3bb3-4a5d-b5fe-fc57db87c134'],['482dcc92-b47f-4ea6-854a-f5ac2aea7842'],"['78206-171-01', '78206-170-01', '78206-173-01', '78206-172-01', '78206-172-02']",['U1O3J18SFL'],,,,03/24/2025,,,,,
Revised,10/31/2017,63323-851-10,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA019034'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-851', '63323-852', '63323-853', '63323-854']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '1724276', '1724338', '1724340', '1724341']",['9e8522c6-595c-46f9-bb25-272aa4683e0f'],['e034eb96-03e0-46e1-8b92-5e1f94555e7b'],"['63323-851-03', '63323-851-10', '63323-851-07', '63323-851-15', '63323-851-50', '63323-852-03', '63323-852-25', '63323-853-03', '63323-853-25', '63323-854-03', '63323-854-10']",['L960UP2KRW'],,,,,,,,,
Revised,01/06/2023,0781-3004-07,Somatropin Injection,800-525-8747,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Omnitrope, Injection, 10 mg/1.5 mL (NDC 0781-3004-07)",Sandoz Inc.,,Resolved,['BLA021426'],['OMNITROPE'],['SOMATROPIN'],['Sandoz Inc'],"['0781-3004', '0781-3001', '0781-4004']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['SOMATROPIN'],"['241975', '645884', '854302', '864110', '1736267', '1736337']",['4285f380-615e-420b-b756-1e0a775f785b'],['58d84ffa-4056-4e36-ad67-7bd4aef444a5'],"['0781-3001-26', '0781-3001-07', '0781-3004-26', '0781-3004-07', '0781-4004-36', '0781-4014-71', '0781-4024-72']",['NQX9KB6PCL'],"['N0000175606', 'M0028842']",['Recombinant Human Growth Hormone [EPC]'],,,,['Human Growth Hormone [CS]'],08/28/2025,,Available
Revised,04/02/2020,0641-6056-10,Midazolam Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA075243'],['MIDAZOLAM'],['MIDAZOLAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6056', '0641-6057', '0641-6059', '0641-6061', '0641-6063', '0641-6060']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['559c03fb-24ea-4b7b-8afd-e33cb3a2340a'],['575d8bf0-7af7-427c-a231-966e2a5e070d'],"['0641-6057-01', '0641-6057-10', '0641-6057-25', '0641-6059-01', '0641-6059-10', '0641-6056-01', '0641-6056-10', '0641-6061-01', '0641-6061-10', '0641-6061-25', '0641-6063-01', '0641-6063-10', '0641-6063-25', '0641-6060-01', '0641-6060-10']",['W7TTW573JJ'],,,,,,,,,
Reverified,03/23/2018,62332-599-25,Ketorolac Tromethamine Injection,908-393-9604,Available,,09/17/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)",Alembic Pharmaceuticals,,Current,['ANDA214456'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Alembic Pharmaceuticals Inc.'],"['62332-599', '62332-600', '62332-601']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['9030f496-5021-4454-ac16-dbb376315608'],['419cf756-3c96-4bb8-ae96-6aea5a5f3afd'],"['62332-599-01', '62332-599-25', '62332-600-01', '62332-600-25', '62332-601-02', '62332-601-25']",['4EVE5946BQ'],,,,,,,,,
Revised,02/08/2019,0641-6145-25,Dexamethasone Sodium Phosphate Injection,800-631-2174,Available,Currently available.  Additional product will be made available as it is released.,10/24/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate Injection, USP, Injection, 4 mg/1 mL (NDC 0641-6145-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA084282'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6145', '0641-0367', '0641-6146']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1116927', '1812194']",['84665497-7e82-4733-bcfd-3177817ac0b3'],['0277cc0a-2fd4-4605-a310-b613be84ee26'],"['0641-0367-21', '0641-0367-25', '0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-10', '0641-6146-25']",['AI9376Y64P'],,,,,,,,,
Reverified,12/08/2020,0990-7171-17,Amino Acid Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,['Gastroenterology'],Injection,"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Otsuka ICU Medical LLC,,Current,['NDA020041'],['AMINOSYN II'],"['ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE']",['ICU Medical Inc.'],"['0990-7171', '0990-7172']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ACETYL L-TYROSINE', 'ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'VALINE']","['800188', '800192', '800237', '800241']",['ea005122-3350-4609-83ad-9d093f25162f'],['5b426208-f090-4650-86c3-89040ba45c2d'],"['0990-7172-17', '0990-7171-17']","['8DUH1N11BX', '30KYC7MIAI', '94ZLA3W45F', 'TTL6G7LIWZ', 'HG18B9YRS7', '2ZD004190S', '04Y7590D77', '9DLQ4CIU6V', '3KX376GY7L', 'DA8G610ZO5', 'TE7660XO1C', '47E5O17Y3R', '452VLY9402', 'AE28F7PNPL', 'OF5P57N2ZX', 'GMW67QNF9C', '4QD397987E']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Revised,12/10/2021,65219-466-60,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-466-60)","Fresenius Kabi USA, LLC",,Resolved,['ANDA207310'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']","['65219-466', '65219-468', '65219-470', '65219-472', '65219-474']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['4110390b-2806-4c92-b283-a90115f89114'],['037ac04d-f8f3-4bb8-993a-ac8f7683ff83'],"['65219-466-05', '65219-466-60', '65219-468-05', '65219-468-50', '65219-470-05', '65219-470-30', '65219-472-05', '65219-472-20', '65219-474-05', '65219-474-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,03/13/2023,16729-277-35,Methotrexate Sodium Injection,"866-941-7875, option 2",Available,,11/04/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",Accord Healthcare Inc.,,Current,['ANDA040716'],['METHOTREXATE'],['METHOTREXATE'],"['Accord Healthcare, Inc.']",['16729-277'],['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE'],"['1655956', '1655959', '1655960']",['2bae3cfe-7aa0-c14c-e063-6294a90a19f4'],['dd035a9f-cd40-4314-b9d8-2294b8a924e2'],"['16729-277-30', '16729-277-03', '16729-277-35']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
Revised,04/07/2020,16729-502-43,Furosemide Injection,866-941-7875,Unavailable,Unavailable,11/04/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA070017'],['FUROSEMIDE'],['FUROSEMIDE'],"['Accord Healthcare, Inc.']","['16729-502', '16729-500', '16729-501']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['1cfab300-d796-6a68-e063-6394a90a73f9'],['f6f64972-714c-4ee9-8a5e-9ffcab41a73b'],"['16729-500-30', '16729-500-08', '16729-501-64', '16729-501-43', '16729-502-03', '16729-502-43']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,06/21/2018,63323-186-10,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-10)","Fresenius Kabi USA, LLC",,Resolved,['ANDA088912'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-186'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807632', '1807636', '1807637', '1807638']","['debc17b5-4d24-473c-8396-e409433ce57c', '75c567e3-582b-4fff-9a72-f326f1d13c8f']","['f2a98378-9678-4738-9670-fc7a215c0606', 'f62481fd-fcdb-4be6-ac13-29c590e925c3']","['63323-186-00', '63323-186-04', '63323-186-02', '63323-186-01', '63323-186-10', '63323-186-03', '63323-186-20']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,47781-589-17,Midazolam Hydrochloride Injection,Athenex: 855-273-0154; Alvogen: 973-532-7840,Unavailable,Distributed by Alvogen,09/29/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-17)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,06/06/2018,0641-6042-25,Ketorolac Tromethamine Injection,800-631-2174,Unavailable,Shortage recovery: TBD,10/24/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['ANDA075772'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6042', '0641-6043', '0641-6041']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['25d6c438-45d2-4162-91c2-b5caa0f86bf3'],['0c2c75c9-ed7b-46a8-9543-429bf2d8f090'],"['0641-6043-01', '0641-6043-25', '0641-6042-01', '0641-6042-25', '0641-6041-01', '0641-6041-25']",['4EVE5946BQ'],,,,,,,,,
Reverified,12/08/2020,0990-4178-03,Amino Acid Injection,1-866-829-9025 or ProductAvailability@icumed.com,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,['Gastroenterology'],Injection,"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)",Otsuka ICU Medical LLC,Shortage of an active ingredient,Current,['NDA019398'],['AMINOSYN-PF'],"['ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE']",['ICU Medical Inc.'],['0990-4178'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'TAURINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['831426', '831430']",['488d78ac-3cd2-4593-8968-2992fe59bb49'],['2d212e10-7e08-4aeb-b63f-dcc927897769'],['0990-4178-03'],"['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '1EQV5MLY3D', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Reverified,02/08/2019,63323-165-01,Dexamethasone Sodium Phosphate Injection,888-386-1300,Available,Check wholesalers for inventory.,11/05/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)","Fresenius Kabi USA, LLC",,Current,['ANDA084916'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Fresenius Kabi USA, LLC']",['63323-165'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['1116927', '1812194']","['a832bff9-0bb3-4350-abb5-d57b9417070c', '9dd90418-e564-4bc5-9077-506a1c2c1bce']","['2b626a48-c7aa-4443-9164-a08ff069ccd1', '4fedef4f-ec96-4f36-b2f0-01e243e3b89e']","['63323-165-11', '63323-165-51', '63323-165-13', '63323-165-53', '63323-165-02', '63323-165-01', '63323-165-03', '63323-165-05', '63323-165-30', '63323-165-16', '63323-165-26']",['AI9376Y64P'],,,,,,,,,
Revised,01/06/2023,0013-2657-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 1.8 mg preservative free (NDC 0013-2657-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2657', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Revised,12/15/2021,0009-0280-02,Methylprednisolone Acetate Injection,844-646-4398,Available,,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)",Pfizer Inc.,,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0280', '0009-0274', '0009-0306']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358510', '1358512', '1358610', '1358612', '1358617', '1358619']",['4cf5a255-1360-4511-9b58-b92e3492ef12'],['823b0010-2b57-4e76-b5ac-4a8c2963438f'],"['0009-0274-01', '0009-0280-02', '0009-0280-51', '0009-0280-03', '0009-0280-52', '0009-0306-02', '0009-0306-12']",['43502P7F0P'],,,,,,,,,
Revised,11/01/2017,0703-0113-03,Hydromorphone Hydrochloride Injection,800-545-8800,Limited Availability,Estimated availability: November 2025,11/06/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA078591'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Teva Parenteral Medicines, Inc.']","['0703-0113', '0703-0110', '0703-0018']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['1724338', '1724340', '1724341']",['c32108cc-7b73-4921-9f9e-54b3d60c1c6e'],['f0b78db9-a38c-41bb-8233-5e93f7f18c5c'],"['0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01']",['L960UP2KRW'],,,,,,,,,
Revised,12/10/2021,0264-7800-20,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-20)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-7800', '0264-7802']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807639', '1807551', '1807552', '1807633', '1807634']","['318417ff-d599-47b8-8181-89c3bb3b2e8d', '9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa']","['47a0313f-36df-4fa6-a828-c9e1946ba9b0', '7f22c06b-6b4d-4b49-a4b2-d2169f2bd653']","['0264-7800-09', '0264-7800-00', '0264-7800-10', '0264-7800-20', '0264-7802-00', '0264-7802-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,09/19/2025,69516-010-30,Obeticholic Acid Tablet,1-844-782-4278,,"Business decision. Products will not be available after November 14, 2025.",09/19/2025,['Gastroenterology'],Tablet,"Ocaliva, Tablet, 10 mg (NDC 69516-010-30)",Intercept Pharmaceuticals,,To Be Discontinued,['NDA207999'],['OCALIVA'],['OBETICHOLIC ACID'],['Intercept Pharmaceuticals Inc'],"['69516-010', '69516-005']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OBETICHOLIC ACID'],"['1798364', '1798370', '1798373', '1798375']",['44a7331c-fc85-4906-948e-01bbba5e7e61'],['cdfbe0cd-eb15-45a1-ac17-531bcda21aec'],"['69516-005-30', '69516-010-30']",['0462Z4S4OZ'],"['N0000192561', 'N0000192560']",['Farnesoid X Receptor Agonist [EPC]'],,09/19/2025,,,,['Farnesoid X Receptor Agonists [MoA]'],
Revised,01/01/2012,70436-120-80,Leucovorin Calcium Injection,888-447-0095,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 500 mg (NDC 70436-120-80)",Slate Run Pharmaceuticals,,Resolved,['ANDA217021'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Slate Run Pharmaceuticals, LLC']","['70436-120', '70436-116', '70436-117', '70436-118', '70436-119']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['2a4aaed3-885e-bc10-e063-6294a90a61af'],['d8bdd60c-9a1c-4ef4-ba6b-b911849128f1'],"['70436-116-80', '70436-116-82', '70436-117-80', '70436-118-80', '70436-120-80', '70436-119-80']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,04/10/2020,16729-239-93,Dexmedetomidine Hydrochloride Injection,"866-941-7875, option 2",Unavailable,Resupply TBD,11/04/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA204023'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],['Accord Healthcare Inc.'],['16729-239'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['309710'],['2de0daf8-b7a3-1dca-e063-6394a90a4d0a'],['2b9881f0-4a66-660f-e054-00144ff88e88'],"['16729-239-30', '16729-239-93']",['1018WH7F9I'],,,,,,,,,
Reverified,04/10/2020,55150-296-10,Dexmedetomidine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)",Eugia US LLC,,Current,['ANDA210321'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['Eugia US LLC'],"['55150-296', '55150-209', '55150-297']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['309710', '1718906', '1718909']",['72d6b6e6-236e-44f8-a747-de2ee97bca87'],['8c162541-986b-4b30-866c-b2631ba2c975'],"['55150-209-02', '55150-296-10', '55150-297-10']",['1018WH7F9I'],,,,,,,,,
Reverified,04/28/2023,0990-6139-22,Sterile Water Irrigant,1-866-829-9025 or ProductAvailability@icumed.com,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)",Otsuka ICU Medical LLC,Other,Current,['NDA017513'],['STERILE WATER'],['WATER'],['ICU Medical Inc.'],"['0990-6139', '0990-7139', '0990-7973']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['514c37b1-817a-4dae-a2de-3d938ea76e4e'],['e3484bc6-ed7f-43ef-9d49-c131a8dff2dd'],"['0990-6139-22', '0990-6139-03', '0990-7139-09', '0990-7139-36', '0990-7973-05', '0990-7973-07', '0990-7973-08']",['059QF0KO0R'],,,,,https://www.fda.gov/media/182619/download?attachment,,,,
New,06/03/2025,65862-063-01,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-063', '65862-062', '65862-064']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
Reverified,10/12/2022,0185-2099-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-525-8747,Available,,11/07/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)",Sandoz Inc.,,Current,['ANDA040439'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Sandoz Inc'],"['0185-2099', '0185-0831', '0185-0842', '0185-0853', '0185-0864', '0185-2098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577961']",['d68cd1d1-3bb4-4afa-9786-687cf1766ae1'],['288dafc4-fe6e-4891-832f-511022c87445'],"['0185-0831-01', '0185-0842-01', '0185-0853-01', '0185-0864-01', '0185-2099-01', '0185-2098-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,04/28/2023,0338-0048-03,Sodium Chloride 0.9% Irrigation,888-229-0001,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-03)",Baxter Healthcare,,Resolved,['NDA017427'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],['0338-0048'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['123eac3f-8e50-4689-bf00-cf9407eb70ee'],['b3b4b176-41f0-4ca8-90d4-3fba5707564a'],"['0338-0048-02', '0338-0048-03', '0338-0048-04', '0338-0048-05']",['451W47IQ8X'],,,,,,,07/02/2025,,
New,01/30/2025,61570-120-01,Ramipril Capsule,844-646-4398,,Discontinuation of the manufacture of the drug,01/30/2025,['Cardiovascular'],Capsule,"Altace, Capsule, 10 mg (NDC 61570-120-01)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/30/2025,,,,,
Reverified,07/14/2023,43547-602-10,Lisdexamfetamine Dimesylate Capsule,866-931-9829,Limited Availability,On allocation,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA216266'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE CAPSULES'],"['Solco Healthcare US,LLC']","['43547-602', '43547-603', '43547-604', '43547-605', '43547-606', '43547-607', '43547-608']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7bb11568-67a4-4221-bb9b-23af37a1791c'],['68b10d9f-ca3e-493d-a309-45f1d7e08061'],"['43547-602-10', '43547-603-10', '43547-604-10', '43547-605-10', '43547-606-10', '43547-607-10', '43547-608-10']",['SJT761GEGS'],,,,,,,,,
Reverified,10/05/2022,0143-9311-10,Etomidate Injection,800-631-2174,Available,Novaplus,10/24/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA202354'],['ETOMIDATE'],['ETOMIDATE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9311', '0143-9310']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['c15bd8c1-34e3-40f2-b31a-634136fe197c'],['4312e3c3-34de-4cb3-8abd-c24d24a4bea1'],"['0143-9310-01', '0143-9310-10', '0143-9311-01', '0143-9311-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Revised,10/05/2022,0143-9507-10,Etomidate Injection,800-631-2174,Unavailable,Additional lots will be available in the January 2026 timeframe.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA202354'],['ETOMIDATE'],['ETOMIDATE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9507', '0143-9506']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['98560882-bfdf-404e-ab8b-3ee2a6875830'],['75bf0494-7cb9-4e8a-8edd-af62f035d236'],"['0143-9506-01', '0143-9506-10', '0143-9507-01', '0143-9507-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Reverified,02/20/2018,0409-1163-01,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070597'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1163', '0409-1159', '0409-1160', '0409-1162', '0409-1165', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,10/31/2025,0603-5167-32,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5167', '0603-5165', '0603-5166', '0603-5168']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
New,07/10/2025,72305-100-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 100 ug (NDC 72305-100-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-100', '72305-025', '72305-050', '72305-075', '72305-088', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
New,06/09/2025,66215-102-03,Bosentan Tablet,800-526-7736,,,06/09/2025,['Cardiovascular'],Tablet,"Tracleer, Tablet, 125 mg (NDC 66215-102-03)",Actelion Pharmaceuticals,,To Be Discontinued,['NDA021290'],['TRACLEER'],['BOSENTAN'],"['Actelion Pharmaceuticals US, Inc.']","['66215-102', '66215-101', '66215-103', '66215-232']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BOSENTAN'],"['349253', '352066', '656659', '656660', '1989081', '1989085']",['3bb9bd6a-b0d2-0723-e063-6394a90afc46'],['749e42fb-2fe0-45dd-9268-b43bb3f4081c'],"['66215-101-06', '66215-101-03', '66215-102-06', '66215-102-03', '66215-103-14', '66215-103-56', '66215-232-14', '66215-232-56']",['Q326023R30'],,,,06/09/2025,,,,,
Reverified,10/12/2022,72516-016-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",855-257-0292,Available,,10/24/2025,['Psychiatry'],Tablet,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)",Oryza Pharmaceuticals Inc.,,Current,['ANDA210293'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Oryza Pharmaceuticals Inc.'],"['72516-016', '72516-015', '72516-014', '72516-013', '72516-012', '72516-011']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['39fb17a2-617d-37dc-e063-6394a90a1be3'],['acd27181-a3f3-4c38-85d8-029a4a82e7c2'],"['72516-016-01', '72516-015-01', '72516-014-01', '72516-013-01', '72516-012-01', '72516-011-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,02/20/2018,55150-165-05,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)",Eugia US LLC,,Current,['ANDA203082'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-165', '55150-161', '55150-162', '55150-163', '55150-164']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737562', '1737566', '1737568', '1737757', '1737761']","['9916b09d-a116-469d-92d5-60e50ea9782b', '9b60bc92-6093-49f9-a6ba-075104ff7bb5']","['9916b09d-a116-469d-92d5-60e50ea9782b', '89701fac-7536-4f16-87fb-f4cc121e74ee']","['55150-161-09', '55150-162-09', '55150-163-00', '55150-164-09', '55150-165-09', '55150-161-02', '55150-162-05', '55150-163-30', '55150-164-02', '55150-165-05']",['V13007Z41A'],,,,,,,,,
Reverified,02/14/2022,0338-0066-20,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0066', '0338-9651', '0338-9649', '0338-9655', '0338-9653', '0338-0078', '0338-0062', '0338-0074', '0338-0070', '0338-0082']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['66eb82f8-6755-42aa-b20c-192a640e8068'],['36e9478c-5df0-4b47-b97d-de3626d7cb29'],"['0338-9651-75', '0338-9649-75', '0338-9655-60', '0338-9653-60', '0338-0078-20', '0338-0062-30', '0338-0074-30', '0338-0066-20', '0338-0070-10', '0338-0070-12', '0338-0082-10']",['LX22YL083G'],,,,,,,,,
Reverified,02/14/2022,0338-0062-30,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0062', '0338-9651', '0338-9649', '0338-9655', '0338-9653', '0338-0078', '0338-0074', '0338-0066', '0338-0070', '0338-0082']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['66eb82f8-6755-42aa-b20c-192a640e8068'],['36e9478c-5df0-4b47-b97d-de3626d7cb29'],"['0338-9651-75', '0338-9649-75', '0338-9655-60', '0338-9653-60', '0338-0078-20', '0338-0062-30', '0338-0074-30', '0338-0066-20', '0338-0070-10', '0338-0070-12', '0338-0082-10']",['LX22YL083G'],,,,,,,,,
Reverified,12/30/2020,63323-494-05,Valproate Sodium Injection,888-386-1300,Available,Checkwholesalers for inventory,11/05/2025,['Neurology'],Injection,"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)","Fresenius Kabi USA, LLC",,Current,['ANDA076539'],['VALPROATE SODIUM'],['VALPROATE SODIUM'],"['Fresenius Kabi USA, LLC']",['63323-494'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['VALPROATE SODIUM'],['1099648'],"['f09a2148-edd9-4918-8359-7554ed263d3a', 'fff889dc-6006-43c2-be57-01b2a5724b26']","['3dfb6da1-f66a-4618-9f74-d2d6c16c0b58', 'c572ece7-03d3-4c2a-aeb5-61f2023b28ea']","['63323-494-41', '63323-494-16', '63323-494-01', '63323-494-05']",['5VOM6GYJ0D'],,,,,,,,,
Reverified,02/29/2024,64850-300-01,Naltrexone Hydrochloride Tablet,888-852-6657,Available,,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-01)","Elite Laboratories, Inc.",,Current,['ANDA075274'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Elite Laboratories, Inc.']",['64850-300'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['cae1ac14-ab22-42d1-8449-5e36c137b905'],['5f188bdc-2009-43aa-ad32-f06dbfac2642'],"['64850-300-30', '64850-300-01']",['Z6375YW9SF'],,,,,,,,,
New,10/24/2025,0002-8214-05,Insulin Glargine Injection,800-545-5979,,A business decision was made to discontinue manufacture of the drug.,10/24/2025,['Endocrinology/Metabolism'],Injection,"Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)",Eli Lilly and Co.,,To Be Discontinued,['BLA205692'],['BASAGLAR TEMPO PEN'],['INSULIN GLARGINE'],['Eli Lilly and Company'],"['0002-8214', '0002-7715']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN GLARGINE'],"['847230', '1736863', '2268064', '2268065']",['dbb5654d-96c0-4cce-adba-5ae8c36acf80'],['0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae'],"['0002-7715-01', '0002-7715-59', '0002-7715-63', '0002-8214-01', '0002-8214-05']",['2ZM8CX04RZ'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,10/24/2025,,['Insulin [CS]'],,,
New,04/10/2025,0781-2076-92,Tamsulosin Hydrochloride Capsule,800-525-8747,,,04/10/2025,['Urology'],Capsule,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-92)",Sandoz Inc.,,To Be Discontinued,['ANDA078015'],['TAMSULOSIN HYDROCHLORIDE'],['TAMSULOSIN HYDROCHLORIDE'],['Sandoz Inc'],['0781-2076'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TAMSULOSIN HYDROCHLORIDE'],['863669'],['98c2abd9-1998-48cd-83f9-f5f94ff39345'],['fb120098-b007-4a33-80b8-b7279c7668ee'],"['0781-2076-01', '0781-2076-10', '0781-2076-92']",['11SV1951MR'],,,,04/10/2025,,,,,
New,07/23/2025,0245-5315-15,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['KLOR-CON'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0245-5315', '0245-5316']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953', '628958', '832718']",['39e77e07-bdc8-28e9-e063-6394a90a120c'],['1ff53330-065c-4213-9c0c-ac498621d09d'],"['0245-5315-11', '0245-5315-15', '0245-5315-89', '0245-5315-01', '0245-5316-11', '0245-5316-15', '0245-5316-89', '0245-5316-01']",['660YQ98I10'],,,,07/23/2025,,,,,
New,01/28/2025,64380-789-23,Lidocaine Ointment,877-244-9825,,,01/28/2025,['Anesthesia'],Ointment,"Lidocaine, Ointment, 5%, 30 gram tubes (NDC 64380-789-23)",Strides Pharma Inc.,,To Be Discontinued,['ANDA210958'],['LIDOCAINE'],['LIDOCAINE'],['Strides Pharma Science Limited'],['64380-789'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['LIDOCAINE'],['1543069'],['e6c9429c-13b9-4932-abad-e605c4c7fb68'],['8b1efeaa-31b1-4f34-960f-7a920ac07355'],"['64380-789-32', '64380-789-23', '64380-789-33']",['98PI200987'],"['N0000175682', 'M0000897', 'N0000175426', 'N0000175976']","['Amide Local Anesthetic [EPC]', 'Antiarrhythmic [EPC]']",['Local Anesthesia [PE]'],01/28/2025,,['Amides [CS]'],,,
New,06/24/2025,0078-0379-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,888-669-6682,,Permanent discontinuation in the manufacturing of the drug,06/24/2025,['Cardiovascular'],Capsule,"Lotrel, Capsule, 10 mg; 40 mg (NDC 0078-0379-05)",Novartis Pharmaceuticals Corporation,,To Be Discontinued,['NDA020364'],['LOTREL'],['AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE'],['Novartis Pharmaceuticals Corporation'],"['0078-0379', '0078-0405', '0078-0406', '0078-0364']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898344', '898346', '898348', '898353', '898355', '898356', '898358']",['b9db75d9-9d1e-4b2d-9876-5f5520feaecc'],['94ae6054-b7ae-4212-a567-4f803af8f2c7'],"['0078-0405-05', '0078-0406-05', '0078-0364-05', '0078-0379-05']","['N1SN99T69T', '864V2Q084H']",,,,06/24/2025,,,,,
New,05/02/2025,0591-5553-05,Doxycycline Hyclate Tablet,800-545-8800,,,05/02/2025,['Anti-Infective'],Tablet,"Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA062421'],['DOXYCYCLINE HYCLATE'],['DOXYCYCLINE HYCLATE'],"['Actavis Pharma, Inc.']",['0591-5553'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DOXYCYCLINE HYCLATE'],['1650143'],['0fb9a3f8-9ebb-4c21-8a73-9f082b39039c'],['a569ba80-ffea-40b2-9fbe-a42810b1fccb'],"['0591-5553-50', '0591-5553-05']",['19XTS3T51U'],,,,,,,,,
New,04/01/2025,10122-901-12,Zileuton Tablet,888-466-6505,,,04/01/2025,['Pulmonary/Allergy'],Tablet,"Zyflo, Tablet, 600 mg (NDC 10122-901-12)","Chiesi USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,04/01/2025,,,,,
New,12/05/2024,62756-129-45,Pantoprazole Sodium Injection,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Gastroenterology'],Injection,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-45)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077674'],['PANTOPRAZOLE SODIUM'],['PANTOPRAZOLE SODIUM'],"['Sun Pharmaceutical Industries, Inc.']",['62756-129'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PANTOPRAZOLE SODIUM'],['283669'],['ef1bb9ed-b534-4698-abf5-836dcce85f45'],['d9fcf6a2-3788-4955-84d9-3c319b13267c'],"['62756-129-40', '62756-129-44', '62756-129-45']",['6871619Q5X'],,,,12/05/2024,,,,,
Reverified,03/23/2018,76045-104-10,Ketorolac Tromethamine Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)","Fresenius Kabi USA, LLC",Other,Current,['ANDA203242'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Fresenius Kabi USA, LLC']","['76045-104', '76045-105', '76045-107', '76045-209']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860113', '860114', '860115']",['0dab642d-7fcf-4301-8ac9-10e64a040c6b'],['3d88cbe6-5230-47aa-80af-0c41283d1f00'],"['76045-104-10', '76045-105-20', '76045-107-10', '76045-209-00', '76045-209-10']",['4EVE5946BQ'],,,,,,,,,
New,04/24/2025,0245-1074-30,"Topiramate Capsule, Extended Release",716-315-2000,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,04/24/2025,['Neurology'],"Capsule, Extended Release","Qudexy XR, Capsule, Extended Release, 100 mg (NDC 0245-1074-30)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA205122'],['QUDEXY XR'],['TOPIRAMATE'],"['Upsher-Smith Laboratories, LLC']","['0245-1074', '0245-1071', '0245-1072', '0245-1075', '0245-1073']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOPIRAMATE'],"['1494766', '1494769', '1494771', '1494775', '1494778', '1494781', '1812419', '1812421', '1812425', '1812427']",['374eeb55-b017-48fd-e063-6294a90a6ad7'],['46f54677-3a22-4c38-9b92-923020164e15'],"['0245-1071-30', '0245-1071-90', '0245-1072-30', '0245-1072-90', '0245-1074-30', '0245-1074-90', '0245-1075-30', '0245-1075-90', '0245-1073-30', '0245-1073-90']",['0H73WJJ391'],"['N0000008486', 'N0000185506', 'N0000182140']",,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],04/24/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
New,06/13/2025,0093-7202-98,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-98)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076056'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-7202', '0093-0771', '0093-7201']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],"['904458', '904467', '904475']",['72579e23-23ef-4ab7-ad64-24d5ea7997eb'],['99e0e848-f8f3-4b42-b880-8fbc42633948'],"['0093-0771-98', '0093-0771-10', '0093-7201-98', '0093-7201-10', '0093-7202-98', '0093-7202-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
Reverified,11/01/2023,60505-4740-1,Lisdexamfetamine Dimesylate Capsule,800-706-5575,Available,Product currently available,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)",Apotex Corp.,,Current,['ANDA216944'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Apotex Corp.'],"['60505-4740', '60505-4739', '60505-4741', '60505-4742', '60505-4743', '60505-4744', '60505-4745']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7a3783a0-bb54-a95b-99f4-9d3aa9788649'],['ecad4442-a644-18e3-6ff2-fdbac45eec47'],"['60505-4739-1', '60505-4740-1', '60505-4741-1', '60505-4742-1', '60505-4743-1', '60505-4744-1', '60505-4745-1']",['SJT761GEGS'],,,,,,,,,
Reverified,10/14/2016,63323-489-17,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-489', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Revised,10/14/2016,63323-487-17,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Unavailable,Next release November 2025. Check wholesalers for inventory.,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-487', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,02/20/2018,63323-472-37,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)","Fresenius Kabi USA, LLC",,Current,['ANDA070554'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-472', '63323-463', '63323-461', '63323-468']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012413', '1012417', '1724786', '1724787', '1724809', '1724810', '1867594', '1867596', '1867618', '1867620']",['cc1f6507-eb3e-4398-a1d3-0c56a2099e6b'],['bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb'],"['63323-472-03', '63323-472-17', '63323-472-01', '63323-472-37', '63323-463-01', '63323-463-57', '63323-461-01', '63323-461-57', '63323-468-02', '63323-468-37', '63323-468-01', '63323-468-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,07/17/2025,0409-1061-01,Pemetrexed Ditromethamine Injection,844-646-4398,,Discontinuation of the manufacture of the drug.,07/17/2025,['Oncology'],Injection,"Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,07/17/2025,,,,,
Revised,10/11/2024,0990-7953-02,Lactated Ringers Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-02)",Otsuka ICU Medical LLC,,Resolved,['NDA017641'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['ICU Medical Inc.'],"['0990-7953', '0990-7929']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']","['847627', '847630']",['179fea68-7eed-4293-b82f-24139e112240'],['d310d170-5eeb-471b-af1a-0e845001d21d'],"['0990-7929-03', '0990-7929-09', '0990-7953-02', '0990-7953-03', '0990-7953-09']","['660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT', 'M4I0D6VV5M', 'LX22YL083G']",,,,,,,10/03/2025,,Available
New,04/23/2025,0832-1055-90,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 20 mg (NDC 0832-1055-90)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1055', '0832-1054']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
Reverified,03/23/2018,63323-285-61,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,10/12/2022,0406-8885-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-325-8888,Available,,11/05/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)",SpecGx LLC,,Current,['ANDA040440'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['SpecGx LLC'],"['0406-8885', '0406-8891', '0406-8884', '0406-8892', '0406-8893', '0406-8894']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['b25a2f3f-ee3a-44c0-a475-f371025c767b'],['72ddd1c9-ddbd-4c95-acd9-003189a353a3'],"['0406-8891-01', '0406-8884-01', '0406-8892-01', '0406-8885-01', '0406-8893-01', '0406-8894-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/07/2020,25021-311-02,Furosemide Injection,866-625-1618,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Gland Pharma Limited,Other,Current,['ANDA213902'],['FUROSEMIDE'],['FUROSEMIDE'],['Sagent Pharmaceuticals'],['25021-311'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['222ce48f-2856-4be2-b16f-6fca38c0dceb'],['d63c1277-dd7e-4d21-9e80-68143f55e2dc'],"['25021-311-02', '25021-311-04', '25021-311-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,02/06/2025,0591-0900-30,"Glipizide Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue manufacture of the drug.,02/06/2025,['Endocrinology/Metabolism'],Tablet,"Glipizide, Tablet, Extended Release, 2.5 mg (NDC 0591-0900-30)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076467'],['GLIPIZIDE ER'],['GLIPIZIDE'],"['Actavis Pharma, Inc.']","['0591-0900', '0591-0844', '0591-0845']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLIPIZIDE'],"['310489', '314006', '315107']",['90e0de65-ed5f-460a-a96f-77d4d76ceedd'],['a430577c-f233-40a7-bfd8-3d2bc6f98aa2'],"['0591-0900-30', '0591-0844-01', '0591-0844-10', '0591-0845-01', '0591-0845-10']",['X7WDT95N5C'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,02/06/2025,,['Sulfonylurea Compounds [CS]'],,,
New,08/15/2025,0591-3982-60,Celecoxib Capsule,800-545-8800,,Discontinuation of the manufacture of the drug,08/15/2025,['Analgesia/Addiction'],Capsule,"Celecoxib, Capsule, 50 mg (NDC 0591-3982-60)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA200562'],['CELECOXIB'],['CELECOXIB'],"['Actavis Pharma, Inc.']","['0591-3982', '0591-3983', '0591-3984', '0591-3985']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CELECOXIB'],"['205322', '205323', '349514', '686379']",['64c601bc-9b67-400f-9e30-e26de56f2f8b'],['05224473-27dc-4f6d-a52a-c40a7af2f2f4'],"['0591-3982-60', '0591-3983-01', '0591-3983-05', '0591-3984-01', '0591-3984-05', '0591-3985-60']",['JCX84Q7J1L'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,08/15/2025,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Reverified,02/15/2023,67457-228-05,Rocuronium Bromide Injection,800-796-9526,Available,,11/06/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)","Mylan Institutional, a Viatris Company",,Current,['ANDA079199'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Mylan Institutional LLC'],['67457-228'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['3316cfdc-67e7-437d-9c90-1c383b53b272'],['f58803b0-f173-4997-b2f8-0f415b94dacf'],"['67457-228-00', '67457-228-05', '67457-228-99', '67457-228-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,07/14/2023,59417-107-10,Lisdexamfetamine Dimesylate Capsule,877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],Capsule,"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA021977'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-107', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
New,07/23/2025,0832-0111-03,Amantadine Hydrochloride Tablet,763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Antiviral', 'Neurology']",Tablet,"Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-03)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076186'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-0111'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849395'],['395d9ef2-7ea2-c602-e063-6394a90a6ef0'],['63d9d4aa-5f92-45b0-98d0-d6ec38b727cb'],"['0832-0111-00', '0832-0111-50', '0832-0111-89', '0832-0111-03']",['M6Q1EO9TD0'],,,,07/23/2025,,,,,
Reverified,12/22/2021,42806-799-01,Rifampin Capsule,(718) 276-8600 ext. 3,Unavailable,Discontinuation of the manufacture of the drug.,10/15/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 300 mg (NDC 42806-799-01)","Epic Pharma, LLC",Discontinuation of the manufacture of the drug,Current,['ANDA064150'],['RIFAMPIN'],['RIFAMPIN'],"['EPIC PHARMA, LLC']","['42806-799', '42806-801']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['a4ac02e8-68ac-4e79-8ca5-0939dd002c87'],['0391f1e1-70d4-4b15-8b58-055bb6a385b8'],"['42806-801-30', '42806-801-01', '42806-799-30', '42806-799-60', '42806-799-01', '42806-799-05']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Revised,07/14/2023,0480-3565-01,Lisdexamfetamine Dimesylate Capsule,800-545-8800,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA202802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Teva Pharmaceuticals, Inc.']","['0480-3565', '0480-3566', '0480-3567', '0480-3568', '0480-3569', '0480-3570', '0480-3564']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['6cfe6c98-51b1-45a4-831c-33624ab129cb'],['c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc'],"['0480-3565-01', '0480-3566-01', '0480-3567-01', '0480-3568-01', '0480-3569-01', '0480-3570-01', '0480-3564-01']",['SJT761GEGS'],,,,,,,,,
Reverified,01/01/2012,0409-9094-22,Fentanyl Citrate Injection,844-646-4398,Available,,10/23/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)","Hospira, Inc., a Pfizer Company",,Current,['NDA019115'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Hospira, Inc.']","['0409-9094', '0409-9093']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735004', '1735006', '1735007', '1735008', '1735013']",['e4b31fdd-00af-416d-b14e-dbac0c83da97'],['bfa8018a-4cbc-434b-e09e-782872b0340a'],"['0409-9093-37', '0409-9093-32', '0409-9093-45', '0409-9093-35', '0409-9093-41', '0409-9093-36', '0409-9093-31', '0409-9093-38', '0409-9094-12', '0409-9094-22', '0409-9094-18', '0409-9094-25', '0409-9094-17', '0409-9094-28', '0409-9094-16', '0409-9094-31', '0409-9094-41', '0409-9094-61']",['MUN5LYG46H'],,,,,,,,,
Revised,12/20/2023,0641-6247-25,Fentanyl Citrate Injection,800-631-2174,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6247', '0641-6024', '0641-6027', '0641-6025', '0641-6028', '0641-6026', '0641-6029', '0641-6030', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
New,10/24/2025,67457-893-08,Busulfan Injection,800-796-9526,,Discontinuation of the manufacture of the drug.,10/24/2025,['Hematology'],Injection,"Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08)","Mylan Institutional, a Viatris Company",,To Be Discontinued,['ANDA208536'],['BUSULFAN'],['BUSULFAN'],['Mylan Institutional LLC'],['67457-893'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['BUSULFAN'],['253113'],['bd76d3b4-198e-46d5-8d00-5b66d4c9454c'],['9955aced-ac32-43e6-b39a-c6c023a50dc3'],"['67457-893-00', '67457-893-08']",['G1LN9045DK'],"['N0000000236', 'N0000175558']",['Alkylating Drug [EPC]'],,10/24/2025,,,,['Alkylating Activity [MoA]'],
New,05/14/2025,0832-0740-60,"Propafenone Hydrochloride Capsule, Extended Release",800-654-2299,,A business decision was made to discontinue the product.,05/14/2025,['Cardiovascular'],"Capsule, Extended Release","Propafenone Hydrochloride, Capsule, Extended Release, 225 mg (NDC 0832-0740-60)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA212744'],['PROPAFENONE HYDROCHLORIDE'],['PROPAFENONE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0740', '0832-0741', '0832-0742']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PROPAFENONE HYDROCHLORIDE'],"['861156', '861164', '861171']",['398513af-dd95-49eb-e063-6394a90a73f4'],['8aa6f58a-2980-4caa-9c54-d55d69d5d132'],"['0832-0740-60', '0832-0741-60', '0832-0742-60']",['33XCH0HOCD'],,,,05/14/2025,,,,,
Revised,02/22/2012,0409-4276-01,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088299'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4276', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
New,05/02/2025,0832-0542-10,Bumetanide Tablet,800-654-2299,,,05/02/2025,['Cardiovascular'],Tablet,"Bumetanide, Tablet, 2 mg (NDC 0832-0542-10)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA209916'],['BUMETANIDE'],['BUMETANIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0542', '0832-0540', '0832-0541']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BUMETANIDE'],"['197417', '197418', '197419']",['d53166d9-64ca-4b76-81a7-b70a60c53b12'],['ff5dc8c6-b2f2-41d3-8e56-a953aa721b59'],"['0832-0540-11', '0832-0541-11', '0832-0541-10', '0832-0542-11', '0832-0542-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],05/02/2025,,,,,
Reverified,01/01/2020,76329-3340-1,Atropine Sulfate Injection,800-423-4136,Available,,10/17/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)","Amphastar Pharmaceuticals, Inc.",,Current,['ANDA212461'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['International Medication Systems, Limited']",['76329-3340'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],['1190546'],['697aa53c-f31f-463a-a752-d2faaad354db'],['b72d0a82-6163-460f-965a-12f6da47370a'],['76329-3340-1'],['03J5ZE7KA5'],,,,,,,,,
Revised,05/03/2018,0641-6047-10,Lorazepam Injection,800-631-2174,Unavailable,Unavailable,10/24/2025,['Neurology'],Injection,"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)","Hikma Pharmaceuticals USA, Inc.",Regulatory delay,Current,['NDA018140'],['LORAZEPAM'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6047', '0641-6044', '0641-6046', '0641-6045']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['238100', '238101', '1665188', '1665326']",['7c73dbc6-2623-4443-9b05-97dec7a0be2e'],['e9b54e42-04cf-4c62-90e1-36f7b31a4e81'],"['0641-6044-01', '0641-6044-25', '0641-6046-01', '0641-6046-10', '0641-6045-01', '0641-6045-25', '0641-6047-01', '0641-6047-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,08/19/2025,0093-7355-98,Finasteride Tablet,800-545-8800,,Discontinuation of the manufacture of the drug product,08/19/2025,['Urology'],Tablet,"Finasteride, Tablet, 5 mg (NDC 0093-7355-98)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076511'],['FINASTERIDE'],['FINASTERIDE'],"['Teva Pharmaceuticals USA, Inc.']",['0093-7355'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FINASTERIDE'],['310346'],['ea83e229-c434-4097-81dd-e3b48814d5dc'],['77589cc3-c440-4695-800c-82a0e5128a6c'],"['0093-7355-56', '0093-7355-98', '0093-7355-05']",['57GNO57U7G'],"['N0000175836', 'N0000000126']",['5-alpha Reductase Inhibitor [EPC]'],,08/19/2025,,,,['5-alpha Reductase Inhibitors [MoA]'],
Reverified,04/07/2020,63323-280-04,Furosemide Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)","Fresenius Kabi USA, LLC",,Current,['NDA018902'],['FUROSEMIDE'],['FUROSEMIDE'],"['Fresenius Kabi USA, LLC']",['63323-280'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['9804efac-5457-417a-8de7-a688467759c0', '64b3fb5f-3516-4e39-b74e-e0e402ed9c4d']","['3747bbcd-783d-4baa-bb5b-b6827bf390e3', 'c794c95a-654e-48fe-9596-201fc122ff75']","['63323-280-41', '63323-280-16', '63323-280-43', '63323-280-26', '63323-280-45', '63323-280-36', '63323-280-01', '63323-280-02', '63323-280-03', '63323-280-04', '63323-280-05', '63323-280-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,07/23/2025,0832-0111-00,Amantadine Hydrochloride Tablet,763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Antiviral', 'Neurology']",Tablet,"Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-00)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076186'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-0111'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849395'],['395d9ef2-7ea2-c602-e063-6394a90a6ef0'],['63d9d4aa-5f92-45b0-98d0-d6ec38b727cb'],"['0832-0111-00', '0832-0111-50', '0832-0111-89', '0832-0111-03']",['M6Q1EO9TD0'],,,,07/23/2025,,,,,
Reverified,01/19/2023,68180-557-09,Quinapril Hydrochloride Tablet,"Lupin Pharmaceuticals, Inc.",Unavailable,,09/18/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)","Lupin Pharmaceuticals, Inc.",Requirements related to complying with good manufacturing practices,Current,['ANDA077690'],['QUINAPRIL'],['QUINAPRIL'],"['Lupin Pharmaceuticals, Inc.']","['68180-557', '68180-556', '68180-558', '68180-554', '68180-559']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['a9598a21-6f99-4c86-ace6-b5638da2bec8'],['8ded0773-3aec-4e89-9836-d22a5a84abf0'],"['68180-556-09', '68180-557-09', '68180-557-03', '68180-558-09', '68180-558-03', '68180-554-09', '68180-554-03', '68180-559-03', '68180-559-09']",['33067B3N2M'],,,,,,,,,
Reverified,02/22/2012,63323-493-91,Lidocaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-493', '63323-492', '63323-496']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737636', '1737637', '1737640', '1737641', '1737763', '1737764']",['fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df'],['d5e0d06f-ba1e-44d4-aa89-39d6c146dc23'],"['63323-492-08', '63323-492-97', '63323-493-03', '63323-493-97', '63323-493-01', '63323-493-91', '63323-496-03', '63323-496-97']",['EC2CNF7XFP'],,,,,,,,,
Reverified,02/20/2018,0409-1746-30,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE WITH EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Hospira, Inc.']","['0409-1746', '0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/15/2023,66794-229-41,Rocuronium Bromide Injection,800-414-1901,Available,,11/04/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)",Piramal Critical Care Inc.,,Current,['ANDA210437'],['ROCURONIUM'],['ROCURONIUM'],['Piramal Critical Care Inc'],"['66794-229', '66794-228']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['3f9e12e4-d3c5-fba6-e063-6294a90a7fd6'],['98255b70-51f9-8d16-e053-2995a90a8f97'],"['66794-229-02', '66794-229-41', '66794-228-02', '66794-228-41']",['I65MW4OFHZ'],,,,,,,,,
Reverified,03/13/2023,0143-9830-01,Methotrexate Sodium Injection,800-631-2174,Available,Currently available.  Additional product will be made available as it is released.,10/24/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA040632'],['METHOTREXATE'],['METHOTREXATE'],['Hikma Pharmaceuticals USA Inc.'],['0143-9830'],['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE'],['311625'],['d295fa12-63ca-4760-b291-44ba56ce1b59'],['b080eb92-fc72-4ce6-a7ab-3f9ce2415526'],['0143-9830-01'],['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
Revised,04/07/2020,55150-322-25,Furosemide Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)",Eugia US LLC,,Current,['ANDA212174'],['FUROSEMIDE'],['FUROSEMIDE'],['Eugia US LLC'],"['55150-322', '55150-323', '55150-324']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['26acfb26-d058-453e-8c05-61ec44b25118'],['421aa6d5-623b-4dc2-abd5-bb9e7765bf37'],"['55150-322-01', '55150-322-25', '55150-323-01', '55150-323-25', '55150-324-01', '55150-324-25']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,04/07/2020,0409-6102-25,Furosemide Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018667'],['FUROSEMIDE'],['FUROSEMIDE'],"['Hospira, Inc.']",['0409-6102'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['c529b0df-a5cb-46ce-8131-38674ee756af', '0d4a39f2-904e-434a-9af1-83bb4febf124']","['aaced7a8-c3d7-4d66-8c07-aa407b8b3f35', '39fd32f2-6bb7-4a65-d298-e48d26bc80c7']","['0409-6102-35', '0409-6102-25', '0409-6102-36', '0409-6102-26', '0409-6102-37', '0409-6102-27', '0409-6102-19', '0409-6102-02', '0409-6102-18', '0409-6102-04', '0409-6102-20', '0409-6102-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,04/28/2023,61703-150-05,Carboplatin Injection,844-646-4398,Available,,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA076517'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']","['61703-150', '61703-360', '61703-262', '61703-600']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5aa72c15-8033-4559-b257-373371b18958'],['47677091-fd20-49af-933c-c9dd2be21de9'],"['61703-360-18', '61703-150-05', '61703-262-05', '61703-600-05']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,06/28/2022,0143-9393-10,Remifentanil Hydrochloride Injection,800-631-2174,Available,Additional lots will be available.  Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA210594'],['REMIFENTANIL HYDROCHLORIDE'],['REMIFENTANIL HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9393', '0143-9391', '0143-9392']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729584', '1729710']",['5c5e498b-d829-4f78-bcca-466631014767'],['9d289052-1eb6-4ba2-a3ca-d2e542a052ae'],"['0143-9391-01', '0143-9391-10', '0143-9392-01', '0143-9392-10', '0143-9393-01', '0143-9393-10']",['5V444H5WIC'],,,,,,,,,
Reverified,07/18/2023,0169-4060-13,Liraglutide Injection,833-493-4689,Limited Availability,Estimated shortage duration TBD,11/04/2025,['Endocrinology/Metabolism'],Injection,"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)","Novo Nordisk, Inc.",Delay in shipping of the drug,Current,['NDA022341'],['VICTOZA'],['LIRAGLUTIDE'],['Novo Nordisk'],['0169-4060'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],"['897122', '897126']",['0d10d10e-0fe0-47ee-b9da-628e34907e98'],['5a9ef4ea-c76a-4d34-a604-27c5b505f5a4'],"['0169-4060-13', '0169-4060-12', '0169-4060-90', '0169-4060-97', '0169-4060-98', '0169-4060-99']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
New,11/07/2025,0409-4928-34,Calcium Chloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Cardiovascular', 'Endocrinology/Metabolism']",Injection,"Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,['CALCIUM CHLORIDE'],['CALCIUM CHLORIDE'],"['Hospira, Inc.']","['0409-4928', '0409-1631']",['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'INTRAVENTRICULAR']",['CALCIUM CHLORIDE'],['828527'],['dfceadc8-421b-4bb7-952f-badbe83eb89b'],['c4c65e48-85f8-4dcf-6281-06e40959cc79'],"['0409-1631-40', '0409-1631-10', '0409-4928-34']",['M4I0D6VV5M'],,,,11/07/2025,,,,,
Revised,12/10/2021,0338-0049-48,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-48)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,07/08/2025,0409-1891-23,Morphine Sulfate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,07/08/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-23)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA202515'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-1891', '0409-1890', '0409-1892', '0409-1893', '0409-1894']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['894912', '998212', '998213', '1729197', '1731995', '1732014']",['cced2ec0-6c94-4cf0-87fb-041667ee3214'],['be420e8b-bcb0-49b5-bb4d-1df8b9959809'],"['0409-1890-03', '0409-1890-01', '0409-1890-13', '0409-1890-23', '0409-1891-03', '0409-1891-01', '0409-1891-13', '0409-1891-23', '0409-1892-03', '0409-1892-01', '0409-1892-13', '0409-1892-23', '0409-1893-03', '0409-1893-01', '0409-1893-13', '0409-1893-23', '0409-1894-03', '0409-1894-01']",['X3P646A2J0'],,,,07/08/2025,,,,,
New,10/24/2025,0002-8235-99,Insulin Lispro-aabc Injection,800-545-5979,,A business decision was made to discontinue manufacture of the drug.,10/24/2025,['Endocrinology/Metabolism'],Injection,"Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)",Eli Lilly and Co.,,To Be Discontinued,['BLA761109'],['LYUMJEV TEMPO PEN'],['INSULIN LISPRO-AABC'],['Eli Lilly and Company'],"['0002-8235', '0002-7728', '0002-7726', '0002-8207', '0002-8351', '0002-8228']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN LISPRO'],"['2380231', '2380236', '2380248', '2380250', '2380254', '2380256', '2380259', '2380260', '2380265', '2380266', '2380267', '2380268']",['280961ff-5a2a-4713-a315-995e6f0b7771'],['c5a056e2-b568-4ca6-9ed8-79c010942d00'],"['0002-7728-01', '0002-7728-99', '0002-7726-01', '0002-7726-05', '0002-8207-01', '0002-8207-05', '0002-8207-61', '0002-8351-01', '0002-8351-05', '0002-8235-01', '0002-8235-05', '0002-8235-99', '0002-8228-01', '0002-8228-27']",['GFX7QIS1II'],"['N0000004931', 'N0000175453']",['Insulin Analog [EPC]'],,10/24/2025,,['Insulin [Chemical/Ingredient]'],,,
Reverified,03/23/2018,63323-162-01,Ketorolac Tromethamine Injection,888-386-1300,Available,Check wholesaler inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)","Fresenius Kabi USA, LLC",,Current,['ANDA075784'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Fresenius Kabi USA, LLC']","['63323-162', '63323-161']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']","['2b1c6066-d9e0-40a0-ade5-776fc35a3626', '55ed7afb-db66-4b28-939b-db45b55bf058', 'ab476c4c-2c72-47b1-bf42-7a89703b0dd4']","['ccf905ca-e164-4779-9485-2d139c821bad', '950b7295-3f68-4027-ac2b-2f7d0f5f8ef9', 'd1920335-8e45-4960-b6e9-e6f1f9e6820c']","['63323-161-41', '63323-161-16', '63323-162-43', '63323-162-16', '63323-162-45', '63323-162-26', '63323-161-21', '63323-161-12', '63323-162-23', '63323-162-12', '63323-162-25', '63323-162-14', '63323-161-00', '63323-161-01', '63323-162-11', '63323-162-51', '63323-162-00', '63323-162-01', '63323-162-03', '63323-162-02']",['4EVE5946BQ'],,,,,,,,,
Reverified,02/08/2019,63323-516-10,Dexamethasone Sodium Phosphate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)","Fresenius Kabi USA, LLC",,Current,['ANDA040572'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Fresenius Kabi USA, LLC']","['63323-516', '63323-506']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1812079']",['5dcedfda-976c-4aa4-a3cf-909c324a09d4'],['cca2c160-9188-48e8-9505-49a52388dcb7'],"['63323-506-00', '63323-506-01', '63323-506-03', '63323-506-13', '63323-516-01', '63323-516-10']",['AI9376Y64P'],,,,,,,,,
Revised,12/10/2021,0338-9543-04,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9543', '0338-9657', '0338-9659', '0338-9661', '0338-9663']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['6680afa2-1474-4bc3-afee-a333a042fd3f'],['958d35f0-6834-43be-a700-fa58f38b4c19'],"['0338-9543-01', '0338-9543-02', '0338-9543-03', '0338-9543-04', '0338-9543-05', '0338-9543-06', '0338-9543-12', '0338-9657-75', '0338-9659-75', '0338-9661-60', '0338-9663-60']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,04/28/2025,0832-1112-60,Memantine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Neurology'],Tablet,"Memantine Hydrochloride, Tablet, 5 mg (NDC 0832-1112-60)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA090043'],['MEMANTINE HYDROCHLORIDE'],['MEMANTINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-1112', '0832-1113']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEMANTINE HYDROCHLORIDE'],"['996561', '996571']",['398273bb-cd0b-d984-e063-6394a90a89ab'],['6e0ade9e-b721-4701-bcb7-de464e19e707'],"['0832-1112-60', '0832-1113-60']",['JY0WD0UA60'],,,,04/28/2025,,,,,
New,08/12/2025,23155-579-01,Desipramine Hydrochloride Tablet,855-228-9470,,Discontinuation of the manufacture of the drug,08/12/2025,['Psychiatry'],Tablet,"Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)","Avet Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA207433'],['DESIPRAMINE HYDROCHLORIDE'],['DESIPRAMINE HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],"['23155-579', '23155-578', '23155-580', '23155-581', '23155-582', '23155-583']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DESIPRAMINE HYDROCHLORIDE'],"['1099288', '1099292', '1099296', '1099300', '1099304', '1099316']",['49984729-ddde-44ed-927b-8a4ba65cefa0'],['ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0'],"['23155-578-01', '23155-579-01', '23155-580-01', '23155-581-01', '23155-582-01', '23155-583-25']",['1Y58DO4MY1'],,,,08/12/2025,,,,,
Reverified,03/23/2018,65219-632-10,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)","Fresenius Kabi USA, LLC",,Current,['ANDA212808'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['FRESENIUS KABI USA, LLC']",['65219-632'],['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],,['7203f32f-2e48-4924-b882-d4f3863ae952'],['da4a7675-97bf-4d2a-9fdc-c1b4b2999126'],"['65219-632-02', '65219-632-10', '65219-632-04', '65219-632-20']",['V910P86109'],,,,,,,,,
Reverified,02/28/2025,68968-5552-3,"Methylphenidate Film, Extended Release",800-455-8070,Unavailable,Estimated availability TBD,10/02/2025,['Psychiatry'],"Film, Extended Release","Daytrana, Film, Extended Release, 10 mg (NDC 68968-5552-3)","Noven Pharmaceuticals, Inc.",Shortage of an active ingredient,Current,['NDA021514'],['DAYTRANA'],['METHYLPHENIDATE'],"['Noven Therapeutics, LLC']","['68968-5552', '68968-5553', '68968-5554', '68968-5555']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443']",['55f4b5f4-6d3c-4677-a94c-d47ffb59a91a'],['2c312c31-3198-4775-91ab-294e0b4b9e7f'],"['68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
New,06/10/2025,0093-8034-01,Glyburide Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/10/2025,['Endocrinology/Metabolism'],Tablet,"Glyburide (Micronized), Tablet, 1.5 mg (NDC 0093-8034-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA074686'],['GLYBURIDE'],['GLYBURIDE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-8034', '0093-8035', '0093-8036']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLYBURIDE'],"['310536', '310539', '314000']",['00e55b1b-81b5-4df1-8a6d-4d54ac403e76'],['e84c0dfc-a4e9-4c89-b6ea-45732eb412f5'],"['0093-8034-01', '0093-8035-01', '0093-8035-05', '0093-8036-01']",['SX6K58TVWC'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,06/10/2025,,['Sulfonylurea Compounds [CS]'],,,
Revised,10/31/2017,63323-853-25,Hydromorphone Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-853', '63323-851', '63323-852', '63323-854']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '1724276', '1724338', '1724340', '1724341']",['9e8522c6-595c-46f9-bb25-272aa4683e0f'],['e034eb96-03e0-46e1-8b92-5e1f94555e7b'],"['63323-851-03', '63323-851-10', '63323-851-07', '63323-851-15', '63323-851-50', '63323-852-03', '63323-852-25', '63323-853-03', '63323-853-25', '63323-854-03', '63323-854-10']",['L960UP2KRW'],,,,,,,,,
Reverified,03/10/2023,72888-152-30,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-152', '72888-153', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,03/23/2018,70069-062-10,Ropivacaine Hydrochloride Injection,732-554-1019,Available,,08/19/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)","Somerset Therapeutics, LLC",,Current,['ANDA207636'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-062', '70069-061', '70069-063', '70069-064', '70069-065', '70069-066', '70069-067']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734203', '1734207', '1734475', '1734483']",['79b226f0-c08a-4f84-bf2b-ae5c60e01d67'],['ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64'],"['70069-061-01', '70069-061-25', '70069-061-10', '70069-062-01', '70069-062-25', '70069-062-10', '70069-063-01', '70069-063-25', '70069-064-01', '70069-064-10', '70069-064-25', '70069-065-01', '70069-065-25', '70069-066-01', '70069-066-25', '70069-066-10', '70069-067-01', '70069-067-25', '70069-067-10']",['V910P86109'],,,,,,,,,
Revised,07/14/2023,57664-052-88,Lisdexamfetamine Dimesylate Capsule,800-818-4555,Limited Availability,Additional supply anticipated in Q4 2025 followed by early 2026,10/21/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['ANDA214484'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-052', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-051', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
Reverified,04/28/2023,50742-448-60,Carboplatin Injection,866-321-5031,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",10/15/2025,['Oncology'],Injection,"Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)",Ingenus Pharmaceuticals LLC,Other,Current,['ANDA208487'],['CARBOPLATIN'],['CARBOPLATIN'],"['Ingenus Pharmaceuticals, LLC']","['50742-448', '50742-447']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['69fafb3c-1c18-4d34-83b2-3ab9ddaa6769'],['475caee0-15a6-4f0d-bca7-f3e472b323f7'],"['50742-447-45', '50742-448-60']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,03/23/2016,63323-032-00,Sodium Acetate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Total Parenteral Nutrition'],Injection,"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)","Fresenius Kabi USA, LLC",,Current,['ANDA206687'],['SODIUM ACETATE'],['SODIUM ACETATE'],"['Fresenius Kabi USA, LLC']",['63323-032'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE'],['312965'],['37c19fc5-c1ce-4ea0-9cba-4cdf32112091'],['d7fabf08-d4e0-4bb5-8416-2e8ffe27c04b'],"['63323-032-04', '63323-032-00']",['4550K0SC9B'],,,,,,,,,
New,01/06/2025,0597-0495-60,Adalimumab-adbm Injection,800-243-0127,,,01/06/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0495-60)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['CYLTEZO'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0495', '0597-0370', '0597-0405', '0597-0400', '0597-0375', '0597-0485']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640889', '2640891', '2640892', '2640893', '2640894', '2640895', '2640898', '2640900', '2640901', '2640902', '2640903', '2680743', '2680746', '2680748', '2680750', '2680756', '2680757', '2680759', '2680760']",['0abec80c-8b06-4e08-bb5a-dd42ef508aa6'],['115ea79b-7209-7f19-b35d-36ec0828fbf5'],"['0597-0370-82', '0597-0370-72', '0597-0370-45', '0597-0405-80', '0597-0405-10', '0597-0400-89', '0597-0375-48', '0597-0375-97', '0597-0375-23', '0597-0375-16', '0597-0375-53', '0597-0485-46', '0597-0485-20', '0597-0480-12', '0597-0495-47', '0597-0495-50', '0597-0495-40', '0597-0495-60', '0597-0490-32']",,,,,01/06/2025,,,,,
Revised,11/14/2017,0338-0431-03,Heparin Sodium Injection,888-229-0001,Limited Availability,Estimated recovery: November 2025,10/22/2025,['Hematology'],Injection,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)",Baxter Healthcare,Demand increase for the drug,Current,['NDA018609'],['HEPARIN SODIUM IN SODIUM CHLORIDE'],['HEPARIN SODIUM'],['Baxter Healthcare Corporation'],"['0338-0431', '0338-0433', '0338-0424', '0338-0428']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['68b37381-6db4-4ac0-ba6b-3204add02665'],['0d929726-76c3-48fc-b4e7-fd06409f9fb3'],"['0338-0431-03', '0338-0433-04', '0338-0424-18', '0338-0428-12']",['ZZ45AB24CA'],,,,,,,,,
New,12/05/2024,47335-472-81,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-81)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-472', '47335-475']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,03/10/2023,0093-3212-01,Clonazepam Tablet,800-545-8800,Available,,10/16/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA074569'],['CLONAZEPAM'],['CLONAZEPAM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-3212', '0093-0832', '0093-3213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['d6abe4e3-7699-4ead-95f4-739a961b23ad'],['8069b1a0-7c06-4252-b44e-e2eef065d9b8'],"['0093-0832-01', '0093-0832-05', '0093-3212-01', '0093-3212-05', '0093-3213-01', '0093-3213-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,06/21/2018,0264-5802-10,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-10)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-5802', '0264-5804']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807552', '1807634', '1807639']",['d34ea9bc-a1f9-402a-97cf-894505cee75d'],['e44c41ae-c9c8-4dd8-ba6c-cebb585378aa'],"['0264-5802-00', '0264-5802-10', '0264-5804-00']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/14/2023,59417-119-01,"Lisdexamfetamine Dimesylate Tablet, Chewable",877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],"Tablet, Chewable","Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA208510'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-119', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Reverified,03/21/2023,0009-0870-26,Clindamycin Phosphate Injection,800-533-4535,Available,,10/23/2025,['Anti-Infective'],Injection,"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)",Pfizer Inc.,,Current,['NDA050441'],['CLEOCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0870', '0009-0775', '0009-0902', '0009-0728', '0009-3124', '0009-3447', '0009-3381', '0009-3375', '0009-3382', '0009-6582']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['205964', '309335', '309336', '309339', '685574', '685576', '685578', '706461', '1737244', '1737245', '1737578', '1737579', '1737581', '1737582']",['cb513686-3220-4de2-8be6-f941273ae842'],['05a75685-0af5-407c-ac57-e380c882b49d'],"['0009-0870-21', '0009-0870-26', '0009-0775-20', '0009-0775-26', '0009-0902-11', '0009-0902-18', '0009-0728-05', '0009-0728-09', '0009-3124-01', '0009-3124-03', '0009-3447-01', '0009-3447-03', '0009-3381-01', '0009-3381-02', '0009-3375-01', '0009-3375-02', '0009-3382-01', '0009-3382-02', '0009-6582-02', '0009-6582-01']",['EH6D7113I8'],,,,,,,,,
Revised,12/10/2021,0409-7101-66,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-66)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA019465'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']","['0409-7101', '0409-7132']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807547', '1807631', '1807632', '1807633']",['9d75502b-257f-4a37-9a85-b98c4278c474'],['a2a964f7-c3ec-4dfb-e3a0-6d8136a80397'],"['0409-7101-68', '0409-7101-66', '0409-7101-69', '0409-7101-67', '0409-7101-04', '0409-7101-02', '0409-7132-68', '0409-7132-66', '0409-7132-69', '0409-7132-67', '0409-7132-04', '0409-7132-02']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,06/03/2025,65862-063-59,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-59)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-063', '65862-062', '65862-064']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
New,12/05/2024,47335-472-88,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-88)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-472', '47335-475']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
New,10/24/2025,0002-8213-05,Insulin Lispro Injection,800-545-5979,,A business decision was made to discontinue manufacture of the drug.,10/24/2025,['Endocrinology/Metabolism'],Injection,"Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05)",Eli Lilly and Co.,,To Be Discontinued,['BLA020563'],['HUMALOG TEMPO PEN'],['INSULIN LISPRO'],['Eli Lilly and Company'],"['0002-8213', '0002-7510', '0002-7533', '0002-8799', '0002-7516', '0002-7714', '0002-0800', '0002-7712', '0002-8208']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN LISPRO'],"['242120', '865098', '1652239', '1652242', '1652639', '1652640', '1652644', '1652646', '1926331', '1926332', '2621571', '2621572']",['3d52c48f-89cd-4d3d-8db6-1789e76a1c79'],['c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f'],"['0002-7510-01', '0002-7510-17', '0002-7510-99', '0002-7533-01', '0002-8799-01', '0002-8799-59', '0002-8799-61', '0002-7516-01', '0002-7516-59', '0002-7516-99', '0002-7714-01', '0002-7714-59', '0002-7714-61', '0002-8213-01', '0002-8213-05', '0002-0800-01', '0002-7712-01', '0002-7712-27', '0002-7712-61', '0002-8208-01', '0002-8208-27']","['GFX7QIS1II', '059QF0KO0R']","['N0000004931', 'N0000175453']",['Insulin Analog [EPC]'],,10/24/2025,,['Insulin [Chemical/Ingredient]'],,,
Reverified,12/08/2020,0338-1130-06,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)",Baxter Healthcare,,Current,['ANDA075880'],['PREMASOL - SULFITE-FREE (AMINO ACID)'],"['LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE']",['Baxter Healthcare Company'],"['0338-1130', '0338-1131']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'CYSTEINE HYDROCHLORIDE', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'TAURINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['801395', '801398', '801403', '801405']",['4083b5c8-ad5f-43f6-ab19-3c87acb2883f'],['9afdcc3e-0d06-47f4-86ca-40da48b2b02b'],"['0338-1130-03', '0338-1130-04', '0338-1130-06', '0338-1131-03']","['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', 'ZT934N0X4W', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '1EQV5MLY3D', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Revised,12/18/2020,0143-9606-01,Azacitidine Injection,1-800-631-2174,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA209337'],['AZACITIDINE'],['AZACITIDINE'],['Hikma Pharmaceuticals USA Inc.'],['0143-9606'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['592a688f-2e42-4e91-a3ea-34befe2a4e07'],['ff73515d-bd55-4eb5-992b-d2138c80887e'],['0143-9606-01'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
New,12/09/2024,0078-0736-10,Lodoxamide Tromethamine Solution,888-669-6682,,"Novartis has made a business decision to permanently discontinue ALOMIDE® (lodoxamide tromethamine) ophthalmic solution, 0.1%
Discontinuation of the product is due in part to manufacturing concerns.
Short-dated material is available until January 2025.",12/09/2024,['Ophthalmology'],Solution,"Alomide, Solution, 1 mg/1 mL (NDC 0078-0736-10)",Novartis Pharmaceuticals Corporation,,To Be Discontinued,,,,,,,,,,,,,,,,,12/09/2024,,,,,
Reverified,03/21/2023,0781-3289-09,Clindamycin Phosphate Injection,800-525-8747,Available,,11/07/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)",Sandoz Inc.,,Current,['ANDA201692'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['Sandoz Inc'],"['0781-3289', '0781-3288', '0781-3290']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN'],"['309335', '309336', '309339']",['e9ea55df-4c10-43a8-97f1-02e6fce12f2b'],['231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca'],"['0781-3288-91', '0781-3288-09', '0781-3289-91', '0781-3289-09', '0781-3290-91', '0781-3290-09']",['3U02EL437C'],"['N0000009982', 'N0000175443', 'M0515779', 'N0000175731']",['Lincosamide Antibacterial [EPC]'],"['Decreased Sebaceous Gland Activity [PE]', 'Neuromuscular Blockade [PE]']",,,['Lincosamides [CS]'],,,
New,09/08/2025,47335-932-44,Vecuronium Bromide Injection,800-818-4555,,The 10 mg presentation remains available.,09/08/2025,['Anesthesia'],Injection,"Vecuronium Bromide, Injection, 20 mg (NDC 47335-932-44)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA079001'],['VECURONIUM BROMIDE'],['VECURONIUM BROMIDE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-932', '47335-931']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['VECURONIUM BROMIDE'],['859437'],['82d6bc45-04a5-409a-9223-da1884b2468f'],['a14da3ee-a731-4282-be9d-407473517470'],"['47335-931-40', '47335-931-44', '47335-932-40', '47335-932-44']",['7E4PHP5N1D'],,,,09/08/2025,,,,,
New,10/31/2025,0603-5168-21,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5168', '0603-5165', '0603-5166', '0603-5167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
Reverified,02/22/2012,83090-006-10,Lidocaine Hydrochloride Injection,"844-425-3131, SinteticaCS@eversana.com",Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X10ML) is Preservative free.",08/19/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)",Sintetica US,,Current,['ANDA214267'],['NA'],['LIDOCAINE HYDROCHLORIDE'],['Sintetica US LLC'],"['83090-006', '83090-001', '83090-002', '83090-003', '83090-004', '83090-005']",['HUMAN PRESCRIPTION DRUG'],['INFILTRATION'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737566', '1737568', '1737570', '1737757', '1737761', '1737763']",['0d18f291-3a92-421e-8841-6be743b1f154'],['aa3e688a-308c-4a82-a268-28ccf1677c55'],"['83090-001-01', '83090-001-10', '83090-002-01', '83090-002-10', '83090-003-01', '83090-003-10', '83090-004-01', '83090-004-10', '83090-005-01', '83090-005-10', '83090-006-01', '83090-006-10']",['EC2CNF7XFP'],,,,,,,,,
Revised,02/22/2012,0409-4282-02,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088294'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4282', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4277', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
Reverified,11/06/2017,0338-1007-02,Dopamine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)",Baxter Healthcare,,Current,['NDA019615'],['DOPAMINE HYDROCHLORIDE AND DEXTROSE'],['DOPAMINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-1007', '0338-1005', '0338-1009']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743869', '1743871', '1743877', '1743879']",['1b91b75f-c6e4-4425-bea8-023458ecf8f9'],['cb97d4a0-89ed-407c-a763-209386b6f75c'],"['0338-1005-02', '0338-1005-03', '0338-1007-02', '0338-1007-03', '0338-1009-02']",['7L3E358N9L'],,,,,,,,,
New,04/23/2025,0832-1054-90,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 0832-1054-90)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1054', '0832-1055']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
Reverified,10/12/2022,47781-178-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)",Alvogen,,Current,['ANDA207388'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 15 MG,CLL']",['Alvogen Inc.'],"['47781-178', '47781-174', '47781-175', '47781-176', '47781-177', '47781-179', '47781-180']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['0374f0f7-9297-810c-38b3-623a72709a7d'],['c907301d-e24d-9609-5529-fed14f94549f'],"['47781-174-30', '47781-174-05', '47781-174-01', '47781-175-30', '47781-175-05', '47781-175-01', '47781-176-30', '47781-176-05', '47781-176-01', '47781-177-30', '47781-177-05', '47781-177-01', '47781-178-30', '47781-178-05', '47781-178-01', '47781-179-30', '47781-179-05', '47781-179-01', '47781-180-30', '47781-180-05', '47781-180-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,04/28/2025,0832-7122-11,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7122', '0832-7123', '0832-7124']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
Revised,01/06/2023,0013-2649-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 0.2 mg preservative free (NDC 0013-2649-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2649', '0013-2626', '0013-2646', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Reverified,02/29/2024,62135-242-60,Naltrexone Hydrochloride Tablet,845-268-5000 Ext. 510,Available,,08/19/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 62135-242-60)",Chartwell Molecular Holdings LLC,,Current,['ANDA207905'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Chartwell RX, LLC']",['62135-242'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['1adc57cf-70f9-75b9-e063-6294a90a0de0'],['adb7c4dc-221a-4d91-9687-0d78913a92ad'],"['62135-242-30', '62135-242-60', '62135-242-90']",['Z6375YW9SF'],,,,,,,,,
New,11/03/2025,0002-4312-61,Lasmiditan Succinate Tablet,800-545-5979,,A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets.,11/03/2025,['Neurology'],Tablet,"Reyvow, Tablet, 50 mg (NDC 0002-4312-61)",Eli Lilly and Co.,,To Be Discontinued,['NDA211280'],['REYVOW'],['LASMIDITAN'],['Eli Lilly and Company'],"['0002-4312', '0002-4491']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LASMIDITAN'],"['2256937', '2256943', '2256945', '2256947']",['75a13e98-3736-4256-8277-6c05bcaddcf5'],['aea3358c-ff41-4490-9e6d-c7bf7b3de13f'],"['0002-4312-08', '0002-4312-61', '0002-4312-62', '0002-4491-08', '0002-4491-61', '0002-4491-62']",['760I9WM792'],,,,11/03/2025,,,,,
Revised,10/11/2024,0264-7751-10,Lactated Ringers Injection,800-227-2862,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-10)",B. Braun Medical Inc.,,Resolved,['NDA019634'],['DEXTROSE IN LACTATED RINGERS'],"['DEXTROSE, SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['B. Braun Medical Inc.'],['0264-7751'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'DEXTROSE MONOHYDRATE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847627'],['63aa1cd2-fda4-4386-8d11-5d1617634ef7'],['190da07e-a616-46e6-b4e5-1c0ba39306e5'],"['0264-7751-00', '0264-7751-10']","['M4I0D6VV5M', 'LX22YL083G', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Reverified,02/14/2022,0990-7923-23,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7923', '0990-7922', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Revised,04/28/2023,0264-7388-50,Sodium Chloride 0.9% Irrigation,800-227-2862,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-50)",B. Braun Medical Inc.,,Resolved,['NDA016733'],['SODIUM CHLORIDE FOR IRRIGATION'],['SODIUM CHLORIDE FOR IRRIGATION'],['B. Braun Medical Inc.'],['0264-7388'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['69f7d8f6-65cd-45bd-83f7-7249905a2e72'],['5bd9b176-0402-4a3f-a6b4-c3f393fc092a'],"['0264-7388-50', '0264-7388-60']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Reverified,07/26/2023,68025-095-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Unavailable,Estimated recovery: TBD,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)","Vertical Pharmaceuticals, LLC",Other,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-095', '68025-088', '68025-089', '68025-096', '68025-097', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
Reverified,02/08/2019,76045-106-10,Dexamethasone Sodium Phosphate Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['ANDA203129'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Fresenius Kabi USA, LLC']",['76045-106'],['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],['1812095'],['916ef348-1e5b-40b4-9d12-508fc2ce567c'],['88d25d19-acff-477b-86c8-9797782045b8'],['76045-106-10'],['AI9376Y64P'],,,,,,,,,
Reverified,11/23/2021,0409-4887-50,Sterile Water Injection,844-646-4398,Available,,10/23/2025,['Other'],Injection,"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)","Hospira, Inc., a Pfizer Company",,Current,['NDA018801'],['STERILE WATER'],['WATER'],"['Hospira, Inc.']",['0409-4887'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['900859c0-a075-4fb1-98ce-0e329acc009a'],['2b9ea23a-f9e9-48a8-25b7-519e3bbd6828'],"['0409-4887-25', '0409-4887-99', '0409-4887-31', '0409-4887-05', '0409-4887-17', '0409-4887-10', '0409-4887-32', '0409-4887-34', '0409-4887-23', '0409-4887-20', '0409-4887-24', '0409-4887-50']",['059QF0KO0R'],,,,,,,,,
Reverified,09/11/2019,68875-0203-2,Parathyroid Hormone Injection,866-888-0660,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,08/15/2025,['Endocrinology/Metabolism'],Powder,"Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Takeda Pharmaceuticals USA Inc.,Discontinuation of the manufacture of the drug,Current,['BLA125511'],['NATPARA (PARATHYROID HORMONE)'],['PARATHYROID HORMONE'],"['Takeda Pharmaceuticals America, Inc.']","['68875-0203', '68875-0202', '68875-0204', '68875-0205']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PARATHYROID HORMONE'],"['1602023', '1602028', '1602032', '1602034', '1602038', '1602040', '1602044', '1602046']",['17d2bb82-605c-43be-9918-63aeb7102d8c'],['d11fba31-0a6c-11e3-8ffd-0800200c9a66'],"['68875-0202-1', '68875-0202-2', '68875-0203-1', '68875-0203-2', '68875-0204-1', '68875-0204-2', '68875-0205-1', '68875-0205-2']",['N19A0T0E5J'],"['M0015931', 'N0000180851']",['Parathyroid Hormone [EPC]'],,,,['Parathyroid Hormone [CS]'],,,
Reverified,10/25/2017,0264-9594-10,Lidocaine Hydrochloride Injection,800-227-2862,Available,,11/04/2025,['Cardiovascular'],Injection,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)",B. Braun Medical Inc.,,Current,['NDA019830'],['LIDOCAINE HYDROCHLORIDE AND DEXTROSE'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE'],['B. Braun Medical Inc.'],"['0264-9594', '0264-9598']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE MONOHYDRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1737723', '1737742', '1737744']",['26f23356-9e1f-4c5f-9959-06d53037a715'],['7dff29d9-522d-40eb-a9d9-42377912d640'],"['0264-9598-20', '0264-9594-20', '0264-9594-10']","['EC2CNF7XFP', 'LX22YL083G']",,,,,,,,,
Revised,10/12/2022,0555-0777-02,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['0555-0777', '0555-0971', '0555-0775', '0555-0972', '0555-0776', '0555-0973', '0555-0974']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['88468f3d-7d03-4cee-aabf-3abc8c9b5e38'],['cffbbb15-d776-41ae-a8a6-687f2c07bfa4'],"['0555-0971-02', '0555-0775-02', '0555-0972-02', '0555-0776-02', '0555-0777-02', '0555-0973-02', '0555-0974-02']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/14/2022,0338-0070-10,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0070', '0338-9651', '0338-9649', '0338-9655', '0338-9653', '0338-0078', '0338-0062', '0338-0074', '0338-0066', '0338-0082']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['66eb82f8-6755-42aa-b20c-192a640e8068'],['36e9478c-5df0-4b47-b97d-de3626d7cb29'],"['0338-9651-75', '0338-9649-75', '0338-9655-60', '0338-9653-60', '0338-0078-20', '0338-0062-30', '0338-0074-30', '0338-0066-20', '0338-0070-10', '0338-0070-12', '0338-0082-10']",['LX22YL083G'],,,,,,,,,
Reverified,04/28/2023,0264-2101-00,Sterile Water Irrigant,800-227-2862,Available,,11/04/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",B. Braun Medical Inc.,,Current,['NDA016734'],['STERILE WATER'],['WATER'],['B. Braun Medical Inc.'],['0264-2101'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['969bdf41-6565-42fb-8ac1-8661a928cc22'],['f4284eb6-e553-46d4-90d8-efc80a90a480'],"['0264-2101-00', '0264-2101-10', '0264-2101-50', '0264-2101-70']",['059QF0KO0R'],,,,,,,,,
Reverified,07/26/2023,13811-706-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Limited Availability,Allocation to current contracted customers,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)","Trigen Laboratories, LLC",Demand increase for the drug,Current,['ANDA205327'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Trigen Laboratories, LLC']","['13811-706', '13811-709', '13811-707', '13811-708', '13811-710']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461']",['54f7316b-8a84-4145-aecf-f380afbf261b'],['c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f'],"['13811-709-10', '13811-706-10', '13811-707-10', '13811-708-10', '13811-710-10', '13811-710-30']",['4B3SC438HI'],,,,,,,,,
Reverified,04/10/2020,66794-230-42,Dexmedetomidine Hydrochloride Injection,855-273-0154,Available,Marketed by Piramal Critical Care Inc.: 800-414-1901,09/29/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)",Gland Pharma Limited,,Current,['ANDA202126'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],['Piramal Critical Care Inc'],['66794-230'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['309710'],['3f76a806-297b-184b-e063-6394a90a7404'],['b93a71ed-0f9e-1ff9-e053-2995a90a789d'],"['66794-230-02', '66794-230-42']",['1018WH7F9I'],,,,,,,,,
New,02/04/2025,0472-0117-20,Tretinoin Cream,800-796-9526,,,02/04/2025,['Dermatology'],Cream,"Avita, Cream, .25 mg/1 g (NDC 0472-0117-20)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA020404'],['TRETINOIN'],['TRETINOIN'],"['Actavis Pharma, Inc.']",['0472-0117'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['TRETINOIN'],['106302'],['b99bedbe-3d36-47dd-b84c-05f8bb394b83'],['b5e385a2-f6f9-41cb-8a33-eedba397043f'],"['0472-0117-20', '0472-0117-45']",['5688UTC01R'],"['N0000175607', 'M0018962']",['Retinoid [EPC]'],,02/04/2025,,['Retinoids [CS]'],,,
Revised,04/26/2023,60793-700-10,Penicillin G Benzathine Injection,844-646-4398,Unavailable,Next Delivery: November 2025,10/23/2025,['Anti-Infective'],Injection,"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)",Pfizer Inc.,Other,Current,['NDA050141'],['BICILLIN L-A'],['PENICILLIN G BENZATHINE'],['Pfizer Laboratories Div Pfizer Inc'],"['60793-700', '60793-701', '60793-702']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PENICILLIN G BENZATHINE'],"['731564', '731566', '731567', '731568', '731570', '731571']",['4b3694af-9d77-487f-8838-b75aec6636da'],['012d46f1-d0a0-4676-a879-cd320297ab16'],"['60793-700-01', '60793-700-10', '60793-701-02', '60793-701-10', '60793-702-04', '60793-702-10']",['RIT82F58GK'],,,,,https://www.fda.gov/media/188355/download,,,,
Revised,02/22/2012,63323-485-57,Lidocaine Hydrochloride Injection,888-386-1300,Unavailable,Backordered. Next release December 2025. Check wholesalers for inventory.,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA006488'],['XYLOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-485', '63323-492', '63323-491', '63323-495', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,02/22/2012,63323-491-57,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-491', '63323-492', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],['INFILTRATION'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,11/06/2017,0338-1073-02,Dobutamine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)",Baxter Healthcare,,Current,['NDA020255'],['DOBUTAMINE HYDROCHLORIDE IN DEXTROSE'],['DOBUTAMINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-1073', '0338-1075', '0338-1077']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],"['309985', '309986', '309987']",['2ac85da3-8337-4b3b-8cda-d9399780542f'],['6b17b98b-e06d-42ed-925f-69aa2699dead'],"['0338-1073-02', '0338-1075-02', '0338-1077-02']",['0WR771DJXV'],,,,,,,,,
New,01/13/2025,0069-1501-30,Talazoparib Tosylate Capsule,800-533-4535,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0546-30",01/13/2025,['Oncology'],Capsule,"Talzenna, Capsule, .5 mg (NDC 0069-1501-30)",Pfizer Inc.,,To Be Discontinued,['NDA211651'],['TALZENNA'],['TALAZOPARIB'],['Pfizer Laboratories Div Pfizer Inc'],"['0069-1501', '0069-0296', '0069-1195', '0069-1751', '0069-1031', '0069-1235']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TALAZOPARIB TOSYLATE'],"['2099946', '2099952', '2099954', '2099956', '2591510', '2591512', '2591520', '2591521', '2639960', '2639962', '2639964', '2639966']",['2cb65f61-9a14-46d9-85a3-a7eea76160c5'],['f2423edd-6d24-495c-aec1-c2f457f08d9a'],"['0069-0296-30', '0069-1195-30', '0069-1501-30', '0069-1751-30', '0069-1031-30', '0069-1235-30']",['02WK9U5NZC'],,,,01/13/2025,,,,,
Reverified,04/02/2020,23155-601-42,Midazolam Hydrochloride Injection,855-228-9470,Available,,11/03/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)","Avet Pharmaceuticals, Inc.",,Current,['ANDA090850'],['MIDAZOLAM HYDROCHLORIDE'],['MIDAZOLAM HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],['23155-601'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],['311702'],['e20feff9-3aca-4bc1-a5c3-44fff8a9459c'],['843cc25e-45ea-4372-ae34-843f805fa869'],"['23155-601-31', '23155-601-41', '23155-601-32', '23155-601-42']",['W7TTW573JJ'],,,,,,,,,
Reverified,03/01/2022,0990-7938-19,Dextrose Monohydrate 10% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)",Otsuka ICU Medical LLC,,Current,['NDA018080'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']",['0990-7938'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],['1795477'],['43f81a41-0a45-45f5-840c-768d768edd3b'],['cb578dba-094c-4787-951d-763d12fd06e1'],['0990-7938-19'],['LX22YL083G'],,,,,,,,,
Revised,04/28/2023,55150-386-01,Carboplatin Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Oncology'],Injection,"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)",Eugia US LLC,,Current,['ANDA205487'],['CARBOPLATIN'],['CARBOPLATIN'],['Eugia US LLC'],"['55150-386', '55150-333', '55150-334', '55150-335']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],"['6029d051-ee8d-44cc-8dae-b91c3385d4c3', '5abfcb87-bb02-4384-9c9d-7d0e3e809311']","['f5fe9a20-47a5-45b9-ab06-c6158d9b6aca', '5abfcb87-bb02-4384-9c9d-7d0e3e809311']","['55150-333-01', '55150-334-01', '55150-335-01', '55150-386-01', '55150-335-00', '55150-386-00']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,06/28/2022,63323-723-03,Remifentanil Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)","Fresenius Kabi USA, LLC",,Current,['ANDA206223'],['REMIFENTANIL HYDROCHLORIDE'],['REMIFENTANIL HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-723', '63323-724', '63323-725']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729584', '1729710']","['406a07e3-a3f8-4fef-901e-021d00743c40', '2f27e51f-2b55-47ee-bd4a-001b71c60622']","['5b8025d2-3424-477b-9cff-3990a98c2a65', 'd2374b84-81c9-44f9-a4a9-1071281b2531']","['63323-723-04', '63323-723-06', '63323-723-01', '63323-723-03', '63323-724-01', '63323-724-05', '63323-725-01', '63323-725-10']",['5V444H5WIC'],,,,,,,,,
Reverified,10/12/2022,70010-117-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",877-770-3183,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)",Granules Pharmaceuticals Inc.,,Current,['ANDA215771'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Granules Pharmaceuticals Inc.'],"['70010-117', '70010-111', '70010-112', '70010-113', '70010-114', '70010-115', '70010-116']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['2fab399e-2a43-5134-e063-6294a90ae09a'],['b0b4eccc-34c7-483d-966f-82d588358e1b'],"['70010-111-01', '70010-111-03', '70010-112-01', '70010-112-03', '70010-113-01', '70010-113-03', '70010-114-01', '70010-114-03', '70010-115-01', '70010-115-03', '70010-116-01', '70010-116-03', '70010-117-01', '70010-117-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,07/14/2023,0480-3567-01,Lisdexamfetamine Dimesylate Capsule,800-545-8800,Limited Availability,Estimated availability: November 2025,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)","Teva Pharmaceuticals USA, Inc.",Other,Current,['ANDA202802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Teva Pharmaceuticals, Inc.']","['0480-3567', '0480-3565', '0480-3566', '0480-3568', '0480-3569', '0480-3570', '0480-3564']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['6cfe6c98-51b1-45a4-831c-33624ab129cb'],['c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc'],"['0480-3565-01', '0480-3566-01', '0480-3567-01', '0480-3568-01', '0480-3569-01', '0480-3570-01', '0480-3564-01']",['SJT761GEGS'],,,,,,,,,
Reverified,01/01/2012,63323-806-02,Fentanyl Citrate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)","Fresenius Kabi USA, LLC",,Current,['ANDA210762'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Fresenius Kabi USA, LLC']",['63323-806'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270']",['341b092a-1f6f-40f1-98f2-9346bf2e1242'],['38d0c14a-a0c1-44cc-a939-0304eb8037d6'],"['63323-806-11', '63323-806-01', '63323-806-12', '63323-806-02', '63323-806-13', '63323-806-05', '63323-806-14', '63323-806-20', '63323-806-50']",['MUN5LYG46H'],,,,,,,,,
Revised,02/20/2018,0409-9045-01,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA071168'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-9045', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,10/12/2022,72516-011-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",855-257-0292,Available,,10/24/2025,['Psychiatry'],Tablet,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)",Oryza Pharmaceuticals Inc.,,Current,['ANDA210293'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Oryza Pharmaceuticals Inc.'],"['72516-011', '72516-016', '72516-015', '72516-014', '72516-013', '72516-012']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['39fb17a2-617d-37dc-e063-6394a90a1be3'],['acd27181-a3f3-4c38-85d8-029a4a82e7c2'],"['72516-016-01', '72516-015-01', '72516-014-01', '72516-013-01', '72516-012-01', '72516-011-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/13/2025,13668-383-90,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-90)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Reverified,02/20/2018,63323-467-57,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)","Fresenius Kabi USA, LLC",,Current,['NDA018304'],['SENSORCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-467', '63323-465', '63323-460', '63323-464', '63323-466', '63323-462']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],['BUPIVACAINE HYDROCHLORIDE'],"['1012391', '1012396', '1012404', '1012421', '1012455', '1012457', '1672917', '1672919', '1673296', '1673298', '1724880', '1724881', '1724884', '1724885', '1725078', '1725082', '1725175', '1725177']",['2b1a1f80-cb29-4ac1-9e72-20225ed45715'],['eb6d8fee-def4-4c96-9972-695e8cea8ea8'],"['63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,05/19/2025,62037-560-10,"Potassium Chloride Capsule, Extended Release",800-545-8800,,,05/19/2025,"['Endocrinology/Metabolism', 'Gastroenterology']","Capsule, Extended Release","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077419'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Actavis Pharma, Inc.']","['62037-560', '62037-559']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312504', '315183']",['b97da107-c56e-48ea-ba34-d3d64a5b9f46'],['ed5baaf6-270b-4dd3-b100-36030c0098fc'],"['62037-559-01', '62037-559-05', '62037-560-01', '62037-560-05', '62037-560-10', '62037-560-90']",['660YQ98I10'],,,,05/19/2025,,,,,
Revised,07/18/2023,0143-9144-02,Liraglutide Injection,800-631-2174,Available,Product will be made available as it is released.,10/24/2025,['Endocrinology/Metabolism'],Injection,"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA215503'],['LIRAGLUTIDE'],['LIRAGLUTIDE'],['Hikma Pharmaceuticals USA Inc.'],['0143-9144'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],['897122'],['f242c0f8-6d4f-4a78-a1fd-433a0672dbd3'],['2100ec49-57b2-4330-ab5f-057ce9b7e4d0'],"['0143-9144-03', '0143-9144-02']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
New,01/28/2025,64380-789-33,Lidocaine Ointment,877-244-9825,,,01/28/2025,['Anesthesia'],Ointment,"Lidocaine, Ointment, 5%, 50 gram jar (NDC 64380-789-33)",Strides Pharma Inc.,,To Be Discontinued,['ANDA210958'],['LIDOCAINE'],['LIDOCAINE'],['Strides Pharma Science Limited'],['64380-789'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['LIDOCAINE'],['1543069'],['e6c9429c-13b9-4932-abad-e605c4c7fb68'],['8b1efeaa-31b1-4f34-960f-7a920ac07355'],"['64380-789-32', '64380-789-23', '64380-789-33']",['98PI200987'],"['N0000175682', 'M0000897', 'N0000175426', 'N0000175976']","['Amide Local Anesthetic [EPC]', 'Antiarrhythmic [EPC]']",['Local Anesthesia [PE]'],01/28/2025,,['Amides [CS]'],,,
New,10/17/2025,0006-3074-02,Elbasvir; Grazoprevir Tablet,800-672-6372,,"To be discontinued December 1, 2025",10/17/2025,['Antiviral'],Tablet,"Zepatier, Tablet, 50 mg; 100 mg (NDC 0006-3074-02)",Merck Sharp & Dohme LLC,,To Be Discontinued,['NDA208261'],['ZEPATIER'],['ELBASVIR AND GRAZOPREVIR'],['Merck Sharp & Dohme LLC'],['0006-3074'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ELBASVIR', 'GRAZOPREVIR ANHYDROUS']","['1734636', '1734642']",['21d93204-5c90-4b70-aec4-f7e60b197fac'],['164dc02a-9180-426a-b8b5-04ab39d2bbd4'],"['0006-3074-01', '0006-3074-02']","['632L571YDK', '8YE81R1X1J']","['N0000191256', 'N0000190113', 'N0000182638', 'N0000182639', 'N0000190114']","['Hepatitis C Virus NS5A Inhibitor [EPC]', 'Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]']",,10/17/2025,,,,"['Breast Cancer Resistance Protein Inhibitors [MoA]', 'HCV NS3/4A Protease Inhibitors [MoA]', 'Cytochrome P450 3A Inhibitors [MoA]']",
New,02/26/2025,58151-099-91,Tolterodine Tartrate Tablet,800-796-9526,,,02/26/2025,['Urology'],Tablet,"Detrol, Tablet, 2 mg (NDC 58151-099-91)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA020771'],['DETROL'],['TOLTERODINE TARTRATE'],['Viatris Specialty LLC'],"['58151-099', '58151-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOLTERODINE TARTRATE'],"['855178', '855180', '855194', '855195']",['f27726af-7a9b-45f4-96e0-1e90a5fdcc18'],['41eb00d2-64e3-4ec9-8732-4bfc81b04180'],"['58151-098-91', '58151-099-91']",['5T619TQR3R'],,,,02/26/2025,,,,,
Revised,04/02/2020,0641-6060-10,Midazolam Hydrochloride Injection,800-631-2174,Unavailable,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,10/24/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA075243'],['MIDAZOLAM'],['MIDAZOLAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6060', '0641-6057', '0641-6059', '0641-6056', '0641-6061', '0641-6063']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['559c03fb-24ea-4b7b-8afd-e33cb3a2340a'],['575d8bf0-7af7-427c-a231-966e2a5e070d'],"['0641-6057-01', '0641-6057-10', '0641-6057-25', '0641-6059-01', '0641-6059-10', '0641-6056-01', '0641-6056-10', '0641-6061-01', '0641-6061-10', '0641-6061-25', '0641-6063-01', '0641-6063-10', '0641-6063-25', '0641-6060-01', '0641-6060-10']",['W7TTW573JJ'],,,,,,,,,
New,01/28/2025,71093-128-03,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-03)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-128', '71093-127']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
Revised,02/20/2018,55150-172-30,Bupivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)",Eugia US LLC,,Current,['ANDA203895'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-172', '55150-167', '55150-168', '55150-169', '55150-170', '55150-171', '55150-249', '55150-250']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
New,05/14/2025,0832-0741-60,"Propafenone Hydrochloride Capsule, Extended Release",800-654-2299,,A business decision was made to discontinue the product.,05/14/2025,['Cardiovascular'],"Capsule, Extended Release","Propafenone Hydrochloride, Capsule, Extended Release, 325 mg (NDC 0832-0741-60)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA212744'],['PROPAFENONE HYDROCHLORIDE'],['PROPAFENONE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0741', '0832-0740', '0832-0742']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PROPAFENONE HYDROCHLORIDE'],"['861156', '861164', '861171']",['398513af-dd95-49eb-e063-6394a90a73f4'],['8aa6f58a-2980-4caa-9c54-d55d69d5d132'],"['0832-0740-60', '0832-0741-60', '0832-0742-60']",['33XCH0HOCD'],,,,05/14/2025,,,,,
Reverified,07/14/2023,47781-562-01,Lisdexamfetamine Dimesylate Capsule,844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)",Alvogen,,Current,['ANDA214547'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Alvogen Inc.'],"['47781-562', '47781-563', '47781-564', '47781-565', '47781-566', '47781-567', '47781-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['567bb281-4098-07f8-9503-92299dc1c4c6'],['7f2dd6ee-3363-c87c-9693-ed838942556c'],"['47781-562-01', '47781-563-01', '47781-564-01', '47781-565-01', '47781-566-01', '47781-567-01', '47781-568-01']",['SJT761GEGS'],,,,,,,,,
Reverified,11/01/2023,60505-4742-1,Lisdexamfetamine Dimesylate Capsule,800-706-5575,Available,Product currently available,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)",Apotex Corp.,,Current,['ANDA216944'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Apotex Corp.'],"['60505-4742', '60505-4739', '60505-4740', '60505-4741', '60505-4743', '60505-4744', '60505-4745']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7a3783a0-bb54-a95b-99f4-9d3aa9788649'],['ecad4442-a644-18e3-6ff2-fdbac45eec47'],"['60505-4739-1', '60505-4740-1', '60505-4741-1', '60505-4742-1', '60505-4743-1', '60505-4744-1', '60505-4745-1']",['SJT761GEGS'],,,,,,,,,
Reverified,10/05/2022,72266-147-10,Etomidate Injection,833-291-9645,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",09/29/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)",Gland Pharma Limited,,Current,['ANDA209058'],['ETOMIDATE'],['ETOMIDATE INJECTION'],['Fosun Pharma USA Inc'],"['72266-147', '72266-146']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['2b365133-b609-3285-e063-6394a90a69a6'],['8b6c54d8-3f3f-4290-841c-976bea01086f'],"['72266-146-01', '72266-146-10', '72266-147-01', '72266-147-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
New,12/23/2024,0006-3025-00,Bezlotoxumab Injection,800-672-6372,,"To be discontinued on January 31, 2025",12/23/2024,['Anti-Infective'],Injection,"Zinplava, Injection, 25 mg/1 mL (NDC 0006-3025-00)",Merck Sharp & Dohme LLC,,To Be Discontinued,['BLA761046'],['ZINPLAVA'],['BEZLOTOXUMAB'],['Merck Sharp & Dohme LLC'],['0006-3025'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['BEZLOTOXUMAB'],"['1855052', '1855057']",['12338d29-efb0-4943-b5f5-826350e9ec46'],['8f479bfe-2bfa-4cc5-9aee-1357364480b0'],"['0006-3025-01', '0006-3025-00']",['4H5YMK1H2E'],,,,12/23/2024,,,,,
Reverified,02/29/2024,0406-1170-03,Naltrexone Hydrochloride Tablet,800-325-8888,Available,,11/05/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-03)",SpecGx LLC,,Current,['ANDA076264'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],['SpecGx LLC'],['0406-1170'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['9ed13551-325e-4b82-a266-72fc89ed27dc'],['06ff2d5a-e62b-4fa4-bbdb-01938535bc65'],"['0406-1170-03', '0406-1170-01']",['Z6375YW9SF'],,,,,,,,,
New,01/31/2025,0173-0519-00,Epoprostenol Sodium Injection,888-825-5249,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",01/31/2025,['Cardiovascular'],Injection,"Flolan, Injection, 1.5 mg (NDC 0173-0519-00)",GlaxoSmithKline,,To Be Discontinued,['NDA020444'],['FLOLAN'],['EPOPROSTENOL SODIUM'],['GlaxoSmithKline LLC'],"['0173-0519', '0173-0517', '0173-0857']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['EPOPROSTENOL SODIUM'],"['211199', '211200', '562501', '562502']",['5e54002e-7b03-46ad-ae01-c76c76967201'],['8e4b636e-ee9c-4111-779d-28c8369d283b'],"['0173-0517-00', '0173-0519-00', '0173-0857-02']","['4K04IQ1OF4', '059QF0KO0R']",,,,01/31/2025,,,,,
New,03/28/2025,60505-6282-1,Carboplatin Injection,800-706-5575,,Discontinuation due to low sales volume. Supply currently available with June 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),03/28/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-1)",Teyro Labs,,To Be Discontinued,['ANDA077861'],['CARBOPLATIN'],['CARBOPLATIN'],['Apotex Corp.'],['60505-6282'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0e68e276-b0df-4f03-e063-6394a90a22b9'],['1c275825-0275-4c73-b650-e4c1519f13b8'],"['60505-6282-1', '60505-6282-3', '60505-6282-6', '60505-6282-7']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,03/28/2025,,,,,
Reverified,01/19/2023,68180-558-09,Quinapril Hydrochloride Tablet,866-587-4617,Unavailable,,09/18/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)","Lupin Pharmaceuticals, Inc.",Requirements related to complying with good manufacturing practices,Current,['ANDA077690'],['QUINAPRIL'],['QUINAPRIL'],"['Lupin Pharmaceuticals, Inc.']","['68180-558', '68180-556', '68180-557', '68180-554', '68180-559']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['a9598a21-6f99-4c86-ace6-b5638da2bec8'],['8ded0773-3aec-4e89-9836-d22a5a84abf0'],"['68180-556-09', '68180-557-09', '68180-557-03', '68180-558-09', '68180-558-03', '68180-554-09', '68180-554-03', '68180-559-03', '68180-559-09']",['33067B3N2M'],,,,,,,,,
Reverified,07/14/2023,59417-101-10,Lisdexamfetamine Dimesylate Capsule,877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],Capsule,"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA021977'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Reverified,07/14/2023,0378-6857-77,Lisdexamfetamine Dimesylate Capsule,800-796-9526,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA202835'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Mylan Pharmaceuticals Inc.'],"['0378-6857', '0378-6854', '0378-6855', '0378-6856', '0378-6858', '0378-6859', '0378-6860']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['63cd6f7c-f976-440e-a35f-e71a9f2fd1bb'],['efbde0f6-b848-4664-b741-c6c630e66108'],"['0378-6854-77', '0378-6855-77', '0378-6856-77', '0378-6857-77', '0378-6858-77', '0378-6859-77', '0378-6860-77']",['SJT761GEGS'],,,,,,,,,
New,06/27/2025,0591-3713-30,Ezetimibe Tablet,800-545-8800,,A business decision was made to discontinue manufacture of the product,06/27/2025,['Cardiovascular'],Tablet,"Ezetimibe, Tablet, 10 mg (NDC 0591-3713-30)","Actavis Pharma, Inc.",,To Be Discontinued,['ANDA200831'],['EZETIMIBE'],['EZETIMIBE'],"['Actavis Pharma, Inc.']",['0591-3713'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['EZETIMIBE'],['349556'],['24aaf5ca-08e0-4db8-9734-cf2a606f8e57'],['f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba'],"['0591-3713-30', '0591-3713-19', '0591-3713-05']",['EOR26LQQ24'],"['N0000008553', 'N0000175911']",['Dietary Cholesterol Absorption Inhibitor [EPC]'],['Decreased Cholesterol Absorption [PE]'],06/27/2025,,,,,
Revised,02/20/2018,0409-1560-29,Bupivacaine Hydrochloride Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: September 2027,10/23/2025,['Anesthesia'],Injection,"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1560', '0409-1559', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,10/09/2025,0781-2859-01,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-01)",Sandoz Inc.,,To Be Discontinued,['ANDA075757'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],"['0781-2859', '0781-2868']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],"['198051', '199119']",['6a54ba13-eeb3-4c8c-800b-dc9aaf961c3f'],['516170d4-4913-4577-a2d2-f5c52d1e79c6'],"['0781-2859-10', '0781-2859-01', '0781-2859-92', '0781-2859-31', '0781-2868-10', '0781-2868-01', '0781-2868-92', '0781-2868-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
New,06/16/2025,0093-7679-02,Ethinyl Estradiol; Etonogestrel Ring,800-545-8800,,Discontinuation of the manufacture of the drug,06/16/2025,['Reproductive'],Ring,"Ethinyl Estradiol; Etonogestrel, Ring, .015 mg/1 d; .12 mg/1 d (NDC 0093-7679-02)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA204305'],['ETONOGESTREL AND ETHINYL ESTRADIOL'],['ETONOGESTREL AND ETHINYL ESTRADIOL'],"['Teva Pharmaceuticals USA, Inc.']",['0093-7679'],['HUMAN PRESCRIPTION DRUG'],['VAGINAL'],"['ETHINYL ESTRADIOL', 'ETONOGESTREL']",['1367436'],['d0827dbf-9df5-4438-a0c2-92d7d593e71c'],['a8cc104a-d522-49ad-af54-2f312b829b61'],"['0093-7679-01', '0093-7679-02']","['423D2T571U', '304GTH6RNH']","['N0000175825', 'N0000000100', 'M0447349', 'N0000175602']","['Estrogen [EPC]', 'Progestin [EPC]']",,06/16/2025,,['Progesterone Congeners [CS]'],,['Estrogen Receptor Agonists [MoA]'],
Reverified,03/10/2023,72888-154-30,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-154', '72888-152', '72888-153']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,12/10/2021,0338-9543-06,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9543', '0338-9657', '0338-9659', '0338-9661', '0338-9663']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['6680afa2-1474-4bc3-afee-a333a042fd3f'],['958d35f0-6834-43be-a700-fa58f38b4c19'],"['0338-9543-01', '0338-9543-02', '0338-9543-03', '0338-9543-04', '0338-9543-05', '0338-9543-06', '0338-9543-12', '0338-9657-75', '0338-9659-75', '0338-9661-60', '0338-9663-60']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,42806-341-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(718) 276-8600 ext. 3,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)","Epic Pharma, LLC",,Current,['ANDA040444'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Epic Pharma, LLC']","['42806-341', '42806-339', '42806-343', '42806-344', '42806-345']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961']",['f11301e2-3b5d-468d-b44c-45839e7e5dfb'],['1757e132-061d-4773-89ed-fdc77f69008f'],"['42806-339-01', '42806-341-01', '42806-343-01', '42806-344-01', '42806-345-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/03/2025,65862-064-01,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-064', '65862-062', '65862-063']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
New,02/06/2025,0013-2576-91,Idarubicin Hydrochloride Injection,844-646-4398,,Replaced with NDC 0013-2576-05,02/06/2025,['Oncology'],Injection,"Idamycin, Injection, 1 mg/1 mL (NDC 0013-2576-91)",Pfizer Inc.,,To Be Discontinued,['NDA050734'],['IDAMYCIN PFS'],['IDARUBICIN HYDROCHLORIDE'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2576', '0013-2586', '0013-2596']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['IDARUBICIN HYDROCHLORIDE'],"['1791493', '1791495', '1791498', '1791499', '1791500', '1791501']",['04db6b10-1bb9-4797-99a2-38e33669c56e'],['0a5a6d93-cc1e-4d7f-8da1-446c134503b3'],"['0013-2576-91', '0013-2576-05', '0013-2586-91', '0013-2586-10', '0013-2596-91', '0013-2596-20']",['5VV3MDU5IE'],,,,02/06/2025,,,,,
New,11/21/2024,0173-0914-13,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-13)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0914', '0173-0897', '0173-0903', '0173-0906', '0173-0911']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Reverified,12/22/2021,68180-659-07,Rifampin Capsule,866-587-4617,Available,,09/18/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 300 mg (NDC 68180-659-07)","Lupin Pharmaceuticals, Inc.",,Current,['ANDA090034'],['RIFAMPIN'],['RIFAMPIN'],"['Lupin Pharmaceuticals, Inc.']","['68180-659', '68180-658']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['3c9f0101-dcf8-487e-985e-09c56746d3a1'],['b56004f0-f23d-47f6-80c7-39884fccbccc'],"['68180-658-06', '68180-658-01', '68180-659-06', '68180-659-07', '68180-659-01']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,10/12/2022,0527-0764-37,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)","Lannett Company, Inc.",,Current,['ANDA215565'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Lannett Company, Inc.']","['0527-0764', '0527-0760', '0527-0761', '0527-0762', '0527-0763', '0527-0765', '0527-0766']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['e0804f43-4685-4017-b839-3212d1167362'],['f92497b5-baea-4760-b615-45a0b6184402'],"['0527-0760-37', '0527-0761-37', '0527-0762-37', '0527-0763-37', '0527-0764-37', '0527-0765-37', '0527-0766-37']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,04/28/2023,0703-4246-01,Carboplatin Injection,800-545-8800,Limited Availability,Limited Availability,10/16/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)","Teva Pharmaceuticals USA, Inc.",Delay in shipping of the drug,Current,['ANDA077269'],['CARBOPLATIN'],['CARBOPLATIN'],"['Teva Parenteral Medicines, Inc.']","['0703-4246', '0703-4244', '0703-4248', '0703-4239']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],"['bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df', 'b943761e-6a46-45a0-bdb4-1fec1e101f8c']","['f330f5a2-2cad-402f-bcbb-26245a753276', 'e176b6ef-2ff6-498b-a9d8-7a634d147f37']","['0703-4244-01', '0703-4246-01', '0703-4248-01', '0703-4239-01', '0703-4244-81', '0703-4246-81', '0703-4248-81', '0703-4239-81']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,03/23/2018,70069-062-25,Ropivacaine Hydrochloride Injection,732-554-1019,Available,,08/19/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)","Somerset Therapeutics, LLC",,Current,['ANDA207636'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-062', '70069-061', '70069-063', '70069-064', '70069-065', '70069-066', '70069-067']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734203', '1734207', '1734475', '1734483']",['79b226f0-c08a-4f84-bf2b-ae5c60e01d67'],['ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64'],"['70069-061-01', '70069-061-25', '70069-061-10', '70069-062-01', '70069-062-25', '70069-062-10', '70069-063-01', '70069-063-25', '70069-064-01', '70069-064-10', '70069-064-25', '70069-065-01', '70069-065-25', '70069-066-01', '70069-066-25', '70069-066-10', '70069-067-01', '70069-067-25', '70069-067-10']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,43547-608-10,Lisdexamfetamine Dimesylate Capsule,866-931-9829,Limited Availability,On allocation,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA216266'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE CAPSULES'],"['Solco Healthcare US,LLC']","['43547-608', '43547-602', '43547-603', '43547-604', '43547-605', '43547-606', '43547-607']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7bb11568-67a4-4221-bb9b-23af37a1791c'],['68b10d9f-ca3e-493d-a309-45f1d7e08061'],"['43547-602-10', '43547-603-10', '43547-604-10', '43547-605-10', '43547-606-10', '43547-607-10', '43547-608-10']",['SJT761GEGS'],,,,,,,,,
Reverified,05/03/2018,76329-8261-1,Lorazepam Injection,800-423-4136,Limited Availability,Limited Availability,10/17/2025,['Neurology'],Injection,"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)","Amphastar Pharmaceuticals, Inc.",Demand increase for the drug,Current,['ANDA076150'],['LORAZEPAM'],['LORAZEPAM'],"['International Medication Systems, Limited']",['76329-8261'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],['238100'],['b85a6695-55b9-4780-a803-33f8f2464138'],['7dda070d-7809-46c4-8592-eb4e4c509707'],['76329-8261-1'],['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,04/07/2020,25021-311-10,Furosemide Injection,866-625-1618,Available,,08/26/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Sagent Pharmaceuticals,,Current,['ANDA213902'],['FUROSEMIDE'],['FUROSEMIDE'],['Sagent Pharmaceuticals'],['25021-311'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['222ce48f-2856-4be2-b16f-6fca38c0dceb'],['d63c1277-dd7e-4d21-9e80-68143f55e2dc'],"['25021-311-02', '25021-311-04', '25021-311-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,04/28/2023,54288-164-01,Carboplatin Injection,"Distributed by BPI Labs, LLC;  Customer service number:  (727) 471-0850 Ext 270",Unavailable,"Discontinued; Distributed by BPI Labs, LLC",09/29/2025,['Oncology'],Injection,"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)",Gland Pharma Limited,Discontinuation of the manufacture of the drug,Current,['ANDA207324'],['CARBOPLATIN'],['CARBOPLATIN'],['BPI Labs LLC'],"['54288-164', '54288-165', '54288-166', '54288-167']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5eb7631e-0b41-4aba-ba7a-f544ac9627fd'],['5484d2f0-0cc2-4bba-8f26-c7f6539a9606'],"['54288-165-01', '54288-166-01', '54288-167-01', '54288-164-01']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,05/19/2025,62037-560-01,"Potassium Chloride Capsule, Extended Release",800-545-8800,,,05/19/2025,"['Endocrinology/Metabolism', 'Gastroenterology']","Capsule, Extended Release","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077419'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Actavis Pharma, Inc.']","['62037-560', '62037-559']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312504', '315183']",['b97da107-c56e-48ea-ba34-d3d64a5b9f46'],['ed5baaf6-270b-4dd3-b100-36030c0098fc'],"['62037-559-01', '62037-559-05', '62037-560-01', '62037-560-05', '62037-560-10', '62037-560-90']",['660YQ98I10'],,,,05/19/2025,,,,,
Reverified,08/03/2022,62135-737-90,Flurazepam Hydrochloride Capsule,845-268-5000 Ext. 510,Available,,08/19/2025,"['Neurology', 'Other']",Capsule,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA072369'],['FLURAZEPAM HYDROCHLORIDE'],['FLURAZEPAM HYDROCHLORIDE'],"['Chartwell RX, LLC']","['62135-737', '62135-736']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLURAZEPAM HYDROCHLORIDE'],"['1298088', '1298091']",['25893c92-c8f1-567a-e063-6294a90a00d4'],['8f476891-1346-4e8c-ac1b-f8cbdc64f5a1'],"['62135-736-30', '62135-736-90', '62135-737-30', '62135-737-90']",['756RDM536M'],,,,,,,,,
Reverified,12/08/2020,0338-0499-06,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)",Baxter Healthcare,,Current,['NDA020849'],['PROSOL'],"['VALINE, LYSINE, HISTIDINE, ISOLEUCINE, LEUCINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE']",['Baxter Healthcare Corporation'],['0338-0499'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['801133', '801136']",['ee240b46-c2a9-42e0-8750-a5a554becea3'],['cc2ace81-5881-43f1-ba94-41b674adc2fc'],['0338-0499-06'],"['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
New,06/10/2025,46163-300-10,Sodium Chloride 0.9% Injection,800-323-5188,,Discontinuation of the manufacture of the drug,06/10/2025,"['Gastroenterology', 'Renal']",Injection,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 46163-300-10)",Fresenius Medical Care North America,,To Be Discontinued,['ANDA078177'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Medical Care de Mexico, S.A. de C.V.']",['46163-300'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],['1807639'],['2658bf7c-78a1-7a7a-e063-6394a90aac0c'],['9a1220fb-6853-45ae-838c-10d8596e1af7'],['46163-300-10'],['451W47IQ8X'],,,,06/10/2025,,,,,
Revised,07/14/2023,72205-132-91,"Lisdexamfetamine Dimesylate Tablet, Chewable",(855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)",Novadoz Pharmaceuticals LLC,Shortage of an active ingredient,Current,['ANDA218306'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Novadoz Pharmaceuticals LLC'],"['72205-132', '72205-133', '72205-134', '72205-135', '72205-136', '72205-137']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],"['72205-132-91', '72205-133-91', '72205-134-91', '72205-135-91', '72205-136-91', '72205-137-91']",['SJT761GEGS'],,,,,,,,,
Reverified,02/28/2025,68968-5554-3,"Methylphenidate Film, Extended Release",800-455-8070,Unavailable,Estimated availability TBD,10/02/2025,['Psychiatry'],"Film, Extended Release","Daytrana, Film, Extended Release, 20 mg (NDC 68968-5554-3)","Noven Pharmaceuticals, Inc.",Shortage of an active ingredient,Current,['NDA021514'],['DAYTRANA'],['METHYLPHENIDATE'],"['Noven Therapeutics, LLC']","['68968-5554', '68968-5552', '68968-5553', '68968-5555']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443']",['55f4b5f4-6d3c-4677-a94c-d47ffb59a91a'],['2c312c31-3198-4775-91ab-294e0b4b9e7f'],"['68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
New,02/06/2025,0591-0845-01,"Glipizide Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue manufacture of the drug.,02/06/2025,['Endocrinology/Metabolism'],Tablet,"Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,02/06/2025,,,,,
New,05/14/2025,0245-0036-60,Cholestyramine Powder,800-654-2299,,A business decision was made to discontinue the product.,05/14/2025,['Cardiovascular'],Powder,"Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-60)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA073263'],['PREVALITE'],['CHOLESTYRAMINE'],"['Upsher-Smith Laboratories, LLC']",['0245-0036'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CHOLESTYRAMINE'],"['848951', '1801279']",['39e73fd2-1ad0-aae8-e063-6294a90acd5a'],['dd434ef8-8af3-434c-a0a0-9a0b18459ba0'],"['0245-0036-89', '0245-0036-42', '0245-0036-60', '0245-0036-23']",['4B33BGI082'],"['N0000180292', 'N0000175365']",['Bile Acid Sequestrant [EPC]'],,05/14/2025,,,,['Bile-acid Binding Activity [MoA]'],
New,07/17/2025,0591-2682-01,"Potassium Citrate Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue.,07/17/2025,['Renal'],Tablet,"Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)",Watson Pharma Private Limited,,To Be Discontinued,['ANDA209758'],['POTASSIUM CITRATE'],['POTASSIUM CITRATE'],"['Actavis Pharma, Inc.']","['0591-2682', '0591-2729', '0591-2742']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CITRATE'],"['199376', '199381', '898490']",['b81078a3-490a-4a03-a9a5-9c64acde67bf'],['ac173781-486b-461c-97ae-8b5c69e20792'],"['0591-2682-01', '0591-2729-01', '0591-2742-01']",['EE90ONI6FF'],,,,07/17/2025,,,,,
Reverified,04/07/2020,83634-302-04,Furosemide Injection,855-228-9470,Available,Distributed by Avenacy; Contact information: 877-283-6229,11/03/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL; 4mL vial (NDC 83634-302-04)","Avet Pharmaceuticals, Inc.",,Current,['ANDA203428'],['FUROSEMIDE'],['FUROSEMIDE'],['Avenacy Inc.'],['83634-302'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['1b3f2803-b618-4447-b5ac-cd2bdc7de3e8'],['7d0db0f7-bf4f-4b0b-9359-2a838626e04b'],"['83634-302-42', '83634-302-02', '83634-302-43', '83634-302-04', '83634-302-41', '83634-302-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/10/2023,72888-152-00,Clonazepam Tablet,sales@advagenpharma.com,Information pending,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-152', '72888-153', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,12/18/2020,43598-305-62,Azacitidine Injection,866-732-3952,Available,Available to existing customers,10/21/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg (NDC 43598-305-62)","Dr. Reddy's Laboratories, Inc.",,Current,['ANDA201537'],['AZACITIDINE'],['AZACITIDINE'],"[""Dr. Reddy's Laboratories Inc.""]",['43598-305'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['08cbdb93-4103-c31c-1b0d-67d870c16ddc'],['71d8d758-86c9-b571-aed1-719654fd4b82'],['43598-305-62'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
Reverified,03/13/2023,61703-350-10,Methotrexate Sodium Injection,844-646-4398,Available,,10/23/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA011719'],['METHOTREXATE'],['METHOTREXATE'],"['Hospira, Inc.']","['61703-350', '61703-408']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['METHOTREXATE SODIUM'],"['1655956', '1946772']","['95b8b8da-da4e-4bba-9038-3cf65f3d5c1a', '37b3e76b-ac3d-4f93-adf1-91f52f676b8a']","['0d63ba29-b692-41b4-87e8-351265c8273f', '0e30eaef-5a09-4104-8a11-c32933eadeab']","['61703-350-37', '61703-350-38', '61703-408-41', '61703-350-09', '61703-350-10', '61703-408-25']",['3IG1E710ZN'],,,,,,,,,
Reverified,10/12/2022,0406-8892-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-325-8888,Available,,11/05/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)",SpecGx LLC,,Current,['ANDA040440'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['SpecGx LLC'],"['0406-8892', '0406-8891', '0406-8884', '0406-8885', '0406-8893', '0406-8894']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['b25a2f3f-ee3a-44c0-a475-f371025c767b'],['72ddd1c9-ddbd-4c95-acd9-003189a353a3'],"['0406-8891-01', '0406-8884-01', '0406-8892-01', '0406-8885-01', '0406-8893-01', '0406-8894-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,10/31/2017,0409-2634-50,Hydromorphone Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)","Hospira, Inc., a Pfizer Company",,Current,['ANDA078591'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']",['0409-2634'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['1724338', '1724340', '1724341']",['f0c8c83c-fb41-4571-a72e-6542311351dd'],['3832ede8-d3fc-455d-ecab-3b77be5869f5'],"['0409-2634-10', '0409-2634-01', '0409-2634-25', '0409-2634-05', '0409-2634-50']",['L960UP2KRW'],,,,,,,01/02/2025,,
New,12/05/2024,63304-693-77,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-77)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-693', '63304-692']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
Reverified,01/19/2023,65862-163-90,Quinapril/Hydrochlorothiazide Tablet,866-850-2876,Unavailable,Discontinuation of the manufacture of the drug,10/15/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)",Aurobindo Pharma USA,Discontinuation of the manufacture of the drug,Current,['ANDA078450'],['QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE'],['QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE'],['Aurobindo Pharma Limited'],"['65862-163', '65862-161', '65862-162']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809']",['5842ecc2-874a-481b-8997-afa9d862dc5d'],['50a58159-9572-4445-9859-b392632597da'],"['65862-161-90', '65862-162-30', '65862-162-90', '65862-163-90']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],,,['Thiazides [CS]'],,,
New,03/24/2025,0472-0337-20,Hydrocortisone Cream,800-545-8800,,A business decision was made to discontinue.,03/24/2025,['Dermatology'],Cream,"Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-20)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA089682'],['HYDROCORTISONE'],['HYDROCORTISONE'],"['Actavis Pharma, Inc.']",['0472-0337'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['HYDROCORTISONE'],['310891'],['527a8d09-450b-4b8e-ad19-78fbba9732c5'],['a5f16c13-2a51-4541-bf9e-d80bc01a8dbd'],"['0472-0337-20', '0472-0337-30']",['WI4X0X7BPJ'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,03/24/2025,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
Reverified,02/14/2022,65219-458-30,Dextrose Monohydrate 5% Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)","Fresenius Kabi USA, LLC",,Current,['ANDA207449'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['FRESENIUS KABI USA, LLC']","['65219-458', '65219-456', '65219-464', '65219-460', '65219-462']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['efc3b0c9-518a-47db-bb3e-ebdfd4646e9b'],['576a22d8-5f2f-497e-80ad-1842ca74bb53'],"['65219-456-05', '65219-456-60', '65219-464-05', '65219-464-50', '65219-458-05', '65219-458-30', '65219-460-05', '65219-460-20', '65219-462-05', '65219-462-10']",['LX22YL083G'],,,,,,,,,
New,01/13/2025,0069-1751-30,Talazoparib Tosylate Capsule,800-533-4535,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0655-30",01/13/2025,['Oncology'],Capsule,"Talzenna, Capsule, .75 mg (NDC 0069-1751-30)",Pfizer Inc.,,To Be Discontinued,['NDA211651'],['TALZENNA'],['TALAZOPARIB'],['Pfizer Laboratories Div Pfizer Inc'],"['0069-1751', '0069-0296', '0069-1195', '0069-1501', '0069-1031', '0069-1235']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TALAZOPARIB TOSYLATE'],"['2099946', '2099952', '2099954', '2099956', '2591510', '2591512', '2591520', '2591521', '2639960', '2639962', '2639964', '2639966']",['2cb65f61-9a14-46d9-85a3-a7eea76160c5'],['f2423edd-6d24-495c-aec1-c2f457f08d9a'],"['0069-0296-30', '0069-1195-30', '0069-1501-30', '0069-1751-30', '0069-1031-30', '0069-1235-30']",['02WK9U5NZC'],,,,01/13/2025,,,,,
Revised,11/03/2017,0641-6125-25,Morphine Sulfate Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA205758'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6125', '0641-6126', '0641-6127']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['1731993', '1732006', '1732011']",['fa18221d-2353-4cf6-a210-fb33ee79d3d9'],['6023606c-150c-40c5-9175-598efe2a56c3'],"['0641-6126-01', '0641-6126-25', '0641-6127-01', '0641-6127-25', '0641-6125-01', '0641-6125-25']",['X3P646A2J0'],,,,,,,,,
Reverified,02/29/2024,16729-081-10,Naltrexone Hydrochloride Tablet,"866-941-7857, option 2",Available,,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-10)",Accord Healthcare Inc.,,Current,['ANDA091205'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Accord Healthcare, Inc.']",['16729-081'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['424db74c-6c0f-1eb3-e063-6294a90a7db8'],['49aa3d6d-2270-4615-aafa-b440859ab870'],"['16729-081-10', '16729-081-01', '16729-081-16', '16729-081-17']",['Z6375YW9SF'],,,,,,,,,
New,07/10/2025,72305-150-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 150 ug (NDC 72305-150-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-150', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
New,12/05/2024,57664-437-88,Digoxin Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Cardiovascular'],Tablet,"Digoxin, Tablet, 125 ug (NDC 57664-437-88)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA076363'],['DIGOXIN'],['DIGOXIN'],"['Sun Pharmaceutical Industries, Inc.']","['57664-437', '57664-441']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIGOXIN'],"['197604', '197606']",['1a3e469c-1452-3d1e-e063-6394a90ae73a'],['62795623-a2bc-4dd2-8989-3b9782bfd80e'],"['57664-437-88', '57664-437-18', '57664-441-88', '57664-441-18']",['73K4184T59'],"['N0000175568', 'M0003451']",['Cardiac Glycoside [EPC]'],,12/05/2024,,['Cardiac Glycosides [CS]'],,,
Revised,12/10/2021,76297-001-31,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-31)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['LABORATORIOS GRIFOLS SA'],['76297-001'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['ff5ef1ef-2a0d-476d-8483-ffd7cd47c635'],['eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf'],"['76297-001-12', '76297-001-11', '76297-001-22', '76297-001-21', '76297-001-32', '76297-001-31', '76297-001-02', '76297-001-01', '76297-001-42', '76297-001-41', '76297-001-52', '76297-001-51', '76297-001-62', '76297-001-61', '76297-001-72', '76297-001-71', '76297-001-82', '76297-001-81', '76297-001-92', '76297-001-91']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,01/01/2012,0143-9555-01,Leucovorin Calcium Injection,800-631-2174,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 0143-9555-01)","Hikma Pharmaceuticals USA, Inc.",,Resolved,['ANDA089384'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9555', '0143-9554', '0143-9553', '0143-9552']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['e2d1484b-2920-45ab-9207-4caa5285fef4'],['cc52077f-5663-4f79-a273-0aecf655e038'],"['0143-9555-01', '0143-9554-01', '0143-9553-01', '0143-9552-01']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,03/10/2023,43547-406-50,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-406', '43547-407', '43547-408']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,04/28/2023,0264-2201-10,Sodium Chloride 0.9% Irrigation,800-227-2862,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-10)",B. Braun Medical Inc.,,Resolved,['NDA016733'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],['0264-2201'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['35e26a6d-60d6-4388-84e9-c481a3b69ee7'],['0d59a04a-32e6-485b-b638-a1e6c09e9642'],"['0264-2201-00', '0264-2201-10', '0264-2201-50', '0264-2201-70']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Revised,12/15/2021,0009-3073-03,Methylprednisolone Acetate Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)",Pfizer Inc.,Other,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-3073', '0009-3475']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE', 'INTRA-ARTICULAR']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743781', '1743855', '1743856']","['bdefc300-8d7c-474c-9771-200628f25035', 'befd723e-d1e2-41b9-83f1-17bca0c2a941']","['bf1b104d-85cb-414d-a366-78068c82c883', '9a7b3837-e038-48bf-97e9-78ad463760dc']","['0009-3073-22', '0009-3073-23', '0009-3475-22', '0009-3475-23', '0009-3073-01', '0009-3073-03', '0009-3475-01', '0009-3475-03']",['43502P7F0P'],,,,,,,,,
Reverified,04/02/2020,76045-211-20,Midazolam Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)","Fresenius Kabi USA, LLC",,Current,['ANDA203460'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['76045-211', '76045-001', '76045-002', '76045-003']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['998211', '1551393', '1551395']",['ec9c9aee-b95f-4645-bf17-df7f1e3967d3'],['1cc9ba6e-fa1b-405e-9de8-720c567b2a73'],"['76045-211-00', '76045-211-20', '76045-001-00', '76045-001-20', '76045-002-00', '76045-002-10', '76045-003-00', '76045-003-20']",['W7TTW573JJ'],,,,,,,,,
Reverified,03/26/2018,0409-3796-01,Ketorolac Tromethamine Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA074802'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Hospira, Inc.']","['0409-3796', '0409-3793', '0409-3795']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['60f4ed51-f1c1-45d4-b43a-969678901bdd'],['8accbb78-fc64-45d5-69b0-35c23a1d2a2e'],"['0409-3793-19', '0409-3793-01', '0409-3793-25', '0409-3795-19', '0409-3795-01', '0409-3795-25', '0409-3796-19', '0409-3796-01', '0409-3796-25']",['4EVE5946BQ'],,,,,,,,,
Reverified,04/10/2020,0338-9557-12,Dexmedetomidine Hydrochloride Injection,888-229-0001,Limited Availability,Estimated recovery: November 2025,10/22/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)",Baxter Healthcare,Demand increase for the drug,Current,['ANDA208532'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Baxter Healthcare Company'],"['0338-9557', '0338-9555']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['34598b0d-5824-4586-b19c-5189a626c27a'],['8ccb45a7-8290-469c-9644-a4dca967d88f'],"['0338-9555-24', '0338-9557-12']",['1018WH7F9I'],,,,,,,,,
Revised,03/23/2018,55150-198-30,Ropivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Injection, 5 mg/1 mL (NDC 55150-198-30)",Eugia US LLC,,Current,['ANDA205612'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-198', '55150-195', '55150-196', '55150-197', '55150-199', '55150-200', '55150-201']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734207', '1734347', '1734475', '1734483']",['34725b26-d6e9-4d1b-95a0-da03764cc102'],['3763b7b6-da49-4658-b93d-28f5da24d09e'],"['55150-195-20', '55150-196-99', '55150-197-20', '55150-198-30', '55150-199-20', '55150-200-10', '55150-201-20']",['V910P86109'],,,,,,,,,
Revised,11/01/2017,0409-4264-01,Hydromorphone Hydrochloride Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: June 2026,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4264', '0409-1283', '0409-1312', '0409-1380', '0409-1805']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1724383', '1724644', '1872271', '2675350']",['53b6867a-0ae3-48ff-b257-9e58cc76de9c'],['f9ca2ef5-46d8-475a-a26e-f7c8becd6db7'],"['0409-1283-17', '0409-1283-37', '0409-1312-16', '0409-1312-36', '0409-1380-11', '0409-1380-01', '0409-4264-11', '0409-4264-01', '0409-1805-10', '0409-1805-01']",['L960UP2KRW'],,,,,,,,,
Reverified,02/08/2019,67457-422-54,Dexamethasone Sodium Phosphate Injection,800-796-9526,Available,,11/06/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)","Mylan Institutional, a Viatris Company",,Current,['ANDA040803'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Mylan Institutional LLC'],"['67457-422', '67457-423', '67457-421', '67457-420']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1116927', '1812194']",['dd5c82b6-a194-462c-9626-34a9b410cfea'],['dff598e8-e662-411f-978d-4ba3fb8ef7db'],"['67457-423-00', '67457-423-12', '67457-422-00', '67457-422-54', '67457-421-00', '67457-421-30', '67457-420-00', '67457-420-10']",['AI9376Y64P'],,,,,,,,,
Revised,01/06/2023,0169-7708-21,Somatropin Injection,609-987-5800,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Norditropin, Injection, 15 mg/1.5 mL (NDC 0169-7708-21)","Novo Nordisk, Inc.",,Resolved,['BLA021148'],['NORDITROPIN'],['SOMATROPIN'],['Novo Nordisk'],"['0169-7708', '0169-7704', '0169-7705', '0169-7703']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['SOMATROPIN'],"['847243', '847245', '847247', '847348', '849850', '849851', '1736262', '1736329']",['b67c2419-4feb-4ce1-b97e-88760a8e1aee'],['1058e17c-9261-459c-a3e6-fae38d196c14'],"['0169-7704-21', '0169-7704-92', '0169-7705-21', '0169-7705-92', '0169-7708-21', '0169-7708-92', '0169-7703-11', '0169-7703-91', '0169-7703-21', '0169-7703-92']",['NQX9KB6PCL'],"['N0000175606', 'M0028842']",['Recombinant Human Growth Hormone [EPC]'],,,,['Human Growth Hormone [CS]'],08/28/2025,,Available
Revised,01/13/2022,0264-5535-32,Metronidazole Injection,800-227-2862,Unavailable,Temporary discontinuation of the manufacture of the drug.,11/04/2025,['Anti-Infective'],Injection,"Metro I.v. In Plastic Container, Injection, 500 mg/100 mL (NDC 0264-5535-32)",B. Braun Medical Inc.,Discontinuation of the manufacture of the drug,Current,['NDA018900'],['METRONIDAZOLE'],['METRONIDAZOLE'],['B. Braun Medical Inc.'],['0264-5535'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['METRONIDAZOLE'],['311683'],['ff10d27d-6a3a-45db-ae74-72ba2f442dd6'],['fd191c06-9d3b-4e46-9f79-90f6af614947'],['0264-5535-32'],['140QMO216E'],"['N0000175435', 'M0014907']",['Nitroimidazole Antimicrobial [EPC]'],,,,['Nitroimidazoles [CS]'],,,
New,07/08/2025,0409-1893-01,Morphine Sulfate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,07/08/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA202515'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-1893', '0409-1890', '0409-1891', '0409-1892', '0409-1894']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['894912', '998212', '998213', '1729197', '1731995', '1732014']",['cced2ec0-6c94-4cf0-87fb-041667ee3214'],['be420e8b-bcb0-49b5-bb4d-1df8b9959809'],"['0409-1890-03', '0409-1890-01', '0409-1890-13', '0409-1890-23', '0409-1891-03', '0409-1891-01', '0409-1891-13', '0409-1891-23', '0409-1892-03', '0409-1892-01', '0409-1892-13', '0409-1892-23', '0409-1893-03', '0409-1893-01', '0409-1893-13', '0409-1893-23', '0409-1894-03', '0409-1894-01']",['X3P646A2J0'],,,,07/08/2025,,,,,
Revised,10/11/2024,0264-7750-20,Lactated Ringers Injection,800-227-2862,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-20)",B. Braun Medical Inc.,,Resolved,['NDA019632'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['B. Braun Medical Inc.'],['0264-7750'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847630'],"['f67c6808-1eeb-4299-a0b7-694863bcad5a', 'ed789cd7-83ae-4ec1-a696-e87c1569da49']","['d3d29c8f-c326-4097-814a-7f4e08c67068', 'f6d82772-638c-4584-b9d3-8833669f5963']","['0264-7750-00', '0264-7750-10', '0264-7750-20', '0264-7750-07']","['M4I0D6VV5M', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Reverified,04/10/2020,0409-1454-20,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1454', '0409-3301', '0409-1174', '0409-2815']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['8d48de06-361f-418b-bfec-8ef85f94d5bc'],['4419162d-81d4-49bd-96de-1729440bdb74'],"['0409-1454-01', '0409-1454-20', '0409-3301-01', '0409-3301-10', '0409-1174-01', '0409-1174-10', '0409-2815-01']",['1018WH7F9I'],,,,,,,,,
Reverified,03/23/2018,63323-286-00,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-286', '63323-285', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
New,07/21/2025,73070-400-11,Insulin Degludec Injection,609-987-5800,,"Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injection,"Insulin Degludec, Injection, 10 mL Insulin Degludec vial (NDC 73070-400-11)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA203314'],['INSULIN DEGLUDEC'],['INSULIN DEGLUDEC'],"['Novo Nordisk Pharma, Inc.']","['73070-400', '73070-403', '73070-503']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN DEGLUDEC'],"['1670011', '1670021', '2107520']",['c1be283d-4b1d-4996-b2a7-4488dbff3037'],['c1be283d-4b1d-4996-b2a7-4488dbff3037'],"['73070-403-15', '73070-503-15', '73070-400-11']",['54Q18076QB'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
Revised,02/08/2019,0641-0367-25,Dexamethasone Sodium Phosphate Injection,800-631-2174,Available,Currently available.  Additional product will be made available as it is released.,10/24/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate Injection, USP, Injection, 10 mg/1 mL (NDC 0641-0367-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA087702'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-0367', '0641-6145', '0641-6146']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1116927', '1812194']",['84665497-7e82-4733-bcfd-3177817ac0b3'],['0277cc0a-2fd4-4605-a310-b613be84ee26'],"['0641-0367-21', '0641-0367-25', '0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-10', '0641-6146-25']",['AI9376Y64P'],,,,,,,,,
Revised,07/12/2022,68118-100-01,"Streptozocin Powder, For Solution",USSZTOrders@esteve.com,Available,,09/17/2025,['Oncology'],"Powder, For Solution","Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)","ESTEVE PHARMACEUTICALS, S.A.",,Current,,['ZANOSAR'],['STREPTOZOCIN'],"['ESTEVE PHARMACEUTICALS, S.A.']",['68118-100'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['STREPTOZOCIN'],"['207948', '239180']",['40804eb3-12a0-f840-e063-6394a90a66ea'],['f31d3bff-6fc6-c35f-e053-2995a90a596b'],['68118-100-01'],['5W494URQ81'],"['N0000000236', 'N0000175558']",['Alkylating Drug [EPC]'],,,https://www.fda.gov/media/187353/download?attachment,,,['Alkylating Activity [MoA]'],
New,04/28/2025,0245-0213-11,Midodrine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Cardiovascular'],Tablet,"Orvaten, Tablet, 10 mg (NDC 0245-0213-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076725'],['MIDODRINE HYDROCHLORIDE'],['MIDODRINE HYDROCHLORIDE'],"['Upsher-Smith laboratories, LLC']","['0245-0213', '0245-0211', '0245-0212']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MIDODRINE HYDROCHLORIDE'],"['993462', '993466', '993470']",['18b0b9f5-6026-479e-af12-92b0e71a9d6b'],['4c3517f3-1c68-4ade-b5f1-c488a3a335c1'],"['0245-0211-11', '0245-0211-89', '0245-0211-01', '0245-0212-11', '0245-0212-89', '0245-0212-01', '0245-0213-11', '0245-0213-89', '0245-0213-01']",['59JV96YTXV'],,,,04/28/2025,,,,,
Reverified,10/12/2022,11534-192-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",732-382-6085 Monday to Friday 9 am to 3:45 pm,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)","Sunrise Pharmaceutical, Inc.",,Current,['ANDA209799'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['SUNRISE PHARMACEUTICAL, INC.']","['11534-192', '11534-190', '11534-191', '11534-193', '11534-194', '11534-195', '11534-196']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['86a00bec-51eb-4d73-a945-b1937970b29a'],['ac102599-3a5b-4154-899e-6ff262be7ff7'],"['11534-190-01', '11534-190-03', '11534-191-01', '11534-191-03', '11534-192-01', '11534-192-03', '11534-193-01', '11534-193-03', '11534-194-01', '11534-194-03', '11534-195-01', '11534-195-03', '11534-196-01', '11534-196-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,10/12/2022,57844-117-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],['ADDERALL'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['57844-117', '57844-105', '57844-110', '57844-112', '57844-115', '57844-120', '57844-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541365', '541878', '541879', '541892', '541894', '577957', '577960', '577961', '577962', '687043', '687045', '1009145', '1009147']",['79af1dc6-c7cf-41b1-a750-e9b47c2187ff'],['f22635fe-821d-4cde-aa12-419f8b53db81'],"['57844-105-01', '57844-117-01', '57844-110-01', '57844-112-01', '57844-115-01', '57844-120-01', '57844-130-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/14/2022,0264-1510-32,Dextrose Monohydrate 5% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)",B. Braun Medical Inc.,,Current,['NDA016730'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],['0264-1510'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795616', '1795618']",['0a144591-6cfa-4aed-a067-c95aebc29057'],['60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5'],"['0264-1510-36', '0264-1510-31', '0264-1510-32']",['LX22YL083G'],,,,,,,,,
Revised,09/18/2023,63323-095-61,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,"['Gastroenterology', 'Endocrinology/Metabolism', 'Total Parenteral Nutrition', 'Pediatric']",Injection,"Sodium Chloride 0.9%, Injection, 4 meq/1 mL (NDC 63323-095-61)","Fresenius Kabi USA, LLC",,Resolved,['ANDA212070'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-095'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],['313016'],['5db02ff9-4936-46b0-8fb5-3fc491895ae1'],['8b44bfd3-70a4-4b47-bc7b-590f63b8cc75'],"['63323-095-02', '63323-095-61']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,06/06/2018,72266-119-25,Ketorolac Tromethamine Injection,833-291-9645,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",09/29/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)",Gland Pharma Limited,,Current,['ANDA204216'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['FOSUN PHARMA USA INC'],"['72266-119', '72266-234', '72266-118']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['228ec94a-f777-f61b-e063-6394a90a21a5'],['1aae6a4d-0909-4672-aa26-e3f2d8c4d413'],"['72266-234-01', '72266-234-25', '72266-118-01', '72266-118-25', '72266-119-01', '72266-119-25']",['4EVE5946BQ'],,,,,,,,,
Reverified,10/05/2022,72572-160-10,Etomidate Injection,800-631-2174,Available,Distributed by Civica,10/24/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA202354'],['ETOMIDATE'],['ETOMIDATE'],"['Civica, Inc.']","['72572-160', '72572-161']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['380f0c88-03f8-4cfa-8823-4766c2f7700c'],['98002094-f065-4b5f-963f-2c34b5241316'],"['72572-160-01', '72572-160-10', '72572-161-01', '72572-161-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
New,05/02/2025,0832-0540-11,Bumetanide Tablet,800-654-2299,,,05/02/2025,['Cardiovascular'],Tablet,"Bumetanide, Tablet, .5 mg (NDC 0832-0540-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA209916'],['BUMETANIDE'],['BUMETANIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0540', '0832-0541', '0832-0542']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BUMETANIDE'],"['197417', '197418', '197419']",['d53166d9-64ca-4b76-81a7-b70a60c53b12'],['ff5dc8c6-b2f2-41d3-8e56-a953aa721b59'],"['0832-0540-11', '0832-0541-11', '0832-0541-10', '0832-0542-11', '0832-0542-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],05/02/2025,,,,,
Reverified,01/19/2023,62135-486-90,Quinapril Hydrochloride Tablet,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,Available,,08/19/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA076803'],['QUINAPRIL'],['QUINAPRIL'],"['Chartwell RX, LLC']","['62135-486', '62135-484', '62135-485', '62135-487']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['09cd5cb9-4fdf-f133-e063-6294a90af691'],['dbc43dbd-94aa-40e2-a9ea-766110cc8687'],"['62135-484-60', '62135-485-90', '62135-486-90', '62135-487-90']",['33067B3N2M'],,,,,,,,,
New,06/13/2025,57844-140-01,Phentermine Hydrochloride Tablet,800-545-8800,,,06/13/2025,['Other'],Tablet,"Adipex-P, Tablet, 37.5 mg (NDC 57844-140-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Revised,07/14/2023,0054-0660-25,Lisdexamfetamine Dimesylate Capsule,800-631-2174,Limited Availability,Available on allocation,10/24/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202827'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-0660', '0054-0370', '0054-0371', '0054-0372', '0054-0373', '0054-0374', '0054-0375']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['5d119550-4386-4bfa-a5d0-bb18e66191b7'],['6740a621-9bec-4178-a4fc-a3fc89f34e0a'],"['0054-0660-25', '0054-0370-25', '0054-0371-25', '0054-0372-25', '0054-0373-25', '0054-0374-25', '0054-0375-25']",['SJT761GEGS'],,,,,,,,,
Reverified,10/14/2016,63323-489-27,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-489', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,02/26/2025,58151-098-91,Tolterodine Tartrate Tablet,800-796-9526,,,02/26/2025,['Urology'],Tablet,"Detrol, Tablet, 1 mg (NDC 58151-098-91)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA020771'],['DETROL'],['TOLTERODINE TARTRATE'],['Viatris Specialty LLC'],"['58151-098', '58151-099']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOLTERODINE TARTRATE'],"['855178', '855180', '855194', '855195']",['f27726af-7a9b-45f4-96e0-1e90a5fdcc18'],['41eb00d2-64e3-4ec9-8732-4bfc81b04180'],"['58151-098-91', '58151-099-91']",['5T619TQR3R'],,,,02/26/2025,,,,,
Reverified,02/14/2022,0338-0017-31,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
New,04/24/2025,0245-1071-30,"Topiramate Capsule, Extended Release",716-315-2000,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,04/24/2025,['Neurology'],"Capsule, Extended Release","Qudexy XR, Capsule, Extended Release, 25 mg (NDC 0245-1071-30)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA205122'],['QUDEXY XR'],['TOPIRAMATE'],"['Upsher-Smith Laboratories, LLC']","['0245-1071', '0245-1072', '0245-1074', '0245-1075', '0245-1073']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOPIRAMATE'],"['1494766', '1494769', '1494771', '1494775', '1494778', '1494781', '1812419', '1812421', '1812425', '1812427']",['374eeb55-b017-48fd-e063-6294a90a6ad7'],['46f54677-3a22-4c38-9b92-923020164e15'],"['0245-1071-30', '0245-1071-90', '0245-1072-30', '0245-1072-90', '0245-1074-30', '0245-1074-90', '0245-1075-30', '0245-1075-90', '0245-1073-30', '0245-1073-90']",['0H73WJJ391'],"['N0000008486', 'N0000185506', 'N0000182140']",,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],04/24/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Reverified,02/29/2024,68094-909-30,Naltrexone Hydrochloride Tablet,888-852-6657,Available,Marketed by Precision Dose; Customer service: 800-397-9228,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-30)","Elite Laboratories, Inc.",,Current,['ANDA075274'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],['Precision Dose Inc.'],['68094-909'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['48b82306-b0ba-4cb8-817d-896ccde0367b'],['b09b4b5e-795a-48e7-b7cc-2e29f41c5660'],"['68094-909-30', '68094-909-50']",['Z6375YW9SF'],,,,,,,,,
Reverified,10/06/2023,0517-4810-25,Nitroglycerin Injection,800-645-1706,Available,,11/04/2025,['Cardiovascular'],Injection,"Nitroglycerin, Injection, 5 mg/1 mL (NDC 0517-4810-25)","American Regent, Inc.",,Current,['ANDA072034'],['NITROGLYCERIN'],['NITROGLYCERIN'],"['American Regent, Inc.']",['0517-4810'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['NITROGLYCERIN'],['237205'],['ee83c8b9-c31a-4f32-9e9d-0370545204cb'],['8c52cdf6-87be-4719-b105-f08be096d462'],"['0517-4810-01', '0517-4810-25']",['G59M7S0WS3'],"['N0000175415', 'M0014874', 'N0000009909']",['Nitrate Vasodilator [EPC]'],['Vasodilation [PE]'],,,['Nitrates [CS]'],,,
Revised,02/22/2012,0409-4277-02,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088327'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4277', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
New,01/28/2025,71093-127-03,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-03)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-127', '71093-128']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
Revised,01/06/2023,0169-7704-21,Somatropin Injection,609-987-5800,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Norditropin, Injection, 5 mg/1.5 mL (NDC 0169-7704-21)","Novo Nordisk, Inc.",,Resolved,['BLA021148'],['NORDITROPIN'],['SOMATROPIN'],['Novo Nordisk'],"['0169-7704', '0169-7705', '0169-7708', '0169-7703']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['SOMATROPIN'],"['847243', '847245', '847247', '847348', '849850', '849851', '1736262', '1736329']",['b67c2419-4feb-4ce1-b97e-88760a8e1aee'],['1058e17c-9261-459c-a3e6-fae38d196c14'],"['0169-7704-21', '0169-7704-92', '0169-7705-21', '0169-7705-92', '0169-7708-21', '0169-7708-92', '0169-7703-11', '0169-7703-91', '0169-7703-21', '0169-7703-92']",['NQX9KB6PCL'],"['N0000175606', 'M0028842']",['Recombinant Human Growth Hormone [EPC]'],,,,['Human Growth Hormone [CS]'],08/28/2025,,Available
New,07/10/2025,72305-075-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 75 ug (NDC 72305-075-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-075', '72305-025', '72305-050', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Revised,11/06/2017,0409-7809-24,Dopamine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018826'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],"['Hospira, Inc.']","['0409-7809', '0409-7810']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743877', '1743879']",['3b4d4d9d-5e19-420f-a447-1ad8346844d9'],['08f23f6e-150d-45ea-098e-f2edf64c21a1'],"['0409-7809-11', '0409-7809-22', '0409-7809-31', '0409-7809-24', '0409-7810-11', '0409-7810-22']",['7L3E358N9L'],,,,,,,,,
New,04/23/2025,0832-1055-10,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 20 mg (NDC 0832-1055-10)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1055', '0832-1054']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
Revised,01/24/2025,82154-0449-1,Peginterferon alfa-2a Injection,"800-506-8501, email: medinfo.us@pharmaand.com",Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",08/19/2025,['Antiviral'],Injection,"Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)",pharmaand GmbH (pharma&),Shortage of an active ingredient,Current,['BLA103964'],['PEGASYS'],['PEGINTERFERON ALFA-2A'],['pharmaand GmbH'],"['82154-0449', '82154-0451']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PEGINTERFERON ALFA-2A'],"['351270', '352297', '731326', '731328']",['3c18e4a2-193f-ef4e-e063-6394a90a56b2'],['d9290e5b-6d40-2318-e053-2995a90a9916'],"['82154-0449-1', '82154-0451-4']",['Q46947FE7K'],"['N0000175521', 'M0025711']",['Interferon alpha [EPC]'],,,,['Interferon-alpha [CS]'],,,
Revised,04/26/2023,60793-702-10,Penicillin G Benzathine Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: January 2026,10/23/2025,['Anti-Infective'],Injection,"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)",Pfizer Inc.,Other,Current,['NDA050141'],['BICILLIN L-A'],['PENICILLIN G BENZATHINE'],['Pfizer Laboratories Div Pfizer Inc'],"['60793-702', '60793-700', '60793-701']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PENICILLIN G BENZATHINE'],"['731564', '731566', '731567', '731568', '731570', '731571']",['4b3694af-9d77-487f-8838-b75aec6636da'],['012d46f1-d0a0-4676-a879-cd320297ab16'],"['60793-700-01', '60793-700-10', '60793-701-02', '60793-701-10', '60793-702-04', '60793-702-10']",['RIT82F58GK'],,,,,https://www.fda.gov/media/188355/download,,,,
Revised,07/14/2023,57664-048-88,Lisdexamfetamine Dimesylate Capsule,800-818-4555,Limited Availability,Additional supply anticipated in Q4 2025 followed by early 2026,10/21/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['ANDA214484'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-048', '57664-047', '57664-046', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
Reverified,02/22/2012,0409-3178-03,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089644'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3178', '0409-1209', '0409-3177', '0409-3181', '0409-3182', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],12/19/2024,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Revised,01/06/2023,0013-2653-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 1.0 mg preservative free (NDC 0013-2653-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2653', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2654', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
New,06/13/2025,0555-9131-67,Drospirenone; Ethinyl Estradiol Tablet,800-545-8800,,,06/13/2025,['Reproductive'],Tablet,"Yasmin, Tablet, Kit (NDC 0555-9131-67)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA021098'],['OCELLA'],['DROSPIRENONE AND ETHINYL ESTRADIOL'],"['TEVA PHARMACEUTICALS USA, INC.']",['0555-9131'],['HUMAN PRESCRIPTION DRUG'],,,"['284207', '748797', '748800', '801185']",['16f205ad-cc9e-4879-9f7c-9cc3577d48fb'],['0d729f4d-2fa3-47f6-8a1f-d8cfea4cff37'],"['0555-9131-79', '0555-9131-67']",,,,,06/13/2025,,,,,
New,06/13/2025,0409-0323-20,Bleomycin Sulfate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,06/13/2025,"['Hematology', 'Oncology', 'Pediatric']",Injection,"Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA065031'],['BLEOMYCIN'],['BLEOMYCIN'],"['Hospira, Inc.']","['0409-0323', '0409-0332']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAPLEURAL', 'INTRAVENOUS', 'SUBCUTANEOUS']",['BLEOMYCIN SULFATE'],"['1726673', '1726676']",['d9e9c332-1b3f-469c-83b8-41e15183e635'],['e629ba5a-4e08-4249-9551-af6dbd98a7e4'],"['0409-0323-20', '0409-0332-20']",['7DP3NTV15T'],,,,06/13/2025,,,,,
New,02/28/2025,0187-5100-01,Pimecrolimus Cream,908-927-1400,,Authorized generic is still marketed and available under NDC 68682-110-01,02/28/2025,['Dermatology'],Cream,"Elidel, Cream, 30gm (NDC 0187-5100-01)","Bausch Health Americas, Inc.",,To Be Discontinued,['NDA021302'],['ELIDEL'],['PIMECROLIMUS'],"['Bausch Health US, LLC']","['0187-5100', '0187-5102', '0187-5101', '0187-5103']",['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['PIMECROLIMUS'],"['352085', '562806']",['2f802a3f-c021-45c1-8693-5689c30c3fc6'],['e4027e5a-0f9b-4070-b196-f60172f45c4c'],"['0187-5102-03', '0187-5101-02', '0187-5100-01', '0187-5103-04']",['7KYV510875'],"['N0000175457', 'N0000175458']",['Calcineurin Inhibitor Immunosuppressant [EPC]'],,02/28/2025,,,,['Calcineurin Inhibitors [MoA]'],
New,01/06/2025,0597-0575-60,Adalimumab-adbm Injection,800-243-0127,,,01/06/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0575-60)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['ADALIMUMAB-ADBM'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0575', '0597-0595', '0597-0555', '0597-0585', '0597-0545', '0597-0565']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640891', '2640893', '2640895', '2640900', '2640902', '2680743', '2680748', '2680756', '2680759']",['d6ed9087-bc5c-4c0e-843b-90b0400b0ed1'],['62f39a7c-00df-4519-a8d4-39bbd0a649ed'],"['0597-0595-20', '0597-0590-26', '0597-0555-80', '0597-0550-06', '0597-0585-89', '0597-0580-37', '0597-0545-22', '0597-0545-44', '0597-0545-66', '0597-0540-10', '0597-0575-50', '0597-0575-40', '0597-0575-60', '0597-0570-32', '0597-0565-20', '0597-0560-12']",,,,,01/06/2025,,,,,
Reverified,07/14/2023,0054-0371-25,Lisdexamfetamine Dimesylate Capsule,800-631-2174,Limited Availability,Available on allocation,10/24/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202827'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-0371', '0054-0660', '0054-0370', '0054-0372', '0054-0373', '0054-0374', '0054-0375']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['5d119550-4386-4bfa-a5d0-bb18e66191b7'],['6740a621-9bec-4178-a4fc-a3fc89f34e0a'],"['0054-0660-25', '0054-0370-25', '0054-0371-25', '0054-0372-25', '0054-0373-25', '0054-0374-25', '0054-0375-25']",['SJT761GEGS'],,,,,,,,,
New,06/13/2025,13668-382-30,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-30)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
New,12/09/2024,62756-200-18,Tiagabine Hydrochloride Tablet,800-818-4555,,Discontinuing for business reasons,12/09/2024,['Neurology'],Tablet,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-18)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077555'],['TIAGABINE HYDROCHLORIDE'],['TIAGABINE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['62756-200', '62756-224']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TIAGABINE HYDROCHLORIDE'],"['1299911', '1299917']",['57975e74-e45b-4fd9-9718-bfc9690acae5'],['7eeb2d81-c5d7-46a0-aa5c-149b55df71bd'],"['62756-200-83', '62756-200-18', '62756-224-83', '62756-224-88', '62756-224-08', '62756-224-18']",['DQH6T6D8OY'],,,,12/05/2024,,,,,
Revised,11/03/2017,0641-0121-25,Hydromorphone Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)","Hikma Pharmaceuticals USA, Inc.",,Current,,['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-0121', '0641-2341']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897745', '1724276']",['65cfa15d-13f8-4848-826a-6eeb4b082932'],['b325028e-0722-4c8c-9fdb-ab6fb0dc460c'],"['0641-0121-21', '0641-0121-25', '0641-2341-39', '0641-2341-41']",['L960UP2KRW'],,,,,,,01/03/2025,,
Revised,03/21/2023,0009-3051-02,Clindamycin Phosphate Injection,800-533-4535,Limited Availability,Limited Supply Available. Next Delivery: February 2026; Estimated Recovery: March 2026,10/23/2025,['Anti-Infective'],Injection,"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)",Pfizer Inc.,Other,Current,['NDA050441'],['CLEOCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Pharmacia & Upjohn Company LLC'],"['0009-3051', '0009-4073', '0009-5095']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['1737244', '1737245', '1737578', '1737579', '1737581', '1737582']",['9c0a7367-763b-48c3-95b1-173b74c50f4b'],['a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b'],"['0009-3051-01', '0009-3051-02', '0009-4073-03', '0009-4073-04', '0009-5095-05', '0009-5095-06']",['EH6D7113I8'],,,,,,,,,
Reverified,07/24/2017,63323-083-05,Sodium Bicarbonate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)","Fresenius Kabi USA, LLC",,Current,['ANDA206688'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Fresenius Kabi USA, LLC']","['63323-083', '63323-089']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],,['9def795c-abcf-483c-8b1d-e4374666efb2'],['0ab55004-bb63-436d-ad77-cd3796905370'],"['63323-083-03', '63323-083-05', '63323-089-25', '63323-089-50']",['8MDF5V39QO'],,,,,,,,,
Reverified,03/27/2018,25021-652-87,Ropivacaine Hydrochloride Injection,Sagent: 866-625-1618,Available,Marketed by Sagent Pharmaceuticals,08/26/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)",InfoRLife SA,,Current,['ANDA206166'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Sagent Pharmaceuticals'],"['25021-652', '25021-671']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734347', '1734355', '1734479', '1734481']",['04d1b1c6-1963-4b42-8479-dbf787b6de17'],['8c5c762f-d266-4b1a-809e-f11bfc89bc2d'],"['25021-671-82', '25021-671-87', '25021-652-82', '25021-652-87']",['V910P86109'],,,,,,,,,
Reverified,07/26/2023,50458-586-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,Available,,11/04/2025,['Psychiatry'],Tablet,"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)",Janssen Pharmaceuticals,,Current,['NDA021121'],['CONCERTA'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Janssen Pharmaceuticals, Inc.']","['50458-586', '50458-585', '50458-588', '50458-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],,['4035a366-ebde-a1aa-e063-6294a90af4c4'],['1a88218c-5b18-4220-8f56-526de1a276cd'],"['50458-585-01', '50458-588-01', '50458-586-01', '50458-587-01']",['4B3SC438HI'],,,,,,,,,
New,09/11/2025,0472-1030-16,Homatropine Methylbromide and Hydrocodone Bitartrate Syrup,800-545-8800,,,09/11/2025,['Analgesia/Addiction'],Syrup,"Hydromet, Syrup, 1.5 mg/5 mL; 5 mg/5 mL (NDC 0472-1030-16)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA088017'],['HYDROMET'],['HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE'],"['Actavis Pharma, Inc.']",['0472-1030'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HOMATROPINE METHYLBROMIDE', 'HYDROCODONE BITARTRATE']","['992668', '992675']",['6edda2e2-7ff0-4cc2-bd99-5a424bb6fbca'],['a324c912-a3ef-4296-b9a8-b0fec687eb06'],['0472-1030-16'],"['68JRS2HC1C', 'NO70W886KK']",,,,09/11/2025,,,,,
New,02/12/2025,42543-493-01,Amantadine Hydrochloride Capsule,877-244-9825,,Discontinuation of manufacture of drug based on business decision,02/12/2025,"['Antiviral', 'Neurology']",Capsule,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA209047'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],['Strides Pharma Inc.'],['42543-493'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849389'],['a3230bf0-95b8-4beb-b1f5-a35614de5afa'],['e4d8f36f-d668-4728-8dca-b1c22bd9aedb'],"['42543-493-01', '42543-493-05']",['M6Q1EO9TD0'],,,,02/12/2025,,,,,
New,01/06/2025,45963-567-30,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-30)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/06/2025,,,,,
Revised,02/20/2018,0409-1582-10,Bupivacaine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Anesthesia'],Injection,"Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1582-10)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1582', '0409-1559', '0409-1560', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,03/23/2018,70069-064-01,Ropivacaine Hydrochloride Injection,732-554-1019,Available,,08/19/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)","Somerset Therapeutics, LLC",,Current,['ANDA207636'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-064', '70069-061', '70069-062', '70069-063', '70069-065', '70069-066', '70069-067']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734203', '1734207', '1734475', '1734483']",['79b226f0-c08a-4f84-bf2b-ae5c60e01d67'],['ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64'],"['70069-061-01', '70069-061-25', '70069-061-10', '70069-062-01', '70069-062-25', '70069-062-10', '70069-063-01', '70069-063-25', '70069-064-01', '70069-064-10', '70069-064-25', '70069-065-01', '70069-065-25', '70069-066-01', '70069-066-25', '70069-066-10', '70069-067-01', '70069-067-25', '70069-067-10']",['V910P86109'],,,,,,,,,
New,07/23/2025,0832-5322-11,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-5322', '0832-5323']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953']",['39e726b1-eab8-fcf4-e063-6394a90a950a'],['616f0de7-8843-44a1-8fa6-274d889286aa'],"['0832-5322-11', '0832-5322-10', '0832-5323-11', '0832-5323-10']",['660YQ98I10'],,,,07/23/2025,,,,,
Revised,09/05/2018,0641-6044-25,Lorazepam Injection,800-631-2174,Limited Availability,Lots are being manufactured to meet demand,10/24/2025,['Neurology'],Injection,"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['NDA018140'],['LORAZEPAM'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6044', '0641-6046', '0641-6045', '0641-6047']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['238100', '238101', '1665188', '1665326']",['7c73dbc6-2623-4443-9b05-97dec7a0be2e'],['e9b54e42-04cf-4c62-90e1-36f7b31a4e81'],"['0641-6044-01', '0641-6044-25', '0641-6046-01', '0641-6046-10', '0641-6045-01', '0641-6045-25', '0641-6047-01', '0641-6047-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,04/14/2025,61314-454-20,Adalimumab-adaz Injection,800-525-8747,,,04/14/2025,['Rheumatology'],Injection,"Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-20)",Sandoz Inc.,,To Be Discontinued,['BLA761071'],['HYRIMOZ'],['ADALIMUMAB-ADAZ'],['Sandoz Inc'],"['61314-454', '61314-473', '61314-476', '61314-509', '61314-517', '61314-531']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['ADALIMUMAB'],"['2641644', '2641650', '2641653', '2641654', '2641655', '2641658', '2641660', '2641661', '2641662', '2641663', '2641664', '2641665', '2641666', '2641667', '2641668', '2641669', '2641670', '2641671', '2641672', '2641673']",['0d5a902f-4ca8-46d2-a790-b167842f62e4'],['1ac7d061-3380-468c-b077-c05f8dfbc829'],"['61314-454-20', '61314-454-36', '61314-454-68', '61314-473-64', '61314-473-20', '61314-473-92', '61314-476-64', '61314-509-64', '61314-517-36', '61314-531-64']",['FYS6T7F842'],"['N0000175610', 'N0000175451', 'M0001357']",['Tumor Necrosis Factor Blocker [EPC]'],,04/14/2025,,"['Antibodies, Monoclonal [CS]']",,['Tumor Necrosis Factor Receptor Blocking Activity [MoA]'],
New,09/29/2025,0009-0017-58,Triazolam Tablet,800-533-4535,,Discontinuation of the manufacture of the drug.,09/29/2025,['Psychiatry'],Tablet,"Halcion, Tablet, .25 mg (NDC 0009-0017-58)",Pfizer Inc.,,To Be Discontinued,['NDA017892'],['HALCION'],['TRIAZOLAM'],['Pharmacia & Upjohn Company LLC'],['0009-0017'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TRIAZOLAM'],"['198318', '208681']",['923c70f5-d9ac-4be2-8c29-9b4b5b7e124d'],['a0da0dba-a56d-486b-a45b-e8a7cdfbeac6'],"['0009-0017-55', '0009-0017-58']",['1HM943223R'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,09/29/2025,,['Benzodiazepines [CS]'],,,
Reverified,04/07/2020,70860-302-04,Furosemide Injection,866-625-1618,Unavailable,Use Sagent NDC 25021-311-04,08/26/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-04)",Sagent Pharmaceuticals,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,02/20/2018,0409-9045-17,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA071168'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-9045', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,12/22/2020,43066-027-10,Ropivacaine Hydrochloride Injection,888-229-0001,Available,Check wholesalers for inventory; Marketed by Baxter,11/04/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)","Caplin Steriles, Ltd.",,Current,['ANDA212808'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['43066-027', '43066-015', '43066-019', '43066-023']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734084', '1734207', '1734475', '1734483']",['ef624077-2197-426c-9521-8f966f49240b'],['781d4b7f-7556-4695-8d48-7772d7a0d8e9'],"['43066-015-01', '43066-015-10', '43066-019-01', '43066-019-10', '43066-023-01', '43066-023-10', '43066-027-01', '43066-027-10']",['V910P86109'],,,,,,,,,
Reverified,01/19/2023,65862-617-90,Quinapril Hydrochloride Tablet,866-850-2876,Unavailable,Discontinuation of the manufacture of the drug,10/15/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)",Aurobindo Pharma USA,Discontinuation of the manufacture of the drug,Current,['ANDA202725'],['QUINAPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-617', '65862-618', '65862-619', '65862-620']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['5263abd5-ce46-4918-9bb0-9632861bcbc9'],['93e6e668-5306-4f26-81d8-cbc3a7a5e787'],"['65862-617-30', '65862-617-90', '65862-617-99', '65862-617-55', '65862-617-10', '65862-617-78', '65862-618-30', '65862-618-90', '65862-618-99', '65862-618-55', '65862-618-10', '65862-618-78', '65862-619-30', '65862-619-90', '65862-619-99', '65862-619-19', '65862-619-10', '65862-619-78', '65862-620-30', '65862-620-90', '65862-620-99', '65862-620-39', '65862-620-10', '65862-620-78']",['33067B3N2M'],,,,,,,,,
Reverified,05/30/2025,0641-6054-25,Meperidine Hydrochloride Injection,800-631-2174,Unavailable,Additional lots scheduled to be available in the October-November 2025 timeframe.,10/24/2025,['Analgesia/Addiction'],Injection,"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA080445'],['MEPERIDINE HYDROCHLORIDE'],['MEPERIDINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6054', '0641-6053', '0641-6052']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['861476', '1665685', '1665697']",['9566d54d-7343-4695-94ff-8b5f2d384c81'],['e0e998da-f056-4fce-be8e-ed60cf3b461b'],"['0641-6053-01', '0641-6053-25', '0641-6054-01', '0641-6054-25', '0641-6052-01', '0641-6052-25']",['N8E7F7Q170'],,,,,,,,,
New,09/18/2025,0832-6006-11,Fluphenazine Hydrochloride Tablet,763-315-2000,,Discontinuation of the manufacture of the drug.,09/18/2025,"['Neurology', 'Psychiatry']",Tablet,"Fluphenazine Hydrochloride, Tablet, 10 mg (NDC 0832-6006-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA213784'],['FLUPHENAZINE HYDROCHLORIDE'],['FLUPHENAZINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories,LLC']","['0832-6006', '0832-6004', '0832-6003', '0832-6005']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLUPHENAZINE HYDROCHLORIDE'],"['859841', '860918', '865117', '865123']",['3bb74f82-8872-9829-e063-6294a90aeace'],['f07bb3f1-c68c-441b-9de4-99a219f2500a'],"['0832-6004-11', '0832-6003-11', '0832-6005-11', '0832-6006-11']",['ZOU145W1XL'],,,,09/18/2025,,,,,
Revised,01/31/2018,0641-6008-10,Bumetanide Injection,800-631-2174,Unavailable,Additional lots will be available in the November 2025 timeframe.  Product will be made available as it is released.,10/24/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA079196'],['BUMETANIDE'],['BUMETANIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6008', '0641-6007']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['99d2fc38-7e1e-4209-aa57-089794eda8a6'],['681b5e9d-e2c7-4f29-aaad-e06d4a528c11'],"['0641-6007-01', '0641-6007-10', '0641-6008-01', '0641-6008-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,04/07/2020,55150-324-25,Furosemide Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)",Eugia US LLC,,Current,['ANDA212174'],['FUROSEMIDE'],['FUROSEMIDE'],['Eugia US LLC'],"['55150-324', '55150-322', '55150-323']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['26acfb26-d058-453e-8c05-61ec44b25118'],['421aa6d5-623b-4dc2-abd5-bb9e7765bf37'],"['55150-322-01', '55150-322-25', '55150-323-01', '55150-323-25', '55150-324-01', '55150-324-25']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,04/28/2023,54288-165-01,Carboplatin Injection,"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270",Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",09/29/2025,['Oncology'],Injection,"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)",Gland Pharma Limited,Demand increase for the drug,Current,['ANDA207324'],['CARBOPLATIN'],['CARBOPLATIN'],['BPI Labs LLC'],"['54288-165', '54288-166', '54288-167', '54288-164']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5eb7631e-0b41-4aba-ba7a-f544ac9627fd'],['5484d2f0-0cc2-4bba-8f26-c7f6539a9606'],"['54288-165-01', '54288-166-01', '54288-167-01', '54288-164-01']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,01/22/2025,71093-131-01,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-131', '71093-129', '71093-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Reverified,06/28/2022,63323-725-10,Remifentanil Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)","Fresenius Kabi USA, LLC",,Current,['ANDA206223'],['REMIFENTANIL HYDROCHLORIDE'],['REMIFENTANIL HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-725', '63323-723', '63323-724']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729584', '1729710']",['2f27e51f-2b55-47ee-bd4a-001b71c60622'],['d2374b84-81c9-44f9-a4a9-1071281b2531'],"['63323-723-01', '63323-723-03', '63323-724-01', '63323-724-05', '63323-725-01', '63323-725-10']",['5V444H5WIC'],,,,,,,,,
Reverified,07/26/2023,68025-097-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Available,,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)","Vertical Pharmaceuticals, LLC",,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-097', '68025-088', '68025-089', '68025-095', '68025-096', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
New,09/11/2025,0409-0181-25,Gemcitabine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,09/11/2025,['Oncology'],Injection,"Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial  NovaPlus (NDC 0409-0181-25)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA200795'],['GEMCITABINE'],['GEMCITABINE'],"['Hospira, Inc.']","['0409-0181', '0409-0183', '0409-0182']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['GEMCITABINE HYDROCHLORIDE'],"['1720960', '1720975', '1720977']","['cc0f68d1-df16-441c-b4d7-da06b4baf1e5', '15f70b30-31dc-4c45-902b-69cad93f7308']","['dc02a23b-3ff9-4441-aa91-8e9e629a7315', 'e18ed1cb-7dd0-4001-bfda-17d1f4587fb8']","['0409-0181-01', '0409-0183-01', '0409-0182-01', '0409-0181-25', '0409-0182-25', '0409-0183-25']",['U347PV74IL'],,,,09/11/2025,,,,,
Reverified,02/20/2018,63323-466-17,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)","Fresenius Kabi USA, LLC",,Current,"['ANDA070553', 'NDA018304']",['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-466', '63323-464', '63323-462', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL', 'INFILTRATION']",['BUPIVACAINE HYDROCHLORIDE'],"['1724880', '1724881', '1725078', '1725175', '1724884', '1724885', '1725082', '1725177', '1672917', '1672919', '1673296', '1673298', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['b41b5dbd-7aff-4d97-ac97-f4355393ee4e', 'd3ba9fb9-63c8-4597-bb0a-cd01d31a24b6', '13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['e700eb7b-8b14-49c9-96b2-331f18776e45', 'b6bfc04a-1868-4630-9ca1-8c027af97ce3', 'dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-464-01', '63323-464-17', '63323-466-03', '63323-466-17', '63323-464-08', '63323-464-38', '63323-466-08', '63323-466-38', '63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,10/11/2024,0990-7953-09,Lactated Ringers Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-09)",Otsuka ICU Medical LLC,,Resolved,['NDA017641'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['ICU Medical Inc.'],"['0990-7953', '0990-7929']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']","['847627', '847630']",['179fea68-7eed-4293-b82f-24139e112240'],['d310d170-5eeb-471b-af1a-0e845001d21d'],"['0990-7929-03', '0990-7929-09', '0990-7953-02', '0990-7953-03', '0990-7953-09']","['660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT', 'M4I0D6VV5M', 'LX22YL083G']",,,,,,,10/03/2025,,Available
Reverified,03/01/2022,0990-7930-02,Dextrose Monohydrate 10% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)",Otsuka ICU Medical LLC,,Current,['NDA018080'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7930', '0990-7923', '0990-7922']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Revised,04/28/2023,0990-6138-03,Sodium Chloride 0.9% Irrigation,1-866-829-9025 or ProductAvailability@icumed.com,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-03)","ICU Medical, Inc.",,Resolved,['NDA017514'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-6138', '0990-7138', '0990-7972']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['ea49c260-0be5-48b8-9e97-bef5a4ca584e'],['3cfdeee0-ff14-4341-8396-b11c2a037c60'],"['0990-7138-09', '0990-7138-36', '0990-6138-22', '0990-6138-03', '0990-7972-05', '0990-7972-07']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Revised,04/28/2023,0338-0048-02,Sodium Chloride 0.9% Irrigation,888-229-0001,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-02)",Baxter Healthcare,,Resolved,['NDA017427'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],['0338-0048'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['123eac3f-8e50-4689-bf00-cf9407eb70ee'],['b3b4b176-41f0-4ca8-90d4-3fba5707564a'],"['0338-0048-02', '0338-0048-03', '0338-0048-04', '0338-0048-05']",['451W47IQ8X'],,,,,,,07/02/2025,,
New,10/20/2025,0781-3315-70,Oxaliplatin Injection,800-525-8747,,Discontinuation of the manufacture of the drug,10/20/2025,['Oncology'],Injection,"Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70)",Sandoz Inc.,,To Be Discontinued,['ANDA078817'],['OXALIPLATIN'],['OXALIPLATIN'],['Sandoz Inc'],"['0781-3315', '0781-3317']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['OXALIPLATIN'],"['1736776', '1736781']",['f3766495-fce3-461c-8c95-e890f5e3383f'],['ab162009-6f84-4d56-ab56-5e84409ec814'],"['0781-3315-70', '0781-3317-80']",['04ZR38536J'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,10/20/2025,,,,,
Reverified,03/23/2018,70860-700-02,Ketorolac Tromethamine Injection,833-291-9645,Available,"Athenex is not active, supplying through Sagent NDC  25021-700-01",09/29/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 70860-700-02)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,03/10/2023,59651-723-01,Clonazepam Tablet,866-850-2876,Available,,10/15/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)",Aurobindo Pharma USA,,Current,['ANDA075150'],['CLONAZEPAM'],['CLONAZEPAM'],['Aurobindo Pharma Limited'],"['59651-723', '59651-722', '59651-724']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['b1582eb7-af35-45d5-a52e-0e380d08527d'],['b1582eb7-af35-45d5-a52e-0e380d08527d'],"['59651-722-01', '59651-722-99', '59651-723-01', '59651-723-99', '59651-724-01', '59651-724-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,10/31/2017,63323-851-50,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-851', '63323-852', '63323-853', '63323-854']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '1724276', '1724338', '1724340', '1724341']",['9e8522c6-595c-46f9-bb25-272aa4683e0f'],['e034eb96-03e0-46e1-8b92-5e1f94555e7b'],"['63323-851-03', '63323-851-10', '63323-851-07', '63323-851-15', '63323-851-50', '63323-852-03', '63323-852-25', '63323-853-03', '63323-853-25', '63323-854-03', '63323-854-10']",['L960UP2KRW'],,,,,,,,,
New,11/21/2024,0173-0914-56,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 8 mg (NDC 0173-0914-56)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0914', '0173-0897', '0173-0903', '0173-0906', '0173-0911']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Revised,06/21/2018,0409-4888-10,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-10)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018803'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']","['0409-4888', '0409-1918']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807628', '1807631', '1807637', '1807638']",['9ee88abb-024a-4a3b-9776-1777eaf2f760'],['8eb172da-dcd4-4660-4a8f-ad44a14b4af7'],"['0409-4888-02', '0409-4888-10', '0409-4888-03', '0409-4888-20', '0409-4888-06', '0409-4888-50', '0409-4888-01', '0409-4888-12', '0409-4888-90', '0409-1918-42', '0409-1918-32', '0409-1918-43', '0409-1918-33', '0409-1918-45', '0409-1918-35']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,03/23/2018,63323-285-10,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,04/02/2020,63323-412-02,Midazolam Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)","Fresenius Kabi USA, LLC",,Current,"['ANDA075154', 'ANDA208878']",['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-412', '63323-411']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']","['9814447b-a93e-42ad-b57e-5db0a5b7f552', 'c2aaa2df-aa73-4ea7-96be-528010260e25']","['a91ce254-14a3-4cbf-8ab8-5da252aa3fdc', '09daf48f-1d44-4b7b-bb53-bd5635b93ca6']","['63323-411-22', '63323-411-27', '63323-411-15', '63323-411-12', '63323-411-18', '63323-411-25', '63323-411-13', '63323-411-10', '63323-412-18', '63323-412-25', '63323-412-03', '63323-412-02', '63323-412-06', '63323-412-05', '63323-412-13', '63323-412-10', '63323-412-00']",['W7TTW573JJ'],,,,,,,,,
New,12/05/2024,47335-475-88,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-88)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-475', '47335-472']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,02/20/2018,63323-462-17,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)","Fresenius Kabi USA, LLC",,Current,['NDA018304'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-462', '63323-464', '63323-466', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1672917', '1672919', '1673296', '1673298', '1724880', '1724881', '1724884', '1724885', '1725078', '1725082', '1725175', '1725177', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,10/12/2022,0185-0842-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-525-8747,Available,,11/07/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)",Sandoz Inc.,,Current,['ANDA040439'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Sandoz Inc'],"['0185-0842', '0185-0831', '0185-0853', '0185-0864', '0185-2099', '0185-2098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577961']",['d68cd1d1-3bb4-4afa-9786-687cf1766ae1'],['288dafc4-fe6e-4891-832f-511022c87445'],"['0185-0831-01', '0185-0842-01', '0185-0853-01', '0185-0864-01', '0185-2099-01', '0185-2098-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/10/2020,43066-555-24,Dexmedetomidine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)",Baxter Healthcare,,Current,['ANDA208532'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['Baxter Healthcare Company'],"['43066-555', '43066-557']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['949ed273-6b79-4f54-8284-a710082edd77'],['aea9a3ad-c244-42be-9cd3-5df83fe2b522'],"['43066-555-24', '43066-557-12']",['1018WH7F9I'],,,,,,,,,
Revised,12/08/2021,0409-1966-05,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-05)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018800'],['BACTERIOSTATIC SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']",['0409-1966'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],['313002'],['2d3125e0-c89b-46d5-a350-07d1e7936ebd'],['376093e7-e09e-4a57-3199-195e45251866'],"['0409-1966-02', '0409-1966-07', '0409-1966-06', '0409-1966-12', '0409-1966-01', '0409-1966-05']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,06/21/2018,63323-186-02,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-02)","Fresenius Kabi USA, LLC",,Resolved,['ANDA088912'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-186'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807632', '1807636', '1807637', '1807638']","['debc17b5-4d24-473c-8396-e409433ce57c', '75c567e3-582b-4fff-9a72-f326f1d13c8f']","['f2a98378-9678-4738-9670-fc7a215c0606', 'f62481fd-fcdb-4be6-ac13-29c590e925c3']","['63323-186-00', '63323-186-04', '63323-186-02', '63323-186-01', '63323-186-10', '63323-186-03', '63323-186-20']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,09/19/2025,69516-005-30,Obeticholic Acid Tablet,1-844-782-4278,,"Business decision. Products will not be available after November 14, 2025.",09/19/2025,['Gastroenterology'],Tablet,"Ocaliva, Tablet, 5 mg (NDC 69516-005-30)",Intercept Pharmaceuticals,,To Be Discontinued,['NDA207999'],['OCALIVA'],['OBETICHOLIC ACID'],['Intercept Pharmaceuticals Inc'],"['69516-005', '69516-010']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OBETICHOLIC ACID'],"['1798364', '1798370', '1798373', '1798375']",['44a7331c-fc85-4906-948e-01bbba5e7e61'],['cdfbe0cd-eb15-45a1-ac17-531bcda21aec'],"['69516-005-30', '69516-010-30']",['0462Z4S4OZ'],"['N0000192561', 'N0000192560']",['Farnesoid X Receptor Agonist [EPC]'],,09/19/2025,,,,['Farnesoid X Receptor Agonists [MoA]'],
New,07/21/2025,73070-102-15,Insulin Aspart Injection,609-987-5800,,"Unbranded Insulin Aspart 3 mL PenFill® cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injection,"Insulin Aspart, Injection, 3 mL Insulin Aspart PenFill® cartridge (NDC 73070-102-15)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA020986'],['INSULIN ASPART'],['INSULIN ASPART'],"['Novo Nordisk Pharma, Inc.']","['73070-102', '73070-100', '73070-103']",['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['INSULIN ASPART'],"['311040', '1653196', '1653202']",['393af9a3-df9a-40b2-a5e6-bfa5434a2552'],['bee5b358-c863-420b-be73-ced2e920c499'],"['73070-100-11', '73070-102-10', '73070-102-15', '73070-103-10', '73070-103-15']",['D933668QVX'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
Revised,04/28/2023,0703-4239-01,Carboplatin Injection,800-545-8800,Available,,10/16/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA077269'],['CARBOPLATIN'],['CARBOPLATIN'],"['Teva Parenteral Medicines, Inc.']","['0703-4239', '0703-4244', '0703-4246', '0703-4248']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],"['bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df', 'b943761e-6a46-45a0-bdb4-1fec1e101f8c']","['f330f5a2-2cad-402f-bcbb-26245a753276', 'e176b6ef-2ff6-498b-a9d8-7a634d147f37']","['0703-4244-01', '0703-4246-01', '0703-4248-01', '0703-4239-01', '0703-4244-81', '0703-4246-81', '0703-4248-81', '0703-4239-81']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,06/06/2018,0641-6041-25,Ketorolac Tromethamine Injection,800-631-2174,Unavailable,Shortage recovery: TBD,10/24/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['ANDA075772'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6041', '0641-6043', '0641-6042']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['25d6c438-45d2-4162-91c2-b5caa0f86bf3'],['0c2c75c9-ed7b-46a8-9543-429bf2d8f090'],"['0641-6043-01', '0641-6043-25', '0641-6042-01', '0641-6042-25', '0641-6041-01', '0641-6041-25']",['4EVE5946BQ'],,,,,,,,,
Revised,04/10/2020,0781-3493-95,Dexmedetomidine Hydrochloride Injection,See Related Information section below for customer service information,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,10/09/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL  (NDC 0781-3493-95)","Jiangsu Hengrui Pharmaceuticals Co., Ltd.",,Current,['ANDA209065'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['Sandoz Inc.'],"['0781-3493', '0781-3494', '0781-3495']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['fdf227d9-008e-60f8-e053-6294a90af5c4'],['809e8f77-390f-4cc8-8c8a-4f67a249c9df'],"['0781-3493-95', '0781-3494-95', '0781-3495-95']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0990-7984-37,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-37)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7984', '0990-7730', '0990-7983', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,12/10/2021,0264-7800-10,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-10)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-7800', '0264-7802']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807639', '1807551', '1807552', '1807633', '1807634']","['318417ff-d599-47b8-8181-89c3bb3b2e8d', '9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa']","['47a0313f-36df-4fa6-a828-c9e1946ba9b0', '7f22c06b-6b4d-4b49-a4b2-d2169f2bd653']","['0264-7800-09', '0264-7800-00', '0264-7800-10', '0264-7800-20', '0264-7802-00', '0264-7802-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,11534-196-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",732-382-6085 Monday to Friday 9 am to 3:45 pm,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)","Sunrise Pharmaceutical, Inc.",,Current,['ANDA209799'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['SUNRISE PHARMACEUTICAL, INC.']","['11534-196', '11534-190', '11534-191', '11534-192', '11534-193', '11534-194', '11534-195']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['86a00bec-51eb-4d73-a945-b1937970b29a'],['ac102599-3a5b-4154-899e-6ff262be7ff7'],"['11534-190-01', '11534-190-03', '11534-191-01', '11534-191-03', '11534-192-01', '11534-192-03', '11534-193-01', '11534-193-03', '11534-194-01', '11534-194-03', '11534-195-01', '11534-195-03', '11534-196-01', '11534-196-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,08/04/2025,45963-614-55,Irinotecan Hydrochloride Injection,800-545-8800,,Product not anticipated to be available beyond mid-late September 2025,08/04/2025,['Oncology'],Injection,"Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA078589'],['IRINOTECAN HYDROCHLORIDE'],['IRINOTECAN HYDROCHLORIDE'],"['Actavis Pharma, Inc.']",['45963-614'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['IRINOTECAN HYDROCHLORIDE'],"['1726319', '1726324']",['8f2da07f-1d3e-4d8b-8083-805da8a780db'],['5e1fdcaa-918f-4cd8-9c7a-4c538d866198'],"['45963-614-51', '45963-614-55']",['042LAQ1IIS'],,,,08/04/2025,,,,,
Revised,03/21/2023,0338-9553-50,Clindamycin Phosphate Injection,888-229-0001,Limited Availability,Estimated recovery: November 2025,10/22/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)",Baxter Healthcare,Demand increase for the drug,Current,['NDA208083'],['CLINDAMYCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Baxter Healthcare Company'],"['0338-9553', '0338-9545', '0338-9549']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN PHOSPHATE'],"['309335', '309336', '309339']",['12bdbbc9-fbb0-4a0a-9147-37df8ac5dc5e'],['44fa506b-90ac-42de-831b-5f3f1a500fc0'],"['0338-9545-50', '0338-9545-24', '0338-9549-50', '0338-9549-24', '0338-9553-50', '0338-9553-24']",['EH6D7113I8'],,,,,,,,,
Reverified,07/14/2023,59417-105-10,Lisdexamfetamine Dimesylate Capsule,877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],Capsule,"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA021977'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-105', '59417-101', '59417-102', '59417-103', '59417-104', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
New,06/13/2025,13668-382-90,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-90)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Reverified,01/31/2018,65219-570-04,Bumetanide Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)","Fresenius Kabi USA, LLC",,Current,['ANDA216434'],['BUMETANIDE'],['BUMETANIDE'],"['Fresenius Kabi USA, LLC']","['65219-570', '65219-572']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['aaff61c4-203b-4905-9138-0f98959ad013'],['a007f3aa-3977-4be3-a9a2-db3d458bca58'],"['65219-570-01', '65219-570-04', '65219-572-01', '65219-572-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,04/23/2025,0832-1055-15,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 20 mg (NDC 0832-1055-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1055', '0832-1054']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
New,01/30/2025,61570-111-01,Ramipril Capsule,844-646-4398,,Discontinuation of the manufacture of the drug,01/30/2025,['Cardiovascular'],Capsule,"Altace, Capsule, 2.5 mg (NDC 61570-111-01)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/30/2025,,,,,
Reverified,02/22/2012,83090-005-10,Lidocaine Hydrochloride Injection,"844-425-3131, SinteticaCS@eversana.com",Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X5ML)  is Preservative free.",08/19/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)",Sintetica US,,Current,['ANDA214267'],['NA'],['LIDOCAINE HYDROCHLORIDE'],['Sintetica US LLC'],"['83090-005', '83090-001', '83090-002', '83090-003', '83090-004', '83090-006']",['HUMAN PRESCRIPTION DRUG'],['INFILTRATION'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737566', '1737568', '1737570', '1737757', '1737761', '1737763']",['0d18f291-3a92-421e-8841-6be743b1f154'],['aa3e688a-308c-4a82-a268-28ccf1677c55'],"['83090-001-01', '83090-001-10', '83090-002-01', '83090-002-10', '83090-003-01', '83090-003-10', '83090-004-01', '83090-004-10', '83090-005-01', '83090-005-10', '83090-006-01', '83090-006-10']",['EC2CNF7XFP'],,,,,,,,,
Reverified,02/14/2022,0990-7922-02,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7922', '0990-7923', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
New,07/10/2025,72305-112-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 112 ug (NDC 72305-112-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-112', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,02/14/2022,0264-1510-31,Dextrose Monohydrate 5% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)",B. Braun Medical Inc.,,Current,['NDA016730'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],['0264-1510'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795616', '1795618']",['0a144591-6cfa-4aed-a067-c95aebc29057'],['60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5'],"['0264-1510-36', '0264-1510-31', '0264-1510-32']",['LX22YL083G'],,,,,,,,,
New,01/13/2025,50222-505-50,Azelaic Acid Gel,978-760-9954,,,01/13/2025,['Dermatology'],Gel,"Finacea, Gel, .15 g/1 g (NDC 50222-505-50)",Leo Pharma Inc.,,To Be Discontinued,['NDA021470'],['FINACEA'],['AZELAIC ACID'],['LEO Pharma Inc.'],['50222-505'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['AZELAIC ACID'],"['1041518', '1043748']",['dd017db5-9d51-45eb-bb37-d3daa5949168'],['bea1957c-55ca-48cd-8cbc-ed44d546a857'],['50222-505-50'],['F2VW3D43YT'],"['N0000008841', 'N0000009982']",,"['Decreased Protein Synthesis [PE]', 'Decreased Sebaceous Gland Activity [PE]']",01/13/2025,,,,,
Revised,01/06/2023,0781-3001-07,Somatropin Injection,800-525-8747,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Omnitrope, Injection, 5 mg/1.5 mL (NDC 0781-3001-07)",Sandoz Inc.,,Resolved,['BLA021426'],['OMNITROPE'],['SOMATROPIN'],['Sandoz Inc'],"['0781-3001', '0781-3004', '0781-4004']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['SOMATROPIN'],"['241975', '645884', '854302', '864110', '1736267', '1736337']",['4285f380-615e-420b-b756-1e0a775f785b'],['58d84ffa-4056-4e36-ad67-7bd4aef444a5'],"['0781-3001-26', '0781-3001-07', '0781-3004-26', '0781-3004-07', '0781-4004-36', '0781-4014-71', '0781-4024-72']",['NQX9KB6PCL'],"['N0000175606', 'M0028842']",['Recombinant Human Growth Hormone [EPC]'],,,,['Human Growth Hormone [CS]'],08/28/2025,,Available
Revised,10/11/2024,46163-206-94,Peritoneal Dialysis Solution,800-323-5188,,,07/07/2025,['Renal'],Solution,"Peritoneal Dialysis, Solution, Various NDCs (NDC 46163-206-94)",Fresenius Medical Care North America,,Resolved,['NDA020171'],['DELFLEX'],"['DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE']","['Fresenius Medical Care de Mexico, S.A. de C.V.']","['46163-206', '46163-209', '46163-212']",['HUMAN PRESCRIPTION DRUG'],['INTRAPERITONEAL'],"['CALCIUM CHLORIDE', 'DEXTROSE MONOHYDRATE', 'MAGNESIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",,['38fb0473-107c-1b7a-e063-6294a90aafb8'],['a98facd6-9daa-4d37-8209-63a0599dbfaa'],"['46163-209-92', '46163-209-94', '46163-209-95', '46163-212-95', '46163-212-92', '46163-212-94', '46163-206-92', '46163-206-94', '46163-206-95']","['02F3473H9O', '451W47IQ8X', 'TU7HW0W0QT', 'M4I0D6VV5M', 'LX22YL083G']",,,,,,,07/07/2025,,Available
New,11/03/2025,0002-4491-62,Lasmiditan Succinate Tablet,800-545-5979,,A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets.,11/03/2025,['Neurology'],Tablet,"Reyvow, Tablet, 100 mg (NDC 0002-4491-62)",Eli Lilly and Co.,,To Be Discontinued,['NDA211280'],['REYVOW'],['LASMIDITAN'],['Eli Lilly and Company'],"['0002-4491', '0002-4312']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LASMIDITAN'],"['2256937', '2256943', '2256945', '2256947']",['75a13e98-3736-4256-8277-6c05bcaddcf5'],['aea3358c-ff41-4490-9e6d-c7bf7b3de13f'],"['0002-4312-08', '0002-4312-61', '0002-4312-62', '0002-4491-08', '0002-4491-61', '0002-4491-62']",['760I9WM792'],,,,11/03/2025,,,,,
Reverified,03/12/2021,0053-6871-00,Desmopressin Acetate Spray,888-337-7464,Unavailable,,09/17/2025,['Hematology'],Spray,"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)",Ferring,Requirements related to complying with good manufacturing practices,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,02/22/2012,0409-9137-05,Lidocaine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: December 2025; Estimated Recovery: March 2026,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA040302'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-9137', '0409-4903', '0409-4904', '0409-1323']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1012066', '1012068']",['477abea3-c873-4265-82e8-5508ef54399f'],['ad1ef0a8-88db-4648-c098-d009eaeb4e5b'],"['0409-4903-11', '0409-4903-34', '0409-4904-11', '0409-4904-34', '0409-1323-15', '0409-1323-05', '0409-9137-11', '0409-9137-05']",['V13007Z41A'],,,,,,,,,
New,12/05/2024,57664-437-18,Digoxin Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Cardiovascular'],Tablet,"Digoxin, Tablet, 125 ug (NDC 57664-437-18)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA076363'],['DIGOXIN'],['DIGOXIN'],"['Sun Pharmaceutical Industries, Inc.']","['57664-437', '57664-441']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIGOXIN'],"['197604', '197606']",['1a3e469c-1452-3d1e-e063-6394a90ae73a'],['62795623-a2bc-4dd2-8989-3b9782bfd80e'],"['57664-437-88', '57664-437-18', '57664-441-88', '57664-441-18']",['73K4184T59'],"['N0000175568', 'M0003451']",['Cardiac Glycoside [EPC]'],,12/05/2024,,['Cardiac Glycosides [CS]'],,,
New,09/08/2025,66993-081-69,Sumatriptan Nasal Spray,866-525-0688,,"This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately February 28, 2026.",09/08/2025,['Neurology'],Nasal Spray,"Imitrex, Nasal Spray, 5 mg/100 uL (NDC 66993-081-69)",Prasco Laboratories,,To Be Discontinued,['NDA020626'],['SUMATRIPTAN'],['SUMATRIPTAN'],['Prasco Laboratories'],"['66993-081', '66993-082']",['HUMAN PRESCRIPTION DRUG'],['NASAL'],['SUMATRIPTAN'],"['313159', '314227']",['b15509b9-4a5b-46ed-be80-b5f6e6e79444'],['f63e616b-ae0c-432b-badc-8c45023aa725'],"['66993-081-69', '66993-082-69']",['8R78F6L9VO'],"['N0000175763', 'N0000175764', 'N0000175765']",['Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]'],,09/08/2025,,,,"['Serotonin 1b Receptor Agonists [MoA]', 'Serotonin 1d Receptor Agonists [MoA]']",
New,04/10/2025,0781-2076-10,Tamsulosin Hydrochloride Capsule,800-525-8747,,,04/10/2025,['Urology'],Capsule,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-10)",Sandoz Inc.,,To Be Discontinued,['ANDA078015'],['TAMSULOSIN HYDROCHLORIDE'],['TAMSULOSIN HYDROCHLORIDE'],['Sandoz Inc'],['0781-2076'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TAMSULOSIN HYDROCHLORIDE'],['863669'],['98c2abd9-1998-48cd-83f9-f5f94ff39345'],['fb120098-b007-4a33-80b8-b7279c7668ee'],"['0781-2076-01', '0781-2076-10', '0781-2076-92']",['11SV1951MR'],,,,04/10/2025,,,,,
New,07/23/2025,0245-5315-11,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['KLOR-CON'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0245-5315', '0245-5316']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953', '628958', '832718']",['39e77e07-bdc8-28e9-e063-6394a90a120c'],['1ff53330-065c-4213-9c0c-ac498621d09d'],"['0245-5315-11', '0245-5315-15', '0245-5315-89', '0245-5315-01', '0245-5316-11', '0245-5316-15', '0245-5316-89', '0245-5316-01']",['660YQ98I10'],,,,07/23/2025,,,,,
Revised,01/01/2012,25021-816-30,Leucovorin Calcium Injection,866-625-1618,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 25021-816-30)",Sagent Pharmaceuticals,,Resolved,['ANDA200855'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Sagent Pharmaceuticals'],"['25021-816', '25021-813', '25021-814', '25021-815']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['ff2ba160-e2f9-4ab9-9e67-2409f02c923e'],['9d0e5356-ff39-4a8e-944c-e808a21ef4b2'],"['25021-813-10', '25021-814-30', '25021-815-30', '25021-816-30']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Revised,02/08/2019,55150-238-05,Dexamethasone Sodium Phosphate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-238-05)",Eugia US LLC,Demand increase for the drug,Current,['ANDA206781'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Eugia US LLC'],"['55150-238', '55150-237', '55150-239']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['1116927', '1812194']",['34b1362a-f970-485f-bdac-3a02217157c9'],['ce7ad5a4-a9c5-42d6-87cc-ca16556208d2'],"['55150-237-01', '55150-238-05', '55150-239-30']",['AI9376Y64P'],,,,,,,,,
Reverified,07/18/2023,0480-3667-22,Liraglutide Injection,833-493-4689,Available,Distributed by Teva,11/04/2025,['Endocrinology/Metabolism'],Injection,"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)","Novo Nordisk, Inc.",,Current,['NDA022341'],['LIRAGLUTIDE'],['LIRAGLUTIDE'],"['Teva Pharmaceuticals USA, Inc.']",['0480-3667'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],['897122'],['b56c797c-a46a-4dbf-a367-9d7f26c7d29d'],['14bf9812-14ee-46ce-93b1-686e4906cbbc'],"['0480-3667-19', '0480-3667-22', '0480-3667-20']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
New,01/28/2025,71093-127-05,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-05)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-127', '71093-128']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
New,06/16/2025,0093-3750-63,Tobramycin Solution,800-545-8800,,Discontinuation of the manufacture of the drug,06/16/2025,['Pulmonary/Allergy'],Solution,"Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-63)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA210915'],['TOBRAMYCIN'],['TOBRAMYCIN'],"['Teva Pharmaceuticals USA, Inc.']",['0093-3750'],['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],['TOBRAMYCIN'],['1314763'],['8aa98982-a156-4bc8-8d31-9a39b88808ed'],['d03079d2-5617-4628-92b9-3caa757b22c0'],"['0093-3750-28', '0093-3750-63']",['VZ8RRZ51VK'],"['N0000175477', 'M0000946']",['Aminoglycoside Antibacterial [EPC]'],,06/16/2025,,['Aminoglycosides [CS]'],,,
New,04/24/2025,0245-1073-30,"Topiramate Capsule, Extended Release",716-315-2000,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,04/24/2025,['Neurology'],"Capsule, Extended Release","Qudexy XR, Capsule, Extended Release, 200 mg (NDC 0245-1073-30)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA205122'],['QUDEXY XR'],['TOPIRAMATE'],"['Upsher-Smith Laboratories, LLC']","['0245-1073', '0245-1071', '0245-1072', '0245-1074', '0245-1075']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOPIRAMATE'],"['1494766', '1494769', '1494771', '1494775', '1494778', '1494781', '1812419', '1812421', '1812425', '1812427']",['374eeb55-b017-48fd-e063-6294a90a6ad7'],['46f54677-3a22-4c38-9b92-923020164e15'],"['0245-1071-30', '0245-1071-90', '0245-1072-30', '0245-1072-90', '0245-1074-30', '0245-1074-90', '0245-1075-30', '0245-1075-90', '0245-1073-30', '0245-1073-90']",['0H73WJJ391'],"['N0000008486', 'N0000185506', 'N0000182140']",,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],04/24/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
New,06/13/2025,0093-7202-10,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076056'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-7202', '0093-0771', '0093-7201']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],"['904458', '904467', '904475']",['72579e23-23ef-4ab7-ad64-24d5ea7997eb'],['99e0e848-f8f3-4b42-b880-8fbc42633948'],"['0093-0771-98', '0093-0771-10', '0093-7201-98', '0093-7201-10', '0093-7202-98', '0093-7202-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
Reverified,10/25/2017,0264-9594-20,Lidocaine Hydrochloride Injection,800-227-2862,Available,,11/04/2025,['Cardiovascular'],Injection,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)",B. Braun Medical Inc.,,Current,['NDA019830'],['LIDOCAINE HYDROCHLORIDE AND DEXTROSE'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE'],['B. Braun Medical Inc.'],"['0264-9594', '0264-9598']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE MONOHYDRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1737723', '1737742', '1737744']",['26f23356-9e1f-4c5f-9959-06d53037a715'],['7dff29d9-522d-40eb-a9d9-42377912d640'],"['0264-9598-20', '0264-9594-20', '0264-9594-10']","['EC2CNF7XFP', 'LX22YL083G']",,,,,,,,,
Reverified,03/01/2022,63323-824-75,Dextrose Monohydrate 10% Injection,888-386-1300,Unavailable,Backordered. Next release November 2025. Check wholesalers for inventory.,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['ANDA209448'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Fresenius Kabi USA, LLC']",['63323-824'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481']",['d4eda8d8-e374-469e-8ac0-9c9fb7a58aaf'],['3b8f2692-4371-4f1a-95af-b41842131fdd'],"['63323-824-24', '63323-824-74', '63323-824-25', '63323-824-75', '63323-824-26', '63323-824-76']",['LX22YL083G'],,,,,,,,,
Revised,05/14/2024,0555-0171-78,Mefloquine Hydrochloride Tablet,800-545-8800,,,08/21/2025,['Anti-Infective'],Tablet,"Mefloquine Hydrochloride, Tablet, 250 mg (NDC 0555-0171-78)","Teva Pharmaceuticals USA, Inc.",,Resolved,['ANDA076392'],['MEFLOQUINE HYDROCHLORIDE'],['MEFLOQUINE HYDROCHLORIDE'],"['Teva Pharmaceuticals USA, Inc.']",['0555-0171'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEFLOQUINE HYDROCHLORIDE'],['835913'],['33a105c5-0e51-4759-857b-6ca8dfae1d13'],['09716a24-d7da-42b2-af29-c03a1b6670bd'],"['0555-0171-88', '0555-0171-78']",['5Y9L3636O3'],,,,,,,08/21/2025,,Available
New,04/14/2025,61314-476-64,Adalimumab-adaz Injection,800-525-8747,,,04/14/2025,['Rheumatology'],Injection,"Hyrimoz, Injection, 20 mg/.2 mL (NDC 61314-476-64)",Sandoz Inc.,,To Be Discontinued,['BLA761071'],['HYRIMOZ'],['ADALIMUMAB-ADAZ'],['Sandoz Inc'],"['61314-476', '61314-454', '61314-473', '61314-509', '61314-517', '61314-531']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['ADALIMUMAB'],"['2641644', '2641650', '2641653', '2641654', '2641655', '2641658', '2641660', '2641661', '2641662', '2641663', '2641664', '2641665', '2641666', '2641667', '2641668', '2641669', '2641670', '2641671', '2641672', '2641673']",['0d5a902f-4ca8-46d2-a790-b167842f62e4'],['1ac7d061-3380-468c-b077-c05f8dfbc829'],"['61314-454-20', '61314-454-36', '61314-454-68', '61314-473-64', '61314-473-20', '61314-473-92', '61314-476-64', '61314-509-64', '61314-517-36', '61314-531-64']",['FYS6T7F842'],"['N0000175610', 'N0000175451', 'M0001357']",['Tumor Necrosis Factor Blocker [EPC]'],,04/14/2025,,"['Antibodies, Monoclonal [CS]']",,['Tumor Necrosis Factor Receptor Blocking Activity [MoA]'],
Reverified,03/10/2023,61269-605-10,Clonazepam Tablet,orders@h2-pharma.com,Available,Marketed by H2-Pharma,11/05/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Klonopin, Tablet, .5 mg (NDC 61269-605-10)",Cheplapharm Arzneimittel GmbH,,Current,['NDA017533'],['KLONOPIN'],['CLONAZEPAM'],"['H2-Pharma, LLC']","['61269-605', '61269-610', '61269-620']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529', '206157', '206159', '206160']",['c8a147a4-9ebc-4c69-a5b6-bf7547dc6334'],['cfa0d79a-843c-4b88-95a1-e9511d649ca1'],"['61269-605-10', '61269-610-10', '61269-620-10']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,04/28/2023,54288-167-01,Carboplatin Injection,"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270",Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",09/29/2025,['Oncology'],Injection,"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)",Gland Pharma Limited,Demand increase for the drug,Current,['ANDA207324'],['CARBOPLATIN'],['CARBOPLATIN'],['BPI Labs LLC'],"['54288-167', '54288-165', '54288-166', '54288-164']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5eb7631e-0b41-4aba-ba7a-f544ac9627fd'],['5484d2f0-0cc2-4bba-8f26-c7f6539a9606'],"['54288-165-01', '54288-166-01', '54288-167-01', '54288-164-01']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,03/23/2018,63323-288-20,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-288', '63323-286', '63323-287', '63323-285']",['HUMAN PRESCRIPTION DRUG'],['EPIDURAL'],['ROPIVACAINE HYDROCHLORIDE'],"['905189', '905191', '1734084', '1734086', '1734090', '1734091', '1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484']","['cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c', '75465ceb-e894-487d-aa80-671fa0841fce']","['23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6', '56dfabf7-f7a8-4601-b17a-cb16fb995b0f']","['63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95', '63323-288-25', '63323-288-27']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,0527-4665-37,Lisdexamfetamine Dimesylate Capsule,844-834-0530,Available,,11/03/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)","Lannett Company, Inc.",,Current,['ANDA215802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Lannett Company, Inc.']","['0527-4665', '0527-4661', '0527-4662', '0527-4663', '0527-4664', '0527-4666', '0527-4667']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7ac942a6-689a-420b-87bf-dc59003400dc'],['2cedb4c2-1e40-4bc4-b9f4-127150c4afbd'],"['0527-4661-37', '0527-4662-37', '0527-4663-37', '0527-4664-37', '0527-4665-37', '0527-4666-37', '0527-4667-37']",['SJT761GEGS'],,,,,,,,,
New,07/29/2025,61570-075-50,Esterified Estrogens Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,07/29/2025,['Endocrinology/Metabolism'],Tablet,"Menest, Tablet, 2.5 mg (NDC 61570-075-50)",Pfizer Inc.,,To Be Discontinued,['ANDA084949'],['MENEST'],['ESTERIFIED ESTROGENS'],['Pfizer Laboratories Div Pfizer Inc'],"['61570-075', '61570-072', '61570-073', '61570-074']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ESTROGENS, ESTERIFIED']","['197666', '197667', '197668', '197669', '212039', '212232', '212373', '212464']",['78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb'],['e0141598-0bb2-4cf0-c9b8-6867b34bbb17'],"['61570-072-01', '61570-073-01', '61570-074-01', '61570-075-50']",['3ASP8Q3768'],,,,07/29/2025,,,,,
Reverified,07/14/2023,64850-553-01,Lisdexamfetamine Dimesylate Capsule,888-852-6657,Limited Availability,Limited Availability,11/04/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA218604'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Elite Laboratories, Inc.']","['64850-553', '64850-550', '64850-551', '64850-552', '64850-554', '64850-555', '64850-556']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['e414bb2e-d404-44ea-931c-5998b0a4c87e'],['0e024b69-567c-4b40-9c3e-a2daec34256c'],"['64850-550-01', '64850-551-01', '64850-552-01', '64850-553-01', '64850-554-01', '64850-555-01', '64850-556-01']",['SJT761GEGS'],,,,,,,,,
New,11/07/2025,0409-4933-01,Epinephrine Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Cardiovascular', 'Endocrinology/Metabolism']",Injection,"Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA209359'],['EPINEPHRINE'],['EPINEPHRINE'],"['Hospira, Inc.']",['0409-4933'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['EPINEPHRINE'],['727373'],['89ecdc19-31ff-40e9-93aa-a916bef2b462'],['ef18a92f-ba83-4bb0-808b-d09d736f6a81'],"['0409-4933-11', '0409-4933-01', '0409-4933-05', '0409-4933-10']",['YKH834O4BH'],"['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,11/07/2025,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Reverified,02/20/2018,71288-725-32,Bupivacaine Hydrochloride Injection,844-824-8426,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,08/19/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)",Kindos Pharmaceuticals Co. Ltd.,,Current,['ANDA216040'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Meitheal Pharmaceuticals Inc'],"['71288-725', '71288-721', '71288-722', '71288-724', '71288-727', '71288-728']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['b085b86e-d32f-494e-8a4a-3080ff240109'],['daec9ee4-b666-485e-a153-4b5e5acc48a1'],"['71288-721-11', '71288-722-32', '71288-724-11', '71288-725-32', '71288-727-11', '71288-728-32']",['7TQO7W3VT8'],,,,,,,,,
New,06/09/2025,66215-101-03,Bosentan Tablet,800-526-7736,,,06/09/2025,['Cardiovascular'],Tablet,"Tracleer, Tablet, 62.5 mg (NDC 66215-101-03)",Actelion Pharmaceuticals,,To Be Discontinued,['NDA021290'],['TRACLEER'],['BOSENTAN'],"['Actelion Pharmaceuticals US, Inc.']","['66215-101', '66215-102', '66215-103', '66215-232']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BOSENTAN'],"['349253', '352066', '656659', '656660', '1989081', '1989085']",['3bb9bd6a-b0d2-0723-e063-6394a90afc46'],['749e42fb-2fe0-45dd-9268-b43bb3f4081c'],"['66215-101-06', '66215-101-03', '66215-102-06', '66215-102-03', '66215-103-14', '66215-103-56', '66215-232-14', '66215-232-56']",['Q326023R30'],,,,06/09/2025,,,,,
Reverified,01/01/2012,63323-580-20,Atropine Sulfate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)","Fresenius Kabi USA, LLC",,Current,['NDA209260'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Fresenius Kabi USA, LLC']",['63323-580'],['HUMAN PRESCRIPTION DRUG'],"['ENDOTRACHEAL', 'INTRAMEDULLARY', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['ATROPINE SULFATE'],['1190776'],['8039a2a4-4c0a-4062-9ca5-78137ba74082'],['310c8a74-ea24-4357-8099-81e394b1634e'],['63323-580-20'],['03J5ZE7KA5'],,,,,,,,,
Revised,07/18/2023,0143-9144-03,Liraglutide Injection,800-631-2174,Available,Product will be made available as it is released.,10/24/2025,['Endocrinology/Metabolism'],Injection,"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA215503'],['LIRAGLUTIDE'],['LIRAGLUTIDE'],['Hikma Pharmaceuticals USA Inc.'],['0143-9144'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],['897122'],['f242c0f8-6d4f-4a78-a1fd-433a0672dbd3'],['2100ec49-57b2-4330-ab5f-057ce9b7e4d0'],"['0143-9144-03', '0143-9144-02']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
Revised,11/06/2017,0409-2344-88,Dobutamine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA074086'],['DOBUTAMINE'],['DOBUTAMINE'],"['Hospira, Inc.']",['0409-2344'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],['1812168'],"['e71e9520-871b-479d-9652-1857fceca863', '5d6b1dfe-d679-4aea-97a6-3d074a202afe']","['dc537761-d5f4-488d-24ab-b2bcd2b17b7a', '89becb0c-da60-4f43-0a98-29ff7a9eca58']","['0409-2344-01', '0409-2344-62', '0409-2344-02', '0409-2344-68', '0409-2344-88']",['0WR771DJXV'],,,,,,,,,
Reverified,07/14/2023,59417-117-01,"Lisdexamfetamine Dimesylate Tablet, Chewable",877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],"Tablet, Chewable","Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA208510'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-117', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Reverified,08/03/2022,62135-736-30,Flurazepam Hydrochloride Capsule,845-268-5000 Ext. 510,Available,,08/19/2025,"['Neurology', 'Other']",Capsule,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)",Chartwell Molecular Holdings LLC,,Current,['ANDA072368'],['FLURAZEPAM HYDROCHLORIDE'],['FLURAZEPAM HYDROCHLORIDE'],"['Chartwell RX, LLC']","['62135-736', '62135-737']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLURAZEPAM HYDROCHLORIDE'],"['1298088', '1298091']",['25893c92-c8f1-567a-e063-6294a90a00d4'],['8f476891-1346-4e8c-ac1b-f8cbdc64f5a1'],"['62135-736-30', '62135-736-90', '62135-737-30', '62135-737-90']",['756RDM536M'],,,,,,,,,
New,12/05/2024,63304-692-77,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-77)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-692', '63304-693']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
New,05/02/2025,0832-0541-11,Bumetanide Tablet,800-654-2299,,,05/02/2025,['Cardiovascular'],Tablet,"Bumetanide, Tablet, 1 mg (NDC 0832-0541-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA209916'],['BUMETANIDE'],['BUMETANIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0541', '0832-0540', '0832-0542']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BUMETANIDE'],"['197417', '197418', '197419']",['d53166d9-64ca-4b76-81a7-b70a60c53b12'],['ff5dc8c6-b2f2-41d3-8e56-a953aa721b59'],"['0832-0540-11', '0832-0541-11', '0832-0541-10', '0832-0542-11', '0832-0542-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],05/02/2025,,,,,
Reverified,12/22/2021,42806-799-60,Rifampin Capsule,(718) 276-8600 ext. 3,Available,,10/15/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 300 mg (NDC 42806-799-60)","Epic Pharma, LLC",,Current,['ANDA064150'],['RIFAMPIN'],['RIFAMPIN'],"['EPIC PHARMA, LLC']","['42806-799', '42806-801']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['a4ac02e8-68ac-4e79-8ca5-0939dd002c87'],['0391f1e1-70d4-4b15-8b58-055bb6a385b8'],"['42806-801-30', '42806-801-01', '42806-799-30', '42806-799-60', '42806-799-01', '42806-799-05']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,01/11/2024,42858-167-01,Lisdexamfetamine Dimesylate Capsule,888-827-0616,Available,,08/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)",Rhodes Pharmaceuticals L.P.,,Current,['ANDA215330'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Rhodes Pharmaceuticals'],"['42858-167', '42858-161', '42858-162', '42858-163', '42858-164', '42858-165', '42858-166']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['047c243d-9336-4ef2-b5a8-a7cae312b1be'],['d918b40d-a461-41bc-b6c0-83dc76c28e32'],"['42858-161-01', '42858-162-01', '42858-163-01', '42858-164-01', '42858-165-01', '42858-166-01', '42858-167-01']",['SJT761GEGS'],,,,,,,,,
New,01/28/2025,71093-127-01,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-127', '71093-128']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
Revised,07/14/2023,72205-136-91,"Lisdexamfetamine Dimesylate Tablet, Chewable",(855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)",Novadoz Pharmaceuticals LLC,Shortage of an active ingredient,Current,['ANDA218306'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Novadoz Pharmaceuticals LLC'],"['72205-136', '72205-132', '72205-133', '72205-134', '72205-135', '72205-137']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],"['72205-132-91', '72205-133-91', '72205-134-91', '72205-135-91', '72205-136-91', '72205-137-91']",['SJT761GEGS'],,,,,,,,,
New,09/11/2025,0409-0182-25,Gemcitabine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,09/11/2025,['Oncology'],Injection,"Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA200795'],['GEMCITABINE'],['GEMCITABINE'],"['Hospira, Inc.']","['0409-0182', '0409-0181', '0409-0183']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['GEMCITABINE HYDROCHLORIDE'],"['1720960', '1720975', '1720977']","['cc0f68d1-df16-441c-b4d7-da06b4baf1e5', '15f70b30-31dc-4c45-902b-69cad93f7308']","['dc02a23b-3ff9-4441-aa91-8e9e629a7315', 'e18ed1cb-7dd0-4001-bfda-17d1f4587fb8']","['0409-0181-01', '0409-0183-01', '0409-0182-01', '0409-0181-25', '0409-0182-25', '0409-0183-25']",['U347PV74IL'],,,,09/11/2025,,,,,
Revised,03/21/2023,0009-0902-18,Clindamycin Phosphate Injection,800-533-4535,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,10/23/2025,['Anti-Infective'],Injection,"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)",Pfizer Inc.,Other,Current,['NDA050441'],['CLEOCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0902', '0009-0870', '0009-0775', '0009-0728', '0009-3124', '0009-3447', '0009-3381', '0009-3375', '0009-3382', '0009-6582']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['205964', '309335', '309336', '309339', '685574', '685576', '685578', '706461', '1737244', '1737245', '1737578', '1737579', '1737581', '1737582']",['cb513686-3220-4de2-8be6-f941273ae842'],['05a75685-0af5-407c-ac57-e380c882b49d'],"['0009-0870-21', '0009-0870-26', '0009-0775-20', '0009-0775-26', '0009-0902-11', '0009-0902-18', '0009-0728-05', '0009-0728-09', '0009-3124-01', '0009-3124-03', '0009-3447-01', '0009-3447-03', '0009-3381-01', '0009-3381-02', '0009-3375-01', '0009-3375-02', '0009-3382-01', '0009-3382-02', '0009-6582-02', '0009-6582-01']",['EH6D7113I8'],,,,,,,,,
Revised,02/20/2018,0409-1746-10,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE WITH EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Hospira, Inc.']","['0409-1746', '0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/15/2023,66794-228-41,Rocuronium Bromide Injection,800-414-1901,Limited Availability,On allocation,11/04/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)",Piramal Critical Care Inc.,Demand increase for the drug,Current,['ANDA210437'],['ROCURONIUM'],['ROCURONIUM'],['Piramal Critical Care Inc'],"['66794-228', '66794-229']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['3f9e12e4-d3c5-fba6-e063-6294a90a7fd6'],['98255b70-51f9-8d16-e053-2995a90a8f97'],"['66794-229-02', '66794-229-41', '66794-228-02', '66794-228-41']",['I65MW4OFHZ'],,,,,,,,,
Reverified,11/01/2023,60505-4745-1,Lisdexamfetamine Dimesylate Capsule,800-706-5575,Available,Product currently available,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)",Apotex Corp.,,Current,['ANDA216944'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Apotex Corp.'],"['60505-4745', '60505-4739', '60505-4740', '60505-4741', '60505-4742', '60505-4743', '60505-4744']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7a3783a0-bb54-a95b-99f4-9d3aa9788649'],['ecad4442-a644-18e3-6ff2-fdbac45eec47'],"['60505-4739-1', '60505-4740-1', '60505-4741-1', '60505-4742-1', '60505-4743-1', '60505-4744-1', '60505-4745-1']",['SJT761GEGS'],,,,,,,,,
Reverified,11/06/2017,0338-1005-02,Dopamine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)",Baxter Healthcare,,Current,['NDA019615'],['DOPAMINE HYDROCHLORIDE AND DEXTROSE'],['DOPAMINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-1005', '0338-1007', '0338-1009']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743869', '1743871', '1743877', '1743879']",['1b91b75f-c6e4-4425-bea8-023458ecf8f9'],['cb97d4a0-89ed-407c-a763-209386b6f75c'],"['0338-1005-02', '0338-1005-03', '0338-1007-02', '0338-1007-03', '0338-1009-02']",['7L3E358N9L'],,,,,,,,,
Reverified,10/12/2022,47781-174-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)",Alvogen,,Current,['ANDA207388'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 5 MG,CLL']",['Alvogen Inc.'],"['47781-174', '47781-175', '47781-176', '47781-177', '47781-178', '47781-179', '47781-180']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['0374f0f7-9297-810c-38b3-623a72709a7d'],['c907301d-e24d-9609-5529-fed14f94549f'],"['47781-174-30', '47781-174-05', '47781-174-01', '47781-175-30', '47781-175-05', '47781-175-01', '47781-176-30', '47781-176-05', '47781-176-01', '47781-177-30', '47781-177-05', '47781-177-01', '47781-178-30', '47781-178-05', '47781-178-01', '47781-179-30', '47781-179-05', '47781-179-01', '47781-180-30', '47781-180-05', '47781-180-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,12/05/2024,68001-490-05,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 100 mg (NDC 68001-490-05)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],['BluePoint Laboratories'],"['68001-490', '68001-491']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['05c9d227-d639-916a-e063-6294a90a66a6'],['be5b9047-155b-59ca-e053-2995a90ad3dc'],"['68001-490-05', '68001-491-04']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,04/10/2021,71288-505-03,Dexmedetomidine Hydrochloride Injection,844-824-8426,Available,,08/19/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA204843'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],['Meitheal Pharmaceuticals Inc.'],['71288-505'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['309710'],['74e25a75-2d63-4f39-b6d0-a73392bd1040'],['8fa36783-b94d-4084-8c41-40ee64192074'],"['71288-505-02', '71288-505-03']",['1018WH7F9I'],,,,,,,,,
New,09/18/2025,0472-0803-04,Desonide Lotion,800-545-8800,,Discontinuation of the manufacture of the drug.,09/18/2025,['Dermatology'],Lotion,"Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-04)","Actavis Pharma, Inc.",,To Be Discontinued,['ANDA072354'],['DESONIDE'],['DESONIDE'],"['Actavis Pharma, Inc.']","['0472-0803', '0472-0804']",['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['DESONIDE'],"['197572', '349351']",['f3953b9e-138f-4d86-8eea-0fc03c3c2747'],['ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99'],"['0472-0804-15', '0472-0804-60', '0472-0803-02', '0472-0803-04']",['J280872D1O'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,09/18/2025,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
Revised,01/06/2023,0013-2646-81,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 12 mg/mL, w/ preservative (NDC 0013-2646-81)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2646', '0013-2626', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Reverified,03/13/2023,61703-350-38,Methotrexate Sodium Injection,844-646-4398,Available,,10/23/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)","Hospira, Inc., a Pfizer Company",,Current,['NDA011719'],['METHOTREXATE'],['METHOTREXATE'],"['Hospira, Inc.']","['61703-350', '61703-408']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['METHOTREXATE SODIUM'],"['1655956', '1946772']","['95b8b8da-da4e-4bba-9038-3cf65f3d5c1a', '37b3e76b-ac3d-4f93-adf1-91f52f676b8a']","['0d63ba29-b692-41b4-87e8-351265c8273f', '0e30eaef-5a09-4104-8a11-c32933eadeab']","['61703-350-37', '61703-350-38', '61703-408-41', '61703-350-09', '61703-350-10', '61703-408-25']",['3IG1E710ZN'],,,,,,,,,
Reverified,04/07/2020,71288-203-05,Furosemide Injection,844-824-8426,Available,,08/19/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA212803'],['FUROSEMIDE'],['FUROSEMIDE'],['Meitheal Pharmaceuticals Inc.'],['71288-203'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['78b32838-f75b-4aba-9b4b-9978f755fced', '53a09c30-7295-4337-89a4-93d3748d6ea3']","['a2e3c748-28ce-4c50-a182-721912919840', '3aadaca7-3661-4bfe-87f8-6368e4ab6536']","['71288-203-02', '71288-203-03', '71288-203-04', '71288-203-05', '71288-203-10', '71288-203-11', '71288-203-91', '71288-203-92', '71288-203-93', '71288-203-94']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/13/2023,63323-122-50,Methotrexate Sodium Injection,888-386-1300,Available,Check wholesaler for inventory,11/05/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)","Fresenius Kabi USA, LLC",,Current,['ANDA040266'],['METHOTREXATE'],['METHOTREXATE SODIUM'],"['Fresenius Kabi USA, LLC']",['63323-122'],['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE SODIUM'],['311625'],['3d21237a-ef53-4592-bf06-0c739696203d'],['ec476b11-0b3c-4139-b1eb-a3daa76bc271'],['63323-122-50'],['3IG1E710ZN'],,,,,,,,,
Reverified,10/12/2022,0527-0761-37,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)","Lannett Company, Inc.",,Current,['ANDA215565'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Lannett Company, Inc.']","['0527-0761', '0527-0760', '0527-0762', '0527-0763', '0527-0764', '0527-0765', '0527-0766']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['e0804f43-4685-4017-b839-3212d1167362'],['f92497b5-baea-4760-b615-45a0b6184402'],"['0527-0760-37', '0527-0761-37', '0527-0762-37', '0527-0763-37', '0527-0764-37', '0527-0765-37', '0527-0766-37']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,11/21/2024,0173-0897-56,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-56)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0897', '0173-0903', '0173-0906', '0173-0911', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Revised,03/21/2023,0009-4073-04,Clindamycin Phosphate Injection,800-533-4535,Limited Availability,Limited Supply Available. Next Delivery: January 2026; Estimated Recovery: March 2026,10/23/2025,['Anti-Infective'],Injection,"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)",Pfizer Inc.,Other,Current,['NDA050441'],['CLEOCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Pharmacia & Upjohn Company LLC'],"['0009-4073', '0009-3051', '0009-5095']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['1737244', '1737245', '1737578', '1737579', '1737581', '1737582']",['9c0a7367-763b-48c3-95b1-173b74c50f4b'],['a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b'],"['0009-3051-01', '0009-3051-02', '0009-4073-03', '0009-4073-04', '0009-5095-05', '0009-5095-06']",['EH6D7113I8'],,,,,,,,,
New,02/20/2025,0023-6142-30,Silodosin Capsule,800-633-9110,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,02/20/2025,['Urology'],Capsule,"Rapaflo, Capsule, 8 mg (NDC 0023-6142-30)",AbbVie Inc.,,To Be Discontinued,['NDA022206'],['RAPAFLO'],['SILODOSIN'],"['Allergan, Inc.']","['0023-6142', '0023-6147']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SILODOSIN'],"['809477', '809481', '826612', '826614']",['34eec0b8-ef99-4d69-bd3f-da1373da2e49'],['da0314f6-b1d6-44ee-8b1e-f763dbb8613f'],"['0023-6142-90', '0023-6142-30', '0023-6147-30']",['CUZ39LUY82'],"['N0000000099', 'N0000175553']",['alpha-Adrenergic Blocker [EPC]'],,02/20/2025,,,,['Adrenergic alpha-Antagonists [MoA]'],
Reverified,10/12/2022,70010-116-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",877-770-3183,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)",Granules Pharmaceuticals Inc.,,Current,['ANDA215771'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Granules Pharmaceuticals Inc.'],"['70010-116', '70010-111', '70010-112', '70010-113', '70010-114', '70010-115', '70010-117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['2fab399e-2a43-5134-e063-6294a90ae09a'],['b0b4eccc-34c7-483d-966f-82d588358e1b'],"['70010-111-01', '70010-111-03', '70010-112-01', '70010-112-03', '70010-113-01', '70010-113-03', '70010-114-01', '70010-114-03', '70010-115-01', '70010-115-03', '70010-116-01', '70010-116-03', '70010-117-01', '70010-117-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,10/05/2022,72485-509-10,Etomidate Injection,908-803-2586,Available,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",11/04/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)","Caplin Steriles, Ltd.",,Current,['ANDA215028'],['ETOMIDATE'],['ETOMIDATE'],['Armas Pharmaceuticals Inc.'],"['72485-509', '72485-508']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['7444860b-36c1-459d-94ba-d7301d9dc2ca'],['75467058-da52-48fa-8d4e-e1025ec7d461'],"['72485-508-01', '72485-508-10', '72485-509-01', '72485-509-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Reverified,02/28/2025,0378-8262-93,"Methylphenidate Film, Extended Release",800-796-9526,Available,,11/06/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 20mg/9hrs (NDC 0378-8262-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA206497'],['METHYLPHENIDATE'],['METHYLPHENIDATE'],['Mylan Pharmaceuticals Inc.'],"['0378-8262', '0378-8260', '0378-8261', '0378-8263']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['435703f5-35b9-4d50-a12a-89546888c61a'],['1643b6a5-80da-4d4f-8c5f-feb907875702'],"['0378-8260-16', '0378-8260-93', '0378-8261-16', '0378-8261-93', '0378-8262-16', '0378-8262-93', '0378-8263-16', '0378-8263-93']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
New,10/01/2025,0071-3112-23,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,10/01/2025,['Cardiovascular'],Tablet,"Accuretic, Tablet, 12.5 mg; 10 mg (NDC 0071-3112-23)",Pfizer Inc.,,To Be Discontinued,['NDA020125'],['ACCURETIC'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],['Parke-Davis Div of Pfizer Inc'],"['0071-3112', '0071-0223', '0071-5212', '0071-7225']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809', '809854', '809858', '882559']",['489727cb-429e-4f04-a973-ae4dc7898519'],['80e9d61d-9674-4ac4-b84c-79a875d408dd'],"['0071-0223-23', '0071-3112-23', '0071-5212-23', '0071-7225-23']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],10/01/2025,,['Thiazides [CS]'],,,
New,08/12/2025,23155-582-01,Desipramine Hydrochloride Tablet,855-228-9470,,Discontinuation of the manufacture of the drug,08/12/2025,['Psychiatry'],Tablet,"Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)","Avet Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA207433'],['DESIPRAMINE HYDROCHLORIDE'],['DESIPRAMINE HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],"['23155-582', '23155-578', '23155-579', '23155-580', '23155-581', '23155-583']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DESIPRAMINE HYDROCHLORIDE'],"['1099288', '1099292', '1099296', '1099300', '1099304', '1099316']",['49984729-ddde-44ed-927b-8a4ba65cefa0'],['ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0'],"['23155-578-01', '23155-579-01', '23155-580-01', '23155-581-01', '23155-582-01', '23155-583-25']",['1Y58DO4MY1'],,,,08/12/2025,,,,,
Reverified,03/21/2023,0781-3288-09,Clindamycin Phosphate Injection,800-525-8747,Available,,11/07/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)",Sandoz Inc.,,Current,['ANDA201692'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['Sandoz Inc'],"['0781-3288', '0781-3289', '0781-3290']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN'],"['309335', '309336', '309339']",['e9ea55df-4c10-43a8-97f1-02e6fce12f2b'],['231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca'],"['0781-3288-91', '0781-3288-09', '0781-3289-91', '0781-3289-09', '0781-3290-91', '0781-3290-09']",['3U02EL437C'],"['N0000009982', 'N0000175443', 'M0515779', 'N0000175731']",['Lincosamide Antibacterial [EPC]'],"['Decreased Sebaceous Gland Activity [PE]', 'Neuromuscular Blockade [PE]']",,,['Lincosamides [CS]'],,,
Revised,12/10/2021,0264-1800-36,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-36)",B. Braun Medical Inc.,,Resolved,['NDA017464'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],['0264-1800'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807630', '1807631', '1807632']",['7d4ee37f-5016-422c-9f66-e675ae22c46a'],['cc14fafd-3dcd-4fc8-bdbd-6f355c375768'],"['0264-1800-36', '0264-1800-31', '0264-1800-32']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/14/2023,43547-607-10,Lisdexamfetamine Dimesylate Capsule,866-931-9829,Limited Availability,On allocation,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA216266'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE CAPSULES'],"['Solco Healthcare US,LLC']","['43547-607', '43547-602', '43547-603', '43547-604', '43547-605', '43547-606', '43547-608']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7bb11568-67a4-4221-bb9b-23af37a1791c'],['68b10d9f-ca3e-493d-a309-45f1d7e08061'],"['43547-602-10', '43547-603-10', '43547-604-10', '43547-605-10', '43547-606-10', '43547-607-10', '43547-608-10']",['SJT761GEGS'],,,,,,,,,
New,11/03/2025,0378-0006-85,Everolimus Tablet,800-796-9526,,Discontinuation of the manufacture of the drug,11/03/2025,['Transplant'],Tablet,"Everolimus, Tablet, 3 mg (NDC 0378-0006-85)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['ANDA210130'],['EVEROLIMUS'],['EVEROLIMUS'],['Mylan Pharmaceuticals Inc.'],"['0378-0006', '0378-0005', '0378-0007']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['EVEROLIMUS'],"['1308428', '1308430', '1308432']",['129ab1eb-61df-49de-953c-fca0f0a28eee'],['ca1a987e-f763-4026-93c5-c545ca95826c'],"['0378-0005-85', '0378-0006-85', '0378-0007-85']",['9HW64Q8G6G'],"['N0000175605', 'N0000175076', 'N0000182141', 'N0000182137', 'N0000175625', 'N0000175624', 'N0000175550']","['Kinase Inhibitor [EPC]', 'mTOR Inhibitor Immunosuppressant [EPC]']",['Decreased Immunologic Activity [PE]'],11/03/2025,,,,"['Protein Kinase Inhibitors [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 2D6 Inhibitors [MoA]', 'mTOR Inhibitors [MoA]']",
Reverified,07/26/2023,43598-440-01,"Methylphenidate Hydrochloride Tablet, Extended Release",866-732-3952,Unavailable,Estimated availability TBD,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 43598-440-01)","Dr. Reddy's Laboratories, Inc.",Other,Current,['ANDA213473'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],['Dr.Reddys Laboratories Inc'],"['43598-440', '43598-438', '43598-439', '43598-441']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['528a86ce-1037-944a-e934-15846984dd73'],['7124df7e-6273-a68d-6e35-dc06122d8686'],"['43598-438-01', '43598-439-01', '43598-440-01', '43598-441-01']",['4B3SC438HI'],,,,,,,,,
Reverified,10/31/2017,0409-3365-10,Hydromorphone Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-3365', '0409-2552', '0409-3356', '0409-2540', '0409-1283', '0409-1312', '0409-1304']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '897756', '897757', '897758', '1433251', '1724276', '1724383', '1724644']",['58ff0e68-b78f-4ebd-a91b-b53bbdefc544'],['e9c9ef18-7dfc-4322-b2fc-29b934c30f8b'],"['0409-2552-11', '0409-2552-01', '0409-3356-11', '0409-3356-01', '0409-2540-11', '0409-2540-01', '0409-3365-11', '0409-3365-01', '0409-3365-10', '0409-1283-03', '0409-1283-31', '0409-1283-09', '0409-1283-10', '0409-1283-04', '0409-1283-05', '0409-1312-03', '0409-1312-30', '0409-1312-09', '0409-1312-10', '0409-1304-03', '0409-1304-31']",['L960UP2KRW'],,,,,,,,,
Reverified,04/10/2020,44567-600-04,Dexmedetomidine Hydrochloride Injection,WG Critical Care 888-493-0861,Available,Marketed by WG Critical Care,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)",HQ Specialty Pharma,,Current,['NDA206628'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],"['WG Critical Care, LLC']","['44567-600', '44567-601', '44567-602', '44567-603']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909', '1788947']",['e6fa3e27-b374-49b6-a678-a5954f5beae8'],['0d2710f2-ee47-4114-ab5c-8dca74cdcb8d'],"['44567-600-04', '44567-601-04', '44567-602-24', '44567-603-24']",['1018WH7F9I'],,,,,,,,,
New,08/12/2025,23155-578-01,Desipramine Hydrochloride Tablet,855-228-9470,,Discontinuation of the manufacture of the drug,08/12/2025,['Psychiatry'],Tablet,"Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)","Avet Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA207433'],['DESIPRAMINE HYDROCHLORIDE'],['DESIPRAMINE HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],"['23155-578', '23155-579', '23155-580', '23155-581', '23155-582', '23155-583']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DESIPRAMINE HYDROCHLORIDE'],"['1099288', '1099292', '1099296', '1099300', '1099304', '1099316']",['49984729-ddde-44ed-927b-8a4ba65cefa0'],['ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0'],"['23155-578-01', '23155-579-01', '23155-580-01', '23155-581-01', '23155-582-01', '23155-583-25']",['1Y58DO4MY1'],,,,08/12/2025,,,,,
Revised,12/10/2021,0338-0049-41,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-41)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,07/14/2023,57664-086-88,"Lisdexamfetamine Dimesylate Tablet, Chewable",800-818-4555,Limited Availability,Available Q4 2025,10/21/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA214134'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-086', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
New,09/29/2025,0781-3465-95,Fondaparinux Sodium Injection,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,09/29/2025,['Hematology'],Injection,"Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95)","Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,To Be Discontinued,['ANDA206812'],['FONDAPARINUX SODIUM'],['FONDAPARINUX SODIUM'],['Sandoz Inc.'],"['0781-3465', '0781-3443', '0781-3454', '0781-3476']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['FONDAPARINUX SODIUM'],"['861356', '861360', '861363', '861365']",['3d5a4b69-462b-7e51-e063-6294a90a0721'],['baa50757-a927-4d56-a933-5d7798fe6ab0'],"['0781-3443-94', '0781-3443-12', '0781-3443-95', '0781-3454-94', '0781-3454-12', '0781-3454-95', '0781-3465-94', '0781-3465-12', '0781-3465-95', '0781-3476-94', '0781-3476-12', '0781-3476-95']",['X0Q6N9USOZ'],,,,09/29/2025,,,,,
New,05/19/2025,62037-559-01,"Potassium Chloride Capsule, Extended Release",800-545-8800,,,05/19/2025,"['Endocrinology/Metabolism', 'Gastroenterology']","Capsule, Extended Release","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077419'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Actavis Pharma, Inc.']","['62037-559', '62037-560']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312504', '315183']",['b97da107-c56e-48ea-ba34-d3d64a5b9f46'],['ed5baaf6-270b-4dd3-b100-36030c0098fc'],"['62037-559-01', '62037-559-05', '62037-560-01', '62037-560-05', '62037-560-10', '62037-560-90']",['660YQ98I10'],,,,05/19/2025,,,,,
Revised,01/01/2012,63323-710-50,Leucovorin Calcium Injection,888-386-1300,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 63323-710-50)","Fresenius Kabi USA, LLC",,Resolved,['ANDA040258'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Fresenius Kabi USA, LLC']","['63323-710', '63323-711']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['1803937', '2055036']","['b70ccebd-b847-41ff-8c30-9779461465e0', '2497bd71-0f85-48ec-9353-d591e1c728f8']","['ab691d4e-e0d1-4ba1-9c7a-1cdcfcc3c17c', 'e3b957dc-a542-4f69-b8a0-7df401ee706f']","['63323-710-59', '63323-710-50', '63323-711-00']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,11/06/2017,0409-2344-01,Dobutamine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA074086'],['DOBUTAMINE'],['DOBUTAMINE'],"['Hospira, Inc.']",['0409-2344'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],['1812168'],"['e71e9520-871b-479d-9652-1857fceca863', '5d6b1dfe-d679-4aea-97a6-3d074a202afe']","['dc537761-d5f4-488d-24ab-b2bcd2b17b7a', '89becb0c-da60-4f43-0a98-29ff7a9eca58']","['0409-2344-01', '0409-2344-62', '0409-2344-02', '0409-2344-68', '0409-2344-88']",['0WR771DJXV'],,,,,,,12/19/2024,,
New,01/28/2025,71093-128-01,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-128', '71093-127']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
New,04/23/2025,50090-6869-0,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 50090-6869-0)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,,,,,,,,,,,,,,,,,04/23/2025,,,,,
Reverified,10/31/2017,0409-1134-05,Morphine Sulfate Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)","Hospira, Inc., a Pfizer Company",,Current,,['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-1134', '0409-1135']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['1731517', '1731537', '1731545']",['a641ae70-f6ba-4f49-b5fc-b2895ef3408f'],['cadc3fdb-8edc-44cd-aaea-89e68aaf9a04'],"['0409-1134-03', '0409-1134-05', '0409-1135-02']",['X3P646A2J0'],,,,,,,01/03/2025,,
Reverified,03/23/2018,70860-701-03,Ketorolac Tromethamine Injection,833-291-9645,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-01",09/29/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-03)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,04/02/2020,44567-610-10,Midazolam Hydrochloride Injection,888-493-0861,Available,Please check wholesalers and distributors for inventory.,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)",WG Critical Care,,Current,['NDA211844'],['MIDAZOLAM IN SODIUM CHLORIDE'],['MIDAZOLAM'],"['WG Critical Care, LLC.']","['44567-610', '44567-611']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MIDAZOLAM'],"['2541170', '2541171']",['8b577103-b84e-4344-a3ff-b18b77f856cc'],['f051776f-94c5-4e34-80ed-f45b9c36881e'],"['44567-610-01', '44567-610-10', '44567-611-01', '44567-611-10']",['R60L0SM5BC'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,07/21/2025,73070-103-15,Insulin Aspart Injection,609-987-5800,,"Unbranded Insulin Aspart 3 mL FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injection,"Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen® (NDC 73070-103-15)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA020986'],['INSULIN ASPART'],['INSULIN ASPART'],"['Novo Nordisk Pharma, Inc.']","['73070-103', '73070-100', '73070-102']",['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['INSULIN ASPART'],"['311040', '1653196', '1653202']",['393af9a3-df9a-40b2-a5e6-bfa5434a2552'],['bee5b358-c863-420b-be73-ced2e920c499'],"['73070-100-11', '73070-102-10', '73070-102-15', '73070-103-10', '73070-103-15']",['D933668QVX'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
Reverified,03/01/2022,0338-0023-03,Dextrose Monohydrate 10% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)",Baxter Healthcare,,Current,['NDA016694'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0023', '0338-0017']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Revised,04/10/2020,0781-3495-95,Dexmedetomidine Hydrochloride Injection,See Related Information section below for customer service information,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,10/09/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)","Jiangsu Hengrui Pharmaceuticals Co., Ltd.",,Current,['ANDA209065'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['Sandoz Inc.'],"['0781-3495', '0781-3493', '0781-3494']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['fdf227d9-008e-60f8-e053-6294a90af5c4'],['809e8f77-390f-4cc8-8c8a-4f67a249c9df'],"['0781-3493-95', '0781-3494-95', '0781-3495-95']",['1018WH7F9I'],,,,,,,,,
Reverified,11/23/2021,0409-4887-20,Sterile Water Injection,844-646-4398,Available,,10/23/2025,['Other'],Injection,"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)","Hospira, Inc., a Pfizer Company",,Current,['NDA018801'],['STERILE WATER'],['WATER'],"['Hospira, Inc.']",['0409-4887'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['900859c0-a075-4fb1-98ce-0e329acc009a'],['2b9ea23a-f9e9-48a8-25b7-519e3bbd6828'],"['0409-4887-25', '0409-4887-99', '0409-4887-31', '0409-4887-05', '0409-4887-17', '0409-4887-10', '0409-4887-32', '0409-4887-34', '0409-4887-23', '0409-4887-20', '0409-4887-24', '0409-4887-50']",['059QF0KO0R'],,,,,,,,,
Reverified,10/12/2022,42806-344-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(718) 276-8600 ext. 3,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)","Epic Pharma, LLC",,Current,['ANDA040444'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Epic Pharma, LLC']","['42806-344', '42806-339', '42806-341', '42806-343', '42806-345']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961']",['f11301e2-3b5d-468d-b44c-45839e7e5dfb'],['1757e132-061d-4773-89ed-fdc77f69008f'],"['42806-339-01', '42806-341-01', '42806-343-01', '42806-344-01', '42806-345-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/13/2025,13668-397-90,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-90)",Torrent Pharma Inc.,,To Be Discontinued,['ANDA203580'],"['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG']","['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 20/5/12.5 MG']",['Torrent Pharmaceuticals Limited'],"['13668-397', '13668-386', '13668-385', '13668-383', '13668-382']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE', 'HYDROCHLOROTHIAZIDE', 'OLMESARTAN MEDOXOMIL']","['999967', '999986', '999991', '999996', '1000001']",['5bedf6c6-6b23-40e7-8c96-2cedcc682973'],['85b8f9c6-aa53-4aa1-85d6-19f823d0d252'],"['13668-397-30', '13668-397-90', '13668-397-05', '13668-386-30', '13668-386-90', '13668-386-05', '13668-385-30', '13668-385-90', '13668-385-05', '13668-383-30', '13668-383-90', '13668-383-05', '13668-382-30', '13668-382-90', '13668-382-05']","['6M97XTV3HD', '1J444QC288', '0J48LPH2TH']","['N0000000069', 'N0000175421', 'N0000175566', 'M0006414', 'N0000190114', 'N0000175359', 'N0000175419', 'M0471776']","['Dihydropyridine Calcium Channel Blocker [EPC]', 'Calcium Channel Blocker [EPC]', 'Thiazide Diuretic [EPC]']",['Increased Diuresis [PE]'],06/13/2025,,"['Dihydropyridines [CS]', 'Thiazides [CS]']",,"['Calcium Channel Antagonists [MoA]', 'Cytochrome P450 3A Inhibitors [MoA]']",
Revised,02/29/2024,47335-326-18,Naltrexone Hydrochloride Tablet,800-818-4555,Unavailable,Currently not marketed,10/21/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-18)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA090356'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']",['47335-326'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['b0c2b60a-dc96-483b-933e-2fed58b64372'],['0f30f885-d0cd-4fa6-a8e0-142f08a56792'],"['47335-326-83', '47335-326-88', '47335-326-08', '47335-326-18']",['Z6375YW9SF'],,,,,,,,,
New,07/01/2025,64950-217-03,Isoniazid Tablet,610-782-9780,,Product expected to be available until August 2025.,07/01/2025,['Anti-Infective'],Tablet,"Isoniazid, Tablet, 300 mg (NDC 64950-217-03)",Genus Lifesciences,,To Be Discontinued,['ANDA080937'],['ISONIAZID'],['ISONIAZID'],['Genus Lifesciences'],"['64950-217', '64950-216']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ISONIAZID'],"['197832', '311166']",['6ea58bc8-a5a8-47a1-81e1-f769924e1502'],['f0b46d1d-2300-457d-a7bd-a88a3f8d2235'],"['64950-216-10', '64950-217-03', '64950-217-10']",['V83O1VOZ8L'],['N0000175483'],['Antimycobacterial [EPC]'],,07/01/2025,,,,,
Revised,01/13/2022,0409-4902-34,Dextrose Monohydrate 50% Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,,['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Hospira, Inc.']","['0409-4902', '0409-7517', '0409-6648', '0409-0505']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['727517', '1795514']",['0fca7d54-4d75-455b-a1d7-d25e31702264'],['4ed365da-4e62-4329-c1b9-c197ab4fb6e1'],"['0409-7517-66', '0409-7517-16', '0409-4902-64', '0409-4902-34', '0409-6648-16', '0409-6648-02', '0409-0505-15', '0409-0505-25']",['LX22YL083G'],,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Monohydrate%2050per%20Injection&st=d,,,,
Reverified,03/01/2022,0990-7930-09,Dextrose Monohydrate 10% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)",Otsuka ICU Medical LLC,,Current,['NDA018080'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7930', '0990-7923', '0990-7922']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
New,03/18/2025,0781-6185-75,Travoprost Solution/Drops,800-525-8747,,Business related decision to discontinue the product,03/18/2025,['Ophthalmology'],Solution/Drops,"Travatan Z, Solution/Drops, 5 mL (NDC 0781-6185-75)",Sandoz Inc.,,To Be Discontinued,['NDA021994'],['TRAVOPROST OPHTHALMIC SOLUTION'],['TRAVOPROST'],['Sandoz Inc'],['0781-6185'],['HUMAN PRESCRIPTION DRUG'],['OPHTHALMIC'],['TRAVOPROST'],['284008'],['c9120f44-4d13-49f1-924f-34e36f35da10'],['c17aa704-1ec6-4610-a448-4964bdb1cba1'],"['0781-6185-56', '0781-6185-75']",['WJ68R08KX9'],"['N0000175454', 'M0017805']",['Prostaglandin Analog [EPC]'],,03/18/2025,,['Prostaglandins [CS]'],,,
Revised,12/15/2021,0009-3073-01,Methylprednisolone Acetate Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: March 2026,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)",Pfizer Inc.,Demand increase for the drug,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-3073', '0009-3475']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE', 'INTRA-ARTICULAR']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743781', '1743855', '1743856']","['bdefc300-8d7c-474c-9771-200628f25035', 'befd723e-d1e2-41b9-83f1-17bca0c2a941']","['bf1b104d-85cb-414d-a366-78068c82c883', '9a7b3837-e038-48bf-97e9-78ad463760dc']","['0009-3073-22', '0009-3073-23', '0009-3475-22', '0009-3475-23', '0009-3073-01', '0009-3073-03', '0009-3475-01', '0009-3475-03']",['43502P7F0P'],,,,,,,,,
Reverified,03/24/2023,0009-0016-12,Hydrocortisone Sodium Succinate Injection,844-646-4398,Available,,10/23/2025,"['Pulmonary/Allergy', 'Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Renal', 'Rheumatology']",Injection,"Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)","Hospira, Inc., a Pfizer Company",,Current,['NDA009866'],['SOLU-CORTEF'],['HYDROCORTISONE SODIUM SUCCINATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0016', '0009-0825', '0009-0011', '0009-0013', '0009-0005']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],"['105398', '238755', '1738586', '1738589', '1738590', '1738592', '1738594', '1738596']",['8512044a-4a54-4634-bb97-9e20126adc61'],['65eefd58-b166-4d71-ade6-45c8fdf86922'],"['0009-0825-01', '0009-0011-03', '0009-0011-04', '0009-0013-05', '0009-0013-06', '0009-0016-12', '0009-0005-01']",['50LQB69S1Z'],,,,,,,,,
New,10/16/2025,0002-7623-01,Pemetrexed Disodium Injection,800-545-5979,,Discontinuation of the manufacture of the drug,10/16/2025,['Oncology'],Injection,"Alimta, Injection, 500 mg/20 mL (NDC 0002-7623-01)",Eli Lilly and Co.,,To Be Discontinued,['NDA021462'],['ALIMTA'],['PEMETREXED DISODIUM'],['Eli Lilly and Company'],"['0002-7623', '0002-7640']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PEMETREXED DISODIUM HEPTAHYDRATE'],"['1728072', '1728075', '1728077', '1728079']",['3af0bc84-13d6-46aa-a4c0-c62410b73bc6'],['f5a860f3-37ec-429c-ae04-9c88d7c55c08'],"['0002-7640-01', '0002-7623-01']",['9T47E4OM16'],,,,10/16/2025,,,,,
Reverified,03/23/2018,70860-701-04,Ketorolac Tromethamine Injection,833-291-9645,Available,"Athenex is not active, supplying through Sagent NDC 25021-701-02",09/29/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-04)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
New,03/04/2025,65862-586-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-05)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-586', '65862-582', '65862-583', '65862-584', '65862-585', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
New,12/05/2024,57664-441-88,Digoxin Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Cardiovascular'],Tablet,"Digoxin, Tablet, 250 ug (NDC 57664-441-88)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA076363'],['DIGOXIN'],['DIGOXIN'],"['Sun Pharmaceutical Industries, Inc.']","['57664-441', '57664-437']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIGOXIN'],"['197604', '197606']",['1a3e469c-1452-3d1e-e063-6394a90ae73a'],['62795623-a2bc-4dd2-8989-3b9782bfd80e'],"['57664-437-88', '57664-437-18', '57664-441-88', '57664-441-18']",['73K4184T59'],"['N0000175568', 'M0003451']",['Cardiac Glycoside [EPC]'],,12/05/2024,,['Cardiac Glycosides [CS]'],,,
New,02/06/2025,0378-5091-85,Varenicline Tartrate Tablet,800-796-9526,,Permanent discontinuation in the manufacturing of the drug,02/06/2025,['Analgesia/Addiction'],Tablet,"Varenicline Tartrate, Tablet, 0.5mg/1mg  (NDC 0378-5091-85)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['ANDA202019'],['VARENICLINE'],['VARENICLINE'],['Mylan Pharmaceuticals Inc.'],"['0378-5091', '0378-5089', '0378-5090']",['HUMAN PRESCRIPTION DRUG'],,,"['636671', '636676', '749289']",['5b7b6e3b-f427-4000-b252-968f3adbaa3b'],['4233fb78-ac6c-49f3-aad8-7e4bee18cac6'],"['0378-5089-73', '0378-5090-73', '0378-5091-85', '0378-5089-46', '0378-5090-23']",['82269ASB48'],,,,02/06/2025,,,,,
New,04/28/2025,0245-0213-01,Midodrine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Cardiovascular'],Tablet,"Orvaten, Tablet, 10 mg (NDC 0245-0213-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076725'],['MIDODRINE HYDROCHLORIDE'],['MIDODRINE HYDROCHLORIDE'],"['Upsher-Smith laboratories, LLC']","['0245-0213', '0245-0211', '0245-0212']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MIDODRINE HYDROCHLORIDE'],"['993462', '993466', '993470']",['18b0b9f5-6026-479e-af12-92b0e71a9d6b'],['4c3517f3-1c68-4ade-b5f1-c488a3a335c1'],"['0245-0211-11', '0245-0211-89', '0245-0211-01', '0245-0212-11', '0245-0212-89', '0245-0212-01', '0245-0213-11', '0245-0213-89', '0245-0213-01']",['59JV96YTXV'],,,,04/28/2025,,,,,
Reverified,10/31/2017,0409-1304-31,Hydromorphone Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)","Hospira, Inc., a Pfizer Company",,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1304', '0409-2552', '0409-3356', '0409-2540', '0409-3365', '0409-1283', '0409-1312']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '897756', '897757', '897758', '1433251', '1724276', '1724383', '1724644']",['58ff0e68-b78f-4ebd-a91b-b53bbdefc544'],['e9c9ef18-7dfc-4322-b2fc-29b934c30f8b'],"['0409-2552-11', '0409-2552-01', '0409-3356-11', '0409-3356-01', '0409-2540-11', '0409-2540-01', '0409-3365-11', '0409-3365-01', '0409-3365-10', '0409-1283-03', '0409-1283-31', '0409-1283-09', '0409-1283-10', '0409-1283-04', '0409-1283-05', '0409-1312-03', '0409-1312-30', '0409-1312-09', '0409-1312-10', '0409-1304-03', '0409-1304-31']",['L960UP2KRW'],,,,,,,01/02/2025,,
Reverified,12/22/2021,68180-658-06,Rifampin Capsule,866-587-4617,Available,,09/18/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 150 mg (NDC 68180-658-06)","Lupin Pharmaceuticals, Inc.",,Current,['ANDA090034'],['RIFAMPIN'],['RIFAMPIN'],"['Lupin Pharmaceuticals, Inc.']","['68180-658', '68180-659']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['3c9f0101-dcf8-487e-985e-09c56746d3a1'],['b56004f0-f23d-47f6-80c7-39884fccbccc'],"['68180-658-06', '68180-658-01', '68180-659-06', '68180-659-07', '68180-659-01']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Revised,12/20/2023,0641-6030-01,Fentanyl Citrate Injection,800-631-2174,Unavailable,Additional lots will be available in the November 2025 timeframe.  Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6030', '0641-6024', '0641-6027', '0641-6025', '0641-6028', '0641-6026', '0641-6029', '0641-6247', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
Reverified,07/14/2023,42858-165-01,Lisdexamfetamine Dimesylate Capsule,888-827-0616,Available,,08/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)",Rhodes Pharmaceuticals L.P.,,Current,['ANDA215330'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Rhodes Pharmaceuticals'],"['42858-165', '42858-161', '42858-162', '42858-163', '42858-164', '42858-166', '42858-167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['047c243d-9336-4ef2-b5a8-a7cae312b1be'],['d918b40d-a461-41bc-b6c0-83dc76c28e32'],"['42858-161-01', '42858-162-01', '42858-163-01', '42858-164-01', '42858-165-01', '42858-166-01', '42858-167-01']",['SJT761GEGS'],,,,,,,,,
Reverified,08/03/2022,62135-736-90,Flurazepam Hydrochloride Capsule,845-268-5000 Ext. 510,Available,,08/19/2025,"['Oncology', 'Other']",Capsule,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA072368'],['FLURAZEPAM HYDROCHLORIDE'],['FLURAZEPAM HYDROCHLORIDE'],"['Chartwell RX, LLC']","['62135-736', '62135-737']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLURAZEPAM HYDROCHLORIDE'],"['1298088', '1298091']",['25893c92-c8f1-567a-e063-6294a90a00d4'],['8f476891-1346-4e8c-ac1b-f8cbdc64f5a1'],"['62135-736-30', '62135-736-90', '62135-737-30', '62135-737-90']",['756RDM536M'],,,,,,,,,
Revised,04/28/2023,55150-335-01,Carboplatin Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Oncology'],Injection,"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)",Eugia US LLC,,Current,['ANDA205487'],['CARBOPLATIN'],['CARBOPLATIN'],['Eugia US LLC'],"['55150-335', '55150-333', '55150-334', '55150-386']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],"['6029d051-ee8d-44cc-8dae-b91c3385d4c3', '5abfcb87-bb02-4384-9c9d-7d0e3e809311']","['f5fe9a20-47a5-45b9-ab06-c6158d9b6aca', '5abfcb87-bb02-4384-9c9d-7d0e3e809311']","['55150-333-01', '55150-334-01', '55150-335-01', '55150-386-01', '55150-335-00', '55150-386-00']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,09/19/2025,0228-2837-11,Pilocarpine Hydrochloride Tablet,800-545-8800,,Discontinuation of the manufacture of the drug.,09/19/2025,['Other'],Tablet,"Salagen, Tablet, 7.5 mg (NDC 0228-2837-11)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA020237'],['PILOCARPINE HYDROCHLORIDE'],['PILOCARPINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0228-2837', '0228-2801']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PILOCARPINE HYDROCHLORIDE'],"['1000913', '1001004']",['7db72b88-d664-4f26-901c-46c901b20d80'],['610022b7-7dc9-405a-a580-104657f43bdf'],"['0228-2801-11', '0228-2837-11']",['0WW6D218XJ'],,,,09/19/2025,,,,,
New,07/10/2025,72305-175-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 175 ug (NDC 72305-175-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-175', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
New,07/23/2025,0245-5316-15,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['KLOR-CON'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0245-5316', '0245-5315']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953', '628958', '832718']",['39e77e07-bdc8-28e9-e063-6394a90a120c'],['1ff53330-065c-4213-9c0c-ac498621d09d'],"['0245-5315-11', '0245-5315-15', '0245-5315-89', '0245-5315-01', '0245-5316-11', '0245-5316-15', '0245-5316-89', '0245-5316-01']",['660YQ98I10'],,,,07/23/2025,,,,,
Reverified,10/14/2016,63323-481-57,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-481', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,10/25/2017,0264-9598-20,Lidocaine Hydrochloride Injection,800-227-2862,Available,,11/04/2025,['Cardiovascular'],Injection,"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)",B. Braun Medical Inc.,,Current,['NDA019830'],['LIDOCAINE HYDROCHLORIDE AND DEXTROSE'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE'],['B. Braun Medical Inc.'],"['0264-9598', '0264-9594']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE MONOHYDRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1737723', '1737742', '1737744']",['26f23356-9e1f-4c5f-9959-06d53037a715'],['7dff29d9-522d-40eb-a9d9-42377912d640'],"['0264-9598-20', '0264-9594-20', '0264-9594-10']","['EC2CNF7XFP', 'LX22YL083G']",,,,,,,,,
New,01/31/2025,0173-0517-00,Epoprostenol Sodium Injection,888-825-5249,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",01/31/2025,['Cardiovascular'],Injection,"Flolan, Injection, .5 mg (NDC 0173-0517-00)",GlaxoSmithKline,,To Be Discontinued,['NDA020444'],['FLOLAN'],['EPOPROSTENOL SODIUM'],['GlaxoSmithKline LLC'],"['0173-0517', '0173-0519', '0173-0857']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['EPOPROSTENOL SODIUM'],"['211199', '211200', '562501', '562502']",['5e54002e-7b03-46ad-ae01-c76c76967201'],['8e4b636e-ee9c-4111-779d-28c8369d283b'],"['0173-0517-00', '0173-0519-00', '0173-0857-02']","['4K04IQ1OF4', '059QF0KO0R']",,,,01/31/2025,,,,,
Reverified,02/20/2018,63323-465-57,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)","Fresenius Kabi USA, LLC",,Current,['NDA018304'],['SENSORCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-465', '63323-467', '63323-460', '63323-464', '63323-466', '63323-462']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012391', '1012396', '1012404', '1012421', '1012455', '1012457', '1672917', '1672919', '1673296', '1673298', '1724880', '1724881', '1724884', '1724885', '1725078', '1725082', '1725175', '1725177']",['2b1a1f80-cb29-4ac1-9e72-20225ed45715'],['eb6d8fee-def4-4c96-9972-695e8cea8ea8'],"['63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/29/2024,68094-909-50,Naltrexone Hydrochloride Tablet,888-852-6657,Available,Marketed by Precision Dose; Customer service: 800-397-9228,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-50)","Elite Laboratories, Inc.",,Current,['ANDA075274'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],['Precision Dose Inc.'],['68094-909'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['48b82306-b0ba-4cb8-817d-896ccde0367b'],['b09b4b5e-795a-48e7-b7cc-2e29f41c5660'],"['68094-909-30', '68094-909-50']",['Z6375YW9SF'],,,,,,,,,
Revised,10/12/2022,57844-115-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],['ADDERALL'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['57844-115', '57844-105', '57844-117', '57844-110', '57844-112', '57844-120', '57844-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541365', '541878', '541879', '541892', '541894', '577957', '577960', '577961', '577962', '687043', '687045', '1009145', '1009147']",['79af1dc6-c7cf-41b1-a750-e9b47c2187ff'],['f22635fe-821d-4cde-aa12-419f8b53db81'],"['57844-105-01', '57844-117-01', '57844-110-01', '57844-112-01', '57844-115-01', '57844-120-01', '57844-130-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,01/19/2023,43547-412-09,Quinapril Hydrochloride Tablet,866-931-9829,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,11/05/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA205823'],['QUINAPRIL'],['QUINAPRIL'],"['Solco Healthcare US, LLC']","['43547-412', '43547-410', '43547-411', '43547-413']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['b8f1731a-cbac-4f64-a8d4-320b80b335e1'],['cd46691d-5593-4a9f-a937-999c6803e312'],"['43547-410-09', '43547-411-09', '43547-412-09', '43547-413-09']",['33067B3N2M'],,,,,,,,,
New,02/14/2025,0378-8075-93,Erythromycin  Topical Gel,800-796-9526,,,02/14/2025,"['Anti-Infective', 'Dermatology']",Topical Gel,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,,,,,,,,,,,,,,,,,02/14/2025,,,,,
Reverified,02/22/2012,83090-004-10,Lidocaine Hydrochloride Injection,"844-425-3131, SinteticaCS@eversana.com",Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X2ML)  is Preservative free.",08/19/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)",Sintetica US,,Current,['ANDA214267'],['NA'],['LIDOCAINE HYDROCHLORIDE'],['Sintetica US LLC'],"['83090-004', '83090-001', '83090-002', '83090-003', '83090-005', '83090-006']",['HUMAN PRESCRIPTION DRUG'],['INFILTRATION'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737566', '1737568', '1737570', '1737757', '1737761', '1737763']",['0d18f291-3a92-421e-8841-6be743b1f154'],['aa3e688a-308c-4a82-a268-28ccf1677c55'],"['83090-001-01', '83090-001-10', '83090-002-01', '83090-002-10', '83090-003-01', '83090-003-10', '83090-004-01', '83090-004-10', '83090-005-01', '83090-005-10', '83090-006-01', '83090-006-10']",['EC2CNF7XFP'],,,,,,,,,
New,06/13/2025,13668-383-30,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-30)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Revised,02/20/2018,55150-171-10,Bupivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)",Eugia US LLC,,Current,['ANDA203895'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-171', '55150-167', '55150-168', '55150-169', '55150-170', '55150-172', '55150-249', '55150-250']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
New,05/14/2025,0832-0038-01,Oxybutynin Chloride Tablet,800-654-2299,,,05/14/2025,['Renal'],Tablet,"Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074625'],['OXYBUTYNIN CHLORIDE'],['OXYBUTYNIN CHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-0038'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXYBUTYNIN CHLORIDE'],['863664'],['2f3b30f0-e463-2de1-e063-6394a90a1b69'],['3ee6835a-7a7d-49a9-8460-2f1dd270ead3'],"['0832-0038-00', '0832-0038-50', '0832-0038-10', '0832-0038-89', '0832-0038-01']",['L9F3D9RENQ'],,,,05/14/2025,,,,,
Reverified,03/26/2018,25021-701-02,Ketorolac Tromethamine Injection,866-625-1618,Available,,08/26/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)",Sagent Pharmaceuticals,,Current,['ANDA204216'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Sagent Pharmaceuticals'],"['25021-701', '25021-700']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['ff55e1ab-2a8d-4a56-8b72-5e0a8e00d866'],['62591551-a644-4b2c-a0de-982e906fabc3'],"['25021-700-01', '25021-701-01', '25021-701-02']",['4EVE5946BQ'],,,,,,,,,
Reverified,01/19/2023,65862-161-90,Quinapril/Hydrochlorothiazide Tablet,866-850-2876,Unavailable,Discontinuation of the manufacture of the drug,10/15/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)",Aurobindo Pharma USA,Discontinuation of the manufacture of the drug,Current,['ANDA078450'],['QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE'],['QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE'],['Aurobindo Pharma Limited'],"['65862-161', '65862-162', '65862-163']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809']",['5842ecc2-874a-481b-8997-afa9d862dc5d'],['50a58159-9572-4445-9859-b392632597da'],"['65862-161-90', '65862-162-30', '65862-162-90', '65862-163-90']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],,,['Thiazides [CS]'],,,
New,06/13/2025,13668-385-90,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-90)",Torrent Pharma Inc.,,To Be Discontinued,['ANDA203580'],"['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 40/5/25 MG']","['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 40/5/25 MG']",['Torrent Pharmaceuticals Limited'],"['13668-385', '13668-397', '13668-386', '13668-383', '13668-382']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE', 'HYDROCHLOROTHIAZIDE', 'OLMESARTAN MEDOXOMIL']","['999967', '999986', '999991', '999996', '1000001']",['5bedf6c6-6b23-40e7-8c96-2cedcc682973'],['85b8f9c6-aa53-4aa1-85d6-19f823d0d252'],"['13668-397-30', '13668-397-90', '13668-397-05', '13668-386-30', '13668-386-90', '13668-386-05', '13668-385-30', '13668-385-90', '13668-385-05', '13668-383-30', '13668-383-90', '13668-383-05', '13668-382-30', '13668-382-90', '13668-382-05']","['6M97XTV3HD', '1J444QC288', '0J48LPH2TH']","['N0000000069', 'N0000175421', 'N0000175566', 'M0006414', 'N0000190114', 'N0000175359', 'N0000175419', 'M0471776']","['Dihydropyridine Calcium Channel Blocker [EPC]', 'Calcium Channel Blocker [EPC]', 'Thiazide Diuretic [EPC]']",['Increased Diuresis [PE]'],06/13/2025,,"['Dihydropyridines [CS]', 'Thiazides [CS]']",,"['Calcium Channel Antagonists [MoA]', 'Cytochrome P450 3A Inhibitors [MoA]']",
Reverified,07/18/2023,0169-2800-15,Liraglutide Injection,833-493-4689,Available,,11/04/2025,['Endocrinology/Metabolism'],Injection,"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)","Novo Nordisk, Inc.",,Current,['NDA206321'],['SAXENDA'],['LIRAGLUTIDE'],['Novo Nordisk'],['0169-2800'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],"['897122', '1598268']",['49c3d82d-a708-46b2-a273-6ea032afa5c3'],['3946d389-0926-4f77-a708-0acb8153b143'],"['0169-2800-15', '0169-2800-90', '0169-2800-97']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
New,06/13/2025,0093-8073-16,Ethinyl Estradiol; Ethinyl Diacetate Tablet,800-545-8800,,,06/13/2025,['Reproductive'],Tablet,"Zovia 1/50E-28, Tablet, Kit (NDC 0093-8073-16)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA072723'],['KELNOR 1/50'],['ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL'],"['Teva Pharmaceuticals USA, Inc.']",['0093-8073'],['HUMAN PRESCRIPTION DRUG'],,,"['315096', '748797', '748806', '2000695']",['ba56e2eb-7101-48d4-9a87-95e4340079b5'],['ed075d59-4b6f-467c-bcb1-4dda272d27aa'],"['0093-8073-28', '0093-8073-16']",,,,,06/13/2025,,,,,
New,03/28/2025,60505-6282-3,Carboplatin Injection,800-706-5575,,Discontinuation due to low sales volume. Supply currently available with November 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),03/28/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-3)",Teyro Labs,,To Be Discontinued,['ANDA077861'],['CARBOPLATIN'],['CARBOPLATIN'],['Apotex Corp.'],['60505-6282'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0e68e276-b0df-4f03-e063-6394a90a22b9'],['1c275825-0275-4c73-b650-e4c1519f13b8'],"['60505-6282-1', '60505-6282-3', '60505-6282-6', '60505-6282-7']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,03/28/2025,,,,,
New,10/07/2025,0074-9037-30,Paricalcitol Capsule,800-633-9110,,Discontinuation of the manufacture of the drug,10/07/2025,['Endocrinology/Metabolism'],Capsule,"Zemplar, Capsule, 2 ug (NDC 0074-9037-30)",AbbVie Inc.,,To Be Discontinued,['NDA021606'],['ZEMPLAR'],['PARICALCITOL'],['AbbVie Inc.'],"['0074-9037', '0074-4314', '0074-4317', '0074-9036']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PARICALCITOL'],"['577315', '577317', '606854', '606859']",['ed8862d9-4037-4a30-9be6-42f2613c34cd'],['1b27c026-2d60-47b4-2a9c-ded1818f21b5'],"['0074-4314-30', '0074-4317-30', '0074-4317-73', '0074-9036-30', '0074-9037-30']",['6702D36OG5'],"['M0007651', 'N0000175907', 'N0000175849']","['Vitamin D2 Analog [EPC]', 'Vitamin D Analog [EPC]']",,10/07/2025,,['Ergocalciferols [CS]'],,,
New,07/10/2025,72305-025-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 25 ug (NDC 72305-025-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Revised,01/01/2020,63323-099-63,Sodium Chloride 23.4% Injection,888-386-1300,,,07/02/2025,"['Gastroenterology', 'Endocrinology/Metabolism', 'Total Parenteral Nutrition', 'Pediatric']",Injection,"Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-099-63)","Fresenius Kabi USA, LLC",,Resolved,['ANDA217796'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-099'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],['313016'],['f5197532-af45-42c9-919b-30d00276650e'],['b6e33138-841a-471f-a934-c4086cbc23f6'],"['63323-099-03', '63323-099-63']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Revised,08/23/2024,66259-936-25,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-25)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
Revised,07/14/2023,57664-088-88,"Lisdexamfetamine Dimesylate Tablet, Chewable",800-818-4555,Limited Availability,Available Q4 2025,10/21/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA214134'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-088', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
Revised,10/31/2017,0409-1312-36,Hydromorphone Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: March 2026,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1312', '0409-1283', '0409-1380', '0409-4264', '0409-1805', '0409-2552', '0409-3356', '0409-2540', '0409-3365', '0409-1304']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1724383', '1724644', '1872271', '2675350', '897653', '897753', '897758', '1724276']","['53b6867a-0ae3-48ff-b257-9e58cc76de9c', '58ff0e68-b78f-4ebd-a91b-b53bbdefc544']","['f9ca2ef5-46d8-475a-a26e-f7c8becd6db7', 'e9c9ef18-7dfc-4322-b2fc-29b934c30f8b']","['0409-1283-17', '0409-1283-37', '0409-1312-16', '0409-1312-36', '0409-1380-11', '0409-1380-01', '0409-4264-11', '0409-4264-01', '0409-1805-10', '0409-1805-01', '0409-2552-11', '0409-2552-01', '0409-3356-11', '0409-3356-01', '0409-2540-11', '0409-2540-01', '0409-3365-11', '0409-3365-01', '0409-3365-10', '0409-1283-03', '0409-1283-31', '0409-1283-09', '0409-1283-10', '0409-1283-04', '0409-1283-05', '0409-1312-03', '0409-1312-30', '0409-1312-09', '0409-1312-10', '0409-1304-03', '0409-1304-31']",['L960UP2KRW'],,,,,,,,,
Reverified,03/10/2023,43547-406-11,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-406', '43547-407', '43547-408']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,01/22/2025,71093-130-05,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-05)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-130', '71093-129', '71093-131']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Reverified,07/14/2023,42858-161-01,Lisdexamfetamine Dimesylate Capsule,888-827-0616,Available,,08/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)",Rhodes Pharmaceuticals L.P.,,Current,['ANDA215330'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Rhodes Pharmaceuticals'],"['42858-161', '42858-162', '42858-163', '42858-164', '42858-165', '42858-166', '42858-167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['047c243d-9336-4ef2-b5a8-a7cae312b1be'],['d918b40d-a461-41bc-b6c0-83dc76c28e32'],"['42858-161-01', '42858-162-01', '42858-163-01', '42858-164-01', '42858-165-01', '42858-166-01', '42858-167-01']",['SJT761GEGS'],,,,,,,,,
Revised,03/23/2018,55150-196-99,Ropivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)",Eugia US LLC,,Current,['ANDA205612'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-196', '55150-195', '55150-197', '55150-198', '55150-199', '55150-200', '55150-201']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734207', '1734347', '1734475', '1734483']",['34725b26-d6e9-4d1b-95a0-da03764cc102'],['3763b7b6-da49-4658-b93d-28f5da24d09e'],"['55150-195-20', '55150-196-99', '55150-197-20', '55150-198-30', '55150-199-20', '55150-200-10', '55150-201-20']",['V910P86109'],,,,,,,,,
New,11/13/2024,0093-0711-01,Flurbiprofen Tablet,800-545-8800,,A business decision was made to discontinue manufacture of the product.,11/13/2024,['Analgesia/Addiction'],Tablet,"Tablet, 100 mg (NDC 0093-0711-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA074431'],['FLURBIPROFEN'],['FLURBIPROFEN'],"['Teva Pharmaceuticals USA, Inc.']",['0093-0711'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLURBIPROFEN'],['197724'],['38a133bd-a325-4de2-bcf2-d6e144cc456b'],['4e5c06f1-f279-4f2f-b10d-0f70005a27e6'],"['0093-0711-01', '0093-0711-05']",['5GRO578KLP'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,11/13/2024,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Reverified,10/12/2022,70010-115-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",877-770-3183,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)",Granules Pharmaceuticals Inc.,,Current,['ANDA215771'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Granules Pharmaceuticals Inc.'],"['70010-115', '70010-111', '70010-112', '70010-113', '70010-114', '70010-116', '70010-117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['2fab399e-2a43-5134-e063-6294a90ae09a'],['b0b4eccc-34c7-483d-966f-82d588358e1b'],"['70010-111-01', '70010-111-03', '70010-112-01', '70010-112-03', '70010-113-01', '70010-113-03', '70010-114-01', '70010-114-03', '70010-115-01', '70010-115-03', '70010-116-01', '70010-116-03', '70010-117-01', '70010-117-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/07/2020,83634-302-02,Furosemide Injection,855-228-9470,Available,Distributed by Avenacy; Contact information: 877-283-6229,11/03/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL; 2mL vial (NDC 83634-302-02)","Avet Pharmaceuticals, Inc.",,Current,['ANDA203428'],['FUROSEMIDE'],['FUROSEMIDE'],['Avenacy Inc.'],['83634-302'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['1b3f2803-b618-4447-b5ac-cd2bdc7de3e8'],['7d0db0f7-bf4f-4b0b-9359-2a838626e04b'],"['83634-302-42', '83634-302-02', '83634-302-43', '83634-302-04', '83634-302-41', '83634-302-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,04/28/2023,0703-4244-01,Carboplatin Injection,800-545-8800,Available,,10/16/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA077269'],['CARBOPLATIN'],['CARBOPLATIN'],"['Teva Parenteral Medicines, Inc.']","['0703-4244', '0703-4246', '0703-4248', '0703-4239']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],"['bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df', 'b943761e-6a46-45a0-bdb4-1fec1e101f8c']","['f330f5a2-2cad-402f-bcbb-26245a753276', 'e176b6ef-2ff6-498b-a9d8-7a634d147f37']","['0703-4244-01', '0703-4246-01', '0703-4248-01', '0703-4239-01', '0703-4244-81', '0703-4246-81', '0703-4248-81', '0703-4239-81']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,01/19/2023,62135-485-90,Quinapril Hydrochloride Tablet,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,Available,,08/19/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA076803'],['QUINAPRIL'],['QUINAPRIL'],"['Chartwell RX, LLC']","['62135-485', '62135-484', '62135-486', '62135-487']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['09cd5cb9-4fdf-f133-e063-6294a90af691'],['dbc43dbd-94aa-40e2-a9ea-766110cc8687'],"['62135-484-60', '62135-485-90', '62135-486-90', '62135-487-90']",['33067B3N2M'],,,,,,,,,
Reverified,02/22/2012,76329-3390-1,Lidocaine Hydrochloride Injection,800-423-4136,Available,old NDC 0548-3390-00,10/17/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)","Amphastar Pharmaceuticals, Inc.",,Current,['ANDA083173'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['International Medication Systems, Limited']",['76329-3390'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],['1012068'],['3d910bb6-792f-41f3-8b28-b33bcbec5ccb'],['5d3e9984-cef9-46f2-a6c9-3be8b26f45b3'],['76329-3390-1'],['V13007Z41A'],,,,,,,,,
Revised,08/02/2018,64253-202-30,Sodium Chloride 0.9% Injection,630-682-4600,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 64253-202-30)","Medefil, Inc.",,Resolved,['NDA202832'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Medefil, Inc.']",['64253-202'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],['727820'],['12dde6de-967e-cb5e-e063-6294a90acede'],['d1468c0f-dd4f-4d38-a84c-c1d110303965'],['64253-202-30'],['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,11/14/2017,63323-519-10,Heparin Sodium Injection,888-386-1300,Unavailable,Backordered. Next release December 2025. Check wholesalers for inventory.,11/05/2025,['Hematology'],Injection,"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)","Fresenius Kabi USA, LLC",Other,Current,['ANDA212441'],['HEPARIN SODIUM'],['HEPARIN SODIUM'],"['Fresenius Kabi USA, LLC']",['63323-519'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['3bbbe74a-1246-41a6-9fc3-ca0230529b40'],['25b0ba06-3274-4a3f-8c39-42d13764ecdf'],"['63323-519-02', '63323-519-77', '63323-519-01', '63323-519-10']",['ZZ45AB24CA'],,,,,,,,,
Reverified,07/14/2023,0527-4664-37,Lisdexamfetamine Dimesylate Capsule,844-834-0530,Limited Availability,Limited Availability,11/03/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA215802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Lannett Company, Inc.']","['0527-4664', '0527-4661', '0527-4662', '0527-4663', '0527-4665', '0527-4666', '0527-4667']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7ac942a6-689a-420b-87bf-dc59003400dc'],['2cedb4c2-1e40-4bc4-b9f4-127150c4afbd'],"['0527-4661-37', '0527-4662-37', '0527-4663-37', '0527-4664-37', '0527-4665-37', '0527-4666-37', '0527-4667-37']",['SJT761GEGS'],,,,,,,,,
Reverified,10/12/2022,0527-0763-37,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)","Lannett Company, Inc.",,Current,['ANDA215565'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Lannett Company, Inc.']","['0527-0763', '0527-0760', '0527-0761', '0527-0762', '0527-0764', '0527-0765', '0527-0766']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['e0804f43-4685-4017-b839-3212d1167362'],['f92497b5-baea-4760-b615-45a0b6184402'],"['0527-0760-37', '0527-0761-37', '0527-0762-37', '0527-0763-37', '0527-0764-37', '0527-0765-37', '0527-0766-37']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,12/08/2020,0264-1933-10,Amino Acid Injection,800-227-2862,Available,,11/04/2025,['Gastroenterology'],Injection,"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)",B. Braun Medical Inc.,,Current,['NDA019018'],['TROPHAMINE'],"['ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, CYSTEINE HYDROCHLORIDE, HISTIDINE, TYROSINE, N-ACETYL-TYROSINE, ALANINE, ARGININE, PROLINE, SERINE, GLYCINE, ASPARTIC ACID, GLUTAMIC ACID, AND TAURINE']",['B. Braun Medical Inc.'],['0264-1933'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ACETYL L-TYROSINE', 'ALANINE', 'ARGININE', 'ASPARTIC ACID', 'CYSTEINE HYDROCHLORIDE', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'TAURINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['800611', '1189640']",['07f53291-419d-4d14-ad81-26f00dc0c474'],['cb6d23ff-3ec5-445a-acbe-f88fd57949bf'],['0264-1933-10'],"['DA8G610ZO5', 'OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', 'ZT934N0X4W', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '1EQV5MLY3D', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Revised,02/15/2023,0409-5160-10,Rocuronium Bromide Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: December 2025,10/23/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA205656'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],"['Hospira, Inc.']","['0409-5160', '0409-1403']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['f01f9986-43f9-40e8-9506-11bfe78f9242'],['f01f9986-43f9-40e8-9506-11bfe78f9242'],"['0409-1403-05', '0409-1403-10', '0409-5160-01', '0409-5160-10']",['I65MW4OFHZ'],,,,,,,,,
Revised,03/05/2025,50102-400-10,Lidocaine Hydrochloride Injection,713-724-0238,,,03/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 50102-400-10)",Afaxys Pharma,,To Be Discontinued,,,,,,,,,,,,,,,,,03/05/2025,,,03/05/2025,,
Revised,12/10/2021,0990-7983-61,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-61)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7983', '0990-7730', '0990-7984', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,03/24/2023,0009-0005-01,Hydrocortisone Sodium Succinate Injection,844-646-4398,Available,,10/23/2025,"['Pulmonary/Allergy', 'Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Renal', 'Rheumatology']",Injection,"Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)","Hospira, Inc., a Pfizer Company",,Current,['NDA009866'],['SOLU-CORTEF'],['HYDROCORTISONE SODIUM SUCCINATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0005', '0009-0825', '0009-0011', '0009-0013', '0009-0016']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],"['105398', '238755', '1738586', '1738589', '1738590', '1738592', '1738594', '1738596']",['8512044a-4a54-4634-bb97-9e20126adc61'],['65eefd58-b166-4d71-ade6-45c8fdf86922'],"['0009-0825-01', '0009-0011-03', '0009-0011-04', '0009-0013-05', '0009-0013-06', '0009-0016-12', '0009-0005-01']",['50LQB69S1Z'],,,,,,,,,
Reverified,07/14/2023,43547-606-10,Lisdexamfetamine Dimesylate Capsule,866-931-9829,Limited Availability,On allocation,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA216266'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE CAPSULES'],"['Solco Healthcare US,LLC']","['43547-606', '43547-602', '43547-603', '43547-604', '43547-605', '43547-607', '43547-608']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7bb11568-67a4-4221-bb9b-23af37a1791c'],['68b10d9f-ca3e-493d-a309-45f1d7e08061'],"['43547-602-10', '43547-603-10', '43547-604-10', '43547-605-10', '43547-606-10', '43547-607-10', '43547-608-10']",['SJT761GEGS'],,,,,,,,,
New,03/24/2025,0472-0321-26,Hydrocortisone Cream,800-545-8800,,A business decision was made to discontinue.,03/24/2025,['Dermatology'],Cream,"Hydrocortisone, Cream, 10 mg/1 g (NDC 0472-0321-26)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA087795'],['HYDROCORTISONE'],['HYDROCORTISONE'],"['Actavis Pharma, Inc.']",['0472-0321'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['HYDROCORTISONE'],['106258'],['d74b9b48-0a47-43d1-a89a-f294c4ca1297'],['aa9dba84-eb38-4ec3-8555-87c948bf2384'],['0472-0321-26'],['WI4X0X7BPJ'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,03/24/2025,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
New,08/01/2025,0591-3916-68,Clindamycin Phosphate; Benzoyl Peroxide Gel,800-545-8800,,A business decision was made to discontinue manufacture of the product.,08/01/2025,['Dermatology'],Gel,"Clindamycin Phosphate; Benzoyl Peroxide, Gel, 25 mg/1 g; 10 mg/1 g (NDC 0591-3916-68)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA205128'],['CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE'],['CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE'],"['Actavis Pharma, Inc.']",['0591-3916'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],"['BENZOYL PEROXIDE', 'CLINDAMYCIN PHOSPHATE']",['885131'],['c2dcadb5-8ef3-4c6a-af4f-bf201184a6d0'],['87622142-000b-460b-977e-92d6735f5337'],['0591-3916-68'],"['W9WZN9A0GM', 'EH6D7113I8']",,,,08/01/2025,,,,,
Reverified,01/01/2012,16729-512-43,Atropine Sulfate Injection,"866-941-7875, option 2",Unavailable,Resupply TBD,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA213424'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],['Accord Healthcare Inc.'],['16729-512'],['HUMAN PRESCRIPTION DRUG'],"['ENDOTRACHEAL', 'INTRAMEDULLARY', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['ATROPINE SULFATE'],['1190776'],['275def6c-5b2d-918b-e063-6294a90aa71f'],['f3cb74e9-b4ac-4efe-bd8e-8a71970ee7c7'],"['16729-512-05', '16729-512-43']",['03J5ZE7KA5'],,,,,,,,,
Reverified,08/15/2023,64850-506-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",888-852-6657,Limited Availability,3 months,11/04/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA211352'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Elite Laboratories, Inc.']","['64850-506', '64850-500', '64850-501', '64850-502', '64850-503', '64850-504', '64850-505']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['b65e0266-7172-4730-8f93-eb42e08fb7b8'],['e677690f-790f-4626-ad78-097cdb6ea540'],"['64850-500-01', '64850-500-05', '64850-500-30', '64850-501-01', '64850-501-05', '64850-501-30', '64850-502-01', '64850-502-05', '64850-502-30', '64850-503-01', '64850-503-05', '64850-503-30', '64850-504-01', '64850-504-05', '64850-504-30', '64850-505-01', '64850-505-05', '64850-505-30', '64850-506-01', '64850-506-05', '64850-506-30']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/16/2025,0591-2925-30,"Testosterone Gel; Gel, Metered",800-545-8800,,Discontinuation of the manufacture of the drug,06/16/2025,['Urology'],"Gel; Gel, Metered","Testosterone, Gel; Gel, Metered, 16.2 mg/1 g (NDC 0591-2925-30)","Actavis Pharma, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,06/16/2025,,,,,
Revised,06/13/2018,0143-9575-10,Lidocaine Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA080407'],['LIDOCAINE'],['LIDOCAINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9575', '0143-9579', '0143-9578', '0143-9577', '0143-9576', '0143-9172', '0143-9173']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671']",['3e5c0afe-9377-4040-ab89-55a6dbb5693c'],['5523fdfe-69fd-49a5-b51f-73e2223d49a9'],"['0143-9579-01', '0143-9579-25', '0143-9578-01', '0143-9578-10', '0143-9577-01', '0143-9577-10', '0143-9576-01', '0143-9576-25', '0143-9575-01', '0143-9575-10', '0143-9172-01', '0143-9172-10', '0143-9173-01', '0143-9173-10']",['V13007Z41A'],,,,,,,,,
New,04/28/2025,0245-0212-11,Midodrine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Cardiovascular'],Tablet,"Orvaten, Tablet, 5 mg (NDC 0245-0212-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076725'],['MIDODRINE HYDROCHLORIDE'],['MIDODRINE HYDROCHLORIDE'],"['Upsher-Smith laboratories, LLC']","['0245-0212', '0245-0211', '0245-0213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MIDODRINE HYDROCHLORIDE'],"['993462', '993466', '993470']",['18b0b9f5-6026-479e-af12-92b0e71a9d6b'],['4c3517f3-1c68-4ade-b5f1-c488a3a335c1'],"['0245-0211-11', '0245-0211-89', '0245-0211-01', '0245-0212-11', '0245-0212-89', '0245-0212-01', '0245-0213-11', '0245-0213-89', '0245-0213-01']",['59JV96YTXV'],,,,04/28/2025,,,,,
Revised,01/01/2012,25021-828-50,Leucovorin Calcium Injection,866-625-1618,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 25021-828-50)",Sagent Pharmaceuticals,,Resolved,['ANDA209110'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Sagent Pharmaceuticals'],['25021-828'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],['2055036'],['4619074b-a86b-41a6-bd98-76d15166764c'],['c0cbcbf6-6fd2-4cf3-877a-bb0fe3df4e59'],['25021-828-50'],['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,02/14/2022,0338-0017-11,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Revised,12/08/2021,0409-1966-12,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-12)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018800'],['BACTERIOSTATIC SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']",['0409-1966'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],['313002'],['2d3125e0-c89b-46d5-a350-07d1e7936ebd'],['376093e7-e09e-4a57-3199-195e45251866'],"['0409-1966-02', '0409-1966-07', '0409-1966-06', '0409-1966-12', '0409-1966-01', '0409-1966-05']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/26/2023,0406-1473-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-325-8888,Unavailable,Next release expected November 2025,11/05/2025,['Psychiatry'],Tablet,"Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA075629'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],['SpecGx LLC'],"['0406-1473', '0406-1445']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091145', '1091225']",['7bfd27d5-70ed-440b-949a-140aa3304d4a'],['ed004cf0-eb23-43d2-96dc-20c4ad63824f'],"['0406-1445-01', '0406-1473-01']",['4B3SC438HI'],,,,,,,,,
Revised,01/06/2023,0013-2651-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 0.6 mg preservative free (NDC 0013-2651-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2651', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
New,11/13/2024,0228-2631-11,Isosorbide Mononitrate Tablet,800-545-8800,,A business decision was made to discontinue manufacture of this product.,11/13/2024,['Cardiovascular'],Tablet,"Tablet, 10 mg (NDC 0228-2631-11)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA075037'],['ISOSORBIDE MONONITRATE'],['ISOSORBIDE MONONITRATE'],"['Actavis Pharma, Inc.']","['0228-2631', '0228-2620']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ISOSORBIDE MONONITRATE'],"['311192', '311197']",['1cb05f66-1c19-4300-8745-8c74c1dccb2b'],['ae8f74f0-e600-4452-8557-958b603e2709'],"['0228-2631-11', '0228-2620-11']",['LX1OH63030'],"['N0000175415', 'M0014874', 'N0000009909']",['Nitrate Vasodilator [EPC]'],['Vasodilation [PE]'],11/13/2024,,['Nitrates [CS]'],,,
Reverified,03/17/2023,68308-115-01,Methamphetamine Hydrochloride Tablet,866-732-3952,Available,Available to existing customers,10/21/2025,['Psychiatry'],Tablet,"Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 68308-115-01)","Dr. Reddy's Laboratories, Inc.",,Current,['ANDA091189'],['METHAMPHETAMINE HYDROCHLORIDE'],['METHAMPHETAMINE HYDROCHLORIDE'],['Mayne Pharma Commercial LLC'],['68308-115'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHAMPHETAMINE HYDROCHLORIDE'],['977860'],['ffc2cd39-e42b-5821-e053-6394a90a9974'],['f31f580f-1f08-4a0f-b078-0b9e3308f712'],['68308-115-01'],['997F43Z9CV'],,,,,,,,,
New,07/21/2025,73070-203-15,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,609-987-5800,,"Unbranded Insulin aspart protamine and insulin aspart FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injectable Suspension,"Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen® (NDC 73070-203-15)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA021172'],['INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30'],['INSULIN ASPART'],"['Novo Nordisk Pharma, Inc.']","['73070-203', '73070-200']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN ASPART'],"['351297', '847191']",['ec67820c-4008-4894-b933-34b28704221d'],['fc94baa4-3606-48bc-a781-9617ab6960ef'],"['73070-200-11', '73070-203-10', '73070-203-15']",['D933668QVX'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
Reverified,02/08/2019,67457-423-12,Dexamethasone Sodium Phosphate Injection,800-796-9526,Available,,11/06/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)","Mylan Institutional, a Viatris Company",,Current,['ANDA040803'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Mylan Institutional LLC'],"['67457-423', '67457-422', '67457-421', '67457-420']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1116927', '1812194']",['dd5c82b6-a194-462c-9626-34a9b410cfea'],['dff598e8-e662-411f-978d-4ba3fb8ef7db'],"['67457-423-00', '67457-423-12', '67457-422-00', '67457-422-54', '67457-421-00', '67457-421-30', '67457-420-00', '67457-420-10']",['AI9376Y64P'],,,,,,,,,
Reverified,03/01/2017,76329-3352-1,Sodium Bicarbonate Injection,800-423-4136,Available,,10/17/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)","Amphastar Pharmaceuticals, Inc.",,Current,['ANDA203449'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['International Medication Systems, Limited']",['76329-3352'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],['792582'],['74a86dc7-0929-40d0-9661-9f9063a8fd7d'],['77698221-a01d-4568-a7bc-d3d4e982875d'],['76329-3352-1'],['8MDF5V39QO'],,,,,,,,,
Revised,07/14/2023,57664-050-88,Lisdexamfetamine Dimesylate Capsule,800-818-4555,Limited Availability,Additional supply anticipated in Q4 2025 followed by early 2026,10/21/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['ANDA214484'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-050', '57664-047', '57664-046', '57664-048', '57664-049', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
New,01/13/2025,0069-1031-30,Talazoparib Tosylate Capsule,800-533-4535,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0252-30",01/13/2025,['Oncology'],Capsule,"Talzenna, Capsule, .1 mg (NDC 0069-1031-30)",Pfizer Inc.,,To Be Discontinued,['NDA211651'],['TALZENNA'],['TALAZOPARIB'],['Pfizer Laboratories Div Pfizer Inc'],"['0069-1031', '0069-0296', '0069-1195', '0069-1501', '0069-1751', '0069-1235']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TALAZOPARIB TOSYLATE'],"['2099946', '2099952', '2099954', '2099956', '2591510', '2591512', '2591520', '2591521', '2639960', '2639962', '2639964', '2639966']",['2cb65f61-9a14-46d9-85a3-a7eea76160c5'],['f2423edd-6d24-495c-aec1-c2f457f08d9a'],"['0069-0296-30', '0069-1195-30', '0069-1501-30', '0069-1751-30', '0069-1031-30', '0069-1235-30']",['02WK9U5NZC'],,,,01/13/2025,,,,,
Revised,01/01/2012,70436-116-82,Leucovorin Calcium Injection,888-447-0095,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 50 mg (NDC 70436-116-82)",Slate Run Pharmaceuticals,,Resolved,['ANDA217021'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Slate Run Pharmaceuticals, LLC']","['70436-116', '70436-117', '70436-118', '70436-120', '70436-119']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['2a4aaed3-885e-bc10-e063-6294a90a61af'],['d8bdd60c-9a1c-4ef4-ba6b-b911849128f1'],"['70436-116-80', '70436-116-82', '70436-117-80', '70436-118-80', '70436-120-80', '70436-119-80']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Revised,03/13/2023,0703-3678-01,Methotrexate Sodium Injection,800-545-8800,Unavailable,Estimated availability: November 2025,11/06/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)","Teva Pharmaceuticals USA, Inc.",Other,Current,['ANDA040843'],['METHOTREXATE'],['METHOTREXATE'],"['Teva Parenteral Medicines, Inc.']","['0703-3678', '0703-3671', '0703-3675']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE SODIUM'],"['1655956', '1655959', '1655960']",['e81074cc-12b4-4ac9-a5bb-749188989b2c'],['346ec9ce-dc98-4a55-b55e-d3af11f2d703'],"['0703-3671-01', '0703-3675-01', '0703-3678-01']",['3IG1E710ZN'],,,,,,,,,
New,11/21/2024,0555-0066-02,Isoniazid Tablet,800-545-8800,,Product available through 12/03/2024,11/21/2024,['Anti-Infective'],Tablet,"Tablet, 100 mg (NDC 0555-0066-02)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA080936'],['ISONIAZID'],['ISONIAZID'],"['Teva Pharmaceuticals USA, Inc.']","['0555-0066', '0555-0071']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ISONIAZID'],"['197832', '311166']",['ead93989-8a7e-4483-917e-388152515e1d'],['9499f1cf-2f46-4047-8b71-90aee7dee854'],"['0555-0066-02', '0555-0071-01', '0555-0071-02']",['V83O1VOZ8L'],['N0000175483'],['Antimycobacterial [EPC]'],,11/21/2024,,,,,
Revised,02/08/2019,0641-6146-25,Dexamethasone Sodium Phosphate Injection,800-631-2174,Unavailable,Additional lots will be available in the November 2025 timeframe.  Product will be made available as it is released.,10/24/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate Injection, USP, Injection, 4 mg/1 mL (NDC 0641-6146-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA084282'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6146', '0641-0367', '0641-6145']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1116927', '1812194']",['84665497-7e82-4733-bcfd-3177817ac0b3'],['0277cc0a-2fd4-4605-a310-b613be84ee26'],"['0641-0367-21', '0641-0367-25', '0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-10', '0641-6146-25']",['AI9376Y64P'],,,,,,,,,
Revised,06/21/2018,63323-186-00,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 63323-186-00)","Fresenius Kabi USA, LLC",,Resolved,['ANDA088912'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-186'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807632', '1807636', '1807637', '1807638']","['debc17b5-4d24-473c-8396-e409433ce57c', '75c567e3-582b-4fff-9a72-f326f1d13c8f']","['f2a98378-9678-4738-9670-fc7a215c0606', 'f62481fd-fcdb-4be6-ac13-29c590e925c3']","['63323-186-00', '63323-186-04', '63323-186-02', '63323-186-01', '63323-186-10', '63323-186-03', '63323-186-20']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/14/2023,0054-0374-25,Lisdexamfetamine Dimesylate Capsule,800-631-2174,Limited Availability,Available on allocation,10/24/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202827'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-0374', '0054-0660', '0054-0370', '0054-0371', '0054-0372', '0054-0373', '0054-0375']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['5d119550-4386-4bfa-a5d0-bb18e66191b7'],['6740a621-9bec-4178-a4fc-a3fc89f34e0a'],"['0054-0660-25', '0054-0370-25', '0054-0371-25', '0054-0372-25', '0054-0373-25', '0054-0374-25', '0054-0375-25']",['SJT761GEGS'],,,,,,,,,
New,04/23/2025,0832-1054-10,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 0832-1054-10)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1054', '0832-1055']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
Revised,01/01/2012,0143-9552-01,Leucovorin Calcium Injection,800-631-2174,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 0143-9552-01)","Hikma Pharmaceuticals USA, Inc.",,Resolved,['ANDA040335'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9552', '0143-9555', '0143-9554', '0143-9553']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['e2d1484b-2920-45ab-9207-4caa5285fef4'],['cc52077f-5663-4f79-a273-0aecf655e038'],"['0143-9555-01', '0143-9554-01', '0143-9553-01', '0143-9552-01']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Revised,12/15/2021,0009-0306-12,Methylprednisolone Acetate Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)",Pfizer Inc.,Demand increase for the drug,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0306', '0009-0274', '0009-0280']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358510', '1358512', '1358610', '1358612', '1358617', '1358619']",['4cf5a255-1360-4511-9b58-b92e3492ef12'],['823b0010-2b57-4e76-b5ac-4a8c2963438f'],"['0009-0274-01', '0009-0280-02', '0009-0280-51', '0009-0280-03', '0009-0280-52', '0009-0306-02', '0009-0306-12']",['43502P7F0P'],,,,,,,,,
Reverified,06/06/2018,72266-118-25,Ketorolac Tromethamine Injection,833-291-9645,Available,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",09/29/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)",Gland Pharma Limited,,Current,['ANDA204216'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['FOSUN PHARMA USA INC'],"['72266-118', '72266-234', '72266-119']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['228ec94a-f777-f61b-e063-6394a90a21a5'],['1aae6a4d-0909-4672-aa26-e3f2d8c4d413'],"['72266-234-01', '72266-234-25', '72266-118-01', '72266-118-25', '72266-119-01', '72266-119-25']",['4EVE5946BQ'],,,,,,,,,
Reverified,02/14/2022,65219-464-50,Dextrose Monohydrate 5% Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)","Fresenius Kabi USA, LLC",,Current,['ANDA207449'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['FRESENIUS KABI USA, LLC']","['65219-464', '65219-456', '65219-458', '65219-460', '65219-462']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['efc3b0c9-518a-47db-bb3e-ebdfd4646e9b'],['576a22d8-5f2f-497e-80ad-1842ca74bb53'],"['65219-456-05', '65219-456-60', '65219-464-05', '65219-464-50', '65219-458-05', '65219-458-30', '65219-460-05', '65219-460-20', '65219-462-05', '65219-462-10']",['LX22YL083G'],,,,,,,,,
Revised,12/10/2021,0338-9543-02,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9543', '0338-9657', '0338-9659', '0338-9661', '0338-9663']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['6680afa2-1474-4bc3-afee-a333a042fd3f'],['958d35f0-6834-43be-a700-fa58f38b4c19'],"['0338-9543-01', '0338-9543-02', '0338-9543-03', '0338-9543-04', '0338-9543-05', '0338-9543-06', '0338-9543-12', '0338-9657-75', '0338-9659-75', '0338-9661-60', '0338-9663-60']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,05/30/2025,0409-1181-30,Meperidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)","Hospira, Inc., a Pfizer Company",,Current,['NDA021171'],['DEMEROL'],['MEPERIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1181', '0409-1176', '0409-1178', '0409-1179', '0409-1180', '0409-1362', '0409-1418']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['860792', '861463', '861473', '861493', '861494', '861522', '861529', '861617', '1242106', '1242503', '2539186', '2539188', '2539191', '2539192']",['1271f15f-ccda-4892-8fb0-9bb2d38ded4a'],['b31d1308-28c3-43f4-e0a6-2f3ed76b8975'],"['0409-1181-30', '0409-1176-03', '0409-1176-30', '0409-1178-03', '0409-1178-30', '0409-1179-03', '0409-1179-30', '0409-1180-59', '0409-1180-69', '0409-1362-11', '0409-1362-01', '0409-1418-11', '0409-1418-01']",['N8E7F7Q170'],,,,,,,,,
New,02/05/2025,0591-4920-01,Amantadine Hydrochloride Capsule,800-545-8800,,A business decision was made to discontinue manufacture of the drug.,02/05/2025,"['Antiviral', 'Neurology']",Capsule,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA208096'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']",['0591-4920'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849395'],['67ce5a52-d507-4333-b0a0-b7177f896aec'],['d9c9eaf7-dcc7-49c1-99d4-49f4dac3779f'],"['0591-4920-01', '0591-4920-05']",['M6Q1EO9TD0'],,,,02/05/2025,,,,,
New,03/03/2025,0597-0375-23,Adalimumab-adbm Injection,800-243-0127,,,03/03/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0375-23)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['CYLTEZO'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0375', '0597-0370', '0597-0405', '0597-0400', '0597-0485', '0597-0495']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640889', '2640891', '2640892', '2640893', '2640894', '2640895', '2640898', '2640900', '2640901', '2640902', '2640903', '2680743', '2680746', '2680748', '2680750', '2680756', '2680757', '2680759', '2680760']",['0abec80c-8b06-4e08-bb5a-dd42ef508aa6'],['115ea79b-7209-7f19-b35d-36ec0828fbf5'],"['0597-0370-82', '0597-0370-72', '0597-0370-45', '0597-0405-80', '0597-0405-10', '0597-0400-89', '0597-0375-48', '0597-0375-97', '0597-0375-23', '0597-0375-16', '0597-0375-53', '0597-0485-46', '0597-0485-20', '0597-0480-12', '0597-0495-47', '0597-0495-50', '0597-0495-40', '0597-0495-60', '0597-0490-32']",,,,,03/03/2025,,,,,
New,09/19/2025,0228-2801-11,Pilocarpine Hydrochloride Tablet,800-545-8800,,Discontinuation of the manufacture of the drug.,09/19/2025,['Other'],Tablet,"Salagen, Tablet, 5 mg (NDC 0228-2801-11)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA020237'],['PILOCARPINE HYDROCHLORIDE'],['PILOCARPINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0228-2801', '0228-2837']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PILOCARPINE HYDROCHLORIDE'],"['1000913', '1001004']",['7db72b88-d664-4f26-901c-46c901b20d80'],['610022b7-7dc9-405a-a580-104657f43bdf'],"['0228-2801-11', '0228-2837-11']",['0WW6D218XJ'],,,,09/19/2025,,,,,
Reverified,07/14/2023,59417-106-10,Lisdexamfetamine Dimesylate Capsule,877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],Capsule,"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA021977'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-106', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
New,01/06/2025,45963-567-08,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-08)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/06/2025,,,,,
Revised,05/03/2022,17478-050-05,Sufentanil Citrate Injection,800-631-2174,Unavailable,Not currently manufactured,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)","Hikma Pharmaceuticals USA, Inc.",Other,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,11/03/2017,0641-6040-01,Morphine Sulfate Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA018565'],['INFUMORPH 500'],['MORPHINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6040', '0641-6039']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL']",['MORPHINE SULFATE'],"['892652', '1731522', '1731998', '1731999']",['cd3674c8-d894-4dcf-8044-7a1198ed8ed9'],['db9ac9e3-d761-4a99-9f34-4946ebe8f255'],"['0641-6039-01', '0641-6040-01']",['X3P646A2J0'],,,,,,,,,
New,02/26/2025,58151-104-77,"Tolterodine Tartrate Capsule, Extended Release",800-796-9526,,,02/26/2025,['Urology'],"Capsule, Extended Release","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA021228'],['DETROL LA'],['TOLTERODINE TARTRATE'],['Viatris Specialty LLC'],"['58151-104', '58151-103']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOLTERODINE TARTRATE'],"['855182', '855184', '855189', '855191']",['a1e49744-9302-47ee-92af-8b19aa0b2fc1'],['d7274947-4f88-47ee-a39f-bd5ac46fcf8d'],"['58151-103-93', '58151-103-77', '58151-103-05', '58151-104-93', '58151-104-77', '58151-104-05']",['5T619TQR3R'],,,,02/26/2025,,,,,
Revised,02/20/2018,55150-163-30,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)",Eugia US LLC,,Current,['ANDA203082'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-163', '55150-161', '55150-162', '55150-164', '55150-165']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737562', '1737566', '1737568', '1737757', '1737761']","['9916b09d-a116-469d-92d5-60e50ea9782b', '9b60bc92-6093-49f9-a6ba-075104ff7bb5']","['9916b09d-a116-469d-92d5-60e50ea9782b', '89701fac-7536-4f16-87fb-f4cc121e74ee']","['55150-161-09', '55150-162-09', '55150-163-00', '55150-164-09', '55150-165-09', '55150-161-02', '55150-162-05', '55150-163-30', '55150-164-02', '55150-165-05']",['V13007Z41A'],,,,,,,,,
Reverified,10/31/2017,0409-1896-20,Morphine Sulfate Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)","Hospira, Inc., a Pfizer Company",,Current,['NDA202515'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-1896', '0409-2022']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['1731537', '1731545']",['47aaa2d4-32ee-4ba8-bb5e-b48ffae6c72e'],['ee8057d1-ed12-4e18-9efa-d83504abf612'],"['0409-1896-20', '0409-2022-01']",['X3P646A2J0'],,,,,,,01/03/2025,,
New,07/10/2025,72305-075-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 75 ug (NDC 72305-075-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-075', '72305-025', '72305-050', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Revised,11/06/2017,0409-7809-22,Dopamine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: January 2026; Estimated Recovery: March 2026,10/23/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018826'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],['DOPAMINE HYDROCHLORIDE IN DEXTROSE'],"['Hospira, Inc.']","['0409-7809', '0409-7810']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743877', '1743879']",['3b4d4d9d-5e19-420f-a447-1ad8346844d9'],['08f23f6e-150d-45ea-098e-f2edf64c21a1'],"['0409-7809-11', '0409-7809-22', '0409-7809-31', '0409-7809-24', '0409-7810-11', '0409-7810-22']",['7L3E358N9L'],,,,,,,,,
Revised,12/10/2021,0990-7984-36,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-36)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7984', '0990-7730', '0990-7983', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,07/26/2023,57664-607-88,"Methylphenidate Hydrochloride Tablet, Extended Release",800-818-4555,Unavailable,Currently not marketed,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)","Sun Pharmaceutical Industries, Inc.",Discontinuation of the manufacture of the drug,Current,['ANDA205135'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-607', '57664-606', '57664-608', '57664-609']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['0da4b745-d498-8823-e063-6394a90a4524'],['d048e52d-7406-4fc1-9a72-c073bafc7439'],"['57664-606-88', '57664-607-88', '57664-608-88', '57664-609-88']",['4B3SC438HI'],,,,,,,,,
Reverified,09/27/2021,82667-800-01,Triamcinolone Acetonide Injection,(615) 733-4734,Limited Availability,Estimated duration: 12 months,09/17/2025,['Ophthalmology'],Injection,"Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)","Harrow Eye, LLC",Requirements related to complying with good manufacturing practices,Current,['NDA022048'],['TRIESENCE'],['TRIAMCINOLONE ACETONIDE'],"['Harrow Eye, LLC']",['82667-800'],['HUMAN PRESCRIPTION DRUG'],['OPHTHALMIC'],['TRIAMCINOLONE ACETONIDE'],"['1086259', '1792144']",['42679191-e5c2-90c6-e063-6294a90a93ed'],['2267978c-72ad-9229-e063-6394a90a09d0'],['82667-800-01'],['F446C597KA'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
Revised,05/18/2023,0121-4950-40,Lidocaine Hydrochloride Solution,800-845-8210,,,08/29/2025,['Anesthesia'],Solution,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-4950-40)",PAI Pharma,,Resolved,['ANDA218138'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['PAI Holdings, LLC dba PAI Pharma']","['0121-4950', '0121-0950']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LIDOCAINE HYDROCHLORIDE'],['1010739'],['8bd8bb07-066a-4c8c-ac5b-76f746318a49'],['d5e23ede-957c-4a32-b1c6-268acb773c31'],"['0121-0950-03', '0121-4950-15', '0121-4950-40']",['V13007Z41A'],,,,,,,08/29/2025,,Available
New,05/14/2025,0832-0038-00,Oxybutynin Chloride Tablet,800-654-2299,,,05/14/2025,['Renal'],Tablet,"Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-00)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074625'],['OXYBUTYNIN CHLORIDE'],['OXYBUTYNIN CHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-0038'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXYBUTYNIN CHLORIDE'],['863664'],['2f3b30f0-e463-2de1-e063-6394a90a1b69'],['3ee6835a-7a7d-49a9-8460-2f1dd270ead3'],"['0832-0038-00', '0832-0038-50', '0832-0038-10', '0832-0038-89', '0832-0038-01']",['L9F3D9RENQ'],,,,05/14/2025,,,,,
Revised,02/22/2012,0409-4713-32,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)","Hospira, Inc., a Pfizer Company",,Current,['ANDA080408'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
New,06/13/2025,0591-5553-50,Doxycycline Hyclate Tablet,800-545-8800,,,06/13/2025,['Anti-Infective'],Tablet,"Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA062421'],['DOXYCYCLINE HYCLATE'],['DOXYCYCLINE HYCLATE'],"['Actavis Pharma, Inc.']",['0591-5553'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DOXYCYCLINE HYCLATE'],['1650143'],['0fb9a3f8-9ebb-4c21-8a73-9f082b39039c'],['a569ba80-ffea-40b2-9fbe-a42810b1fccb'],"['0591-5553-50', '0591-5553-05']",['19XTS3T51U'],,,,06/13/2025,,,,,
Revised,04/28/2023,0990-6138-22,Sodium Chloride 0.9% Irrigation,1-866-829-9025 or ProductAvailability@icumed.com,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-22)","ICU Medical, Inc.",,Resolved,['NDA017514'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-6138', '0990-7138', '0990-7972']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['ea49c260-0be5-48b8-9e97-bef5a4ca584e'],['3cfdeee0-ff14-4341-8396-b11c2a037c60'],"['0990-7138-09', '0990-7138-36', '0990-6138-22', '0990-6138-03', '0990-7972-05', '0990-7972-07']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Revised,04/02/2020,0641-6059-01,Midazolam Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA075243'],['MIDAZOLAM'],['MIDAZOLAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6059', '0641-6057', '0641-6056', '0641-6061', '0641-6063', '0641-6060']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['559c03fb-24ea-4b7b-8afd-e33cb3a2340a'],['575d8bf0-7af7-427c-a231-966e2a5e070d'],"['0641-6057-01', '0641-6057-10', '0641-6057-25', '0641-6059-01', '0641-6059-10', '0641-6056-01', '0641-6056-10', '0641-6061-01', '0641-6061-10', '0641-6061-25', '0641-6063-01', '0641-6063-10', '0641-6063-25', '0641-6060-01', '0641-6060-10']",['W7TTW573JJ'],,,,,,,,,
Reverified,12/13/2017,72205-102-01,Bumetanide Injection,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)",MSN Laboratories Private Limited,,Current,['ANDA215364'],['BUMETANIDE'],['BUMETANIDE'],['Novadoz Pharmaceuticals LLC'],"['72205-102', '72205-101']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],"['72205-101-01', '72205-101-07', '72205-102-01', '72205-102-07']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,10/12/2022,64850-505-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",888-852-6657,Limited Availability,3 months,11/04/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA211352'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Elite Laboratories, Inc.']","['64850-505', '64850-500', '64850-501', '64850-502', '64850-503', '64850-504', '64850-506']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['b65e0266-7172-4730-8f93-eb42e08fb7b8'],['e677690f-790f-4626-ad78-097cdb6ea540'],"['64850-500-01', '64850-500-05', '64850-500-30', '64850-501-01', '64850-501-05', '64850-501-30', '64850-502-01', '64850-502-05', '64850-502-30', '64850-503-01', '64850-503-05', '64850-503-30', '64850-504-01', '64850-504-05', '64850-504-30', '64850-505-01', '64850-505-05', '64850-505-30', '64850-506-01', '64850-506-05', '64850-506-30']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,10/07/2025,0074-9036-30,Paricalcitol Capsule,800-633-9110,,Discontinuation of the manufacture of the drug,10/07/2025,['Endocrinology/Metabolism'],Capsule,"Zemplar, Capsule, 1 ug (NDC 0074-9036-30)",AbbVie Inc.,,To Be Discontinued,['NDA021606'],['ZEMPLAR'],['PARICALCITOL'],['AbbVie Inc.'],"['0074-9036', '0074-4314', '0074-4317', '0074-9037']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PARICALCITOL'],"['577315', '577317', '606854', '606859']",['ed8862d9-4037-4a30-9be6-42f2613c34cd'],['1b27c026-2d60-47b4-2a9c-ded1818f21b5'],"['0074-4314-30', '0074-4317-30', '0074-4317-73', '0074-9036-30', '0074-9037-30']",['6702D36OG5'],"['M0007651', 'N0000175907', 'N0000175849']","['Vitamin D2 Analog [EPC]', 'Vitamin D Analog [EPC]']",,10/07/2025,,['Ergocalciferols [CS]'],,,
Reverified,07/18/2023,0169-4060-12,Liraglutide Injection,833-493-4689,Limited Availability,Estimated shortage duration TBD,11/04/2025,['Endocrinology/Metabolism'],Injection,"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)","Novo Nordisk, Inc.",Delay in shipping of the drug,Current,['NDA022341'],['VICTOZA'],['LIRAGLUTIDE'],['Novo Nordisk'],['0169-4060'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],"['897122', '897126']",['0d10d10e-0fe0-47ee-b9da-628e34907e98'],['5a9ef4ea-c76a-4d34-a604-27c5b505f5a4'],"['0169-4060-13', '0169-4060-12', '0169-4060-90', '0169-4060-97', '0169-4060-98', '0169-4060-99']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
Reverified,10/05/2022,65219-445-20,Etomidate Injection,800-551-7176,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi,11/04/2025,['Anesthesia'],Injection,"Etomidate, Injection, 40 mg/20 mL (NDC 65219-445-20)","Caplin Steriles, Ltd.",,Current,['ANDA215028'],['ETOMIDATE'],['ETOMIDATE'],"['Fresenius Kabi USA, LLC']","['65219-445', '65219-447']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']","['446487f1-002e-41d3-846a-67570e797171', '30488a7e-ea9e-4a27-95a9-a07149c50282']","['f38fad46-f2dd-4692-a2a9-a13d0a717bf8', 'd07efb9e-5264-461d-96d8-e11fa71c5751']","['65219-445-12', '65219-445-22', '65219-445-01', '65219-445-10', '65219-447-02', '65219-447-20']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Revised,12/22/2020,55150-393-01,Azacitidine Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",Eugia US LLC,Demand increase for the drug,Current,['ANDA215066'],['AZACITIDINE'],['AZACITIDINE'],['Eugia US LLC'],['55150-393'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['e89b9510-86df-4095-b6d3-4eb05b613c4f'],['ecd108bd-bb5f-4b2e-ad91-210fca452e9b'],['55150-393-01'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
Reverified,04/02/2020,70860-600-02,Midazolam Hydrochloride Injection,Athenex: 855-273-0154; Alvogen: 973-532-7840,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 70860-600-02)",Gland Pharma Limited,Other,Current,['ANDA090696'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Athenex Pharmaceutical Division, LLC.']",['70860-600'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],['1666798'],['12dd97c1-4ccf-a310-e063-6294a90a4316'],['401a66d1-9374-40af-acd2-73e573584da2'],"['70860-600-41', '70860-600-02']",['W7TTW573JJ'],,,,,,,,,
Reverified,04/28/2023,16729-295-12,Carboplatin Injection,"866-941-7875, option 2",Available,,11/04/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)",Accord Healthcare Inc.,,Current,['ANDA206775'],['CARBOPLATIN'],['CARBOPLATIN'],"['Accord Healthcare, Inc.']",['16729-295'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['35cf6068-f31a-211b-e063-6294a90a6b53'],['48aa7ef3-9f44-2a08-e054-00144ff88e88'],"['16729-295-31', '16729-295-33', '16729-295-34', '16729-295-12', '16729-295-38']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,10/12/2022,13107-074-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(866) 850-2876 OR CustomerService@AurobindoUSA.com,Unavailable,Estimated availability February 2026,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)",Aurobindo Pharma USA,Shortage of an active ingredient,Current,['ANDA202424'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Aurolife Pharma, LLC']","['13107-074', '13107-068', '13107-069', '13107-070', '13107-071', '13107-072', '13107-073']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['95842af2-8d9d-4eb1-ba39-86cdbd829a79'],['a582d57f-d191-4ca5-b105-585b2d8a0e3e'],"['13107-068-50', '13107-068-01', '13107-068-25', '13107-068-05', '13107-068-99', '13107-069-50', '13107-069-01', '13107-069-25', '13107-069-05', '13107-069-99', '13107-070-50', '13107-070-01', '13107-070-25', '13107-070-05', '13107-070-99', '13107-071-50', '13107-071-01', '13107-071-25', '13107-071-05', '13107-071-99', '13107-072-50', '13107-072-01', '13107-072-25', '13107-072-05', '13107-072-99', '13107-073-50', '13107-073-01', '13107-073-25', '13107-073-05', '13107-073-99', '13107-074-50', '13107-074-01', '13107-074-25', '13107-074-05', '13107-074-99']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,01/01/2012,16729-525-08,Atropine Sulfate Injection,"866-941-7875, option 2",Unavailable,30 days,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['NDA214652'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],['Accord Healthcare Inc.'],"['16729-525', '16729-526']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190795', '1666781']",['419aa7b6-eb26-8cb2-e063-6294a90ab8d3'],['d5e07279-48ca-4f83-9633-299e65a7f821'],"['16729-525-63', '16729-525-03', '16729-525-08', '16729-526-63', '16729-526-03', '16729-526-08']",['03J5ZE7KA5'],,,,,,,,,
Revised,07/14/2023,72205-137-91,"Lisdexamfetamine Dimesylate Tablet, Chewable",(855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)",Novadoz Pharmaceuticals LLC,Shortage of an active ingredient,Current,['ANDA218306'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Novadoz Pharmaceuticals LLC'],"['72205-137', '72205-132', '72205-133', '72205-134', '72205-135', '72205-136']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],"['72205-132-91', '72205-133-91', '72205-134-91', '72205-135-91', '72205-136-91', '72205-137-91']",['SJT761GEGS'],,,,,,,,,
Revised,10/31/2017,63323-851-15,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Next release January 2026. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-851', '63323-852', '63323-853', '63323-854']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '1724276', '1724338', '1724340', '1724341']",['9e8522c6-595c-46f9-bb25-272aa4683e0f'],['e034eb96-03e0-46e1-8b92-5e1f94555e7b'],"['63323-851-03', '63323-851-10', '63323-851-07', '63323-851-15', '63323-851-50', '63323-852-03', '63323-852-25', '63323-853-03', '63323-853-25', '63323-854-03', '63323-854-10']",['L960UP2KRW'],,,,,,,,,
New,12/05/2024,63304-692-05,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-05)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-692', '63304-693']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
New,06/13/2025,0480-7270-98,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-98)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077793'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals, Inc.']",['0480-7270'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],['904481'],['95e8c960-5096-43a9-8807-89cdf404a214'],['f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8'],"['0480-7270-98', '0480-7270-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
Reverified,02/20/2018,63323-464-37,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)","Fresenius Kabi USA, LLC",,Current,"['ANDA070552', 'NDA018304']",['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-464', '63323-466', '63323-462', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1724880', '1724881', '1725078', '1725175', '1724884', '1724885', '1725082', '1725177', '1672917', '1672919', '1673296', '1673298', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['b41b5dbd-7aff-4d97-ac97-f4355393ee4e', 'd3ba9fb9-63c8-4597-bb0a-cd01d31a24b6', '13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['e700eb7b-8b14-49c9-96b2-331f18776e45', 'b6bfc04a-1868-4630-9ca1-8c027af97ce3', 'dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-464-01', '63323-464-17', '63323-466-03', '63323-466-17', '63323-464-08', '63323-464-38', '63323-466-08', '63323-466-38', '63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,07/14/2023,47781-568-01,Lisdexamfetamine Dimesylate Capsule,844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)",Alvogen,,Current,['ANDA214547'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Alvogen Inc.'],"['47781-568', '47781-562', '47781-563', '47781-564', '47781-565', '47781-566', '47781-567']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['567bb281-4098-07f8-9503-92299dc1c4c6'],['7f2dd6ee-3363-c87c-9693-ed838942556c'],"['47781-562-01', '47781-563-01', '47781-564-01', '47781-565-01', '47781-566-01', '47781-567-01', '47781-568-01']",['SJT761GEGS'],,,,,,,,,
Reverified,11/21/2023,39822-5550-6,Promethazine Hydrochloride Injection,866-390-4411,Unavailable,Next lots scheduled for release February 2026.,10/23/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Other', 'Pulmonary/Allergy']",Injection,"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)","XGen Pharmaceuticals DJB, Inc.",Demand increase for the drug,Current,['ANDA040737'],['PROMETHAZINE HYDROCHLORIDE'],['PROMETHAZINE HYDROCHLORIDE'],"['XGen Pharmaceuticals DJB, Inc.']",['39822-5550'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['PROMETHAZINE HYDROCHLORIDE'],['992858'],['0e860109-725f-1c28-e063-6394a90a50ef'],['b6f6698f-f23c-452a-9b38-bbb96ab88ae4'],"['39822-5550-5', '39822-5550-6']",['R61ZEH7I1I'],,,,,,,,,
Revised,07/14/2023,57664-051-88,Lisdexamfetamine Dimesylate Capsule,800-818-4555,Limited Availability,Additional supply anticipated in Q4 2025 followed by early 2026,10/21/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['ANDA214484'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-051', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
Reverified,04/07/2020,70860-302-02,Furosemide Injection,866-625-1618,"Unavailable, Please use Sagent label",Use Sagent NDC 25021-311-02,08/26/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-02)",Sagent Pharmaceuticals,Other,Current,,,,,,,,,,,,,,,,,,,,,,
New,06/16/2025,0093-3750-28,Tobramycin Solution,800-545-8800,,Discontinuation of the manufacture of the drug,06/16/2025,['Pulmonary/Allergy'],Solution,"Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-28)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA210915'],['TOBRAMYCIN'],['TOBRAMYCIN'],"['Teva Pharmaceuticals USA, Inc.']",['0093-3750'],['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],['TOBRAMYCIN'],['1314763'],['8aa98982-a156-4bc8-8d31-9a39b88808ed'],['d03079d2-5617-4628-92b9-3caa757b22c0'],"['0093-3750-28', '0093-3750-63']",['VZ8RRZ51VK'],"['N0000175477', 'M0000946']",['Aminoglycoside Antibacterial [EPC]'],,06/16/2025,,['Aminoglycosides [CS]'],,,
New,10/09/2025,0781-2234-10,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-10)",Sandoz Inc.,,To Be Discontinued,['ANDA076515'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],['0781-2234'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],['200329'],['a7952460-51d0-4188-b3e0-ec8e81e19585'],['5a09ce48-7139-4fc7-9b6e-439459c8e866'],"['0781-2234-10', '0781-2234-01', '0781-2234-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Revised,02/20/2018,0409-9042-01,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA071165'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-9042', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,07/14/2023,65162-027-09,Lisdexamfetamine Dimesylate Capsule,866-525-7270,Unavailable,Shortage of an active ingredient,11/07/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)",Amneal Pharmaceuticals,Shortage of an active ingredient,Current,['ANDA202830'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Amneal Pharmaceuticals LLC'],"['65162-027', '65162-023', '65162-024', '65162-025', '65162-026', '65162-028']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850']",['5fde01e6-09ba-4a92-bd47-aad0d7c518e4'],['c11cb3b6-3dff-477b-a249-b4c3118edc5f'],"['65162-023-09', '65162-024-09', '65162-025-09', '65162-026-09', '65162-027-09', '65162-028-09']",['SJT761GEGS'],,,,,,,,,
Reverified,01/19/2023,62135-484-60,Quinapril Hydrochloride Tablet,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,Available,,08/19/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)",Chartwell Molecular Holdings LLC,,Current,['ANDA076803'],['QUINAPRIL'],['QUINAPRIL'],"['Chartwell RX, LLC']","['62135-484', '62135-485', '62135-486', '62135-487']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['09cd5cb9-4fdf-f133-e063-6294a90af691'],['dbc43dbd-94aa-40e2-a9ea-766110cc8687'],"['62135-484-60', '62135-485-90', '62135-486-90', '62135-487-90']",['33067B3N2M'],,,,,,,,,
Reverified,07/14/2023,64850-554-01,Lisdexamfetamine Dimesylate Capsule,888-852-6657,Limited Availability,Limited Availability,11/04/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA218604'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Elite Laboratories, Inc.']","['64850-554', '64850-550', '64850-551', '64850-552', '64850-553', '64850-555', '64850-556']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['e414bb2e-d404-44ea-931c-5998b0a4c87e'],['0e024b69-567c-4b40-9c3e-a2daec34256c'],"['64850-550-01', '64850-551-01', '64850-552-01', '64850-553-01', '64850-554-01', '64850-555-01', '64850-556-01']",['SJT761GEGS'],,,,,,,,,
Revised,04/07/2020,55150-323-25,Furosemide Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)",Eugia US LLC,,Current,['ANDA212174'],['FUROSEMIDE'],['FUROSEMIDE'],['Eugia US LLC'],"['55150-323', '55150-322', '55150-324']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['26acfb26-d058-453e-8c05-61ec44b25118'],['421aa6d5-623b-4dc2-abd5-bb9e7765bf37'],"['55150-322-01', '55150-322-25', '55150-323-01', '55150-323-25', '55150-324-01', '55150-324-25']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,01/31/2018,25021-321-10,Bumetanide Injection,866-625-1618,Available,,08/25/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)",Sagent Pharmaceuticals,,Current,['ANDA074441'],['BUMETANIDE'],['BUMETANIDE'],['Sagent Pharmaceuticals'],['25021-321'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['befc1cf3-b71c-4228-bc42-3495b1d4b00d'],['c38a404d-a919-4a2c-9fbb-d0655dee9516'],"['25021-321-04', '25021-321-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,04/22/2025,50742-406-20,Oxaliplatin Injection,866-321-5031 (Ingenus Pharmaceuticals),,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,04/22/2025,['Oncology'],Injection,"Oxaliplatin, Injection, 100 mg/20 mL (NDC 50742-406-20)",Novast Labs,,To Be Discontinued,['ANDA207562'],['OXALIPLATIN'],['OXALIPLATIN'],"['Ingenus Pharmaceuticals, LLC']","['50742-406', '50742-405']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['OXALIPLATIN'],"['1736776', '1736781']",['91b1d13f-6401-496f-a2e5-76e84775efd0'],['9613ae3d-72e2-40f7-8151-b43e915a6f1c'],"['50742-405-10', '50742-406-20']",['04ZR38536J'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,04/22/2025,,,,,
Reverified,02/20/2018,63323-468-17,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)","Fresenius Kabi USA, LLC",,Current,['ANDA070966'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-468', '63323-472', '63323-463', '63323-461']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1867594', '1867596', '1867618', '1867620', '1012377', '1012384', '1012413', '1012417', '1724786', '1724787', '1724809', '1724810']","['b671015d-f620-4930-a890-5e27a40ae42f', 'cc1f6507-eb3e-4398-a1d3-0c56a2099e6b']","['b671015d-f620-4930-a890-5e27a40ae42f', 'bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb']","['63323-468-08', '63323-468-38', '63323-472-03', '63323-472-17', '63323-472-01', '63323-472-37', '63323-463-01', '63323-463-57', '63323-461-01', '63323-461-57', '63323-468-02', '63323-468-37', '63323-468-01', '63323-468-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,07/14/2023,64850-555-01,Lisdexamfetamine Dimesylate Capsule,888-852-6657,Limited Availability,Limited Availability,11/04/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA218604'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Elite Laboratories, Inc.']","['64850-555', '64850-550', '64850-551', '64850-552', '64850-553', '64850-554', '64850-556']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['e414bb2e-d404-44ea-931c-5998b0a4c87e'],['0e024b69-567c-4b40-9c3e-a2daec34256c'],"['64850-550-01', '64850-551-01', '64850-552-01', '64850-553-01', '64850-554-01', '64850-555-01', '64850-556-01']",['SJT761GEGS'],,,,,,,,,
Reverified,02/15/2023,0409-7037-10,Rocuronium Bromide Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)","Hospira, Inc., a Pfizer Company",,Current,['ANDA205656'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],"['Hospira, Inc.']","['0409-7037', '0409-3189']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['c96726ef-f1fa-4ebb-ba33-3479c3902a8e'],['c96726ef-f1fa-4ebb-ba33-3479c3902a8e'],"['0409-3189-05', '0409-3189-10', '0409-7037-01', '0409-7037-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,07/14/2023,59417-118-01,"Lisdexamfetamine Dimesylate Tablet, Chewable",877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],"Tablet, Chewable","Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA208510'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-118', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Revised,11/01/2017,0703-0018-01,Hydromorphone Hydrochloride Injection,800-545-8800,Available,,11/06/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA078591'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Teva Parenteral Medicines, Inc.']","['0703-0018', '0703-0110', '0703-0113']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['1724338', '1724340', '1724341']",['c32108cc-7b73-4921-9f9e-54b3d60c1c6e'],['f0b78db9-a38c-41bb-8233-5e93f7f18c5c'],"['0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01']",['L960UP2KRW'],,,,,,,,,
Reverified,02/20/2018,71288-722-32,Bupivacaine Hydrochloride Injection,844-824-8426,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,08/19/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)",Kindos Pharmaceuticals Co. Ltd.,,Current,['ANDA216040'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Meitheal Pharmaceuticals Inc'],"['71288-722', '71288-721', '71288-724', '71288-725', '71288-727', '71288-728']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['b085b86e-d32f-494e-8a4a-3080ff240109'],['daec9ee4-b666-485e-a153-4b5e5acc48a1'],"['71288-721-11', '71288-722-32', '71288-724-11', '71288-725-32', '71288-727-11', '71288-728-32']",['7TQO7W3VT8'],,,,,,,,,
Revised,10/12/2022,72516-013-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",855-257-0292,Available,,10/24/2025,['Psychiatry'],Tablet,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)",Oryza Pharmaceuticals Inc.,,Current,['ANDA210293'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Oryza Pharmaceuticals Inc.'],"['72516-013', '72516-016', '72516-015', '72516-014', '72516-012', '72516-011']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['39fb17a2-617d-37dc-e063-6394a90a1be3'],['acd27181-a3f3-4c38-85d8-029a4a82e7c2'],"['72516-016-01', '72516-015-01', '72516-014-01', '72516-013-01', '72516-012-01', '72516-011-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,03/01/2022,0264-7520-20,Dextrose Monohydrate 10% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)",B. Braun Medical Inc.,,Current,['NDA019626'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],"['0264-7520', '0264-7510']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE, UNSPECIFIED FORM']","['1795477', '1795480', '1795481', '1795607', '1795610', '1795612']",['c9f87749-8dd5-41fd-b393-f63d45fd00ef'],['085614c7-ada4-4e2c-87c0-c9bc2f18365a'],"['0264-7510-00', '0264-7510-10', '0264-7510-20', '0264-7520-00', '0264-7520-10', '0264-7520-20']",['IY9XDZ35W2'],,,,,,,,,
New,06/03/2025,65862-062-99,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-99)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-062', '65862-063', '65862-064']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
Revised,12/08/2021,63323-924-10,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-10)","Fresenius Kabi USA, LLC",,Resolved,['ANDA088911'],['BACTERIOSTATIC SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-924'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],['313002'],['d83b23bf-9f14-4e45-a569-b227cbb08e88'],['e5e325d1-0d58-40c9-9645-3ae402ff9d92'],"['63323-924-01', '63323-924-10', '63323-924-03', '63323-924-30']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,44567-611-10,Midazolam Hydrochloride Injection,888-493-0861,Available,Please check wholesalers and distributors for inventory.,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)",WG Critical Care,,Current,['NDA211844'],['MIDAZOLAM IN SODIUM CHLORIDE'],['MIDAZOLAM'],"['WG Critical Care, LLC.']","['44567-611', '44567-610']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MIDAZOLAM'],"['2541170', '2541171']",['8b577103-b84e-4344-a3ff-b18b77f856cc'],['f051776f-94c5-4e34-80ed-f45b9c36881e'],"['44567-610-01', '44567-610-10', '44567-611-01', '44567-611-10']",['R60L0SM5BC'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,07/10/2025,72305-100-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 100 ug (NDC 72305-100-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-100', '72305-025', '72305-050', '72305-075', '72305-088', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,04/10/2020,70121-1388-8,Dexmedetomidine Hydrochloride Injection,866-525-7270,Available,,09/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)",Amneal Pharmaceuticals,,Current,['ANDA207551'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Amneal Pharmaceuticals LLC'],"['70121-1388', '70121-1389']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['795f643f-855c-4ba4-9bad-a96334c1a2fb'],['eb1ba463-ab42-4f49-9ebe-3ad5af108326'],"['70121-1388-1', '70121-1388-8', '70121-1389-1', '70121-1389-7']",['1018WH7F9I'],,,,,,,,,
Reverified,03/23/2018,63323-285-65,Ropivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,03/21/2023,0338-9545-50,Clindamycin Phosphate Injection,888-229-0001,Unavailable,Estimated recovery: November 2025,10/22/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)",Baxter Healthcare,Demand increase for the drug,Current,['NDA208083'],['CLINDAMYCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Baxter Healthcare Company'],"['0338-9545', '0338-9549', '0338-9553']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN PHOSPHATE'],"['309335', '309336', '309339']",['12bdbbc9-fbb0-4a0a-9147-37df8ac5dc5e'],['44fa506b-90ac-42de-831b-5f3f1a500fc0'],"['0338-9545-50', '0338-9545-24', '0338-9549-50', '0338-9549-24', '0338-9553-50', '0338-9553-24']",['EH6D7113I8'],,,,,,,,,
New,08/29/2025,82497-025-04,Methotrexate Injection,224-441-6390,,Discontinuation of the manufacture of the drug,08/29/2025,['Rheumatology'],Injection,"Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)","Assertio Specialty Pharmaceuticals, LLC",,To Be Discontinued,['NDA204824'],['OTREXUP'],['METHOTREXATE'],"['Otter Pharmaceuticals, LLC']","['82497-025', '82497-010', '82497-012', '82497-015', '82497-017', '82497-020', '82497-022']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['METHOTREXATE'],"['1441402', '1441407', '1441411', '1441413', '1441416', '1441418', '1441422', '1441424', '1747179', '1747181', '1747185', '1747187', '1747192', '1747194']",['9aaba145-f343-4498-b754-fb7c78181bd7'],['7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f'],"['82497-010-02', '82497-010-04', '82497-012-02', '82497-012-04', '82497-015-02', '82497-015-04', '82497-017-02', '82497-017-04', '82497-020-02', '82497-020-04', '82497-022-02', '82497-022-04', '82497-025-02', '82497-025-04']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,08/29/2025,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
New,01/22/2025,71093-130-03,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-03)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-130', '71093-129', '71093-131']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Revised,05/14/2024,62135-973-25,Mefloquine Hydrochloride Tablet,845-268-5000,,,08/21/2025,['Anti-Infective'],Tablet,"Mefloquine Hydrochloride, Tablet, 250 mg (NDC 62135-973-25)",Chartwell Molecular Holdings LLC,,Resolved,['ANDA076175'],['MEFLOQUINE HYDROCHLORIDE'],['MEFLOQUINE HYDROCHLORIDE'],"['Chartwell RX, LLC']",['62135-973'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEFLOQUINE HYDROCHLORIDE'],['835913'],['2732839a-191a-570f-e063-6294a90a40a4'],['b884d22b-aae7-4f14-9a04-ae4029a229f0'],"['62135-973-25', '62135-973-11']",['5Y9L3636O3'],,,,,,,08/21/2025,,Available
Reverified,10/12/2022,0185-0853-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-525-8747,Available,,11/07/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)",Sandoz Inc.,,Current,['ANDA040439'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Sandoz Inc'],"['0185-0853', '0185-0831', '0185-0842', '0185-0864', '0185-2099', '0185-2098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577961']",['d68cd1d1-3bb4-4afa-9786-687cf1766ae1'],['288dafc4-fe6e-4891-832f-511022c87445'],"['0185-0831-01', '0185-0842-01', '0185-0853-01', '0185-0864-01', '0185-2099-01', '0185-2098-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,03/10/2023,16729-138-16,Clonazepam Tablet,"866-941-7875, option 2",Available,,11/04/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)",Accord Healthcare Inc.,,Current,['ANDA077147'],['CLONAZEPAM'],['CLONAZEPAM'],['Accord Healthcare Inc.'],"['16729-138', '16729-136', '16729-137']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['0e1e7f41-f78b-27cf-e063-6394a90a1ae0'],['ebc11109-e7bf-452d-b675-4b3236d54164'],"['16729-136-00', '16729-136-16', '16729-137-00', '16729-137-16', '16729-138-00', '16729-138-16']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,06/28/2022,72078-036-05,Remifentanil Hydrochloride Injection,800-796-9526,Available,,11/06/2025,['Analgesia/Addiction'],Injection,"Ultiva, Injection, 5 mg (NDC 72078-036-05)","Mylan Institutional, a Viatris Company",,Current,['NDA020630'],['ULTIVA'],['REMIFENTANIL HYDROCHLORIDE'],['Mylan Institutional LLC'],"['72078-036', '72078-034', '72078-035']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729581', '1729584', '1729586', '1729710', '1729712']",['c10cf43f-066a-43ff-9166-242cbb7754af'],['8b4c8696-e23e-4c51-a4d2-babab5bd945a'],"['72078-034-00', '72078-034-01', '72078-035-00', '72078-035-02', '72078-036-00', '72078-036-05']",['5V444H5WIC'],,,,,,,,,
Reverified,03/12/2021,55566-2500-0,Desmopressin Acetate Spray,888-337-7464,Unavailable,,09/17/2025,['Hematology'],Spray,"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)",Ferring,Requirements related to complying with good manufacturing practices,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,03/13/2023,16729-277-30,Methotrexate Sodium Injection,"866-941-7875, option 2",Limited Availability,Resupply: estimated 30 days,11/04/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",Accord Healthcare Inc.,Shortage of an active ingredient,Current,['ANDA040716'],['METHOTREXATE'],['METHOTREXATE'],"['Accord Healthcare, Inc.']",['16729-277'],['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE'],"['1655956', '1655959', '1655960']",['2bae3cfe-7aa0-c14c-e063-6294a90a19f4'],['dd035a9f-cd40-4314-b9d8-2294b8a924e2'],"['16729-277-30', '16729-277-03', '16729-277-35']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
Revised,03/01/2017,0409-6637-14,Sodium Bicarbonate Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d,,,,
Reverified,02/28/2025,0378-8263-93,"Methylphenidate Film, Extended Release",800-796-9526,Available,,11/06/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 30mg/9hrs (NDC 0378-8263-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA206497'],['METHYLPHENIDATE'],['METHYLPHENIDATE'],['Mylan Pharmaceuticals Inc.'],"['0378-8263', '0378-8260', '0378-8261', '0378-8262']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['435703f5-35b9-4d50-a12a-89546888c61a'],['1643b6a5-80da-4d4f-8c5f-feb907875702'],"['0378-8260-16', '0378-8260-93', '0378-8261-16', '0378-8261-93', '0378-8262-16', '0378-8262-93', '0378-8263-16', '0378-8263-93']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
Reverified,03/23/2018,76045-105-20,Ketorolac Tromethamine Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)","Fresenius Kabi USA, LLC",Other,Current,['ANDA203242'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Fresenius Kabi USA, LLC']","['76045-105', '76045-104', '76045-107', '76045-209']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['KETOROLAC TROMETHAMINE'],"['860113', '860114', '860115']",['0dab642d-7fcf-4301-8ac9-10e64a040c6b'],['3d88cbe6-5230-47aa-80af-0c41283d1f00'],"['76045-104-10', '76045-105-20', '76045-107-10', '76045-209-00', '76045-209-10']",['4EVE5946BQ'],,,,,,,,,
New,11/21/2024,0173-0897-13,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 1 mg (NDC 0173-0897-13)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0897', '0173-0903', '0173-0906', '0173-0911', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Reverified,02/15/2023,67457-228-10,Rocuronium Bromide Injection,800-796-9526,Available,,11/06/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)","Mylan Institutional, a Viatris Company",,Current,['ANDA079199'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Mylan Institutional LLC'],['67457-228'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['3316cfdc-67e7-437d-9c90-1c383b53b272'],['f58803b0-f173-4997-b2f8-0f415b94dacf'],"['67457-228-00', '67457-228-05', '67457-228-99', '67457-228-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,04/10/2020,67457-251-02,Dexmedetomidine Hydrochloride Injection,800-796-9526,Available,,11/06/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)","Mylan Institutional, a Viatris Company",,Current,['ANDA202881'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],['Mylan Institutional LLC'],['67457-251'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['309710'],['7c66a6ac-0548-4555-b9d1-077feb277c37'],['ebdfe2e8-30ca-4f18-935a-41bcbbce4937'],"['67457-251-00', '67457-251-02']",['1018WH7F9I'],,,,,,,,,
Reverified,12/15/2021,0009-0274-01,Methylprednisolone Acetate Injection,844-646-4398,Available,,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)",Pfizer Inc.,,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0274', '0009-0280', '0009-0306']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358510', '1358512', '1358610', '1358612', '1358617', '1358619']",['4cf5a255-1360-4511-9b58-b92e3492ef12'],['823b0010-2b57-4e76-b5ac-4a8c2963438f'],"['0009-0274-01', '0009-0280-02', '0009-0280-51', '0009-0280-03', '0009-0280-52', '0009-0306-02', '0009-0306-12']",['43502P7F0P'],,,,,,,,,
Revised,12/10/2021,0338-0049-38,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-38)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/26/2023,43598-441-01,"Methylphenidate Hydrochloride Tablet, Extended Release",866-732-3952,Unavailable,Estimated availability TBD,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 43598-441-01)","Dr. Reddy's Laboratories, Inc.",Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,10/11/2024,0990-7953-03,Lactated Ringers Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-03)",Otsuka ICU Medical LLC,,Resolved,['NDA017641'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['ICU Medical Inc.'],"['0990-7953', '0990-7929']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']","['847627', '847630']",['179fea68-7eed-4293-b82f-24139e112240'],['d310d170-5eeb-471b-af1a-0e845001d21d'],"['0990-7929-03', '0990-7929-09', '0990-7953-02', '0990-7953-03', '0990-7953-09']","['660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT', 'M4I0D6VV5M', 'LX22YL083G']",,,,,,,10/03/2025,,Available
New,08/12/2025,23155-581-01,Desipramine Hydrochloride Tablet,855-228-9470,,Discontinuation of the manufacture of the drug,08/12/2025,['Psychiatry'],Tablet,"Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)","Avet Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA207433'],['DESIPRAMINE HYDROCHLORIDE'],['DESIPRAMINE HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],"['23155-581', '23155-578', '23155-579', '23155-580', '23155-582', '23155-583']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DESIPRAMINE HYDROCHLORIDE'],"['1099288', '1099292', '1099296', '1099300', '1099304', '1099316']",['49984729-ddde-44ed-927b-8a4ba65cefa0'],['ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0'],"['23155-578-01', '23155-579-01', '23155-580-01', '23155-581-01', '23155-582-01', '23155-583-25']",['1Y58DO4MY1'],,,,08/12/2025,,,,,
Revised,01/01/2012,0409-9630-05,Atropine Sulfate Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)","Hospira, Inc., a Pfizer Company",,Current,['NDA021146'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Hospira, Inc.']","['0409-9630', '0409-1630', '0409-4910', '0409-4911']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['9211a9e9-35d0-457d-ac95-4ad43ea6bf28'],['ad8916e7-206e-409e-2582-30d072845dd4'],"['0409-1630-15', '0409-1630-10', '0409-9630-15', '0409-9630-05', '0409-4910-11', '0409-4910-34', '0409-4911-11', '0409-4911-34']",['03J5ZE7KA5'],,,,,,,,,
New,01/15/2025,0409-1732-01,Docetaxel Injection,844-646-4398,,Discontinuation of the manufacture of the drug,01/15/2025,['Oncology'],Injection,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-1732-01)",Pfizer Inc.,,To Be Discontinued,['NDA022234'],['DOCETAXEL'],['DOCETAXEL ANHYDROUS'],"['Hospira, Inc.']","['0409-1732', '0409-7870']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOCETAXEL ANHYDROUS'],['1093280'],['5b12d54f-e7fd-4369-afb3-431f6f08ec76'],['644c5035-20d2-4686-beaa-bef08e99051c'],"['0409-7870-01', '0409-1732-01']",['699121PHCA'],"['N0000175085', 'N0000175592']",['Microtubule Inhibitor [EPC]'],['Microtubule Inhibition [PE]'],01/15/2025,,,,,
New,12/05/2024,62756-129-44,Pantoprazole Sodium Injection,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Gastroenterology'],Injection,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-44)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077674'],['PANTOPRAZOLE SODIUM'],['PANTOPRAZOLE SODIUM'],"['Sun Pharmaceutical Industries, Inc.']",['62756-129'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PANTOPRAZOLE SODIUM'],['283669'],['ef1bb9ed-b534-4698-abf5-836dcce85f45'],['d9fcf6a2-3788-4955-84d9-3c319b13267c'],"['62756-129-40', '62756-129-44', '62756-129-45']",['6871619Q5X'],,,,12/05/2024,,,,,
Reverified,11/23/2021,63323-178-76,Sterile Water Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Other'],Injection,"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)","Fresenius Kabi USA, LLC",,Current,['ANDA209689'],['STERILE WATER'],['WATER'],"['Fresenius Kabi USA, LLC']",['63323-178'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['WATER'],,['d40f0ff2-4abf-4030-b4e1-2b85ad7448a0'],['b45e9f1d-9c48-4b46-8541-d846b89540df'],['63323-178-76'],['059QF0KO0R'],,,,,,,,,
New,10/16/2025,0002-7640-01,Pemetrexed Disodium Injection,800-545-5979,,Discontinuation of the manufacture of the drug,10/16/2025,['Oncology'],Injection,"Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01)",Eli Lilly and Co.,,To Be Discontinued,['NDA021462'],['ALIMTA'],['PEMETREXED DISODIUM'],['Eli Lilly and Company'],"['0002-7640', '0002-7623']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PEMETREXED DISODIUM HEPTAHYDRATE'],"['1728072', '1728075', '1728077', '1728079']",['3af0bc84-13d6-46aa-a4c0-c62410b73bc6'],['f5a860f3-37ec-429c-ae04-9c88d7c55c08'],"['0002-7640-01', '0002-7623-01']",['9T47E4OM16'],,,,10/16/2025,,,,,
Reverified,07/14/2023,47781-563-01,Lisdexamfetamine Dimesylate Capsule,844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)",Alvogen,,Current,['ANDA214547'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Alvogen Inc.'],"['47781-563', '47781-562', '47781-564', '47781-565', '47781-566', '47781-567', '47781-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['567bb281-4098-07f8-9503-92299dc1c4c6'],['7f2dd6ee-3363-c87c-9693-ed838942556c'],"['47781-562-01', '47781-563-01', '47781-564-01', '47781-565-01', '47781-566-01', '47781-567-01', '47781-568-01']",['SJT761GEGS'],,,,,,,,,
New,03/04/2025,65862-586-01,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-586', '65862-582', '65862-583', '65862-584', '65862-585', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
Revised,12/10/2021,0409-7101-02,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-02)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA019465'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']","['0409-7101', '0409-7132']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807547', '1807631', '1807632', '1807633']",['9d75502b-257f-4a37-9a85-b98c4278c474'],['a2a964f7-c3ec-4dfb-e3a0-6d8136a80397'],"['0409-7101-68', '0409-7101-66', '0409-7101-69', '0409-7101-67', '0409-7101-04', '0409-7101-02', '0409-7132-68', '0409-7132-66', '0409-7132-69', '0409-7132-67', '0409-7132-04', '0409-7132-02']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,02/14/2022,65219-462-10,Dextrose Monohydrate 5% Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)","Fresenius Kabi USA, LLC",,Current,['ANDA207449'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['FRESENIUS KABI USA, LLC']","['65219-462', '65219-456', '65219-464', '65219-458', '65219-460']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['efc3b0c9-518a-47db-bb3e-ebdfd4646e9b'],['576a22d8-5f2f-497e-80ad-1842ca74bb53'],"['65219-456-05', '65219-456-60', '65219-464-05', '65219-464-50', '65219-458-05', '65219-458-30', '65219-460-05', '65219-460-20', '65219-462-05', '65219-462-10']",['LX22YL083G'],,,,,,,,,
New,01/17/2025,16729-108-11,Mitomycin Injection,866-941-7875,,Permanent discontinuation in the manufacturing of the drug.,01/17/2025,['Anti-Infective'],Injection,"Mitomycin, Injection, 20 mg/40 mL (NDC 16729-108-11)",Accord Healthcare Inc.,,To Be Discontinued,['ANDA064144'],['MITOMYCIN'],['MITOMYCIN'],"['Accord Healthcare, Inc.']","['16729-108', '16729-116', '16729-115']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MITOMYCIN'],"['1740894', '1740898', '1740900']",['3363b2a9-5d4f-d921-e063-6294a90a7fbb'],['ff676355-313d-4575-8f2f-e4a1e9527477'],"['16729-116-38', '16729-108-11', '16729-115-05']",['50SG953SK6'],"['N0000000236', 'N0000175558']",['Alkylating Drug [EPC]'],,01/17/2025,,,,['Alkylating Activity [MoA]'],
Revised,12/10/2021,0990-7984-13,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-13)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7984', '0990-7730', '0990-7983', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,47781-176-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)",Alvogen,,Current,['ANDA207388'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 10 MG,CLL']",['Alvogen Inc.'],"['47781-176', '47781-174', '47781-175', '47781-177', '47781-178', '47781-179', '47781-180']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['0374f0f7-9297-810c-38b3-623a72709a7d'],['c907301d-e24d-9609-5529-fed14f94549f'],"['47781-174-30', '47781-174-05', '47781-174-01', '47781-175-30', '47781-175-05', '47781-175-01', '47781-176-30', '47781-176-05', '47781-176-01', '47781-177-30', '47781-177-05', '47781-177-01', '47781-178-30', '47781-178-05', '47781-178-01', '47781-179-30', '47781-179-05', '47781-179-01', '47781-180-30', '47781-180-05', '47781-180-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,02/20/2018,55150-158-72,Lidocaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-158-72)",Eugia US LLC,Demand increase for the drug,Current,['ANDA203040'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-158', '55150-159', '55150-160']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737566', '1737568', '1737757']",['e2600451-756c-4986-9e8e-26ce1d865afd'],['5524cbfd-d6e6-42eb-aaa5-22495e0a86b6'],"['55150-158-72', '55150-159-74', '55150-160-72']",['V13007Z41A'],,,,,,,,,
Revised,04/10/2020,63323-421-02,Dexmedetomidine Hydrochloride Injection,888-386-1300,Available,Short-dated supply (6 months from expiry) available upon request. Check wholesaler for inventory.,10/21/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)","Fresenius Kabi USA, LLC",,Current,['ANDA201072'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-421'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['309710'],['56e0af34-aeb5-4b37-8c61-2e90b2c8ca6c'],['c1b8eb58-596b-481d-beb6-ba9d2237abf4'],"['63323-421-01', '63323-421-02']",['1018WH7F9I'],,,,,,,,,
New,11/03/2025,45802-580-46,Scopolamine Transdermal System,866-634-9120,,Discontinuation of the manufacture of the drug,11/03/2025,"['Gastroenterology', 'Neurology', 'Other']",Transdermal System,"Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)",Padagis US LLC,,To Be Discontinued,['ANDA078830'],['SCOPOLAMINE TRANSDERMAL SYSTEM'],['SCOPOLAMINE TRANSDERMAL SYSTEM'],['Padagis Israel Pharmaceuticals Ltd'],['45802-580'],['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['SCOPOLAMINE'],['226552'],['afd90135-c2d2-4058-8bd3-03d72f3a1534'],['cb93bfad-3e37-4a27-92f6-f21703ae7bdf'],"['45802-580-84', '45802-580-46', '45802-580-62', '45802-580-01']",['DL48G20X8X'],"['N0000175574', 'N0000175370']",['Anticholinergic [EPC]'],,11/03/2025,,,,['Cholinergic Antagonists [MoA]'],
Reverified,10/11/2024,0264-7387-50,Dextrose Monohydrate 70% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)",B. Braun Medical Inc.,,Current,['NDA019626'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],['0264-7387'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE'],['237656'],['200c4b9e-283a-4dea-b33a-9bb4936b2b99'],['8ccb10fe-75a5-440b-8cd4-b11f4e98f7b0'],['0264-7387-50'],['IY9XDZ35W2'],,,,,,,,,
Reverified,11/03/2017,0641-6039-01,Morphine Sulfate Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA018565'],['INFUMORPH 200'],['MORPHINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6039', '0641-6040']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL']",['MORPHINE SULFATE'],"['892652', '1731522', '1731998', '1731999']",['cd3674c8-d894-4dcf-8044-7a1198ed8ed9'],['db9ac9e3-d761-4a99-9f34-4946ebe8f255'],"['0641-6039-01', '0641-6040-01']",['X3P646A2J0'],,,,,,,,,
Reverified,12/18/2020,71288-115-30,Azacitidine Injection,844-824-8426,Available,,08/19/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA212128'],['AZACITIDINE'],['AZACITIDINE'],['Meitheal Pharmaceuticals Inc.'],['71288-115'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['bad343f5-0c12-47de-93e7-9b2af3670b7c'],['97b0917a-03fa-4cc4-91cf-1bed57a988c9'],['71288-115-30'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
Reverified,02/29/2024,0406-1170-01,Naltrexone Hydrochloride Tablet,800-325-8888,Available,,11/05/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-01)",SpecGx LLC,,Current,['ANDA076264'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],['SpecGx LLC'],['0406-1170'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['9ed13551-325e-4b82-a266-72fc89ed27dc'],['06ff2d5a-e62b-4fa4-bbdb-01938535bc65'],"['0406-1170-03', '0406-1170-01']",['Z6375YW9SF'],,,,,,,,,
Reverified,02/22/2012,63323-492-27,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487', '63323-493', '63323-496']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029', '1737636', '1737637', '1737640', '1737641', '1737763', '1737764']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33', 'fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74', 'd5e0d06f-ba1e-44d4-aa89-39d6c146dc23']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26', '63323-492-08', '63323-492-97', '63323-493-03', '63323-493-97', '63323-493-01', '63323-493-91', '63323-496-03', '63323-496-97']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,04/10/2020,70121-1389-1,Dexmedetomidine Hydrochloride Injection,866-525-7270,Available,,09/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)",Amneal Pharmaceuticals,,Current,['ANDA207551'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Amneal Pharmaceuticals LLC'],"['70121-1389', '70121-1388']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['795f643f-855c-4ba4-9bad-a96334c1a2fb'],['eb1ba463-ab42-4f49-9ebe-3ad5af108326'],"['70121-1388-1', '70121-1388-8', '70121-1389-1', '70121-1389-7']",['1018WH7F9I'],,,,,,,,,
Revised,02/03/2016,0409-3299-06,Sodium Acetate Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018893'],['SODIUM ACETATE'],['SODIUM ACETATE'],"['Hospira, Inc.']",['0409-3299'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE ANHYDROUS'],['237371'],"['eadea22b-c475-4596-8c15-e738af5a711d', '99255488-8958-49ab-965c-083119f5ba3c']","['abc41ed1-9512-4bea-9295-1a9ca134b6c2', 'c3be2468-45e8-4ecc-a30b-e966743a563f']","['0409-3299-15', '0409-3299-05', '0409-3299-16', '0409-3299-06', '0409-3299-45', '0409-3299-25', '0409-3299-46', '0409-3299-26']",['NVG71ZZ7P0'],,,,,,,,,
New,04/28/2025,0832-7124-15,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7124', '0832-7122', '0832-7123']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
Reverified,02/29/2024,64850-300-30,Naltrexone Hydrochloride Tablet,888-852-6657,Available,,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-30)","Elite Laboratories, Inc.",,Current,['ANDA075274'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Elite Laboratories, Inc.']",['64850-300'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['cae1ac14-ab22-42d1-8449-5e36c137b905'],['5f188bdc-2009-43aa-ad32-f06dbfac2642'],"['64850-300-30', '64850-300-01']",['Z6375YW9SF'],,,,,,,,,
Revised,04/28/2023,0338-0048-04,Sodium Chloride 0.9% Irrigation,888-229-0001,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-04)",Baxter Healthcare,,Resolved,['NDA017427'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],['0338-0048'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['123eac3f-8e50-4689-bf00-cf9407eb70ee'],['b3b4b176-41f0-4ca8-90d4-3fba5707564a'],"['0338-0048-02', '0338-0048-03', '0338-0048-04', '0338-0048-05']",['451W47IQ8X'],,,,,,,07/02/2025,,
New,10/09/2025,0781-2234-31,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-31)",Sandoz Inc.,,To Be Discontinued,['ANDA076515'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],['0781-2234'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],['200329'],['a7952460-51d0-4188-b3e0-ec8e81e19585'],['5a09ce48-7139-4fc7-9b6e-439459c8e866'],"['0781-2234-10', '0781-2234-01', '0781-2234-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Reverified,07/18/2023,71288-563-84,Liraglutide Injection,844-824-8426,Available,,08/19/2025,['Endocrinology/Metabolism'],Injection,"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA218115'],['LIRAGLUTIDE'],['LIRAGLUTIDE'],['Meitheal Pharmaceuticals Inc.'],['71288-563'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],['897122'],['31f901b4-0477-38aa-e063-6294a90ac708'],['0efc3a89-211a-4496-baab-e8265e07de2b'],"['71288-563-84', '71288-563-85']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
Reverified,03/01/2022,0338-0023-02,Dextrose Monohydrate 10% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)",Baxter Healthcare,,Current,['NDA016694'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0023', '0338-0017']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Revised,03/01/2017,0409-4916-14,Sodium Bicarbonate Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d,,,,
New,06/13/2025,59310-822-06,Fluticasone Propionate; Salmeterol Xinafoate Powder,800-545-8800,,,06/13/2025,['Pulmonary/Allergy'],Powder,"AirDuo RespiClick, Powder, 232 ug; 14 ug (NDC 59310-822-06)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA208799'],['AIRDUO RESPICLICK'],['FLUTICASONE PROPIONATE AND SALMETEROL'],"['Teva Respiratory, LLC']","['59310-822', '59310-805', '59310-812']",['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],"['FLUTICASONE PROPIONATE', 'SALMETEROL XINAFOATE']","['1918194', '1918199', '1918203', '1918205', '1918209', '1918211']",['b597bc2d-bf1e-4f9b-826a-b3e39ed56545'],['9c122b91-a11f-49ca-80bb-3eec5112db87'],"['59310-805-06', '59310-805-08', '59310-812-06', '59310-812-08', '59310-822-06', '59310-822-08']","['6EW8Q962A5', 'O2GMZ0LF5W']",,,,06/13/2025,,,,,
Reverified,01/19/2023,68180-556-09,Quinapril Hydrochloride Tablet,866-587-4617,Unavailable,,09/18/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)","Lupin Pharmaceuticals, Inc.",Requirements related to complying with good manufacturing practices,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,02/20/2018,0409-1162-02,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070584'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1162', '0409-1159', '0409-1160', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,01/19/2023,65862-162-90,Quinapril/Hydrochlorothiazide Tablet,866-850-2876,Unavailable,Discontinuation of the manufacture of the drug,10/15/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)",Aurobindo Pharma USA,Discontinuation of the manufacture of the drug,Current,['ANDA078450'],['QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE'],['QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE'],['Aurobindo Pharma Limited'],"['65862-162', '65862-161', '65862-163']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809']",['5842ecc2-874a-481b-8997-afa9d862dc5d'],['50a58159-9572-4445-9859-b392632597da'],"['65862-161-90', '65862-162-30', '65862-162-90', '65862-163-90']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],,,['Thiazides [CS]'],,,
Revised,07/14/2023,72205-133-91,"Lisdexamfetamine Dimesylate Tablet, Chewable",(855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)",Novadoz Pharmaceuticals LLC,Shortage of an active ingredient,Current,['ANDA218306'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Novadoz Pharmaceuticals LLC'],"['72205-133', '72205-132', '72205-134', '72205-135', '72205-136', '72205-137']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],"['72205-132-91', '72205-133-91', '72205-134-91', '72205-135-91', '72205-136-91', '72205-137-91']",['SJT761GEGS'],,,,,,,,,
New,06/13/2025,13668-385-30,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-30)",Torrent Pharma Inc.,,To Be Discontinued,['ANDA203580'],"['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 40/5/25 MG']","['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 40/5/25 MG']",['Torrent Pharmaceuticals Limited'],"['13668-385', '13668-397', '13668-386', '13668-383', '13668-382']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE', 'HYDROCHLOROTHIAZIDE', 'OLMESARTAN MEDOXOMIL']","['999967', '999986', '999991', '999996', '1000001']",['5bedf6c6-6b23-40e7-8c96-2cedcc682973'],['85b8f9c6-aa53-4aa1-85d6-19f823d0d252'],"['13668-397-30', '13668-397-90', '13668-397-05', '13668-386-30', '13668-386-90', '13668-386-05', '13668-385-30', '13668-385-90', '13668-385-05', '13668-383-30', '13668-383-90', '13668-383-05', '13668-382-30', '13668-382-90', '13668-382-05']","['6M97XTV3HD', '1J444QC288', '0J48LPH2TH']","['N0000000069', 'N0000175421', 'N0000175566', 'M0006414', 'N0000190114', 'N0000175359', 'N0000175419', 'M0471776']","['Dihydropyridine Calcium Channel Blocker [EPC]', 'Calcium Channel Blocker [EPC]', 'Thiazide Diuretic [EPC]']",['Increased Diuresis [PE]'],06/13/2025,,"['Dihydropyridines [CS]', 'Thiazides [CS]']",,"['Calcium Channel Antagonists [MoA]', 'Cytochrome P450 3A Inhibitors [MoA]']",
New,01/23/2025,0591-2882-01,"Verapamil Hydrochloride Capsule, Extended Release",800-545-8800,,,01/23/2025,['Cardiovascular'],"Capsule, Extended Release","Verelan, Capsule, Extended Release, 180 mg (NDC 0591-2882-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA019614'],['VERAPAMIL HYDROCHLORIDE'],['VERAPAMIL HYDROCHLORIDE'],['Teva Pharmaceuticals Inc'],"['0591-2882', '0591-2880', '0591-2884', '0591-2886']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VERAPAMIL HYDROCHLORIDE'],['897624'],['319554df-fc0d-428a-9799-a352100f1ce9'],['0742cf97-601b-4c13-a6c3-1a6a616ed292'],"['0591-2880-01', '0591-2882-01', '0591-2884-01', '0591-2886-01']",['V3888OEY5R'],,,,01/23/2025,,,,,
Revised,11/06/2017,0409-5820-01,Dopamine Hydrochloride Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018132'],['DOPAMINE HYDROCHLORIDE'],['DOPAMINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-5820', '0409-9104']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1743938', '1743941']",['a3fac375-0709-4cc0-84db-b0e5a60b7200'],['1f306ad2-3606-4525-5a8a-ce78f426c1a2'],"['0409-5820-11', '0409-5820-01', '0409-9104-21', '0409-9104-20']",['7L3E358N9L'],,,,,,,,,
New,07/17/2025,0409-1060-01,Pemetrexed Ditromethamine Injection,844-646-4398,,Discontinuation of the manufacture of the drug.,07/17/2025,['Oncology'],Injection,"Pemetrexed Ditromethamine, Injection, 100 mg Single Dose Vial (NDC 0409-1060-01)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,07/17/2025,,,,,
Revised,05/03/2022,17478-050-02,Sufentanil Citrate Injection,800-631-2174,Unavailable,Not currently manufactured,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)","Hikma Pharmaceuticals USA, Inc.",Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,10/12/2022,72516-012-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",855-257-0292,Available,,10/24/2025,['Psychiatry'],Tablet,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)",Oryza Pharmaceuticals Inc.,,Current,['ANDA210293'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Oryza Pharmaceuticals Inc.'],"['72516-012', '72516-016', '72516-015', '72516-014', '72516-013', '72516-011']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['39fb17a2-617d-37dc-e063-6394a90a1be3'],['acd27181-a3f3-4c38-85d8-029a4a82e7c2'],"['72516-016-01', '72516-015-01', '72516-014-01', '72516-013-01', '72516-012-01', '72516-011-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,07/14/2023,59417-102-10,Lisdexamfetamine Dimesylate Capsule,877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],Capsule,"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA021977'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-102', '59417-101', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Revised,01/13/2022,0409-7517-16,Dextrose Monohydrate 50% Injection,844-646-4398,Available,,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)","Hospira, Inc., a Pfizer Company",,Current,['NDA019445'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Hospira, Inc.']","['0409-7517', '0409-4902', '0409-6648', '0409-0505']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['727517', '1795514']",['0fca7d54-4d75-455b-a1d7-d25e31702264'],['4ed365da-4e62-4329-c1b9-c197ab4fb6e1'],"['0409-7517-66', '0409-7517-16', '0409-4902-64', '0409-4902-34', '0409-6648-16', '0409-6648-02', '0409-0505-15', '0409-0505-25']",['LX22YL083G'],,,,,,,,,
Revised,12/10/2021,0338-0049-02,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-02)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,07/29/2025,61570-073-01,Esterified Estrogens Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,07/29/2025,['Endocrinology/Metabolism'],Tablet,"Menest, Tablet, .625 mg (NDC 61570-073-01)",Pfizer Inc.,,To Be Discontinued,['ANDA084948'],['MENEST'],['ESTERIFIED ESTROGENS'],['Pfizer Laboratories Div Pfizer Inc'],"['61570-073', '61570-072', '61570-074', '61570-075']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ESTROGENS, ESTERIFIED']","['197666', '197667', '197668', '197669', '212039', '212232', '212373', '212464']",['78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb'],['e0141598-0bb2-4cf0-c9b8-6867b34bbb17'],"['61570-072-01', '61570-073-01', '61570-074-01', '61570-075-50']",['3ASP8Q3768'],,,,07/29/2025,,,,,
New,10/31/2025,0603-5167-21,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5167', '0603-5165', '0603-5166', '0603-5168']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
New,01/17/2025,0781-3481-92,Tigecycline Injection,800-525-8747,,,01/17/2025,['Anti-Infective'],Injection,"Tigecycline, Injection, 50 mg/10 mL (NDC 0781-3481-92)",Sandoz Inc.,,To Be Discontinued,['ANDA091620'],['TIGECYCLINE'],['TIGECYCLINE'],['Sandoz Inc'],['0781-3481'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'PARENTERAL']",['TIGECYCLINE'],['581531'],['7eeef6bf-1bb2-42d7-9ee2-1a3865b9b11c'],['50605463-2dc2-4b27-bc51-4d87bb9a8539'],"['0781-3481-70', '0781-3481-92']",['70JE2N95KR'],"['N0000175938', 'M0021223']",['Tetracycline-class Antibacterial [EPC]'],,01/17/2025,,['Tetracyclines [CS]'],,,
New,05/19/2025,62037-559-05,"Potassium Chloride Capsule, Extended Release",800-545-8800,,,05/19/2025,"['Endocrinology/Metabolism', 'Gastroenterology']","Capsule, Extended Release","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077419'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Actavis Pharma, Inc.']","['62037-559', '62037-560']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312504', '315183']",['b97da107-c56e-48ea-ba34-d3d64a5b9f46'],['ed5baaf6-270b-4dd3-b100-36030c0098fc'],"['62037-559-01', '62037-559-05', '62037-560-01', '62037-560-05', '62037-560-10', '62037-560-90']",['660YQ98I10'],,,,05/19/2025,,,,,
Reverified,07/14/2023,64850-550-01,Lisdexamfetamine Dimesylate Capsule,888-852-6657,Limited Availability,Limited Availability,11/04/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA218604'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Elite Laboratories, Inc.']","['64850-550', '64850-551', '64850-552', '64850-553', '64850-554', '64850-555', '64850-556']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['e414bb2e-d404-44ea-931c-5998b0a4c87e'],['0e024b69-567c-4b40-9c3e-a2daec34256c'],"['64850-550-01', '64850-551-01', '64850-552-01', '64850-553-01', '64850-554-01', '64850-555-01', '64850-556-01']",['SJT761GEGS'],,,,,,,,,
Revised,11/06/2017,0409-3724-32,Dobutamine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: April 2026; Estimated Recovery: June 2026,10/23/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA020201'],['DOBUTAMINE IN DEXTROSE'],['DOBUTAMINE IN DEXTROSE'],"['Hospira, Inc.']","['0409-3724', '0409-2347', '0409-2346']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],"['309985', '309986', '309987']",['2cd41f69-c1ea-44a0-9b56-b6f9d963f6a5'],['9943a961-3b50-4847-8a84-d8414ce38daa'],"['0409-2347-31', '0409-2347-32', '0409-2346-31', '0409-2346-32', '0409-3724-11', '0409-3724-32']",['0WR771DJXV'],,,,,,,12/19/2024,,
Revised,12/10/2021,79672-613-01,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, 50 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Nextgen Pharmaceuticals LLC'],['79672-613'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['3c545b9f-67e4-489d-bb60-c39c990d7dda'],['28f79c75-82d2-4912-81fc-a723b5ccf4c1'],"['79672-613-01', '79672-613-10', '79672-613-02', '79672-613-20', '79672-613-03', '79672-613-30', '79672-613-04', '79672-613-40', '79672-613-05', '79672-613-50']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,10/05/2022,0409-6695-02,Etomidate Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2025,10/23/2025,['Anesthesia'],Injection,"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018227'],['AMIDATE'],['ETOMIDATE'],"['Hospira, Inc.']",['0409-6695'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008', '1654009', '1654011']",['b59f4852-2843-4a8f-a597-306ebddb259a'],['b7ed5bf8-ba75-44dc-8f81-96b4ad5766be'],"['0409-6695-11', '0409-6695-01', '0409-6695-12', '0409-6695-02']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Revised,11/21/2023,0641-6083-25,Promethazine Hydrochloride Injection,800-631-2174,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA083312'],['PHENERGAN'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6083', '0641-6082']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992462', '992858', '992876']",['a64f0625-8d56-4994-8908-13614ca7b09f'],['6f7e47cc-f823-4336-8107-f980e3049617'],"['0641-6082-01', '0641-6082-25', '0641-6083-01', '0641-6083-25']",['R61ZEH7I1I'],,,,,,,,,
New,01/31/2018,25021-321-04,Bumetanide Injection,866-625-1618,Available,,08/25/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)",Sagent Pharmaceuticals,,Current,['ANDA074441'],['BUMETANIDE'],['BUMETANIDE'],['Sagent Pharmaceuticals'],['25021-321'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['befc1cf3-b71c-4228-bc42-3495b1d4b00d'],['c38a404d-a919-4a2c-9fbb-d0655dee9516'],"['25021-321-04', '25021-321-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,07/23/2025,0245-5316-11,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['KLOR-CON'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0245-5316', '0245-5315']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953', '628958', '832718']",['39e77e07-bdc8-28e9-e063-6394a90a120c'],['1ff53330-065c-4213-9c0c-ac498621d09d'],"['0245-5315-11', '0245-5315-15', '0245-5315-89', '0245-5315-01', '0245-5316-11', '0245-5316-15', '0245-5316-89', '0245-5316-01']",['660YQ98I10'],,,,07/23/2025,,,,,
Revised,10/12/2022,13107-068-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(866) 850-2876 or CustomerService@AurobindoUSA.com,Unavailable,Estimated availability February 2026,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)",Aurobindo Pharma USA,Shortage of an active ingredient,Current,['ANDA202424'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Aurolife Pharma, LLC']","['13107-068', '13107-069', '13107-070', '13107-071', '13107-072', '13107-073', '13107-074']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['95842af2-8d9d-4eb1-ba39-86cdbd829a79'],['a582d57f-d191-4ca5-b105-585b2d8a0e3e'],"['13107-068-50', '13107-068-01', '13107-068-25', '13107-068-05', '13107-068-99', '13107-069-50', '13107-069-01', '13107-069-25', '13107-069-05', '13107-069-99', '13107-070-50', '13107-070-01', '13107-070-25', '13107-070-05', '13107-070-99', '13107-071-50', '13107-071-01', '13107-071-25', '13107-071-05', '13107-071-99', '13107-072-50', '13107-072-01', '13107-072-25', '13107-072-05', '13107-072-99', '13107-073-50', '13107-073-01', '13107-073-25', '13107-073-05', '13107-073-99', '13107-074-50', '13107-074-01', '13107-074-25', '13107-074-05', '13107-074-99']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/22/2012,0409-3183-01,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089651'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3183', '0409-1209', '0409-3177', '0409-3178', '0409-3181', '0409-3182', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Revised,11/23/2021,63323-185-10,Sterile Water Injection,888-386-1300,Unavailable,Next release November 2025. Check wholesalers for inventory.,11/05/2025,['Other'],Injection,"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['ANDA088400'],['STERILE WATER'],['WATER'],"['Fresenius Kabi USA, LLC']",['63323-185'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['42c6c812-706a-425b-b8cb-931006e40484'],['e71c6c83-d518-496c-b2ab-efd5987e4783'],"['63323-185-07', '63323-185-10', '63323-185-09', '63323-185-50', '63323-185-08', '63323-185-20', '63323-185-04', '63323-185-05']",['059QF0KO0R'],,,,,,,,,
Revised,08/23/2024,66259-937-26,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-26)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
New,11/07/2025,0409-6637-14,Sodium Bicarbonate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,,,,,,,,,,,,,,,,11/07/2025,,,,,
New,03/03/2025,0310-6780-30,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,800-236-9933,,,03/03/2025,['Endocrinology/Metabolism'],Tablet,"Qtern, Tablet, 10 mg; 5 mg (NDC 0310-6780-30)",AstraZeneca AB,,To Be Discontinued,['NDA209091'],['QTERN'],['DAPAGLIFLOZIN AND SAXAGLIPTIN'],['AstraZeneca Pharmaceuticals LP'],"['0310-6780', '0310-6770']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['DAPAGLIFLOZIN', 'SAXAGLIPTIN HYDROCHLORIDE']","['1925498', '1925504', '2169274', '2169276']",['d675ddaa-3a40-4323-9edd-b04f13f10a03'],['423c489c-085b-4320-b892-7868ebd6dc6b'],"['0310-6780-30', '0310-6780-95', '0310-6770-30', '0310-6770-95']","['1ULL0QJ8UC', 'Z8J84YIX6L']","['N0000187059', 'N0000187058']",['Sodium-Glucose Cotransporter 2 Inhibitor [EPC]'],,03/03/2025,,,,['Sodium-Glucose Transporter 2 Inhibitors [MoA]'],
Revised,12/10/2021,76297-001-21,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-21)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['LABORATORIOS GRIFOLS SA'],['76297-001'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['ff5ef1ef-2a0d-476d-8483-ffd7cd47c635'],['eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf'],"['76297-001-12', '76297-001-11', '76297-001-22', '76297-001-21', '76297-001-32', '76297-001-31', '76297-001-02', '76297-001-01', '76297-001-42', '76297-001-41', '76297-001-52', '76297-001-51', '76297-001-62', '76297-001-61', '76297-001-72', '76297-001-71', '76297-001-82', '76297-001-81', '76297-001-92', '76297-001-91']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,12/15/2021,0009-3073-22,Methylprednisolone Acetate Injection,844-646-4398,Available,,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)",Pfizer Inc.,,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-3073', '0009-3475']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE', 'INTRA-ARTICULAR']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743781', '1743855', '1743856']","['bdefc300-8d7c-474c-9771-200628f25035', 'befd723e-d1e2-41b9-83f1-17bca0c2a941']","['bf1b104d-85cb-414d-a366-78068c82c883', '9a7b3837-e038-48bf-97e9-78ad463760dc']","['0009-3073-22', '0009-3073-23', '0009-3475-22', '0009-3475-23', '0009-3073-01', '0009-3073-03', '0009-3475-01', '0009-3475-03']",['43502P7F0P'],,,,,,,,,
Reverified,11/14/2017,63323-519-77,Heparin Sodium Injection,888-386-1300,Unavailable,Backordered. Next release December 2025. Check wholesalers for inventory.,11/05/2025,['Hematology'],Injection,"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)","Fresenius Kabi USA, LLC",Other,Current,['ANDA212441'],['HEPARIN SODIUM'],['HEPARIN SODIUM'],"['Fresenius Kabi USA, LLC']",['63323-519'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['3bbbe74a-1246-41a6-9fc3-ca0230529b40'],['25b0ba06-3274-4a3f-8c39-42d13764ecdf'],"['63323-519-02', '63323-519-77', '63323-519-01', '63323-519-10']",['ZZ45AB24CA'],,,,,,,,,
Revised,12/08/2020,0338-0644-04,Amino Acid Injection,888-229-0001,Limited Availability,Estimated recovery: November 2025,10/22/2025,['Gastroenterology'],Injection,"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)",Baxter Healthcare,Other,Current,['NDA018931'],['TRAVASOL'],"['LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE']",['Baxter Healthcare Corporation'],['0338-0644'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE HYDROCHLORIDE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['801644', '801648']",['e0279078-016d-48fd-8de1-c894422b33ff'],['8543b5be-0f43-4891-9e56-d7c39fe839b5'],"['0338-0644-03', '0338-0644-04', '0338-0644-06']","['OF5P57N2ZX', '94ZLA3W45F', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'JNJ23Q2COM', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
New,06/13/2025,13668-397-05,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-05)",Torrent Pharma Inc.,,To Be Discontinued,['ANDA203580'],"['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG']","['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 20/5/12.5 MG']",['Torrent Pharmaceuticals Limited'],"['13668-397', '13668-386', '13668-385', '13668-383', '13668-382']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE', 'HYDROCHLOROTHIAZIDE', 'OLMESARTAN MEDOXOMIL']","['999967', '999986', '999991', '999996', '1000001']",['5bedf6c6-6b23-40e7-8c96-2cedcc682973'],['85b8f9c6-aa53-4aa1-85d6-19f823d0d252'],"['13668-397-30', '13668-397-90', '13668-397-05', '13668-386-30', '13668-386-90', '13668-386-05', '13668-385-30', '13668-385-90', '13668-385-05', '13668-383-30', '13668-383-90', '13668-383-05', '13668-382-30', '13668-382-90', '13668-382-05']","['6M97XTV3HD', '1J444QC288', '0J48LPH2TH']","['N0000000069', 'N0000175421', 'N0000175566', 'M0006414', 'N0000190114', 'N0000175359', 'N0000175419', 'M0471776']","['Dihydropyridine Calcium Channel Blocker [EPC]', 'Calcium Channel Blocker [EPC]', 'Thiazide Diuretic [EPC]']",['Increased Diuresis [PE]'],06/13/2025,,"['Dihydropyridines [CS]', 'Thiazides [CS]']",,"['Calcium Channel Antagonists [MoA]', 'Cytochrome P450 3A Inhibitors [MoA]']",
Reverified,02/15/2023,25021-687-05,Rocuronium Bromide Injection,866-625-1618,Available,,08/26/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)",Sagent Pharmaceuticals,,Current,['ANDA205656'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Sagent Pharmaceuticals'],['25021-687'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['1d066c67-eac2-494a-ad10-ba7e9c60b0e9'],['01825411-be08-4402-b101-cb546291c972'],"['25021-687-05', '25021-687-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,02/20/2018,71288-726-52,Bupivacaine Hydrochloride Injection,844-824-8426,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,08/19/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)",Kindos Pharmaceuticals Co. Ltd.,,Current,['ANDA216039'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Meitheal Pharmaceuticals Inc'],"['71288-726', '71288-723']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404']",['0949c302-51ce-4fc9-8b99-1df94e693718'],['fe340f98-a0f3-446e-b281-47fd91c1e537'],"['71288-723-52', '71288-726-52']",['7TQO7W3VT8'],,,,,,,,,
Reverified,12/22/2021,68180-659-06,Rifampin Capsule,866-587-4617,Available,,09/18/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 300 mg (NDC 68180-659-06)","Lupin Pharmaceuticals, Inc.",,Current,['ANDA090034'],['RIFAMPIN'],['RIFAMPIN'],"['Lupin Pharmaceuticals, Inc.']","['68180-659', '68180-658']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['3c9f0101-dcf8-487e-985e-09c56746d3a1'],['b56004f0-f23d-47f6-80c7-39884fccbccc'],"['68180-658-06', '68180-658-01', '68180-659-06', '68180-659-07', '68180-659-01']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,03/13/2023,61703-408-41,Methotrexate Sodium Injection,844-646-4398,Available,,10/23/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)","Hospira, Inc., a Pfizer Company",,Current,['NDA011719'],['METHOTREXATE'],['METHOTREXATE'],"['Hospira, Inc.']","['61703-408', '61703-350']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS', 'SUBCUTANEOUS']",['METHOTREXATE SODIUM'],"['1655956', '1946772']","['95b8b8da-da4e-4bba-9038-3cf65f3d5c1a', '37b3e76b-ac3d-4f93-adf1-91f52f676b8a']","['0d63ba29-b692-41b4-87e8-351265c8273f', '0e30eaef-5a09-4104-8a11-c32933eadeab']","['61703-350-37', '61703-350-38', '61703-408-41', '61703-350-09', '61703-350-10', '61703-408-25']",['3IG1E710ZN'],,,,,,,,,
Revised,12/20/2023,0641-6029-25,Fentanyl Citrate Injection,800-631-2174,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6029', '0641-6024', '0641-6027', '0641-6025', '0641-6028', '0641-6026', '0641-6030', '0641-6247', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
Revised,02/20/2018,55150-250-50,Bupivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)",Eugia US LLC,,Current,['ANDA207183'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-250', '55150-167', '55150-168', '55150-169', '55150-170', '55150-171', '55150-172', '55150-249']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
Reverified,03/24/2023,0009-0013-06,Hydrocortisone Sodium Succinate Injection,844-646-4398,Available,,10/23/2025,"['Pulmonary/Allergy', 'Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Renal', 'Rheumatology']",Injection,"Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)","Hospira, Inc., a Pfizer Company",,Current,['NDA009866'],['SOLU-CORTEF'],['HYDROCORTISONE SODIUM SUCCINATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0013', '0009-0825', '0009-0011', '0009-0016', '0009-0005']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],"['105398', '238755', '1738586', '1738589', '1738590', '1738592', '1738594', '1738596']",['8512044a-4a54-4634-bb97-9e20126adc61'],['65eefd58-b166-4d71-ade6-45c8fdf86922'],"['0009-0825-01', '0009-0011-03', '0009-0011-04', '0009-0013-05', '0009-0013-06', '0009-0016-12', '0009-0005-01']",['50LQB69S1Z'],,,,,,,,,
Reverified,03/23/2018,70069-061-25,Ropivacaine Hydrochloride Injection,732-554-1019,Available,,08/19/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)","Somerset Therapeutics, LLC",,Current,['ANDA207636'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-061', '70069-062', '70069-063', '70069-064', '70069-065', '70069-066', '70069-067']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734203', '1734207', '1734475', '1734483']",['79b226f0-c08a-4f84-bf2b-ae5c60e01d67'],['ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64'],"['70069-061-01', '70069-061-25', '70069-061-10', '70069-062-01', '70069-062-25', '70069-062-10', '70069-063-01', '70069-063-25', '70069-064-01', '70069-064-10', '70069-064-25', '70069-065-01', '70069-065-25', '70069-066-01', '70069-066-25', '70069-066-10', '70069-067-01', '70069-067-25', '70069-067-10']",['V910P86109'],,,,,,,,,
New,12/05/2024,63304-692-03,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-03)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-692', '63304-693']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
Revised,03/23/2018,55150-197-20,Ropivacaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Injection, 5 mg/1 mL (NDC 55150-197-20)",Eugia US LLC,Demand increase for the drug,Current,['ANDA205612'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-197', '55150-195', '55150-196', '55150-198', '55150-199', '55150-200', '55150-201']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734207', '1734347', '1734475', '1734483']",['34725b26-d6e9-4d1b-95a0-da03764cc102'],['3763b7b6-da49-4658-b93d-28f5da24d09e'],"['55150-195-20', '55150-196-99', '55150-197-20', '55150-198-30', '55150-199-20', '55150-200-10', '55150-201-20']",['V910P86109'],,,,,,,,,
Revised,02/28/2025,0574-2430-65,"Methylphenidate Film, Extended Release",800-455-8070,Available,Available. Distributed by Padagis US LLC,10/02/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)","Noven Pharmaceuticals, Inc.",,Current,['NDA021514'],['METHYLPHENIDATE TRANSDERMAL SYSTEM'],['METHYLPHENIDATE'],['PADAGIS US LLC'],"['0574-2430', '0574-2410', '0574-2415', '0574-2420']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['b743ef45-2fc0-4086-8a02-6078e6a09eaa'],['7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb'],"['0574-2410-65', '0574-2415-65', '0574-2420-65', '0574-2430-65']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
Reverified,08/03/2022,0378-4430-01,Flurazepam Hydrochloride Capsule,1-844-874-7464,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,08/19/2025,"['Neurology', 'Other']",Capsule,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)","Rising Pharma Holdings, Inc.",Regulatory delay,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,04/28/2023,16729-295-31,Carboplatin Injection,"866-941-7875, option 2",Unavailable,Discontinuation of the manufacture of the drug,11/04/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA206775'],['CARBOPLATIN'],['CARBOPLATIN'],"['Accord Healthcare, Inc.']",['16729-295'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['35cf6068-f31a-211b-e063-6294a90a6b53'],['48aa7ef3-9f44-2a08-e054-00144ff88e88'],"['16729-295-31', '16729-295-33', '16729-295-34', '16729-295-12', '16729-295-38']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,10/31/2017,0409-1283-31,Hydromorphone Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: June 2026,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1283', '0409-1312', '0409-1380', '0409-4264', '0409-1805', '0409-2552', '0409-3356', '0409-2540', '0409-3365', '0409-1304']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1724383', '1724644', '1872271', '2675350', '897653', '897753', '897758', '1724276']","['53b6867a-0ae3-48ff-b257-9e58cc76de9c', '58ff0e68-b78f-4ebd-a91b-b53bbdefc544']","['f9ca2ef5-46d8-475a-a26e-f7c8becd6db7', 'e9c9ef18-7dfc-4322-b2fc-29b934c30f8b']","['0409-1283-17', '0409-1283-37', '0409-1312-16', '0409-1312-36', '0409-1380-11', '0409-1380-01', '0409-4264-11', '0409-4264-01', '0409-1805-10', '0409-1805-01', '0409-2552-11', '0409-2552-01', '0409-3356-11', '0409-3356-01', '0409-2540-11', '0409-2540-01', '0409-3365-11', '0409-3365-01', '0409-3365-10', '0409-1283-03', '0409-1283-31', '0409-1283-09', '0409-1283-10', '0409-1283-04', '0409-1283-05', '0409-1312-03', '0409-1312-30', '0409-1312-09', '0409-1312-10', '0409-1304-03', '0409-1304-31']",['L960UP2KRW'],,,,,,,01/02/2025,,
Revised,03/01/2017,0409-5555-01,Sodium Bicarbonate Injection,844-646-4398,Available,,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA202981'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Hospira, Inc.']",['0409-5555'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],['1868469'],"['6493c4d8-9ef7-4ec3-b373-6b3ecf5db9b0', '037c4aeb-4a95-4c37-8214-a30110b1d47f']","['0c24b592-4bc8-456f-acac-9c9525844a06', 'ea9f4498-0d43-4043-8dd1-f22537841c21']","['0409-5555-11', '0409-5555-01', '0409-5555-12', '0409-5555-02']",['8MDF5V39QO'],,,,,,,,,
Reverified,03/10/2023,16729-138-00,Clonazepam Tablet,"866-941-7875, option 2",Available,,11/04/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)",Accord Healthcare Inc.,,Current,['ANDA077147'],['CLONAZEPAM'],['CLONAZEPAM'],['Accord Healthcare Inc.'],"['16729-138', '16729-136', '16729-137']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['0e1e7f41-f78b-27cf-e063-6394a90a1ae0'],['ebc11109-e7bf-452d-b675-4b3236d54164'],"['16729-136-00', '16729-136-16', '16729-137-00', '16729-137-16', '16729-138-00', '16729-138-16']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,06/21/2018,0641-0497-25,Sodium Chloride 0.9% Injection,800-631-2174,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 0641-0497-25)","Hikma Pharmaceuticals USA, Inc.",,Resolved,['ANDA201833'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-0497', '0641-6144']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807636', '1807637']",['0950e98d-bfec-40e8-9f56-ba90e0d6e8c8'],['e5ee8caa-b6ca-45ba-98fb-8305e6282141'],"['0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,42806-343-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(718) 276-8600 ext. 3,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)","Epic Pharma, LLC",,Current,['ANDA040444'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Epic Pharma, LLC']","['42806-343', '42806-339', '42806-341', '42806-344', '42806-345']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961']",['f11301e2-3b5d-468d-b44c-45839e7e5dfb'],['1757e132-061d-4773-89ed-fdc77f69008f'],"['42806-339-01', '42806-341-01', '42806-343-01', '42806-344-01', '42806-345-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,04/07/2020,0409-6102-04,Furosemide Injection,844-646-4398,Available,,10/23/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)","Hospira, Inc., a Pfizer Company",,Current,['NDA018667'],['FUROSEMIDE'],['FUROSEMIDE'],"['Hospira, Inc.']",['0409-6102'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['c529b0df-a5cb-46ce-8131-38674ee756af', '0d4a39f2-904e-434a-9af1-83bb4febf124']","['aaced7a8-c3d7-4d66-8c07-aa407b8b3f35', '39fd32f2-6bb7-4a65-d298-e48d26bc80c7']","['0409-6102-35', '0409-6102-25', '0409-6102-36', '0409-6102-26', '0409-6102-37', '0409-6102-27', '0409-6102-19', '0409-6102-02', '0409-6102-18', '0409-6102-04', '0409-6102-20', '0409-6102-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,02/17/2015,21586-012-02,"Cefotaxime Sodium Powder, for Solution",800-881-3550,Available,,08/19/2025,"['Anti-Infective', 'Pediatric']","Powder, For Solution","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)","SteriMax, Inc.",,Current,,['CEFOTAXIME'],['CEFOTAXIME INJECTION'],['SteriMax Inc.'],"['21586-012', '21586-011']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CEFOTAXIME SODIUM'],"['1656313', '1656318']",['425c90b3-5006-427e-95f6-93ee7918fb8b'],['8efe3bd0-c43a-2bd6-e053-2a95a90a92fa'],"['21586-011-01', '21586-011-02', '21586-012-01', '21586-012-02']",['258J72S7TZ'],,,,,https://www.fda.gov/media/152896/download,,,,
New,07/10/2025,72305-150-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 150 ug (NDC 72305-150-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-150', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
New,06/24/2025,0409-2026-01,Docetaxel Injection,844-646-4398,,Discontinuation of the manufacture of the drug,06/24/2025,['Oncology'],Injection,"Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-2026-01)",Pfizer Inc.,,To Be Discontinued,['NDA022234'],['DOCETAXEL'],['DOCETAXEL ANHYDROUS'],"['Hospira, Inc.']","['0409-2026', '0409-0016']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOCETAXEL ANHYDROUS'],"['1093280', '1860619']",['8156a5f8-7002-479d-a08d-3c68f92c1396'],['00c61d11-d6b7-4618-b6f6-2592dbcc8af7'],"['0409-2026-01', '0409-0016-01']",['699121PHCA'],"['N0000175085', 'N0000175592']",['Microtubule Inhibitor [EPC]'],['Microtubule Inhibition [PE]'],06/24/2025,,,,,
Reverified,11/23/2021,0487-6105-01,Sterile Water Injection,800-443-4313,Unavailable,Product can be manufactured as requested,10/24/2025,['Other'],Injection,"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)",Nephron Pharmaceuticals Corporation,Other,Current,['ANDA211222'],['STERILE WATER'],['STERILE WATER'],['Nephron Pharmaceuticals Corporation'],['0487-6105'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['39ada97d-53b0-5144-e063-6294a90a91ba'],['bc04a883-babc-87a6-e053-2995a90a3dfd'],['0487-6105-01'],['059QF0KO0R'],,,,,,,,,
New,10/09/2025,0781-2868-10,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-10)",Sandoz Inc.,,To Be Discontinued,['ANDA075757'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],"['0781-2868', '0781-2859']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],"['198051', '199119']",['6a54ba13-eeb3-4c8c-800b-dc9aaf961c3f'],['516170d4-4913-4577-a2d2-f5c52d1e79c6'],"['0781-2859-10', '0781-2859-01', '0781-2859-92', '0781-2859-31', '0781-2868-10', '0781-2868-01', '0781-2868-92', '0781-2868-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Reverified,06/14/2018,65282-1605-1,Lidocaine Hydrochloride Injection,978-657-0889 ext. 5231,Available,,10/01/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)","Spectra Medical Devices, LLC",,Current,['ANDA208017'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['Spectra Medical Devices, LLC']",['65282-1605'],['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],['1737566'],['0e8f7cf3-12eb-12f6-e063-6294a90a5da6'],['e8ba012a-08a9-4f67-9f88-3284377e80be'],['65282-1605-1'],['EC2CNF7XFP'],,,,,,,,,
Reverified,03/10/2023,43547-406-10,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-406', '43547-407', '43547-408']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,06/21/2018,0264-5802-00,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-00)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-5802', '0264-5804']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807552', '1807634', '1807639']",['d34ea9bc-a1f9-402a-97cf-894505cee75d'],['e44c41ae-c9c8-4dd8-ba6c-cebb585378aa'],"['0264-5802-00', '0264-5802-10', '0264-5804-00']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,04/26/2023,84383-110-01,Penicillin G Benzathine Injection,Mark Cuban Cost Plus Drug Company: 682-428-8081,Available,,10/08/2025,['Anti-Infective'],Injection,"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)",Laboratorios Atral,,Current,,['LENTOCILIN'],['PENICILLIN G BENZATHIN'],"['LABORATRIOS ATRAL, S.A.']",['84383-110'],['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PENICILLIN G BENZATHINE'],"['2671687', '2684991']",['1a4e5124-618c-ce44-e063-6394a90a43e3'],['1a4e5124-618b-ce44-e063-6394a90a43e3'],['84383-110-01'],['RIT82F58GK'],,,,,https://www.accessdata.fda.gov/drugsatfda_docs/DS/Dear Healthcare Provider Letter1.pdf,,,,
Reverified,10/12/2022,0185-2098-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-525-8747,Available,,11/07/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)",Sandoz Inc.,,Current,['ANDA040439'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Sandoz Inc'],"['0185-2098', '0185-0831', '0185-0842', '0185-0853', '0185-0864', '0185-2099']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577961']",['d68cd1d1-3bb4-4afa-9786-687cf1766ae1'],['288dafc4-fe6e-4891-832f-511022c87445'],"['0185-0831-01', '0185-0842-01', '0185-0853-01', '0185-0864-01', '0185-2099-01', '0185-2098-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,03/01/2022,0264-7520-10,Dextrose Monohydrate 10% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)",B. Braun Medical Inc.,,Current,['NDA019626'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],"['0264-7520', '0264-7510']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE, UNSPECIFIED FORM']","['1795477', '1795480', '1795481', '1795607', '1795610', '1795612']",['c9f87749-8dd5-41fd-b393-f63d45fd00ef'],['085614c7-ada4-4e2c-87c0-c9bc2f18365a'],"['0264-7510-00', '0264-7510-10', '0264-7510-20', '0264-7520-00', '0264-7520-10', '0264-7520-20']",['IY9XDZ35W2'],,,,,,,,,
Reverified,02/03/2016,69784-229-10,Sodium Acetate Injection,833-251-8463,Available,,11/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 69784-229-10)",Milla Pharmaceuticals,,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,12/15/2021,25021-821-05,Methylprednisolone Acetate Injection,866-625-1618,Available,,08/26/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)",Sagent Pharmaceuticals,,Current,['ANDA201835'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Sagent Pharmaceuticals'],"['25021-821', '25021-820']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358610', '1358617']",['13e1ca54-4fc4-4e93-a52d-c9320865e3cb'],['f98314ea-a4e4-4f78-987b-3e9b45a08bb4'],"['25021-820-05', '25021-820-10', '25021-821-05']",['43502P7F0P'],,,,,,,,,
Revised,10/12/2022,57844-105-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],['ADDERALL'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['57844-105', '57844-117', '57844-110', '57844-112', '57844-115', '57844-120', '57844-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541365', '541878', '541879', '541892', '541894', '577957', '577960', '577961', '577962', '687043', '687045', '1009145', '1009147']",['79af1dc6-c7cf-41b1-a750-e9b47c2187ff'],['f22635fe-821d-4cde-aa12-419f8b53db81'],"['57844-105-01', '57844-117-01', '57844-110-01', '57844-112-01', '57844-115-01', '57844-120-01', '57844-130-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/28/2023,61703-600-05,Carboplatin Injection,844-646-4398,Available,,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA077059'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']","['61703-600', '61703-360', '61703-150', '61703-262']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5aa72c15-8033-4559-b257-373371b18958'],['47677091-fd20-49af-933c-c9dd2be21de9'],"['61703-360-18', '61703-150-05', '61703-262-05', '61703-600-05']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,11/07/2025,0409-4900-14,Sodium Bicarbonate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,,,,,,,,,,,,,,,,11/07/2025,,,,,
Reverified,10/12/2022,11534-191-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",732-382-6085 Monday to Friday 9 am to 3:45 pm,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)","Sunrise Pharmaceutical, Inc.",,Current,['ANDA209799'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['SUNRISE PHARMACEUTICAL, INC.']","['11534-191', '11534-190', '11534-192', '11534-193', '11534-194', '11534-195', '11534-196']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['86a00bec-51eb-4d73-a945-b1937970b29a'],['ac102599-3a5b-4154-899e-6ff262be7ff7'],"['11534-190-01', '11534-190-03', '11534-191-01', '11534-191-03', '11534-192-01', '11534-192-03', '11534-193-01', '11534-193-03', '11534-194-01', '11534-194-03', '11534-195-01', '11534-195-03', '11534-196-01', '11534-196-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,10/11/2024,0338-0117-04,Lactated Ringers Injection,888-229-0001,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0117-04)",Baxter Healthcare,,Resolved,['NDA016682'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE']",['Baxter Healthcare Company'],['0338-0117'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847630'],['a3c6770a-d279-4ea9-b8ed-5484be18121e'],['dad7735c-709b-40ea-ab7a-15577e24a966'],"['0338-0117-02', '0338-0117-03', '0338-0117-04']","['M4I0D6VV5M', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Reverified,10/11/2024,0990-7120-07,Dextrose Monohydrate 70% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)",Otsuka ICU Medical LLC,,Current,['NDA019893'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['ICU Medical Inc.'],['0990-7120'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],['237656'],['2221fdbf-4b3f-4296-80bc-96c446156fff'],['cdf35d11-fbc8-4f8e-85a8-33220312c0b4'],['0990-7120-07'],['LX22YL083G'],,,,,,,,,
Revised,12/10/2021,65219-472-20,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-472-20)","Fresenius Kabi USA, LLC",,Resolved,['ANDA207310'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']","['65219-472', '65219-466', '65219-468', '65219-470', '65219-474']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['4110390b-2806-4c92-b283-a90115f89114'],['037ac04d-f8f3-4bb8-993a-ac8f7683ff83'],"['65219-466-05', '65219-466-60', '65219-468-05', '65219-468-50', '65219-470-05', '65219-470-30', '65219-472-05', '65219-472-20', '65219-474-05', '65219-474-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,0409-2596-05,Midazolam Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA075293'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2596', '0409-2587']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['923cfac2-557d-40b4-9ee0-3e933685a5fc'],['affecd4d-1f78-4bbe-5a8d-86849bbdc520'],"['0409-2587-04', '0409-2587-05', '0409-2596-13', '0409-2596-03', '0409-2596-15', '0409-2596-05']",['W7TTW573JJ'],,,,,,,,,
Revised,10/11/2024,0264-7750-10,Lactated Ringers Injection,800-227-2862,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-10)",B. Braun Medical Inc.,,Resolved,['NDA019632'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['B. Braun Medical Inc.'],['0264-7750'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847630'],"['f67c6808-1eeb-4299-a0b7-694863bcad5a', 'ed789cd7-83ae-4ec1-a696-e87c1569da49']","['d3d29c8f-c326-4097-814a-7f4e08c67068', 'f6d82772-638c-4584-b9d3-8833669f5963']","['0264-7750-00', '0264-7750-10', '0264-7750-20', '0264-7750-07']","['M4I0D6VV5M', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
New,01/14/2025,60505-4553-3,Ambrisentan Tablet,Tablet,,,01/14/2025,['Cardiovascular'],Tablet,"Ambrisentan, Tablet, 10 mg (NDC 60505-4553-3)",Apotex Corp.,,To Be Discontinued,['ANDA210701'],['AMBRISENTAN'],['AMBRISENTAN'],['Apotex Corp.'],"['60505-4553', '60505-4552']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMBRISENTAN'],"['722116', '722122']",['9525d4e3-a712-40cf-a52f-9d16bc156220'],['291a782a-77e1-8a8e-e1c8-2626f305c2b7'],"['60505-4552-1', '60505-4552-0', '60505-4552-3', '60505-4553-1', '60505-4553-0', '60505-4553-3']",['HW6NV07QEC'],"['N0000175581', 'N0000175364']",['Endothelin Receptor Antagonist [EPC]'],,01/14/2025,,,,['Endothelin Receptor Antagonists [MoA]'],
Revised,12/10/2021,0338-0049-18,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-18)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,02/29/2024,51224-206-50,Naltrexone Hydrochloride Tablet,888-852-6657,Available,Marketed by Tagi Pharma; Customer service: 800-397-9228,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-50)","Elite Laboratories, Inc.",,Current,['ANDA075274'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],['TAGI Pharma Inc.'],['51224-206'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['c82a0ed4-3236-4166-90a8-f5e43e6dd883'],['60276f5c-657a-4b60-bcd0-44234903d7e0'],"['51224-206-30', '51224-206-50']",['Z6375YW9SF'],,,,,,,,,
New,07/10/2025,72305-112-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 112 ug (NDC 72305-112-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-112', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
New,04/28/2025,0832-7124-11,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7124', '0832-7122', '0832-7123']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
Revised,12/10/2021,0338-9543-04,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9543', '0338-9657', '0338-9659', '0338-9661', '0338-9663']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['6680afa2-1474-4bc3-afee-a333a042fd3f'],['958d35f0-6834-43be-a700-fa58f38b4c19'],"['0338-9543-01', '0338-9543-02', '0338-9543-03', '0338-9543-04', '0338-9543-05', '0338-9543-06', '0338-9543-12', '0338-9657-75', '0338-9659-75', '0338-9661-60', '0338-9663-60']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,12/06/2018,76329-1912-1,Morphine Sulfate Injection,800-423-4136,Available,,10/17/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)","Amphastar Pharmaceuticals, Inc.",,Current,['ANDA202861'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['International Medication Systems, Limited']",['76329-1912'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],,['99799101-d92b-485b-93ec-f2b5a2e5ca26'],['1034467f-d436-4b87-a902-c7e8885daa8a'],"['76329-1912-0', '76329-1912-1']",['X3P646A2J0'],,,,,,,,,
New,07/10/2025,72305-050-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 50 ug (NDC 72305-050-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-050', '72305-025', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,03/21/2023,72572-076-24,Clindamycin Phosphate Injection,800-525-8747,Available,Civica Label,11/07/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)",Sandoz Inc.,,Current,['ANDA201692'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],"['Civica, Inc.']","['72572-076', '72572-074']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN'],"['309335', '309336']",['e40b6e7f-1d37-4d0a-ace3-e5accc461e02'],['80217bd6-2bc4-401c-9345-22532b36a24f'],"['72572-074-01', '72572-074-24', '72572-076-01', '72572-076-24']",['3U02EL437C'],"['N0000009982', 'N0000175443', 'M0515779', 'N0000175731']",['Lincosamide Antibacterial [EPC]'],"['Decreased Sebaceous Gland Activity [PE]', 'Neuromuscular Blockade [PE]']",,,['Lincosamides [CS]'],,,
Revised,12/10/2021,0338-9151-30,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 450 mg/100 mL (NDC 0338-9151-30)",Baxter Healthcare,,Resolved,['NDA020178'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9151', '0338-9159']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632']",['39f15dfb-4e73-4959-ad9b-4ee502278b4b'],['aeaed9cb-b629-4019-88d2-a916179427de'],"['0338-9159-30', '0338-9151-30']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,05/23/2025,0093-0813-05,Nortriptyline Hydrochloride Capsule,800-545-8800,,Permanent discontinuation of specific package size/ SKU for business reasons.,05/23/2025,['Psychiatry'],Capsule,"Nortriptyline Hydrochloride, Capsule, 75 mg (NDC 0093-0813-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA074132'],['NORTRIPTYLINE HYDROCHLORIDE'],['NORTRIPTYLINE HYDROCHLORIDE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-0813', '0093-0810', '0093-0811', '0093-0812']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NORTRIPTYLINE HYDROCHLORIDE'],,['314d74dc-7394-40b9-be81-cb67b6e925a1'],['b58d473a-b19f-4d2a-b1ae-dd398d7a29e1'],"['0093-0810-01', '0093-0810-05', '0093-0811-01', '0093-0811-05', '0093-0812-01', '0093-0812-05', '0093-0813-01', '0093-0813-05']",['00FN6IH15D'],,,,05/23/2025,,,,,
Revised,01/01/2012,67457-529-20,Leucovorin Calcium Injection,800-796-9526,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium Preservative Free, Injection, 200 mg/20 mL (NDC 67457-529-20)","Mylan Institutional, a Viatris Company",,Resolved,['ANDA203800'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Mylan Institutional LLC'],"['67457-529', '67457-528', '67457-530']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803932', '1803937']",['2890b03c-dbef-4db8-8b07-c042d7765677'],['1cb701ca-2478-4268-9d69-80293965d59d'],"['67457-528-10', '67457-529-20', '67457-530-35']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,04/28/2023,0264-2101-10,Sterile Water Irrigant,800-227-2862,Available,,11/04/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",B. Braun Medical Inc.,,Current,['NDA016734'],['STERILE WATER'],['WATER'],['B. Braun Medical Inc.'],['0264-2101'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['969bdf41-6565-42fb-8ac1-8661a928cc22'],['f4284eb6-e553-46d4-90d8-efc80a90a480'],"['0264-2101-00', '0264-2101-10', '0264-2101-50', '0264-2101-70']",['059QF0KO0R'],,,,,,,,,
Revised,04/10/2020,83634-600-02,Dexmedetomidine Hydrochloride Injection,See Related Information section below for customer service information,Available,Distributed by Avenacy; Contact information: 877-283-6229,10/09/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)","Jiangsu Hengrui Pharmaceuticals Co., Ltd.",,Current,['ANDA209065'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],['Avenacy Inc.'],['83634-600'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['309710'],['3e30e931-4d42-465c-9e4b-cd3137ba5fe2'],['eee6145b-d83f-4596-92d3-733934d8a3a4'],"['83634-600-41', '83634-600-02']",['1018WH7F9I'],,,,,,,,,
New,04/23/2025,0832-1054-11,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 0832-1054-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1054', '0832-1055']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
Revised,01/24/2025,82154-0451-4,Peginterferon alfa-2a Injection,"800-506-8501, email: medinfo.us@pharmaand.com",Limited Availability,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",08/19/2025,['Antiviral'],Injection,"Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)",pharmaand GmbH (pharma&),Shortage of an active ingredient,Current,['BLA103964'],['PEGASYS'],['PEGINTERFERON ALFA-2A'],['pharmaand GmbH'],"['82154-0451', '82154-0449']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PEGINTERFERON ALFA-2A'],"['351270', '352297', '731326', '731328']",['3c18e4a2-193f-ef4e-e063-6394a90a56b2'],['d9290e5b-6d40-2318-e053-2995a90a9916'],"['82154-0449-1', '82154-0451-4']",['Q46947FE7K'],"['N0000175521', 'M0025711']",['Interferon alpha [EPC]'],,,,['Interferon-alpha [CS]'],,,
Revised,01/01/2012,71288-164-50,Leucovorin Calcium Injection,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 500 mg/50 mL (NDC 71288-164-50)",Kindos Pharmaceuticals Co. Ltd.,,Resolved,['ANDA216590'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Meitheal Pharmaceuticals Inc.'],"['71288-164', '71288-160', '71288-161', '71288-162', '71288-163']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['077a459b-e884-4452-aed3-0857a38ce26f'],['9df20901-6980-4d4e-89ec-40f3c1f91852'],"['71288-160-10', '71288-161-20', '71288-162-30', '71288-163-30', '71288-164-50']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,11/03/2023,0037-0678-96,Cromolyn Sodium Concentrate,(800) 796-9526,Available,,11/06/2025,['Pulmonary/Allergy'],Concentrate,"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)","Mylan Specialty, a Viatris Company",,Current,['NDA020479'],['GASTROCROM'],['CROMOLYN SODIUM'],['Viatris Specialty LLC'],['0037-0678'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CROMOLYN SODIUM'],"['831261', '831269']",['15aec235-80e7-4d95-b48c-bbca69b4b04d'],['00623958-a8fe-47d1-a0d2-0aa4e2f7966e'],"['0037-0678-08', '0037-0678-96']",['Q2WXR1I0PK'],,,,,,,,,
Revised,10/12/2022,57844-110-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],['ADDERALL'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['57844-110', '57844-105', '57844-117', '57844-112', '57844-115', '57844-120', '57844-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541365', '541878', '541879', '541892', '541894', '577957', '577960', '577961', '577962', '687043', '687045', '1009145', '1009147']",['79af1dc6-c7cf-41b1-a750-e9b47c2187ff'],['f22635fe-821d-4cde-aa12-419f8b53db81'],"['57844-105-01', '57844-117-01', '57844-110-01', '57844-112-01', '57844-115-01', '57844-120-01', '57844-130-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,12/18/2020,63323-771-39,Azacitidine Injection,1-888-386-1300,Available,Check wholesaler inventory,11/05/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)","Fresenius Kabi USA, LLC",,Current,['ANDA207518'],['AZACITIDINE'],['AZACITIDINE'],"['Fresenius Kabi USA, LLC']",['63323-771'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['4becda8d-8042-4cf1-bef3-c0ec3c23eebe'],['3b594aba-e798-4105-b801-0b0d970747c1'],['63323-771-39'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
Reverified,04/10/2020,67457-925-10,Dexmedetomidine Hydrochloride Injection,800-796-9526,Available,,11/06/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)","Mylan Institutional, a Viatris Company",,Current,['ANDA212571'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Mylan Institutional LLC'],"['67457-925', '67457-924']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['b51a1fb0-fcee-4a76-9eaf-91c35813c242'],['f140de5a-f13d-46b4-a742-049c63e474f5'],"['67457-924-00', '67457-924-50', '67457-925-00', '67457-925-10']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0990-7983-02,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-02)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7983', '0990-7730', '0990-7984', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,01/13/2022,0338-1055-48,Metronidazole Injection,888-229-0001,Available,,10/22/2025,['Anti-Infective'],Injection,"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)",Baxter Healthcare,,Current,['NDA018657'],['METRONIDAZOLE'],['METRONIDAZOLE'],['Baxter Healthcare Corporation'],['0338-1055'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['METRONIDAZOLE'],['311683'],['3e7d4d73-778e-4e49-bd5b-2c70c5c92488'],['d2112f37-5080-4a19-bcc3-6386b49abe1d'],['0338-1055-48'],['140QMO216E'],"['N0000175435', 'M0014907']",['Nitroimidazole Antimicrobial [EPC]'],,,,['Nitroimidazoles [CS]'],,,
Revised,03/24/2023,69097-004-67,Hydrocortisone Sodium Succinate Injection,844-247-5287,"Limited Availability, 1 to 3 months",Limited Supply Available,11/07/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Pulmonary/Allergy', 'Renal', 'Rheumatology']",Injection,"Hydrocortisone Sodium Succinate, Injection, 100 mg/ Vial (NDC 69097-004-67)",Cipla Limited,Demand increase for the drug,Current,['ANDA214050'],['HYDROCORTISONE SODIUM SUCCINATE'],['HYDROCORTISONE SODIUM SUCCINATE'],['Cipla USA Inc.'],['69097-004'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],['238755'],['44159bea-88a1-49ac-a51e-1c27dc89d9ff'],['451d6d04-b7d9-47d9-ba71-43cc5b9b3054'],['69097-004-67'],['50LQB69S1Z'],,,,,,,,,
Reverified,03/10/2023,59651-722-01,Clonazepam Tablet,866-850-2876,Available,,10/15/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)",Aurobindo Pharma USA,,Current,['ANDA075150'],['CLONAZEPAM'],['CLONAZEPAM'],['Aurobindo Pharma Limited'],"['59651-722', '59651-723', '59651-724']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['b1582eb7-af35-45d5-a52e-0e380d08527d'],['b1582eb7-af35-45d5-a52e-0e380d08527d'],"['59651-722-01', '59651-722-99', '59651-723-01', '59651-723-99', '59651-724-01', '59651-724-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,03/23/2018,62332-600-25,Ketorolac Tromethamine Injection,908-393-9604,Available,,09/17/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)",Alembic Pharmaceuticals,,Current,['ANDA214456'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Alembic Pharmaceuticals Inc.'],"['62332-600', '62332-599', '62332-601']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['9030f496-5021-4454-ac16-dbb376315608'],['419cf756-3c96-4bb8-ae96-6aea5a5f3afd'],"['62332-599-01', '62332-599-25', '62332-600-01', '62332-600-25', '62332-601-02', '62332-601-25']",['4EVE5946BQ'],,,,,,,,,
Revised,12/10/2021,0338-9543-02,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9543', '0338-9657', '0338-9659', '0338-9661', '0338-9663']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['6680afa2-1474-4bc3-afee-a333a042fd3f'],['958d35f0-6834-43be-a700-fa58f38b4c19'],"['0338-9543-01', '0338-9543-02', '0338-9543-03', '0338-9543-04', '0338-9543-05', '0338-9543-06', '0338-9543-12', '0338-9657-75', '0338-9659-75', '0338-9661-60', '0338-9663-60']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/10/2020,63323-671-00,Dexmedetomidine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['ANDA208129'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-671'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['27411591-44a1-44c4-89c3-dd8c2687f0e2'],['4d5d2294-89a0-4b6f-aa00-d39a0393b6a8'],"['63323-671-02', '63323-671-20', '63323-671-05', '63323-671-50', '63323-671-01', '63323-671-00']",['1018WH7F9I'],,,,,,,,,
Revised,09/18/2023,63323-093-30,Sodium Chloride 23.4% Injection,888-386-1300,,,07/02/2025,"['Gastroenterology', 'Endocrinology/Metabolism', 'Total Parenteral Nutrition', 'Pediatric']",Injection,"Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-093-30)","Fresenius Kabi USA, LLC",,Resolved,['ANDA212248'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-093'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],['1807571'],['570d0b0e-2f05-4b8b-af0f-ad8e7588aad9'],['4a655cde-283f-4ec8-a3d9-5f539c55c204'],"['63323-093-01', '63323-093-30']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Revised,11/03/2017,0641-6126-25,Morphine Sulfate Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA205758'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6126', '0641-6127', '0641-6125']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['1731993', '1732006', '1732011']",['fa18221d-2353-4cf6-a210-fb33ee79d3d9'],['6023606c-150c-40c5-9175-598efe2a56c3'],"['0641-6126-01', '0641-6126-25', '0641-6127-01', '0641-6127-25', '0641-6125-01', '0641-6125-25']",['X3P646A2J0'],,,,,,,,,
Revised,08/23/2024,66259-306-13,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-13)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
Reverified,03/10/2023,72888-154-05,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-154', '72888-152', '72888-153']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,06/06/2018,0641-6043-25,Ketorolac Tromethamine Injection,800-631-2174,Unavailable,Shortage recovery: TBD,10/24/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['ANDA075772'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6043', '0641-6042', '0641-6041']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['25d6c438-45d2-4162-91c2-b5caa0f86bf3'],['0c2c75c9-ed7b-46a8-9543-429bf2d8f090'],"['0641-6043-01', '0641-6043-25', '0641-6042-01', '0641-6042-25', '0641-6041-01', '0641-6041-25']",['4EVE5946BQ'],,,,,,,,,
Revised,04/28/2023,0264-7388-60,Sodium Chloride 0.9% Irrigation,800-227-2862,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-60)",B. Braun Medical Inc.,,Resolved,['NDA016733'],['SODIUM CHLORIDE FOR IRRIGATION'],['SODIUM CHLORIDE FOR IRRIGATION'],['B. Braun Medical Inc.'],['0264-7388'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['69f7d8f6-65cd-45bd-83f7-7249905a2e72'],['5bd9b176-0402-4a3f-a6b4-c3f393fc092a'],"['0264-7388-50', '0264-7388-60']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
Reverified,04/10/2020,70121-1388-1,Dexmedetomidine Hydrochloride Injection,877-835-5472,Available,,09/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)",Amneal Pharmaceuticals,,Current,['ANDA207551'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Amneal Pharmaceuticals LLC'],"['70121-1388', '70121-1389']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['795f643f-855c-4ba4-9bad-a96334c1a2fb'],['eb1ba463-ab42-4f49-9ebe-3ad5af108326'],"['70121-1388-1', '70121-1388-8', '70121-1389-1', '70121-1389-7']",['1018WH7F9I'],,,,,,,,,
Revised,01/06/2023,0013-2652-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 0.8 mg preservative free (NDC 0013-2652-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2652', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Revised,02/29/2024,47335-326-88,Naltrexone Hydrochloride Tablet,800-818-4555,Limited Availability,Additional supply anticipated early 2026,10/21/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-88)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA090356'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']",['47335-326'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['b0c2b60a-dc96-483b-933e-2fed58b64372'],['0f30f885-d0cd-4fa6-a8e0-142f08a56792'],"['47335-326-83', '47335-326-88', '47335-326-08', '47335-326-18']",['Z6375YW9SF'],,,,,,,,,
New,11/13/2024,0228-2620-11,Isosorbide Mononitrate Tablet,800-545-8800,,A business decision was made to discontinue manufacture of this product.,11/13/2024,['Cardiovascular'],Tablet,"Tablet, 20 mg (NDC 0228-2620-11)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA075037'],['ISOSORBIDE MONONITRATE'],['ISOSORBIDE MONONITRATE'],"['Actavis Pharma, Inc.']","['0228-2620', '0228-2631']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ISOSORBIDE MONONITRATE'],"['311192', '311197']",['1cb05f66-1c19-4300-8745-8c74c1dccb2b'],['ae8f74f0-e600-4452-8557-958b603e2709'],"['0228-2631-11', '0228-2620-11']",['LX1OH63030'],"['N0000175415', 'M0014874', 'N0000009909']",['Nitrate Vasodilator [EPC]'],['Vasodilation [PE]'],11/13/2024,,['Nitrates [CS]'],,,
Reverified,03/10/2023,43547-407-11,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-407', '43547-406', '43547-408']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,10/12/2022,64850-503-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",888-852-6657,Limited Availability,3 months,11/04/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA211352'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Elite Laboratories, Inc.']","['64850-503', '64850-500', '64850-501', '64850-502', '64850-504', '64850-505', '64850-506']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['b65e0266-7172-4730-8f93-eb42e08fb7b8'],['e677690f-790f-4626-ad78-097cdb6ea540'],"['64850-500-01', '64850-500-05', '64850-500-30', '64850-501-01', '64850-501-05', '64850-501-30', '64850-502-01', '64850-502-05', '64850-502-30', '64850-503-01', '64850-503-05', '64850-503-30', '64850-504-01', '64850-504-05', '64850-504-30', '64850-505-01', '64850-505-05', '64850-505-30', '64850-506-01', '64850-506-05', '64850-506-30']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/20/2018,0409-1560-10,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1560', '0409-1559', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,11/06/2017,0409-2347-32,Dobutamine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: April 2026; Estimated Recovery: June 2026,10/23/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA020201'],['DOBUTAMINE IN DEXTROSE'],['DOBUTAMINE IN DEXTROSE'],"['Hospira, Inc.']","['0409-2347', '0409-2346', '0409-3724']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],"['309985', '309986', '309987']",['2cd41f69-c1ea-44a0-9b56-b6f9d963f6a5'],['9943a961-3b50-4847-8a84-d8414ce38daa'],"['0409-2347-31', '0409-2347-32', '0409-2346-31', '0409-2346-32', '0409-3724-11', '0409-3724-32']",['0WR771DJXV'],,,,,,,12/19/2024,,
Reverified,12/13/2017,72205-102-07,Bumetanide Injection,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)",MSN Laboratories Private Limited,,Current,['ANDA215364'],['BUMETANIDE'],['BUMETANIDE'],['Novadoz Pharmaceuticals LLC'],"['72205-102', '72205-101']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],"['72205-101-01', '72205-101-07', '72205-102-01', '72205-102-07']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/23/2018,70069-064-10,Ropivacaine Hydrochloride Injection,732-554-1019,Available,,08/19/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)","Somerset Therapeutics, LLC",,Current,['ANDA207636'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-064', '70069-061', '70069-062', '70069-063', '70069-065', '70069-066', '70069-067']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734203', '1734207', '1734475', '1734483']",['79b226f0-c08a-4f84-bf2b-ae5c60e01d67'],['ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64'],"['70069-061-01', '70069-061-25', '70069-061-10', '70069-062-01', '70069-062-25', '70069-062-10', '70069-063-01', '70069-063-25', '70069-064-01', '70069-064-10', '70069-064-25', '70069-065-01', '70069-065-25', '70069-066-01', '70069-066-25', '70069-066-10', '70069-067-01', '70069-067-25', '70069-067-10']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,0378-6856-77,Lisdexamfetamine Dimesylate Capsule,800-796-9526,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA202835'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Mylan Pharmaceuticals Inc.'],"['0378-6856', '0378-6854', '0378-6855', '0378-6857', '0378-6858', '0378-6859', '0378-6860']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['63cd6f7c-f976-440e-a35f-e71a9f2fd1bb'],['efbde0f6-b848-4664-b741-c6c630e66108'],"['0378-6854-77', '0378-6855-77', '0378-6856-77', '0378-6857-77', '0378-6858-77', '0378-6859-77', '0378-6860-77']",['SJT761GEGS'],,,,,,,,,
New,03/04/2025,65862-583-01,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-583', '65862-582', '65862-584', '65862-585', '65862-586', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
Reverified,06/13/2018,0143-9594-25,Lidocaine Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA084625'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9594', '0143-9595']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737566', '1737761']",['94a2c3cf-9d57-4185-884d-e52af6c139c8'],['1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1'],"['0143-9595-01', '0143-9595-25', '0143-9594-01', '0143-9594-25']",['V13007Z41A'],,,,,,,,,
New,01/13/2025,0069-1235-30,Talazoparib Tosylate Capsule,800-533-4535,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0454-30",01/13/2025,['Oncology'],Capsule,"Talzenna, Capsule, .35 mg (NDC 0069-1235-30)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/13/2025,,,,,
Reverified,02/14/2022,0338-0551-18,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)",Baxter Healthcare,,Current,['NDA020179'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Company'],['0338-0551'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795616']",['e702be26-651e-4d4a-9d79-4df9f53821c9'],['7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e'],"['0338-0551-11', '0338-0551-18']",['LX22YL083G'],,,,,,,,,
New,12/09/2024,62756-200-83,Tiagabine Hydrochloride Tablet,800-818-4555,,Discontinuing for business reasons,12/09/2024,['Neurology'],Tablet,"Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-83)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077555'],['TIAGABINE HYDROCHLORIDE'],['TIAGABINE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['62756-200', '62756-224']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TIAGABINE HYDROCHLORIDE'],"['1299911', '1299917']",['57975e74-e45b-4fd9-9718-bfc9690acae5'],['7eeb2d81-c5d7-46a0-aa5c-149b55df71bd'],"['62756-200-83', '62756-200-18', '62756-224-83', '62756-224-88', '62756-224-08', '62756-224-18']",['DQH6T6D8OY'],,,,12/09/2024,,,,,
New,02/28/2025,0187-5101-02,Pimecrolimus Cream,908-927-1400,,Authorized generics is still marketed and available under NDC 68682-111-02,02/28/2025,['Dermatology'],Cream,"Elidel, Cream, 60gm (NDC 0187-5101-02)","Bausch Health Americas, Inc.",,To Be Discontinued,['NDA021302'],['ELIDEL'],['PIMECROLIMUS'],"['Bausch Health US, LLC']","['0187-5101', '0187-5102', '0187-5100', '0187-5103']",['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['PIMECROLIMUS'],"['352085', '562806']",['2f802a3f-c021-45c1-8693-5689c30c3fc6'],['e4027e5a-0f9b-4070-b196-f60172f45c4c'],"['0187-5102-03', '0187-5101-02', '0187-5100-01', '0187-5103-04']",['7KYV510875'],"['N0000175457', 'N0000175458']",['Calcineurin Inhibitor Immunosuppressant [EPC]'],,02/28/2025,,,,['Calcineurin Inhibitors [MoA]'],
Reverified,02/22/2012,63323-484-57,Lidocaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA006488'],['XYLOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-484', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,02/08/2019,67457-420-10,Dexamethasone Sodium Phosphate Injection,800-796-9526,Available,,11/06/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)","Mylan Institutional, a Viatris Company",,Current,['ANDA040802'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Mylan Institutional LLC'],"['67457-420', '67457-423', '67457-422', '67457-421']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1116927', '1812194']",['dd5c82b6-a194-462c-9626-34a9b410cfea'],['dff598e8-e662-411f-978d-4ba3fb8ef7db'],"['67457-423-00', '67457-423-12', '67457-422-00', '67457-422-54', '67457-421-00', '67457-421-30', '67457-420-00', '67457-420-10']",['AI9376Y64P'],,,,,,,,,
Revised,02/20/2018,55150-161-02,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)",Eugia US LLC,,Current,['ANDA203082'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-161', '55150-162', '55150-163', '55150-164', '55150-165']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737562', '1737566', '1737568', '1737757', '1737761']","['9916b09d-a116-469d-92d5-60e50ea9782b', '9b60bc92-6093-49f9-a6ba-075104ff7bb5']","['9916b09d-a116-469d-92d5-60e50ea9782b', '89701fac-7536-4f16-87fb-f4cc121e74ee']","['55150-161-09', '55150-162-09', '55150-163-00', '55150-164-09', '55150-165-09', '55150-161-02', '55150-162-05', '55150-163-30', '55150-164-02', '55150-165-05']",['V13007Z41A'],,,,,,,,,
New,04/23/2025,0832-1054-15,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 0832-1054-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1054', '0832-1055']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
New,03/04/2025,65862-585-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-05)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-585', '65862-582', '65862-583', '65862-584', '65862-586', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
New,02/26/2025,58151-104-93,"Tolterodine Tartrate Capsule, Extended Release",800-796-9526,,,02/26/2025,['Urology'],"Capsule, Extended Release","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA021228'],['DETROL LA'],['TOLTERODINE TARTRATE'],['Viatris Specialty LLC'],"['58151-104', '58151-103']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOLTERODINE TARTRATE'],"['855182', '855184', '855189', '855191']",['a1e49744-9302-47ee-92af-8b19aa0b2fc1'],['d7274947-4f88-47ee-a39f-bd5ac46fcf8d'],"['58151-103-93', '58151-103-77', '58151-103-05', '58151-104-93', '58151-104-77', '58151-104-05']",['5T619TQR3R'],,,,02/26/2025,,,,,
Reverified,01/19/2023,62135-487-90,Quinapril Hydrochloride Tablet,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,Available,,08/19/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA076803'],['QUINAPRIL'],['QUINAPRIL'],"['Chartwell RX, LLC']","['62135-487', '62135-484', '62135-485', '62135-486']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['09cd5cb9-4fdf-f133-e063-6294a90af691'],['dbc43dbd-94aa-40e2-a9ea-766110cc8687'],"['62135-484-60', '62135-485-90', '62135-486-90', '62135-487-90']",['33067B3N2M'],,,,,,,,,
New,01/28/2025,64380-789-32,Lidocaine Ointment,877-244-9825,,,01/28/2025,['Anesthesia'],Ointment,"Lidocaine, Ointment, 5%, 35.44 gram tubes (NDC 64380-789-32)",Strides Pharma Inc.,,To Be Discontinued,['ANDA210958'],['LIDOCAINE'],['LIDOCAINE'],['Strides Pharma Science Limited'],['64380-789'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['LIDOCAINE'],['1543069'],['e6c9429c-13b9-4932-abad-e605c4c7fb68'],['8b1efeaa-31b1-4f34-960f-7a920ac07355'],"['64380-789-32', '64380-789-23', '64380-789-33']",['98PI200987'],"['N0000175682', 'M0000897', 'N0000175426', 'N0000175976']","['Amide Local Anesthetic [EPC]', 'Antiarrhythmic [EPC]']",['Local Anesthesia [PE]'],01/28/2025,,['Amides [CS]'],,,
Reverified,04/10/2020,43598-976-58,Dexmedetomidine Hydrochloride Injection,Distributed by DRL,Available,Distributed by DRL,09/29/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)",Gland Pharma Limited,,Current,['ANDA209307'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"[""Dr.Reddy's Laboratories Inc""]","['43598-976', '43598-975']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['5785a11f-7784-4ae0-8029-f50b782eaf4a'],['d174c19d-56f1-4ef4-087c-23c26db8e40b'],"['43598-976-11', '43598-976-58', '43598-975-11', '43598-975-58']",['1018WH7F9I'],,,,,,,,,
Revised,02/22/2012,0409-4275-01,Lidocaine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA088325'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
New,01/27/2025,60505-6096-0,Bendamustine Hydrochloride Injection,800-706-5575,,Discontinuation of the manufacture of the drug,01/27/2025,['Oncology'],Injection,"Bendamustine Hydrochloride, Injection, 100 mg (NDC 60505-6096-0)",Apotex Corp.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/27/2025,,,,,
Reverified,01/13/2022,76329-3302-1,Dextrose Monohydrate 50% Injection,800-423-4136,Available,,10/17/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)","Amphastar Pharmaceuticals, Inc.",,Current,['ANDA203451'],['DEXTROSE MONOHYDRATE'],['DEXTROSE MONOHYDRATE'],"['International Medication Systems, Limited']",['76329-3302'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],['727517'],['45b366a9-6c0c-4643-9951-4ff880b29c83'],['fcc7ac79-cd70-4f03-a4de-f051f9ca1f7d'],['76329-3302-1'],['LX22YL083G'],,,,,,,,,
Reverified,05/04/2021,59137-570-01,Triamcinolone Hexacetonide Injection,1-855-336-3322 Option 9,Unavailable,,09/17/2025,['Rheumatology'],Injection,"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)",Medexus,Delay in shipping of the drug,Current,,['HEXATRIONE 2%'],['TRIAMCINOLONE HEXACETONIDE'],"['Medexus Pharma, Inc.']",['59137-570'],['HUMAN PRESCRIPTION DRUG'],['INTRA-ARTICULAR'],['TRIAMCINOLONE HEXACETONIDE'],"['2539176', '2539181']",['f1eb64e8-05c0-931b-e053-2995a90a2fe8'],['bc07ae9f-8a74-6bc8-e053-2995a90afc0d'],['59137-570-01'],['I7GT1U99Y9'],,,,,https://www.fda.gov/media/154709/download,,,,
New,10/01/2025,0071-0530-23,Quinapril Hydrochloride Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,10/01/2025,['Cardiovascular'],Tablet,"Accupril, Tablet, 10 mg (NDC 0071-0530-23)",Pfizer Inc.,,To Be Discontinued,['NDA019885'],['ACCUPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Parke-Davis Div of Pfizer Inc'],"['0071-0530', '0071-0527', '0071-0532', '0071-0535', '0071-1205', '0071-1410', '0071-1620', '0071-1840']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['207891', '207892', '207893', '207895', '312748', '312749', '312750', '314203']",['ee20d3b1-a5c8-4510-a931-3872df7b77f4'],['63cf5651-d52c-4d27-9fd4-ed9cd9724dff'],"['0071-0527-23', '0071-0530-23', '0071-0530-40', '0071-0532-23', '0071-0532-40', '0071-0535-23', '0071-1205-23', '0071-1410-23', '0071-1620-23', '0071-1840-23']",['33067B3N2M'],,,,10/01/2025,,,,,
Reverified,11/01/2023,60505-4741-1,Lisdexamfetamine Dimesylate Capsule,800-706-5575,Available,Product currently available,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)",Apotex Corp.,,Current,['ANDA216944'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Apotex Corp.'],"['60505-4741', '60505-4739', '60505-4740', '60505-4742', '60505-4743', '60505-4744', '60505-4745']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7a3783a0-bb54-a95b-99f4-9d3aa9788649'],['ecad4442-a644-18e3-6ff2-fdbac45eec47'],"['60505-4739-1', '60505-4740-1', '60505-4741-1', '60505-4742-1', '60505-4743-1', '60505-4744-1', '60505-4745-1']",['SJT761GEGS'],,,,,,,,,
Reverified,04/10/2020,0409-1660-50,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1660', '0409-1638', '0409-1434', '0409-1596', '0409-7838', '0409-7853', '0409-7875']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['284397', '309710', '1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['231f50fe-2c91-44b9-946e-33b836c07b94'],['548a88c0-afda-427e-75ac-5af0cfa2224c'],"['0409-1660-55', '0409-1660-50', '0409-1660-35', '0409-1660-10', '0409-1660-22', '0409-1660-20', '0409-1638-32', '0409-1638-02', '0409-1434-01', '0409-1596-01', '0409-1596-10', '0409-7838-01', '0409-7838-24', '0409-7853-01', '0409-7853-24', '0409-7875-01', '0409-7875-12']",['1018WH7F9I'],,,,,,,,,
Revised,10/12/2022,13107-072-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(866) 850-2876 OR CustomerService@AurobindoUSA.com,Unavailable,Estimated availability February 2026,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)",Aurobindo Pharma USA,Shortage of an active ingredient,Current,['ANDA202424'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Aurolife Pharma, LLC']","['13107-072', '13107-068', '13107-069', '13107-070', '13107-071', '13107-073', '13107-074']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['95842af2-8d9d-4eb1-ba39-86cdbd829a79'],['a582d57f-d191-4ca5-b105-585b2d8a0e3e'],"['13107-068-50', '13107-068-01', '13107-068-25', '13107-068-05', '13107-068-99', '13107-069-50', '13107-069-01', '13107-069-25', '13107-069-05', '13107-069-99', '13107-070-50', '13107-070-01', '13107-070-25', '13107-070-05', '13107-070-99', '13107-071-50', '13107-071-01', '13107-071-25', '13107-071-05', '13107-071-99', '13107-072-50', '13107-072-01', '13107-072-25', '13107-072-05', '13107-072-99', '13107-073-50', '13107-073-01', '13107-073-25', '13107-073-05', '13107-073-99', '13107-074-50', '13107-074-01', '13107-074-25', '13107-074-05', '13107-074-99']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,11/03/2023,42571-132-52,Cromolyn Sodium Concentrate,(908) 484-7410,Available,,11/04/2025,['Pulmonary/Allergy'],Concentrate,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)",Micro Labs LTD,,Current,['ANDA202745'],['CROMOLYN SODIUM'],['CROMOLYN SODIUM'],['Micro Labs Limited'],['42571-132'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CROMOLYN SODIUM'],['831261'],['22ffea9c-cd39-22dd-e063-6394a90aae4b'],['93f80edb-3b38-423e-8cd6-5b5cb4393ec2'],"['42571-132-21', '42571-132-52']",['Q2WXR1I0PK'],,,,,,,,,
Revised,04/07/2020,0409-6102-02,Furosemide Injection,844-646-4398,Available,,10/23/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)","Hospira, Inc., a Pfizer Company",,Current,['NDA018667'],['FUROSEMIDE'],['FUROSEMIDE'],"['Hospira, Inc.']",['0409-6102'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['c529b0df-a5cb-46ce-8131-38674ee756af', '0d4a39f2-904e-434a-9af1-83bb4febf124']","['aaced7a8-c3d7-4d66-8c07-aa407b8b3f35', '39fd32f2-6bb7-4a65-d298-e48d26bc80c7']","['0409-6102-35', '0409-6102-25', '0409-6102-36', '0409-6102-26', '0409-6102-37', '0409-6102-27', '0409-6102-19', '0409-6102-02', '0409-6102-18', '0409-6102-04', '0409-6102-20', '0409-6102-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,04/28/2023,63323-172-60,Carboplatin Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Oncology'],Injection,"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)","Fresenius Kabi USA, LLC",,Current,['ANDA077266'],['CARBOPLATIN'],['CARBOPLATIN'],"['Fresenius Kabi USA, LLC']",['63323-172'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['3a1dd588-13b0-4d58-8d46-3a25a4fc6b40'],['b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6'],['63323-172-60'],['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,12/08/2021,0409-1966-07,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-07)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018800'],['BACTERIOSTATIC SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']",['0409-1966'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],['313002'],['2d3125e0-c89b-46d5-a350-07d1e7936ebd'],['376093e7-e09e-4a57-3199-195e45251866'],"['0409-1966-02', '0409-1966-07', '0409-1966-06', '0409-1966-12', '0409-1966-01', '0409-1966-05']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,0406-8891-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-325-8888,Available,,11/05/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)",SpecGx LLC,,Current,['ANDA040440'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['SpecGx LLC'],"['0406-8891', '0406-8884', '0406-8892', '0406-8885', '0406-8893', '0406-8894']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['b25a2f3f-ee3a-44c0-a475-f371025c767b'],['72ddd1c9-ddbd-4c95-acd9-003189a353a3'],"['0406-8891-01', '0406-8884-01', '0406-8892-01', '0406-8885-01', '0406-8893-01', '0406-8894-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,01/06/2025,45963-568-30,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-30)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA202968'],['EZETIMIBE AND SIMVASTATIN'],['EZETIMIBE AND SIMVASTATIN'],"['Actavis Pharma, Inc.']","['45963-568', '45963-565', '45963-566', '45963-567']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['EZETIMIBE', 'SIMVASTATIN']","['476345', '476349', '476350', '476351']",['bd64aee1-c95f-4767-8d31-af93dd0ab692'],['00680bea-d2fb-4362-ba67-e866b732e9ed'],"['45963-565-30', '45963-565-08', '45963-566-30', '45963-566-08', '45963-567-30', '45963-567-08', '45963-568-30', '45963-568-08']","['AGG2FN16EV', 'EOR26LQQ24']","['N0000175589', 'N0000000121', 'N0000008553', 'N0000175911']","['HMG-CoA Reductase Inhibitor [EPC]', 'Dietary Cholesterol Absorption Inhibitor [EPC]']",['Decreased Cholesterol Absorption [PE]'],01/06/2025,,,,['Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]'],
Revised,12/08/2023,72888-125-26,Lidocaine Hydrochloride Solution,Daliya.Bharati@advagenpharma.com,,,08/29/2025,['Anesthesia'],Solution,"Lidocaine Hydrochloride, Solution, 20 mg/1 mL (NDC 72888-125-26)",Rubicon Research Private Limited,,Resolved,['ANDA216780'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Advagen Pharma Ltd'],['72888-125'],['HUMAN PRESCRIPTION DRUG'],"['ORAL', 'TOPICAL']",['LIDOCAINE HYDROCHLORIDE'],['1010739'],['314135bb-9f25-3673-e063-6294a90ae8c2'],['ae40021b-8df8-4b16-aac0-dcec88f76c7d'],['72888-125-26'],['V13007Z41A'],,,,,,,08/29/2025,,Available
Revised,02/20/2018,0409-9043-01,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA071167'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-9043', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,12/19/2024,,
Reverified,02/22/2012,0409-3182-03,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089646'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3182', '0409-1209', '0409-3177', '0409-3178', '0409-3181', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Reverified,02/20/2018,63323-464-31,Bupivacaine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,"['ANDA070552', 'NDA018304']",['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-464', '63323-466', '63323-462', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1724880', '1724881', '1725078', '1725175', '1724884', '1724885', '1725082', '1725177', '1672917', '1672919', '1673296', '1673298', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['b41b5dbd-7aff-4d97-ac97-f4355393ee4e', 'd3ba9fb9-63c8-4597-bb0a-cd01d31a24b6', '13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['e700eb7b-8b14-49c9-96b2-331f18776e45', 'b6bfc04a-1868-4630-9ca1-8c027af97ce3', 'dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-464-01', '63323-464-17', '63323-466-03', '63323-466-17', '63323-464-08', '63323-464-38', '63323-466-08', '63323-466-38', '63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,03/27/2018,25021-671-82,Ropivacaine Hydrochloride Injection,Sagent: 866-625-1618,Available,Marketed by Sagent Pharmaceuticals,08/26/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)",InfoRLife SA,,Current,['ANDA206166'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Sagent Pharmaceuticals'],"['25021-671', '25021-652']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734347', '1734355', '1734479', '1734481']","['04d1b1c6-1963-4b42-8479-dbf787b6de17', '2eb59cb8-dab8-43f4-ad73-672446e104ca']","['8c5c762f-d266-4b1a-809e-f11bfc89bc2d', '9572b3de-684c-4028-a577-5aa69ba6b02d']","['25021-671-82', '25021-671-87', '25021-652-82', '25021-652-87', '25021-671-66', '25021-671-67']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,43547-603-10,Lisdexamfetamine Dimesylate Capsule,866-931-9829,Limited Availability,On allocation,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA216266'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE CAPSULES'],"['Solco Healthcare US,LLC']","['43547-603', '43547-602', '43547-604', '43547-605', '43547-606', '43547-607', '43547-608']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7bb11568-67a4-4221-bb9b-23af37a1791c'],['68b10d9f-ca3e-493d-a309-45f1d7e08061'],"['43547-602-10', '43547-603-10', '43547-604-10', '43547-605-10', '43547-606-10', '43547-607-10', '43547-608-10']",['SJT761GEGS'],,,,,,,,,
Reverified,02/14/2022,0338-0017-18,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Reverified,07/14/2023,47781-566-01,Lisdexamfetamine Dimesylate Capsule,844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)",Alvogen,,Current,['ANDA214547'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Alvogen Inc.'],"['47781-566', '47781-562', '47781-563', '47781-564', '47781-565', '47781-567', '47781-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['567bb281-4098-07f8-9503-92299dc1c4c6'],['7f2dd6ee-3363-c87c-9693-ed838942556c'],"['47781-562-01', '47781-563-01', '47781-564-01', '47781-565-01', '47781-566-01', '47781-567-01', '47781-568-01']",['SJT761GEGS'],,,,,,,,,
New,05/14/2025,0245-0036-42,Cholestyramine Powder,800-654-2299,,A business decision was made to discontinue the product.,05/14/2025,['Cardiovascular'],Powder,"Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-42)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA073263'],['PREVALITE'],['CHOLESTYRAMINE'],"['Upsher-Smith Laboratories, LLC']",['0245-0036'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CHOLESTYRAMINE'],"['848951', '1801279']",['39e73fd2-1ad0-aae8-e063-6294a90acd5a'],['dd434ef8-8af3-434c-a0a0-9a0b18459ba0'],"['0245-0036-89', '0245-0036-42', '0245-0036-60', '0245-0036-23']",['4B33BGI082'],"['N0000180292', 'N0000175365']",['Bile Acid Sequestrant [EPC]'],,05/14/2025,,,,['Bile-acid Binding Activity [MoA]'],
New,06/13/2025,13668-385-05,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-05)",Torrent Pharma Inc.,,To Be Discontinued,['ANDA203580'],"['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 40/5/25 MG']","['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 40/5/25 MG']",['Torrent Pharmaceuticals Limited'],"['13668-385', '13668-397', '13668-386', '13668-383', '13668-382']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE', 'HYDROCHLOROTHIAZIDE', 'OLMESARTAN MEDOXOMIL']","['999967', '999986', '999991', '999996', '1000001']",['5bedf6c6-6b23-40e7-8c96-2cedcc682973'],['85b8f9c6-aa53-4aa1-85d6-19f823d0d252'],"['13668-397-30', '13668-397-90', '13668-397-05', '13668-386-30', '13668-386-90', '13668-386-05', '13668-385-30', '13668-385-90', '13668-385-05', '13668-383-30', '13668-383-90', '13668-383-05', '13668-382-30', '13668-382-90', '13668-382-05']","['6M97XTV3HD', '1J444QC288', '0J48LPH2TH']","['N0000000069', 'N0000175421', 'N0000175566', 'M0006414', 'N0000190114', 'N0000175359', 'N0000175419', 'M0471776']","['Dihydropyridine Calcium Channel Blocker [EPC]', 'Calcium Channel Blocker [EPC]', 'Thiazide Diuretic [EPC]']",['Increased Diuresis [PE]'],06/13/2025,,"['Dihydropyridines [CS]', 'Thiazides [CS]']",,"['Calcium Channel Antagonists [MoA]', 'Cytochrome P450 3A Inhibitors [MoA]']",
New,02/05/2025,0591-4920-05,Amantadine Hydrochloride Capsule,800-545-8800,,A business decision was made to discontinue manufacture of the drug.,02/05/2025,"['Antiviral', 'Neurology']",Capsule,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA208096'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']",['0591-4920'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849395'],['67ce5a52-d507-4333-b0a0-b7177f896aec'],['d9c9eaf7-dcc7-49c1-99d4-49f4dac3779f'],"['0591-4920-01', '0591-4920-05']",['M6Q1EO9TD0'],,,,02/05/2025,,,,,
Reverified,07/24/2017,63323-089-50,Sodium Bicarbonate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)","Fresenius Kabi USA, LLC",,Current,['ANDA206688'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Fresenius Kabi USA, LLC']","['63323-089', '63323-083']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],,['9def795c-abcf-483c-8b1d-e4374666efb2'],['0ab55004-bb63-436d-ad77-cd3796905370'],"['63323-083-03', '63323-083-05', '63323-089-25', '63323-089-50']",['8MDF5V39QO'],,,,,,,,,
Revised,07/14/2023,0480-3566-01,Lisdexamfetamine Dimesylate Capsule,800-545-8800,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA202802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Teva Pharmaceuticals, Inc.']","['0480-3566', '0480-3565', '0480-3567', '0480-3568', '0480-3569', '0480-3570', '0480-3564']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['6cfe6c98-51b1-45a4-831c-33624ab129cb'],['c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc'],"['0480-3565-01', '0480-3566-01', '0480-3567-01', '0480-3568-01', '0480-3569-01', '0480-3570-01', '0480-3564-01']",['SJT761GEGS'],,,,,,,,,
Revised,12/15/2022,0002-1433-80,Dulaglutide Injection,800-545-5979,,,06/13/2025,['Endocrinology/Metabolism'],Injection,"Trulicity, Injection, .75 mg/.5 mL (NDC 0002-1433-80)",Eli Lilly and Co.,,Resolved,['BLA125469'],['TRULICITY'],['DULAGLUTIDE'],['Eli Lilly and Company'],"['0002-1433', '0002-1434', '0002-2236', '0002-3182']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['DULAGLUTIDE'],"['1551295', '1551300', '1551304', '1551306', '2395777', '2395779', '2395783', '2395785']",['2a046089-7cd3-43d3-9f7f-27e3e4b49f0d'],['463050bd-2b1c-40f5-b3c3-0a04bb433309'],"['0002-1433-01', '0002-1433-80', '0002-1433-61', '0002-1434-01', '0002-1434-80', '0002-1434-61', '0002-2236-01', '0002-2236-80', '0002-2236-61', '0002-3182-01', '0002-3182-80', '0002-3182-61']",['WTT295HSY5'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],06/13/2025,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],Available
Reverified,07/14/2023,65162-025-09,Lisdexamfetamine Dimesylate Capsule,866-525-7270,Unavailable,Shortage of an active ingredient,11/07/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)",Amneal Pharmaceuticals,Shortage of an active ingredient,Current,['ANDA202830'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Amneal Pharmaceuticals LLC'],"['65162-025', '65162-023', '65162-024', '65162-026', '65162-027', '65162-028']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850']",['5fde01e6-09ba-4a92-bd47-aad0d7c518e4'],['c11cb3b6-3dff-477b-a249-b4c3118edc5f'],"['65162-023-09', '65162-024-09', '65162-025-09', '65162-026-09', '65162-027-09', '65162-028-09']",['SJT761GEGS'],,,,,,,,,
New,12/05/2024,63304-693-62,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-62)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-693', '63304-692']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
Revised,12/20/2023,0641-6028-25,Fentanyl Citrate Injection,800-631-2174,Available,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6028', '0641-6024', '0641-6027', '0641-6025', '0641-6026', '0641-6029', '0641-6030', '0641-6247', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
Reverified,02/20/2018,63323-468-37,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)","Fresenius Kabi USA, LLC",,Current,['ANDA070966'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-468', '63323-472', '63323-463', '63323-461']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1867594', '1867596', '1867618', '1867620', '1012377', '1012384', '1012413', '1012417', '1724786', '1724787', '1724809', '1724810']","['b671015d-f620-4930-a890-5e27a40ae42f', 'cc1f6507-eb3e-4398-a1d3-0c56a2099e6b']","['b671015d-f620-4930-a890-5e27a40ae42f', 'bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb']","['63323-468-08', '63323-468-38', '63323-472-03', '63323-472-17', '63323-472-01', '63323-472-37', '63323-463-01', '63323-463-57', '63323-461-01', '63323-461-57', '63323-468-02', '63323-468-37', '63323-468-01', '63323-468-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,06/21/2018,0409-4888-12,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-12)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018803'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']","['0409-4888', '0409-1918']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807628', '1807631', '1807637', '1807638']",['9ee88abb-024a-4a3b-9776-1777eaf2f760'],['8eb172da-dcd4-4660-4a8f-ad44a14b4af7'],"['0409-4888-02', '0409-4888-10', '0409-4888-03', '0409-4888-20', '0409-4888-06', '0409-4888-50', '0409-4888-01', '0409-4888-12', '0409-4888-90', '0409-1918-42', '0409-1918-32', '0409-1918-43', '0409-1918-33', '0409-1918-45', '0409-1918-35']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,05/03/2018,0409-1985-30,Lorazepam Injection,844-646-4398,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,10/23/2025,['Neurology'],Injection,"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA074243'],['LORAZEPAM'],['LORAZEPAM'],"['Hospira, Inc.']","['0409-1985', '0409-1539']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['763028', '763029']",['e90a536c-421f-4774-8f88-013e18a8163e'],['20140b19-846b-425f-b191-670e17809945'],"['0409-1539-03', '0409-1539-31', '0409-1985-03', '0409-1985-30']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,10/05/2022,65219-447-20,Etomidate Injection,800-551-7176,Available,Check wholesalers for inventory; Marketed by Fresenius Kabi 800-551-7176,11/04/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/mL (NDC 65219-447-20)","Caplin Steriles, Ltd.",,Current,['ANDA215028'],['ETOMIDATE'],['ETOMIDATE'],"['Fresenius Kabi USA, LLC']","['65219-447', '65219-445']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['30488a7e-ea9e-4a27-95a9-a07149c50282'],['d07efb9e-5264-461d-96d8-e11fa71c5751'],"['65219-445-01', '65219-445-10', '65219-447-02', '65219-447-20']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Revised,12/15/2021,0009-3475-03,Methylprednisolone Acetate Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: June 2026,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)",Pfizer Inc.,Other,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-3475', '0009-3073']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743781', '1743855', '1743856']",['befd723e-d1e2-41b9-83f1-17bca0c2a941'],['9a7b3837-e038-48bf-97e9-78ad463760dc'],"['0009-3073-01', '0009-3073-03', '0009-3475-01', '0009-3475-03']",['43502P7F0P'],,,,,,,,,
Reverified,02/14/2022,0264-7510-20,Dextrose Monohydrate 5% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)",B. Braun Medical Inc.,,Current,['NDA019626'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],"['0264-7510', '0264-7520']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE, UNSPECIFIED FORM']","['1795477', '1795480', '1795481', '1795607', '1795610', '1795612']",['c9f87749-8dd5-41fd-b393-f63d45fd00ef'],['085614c7-ada4-4e2c-87c0-c9bc2f18365a'],"['0264-7510-00', '0264-7510-10', '0264-7510-20', '0264-7520-00', '0264-7520-10', '0264-7520-20']",['IY9XDZ35W2'],,,,,,,,,
Revised,08/23/2024,66259-903-14,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-14)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
Reverified,04/10/2020,42023-146-25,Dexmedetomidine Hydrochloride Injection,800-828-9393,Available,Please check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)","Par Pharmaceutical, Inc.",,Current,['ANDA203972'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['ENDO USA, Inc.']","['42023-146', '42023-186', '42023-187']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['309710', '1718906', '1718909']",['d518b2d2-b39c-47ac-b45f-8c6a045a8dae'],['1ee59985-4c1d-48f7-b8f9-5584c2d55e08'],"['42023-146-25', '42023-186-20', '42023-187-10']",['1018WH7F9I'],,,,,,,,,
New,09/08/2025,66993-082-69,Sumatriptan Nasal Spray,866-525-0688,,"This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.",09/08/2025,['Neurology'],Nasal Spray,"Imitrex, Nasal Spray, 20 mg/100 uL (NDC 66993-082-69)",Prasco Laboratories,,To Be Discontinued,['NDA020626'],['SUMATRIPTAN'],['SUMATRIPTAN'],['Prasco Laboratories'],"['66993-082', '66993-081']",['HUMAN PRESCRIPTION DRUG'],['NASAL'],['SUMATRIPTAN'],"['313159', '314227']",['b15509b9-4a5b-46ed-be80-b5f6e6e79444'],['f63e616b-ae0c-432b-badc-8c45023aa725'],"['66993-081-69', '66993-082-69']",['8R78F6L9VO'],"['N0000175763', 'N0000175764', 'N0000175765']",['Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]'],,09/08/2025,,,,"['Serotonin 1b Receptor Agonists [MoA]', 'Serotonin 1d Receptor Agonists [MoA]']",
New,01/06/2025,0597-0575-40,Adalimumab-adbm Injection,800-243-0127,,,01/06/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0575-40)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['ADALIMUMAB-ADBM'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0575', '0597-0595', '0597-0555', '0597-0585', '0597-0545', '0597-0565']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640891', '2640893', '2640895', '2640900', '2640902', '2680743', '2680748', '2680756', '2680759']",['d6ed9087-bc5c-4c0e-843b-90b0400b0ed1'],['62f39a7c-00df-4519-a8d4-39bbd0a649ed'],"['0597-0595-20', '0597-0590-26', '0597-0555-80', '0597-0550-06', '0597-0585-89', '0597-0580-37', '0597-0545-22', '0597-0545-44', '0597-0545-66', '0597-0540-10', '0597-0575-50', '0597-0575-40', '0597-0575-60', '0597-0570-32', '0597-0565-20', '0597-0560-12']",,,,,01/06/2025,,,,,
New,04/07/2025,10147-0921-3,Haloperidol Decanoate Injection,800-526-7736,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 5/31/2025,04/07/2025,['Psychiatry'],Injection,"Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 10147-0921-3)",Janssen Pharmaceuticals,,To Be Discontinued,['NDA018701'],['HALOPERIDOL DECANOATE'],['HALOPERIDOL DECANOATE'],['Patriot Pharmaceuticals LLC'],"['10147-0921', '10147-0922']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['HALOPERIDOL DECANOATE'],"['1719803', '1719862']",['2e815b50-b5db-72e4-e063-6294a90afd55'],['9f0f42a8-5f7c-4be7-93ef-3ec225502cc6'],"['10147-0921-3', '10147-0922-5']",['AC20PJ4101'],,,,04/07/2025,,,,,
New,08/29/2025,82497-020-04,Methotrexate Injection,224-441-6390,,Discontinuation of the manufacture of the drug,08/29/2025,['Rheumatology'],Injection,"Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)","Assertio Specialty Pharmaceuticals, LLC",,To Be Discontinued,['NDA204824'],['OTREXUP'],['METHOTREXATE'],"['Otter Pharmaceuticals, LLC']","['82497-020', '82497-010', '82497-012', '82497-015', '82497-017', '82497-022', '82497-025']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['METHOTREXATE'],"['1441402', '1441407', '1441411', '1441413', '1441416', '1441418', '1441422', '1441424', '1747179', '1747181', '1747185', '1747187', '1747192', '1747194']",['9aaba145-f343-4498-b754-fb7c78181bd7'],['7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f'],"['82497-010-02', '82497-010-04', '82497-012-02', '82497-012-04', '82497-015-02', '82497-015-04', '82497-017-02', '82497-017-04', '82497-020-02', '82497-020-04', '82497-022-02', '82497-022-04', '82497-025-02', '82497-025-04']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,08/29/2025,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
New,11/21/2024,0173-0911-56,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-56)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0911', '0173-0897', '0173-0903', '0173-0906', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Reverified,11/14/2017,0264-9872-00,Heparin Sodium Injection,800-227-2862,Available,,11/04/2025,['Hematology'],Injection,"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)",B. Braun Medical Inc.,,Current,['NDA019953'],['HEPARIN SODIUM IN SODIUM CHLORIDE'],['HEPARIN SODIUM IN SODIUM CHLORIDE'],['B. Braun Medical Inc.'],['0264-9872'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['48e17807-e73d-4ea2-81bc-901355903aa7'],['a3041c04-0ea8-4d36-81ce-c5091c906316'],"['0264-9872-10', '0264-9872-00']",['ZZ45AB24CA'],,,,,,,,,
Revised,03/21/2023,0338-9549-50,Clindamycin Phosphate Injection,888-229-0001,Unavailable,Estimated recovery: November 2025,10/22/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)",Baxter Healthcare,Other,Current,['NDA208083'],['CLINDAMYCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Baxter Healthcare Company'],"['0338-9549', '0338-9545', '0338-9553']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN PHOSPHATE'],"['309335', '309336', '309339']",['12bdbbc9-fbb0-4a0a-9147-37df8ac5dc5e'],['44fa506b-90ac-42de-831b-5f3f1a500fc0'],"['0338-9545-50', '0338-9545-24', '0338-9549-50', '0338-9549-24', '0338-9553-50', '0338-9553-24']",['EH6D7113I8'],,,,,,,,,
Revised,12/10/2021,0990-7984-23,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-23)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7984', '0990-7730', '0990-7983', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,02/28/2025,68968-5553-3,"Methylphenidate Film, Extended Release",800-455-8070,Unavailable,Estimated availability TBD,10/02/2025,['Psychiatry'],"Film, Extended Release","Daytrana, Film, Extended Release, 15 mg (NDC 68968-5553-3)","Noven Pharmaceuticals, Inc.",Shortage of an active ingredient,Current,['NDA021514'],['DAYTRANA'],['METHYLPHENIDATE'],"['Noven Therapeutics, LLC']","['68968-5553', '68968-5552', '68968-5554', '68968-5555']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443']",['55f4b5f4-6d3c-4677-a94c-d47ffb59a91a'],['2c312c31-3198-4775-91ab-294e0b4b9e7f'],"['68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
Reverified,01/01/2012,0409-9094-61,Fentanyl Citrate Injection,844-646-4398,Available,,10/23/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)","Hospira, Inc., a Pfizer Company",,Current,['NDA019115'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Hospira, Inc.']","['0409-9094', '0409-9093']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735004', '1735006', '1735007', '1735008', '1735013']",['e4b31fdd-00af-416d-b14e-dbac0c83da97'],['bfa8018a-4cbc-434b-e09e-782872b0340a'],"['0409-9093-37', '0409-9093-32', '0409-9093-45', '0409-9093-35', '0409-9093-41', '0409-9093-36', '0409-9093-31', '0409-9093-38', '0409-9094-12', '0409-9094-22', '0409-9094-18', '0409-9094-25', '0409-9094-17', '0409-9094-28', '0409-9094-16', '0409-9094-31', '0409-9094-41', '0409-9094-61']",['MUN5LYG46H'],,,,,,,,,
Revised,07/26/2023,62037-727-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-545-8800,Limited Availability,Estimated availability: November 2025,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 54 mg (NDC 62037-727-01)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA076655'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['62037-727', '62037-725', '62037-734', '62037-726']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['89caac38-0ada-4326-8b3e-65f0d23cbb1b'],['85ef422d-af27-4126-9841-6892af1871d6'],"['62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01']",['4B3SC438HI'],,,,,,,,,
Reverified,04/10/2020,0338-9555-24,Dexmedetomidine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)",Baxter Healthcare,,Current,['ANDA208532'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Baxter Healthcare Company'],"['0338-9555', '0338-9557']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['34598b0d-5824-4586-b19c-5189a626c27a'],['8ccb45a7-8290-469c-9644-a4dca967d88f'],"['0338-9555-24', '0338-9557-12']",['1018WH7F9I'],,,,,,,,,
New,03/24/2025,0472-0337-30,Hydrocortisone Cream,800-545-8800,,A business decision was made to discontinue.,03/24/2025,['Dermatology'],Cream,"Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-30)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA089682'],['HYDROCORTISONE'],['HYDROCORTISONE'],"['Actavis Pharma, Inc.']",['0472-0337'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['HYDROCORTISONE'],['310891'],['527a8d09-450b-4b8e-ad19-78fbba9732c5'],['a5f16c13-2a51-4541-bf9e-d80bc01a8dbd'],"['0472-0337-20', '0472-0337-30']",['WI4X0X7BPJ'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,03/24/2025,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
Revised,03/12/2021,60505-0815-0,Desmopressin Acetate Spray,800-706-5575,Limited Availability,Next replenishment expected January 2026,11/05/2025,['Hematology'],Spray,"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)",Apotex Corp.,Delay in shipping of the drug,Current,['ANDA076703'],['DESMOPRESSIN ACETATE'],['DESMOPRESSIN ACETATE'],['Apotex Corp.'],['60505-0815'],['HUMAN PRESCRIPTION DRUG'],['NASAL'],['DESMOPRESSIN ACETATE'],['849506'],['f90935bd-bb23-2f9c-3271-8508e92d45c4'],['1ac423b8-27a6-4cef-4a82-c50bf81b4f49'],['60505-0815-0'],['XB13HYU18U'],,,,,,,,,
Revised,04/28/2023,0990-7138-09,Sodium Chloride 0.9% Irrigation,1-866-829-9025 or ProductAvailability@icumed.com,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-09)","ICU Medical, Inc.",,Resolved,['NDA017514'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7138', '0990-6138', '0990-7972']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['ea49c260-0be5-48b8-9e97-bef5a4ca584e'],['3cfdeee0-ff14-4341-8396-b11c2a037c60'],"['0990-7138-09', '0990-7138-36', '0990-6138-22', '0990-6138-03', '0990-7972-05', '0990-7972-07']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
New,06/03/2025,65862-063-99,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-99)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-063', '65862-062', '65862-064']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
Revised,04/07/2020,0409-6102-27,Furosemide Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA018667'],['FUROSEMIDE'],['FUROSEMIDE'],"['Hospira, Inc.']",['0409-6102'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['c529b0df-a5cb-46ce-8131-38674ee756af', '0d4a39f2-904e-434a-9af1-83bb4febf124']","['aaced7a8-c3d7-4d66-8c07-aa407b8b3f35', '39fd32f2-6bb7-4a65-d298-e48d26bc80c7']","['0409-6102-35', '0409-6102-25', '0409-6102-36', '0409-6102-26', '0409-6102-37', '0409-6102-27', '0409-6102-19', '0409-6102-02', '0409-6102-18', '0409-6102-04', '0409-6102-20', '0409-6102-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,12/15/2021,70121-1574-1,Methylprednisolone Acetate Injection,866-525-7270,Available,"Currently product is under backorder as per current demand. 
Next supply: week of 11/24/2025",11/07/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)",Amneal Pharmaceuticals,Other,Current,['ANDA210043'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Amneal Pharmaceuticals LLC'],"['70121-1574', '70121-1573']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743855']",['0bdaa3cf-cf32-4959-b87a-65215ac4648d'],['d944240d-2c19-46ba-ad4f-3fbee7b8629c'],"['70121-1573-1', '70121-1573-5', '70121-1574-1', '70121-1574-5']",['43502P7F0P'],,,,,,,,,
Revised,04/10/2020,0409-2815-01,Dexmedetomidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2025,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)",Pfizer Inc.,Demand increase for the drug,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2815', '0409-1454', '0409-3301', '0409-1174']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['8d48de06-361f-418b-bfec-8ef85f94d5bc'],['4419162d-81d4-49bd-96de-1729440bdb74'],"['0409-1454-01', '0409-1454-20', '0409-3301-01', '0409-3301-10', '0409-1174-01', '0409-1174-10', '0409-2815-01']",['1018WH7F9I'],,,,,,,,,
New,03/05/2025,67457-366-10,Ibutilide Fumarate Injection,888-282-0125,,,03/05/2025,['Cardiovascular'],Injection,"Ibutilide Fumarate, Injection, .1 mg/1 mL (NDC 67457-366-10)",Norvium Bioscience LLC,,To Be Discontinued,['ANDA090643'],['IBUTILIDE FUMARATE'],['IBUTILIDE FUMARATE'],['Mylan Institutional LLC'],['67457-366'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['IBUTILIDE FUMARATE'],['979120'],['88628540-e907-4411-8aa3-bc2a368e460d'],['c25d21e7-6136-4a7a-b139-12f53116fc3d'],['67457-366-10'],['9L5X4M5L6I'],,,,03/05/2025,,,,,
Revised,02/08/2019,55150-237-01,Dexamethasone Sodium Phosphate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-237-01)",Eugia US LLC,Demand increase for the drug,Current,['ANDA206781'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Eugia US LLC'],"['55150-237', '55150-238', '55150-239']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['1116927', '1812194']",['34b1362a-f970-485f-bdac-3a02217157c9'],['ce7ad5a4-a9c5-42d6-87cc-ca16556208d2'],"['55150-237-01', '55150-238-05', '55150-239-30']",['AI9376Y64P'],,,,,,,,,
New,09/04/2025,0378-3458-23,Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray,800-796-9526,,Discontinuation of the manufacture of the drug,09/04/2025,['Pulmonary/Allergy'],Nasal Spray,"Azelastine Hydrochloride; Fluticasone Propionate, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA202236'],['AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE'],['AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE'],['Mylan Pharmaceuticals Inc.'],['0378-3458'],['HUMAN PRESCRIPTION DRUG'],['NASAL'],"['AZELASTINE HYDROCHLORIDE', 'FLUTICASONE PROPIONATE']",,['6e1e173a-2d01-4e67-8361-dd30604bc8aa'],['7b5cc5a0-0d47-46b5-b5fb-eb9cc248ae9e'],['0378-3458-23'],"['0L591QR10I', 'O2GMZ0LF5W']",,,,09/04/2025,,,,,
New,07/08/2025,0409-1892-01,Morphine Sulfate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,07/08/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,,,,,,,,,,,,,,,,07/08/2025,,,,,
Revised,04/07/2020,36000-282-25,Furosemide Injection,888-229-0001,Limited Availability,Estimated recovery: November 2025,10/22/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)",Baxter Healthcare,Other,Current,['ANDA202747'],['FUROSEMIDE'],['FUROSEMIDE'],['Baxter Healthcare Corporation'],"['36000-282', '36000-063', '36000-064', '36000-065', '36000-283', '36000-284']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53'],['c71371a7-75c5-45b8-b762-8d782d4c71bc'],"['36000-063-05', '36000-064-05', '36000-065-05', '36000-282-25', '36000-283-25', '36000-284-25']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,10/31/2017,66794-162-02,Morphine Sulfate Injection,800-414-1901,Available,,11/04/2025,['Analgesia/Addiction'],Injection,"Mitigo (Morphine Sulfate Injection, USP), Injection, 500 mg/20 mL (NDC 66794-162-02)",Piramal Critical Care Inc.,,Current,['ANDA204393'],['MITIGO'],['MORPHINE SULFATE'],"['Piramal Critical Care, Inc.']","['66794-162', '66794-160']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL']",['MORPHINE SULFATE'],"['1731522', '1731998', '2055307', '2055311']",['3f72fcc3-7855-bdf8-e063-6294a90a20b2'],['728f3d83-9a63-0c1f-e053-2a91aa0ac7db'],"['66794-160-02', '66794-162-02']",['X3P646A2J0'],,,,,,,,,
Reverified,02/22/2012,0409-3178-02,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089644'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3178', '0409-1209', '0409-3177', '0409-3181', '0409-3182', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Reverified,02/22/2012,63323-492-57,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487', '63323-493', '63323-496']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029', '1737636', '1737637', '1737640', '1737641', '1737763', '1737764']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33', 'fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74', 'd5e0d06f-ba1e-44d4-aa89-39d6c146dc23']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26', '63323-492-08', '63323-492-97', '63323-493-03', '63323-493-97', '63323-493-01', '63323-493-91', '63323-496-03', '63323-496-97']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,01/15/2025,0409-7870-01,Docetaxel Injection,844-646-4398,,Discontinuation of the manufacture of the drug,01/15/2025,['Oncology'],Injection,"Docetaxel, Injection, 10 mg/1 mL (NDC 0409-7870-01)",Pfizer Inc.,,To Be Discontinued,['NDA022234'],['DOCETAXEL'],['DOCETAXEL ANHYDROUS'],"['Hospira, Inc.']","['0409-7870', '0409-1732']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOCETAXEL ANHYDROUS'],['1093280'],['5b12d54f-e7fd-4369-afb3-431f6f08ec76'],['644c5035-20d2-4686-beaa-bef08e99051c'],"['0409-7870-01', '0409-1732-01']",['699121PHCA'],"['N0000175085', 'N0000175592']",['Microtubule Inhibitor [EPC]'],['Microtubule Inhibition [PE]'],01/15/2025,,,,,
Reverified,01/31/2018,65219-572-10,Bumetanide Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)","Fresenius Kabi USA, LLC",,Current,['ANDA216434'],['BUMETANIDE'],['BUMETANIDE'],"['Fresenius Kabi USA, LLC']","['65219-572', '65219-570']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['aaff61c4-203b-4905-9138-0f98959ad013'],['a007f3aa-3977-4be3-a9a2-db3d458bca58'],"['65219-570-01', '65219-570-04', '65219-572-01', '65219-572-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,09/11/2019,68875-0204-2,Parathyroid Hormone Injection,866-888-0660,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,08/15/2025,['Endocrinology/Metabolism'],Powder,"Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Takeda Pharmaceuticals USA Inc.,Discontinuation of the manufacture of the drug,Current,['BLA125511'],['NATPARA (PARATHYROID HORMONE)'],['PARATHYROID HORMONE'],"['Takeda Pharmaceuticals America, Inc.']","['68875-0204', '68875-0202', '68875-0203', '68875-0205']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PARATHYROID HORMONE'],"['1602023', '1602028', '1602032', '1602034', '1602038', '1602040', '1602044', '1602046']",['17d2bb82-605c-43be-9918-63aeb7102d8c'],['d11fba31-0a6c-11e3-8ffd-0800200c9a66'],"['68875-0202-1', '68875-0202-2', '68875-0203-1', '68875-0203-2', '68875-0204-1', '68875-0204-2', '68875-0205-1', '68875-0205-2']",['N19A0T0E5J'],"['M0015931', 'N0000180851']",['Parathyroid Hormone [EPC]'],,,,['Parathyroid Hormone [CS]'],,,
New,07/10/2025,72305-200-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 200 ug (NDC 72305-200-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-200', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,04/02/2020,70860-601-05,Midazolam Hydrochloride Injection,Athenex: 855-273-0154; Alvogen: 973-532-7840,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-05)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,10/11/2024,0338-0719-06,Dextrose Monohydrate 70% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)",Baxter Healthcare,,Current,['NDA020047'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],['0338-0719'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],['237656'],['aa64f648-e931-4a99-9b81-791a3827272c'],['0332f34a-7038-47cc-ba59-d55cad6b73ca'],['0338-0719-06'],['LX22YL083G'],,,,,,,,,
New,11/21/2024,0555-0071-02,Isoniazid Tablet,800-545-8800,,Product available through 12/03/2024,11/21/2024,['Anti-Infective'],Tablet,"Tablet, 300 mg (NDC 0555-0071-02)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA080937'],['ISONIAZID'],['ISONIAZID'],"['Teva Pharmaceuticals USA, Inc.']","['0555-0071', '0555-0066']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ISONIAZID'],"['197832', '311166']",['ead93989-8a7e-4483-917e-388152515e1d'],['9499f1cf-2f46-4047-8b71-90aee7dee854'],"['0555-0066-02', '0555-0071-01', '0555-0071-02']",['V83O1VOZ8L'],['N0000175483'],['Antimycobacterial [EPC]'],,11/21/2024,,,,,
Reverified,03/01/2022,63323-824-74,Dextrose Monohydrate 10% Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)","Fresenius Kabi USA, LLC",,Current,['ANDA209448'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Fresenius Kabi USA, LLC']",['63323-824'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481']",['d4eda8d8-e374-469e-8ac0-9c9fb7a58aaf'],['3b8f2692-4371-4f1a-95af-b41842131fdd'],"['63323-824-24', '63323-824-74', '63323-824-25', '63323-824-75', '63323-824-26', '63323-824-76']",['LX22YL083G'],,,,,,,,,
Revised,12/27/2023,45567-0060-2,Technetium TC-99M Pyrophosphate Kit Injection,800-818-4555,Limited Availability,Additional supply anticipated early 2026,10/21/2025,['Medical Imaging'],Injection,"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['NDA019039'],['KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE'],['TECHNETIUM TC99M PYROPHOSPHATE'],"['Sun Pharmaceutical Industries, Inc.']",['45567-0060'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['TECHNETIUM TC-99M PYROPHOSPHATE'],,['3010b45e-eed1-a5d0-e063-6294a90a40cf'],['1f0cbd23-2fb3-43b7-b8af-7de246151149'],"['45567-0060-1', '45567-0060-2']",['5L76I61H2B'],"['N0000177914', 'N0000000205']",['Radioactive Diagnostic Agent [EPC]'],,,,,,['Radiopharmaceutical Activity [MoA]'],
Reverified,10/12/2022,11534-190-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",732-382-6085 Monday to Friday 9 am to 3:45 pm,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)","Sunrise Pharmaceutical, Inc.",,Current,['ANDA209799'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['SUNRISE PHARMACEUTICAL, INC.']","['11534-190', '11534-191', '11534-192', '11534-193', '11534-194', '11534-195', '11534-196']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['86a00bec-51eb-4d73-a945-b1937970b29a'],['ac102599-3a5b-4154-899e-6ff262be7ff7'],"['11534-190-01', '11534-190-03', '11534-191-01', '11534-191-03', '11534-192-01', '11534-192-03', '11534-193-01', '11534-193-03', '11534-194-01', '11534-194-03', '11534-195-01', '11534-195-03', '11534-196-01', '11534-196-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,11/01/2017,76045-121-11,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['DILAUDID'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['76045-121', '76045-009', '76045-010']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1872265', '1872269', '1872752', '2277368', '2277370']",['97bfcafb-2037-47dc-a0ae-f7b8007c47df'],['9eebd88a-5632-460f-b7b6-26c8a180540d'],"['76045-009-96', '76045-009-06', '76045-009-01', '76045-009-11', '76045-010-01', '76045-010-11', '76045-121-01', '76045-121-11']",['L960UP2KRW'],,,,,,,,,
New,01/22/2025,64380-155-01,Minocycline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Antiviral'],Tablet,"Minocycline Hydrochloride, Tablet, 75 mg (NDC 64380-155-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA065131'],['MINOCYCLINE HYDROCHLORIDE'],['MINOCYCLINE HYDROCHLORIDE'],['Strides Pharma Science Limited'],"['64380-155', '64380-154', '64380-156']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MINOCYCLINE HYDROCHLORIDE'],"['207362', '207364', '403840']",['73a30dc4-352b-4307-b902-07ffefc99a99'],['d6e136ba-c9b1-4846-ae2a-98a29cb4504d'],"['64380-154-01', '64380-155-01', '64380-156-01']",['0020414E5U'],,,,01/22/2025,,,,,
New,03/03/2025,0591-1159-30,Acyclovir Ointment,800-545-8800,,,03/03/2025,['Dermatology'],Ointment,"Zovirax, Ointment, 50 mg/1 g (NDC 0591-1159-30)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA018604'],['ACYCLOVIR'],['ACYCLOVIR'],"['ACTAVIS PHARMA, INC.']",['0591-1159'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['ACYCLOVIR'],['197312'],['9a0c599a-742a-48f5-ae69-cd9e8cbaa604'],['b360a808-a24d-4f3c-89a7-9941422d17d6'],['0591-1159-30'],['X4HES1O11F'],"['N0000020060', 'N0000180187', 'N0000180188', 'N0000175468', 'N0000175459']","['Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]', 'Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]', 'Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]']",,03/03/2025,,,,['DNA Polymerase Inhibitors [MoA]'],
Revised,01/01/2012,71288-163-30,Leucovorin Calcium Injection,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 71288-163-30)",Kindos Pharmaceuticals Co. Ltd.,,Resolved,['ANDA216590'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Meitheal Pharmaceuticals Inc.'],"['71288-163', '71288-160', '71288-161', '71288-162', '71288-164']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['077a459b-e884-4452-aed3-0857a38ce26f'],['9df20901-6980-4d4e-89ec-40f3c1f91852'],"['71288-160-10', '71288-161-20', '71288-162-30', '71288-163-30', '71288-164-50']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,02/14/2022,65219-456-60,Dextrose Monohydrate 5% Injection,888-386-1300,Available,Check wholealers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)","Fresenius Kabi USA, LLC",,Current,['ANDA207449'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['FRESENIUS KABI USA, LLC']","['65219-456', '65219-464', '65219-458', '65219-460', '65219-462']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795607', '1795609', '1795610', '1795612', '1795616']",['efc3b0c9-518a-47db-bb3e-ebdfd4646e9b'],['576a22d8-5f2f-497e-80ad-1842ca74bb53'],"['65219-456-05', '65219-456-60', '65219-464-05', '65219-464-50', '65219-458-05', '65219-458-30', '65219-460-05', '65219-460-20', '65219-462-05', '65219-462-10']",['LX22YL083G'],,,,,,,,,
New,06/16/2025,0093-4085-63,Tobramycin Solution,800-545-8800,,Discontinuation of the manufacture of the drug,06/16/2025,['Pulmonary/Allergy'],Solution,"Tobramycin, Solution, 300 mg/5 mL (NDC 0093-4085-63)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA091589'],['TOBRAMYCIN'],['TOBRAMYCIN'],"['Teva Pharmaceuticals USA, Inc.']",['0093-4085'],['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],['TOBRAMYCIN'],['348719'],['f42ab3e7-da6a-435e-987f-f99b1dc649f0'],['c5f65e5b-c851-45da-a0e8-215d9a4e6ad3'],['0093-4085-63'],['VZ8RRZ51VK'],"['N0000175477', 'M0000946']",['Aminoglycoside Antibacterial [EPC]'],,06/16/2025,,['Aminoglycosides [CS]'],,,
Reverified,02/29/2024,16729-081-01,Naltrexone Hydrochloride Tablet,"866-941-7875, option 2",Available,,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-01)",Accord Healthcare Inc.,,Current,['ANDA091205'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Accord Healthcare, Inc.']",['16729-081'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['424db74c-6c0f-1eb3-e063-6294a90a7db8'],['49aa3d6d-2270-4615-aafa-b440859ab870'],"['16729-081-10', '16729-081-01', '16729-081-16', '16729-081-17']",['Z6375YW9SF'],,,,,,,,,
Revised,10/11/2024,0338-0117-02,Lactated Ringers Injection,888-229-0001,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 250 mL bag, 36 count (NDC 0338-0117-02)",Baxter Healthcare,,Resolved,['NDA016682'],['LACTATED RINGERS'],"['SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE']",['Baxter Healthcare Company'],['0338-0117'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847630'],['a3c6770a-d279-4ea9-b8ed-5484be18121e'],['dad7735c-709b-40ea-ab7a-15577e24a966'],"['0338-0117-02', '0338-0117-03', '0338-0117-04']","['M4I0D6VV5M', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Reverified,11/03/2017,0641-6019-10,Morphine Sulfate Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Duramorph (Morphine Sulfate Injection, USP), Injection, 1 mg/1 mL (NDC 0641-6019-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA018565'],['DURAMORPH'],['MORPHINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6019', '0641-6020']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['892473', '892489', '1728783', '1728800']",['d8bb0ae2-68bc-40ff-ad67-867bb8b71bc7'],['ebb18761-e5c4-4238-bb84-f9549f500210'],"['0641-6020-01', '0641-6020-10', '0641-6019-01', '0641-6019-10']",['X3P646A2J0'],,,,,,,,,
New,06/13/2025,13668-382-05,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-05)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Revised,02/20/2018,55150-159-74,Lidocaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)",Eugia US LLC,Demand increase for the drug,Current,['ANDA203040'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-159', '55150-158', '55150-160']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737566', '1737568', '1737757']",['e2600451-756c-4986-9e8e-26ce1d865afd'],['5524cbfd-d6e6-42eb-aaa5-22495e0a86b6'],"['55150-158-72', '55150-159-74', '55150-160-72']",['V13007Z41A'],,,,,,,,,
New,08/27/2025,0409-2344-88,Dobutamine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,08/27/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)",Pfizer Inc.,,To Be Discontinued,['ANDA074086'],['DOBUTAMINE'],['DOBUTAMINE'],"['Hospira, Inc.']",['0409-2344'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],['1812168'],"['e71e9520-871b-479d-9652-1857fceca863', '5d6b1dfe-d679-4aea-97a6-3d074a202afe']","['dc537761-d5f4-488d-24ab-b2bcd2b17b7a', '89becb0c-da60-4f43-0a98-29ff7a9eca58']","['0409-2344-01', '0409-2344-62', '0409-2344-02', '0409-2344-68', '0409-2344-88']",['0WR771DJXV'],,,,08/27/2025,,,,,
Reverified,10/25/2022,64980-642-03,Albuterol Sulfate Solution,201-961-9000,Available,,08/15/2025,"['Pediatric', 'Pulmonary/Allergy']",Solution,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)","Rising Pharma Holdings, Inc.",,Current,['ANDA075664'],['ALBUTEROL SULFATE'],['ALBUTEROL SULFATE'],"['Rising Pharma Holdings, Inc.']",['64980-642'],['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],['ALBUTEROL SULFATE'],['245314'],['33015e7c-a4d2-ecac-e063-6394a90aae00'],['3236f82c-14e9-dfd4-e063-6294a90ac43d'],['64980-642-03'],['021SEF3731'],,,,,,,,,
Revised,10/06/2023,0338-1047-02,Nitroglycerin Injection,Baxter Healthcare 888-229-0001,Unavailable,Manufacturing delay; Recovery in November 2025,10/22/2025,['Cardiovascular'],Injection,"Nitroglycerin in Dextrose 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)",Baxter Healthcare,Other,Current,['NDA019970'],['NITROGLYCERIN IN DEXTROSE'],['NITROGLYCERIN'],['Baxter Healthcare Company'],"['0338-1047', '0338-1049', '0338-1051']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['NITROGLYCERIN'],"['312004', '1868494', '1868562']",['71811937-e908-4b65-aff2-4b345fa0954b'],['457a026c-ebce-4701-9deb-2d7652759a99'],"['0338-1047-02', '0338-1049-02', '0338-1051-02']",['G59M7S0WS3'],"['N0000175415', 'M0014874', 'N0000009909']",['Nitrate Vasodilator [EPC]'],['Vasodilation [PE]'],,,['Nitrates [CS]'],,,
New,07/10/2025,72305-125-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 125 ug (NDC 72305-125-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-125', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,02/15/2023,39822-4200-2,Rocuronium Bromide Injection,866-390-4411,Available,Tamarang is the application holder and X-Gen is the distributor/labeler,10/23/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)","XGen Pharmaceuticals DJB, Inc.",,Current,['ANDA091115'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],"['XGen Pharmaceuticals DJB, Inc.']",['39822-4200'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['eedcfb07-4e23-3152-e053-2995a90a6e6a'],['b73f192c-2912-4ec3-9b4f-05a58d9b35ba'],"['39822-4200-1', '39822-4200-2', '39822-4200-5', '39822-4200-6']",['I65MW4OFHZ'],,,,,,,,,
New,02/05/2025,60505-4512-3,Gefitinib Tablet,800-706-5575,,,02/05/2025,['Oncology'],Tablet,"Gefitinib, Tablet, 250 mg (NDC 60505-4512-3)",Apotex Corp.,,To Be Discontinued,['ANDA209532'],['GEFITINIB'],['GEFITINIB'],['Apotex Corp.'],['60505-4512'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GEFITINIB'],['349472'],['54a3934f-8705-b2e7-f5c5-a85ac5c546d8'],['257a3e9c-019e-ef38-de25-1ebd7585c3ea'],"['60505-4512-1', '60505-4512-3']",['S65743JHBS'],"['N0000175605', 'N0000175076']",['Kinase Inhibitor [EPC]'],,02/05/2025,,,,['Protein Kinase Inhibitors [MoA]'],
Reverified,07/14/2023,64850-551-01,Lisdexamfetamine Dimesylate Capsule,888-852-6657,Limited Availability,Limited Availability,11/04/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA218604'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Elite Laboratories, Inc.']","['64850-551', '64850-550', '64850-552', '64850-553', '64850-554', '64850-555', '64850-556']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['e414bb2e-d404-44ea-931c-5998b0a4c87e'],['0e024b69-567c-4b40-9c3e-a2daec34256c'],"['64850-550-01', '64850-551-01', '64850-552-01', '64850-553-01', '64850-554-01', '64850-555-01', '64850-556-01']",['SJT761GEGS'],,,,,,,,,
New,09/29/2025,0781-3476-95,Fondaparinux Sodium Injection,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,09/29/2025,['Hematology'],Injection,"Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95)","Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,To Be Discontinued,['ANDA206812'],['FONDAPARINUX SODIUM'],['FONDAPARINUX SODIUM'],['Sandoz Inc.'],"['0781-3476', '0781-3443', '0781-3454', '0781-3465']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['FONDAPARINUX SODIUM'],"['861356', '861360', '861363', '861365']",['3d5a4b69-462b-7e51-e063-6294a90a0721'],['baa50757-a927-4d56-a933-5d7798fe6ab0'],"['0781-3443-94', '0781-3443-12', '0781-3443-95', '0781-3454-94', '0781-3454-12', '0781-3454-95', '0781-3465-94', '0781-3465-12', '0781-3465-95', '0781-3476-94', '0781-3476-12', '0781-3476-95']",['X0Q6N9USOZ'],,,,09/29/2025,,,,,
Reverified,03/21/2023,25021-115-02,Clindamycin Phosphate Injection,866-625-1618,Available,,08/26/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)",Sagent Pharmaceuticals,,Current,['ANDA090108'],['CLINDAMYCIN'],['CLINDAMYCIN PHOSPHATE'],['Sagent Pharmaceuticals'],['25021-115'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['1737244', '1737578', '1737581']",['4662502b-ce7c-4278-854d-cf8632ac9b83'],['7a6967b3-5563-4bed-9eee-d400f800e799'],"['25021-115-02', '25021-115-04', '25021-115-06']",['EH6D7113I8'],,,,,,,,,
Reverified,01/19/2023,68180-554-09,Quinapril Hydrochloride Tablet,866-587-4617,Unavailable,,09/18/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)","Lupin Pharmaceuticals, Inc.",Requirements related to complying with good manufacturing practices,Current,['ANDA077690'],['QUINAPRIL'],['QUINAPRIL'],"['Lupin Pharmaceuticals, Inc.']","['68180-554', '68180-556', '68180-557', '68180-558', '68180-559']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['a9598a21-6f99-4c86-ace6-b5638da2bec8'],['8ded0773-3aec-4e89-9836-d22a5a84abf0'],"['68180-556-09', '68180-557-09', '68180-557-03', '68180-558-09', '68180-558-03', '68180-554-09', '68180-554-03', '68180-559-03', '68180-559-09']",['33067B3N2M'],,,,,,,,,
Reverified,10/12/2022,70010-112-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",877-770-3183,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)",Granules Pharmaceuticals Inc.,,Current,['ANDA215771'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Granules Pharmaceuticals Inc.'],"['70010-112', '70010-111', '70010-113', '70010-114', '70010-115', '70010-116', '70010-117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['2fab399e-2a43-5134-e063-6294a90ae09a'],['b0b4eccc-34c7-483d-966f-82d588358e1b'],"['70010-111-01', '70010-111-03', '70010-112-01', '70010-112-03', '70010-113-01', '70010-113-03', '70010-114-01', '70010-114-03', '70010-115-01', '70010-115-03', '70010-116-01', '70010-116-03', '70010-117-01', '70010-117-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,08/13/2025,66658-231-01,Palivizumab Injection,866-773-5274,,Discontinuation of the manufacture of the drug,08/13/2025,['Antiviral'],Injection,"Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)",Swedish Orphan Biovitrum AB,,To Be Discontinued,['BLA103770'],['SYNAGIS'],['PALIVIZUMAB'],['Swedish Orphan Biovitrum AB (publ)'],"['66658-231', '66658-230']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PALIVIZUMAB'],"['1657341', '1657343', '1657361', '1657362']",['825a4b3c-e419-457c-8862-fd7b74a171ed'],['3a0096c7-8139-44cd-bba4-520ab05c2cb2'],"['66658-231-01', '66658-230-01']",['DQ448MW7KS'],"['M0001357', 'N0000175615', 'N0000175623']",['Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]'],,08/13/2025,,"['Antibodies, Monoclonal [CS]']",,['Fusion Protein Inhibitors [MoA]'],
Reverified,10/14/2016,63323-488-37,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-488', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,07/18/2023,71288-563-85,Liraglutide Injection,844-824-8426,Available,,08/19/2025,['Endocrinology/Metabolism'],Injection,"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA218115'],['LIRAGLUTIDE'],['LIRAGLUTIDE'],['Meitheal Pharmaceuticals Inc.'],['71288-563'],['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['LIRAGLUTIDE'],['897122'],['31f901b4-0477-38aa-e063-6294a90ac708'],['0efc3a89-211a-4496-baab-e8265e07de2b'],"['71288-563-84', '71288-563-85']",['839I73S42A'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],
Reverified,11/06/2017,0409-9104-20,Dopamine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)","Hospira, Inc., a Pfizer Company",,Current,['NDA018132'],['DOPAMINE HYDROCHLORIDE'],['DOPAMINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-9104', '0409-5820']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1743938', '1743941']",['a3fac375-0709-4cc0-84db-b0e5a60b7200'],['1f306ad2-3606-4525-5a8a-ce78f426c1a2'],"['0409-5820-11', '0409-5820-01', '0409-9104-21', '0409-9104-20']",['7L3E358N9L'],,,,,,,,,
Reverified,02/20/2018,71288-728-32,Bupivacaine Hydrochloride Injection,844-824-8426,Available,Meitheal Pharmaceuticals is distributor/labeler; product is available,08/19/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)",Kindos Pharmaceuticals Co. Ltd.,,Current,['ANDA216040'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Meitheal Pharmaceuticals Inc'],"['71288-728', '71288-721', '71288-722', '71288-724', '71288-725', '71288-727']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['b085b86e-d32f-494e-8a4a-3080ff240109'],['daec9ee4-b666-485e-a153-4b5e5acc48a1'],"['71288-721-11', '71288-722-32', '71288-724-11', '71288-725-32', '71288-727-11', '71288-728-32']",['7TQO7W3VT8'],,,,,,,,,
Revised,04/26/2023,60793-701-10,Penicillin G Benzathine Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: November 2025,10/23/2025,['Anti-Infective'],Injection,"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)",Pfizer Inc.,Other,Current,['NDA050141'],['BICILLIN L-A'],['PENICILLIN G BENZATHINE'],['Pfizer Laboratories Div Pfizer Inc'],"['60793-701', '60793-700', '60793-702']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PENICILLIN G BENZATHINE'],"['731564', '731566', '731567', '731568', '731570', '731571']",['4b3694af-9d77-487f-8838-b75aec6636da'],['012d46f1-d0a0-4676-a879-cd320297ab16'],"['60793-700-01', '60793-700-10', '60793-701-02', '60793-701-10', '60793-702-04', '60793-702-10']",['RIT82F58GK'],,,,,https://www.fda.gov/media/188355/download,,,,
Reverified,02/22/2012,63323-492-31,Lidocaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487', '63323-493', '63323-496']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029', '1737636', '1737637', '1737640', '1737641', '1737763', '1737764']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33', 'fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74', 'd5e0d06f-ba1e-44d4-aa89-39d6c146dc23']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26', '63323-492-08', '63323-492-97', '63323-493-03', '63323-493-97', '63323-493-01', '63323-493-91', '63323-496-03', '63323-496-97']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,10/31/2025,0603-5166-21,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5166', '0603-5165', '0603-5167', '0603-5168']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
Reverified,01/01/2012,0409-9094-31,Fentanyl Citrate Injection,844-646-4398,Available,,10/23/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)","Hospira, Inc., a Pfizer Company",,Current,['NDA019115'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Hospira, Inc.']","['0409-9094', '0409-9093']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735004', '1735006', '1735007', '1735008', '1735013']",['e4b31fdd-00af-416d-b14e-dbac0c83da97'],['bfa8018a-4cbc-434b-e09e-782872b0340a'],"['0409-9093-37', '0409-9093-32', '0409-9093-45', '0409-9093-35', '0409-9093-41', '0409-9093-36', '0409-9093-31', '0409-9093-38', '0409-9094-12', '0409-9094-22', '0409-9094-18', '0409-9094-25', '0409-9094-17', '0409-9094-28', '0409-9094-16', '0409-9094-31', '0409-9094-41', '0409-9094-61']",['MUN5LYG46H'],,,,,,,,,
Reverified,07/14/2023,47781-564-01,Lisdexamfetamine Dimesylate Capsule,844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)",Alvogen,,Current,['ANDA214547'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Alvogen Inc.'],"['47781-564', '47781-562', '47781-563', '47781-565', '47781-566', '47781-567', '47781-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['567bb281-4098-07f8-9503-92299dc1c4c6'],['7f2dd6ee-3363-c87c-9693-ed838942556c'],"['47781-562-01', '47781-563-01', '47781-564-01', '47781-565-01', '47781-566-01', '47781-567-01', '47781-568-01']",['SJT761GEGS'],,,,,,,,,
New,07/29/2025,61570-074-01,Esterified Estrogens Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,07/29/2025,['Endocrinology/Metabolism'],Tablet,"Menest, Tablet, 1.25 mg (NDC 61570-074-01)",Pfizer Inc.,,To Be Discontinued,['ANDA084950'],['MENEST'],['ESTERIFIED ESTROGENS'],['Pfizer Laboratories Div Pfizer Inc'],"['61570-074', '61570-072', '61570-073', '61570-075']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ESTROGENS, ESTERIFIED']","['197666', '197667', '197668', '197669', '212039', '212232', '212373', '212464']",['78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb'],['e0141598-0bb2-4cf0-c9b8-6867b34bbb17'],"['61570-072-01', '61570-073-01', '61570-074-01', '61570-075-50']",['3ASP8Q3768'],,,,07/29/2025,,,,,
Reverified,02/20/2018,0409-1755-50,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE WITH EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Hospira, Inc.']","['0409-1755', '0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],"['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,10/31/2025,0603-5168-32,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5168', '0603-5165', '0603-5166', '0603-5167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
Reverified,02/22/2012,83090-001-10,Lidocaine Hydrochloride Injection,"844-425-3131, SinteticaCS@eversana.com",Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X2ML) is Preservative free.",08/19/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)",Sintetica US,,Current,['ANDA214267'],['NA'],['LIDOCAINE HYDROCHLORIDE'],['Sintetica US LLC'],"['83090-001', '83090-002', '83090-003', '83090-004', '83090-005', '83090-006']",['HUMAN PRESCRIPTION DRUG'],['INFILTRATION'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737566', '1737568', '1737570', '1737757', '1737761', '1737763']",['0d18f291-3a92-421e-8841-6be743b1f154'],['aa3e688a-308c-4a82-a268-28ccf1677c55'],"['83090-001-01', '83090-001-10', '83090-002-01', '83090-002-10', '83090-003-01', '83090-003-10', '83090-004-01', '83090-004-10', '83090-005-01', '83090-005-10', '83090-006-01', '83090-006-10']",['EC2CNF7XFP'],,,,,,,,,
Revised,11/21/2023,0641-6085-25,Promethazine Hydrochloride Injection,800-631-2174,Unavailable,This presentation is temporarily on backorder.,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['ANDA083312'],['PHENERGAN'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6085', '0641-6084']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992462', '992858', '992876']",['7d6e64fc-bbf2-4ea9-b866-8115c448e687'],['481866da-a712-48a5-853f-8e84aacaab6d'],"['0641-6084-01', '0641-6084-25', '0641-6085-01', '0641-6085-25']",['R61ZEH7I1I'],,,,,,,,,
New,09/18/2025,0832-6005-11,Fluphenazine Hydrochloride Tablet,763-315-2000,,Discontinuation of the manufacture of the drug.,09/18/2025,"['Neurology', 'Psychiatry']",Tablet,"Fluphenazine Hydrochloride, Tablet, 5 mg (NDC 0832-6005-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA213784'],['FLUPHENAZINE HYDROCHLORIDE'],['FLUPHENAZINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories,LLC']","['0832-6005', '0832-6004', '0832-6003', '0832-6006']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLUPHENAZINE HYDROCHLORIDE'],"['859841', '860918', '865117', '865123']",['3bb74f82-8872-9829-e063-6294a90aeace'],['f07bb3f1-c68c-441b-9de4-99a219f2500a'],"['0832-6004-11', '0832-6003-11', '0832-6005-11', '0832-6006-11']",['ZOU145W1XL'],,,,09/18/2025,,,,,
Reverified,07/14/2023,59417-103-10,Lisdexamfetamine Dimesylate Capsule,877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],Capsule,"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA021977'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-103', '59417-101', '59417-102', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
New,11/03/2025,0378-0005-85,Everolimus Tablet,800-796-9526,,Discontinuation of the manufacture of the drug,11/03/2025,['Transplant'],Tablet,"Everolimus, Tablet, 2 mg (NDC 0378-0005-85)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['ANDA210130'],['EVEROLIMUS'],['EVEROLIMUS'],['Mylan Pharmaceuticals Inc.'],"['0378-0005', '0378-0006', '0378-0007']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['EVEROLIMUS'],"['1308428', '1308430', '1308432']",['129ab1eb-61df-49de-953c-fca0f0a28eee'],['ca1a987e-f763-4026-93c5-c545ca95826c'],"['0378-0005-85', '0378-0006-85', '0378-0007-85']",['9HW64Q8G6G'],"['N0000175605', 'N0000175076', 'N0000182141', 'N0000182137', 'N0000175625', 'N0000175624', 'N0000175550']","['Kinase Inhibitor [EPC]', 'mTOR Inhibitor Immunosuppressant [EPC]']",['Decreased Immunologic Activity [PE]'],11/03/2025,,,,"['Protein Kinase Inhibitors [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 2D6 Inhibitors [MoA]', 'mTOR Inhibitors [MoA]']",
New,12/05/2024,63304-693-01,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-01)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-693', '63304-692']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
New,05/19/2025,62037-560-90,"Potassium Chloride Capsule, Extended Release",800-545-8800,,,05/19/2025,"['Endocrinology/Metabolism', 'Gastroenterology']","Capsule, Extended Release","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-90)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077419'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Actavis Pharma, Inc.']","['62037-560', '62037-559']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312504', '315183']",['b97da107-c56e-48ea-ba34-d3d64a5b9f46'],['ed5baaf6-270b-4dd3-b100-36030c0098fc'],"['62037-559-01', '62037-559-05', '62037-560-01', '62037-560-05', '62037-560-10', '62037-560-90']",['660YQ98I10'],,,,05/19/2025,,,,,
Reverified,07/14/2023,42858-163-01,Lisdexamfetamine Dimesylate Capsule,888-827-0616,Available,,08/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)",Rhodes Pharmaceuticals L.P.,,Current,['ANDA215330'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Rhodes Pharmaceuticals'],"['42858-163', '42858-161', '42858-162', '42858-164', '42858-165', '42858-166', '42858-167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['047c243d-9336-4ef2-b5a8-a7cae312b1be'],['d918b40d-a461-41bc-b6c0-83dc76c28e32'],"['42858-161-01', '42858-162-01', '42858-163-01', '42858-164-01', '42858-165-01', '42858-166-01', '42858-167-01']",['SJT761GEGS'],,,,,,,,,
New,11/07/2025,0409-4916-14,Sodium Bicarbonate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,,,,,,,,,,,,,,,,11/07/2025,,,,,
New,08/04/2025,45963-614-51,Irinotecan Hydrochloride Injection,800-545-8800,,Product not anticipated to be available beyond mid-late October 2025,08/04/2025,['Oncology'],Injection,"Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA078589'],['IRINOTECAN HYDROCHLORIDE'],['IRINOTECAN HYDROCHLORIDE'],"['Actavis Pharma, Inc.']",['45963-614'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['IRINOTECAN HYDROCHLORIDE'],"['1726319', '1726324']",['8f2da07f-1d3e-4d8b-8083-805da8a780db'],['5e1fdcaa-918f-4cd8-9c7a-4c538d866198'],"['45963-614-51', '45963-614-55']",['042LAQ1IIS'],,,,08/04/2025,,,,,
Reverified,03/13/2023,61703-408-25,Methotrexate Sodium Injection,844-646-4398,Available,,10/23/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)","Hospira, Inc., a Pfizer Company",,Current,['NDA011719'],['METHOTREXATE'],['METHOTREXATE'],"['Hospira, Inc.']","['61703-408', '61703-350']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS', 'SUBCUTANEOUS']",['METHOTREXATE SODIUM'],"['1655956', '1946772']","['95b8b8da-da4e-4bba-9038-3cf65f3d5c1a', '37b3e76b-ac3d-4f93-adf1-91f52f676b8a']","['0d63ba29-b692-41b4-87e8-351265c8273f', '0e30eaef-5a09-4104-8a11-c32933eadeab']","['61703-350-37', '61703-350-38', '61703-408-41', '61703-350-09', '61703-350-10', '61703-408-25']",['3IG1E710ZN'],,,,,,,,,
Revised,10/31/2017,0409-1312-30,Hydromorphone Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2025,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1312', '0409-1283', '0409-1380', '0409-4264', '0409-1805', '0409-2552', '0409-3356', '0409-2540', '0409-3365', '0409-1304']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1724383', '1724644', '1872271', '2675350', '897653', '897753', '897758', '1724276']","['53b6867a-0ae3-48ff-b257-9e58cc76de9c', '58ff0e68-b78f-4ebd-a91b-b53bbdefc544']","['f9ca2ef5-46d8-475a-a26e-f7c8becd6db7', 'e9c9ef18-7dfc-4322-b2fc-29b934c30f8b']","['0409-1283-17', '0409-1283-37', '0409-1312-16', '0409-1312-36', '0409-1380-11', '0409-1380-01', '0409-4264-11', '0409-4264-01', '0409-1805-10', '0409-1805-01', '0409-2552-11', '0409-2552-01', '0409-3356-11', '0409-3356-01', '0409-2540-11', '0409-2540-01', '0409-3365-11', '0409-3365-01', '0409-3365-10', '0409-1283-03', '0409-1283-31', '0409-1283-09', '0409-1283-10', '0409-1283-04', '0409-1283-05', '0409-1312-03', '0409-1312-30', '0409-1312-09', '0409-1312-10', '0409-1304-03', '0409-1304-31']",['L960UP2KRW'],,,,,,,01/02/2025,,
Reverified,04/10/2020,0409-3301-10,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-3301', '0409-1454', '0409-1174', '0409-2815']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['8d48de06-361f-418b-bfec-8ef85f94d5bc'],['4419162d-81d4-49bd-96de-1729440bdb74'],"['0409-1454-01', '0409-1454-20', '0409-3301-01', '0409-3301-10', '0409-1174-01', '0409-1174-10', '0409-2815-01']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0264-7800-00,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-00)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-7800', '0264-7802']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807639', '1807551', '1807552', '1807633', '1807634']","['318417ff-d599-47b8-8181-89c3bb3b2e8d', '9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa']","['47a0313f-36df-4fa6-a828-c9e1946ba9b0', '7f22c06b-6b4d-4b49-a4b2-d2169f2bd653']","['0264-7800-09', '0264-7800-00', '0264-7800-10', '0264-7800-20', '0264-7802-00', '0264-7802-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/26/2023,0406-0136-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-325-8888,Unavailable,Backorder with next release expected in November 2025,11/05/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 0406-0136-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA202608'],['METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE'],['METHYLPHENIDATE HYDROCHLORIDE'],['SpecGx LLC'],"['0406-0136', '0406-0127', '0406-0154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2001565', '2001566', '2001568']",['7a3a8731-e545-455e-83c3-888f4923e901'],['b1b0f2ff-d9df-42ab-b471-226ecf97e075'],"['0406-0127-01', '0406-0136-01', '0406-0154-01']",['4B3SC438HI'],,,,,,,,,
Reverified,03/27/2018,25021-671-67,Ropivacaine Hydrochloride Injection,Sagent: 866-625-1618,Available,Marketed by Sagent Pharmaceuticals,08/26/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)",InfoRLife SA,,Current,['ANDA206166'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Sagent Pharmaceuticals'],"['25021-671', '25021-652']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734347', '1734355', '1734479', '1734481']","['04d1b1c6-1963-4b42-8479-dbf787b6de17', '2eb59cb8-dab8-43f4-ad73-672446e104ca']","['8c5c762f-d266-4b1a-809e-f11bfc89bc2d', '9572b3de-684c-4028-a577-5aa69ba6b02d']","['25021-671-82', '25021-671-87', '25021-652-82', '25021-652-87', '25021-671-66', '25021-671-67']",['V910P86109'],,,,,,,,,
Reverified,11/14/2017,0264-9872-10,Heparin Sodium Injection,800-227-2862,Available,,11/04/2025,['Hematology'],Injection,"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)",B. Braun Medical Inc.,,Current,['NDA019953'],['HEPARIN SODIUM IN SODIUM CHLORIDE'],['HEPARIN SODIUM IN SODIUM CHLORIDE'],['B. Braun Medical Inc.'],['0264-9872'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['48e17807-e73d-4ea2-81bc-901355903aa7'],['a3041c04-0ea8-4d36-81ce-c5091c906316'],"['0264-9872-10', '0264-9872-00']",['ZZ45AB24CA'],,,,,,,,,
Revised,10/12/2022,13107-069-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(866) 850-2876 or CustomerService@AurobindoUSA.com,Unavailable,Estimated availability February 2026,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)",Aurobindo Pharma USA,Shortage of an active ingredient,Current,['ANDA202424'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Aurolife Pharma, LLC']","['13107-069', '13107-068', '13107-070', '13107-071', '13107-072', '13107-073', '13107-074']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['95842af2-8d9d-4eb1-ba39-86cdbd829a79'],['a582d57f-d191-4ca5-b105-585b2d8a0e3e'],"['13107-068-50', '13107-068-01', '13107-068-25', '13107-068-05', '13107-068-99', '13107-069-50', '13107-069-01', '13107-069-25', '13107-069-05', '13107-069-99', '13107-070-50', '13107-070-01', '13107-070-25', '13107-070-05', '13107-070-99', '13107-071-50', '13107-071-01', '13107-071-25', '13107-071-05', '13107-071-99', '13107-072-50', '13107-072-01', '13107-072-25', '13107-072-05', '13107-072-99', '13107-073-50', '13107-073-01', '13107-073-25', '13107-073-05', '13107-073-99', '13107-074-50', '13107-074-01', '13107-074-25', '13107-074-05', '13107-074-99']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/13/2025,13668-397-30,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-30)",Torrent Pharma Inc.,,To Be Discontinued,['ANDA203580'],"['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG']","['OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 20/5/12.5 MG']",['Torrent Pharmaceuticals Limited'],"['13668-397', '13668-386', '13668-385', '13668-383', '13668-382']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE', 'HYDROCHLOROTHIAZIDE', 'OLMESARTAN MEDOXOMIL']","['999967', '999986', '999991', '999996', '1000001']",['5bedf6c6-6b23-40e7-8c96-2cedcc682973'],['85b8f9c6-aa53-4aa1-85d6-19f823d0d252'],"['13668-397-30', '13668-397-90', '13668-397-05', '13668-386-30', '13668-386-90', '13668-386-05', '13668-385-30', '13668-385-90', '13668-385-05', '13668-383-30', '13668-383-90', '13668-383-05', '13668-382-30', '13668-382-90', '13668-382-05']","['6M97XTV3HD', '1J444QC288', '0J48LPH2TH']","['N0000000069', 'N0000175421', 'N0000175566', 'M0006414', 'N0000190114', 'N0000175359', 'N0000175419', 'M0471776']","['Dihydropyridine Calcium Channel Blocker [EPC]', 'Calcium Channel Blocker [EPC]', 'Thiazide Diuretic [EPC]']",['Increased Diuresis [PE]'],06/13/2025,,"['Dihydropyridines [CS]', 'Thiazides [CS]']",,"['Calcium Channel Antagonists [MoA]', 'Cytochrome P450 3A Inhibitors [MoA]']",
New,11/21/2024,0173-0903-13,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-13)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0903', '0173-0897', '0173-0906', '0173-0911', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Reverified,06/28/2022,63323-724-05,Remifentanil Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)","Fresenius Kabi USA, LLC",,Current,['ANDA206223'],['REMIFENTANIL HYDROCHLORIDE'],['REMIFENTANIL HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-724', '63323-723', '63323-725']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729584', '1729710']",['2f27e51f-2b55-47ee-bd4a-001b71c60622'],['d2374b84-81c9-44f9-a4a9-1071281b2531'],"['63323-723-01', '63323-723-03', '63323-724-01', '63323-724-05', '63323-725-01', '63323-725-10']",['5V444H5WIC'],,,,,,,,,
Reverified,07/14/2023,0527-4661-37,Lisdexamfetamine Dimesylate Capsule,844-834-0530,Limited Availability,Limited Availability,11/03/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA215802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Lannett Company, Inc.']","['0527-4661', '0527-4662', '0527-4663', '0527-4664', '0527-4665', '0527-4666', '0527-4667']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7ac942a6-689a-420b-87bf-dc59003400dc'],['2cedb4c2-1e40-4bc4-b9f4-127150c4afbd'],"['0527-4661-37', '0527-4662-37', '0527-4663-37', '0527-4664-37', '0527-4665-37', '0527-4666-37', '0527-4667-37']",['SJT761GEGS'],,,,,,,,,
Reverified,03/23/2018,63323-286-31,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-286', '63323-285', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
New,12/05/2024,47335-475-83,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-83)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-475', '47335-472']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,07/14/2023,59417-115-01,"Lisdexamfetamine Dimesylate Tablet, Chewable",877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],"Tablet, Chewable","Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA208510'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-115', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-116', '59417-117', '59417-118', '59417-119', '59417-120']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
Reverified,04/07/2020,71288-205-03,Furosemide Injection,844-824-8426,Available,,08/19/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA217501'],['HYDRALAZINE HYDROCHLORIDE'],['HYDRALAZINE HYDROCHLORIDE'],['Meitheal Pharmaceuticals Inc.'],['71288-205'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDRALAZINE HYDROCHLORIDE'],['966571'],['9c7f84bf-c884-49fd-8f1f-d368f64d63ff'],['f3c806a4-b971-421c-bcb9-9979c6d7aaec'],"['71288-205-01', '71288-205-02']",['FD171B778Y'],,,,,,,,,
New,08/12/2025,23155-583-25,Desipramine Hydrochloride Tablet,855-228-9470,,Discontinuation of the manufacture of the drug,08/12/2025,['Psychiatry'],Tablet,"Desipramine Hydrochloride, Tablet, 150 mg (NDC 23155-583-25)","Avet Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA207433'],['DESIPRAMINE HYDROCHLORIDE'],['DESIPRAMINE HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],"['23155-583', '23155-578', '23155-579', '23155-580', '23155-581', '23155-582']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DESIPRAMINE HYDROCHLORIDE'],"['1099288', '1099292', '1099296', '1099300', '1099304', '1099316']",['49984729-ddde-44ed-927b-8a4ba65cefa0'],['ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0'],"['23155-578-01', '23155-579-01', '23155-580-01', '23155-581-01', '23155-582-01', '23155-583-25']",['1Y58DO4MY1'],,,,08/12/2025,,,,,
Reverified,03/27/2018,25021-652-82,Ropivacaine Hydrochloride Injection,Sagent: 866-625-1618,Available,Marketed by Sagent Pharmaceuticals,08/26/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)",InfoRLife SA,,Current,['ANDA206166'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Sagent Pharmaceuticals'],"['25021-652', '25021-671']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734347', '1734355', '1734479', '1734481']",['04d1b1c6-1963-4b42-8479-dbf787b6de17'],['8c5c762f-d266-4b1a-809e-f11bfc89bc2d'],"['25021-671-82', '25021-671-87', '25021-652-82', '25021-652-87']",['V910P86109'],,,,,,,,,
Revised,05/30/2025,0409-1180-69,Meperidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Analgesia/Addiction'],Injection,"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA021171'],['DEMEROL'],['MEPERIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1180', '0409-1181', '0409-1176', '0409-1178', '0409-1179', '0409-1362', '0409-1418']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['860792', '861463', '861473', '861493', '861494', '861522', '861529', '861617', '1242106', '1242503', '2539186', '2539188', '2539191', '2539192']",['1271f15f-ccda-4892-8fb0-9bb2d38ded4a'],['b31d1308-28c3-43f4-e0a6-2f3ed76b8975'],"['0409-1181-30', '0409-1176-03', '0409-1176-30', '0409-1178-03', '0409-1178-30', '0409-1179-03', '0409-1179-30', '0409-1180-59', '0409-1180-69', '0409-1362-11', '0409-1362-01', '0409-1418-11', '0409-1418-01']",['N8E7F7Q170'],,,,,,,,,
Revised,07/24/2017,51754-5012-4,Sodium Bicarbonate Injection,828-758-5474 ext. 154,Unavailable,Next batch release expected in 2 weeks.,11/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)","Exela Pharma Sciences, LLC",Demand increase for the drug,Current,['ANDA211091'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Exela Pharma Sciences, LLC']","['51754-5012', '51754-5001', '51754-5011', '51754-5002']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],"['807284', '1868486', '1923484', '2198792']",['4da0ba66-756d-4b4d-8018-81ca16578ef1'],['e9698a4f-1a95-4f28-a945-e8009d1d6dd4'],"['51754-5001-5', '51754-5001-4', '51754-5011-4', '51754-5002-5', '51754-5012-4']",['8MDF5V39QO'],,,,,,,,,
New,07/21/2025,73070-100-11,Insulin Aspart Injection,609-987-5800,,"Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injection,"Insulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA020986'],['INSULIN ASPART'],['INSULIN ASPART'],"['Novo Nordisk Pharma, Inc.']","['73070-100', '73070-102', '73070-103']",['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['INSULIN ASPART'],"['311040', '1653196', '1653202']",['393af9a3-df9a-40b2-a5e6-bfa5434a2552'],['bee5b358-c863-420b-be73-ced2e920c499'],"['73070-100-11', '73070-102-10', '73070-102-15', '73070-103-10', '73070-103-15']",['D933668QVX'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
Revised,07/14/2023,72205-134-91,"Lisdexamfetamine Dimesylate Tablet, Chewable",(855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)",Novadoz Pharmaceuticals LLC,Shortage of an active ingredient,Current,['ANDA218306'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Novadoz Pharmaceuticals LLC'],"['72205-134', '72205-132', '72205-133', '72205-135', '72205-136', '72205-137']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],['a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811'],"['72205-132-91', '72205-133-91', '72205-134-91', '72205-135-91', '72205-136-91', '72205-137-91']",['SJT761GEGS'],,,,,,,,,
Reverified,03/24/2023,0009-0013-05,Hydrocortisone Sodium Succinate Injection,844-646-4398,Available,,10/23/2025,"['Pulmonary/Allergy', 'Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Renal', 'Rheumatology']",Injection,"Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)","Hospira, Inc., a Pfizer Company",,Current,['NDA009866'],['SOLU-CORTEF'],['HYDROCORTISONE SODIUM SUCCINATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0013', '0009-0825', '0009-0011', '0009-0016', '0009-0005']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],"['105398', '238755', '1738586', '1738589', '1738590', '1738592', '1738594', '1738596']",['8512044a-4a54-4634-bb97-9e20126adc61'],['65eefd58-b166-4d71-ade6-45c8fdf86922'],"['0009-0825-01', '0009-0011-03', '0009-0011-04', '0009-0013-05', '0009-0013-06', '0009-0016-12', '0009-0005-01']",['50LQB69S1Z'],,,,,,,,,
Reverified,04/10/2020,44567-601-04,Dexmedetomidine Hydrochloride Injection,WG Critical Care 888-493-0861,Available,Marketed by WG Critical Care,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)",HQ Specialty Pharma,,Current,['NDA206628'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],"['WG Critical Care, LLC']","['44567-601', '44567-600', '44567-602', '44567-603']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909', '1788947']",['e6fa3e27-b374-49b6-a678-a5954f5beae8'],['0d2710f2-ee47-4114-ab5c-8dca74cdcb8d'],"['44567-600-04', '44567-601-04', '44567-602-24', '44567-603-24']",['1018WH7F9I'],,,,,,,,,
New,06/10/2025,49230-300-10,Sodium Chloride 0.9% Injection,800-323-5188,,Discontinuation of the manufacture of the drug,06/10/2025,"['Gastroenterology', 'Renal']",Injection,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 49230-300-10)",Fresenius Medical Care North America,,To Be Discontinued,['ANDA078177'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Fresenius Medical Care North America'],['49230-300'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],['1807639'],['26587576-d68d-4c98-e063-6394a90ac53d'],['af5cdf1a-19f4-11e2-892e-0800200c9a66'],['49230-300-10'],['451W47IQ8X'],,,,06/10/2025,,,,,
Reverified,03/13/2023,0143-9519-10,Methotrexate Sodium Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,10/24/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA089340'],['METHOTREXATE'],['METHOTREXATE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9519', '0143-9518', '0143-9517', '0143-9516']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE'],"['1655959', '1655960', '1655967', '1655968']",['3046ff78-3565-46d1-a88b-283e5ff6e7c3'],['3989d30d-56e5-4e8d-9379-c30fecc894f2'],"['0143-9519-10', '0143-9518-01', '0143-9517-01', '0143-9516-01']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
Reverified,04/28/2023,0338-0004-03,Sterile Water Irrigant,888-229-0001,Available,,10/22/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)",Baxter Healthcare,,Current,['NDA017428'],['STERILE WATER'],['WATER'],['Baxter Healthcare Corporation'],"['0338-0004', '0338-0003']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['43dc7530-ed0a-4976-af2a-0d39a2532fb7'],['ef3e79c5-3f58-4b36-a296-64b7d9a651c1'],"['0338-0003-44', '0338-0003-46', '0338-0003-47', '0338-0004-02', '0338-0004-03', '0338-0004-04', '0338-0004-05']",['059QF0KO0R'],,,,,,,,,
Reverified,01/13/2022,0409-0152-24,Metronidazole Injection,866-625-1618,Limited Availability,Labeler: Hospira Inc.,09/22/2025,['Anti-Infective'],Injection,"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)",InfoRLife SA,Other,Current,['ANDA206191'],['METRONIDAZOLE'],['METRONIDAZOLE'],"['Hospira, Inc.']",['0409-0152'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['METRONIDAZOLE'],['311683'],['016415af-48d9-4058-a80e-f5dd1704e6fc'],['49360d6f-c8b3-420e-af75-154cf7b05255'],"['0409-0152-01', '0409-0152-24']",['140QMO216E'],"['N0000175435', 'M0014907']",['Nitroimidazole Antimicrobial [EPC]'],,,,['Nitroimidazoles [CS]'],,,
Revised,01/01/2012,67457-530-35,Leucovorin Calcium Injection,800-796-9526,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium Preservative Free, Injection, 350 mg/17.5 mL (NDC 67457-530-35)","Mylan Institutional, a Viatris Company",,Resolved,['ANDA203800'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Mylan Institutional LLC'],"['67457-530', '67457-528', '67457-529']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803932', '1803937']",['2890b03c-dbef-4db8-8b07-c042d7765677'],['1cb701ca-2478-4268-9d69-80293965d59d'],"['67457-528-10', '67457-529-20', '67457-530-35']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
New,04/28/2025,0832-7123-15,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7123', '0832-7122', '0832-7124']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
Revised,01/06/2023,0169-7703-21,Somatropin Injection,609-987-5800,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)","Novo Nordisk, Inc.",,Resolved,['BLA021148'],['NORDITROPIN'],['SOMATROPIN'],['Novo Nordisk'],"['0169-7703', '0169-7704', '0169-7705', '0169-7708']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['SOMATROPIN'],"['847243', '847245', '847247', '847348', '849850', '849851', '1736262', '1736329']",['b67c2419-4feb-4ce1-b97e-88760a8e1aee'],['1058e17c-9261-459c-a3e6-fae38d196c14'],"['0169-7704-21', '0169-7704-92', '0169-7705-21', '0169-7705-92', '0169-7708-21', '0169-7708-92', '0169-7703-11', '0169-7703-91', '0169-7703-21', '0169-7703-92']",['NQX9KB6PCL'],"['N0000175606', 'M0028842']",['Recombinant Human Growth Hormone [EPC]'],,,,['Human Growth Hormone [CS]'],08/28/2025,,Available
Revised,10/31/2017,0409-1891-01,Morphine Sulfate Injection,844-646-4398,Unavailable,Next Delivery: November 2025; Estimated Recovery: March 2026,10/23/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA202515'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-1891', '0409-1890', '0409-1892', '0409-1893', '0409-1894']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['894912', '998212', '998213', '1729197', '1731995', '1732014']",['cced2ec0-6c94-4cf0-87fb-041667ee3214'],['be420e8b-bcb0-49b5-bb4d-1df8b9959809'],"['0409-1890-03', '0409-1890-01', '0409-1890-13', '0409-1890-23', '0409-1891-03', '0409-1891-01', '0409-1891-13', '0409-1891-23', '0409-1892-03', '0409-1892-01', '0409-1892-13', '0409-1892-23', '0409-1893-03', '0409-1893-01', '0409-1893-13', '0409-1893-23', '0409-1894-03', '0409-1894-01']",['X3P646A2J0'],,,,,,,,,
Revised,06/13/2018,55150-252-20,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)",Eugia US LLC,,Current,['ANDA207182'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-252', '55150-251', '55150-254', '55150-255', '55150-253', '55150-256']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', '0b1f03c2-db2f-4f90-acc0-d73abd731bf6']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', 'ef782e5e-e2d7-465a-99c6-b12611f3158c']","['55150-251-24', '55150-252-24', '55150-254-24', '55150-255-24', '55150-251-10', '55150-252-20', '55150-253-50', '55150-254-10', '55150-255-20', '55150-256-50']",['V13007Z41A'],,,,,,,,,
Reverified,01/01/2012,0517-1004-25,Atropine Sulfate Injection,800-645-1706,Available,old NDC 0517-0401-25,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)","American Regent, Inc.",,Current,['ANDA216120'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['American Regent, Inc.']","['0517-1004', '0517-1001']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190795', '1666781']",['1c500ed9-94a9-472c-bfb7-50e1fcfc31fb'],['6fee1727-52b7-4f73-ab45-ef47d6a1c5bb'],"['0517-1004-01', '0517-1004-25', '0517-1001-01', '0517-1001-25']",['03J5ZE7KA5'],,,,,,,,,
New,11/03/2025,0002-4491-61,Lasmiditan Succinate Tablet,800-545-5979,,A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets.,11/03/2025,['Neurology'],Tablet,"Reyvow, Tablet, 100 mg (NDC 0002-4491-61)",Eli Lilly and Co.,,To Be Discontinued,['NDA211280'],['REYVOW'],['LASMIDITAN'],['Eli Lilly and Company'],"['0002-4491', '0002-4312']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LASMIDITAN'],"['2256937', '2256943', '2256945', '2256947']",['75a13e98-3736-4256-8277-6c05bcaddcf5'],['aea3358c-ff41-4490-9e6d-c7bf7b3de13f'],"['0002-4312-08', '0002-4312-61', '0002-4312-62', '0002-4491-08', '0002-4491-61', '0002-4491-62']",['760I9WM792'],,,,11/03/2025,,,,,
Reverified,02/28/2025,0378-8260-93,"Methylphenidate Film, Extended Release",800-796-9526,Available,,11/06/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 10mg/9hrs (NDC 0378-8260-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA206497'],['METHYLPHENIDATE'],['METHYLPHENIDATE'],['Mylan Pharmaceuticals Inc.'],"['0378-8260', '0378-8261', '0378-8262', '0378-8263']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['435703f5-35b9-4d50-a12a-89546888c61a'],['1643b6a5-80da-4d4f-8c5f-feb907875702'],"['0378-8260-16', '0378-8260-93', '0378-8261-16', '0378-8261-93', '0378-8262-16', '0378-8262-93', '0378-8263-16', '0378-8263-93']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
Revised,10/12/2022,57844-112-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],['ADDERALL'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['57844-112', '57844-105', '57844-117', '57844-110', '57844-115', '57844-120', '57844-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541365', '541878', '541879', '541892', '541894', '577957', '577960', '577961', '577962', '687043', '687045', '1009145', '1009147']",['79af1dc6-c7cf-41b1-a750-e9b47c2187ff'],['f22635fe-821d-4cde-aa12-419f8b53db81'],"['57844-105-01', '57844-117-01', '57844-110-01', '57844-112-01', '57844-115-01', '57844-120-01', '57844-130-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,03/01/2022,0338-0023-04,Dextrose Monohydrate 10% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)",Baxter Healthcare,,Current,['NDA016694'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0023', '0338-0017']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Revised,06/21/2018,0019-1188-81,Sodium Chloride 0.9% Injection,877-729-6679,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-81)",Guerbet LLC,,Resolved,['NDA021569'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Liebel-Flarsheim Company LLC'],['0019-1188'],['HUMAN PRESCRIPTION DRUG'],['INTRAVASCULAR'],['SODIUM CHLORIDE'],,['cdff7813-7b00-4f61-a017-18ab8910d49d'],['e4540d03-06b4-4b4d-b859-75c13e5c20dd'],"['0019-1188-81', '0019-1188-27']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,07/26/2023,57664-609-88,"Methylphenidate Hydrochloride Tablet, Extended Release",800-818-4555,Unavailable,Currently not marketed,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)","Sun Pharmaceutical Industries, Inc.",Discontinuation of the manufacture of the drug,Current,['ANDA205135'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-609', '57664-606', '57664-607', '57664-608']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['0da4b745-d498-8823-e063-6394a90a4524'],['d048e52d-7406-4fc1-9a72-c073bafc7439'],"['57664-606-88', '57664-607-88', '57664-608-88', '57664-609-88']",['4B3SC438HI'],,,,,,,,,
Revised,12/10/2021,0338-9159-30,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-9159-30)",Baxter Healthcare,,Resolved,['NDA020178'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9159', '0338-9151']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632']",['39f15dfb-4e73-4959-ad9b-4ee502278b4b'],['aeaed9cb-b629-4019-88d2-a916179427de'],"['0338-9159-30', '0338-9151-30']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,01/01/2012,25021-815-30,Leucovorin Calcium Injection,866-625-1618,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 25021-815-30)",Sagent Pharmaceuticals,,Resolved,['ANDA200753'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Sagent Pharmaceuticals'],"['25021-815', '25021-813', '25021-814', '25021-816']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['ff2ba160-e2f9-4ab9-9e67-2409f02c923e'],['9d0e5356-ff39-4a8e-944c-e808a21ef4b2'],"['25021-813-10', '25021-814-30', '25021-815-30', '25021-816-30']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,10/12/2022,42806-345-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(718) 276-8600 ext. 3,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)","Epic Pharma, LLC",,Current,['ANDA040444'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Epic Pharma, LLC']","['42806-345', '42806-339', '42806-341', '42806-343', '42806-344']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961']",['f11301e2-3b5d-468d-b44c-45839e7e5dfb'],['1757e132-061d-4773-89ed-fdc77f69008f'],"['42806-339-01', '42806-341-01', '42806-343-01', '42806-344-01', '42806-345-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,03/23/2018,62332-601-25,Ketorolac Tromethamine Injection,908-393-9604,Available,,09/17/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)",Alembic Pharmaceuticals,,Current,['ANDA214456'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Alembic Pharmaceuticals Inc.'],"['62332-601', '62332-599', '62332-600']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['9030f496-5021-4454-ac16-dbb376315608'],['419cf756-3c96-4bb8-ae96-6aea5a5f3afd'],"['62332-599-01', '62332-599-25', '62332-600-01', '62332-600-25', '62332-601-02', '62332-601-25']",['4EVE5946BQ'],,,,,,,,,
Revised,01/13/2022,0409-6648-02,Dextrose Monohydrate 50% Injection,844-646-4398,Available,,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)","Hospira, Inc., a Pfizer Company",,Current,['NDA019445'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Hospira, Inc.']","['0409-6648', '0409-7517', '0409-4902', '0409-0505']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['727517', '1795514']",['0fca7d54-4d75-455b-a1d7-d25e31702264'],['4ed365da-4e62-4329-c1b9-c197ab4fb6e1'],"['0409-7517-66', '0409-7517-16', '0409-4902-64', '0409-4902-34', '0409-6648-16', '0409-6648-02', '0409-0505-15', '0409-0505-25']",['LX22YL083G'],,,,,,,,,
Reverified,12/18/2020,72485-201-01,Azacitidine Injection,1-732-637-1971,Available,,09/16/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg (NDC 72485-201-01)",Armas Pharmaceuticals Inc,,Current,['ANDA207518'],['AZACITIDINE'],['AZACITIDINE'],['Armas Pharmaceuticals Inc.'],['72485-201'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['ca345575-17a6-43a3-aa02-3d4bb9d136c5'],['5c0a2d5f-8c34-4c04-8425-7543965cedd4'],['72485-201-01'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
Revised,12/15/2021,0009-0280-51,Methylprednisolone Acetate Injection,844-646-4398,Available,,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)",Pfizer Inc.,,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0280', '0009-0274', '0009-0306']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358510', '1358512', '1358610', '1358612', '1358617', '1358619']",['4cf5a255-1360-4511-9b58-b92e3492ef12'],['823b0010-2b57-4e76-b5ac-4a8c2963438f'],"['0009-0274-01', '0009-0280-02', '0009-0280-51', '0009-0280-03', '0009-0280-52', '0009-0306-02', '0009-0306-12']",['43502P7F0P'],,,,,,,,,
Revised,12/10/2021,0264-7802-00,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-00)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-7802', '0264-7800']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807633', '1807634', '1807639']",['9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa'],['7f22c06b-6b4d-4b49-a4b2-d2169f2bd653'],"['0264-7800-00', '0264-7800-10', '0264-7800-20', '0264-7802-00', '0264-7802-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,12/15/2021,0009-3073-23,Methylprednisolone Acetate Injection,844-646-4398,Available,,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)",Pfizer Inc.,,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-3073', '0009-3475']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE', 'INTRA-ARTICULAR']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743781', '1743855', '1743856']","['bdefc300-8d7c-474c-9771-200628f25035', 'befd723e-d1e2-41b9-83f1-17bca0c2a941']","['bf1b104d-85cb-414d-a366-78068c82c883', '9a7b3837-e038-48bf-97e9-78ad463760dc']","['0009-3073-22', '0009-3073-23', '0009-3475-22', '0009-3475-23', '0009-3073-01', '0009-3073-03', '0009-3475-01', '0009-3475-03']",['43502P7F0P'],,,,,,,,,
Reverified,03/26/2018,25021-700-01,Ketorolac Tromethamine Injection,866-625-1618,Available,,08/26/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)",Sagent Pharmaceuticals,,Current,['ANDA204216'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Sagent Pharmaceuticals'],"['25021-700', '25021-701']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['ff55e1ab-2a8d-4a56-8b72-5e0a8e00d866'],['62591551-a644-4b2c-a0de-982e906fabc3'],"['25021-700-01', '25021-701-01', '25021-701-02']",['4EVE5946BQ'],,,,,,,,,
New,03/04/2025,65862-587-01,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 40 mg (NDC 65862-587-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-587', '65862-582', '65862-583', '65862-584', '65862-585', '65862-586']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
Revised,04/28/2023,0264-2201-00,Sodium Chloride 0.9% Irrigation,800-227-2862,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-00)",B. Braun Medical Inc.,,Resolved,['NDA016733'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],['0264-2201'],['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['35e26a6d-60d6-4388-84e9-c481a3b69ee7'],['0d59a04a-32e6-485b-b638-a1e6c09e9642'],"['0264-2201-00', '0264-2201-10', '0264-2201-50', '0264-2201-70']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
New,04/28/2025,0245-0211-01,Midodrine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Cardiovascular'],Tablet,"Orvaten, Tablet, 2.5 mg (NDC 0245-0211-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076725'],['MIDODRINE HYDROCHLORIDE'],['MIDODRINE HYDROCHLORIDE'],"['Upsher-Smith laboratories, LLC']","['0245-0211', '0245-0212', '0245-0213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MIDODRINE HYDROCHLORIDE'],"['993462', '993466', '993470']",['18b0b9f5-6026-479e-af12-92b0e71a9d6b'],['4c3517f3-1c68-4ade-b5f1-c488a3a335c1'],"['0245-0211-11', '0245-0211-89', '0245-0211-01', '0245-0212-11', '0245-0212-89', '0245-0212-01', '0245-0213-11', '0245-0213-89', '0245-0213-01']",['59JV96YTXV'],,,,04/28/2025,,,,,
New,11/03/2025,60951-602-70,Acetaminophen; Oxycodone Hydrochloride Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,11/03/2025,['Analgesia/Addiction'],Tablet,"Percocet, Tablet, 325 mg; 5 mg (NDC 60951-602-70)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA040330'],['ENDOCET'],['OXYCODONE AND ACETAMINOPHEN'],"['ENDO USA, Inc.']","['60951-602', '60951-700', '60951-712', '60951-701']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ACETAMINOPHEN', 'OXYCODONE HYDROCHLORIDE']","['1049214', '1049216', '1049221', '1049223', '1049225', '1049227', '1049635', '1487288']",['2a088d17-73b2-457f-99f6-efcd32f648a5'],['944d3e60-7eee-11de-a413-0002a5d5c51b'],"['60951-602-70', '60951-602-85', '60951-700-70', '60951-712-70', '60951-701-70']","['C1ENJ2TE6C', '362O9ITL9D']",,,,11/03/2025,,,,,
New,12/05/2024,63304-693-11,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-11)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-693', '63304-692']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
New,02/28/2025,0187-5102-03,Pimecrolimus Cream,908-927-1400,,Authorized generics is still marketed and available under NDC 68682-112-03,02/28/2025,['Dermatology'],Cream,"Elidel, Cream, 100gm (NDC 0187-5102-03)","Bausch Health Americas, Inc.",,To Be Discontinued,['NDA021302'],['ELIDEL'],['PIMECROLIMUS'],"['Bausch Health US, LLC']","['0187-5102', '0187-5101', '0187-5100', '0187-5103']",['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['PIMECROLIMUS'],"['352085', '562806']",['2f802a3f-c021-45c1-8693-5689c30c3fc6'],['e4027e5a-0f9b-4070-b196-f60172f45c4c'],"['0187-5102-03', '0187-5101-02', '0187-5100-01', '0187-5103-04']",['7KYV510875'],"['N0000175457', 'N0000175458']",['Calcineurin Inhibitor Immunosuppressant [EPC]'],,02/28/2025,,,,['Calcineurin Inhibitors [MoA]'],
Revised,12/08/2023,0054-3500-49,Lidocaine Hydrochloride Solution,800-631-2174,,,08/29/2025,['Anesthesia'],Solution,"Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-3500-49)","Hikma Pharmaceuticals USA, Inc.",,Resolved,['ANDA088802'],['LIDOCAINE VISCOUS'],['LIDOCAINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-3500', '0054-0548']",['HUMAN PRESCRIPTION DRUG'],"['ORAL', 'TOPICAL']",['LIDOCAINE HYDROCHLORIDE'],['1010739'],['182f3e6b-1622-4eef-80e5-d08ffbbbd30e'],['79b42076-359d-4258-b1d8-f40e67ac5424'],"['0054-3500-49', '0054-0548-44']",['V13007Z41A'],,,,,,,08/29/2025,,Available
New,06/13/2025,13668-386-05,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-05)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
New,06/13/2025,0409-0332-20,Bleomycin Sulfate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,06/13/2025,"['Hematology', 'Oncology', 'Pediatric']",Injection,"Bleomycin Sulfate, Injection, 15 [USP'U] (NDC 0409-0332-20)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA065031'],['BLEOMYCIN'],['BLEOMYCIN'],"['Hospira, Inc.']","['0409-0332', '0409-0323']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAPLEURAL', 'INTRAVENOUS', 'SUBCUTANEOUS']",['BLEOMYCIN SULFATE'],"['1726673', '1726676']",['d9e9c332-1b3f-469c-83b8-41e15183e635'],['e629ba5a-4e08-4249-9551-af6dbd98a7e4'],"['0409-0323-20', '0409-0332-20']",['7DP3NTV15T'],,,,06/13/2025,,,,,
Revised,06/28/2022,0143-9392-10,Remifentanil Hydrochloride Injection,800-631-2174,Available,Additional lots will be available.  Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA210594'],['REMIFENTANIL HYDROCHLORIDE'],['REMIFENTANIL HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9392', '0143-9391', '0143-9393']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729584', '1729710']",['5c5e498b-d829-4f78-bcca-466631014767'],['9d289052-1eb6-4ba2-a3ca-d2e542a052ae'],"['0143-9391-01', '0143-9391-10', '0143-9392-01', '0143-9392-10', '0143-9393-01', '0143-9393-10']",['5V444H5WIC'],,,,,,,,,
Reverified,09/20/2023,0527-4666-37,Lisdexamfetamine Dimesylate Capsule,844-834-0530,Limited Availability,Limited Availability,11/03/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA215802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Lannett Company, Inc.']","['0527-4666', '0527-4661', '0527-4662', '0527-4663', '0527-4664', '0527-4665', '0527-4667']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7ac942a6-689a-420b-87bf-dc59003400dc'],['2cedb4c2-1e40-4bc4-b9f4-127150c4afbd'],"['0527-4661-37', '0527-4662-37', '0527-4663-37', '0527-4664-37', '0527-4665-37', '0527-4666-37', '0527-4667-37']",['SJT761GEGS'],,,,,,,,,
New,02/07/2025,65862-118-01,Benazepril Hydrochloride Tablet,866-850-2876,,,02/07/2025,['Cardiovascular'],Tablet,"Benazepril Hydrochloride, Tablet, 40 mg (NDC 65862-118-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA078212'],['BENAZEPRIL HYDROCHLORIDE'],['BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-118', '65862-116', '65862-117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BENAZEPRIL HYDROCHLORIDE'],"['898687', '898690', '898719']",['65334c7f-e49f-44d9-a6c1-6c1ce6e88fbe'],['09e383a8-e912-4cf7-8fb3-05545af80dd0'],"['65862-116-90', '65862-116-01', '65862-117-90', '65862-117-01', '65862-118-90', '65862-118-01']",['N1SN99T69T'],,,,02/07/2025,,,,,
Revised,11/03/2017,0641-6127-25,Morphine Sulfate Injection,800-631-2174,Unavailable,Additional Lots scheduled to be available in the November 2025 timeframe.,10/24/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA205758'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6127', '0641-6126', '0641-6125']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['1731993', '1732006', '1732011']",['fa18221d-2353-4cf6-a210-fb33ee79d3d9'],['6023606c-150c-40c5-9175-598efe2a56c3'],"['0641-6126-01', '0641-6126-25', '0641-6127-01', '0641-6127-25', '0641-6125-01', '0641-6125-25']",['X3P646A2J0'],,,,,,,,,
Revised,06/13/2018,55150-255-20,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)",Eugia US LLC,,Current,['ANDA207182'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-255', '55150-251', '55150-252', '55150-254', '55150-253', '55150-256']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', '0b1f03c2-db2f-4f90-acc0-d73abd731bf6']","['ccc38d8a-43fd-44c0-985e-32af9ed956ab', 'ef782e5e-e2d7-465a-99c6-b12611f3158c']","['55150-251-24', '55150-252-24', '55150-254-24', '55150-255-24', '55150-251-10', '55150-252-20', '55150-253-50', '55150-254-10', '55150-255-20', '55150-256-50']",['V13007Z41A'],,,,,,,,,
Reverified,11/06/2017,0409-2344-02,Dobutamine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA074086'],['DOBUTAMINE'],['DOBUTAMINE'],"['Hospira, Inc.']",['0409-2344'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],['1812168'],"['e71e9520-871b-479d-9652-1857fceca863', '5d6b1dfe-d679-4aea-97a6-3d074a202afe']","['dc537761-d5f4-488d-24ab-b2bcd2b17b7a', '89becb0c-da60-4f43-0a98-29ff7a9eca58']","['0409-2344-01', '0409-2344-62', '0409-2344-02', '0409-2344-68', '0409-2344-88']",['0WR771DJXV'],,,,,,,12/19/2024,,
New,04/10/2025,0781-2076-01,Tamsulosin Hydrochloride Capsule,800-525-8747,,,04/10/2025,['Urology'],Capsule,"Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-01)",Sandoz Inc.,,To Be Discontinued,['ANDA078015'],['TAMSULOSIN HYDROCHLORIDE'],['TAMSULOSIN HYDROCHLORIDE'],['Sandoz Inc'],['0781-2076'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TAMSULOSIN HYDROCHLORIDE'],['863669'],['98c2abd9-1998-48cd-83f9-f5f94ff39345'],['fb120098-b007-4a33-80b8-b7279c7668ee'],"['0781-2076-01', '0781-2076-10', '0781-2076-92']",['11SV1951MR'],,,,04/10/2025,,,,,
Revised,12/04/2024,0228-2067-10,Oxazepam Capsule,800-545-8800,,,07/03/2025,"['Neurology', 'Psychiatry']",Capsule,"Oxazepam, Capsule, 10 mg (NDC 0228-2067-10)","Teva Pharmaceuticals USA, Inc.",,Resolved,['ANDA072253'],['OXAZEPAM'],['OXAZEPAM'],"['Actavis Pharma, Inc.']","['0228-2067', '0228-2069', '0228-2073']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXAZEPAM'],"['198057', '198059', '312134']",['f191a7db-b292-4119-b144-b25c0555b050'],['a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43'],"['0228-2067-10', '0228-2069-10', '0228-2073-10']",['6GOW6DWN2A'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],07/03/2025,,Available
Revised,10/12/2022,0555-0971-02,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Limited Availability,Estimated availability: January 2026,11/06/2025,['Psychiatry'],Tablet,"Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA040422'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['0555-0971', '0555-0775', '0555-0972', '0555-0776', '0555-0777', '0555-0973', '0555-0974']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['88468f3d-7d03-4cee-aabf-3abc8c9b5e38'],['cffbbb15-d776-41ae-a8a6-687f2c07bfa4'],"['0555-0971-02', '0555-0775-02', '0555-0972-02', '0555-0776-02', '0555-0777-02', '0555-0973-02', '0555-0974-02']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,02/20/2018,0409-1559-30,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,02/29/2024,47335-326-83,Naltrexone Hydrochloride Tablet,800-818-4555,Limited Availability,Additional supply anticipated early 2026,10/21/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-83)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA090356'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']",['47335-326'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['b0c2b60a-dc96-483b-933e-2fed58b64372'],['0f30f885-d0cd-4fa6-a8e0-142f08a56792'],"['47335-326-83', '47335-326-88', '47335-326-08', '47335-326-18']",['Z6375YW9SF'],,,,,,,,,
Reverified,10/12/2022,64850-501-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",888-852-6657,Limited Availability,3 months,11/04/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA211352'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Elite Laboratories, Inc.']","['64850-501', '64850-500', '64850-502', '64850-503', '64850-504', '64850-505', '64850-506']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['b65e0266-7172-4730-8f93-eb42e08fb7b8'],['e677690f-790f-4626-ad78-097cdb6ea540'],"['64850-500-01', '64850-500-05', '64850-500-30', '64850-501-01', '64850-501-05', '64850-501-30', '64850-502-01', '64850-502-05', '64850-502-30', '64850-503-01', '64850-503-05', '64850-503-30', '64850-504-01', '64850-504-05', '64850-504-30', '64850-505-01', '64850-505-05', '64850-505-30', '64850-506-01', '64850-506-05', '64850-506-30']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,10/14/2016,63323-482-27,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-482', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,04/24/2025,0245-1072-30,"Topiramate Capsule, Extended Release",716-315-2000,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,04/24/2025,['Neurology'],"Capsule, Extended Release","Qudexy XR, Capsule, Extended Release, 50 mg (NDC 0245-1072-30)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA205122'],['QUDEXY XR'],['TOPIRAMATE'],"['Upsher-Smith Laboratories, LLC']","['0245-1072', '0245-1071', '0245-1074', '0245-1075', '0245-1073']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOPIRAMATE'],"['1494766', '1494769', '1494771', '1494775', '1494778', '1494781', '1812419', '1812421', '1812425', '1812427']",['374eeb55-b017-48fd-e063-6294a90a6ad7'],['46f54677-3a22-4c38-9b92-923020164e15'],"['0245-1071-30', '0245-1071-90', '0245-1072-30', '0245-1072-90', '0245-1074-30', '0245-1074-90', '0245-1075-30', '0245-1075-90', '0245-1073-30', '0245-1073-90']",['0H73WJJ391'],"['N0000008486', 'N0000185506', 'N0000182140']",,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],04/24/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
New,04/28/2023,0069-4370-71,Prazosin Hydrochloride Capsule,800-533-4535,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,04/28/2023,['Cardiovascular'],Capsule,"Minipress, Capsule, 2 mg (NDC 0069-4370-71)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,04/28/2023,,,04/28/2023,,
Reverified,02/22/2012,63323-486-57,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-486', '63323-492', '63323-491', '63323-495', '63323-485', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,08/15/2025,0591-3985-60,Celecoxib Capsule,800-545-8800,,Discontinuation of the manufacture of the drug,08/15/2025,['Analgesia/Addiction'],Capsule,"Celecoxib, Capsule, 400 mg (NDC 0591-3985-60)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA200562'],['CELECOXIB'],['CELECOXIB'],"['Actavis Pharma, Inc.']","['0591-3985', '0591-3982', '0591-3983', '0591-3984']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CELECOXIB'],"['205322', '205323', '349514', '686379']",['64c601bc-9b67-400f-9e30-e26de56f2f8b'],['05224473-27dc-4f6d-a52a-c40a7af2f2f4'],"['0591-3982-60', '0591-3983-01', '0591-3983-05', '0591-3984-01', '0591-3984-05', '0591-3985-60']",['JCX84Q7J1L'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,08/15/2025,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
New,10/10/2025,0781-3518-76,Pemetrexed Disodium Injection,800-525-8747,,Discontinuation of the manufacture of the drug,10/10/2025,['Oncology'],Injection,"Pemetrexed Disodium, Injection, 100 mg/4 mL (NDC 0781-3518-76)",Sandoz Inc.,,To Be Discontinued,['NDA214657'],['PEMETREXED'],['PEMETREXED DISODIUM'],['Sandoz Inc.'],"['0781-3518', '0781-3519', '0781-3520']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PEMETREXED DISODIUM'],"['2602363', '2602365', '2602366']",['770c3cd5-b229-4666-b004-ca43e69fbade'],['7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3'],"['0781-3518-76', '0781-3519-90', '0781-3520-91']",['2PKU919BA9'],,,,10/10/2025,,,,,
Reverified,02/22/2012,63323-495-07,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-495', '63323-492', '63323-491', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,02/14/2025,0378-8212-60,Erythromycin  Topical Gel,800-796-9526,,,02/14/2025,"['Anti-Infective', 'Dermatology']",Topical Gel,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-60)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,,,,,,,,,,,,,,,,,02/14/2025,,,,,
New,04/23/2025,0832-1055-11,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 20 mg (NDC 0832-1055-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074584'],['BACLOFEN'],['BACLOFEN'],"['Upsher-Smith Laboratories, LLC']","['0832-1055', '0832-1054']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BACLOFEN'],"['197391', '197392']",['395d77da-1674-a9a4-e063-6394a90aa3d7'],['b2747a9d-5fca-4657-9e4b-4112607f30d8'],"['0832-1054-90', '0832-1054-11', '0832-1054-15', '0832-1054-10', '0832-1055-90', '0832-1055-11', '0832-1055-15', '0832-1055-10']",['H789N3FKE8'],"['N0000000196', 'N0000000116', 'N0000175759']",['gamma-Aminobutyric Acid-ergic Agonist [EPC]'],,04/23/2025,,,,"['GABA A Agonists [MoA]', 'GABA B Agonists [MoA]']",
New,05/14/2025,0832-0742-60,"Propafenone Hydrochloride Capsule, Extended Release",800-654-2299,,A business decision was made to discontinue the product.,05/14/2025,['Cardiovascular'],"Capsule, Extended Release","Propafenone Hydrochloride, Capsule, Extended Release, 425 mg (NDC 0832-0742-60)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA212744'],['PROPAFENONE HYDROCHLORIDE'],['PROPAFENONE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0742', '0832-0740', '0832-0741']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PROPAFENONE HYDROCHLORIDE'],"['861156', '861164', '861171']",['398513af-dd95-49eb-e063-6394a90a73f4'],['8aa6f58a-2980-4caa-9c54-d55d69d5d132'],"['0832-0740-60', '0832-0741-60', '0832-0742-60']",['33XCH0HOCD'],,,,05/14/2025,,,,,
Reverified,07/14/2023,0406-5115-01,Lisdexamfetamine Dimesylate Capsule,800-325-8888,Limited Availability,Allocation to all customers. Backorder expected in November with next release in December 2025.,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA211840'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['SpecGx LLC'],"['0406-5115', '0406-5111', '0406-5112', '0406-5113', '0406-5114', '0406-5116', '0406-5117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['3ffc0695-83f7-4898-9fd7-451c0989cfe0'],['806a1c15-0842-4787-b2ad-09a21fd96b37'],"['0406-5111-01', '0406-5112-01', '0406-5113-01', '0406-5114-01', '0406-5115-01', '0406-5116-01', '0406-5117-01']",['SJT761GEGS'],,,,,,,,,
New,11/21/2024,0173-0906-56,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 4 mg (NDC 0173-0906-56)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0906', '0173-0897', '0173-0903', '0173-0911', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Reverified,03/27/2018,25021-671-87,Ropivacaine Hydrochloride Injection,Sagent: 866-625-1618,Available,Marketed by Sagent Pharmaceuticals,08/26/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)",InfoRLife SA,,Current,['ANDA206166'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Sagent Pharmaceuticals'],"['25021-671', '25021-652']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734347', '1734355', '1734479', '1734481']","['04d1b1c6-1963-4b42-8479-dbf787b6de17', '2eb59cb8-dab8-43f4-ad73-672446e104ca']","['8c5c762f-d266-4b1a-809e-f11bfc89bc2d', '9572b3de-684c-4028-a577-5aa69ba6b02d']","['25021-671-82', '25021-671-87', '25021-652-82', '25021-652-87', '25021-671-66', '25021-671-67']",['V910P86109'],,,,,,,,,
New,08/29/2025,82497-015-04,Methotrexate Injection,224-441-6390,,Discontinuation of the manufacture of the drug,08/29/2025,['Rheumatology'],Injection,"Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)","Assertio Specialty Pharmaceuticals, LLC",,To Be Discontinued,['NDA204824'],['OTREXUP'],['METHOTREXATE'],"['Otter Pharmaceuticals, LLC']","['82497-015', '82497-010', '82497-012', '82497-017', '82497-020', '82497-022', '82497-025']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['METHOTREXATE'],"['1441402', '1441407', '1441411', '1441413', '1441416', '1441418', '1441422', '1441424', '1747179', '1747181', '1747185', '1747187', '1747192', '1747194']",['9aaba145-f343-4498-b754-fb7c78181bd7'],['7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f'],"['82497-010-02', '82497-010-04', '82497-012-02', '82497-012-04', '82497-015-02', '82497-015-04', '82497-017-02', '82497-017-04', '82497-020-02', '82497-020-04', '82497-022-02', '82497-022-04', '82497-025-02', '82497-025-04']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,08/29/2025,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
Reverified,03/24/2023,0009-0825-01,Hydrocortisone Sodium Succinate Injection,844-646-4398,Available,,10/23/2025,"['Pulmonary/Allergy', 'Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Renal', 'Rheumatology']",Injection,"Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)","Hospira, Inc., a Pfizer Company",,Current,['NDA009866'],['SOLU-CORTEF'],['HYDROCORTISONE SODIUM SUCCINATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0825', '0009-0011', '0009-0013', '0009-0016', '0009-0005']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],"['105398', '238755', '1738586', '1738589', '1738590', '1738592', '1738594', '1738596']",['8512044a-4a54-4634-bb97-9e20126adc61'],['65eefd58-b166-4d71-ade6-45c8fdf86922'],"['0009-0825-01', '0009-0011-03', '0009-0011-04', '0009-0013-05', '0009-0013-06', '0009-0016-12', '0009-0005-01']",['50LQB69S1Z'],,,,,https://www.fda.gov/media/187228/download,,,,
Revised,03/21/2023,0009-5095-06,Clindamycin Phosphate Injection,800-533-4535,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: March 2026,10/23/2025,['Anti-Infective'],Injection,"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)",Pfizer Inc.,Other,Current,['NDA050441'],['CLEOCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Pharmacia & Upjohn Company LLC'],"['0009-5095', '0009-3051', '0009-4073']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['1737244', '1737245', '1737578', '1737579', '1737581', '1737582']",['9c0a7367-763b-48c3-95b1-173b74c50f4b'],['a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b'],"['0009-3051-01', '0009-3051-02', '0009-4073-03', '0009-4073-04', '0009-5095-05', '0009-5095-06']",['EH6D7113I8'],,,,,,,,,
New,01/22/2025,71093-129-03,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-03)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-129', '71093-130', '71093-131']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Reverified,07/26/2023,62175-313-37,"Methylphenidate Hydrochloride Tablet, Extended Release",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)","Lannett Company, Inc.",,Current,['ANDA091695'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Lannett Company, Inc.']","['62175-313', '62175-310', '62175-311', '62175-312']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2001564', '2001565', '2001566', '2001568']",['fd0e4ddf-c516-4464-aeca-eb1d3bd24667'],['3d1f5aff-5d39-496c-b5ed-7f3c70ec641c'],"['62175-310-37', '62175-311-37', '62175-312-37', '62175-313-37']",['4B3SC438HI'],,,,,,,,,
Reverified,03/10/2023,72888-153-05,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-153', '72888-152', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,01/19/2023,43547-410-09,Quinapril Hydrochloride Tablet,866-931-9829,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,11/05/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA205823'],['QUINAPRIL'],['QUINAPRIL'],"['Solco Healthcare US, LLC']","['43547-410', '43547-411', '43547-412', '43547-413']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['b8f1731a-cbac-4f64-a8d4-320b80b335e1'],['cd46691d-5593-4a9f-a937-999c6803e312'],"['43547-410-09', '43547-411-09', '43547-412-09', '43547-413-09']",['33067B3N2M'],,,,,,,,,
Reverified,07/14/2023,0406-5117-01,Lisdexamfetamine Dimesylate Capsule,800-325-8888,Limited Availability,Allocation to all customers.,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA211840'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['SpecGx LLC'],"['0406-5117', '0406-5111', '0406-5112', '0406-5113', '0406-5114', '0406-5115', '0406-5116']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['3ffc0695-83f7-4898-9fd7-451c0989cfe0'],['806a1c15-0842-4787-b2ad-09a21fd96b37'],"['0406-5111-01', '0406-5112-01', '0406-5113-01', '0406-5114-01', '0406-5115-01', '0406-5116-01', '0406-5117-01']",['SJT761GEGS'],,,,,,,,,
New,08/19/2025,0093-7355-05,Finasteride Tablet,800-545-8800,,Discontinuation of the manufacture of the drug product,08/19/2025,['Urology'],Tablet,"Finasteride, Tablet, 5 mg (NDC 0093-7355-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076511'],['FINASTERIDE'],['FINASTERIDE'],"['Teva Pharmaceuticals USA, Inc.']",['0093-7355'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FINASTERIDE'],['310346'],['ea83e229-c434-4097-81dd-e3b48814d5dc'],['77589cc3-c440-4695-800c-82a0e5128a6c'],"['0093-7355-56', '0093-7355-98', '0093-7355-05']",['57GNO57U7G'],"['N0000175836', 'N0000000126']",['5-alpha Reductase Inhibitor [EPC]'],,08/19/2025,,,,['5-alpha Reductase Inhibitors [MoA]'],
New,05/02/2025,0832-0541-10,Bumetanide Tablet,800-654-2299,,,05/02/2025,['Cardiovascular'],Tablet,"Bumetanide, Tablet, 1 mg (NDC 0832-0541-10)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA209916'],['BUMETANIDE'],['BUMETANIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0541', '0832-0540', '0832-0542']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BUMETANIDE'],"['197417', '197418', '197419']",['d53166d9-64ca-4b76-81a7-b70a60c53b12'],['ff5dc8c6-b2f2-41d3-8e56-a953aa721b59'],"['0832-0540-11', '0832-0541-11', '0832-0541-10', '0832-0542-11', '0832-0542-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],05/02/2025,,,,,
Reverified,02/15/2023,71288-718-11,Rocuronium Bromide Injection,844-824-8426,Available,,08/19/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA213453'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Meitheal Pharmaceuticals Inc.'],"['71288-718', '71288-700']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['37295b13-65a4-40fa-8d6c-53aeb45e2939'],['b9abaf64-760d-43e0-8669-a9ca70feab11'],"['71288-700-05', '71288-700-06', '71288-718-10', '71288-718-11']",['I65MW4OFHZ'],,,,,,,,,
Revised,07/14/2023,57664-087-88,"Lisdexamfetamine Dimesylate Tablet, Chewable",800-818-4555,Limited Availability,Available Q4 2025,10/21/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA214134'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-087', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
New,11/03/2025,60951-712-70,Acetaminophen; Oxycodone Hydrochloride Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,11/03/2025,['Analgesia/Addiction'],Tablet,"Percocet, Tablet, 325 mg; 10 mg (NDC 60951-712-70)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA040330'],['ENDOCET'],['OXYCODONE AND ACETAMINOPHEN'],"['ENDO USA, Inc.']","['60951-712', '60951-602', '60951-700', '60951-701']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ACETAMINOPHEN', 'OXYCODONE HYDROCHLORIDE']","['1049214', '1049216', '1049221', '1049223', '1049225', '1049227', '1049635', '1487288']",['2a088d17-73b2-457f-99f6-efcd32f648a5'],['944d3e60-7eee-11de-a413-0002a5d5c51b'],"['60951-602-70', '60951-602-85', '60951-700-70', '60951-712-70', '60951-701-70']","['C1ENJ2TE6C', '362O9ITL9D']",,,,11/03/2025,,,,,
New,10/01/2025,0071-0532-23,Quinapril Hydrochloride Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,10/01/2025,['Cardiovascular'],Tablet,"Accupril, Tablet, 20 mg (NDC 0071-0532-23)",Pfizer Inc.,,To Be Discontinued,['NDA019885'],['ACCUPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Parke-Davis Div of Pfizer Inc'],"['0071-0532', '0071-0527', '0071-0530', '0071-0535', '0071-1205', '0071-1410', '0071-1620', '0071-1840']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['207891', '207892', '207893', '207895', '312748', '312749', '312750', '314203']",['ee20d3b1-a5c8-4510-a931-3872df7b77f4'],['63cf5651-d52c-4d27-9fd4-ed9cd9724dff'],"['0071-0527-23', '0071-0530-23', '0071-0530-40', '0071-0532-23', '0071-0532-40', '0071-0535-23', '0071-1205-23', '0071-1410-23', '0071-1620-23', '0071-1840-23']",['33067B3N2M'],,,,10/01/2025,,,,,
Reverified,07/14/2023,65162-023-09,Lisdexamfetamine Dimesylate Capsule,866-525-7270,Unavailable,Shortage of an active ingredient,11/07/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)",Amneal Pharmaceuticals,Shortage of an active ingredient,Current,['ANDA202830'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Amneal Pharmaceuticals LLC'],"['65162-023', '65162-024', '65162-025', '65162-026', '65162-027', '65162-028']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850']",['5fde01e6-09ba-4a92-bd47-aad0d7c518e4'],['c11cb3b6-3dff-477b-a249-b4c3118edc5f'],"['65162-023-09', '65162-024-09', '65162-025-09', '65162-026-09', '65162-027-09', '65162-028-09']",['SJT761GEGS'],,,,,,,,,
New,11/13/2024,0093-0711-05,Flurbiprofen Tablet,800-545-8800,,A business decision was made to discontinue manufacture of the product.,11/13/2024,['Analgesia/Addiction'],Tablet,"Tablet, 100 mg (NDC 0093-0711-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA074431'],['FLURBIPROFEN'],['FLURBIPROFEN'],"['Teva Pharmaceuticals USA, Inc.']",['0093-0711'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLURBIPROFEN'],['197724'],['38a133bd-a325-4de2-bcf2-d6e144cc456b'],['4e5c06f1-f279-4f2f-b10d-0f70005a27e6'],"['0093-0711-01', '0093-0711-05']",['5GRO578KLP'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,11/13/2024,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Revised,02/20/2018,0409-9046-01,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA071170'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-9046', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],['PERINEURAL'],"['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/15/2023,0781-3220-92,Rocuronium Bromide Injection,800-525-8747,Available,,11/07/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)",Sandoz Inc.,,Current,['ANDA079195'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Sandoz Inc'],['0781-3220'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['eaf32464-7950-434a-e053-2a95a90aa2dc'],['cb28d869-6510-4402-9462-f6bb25fa0fa8'],"['0781-3220-70', '0781-3220-92', '0781-3220-75', '0781-3220-95']",['I65MW4OFHZ'],,,,,,,,,
New,11/21/2024,0591-3875-60,Memantine Hydrochloride Tablet,800-545-8800,,,11/21/2024,['Neurology'],Tablet,"Namenda, Tablet, 10 mg (NDC 0591-3875-60)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA021487'],['MEMANTINE HYDROCHLORIDE'],['MEMANTINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0591-3875', '0591-3870', '0591-3900']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEMANTINE HYDROCHLORIDE'],"['996561', '996571', '996572']",['985e1190-b8a0-4775-9a20-ad1924b14fb2'],['72973b46-f307-4a9e-8fb1-ad2cbccfd736'],"['0591-3870-60', '0591-3870-45', '0591-3870-44', '0591-3875-60', '0591-3875-45', '0591-3875-44', '0591-3900-87']",['JY0WD0UA60'],,,,11/21/2024,,,,,
Reverified,03/14/2022,66220-160-10,Conivaptan Hydrochloride Injection,615-255-0068,Unavailable,,11/04/2025,['Cardiovascular'],Injection,"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)",Cumberland Pharmaceuticals Inc.,Delay in shipping of the drug,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,03/23/2018,70069-064-25,Ropivacaine Hydrochloride Injection,732-554-1019,Available,,08/19/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)","Somerset Therapeutics, LLC",,Current,['ANDA207636'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-064', '70069-061', '70069-062', '70069-063', '70069-065', '70069-066', '70069-067']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734203', '1734207', '1734475', '1734483']",['79b226f0-c08a-4f84-bf2b-ae5c60e01d67'],['ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64'],"['70069-061-01', '70069-061-25', '70069-061-10', '70069-062-01', '70069-062-25', '70069-062-10', '70069-063-01', '70069-063-25', '70069-064-01', '70069-064-10', '70069-064-25', '70069-065-01', '70069-065-25', '70069-066-01', '70069-066-25', '70069-066-10', '70069-067-01', '70069-067-25', '70069-067-10']",['V910P86109'],,,,,,,,,
Revised,05/30/2025,0641-6052-25,Meperidine Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA080445'],['MEPERIDINE HYDROCHLORIDE'],['MEPERIDINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6052', '0641-6053', '0641-6054']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['861476', '1665685', '1665697']",['9566d54d-7343-4695-94ff-8b5f2d384c81'],['e0e998da-f056-4fce-be8e-ed60cf3b461b'],"['0641-6053-01', '0641-6053-25', '0641-6054-01', '0641-6054-25', '0641-6052-01', '0641-6052-25']",['N8E7F7Q170'],,,,,,,,,
Reverified,11/14/2017,0338-0424-18,Heparin Sodium Injection,888-229-0001,Unavailable,Product Discontinued - Product code AHB0953U replaced by Product Code 2B0953,10/22/2025,['Hematology'],Injection,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18)",Baxter Healthcare,Discontinuation of the manufacture of the drug,Current,['NDA018609'],['HEPARIN SODIUM IN SODIUM CHLORIDE'],['HEPARIN SODIUM'],['Baxter Healthcare Corporation'],"['0338-0424', '0338-0431', '0338-0433', '0338-0428']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['68b37381-6db4-4ac0-ba6b-3204add02665'],['0d929726-76c3-48fc-b4e7-fd06409f9fb3'],"['0338-0431-03', '0338-0433-04', '0338-0424-18', '0338-0428-12']",['ZZ45AB24CA'],,,,,,,,,
Reverified,04/28/2023,54288-166-01,Carboplatin Injection,"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270",Limited Availability,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",09/29/2025,['Oncology'],Injection,"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)",Gland Pharma Limited,Demand increase for the drug,Current,['ANDA207324'],['CARBOPLATIN'],['CARBOPLATIN'],['BPI Labs LLC'],"['54288-166', '54288-165', '54288-167', '54288-164']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['5eb7631e-0b41-4aba-ba7a-f544ac9627fd'],['5484d2f0-0cc2-4bba-8f26-c7f6539a9606'],"['54288-165-01', '54288-166-01', '54288-167-01', '54288-164-01']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,01/01/2012,0409-4911-34,Atropine Sulfate Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2)  (NDC 0409-4911-34)""","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,['NDA021146'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Hospira, Inc.']","['0409-4911', '0409-1630', '0409-9630', '0409-4910']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['9211a9e9-35d0-457d-ac95-4ad43ea6bf28'],['ad8916e7-206e-409e-2582-30d072845dd4'],"['0409-1630-15', '0409-1630-10', '0409-9630-15', '0409-9630-05', '0409-4910-11', '0409-4910-34', '0409-4911-11', '0409-4911-34']",['03J5ZE7KA5'],,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2,,,,
New,08/29/2025,82497-010-04,Methotrexate Injection,224-441-6390,,Discontinuation of the manufacture of the drug,08/29/2025,['Rheumatology'],Injection,"Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)","Assertio Specialty Pharmaceuticals, LLC",,To Be Discontinued,['NDA204824'],['OTREXUP'],['METHOTREXATE'],"['Otter Pharmaceuticals, LLC']","['82497-010', '82497-012', '82497-015', '82497-017', '82497-020', '82497-022', '82497-025']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['METHOTREXATE'],"['1441402', '1441407', '1441411', '1441413', '1441416', '1441418', '1441422', '1441424', '1747179', '1747181', '1747185', '1747187', '1747192', '1747194']",['9aaba145-f343-4498-b754-fb7c78181bd7'],['7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f'],"['82497-010-02', '82497-010-04', '82497-012-02', '82497-012-04', '82497-015-02', '82497-015-04', '82497-017-02', '82497-017-04', '82497-020-02', '82497-020-04', '82497-022-02', '82497-022-04', '82497-025-02', '82497-025-04']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,08/29/2025,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
New,03/03/2025,0597-0375-16,Adalimumab-adbm Injection,800-243-0127,,,03/03/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0375-16)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['CYLTEZO'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0375', '0597-0370', '0597-0405', '0597-0400', '0597-0485', '0597-0495']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640889', '2640891', '2640892', '2640893', '2640894', '2640895', '2640898', '2640900', '2640901', '2640902', '2640903', '2680743', '2680746', '2680748', '2680750', '2680756', '2680757', '2680759', '2680760']",['0abec80c-8b06-4e08-bb5a-dd42ef508aa6'],['115ea79b-7209-7f19-b35d-36ec0828fbf5'],"['0597-0370-82', '0597-0370-72', '0597-0370-45', '0597-0405-80', '0597-0405-10', '0597-0400-89', '0597-0375-48', '0597-0375-97', '0597-0375-23', '0597-0375-16', '0597-0375-53', '0597-0485-46', '0597-0485-20', '0597-0480-12', '0597-0495-47', '0597-0495-50', '0597-0495-40', '0597-0495-60', '0597-0490-32']",,,,,03/03/2025,,,,,
Reverified,02/14/2022,0264-7510-10,Dextrose Monohydrate 5% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)",B. Braun Medical Inc.,,Current,['NDA019626'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],"['0264-7510', '0264-7520']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE, UNSPECIFIED FORM']","['1795477', '1795480', '1795481', '1795607', '1795610', '1795612']",['c9f87749-8dd5-41fd-b393-f63d45fd00ef'],['085614c7-ada4-4e2c-87c0-c9bc2f18365a'],"['0264-7510-00', '0264-7510-10', '0264-7510-20', '0264-7520-00', '0264-7520-10', '0264-7520-20']",['IY9XDZ35W2'],,,,,,,,,
Revised,04/28/2023,0990-7138-36,Sodium Chloride 0.9% Irrigation,1-866-829-9025 or ProductAvailability@icumed.com,,,07/02/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigation,"Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-36)","ICU Medical, Inc.",,Resolved,['NDA017514'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7138', '0990-6138', '0990-7972']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['SODIUM CHLORIDE'],['486515'],['ea49c260-0be5-48b8-9e97-bef5a4ca584e'],['3cfdeee0-ff14-4341-8396-b11c2a037c60'],"['0990-7138-09', '0990-7138-36', '0990-6138-22', '0990-6138-03', '0990-7972-05', '0990-7972-07']",['451W47IQ8X'],,,,,,,07/02/2025,,Available
New,05/23/2025,0591-3153-01,Minocycline Hydrochloride Capsule,800-545-8800,,Permanent discontinuation of manufacture due to business decision.,05/23/2025,['Anti-Infective'],Capsule,"Minocycline Hydrochloride, Capsule, 75 mg (NDC 0591-3153-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA063065'],['MINOCYCLINE HYDROCHLORIDE'],['MINOCYCLINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0591-3153', '0591-5694', '0591-5695']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MINOCYCLINE HYDROCHLORIDE'],"['197984', '197985', '314108']",['2d74faa2-99c4-4f01-adc6-60110d2b24da'],['a5fc4d50-50b2-46e0-b722-4c6b2ec47d06'],"['0591-5694-60', '0591-5694-01', '0591-3153-01', '0591-5695-50']",['0020414E5U'],,,,05/23/2025,,,,,
Revised,03/23/2018,63323-631-10,Leucovorin Calcium Injection,888-386-1300,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-10)","Fresenius Kabi USA, LLC",,Resolved,"['ANDA207241', 'ANDA207226']",['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Fresenius Kabi USA, LLC']",['63323-631'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['2099993', '2104714']","['d1c72e5d-c25e-4b9c-b3dc-a8d0b746db3f', 'a0d41f71-6197-4c9a-8cd2-217945cb722b']","['d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee', '4b72d1fd-f389-45d9-b43b-510b45c92263']","['63323-631-10', '63323-631-50']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Revised,04/10/2020,0781-3494-95,Dexmedetomidine Hydrochloride Injection,See Related Information section below for customer service information,Available,Marketed by Sandoz Inc.; Customer service: 800-525-8747,10/09/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL  (NDC 0781-3494-95)","Jiangsu Hengrui Pharmaceuticals Co., Ltd.",,Current,['ANDA209065'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['Sandoz Inc.'],"['0781-3494', '0781-3493', '0781-3495']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718906', '1718909']",['fdf227d9-008e-60f8-e053-6294a90af5c4'],['809e8f77-390f-4cc8-8c8a-4f67a249c9df'],"['0781-3493-95', '0781-3494-95', '0781-3495-95']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,79672-613-03,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, 250 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Nextgen Pharmaceuticals LLC'],['79672-613'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['3c545b9f-67e4-489d-bb60-c39c990d7dda'],['28f79c75-82d2-4912-81fc-a723b5ccf4c1'],"['79672-613-01', '79672-613-10', '79672-613-02', '79672-613-20', '79672-613-03', '79672-613-30', '79672-613-04', '79672-613-40', '79672-613-05', '79672-613-50']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/31/2017,63323-452-01,Morphine Sulfate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA204223'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Fresenius Kabi USA, LLC']","['63323-452', '63323-454', '63323-455', '63323-458', '63323-451']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['1731993', '1732006', '1732011', '1732136', '2003714']",['dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc'],['582f42e5-444e-4246-af8c-e7e28097c69a'],"['63323-452-00', '63323-452-01', '63323-454-00', '63323-454-01', '63323-455-00', '63323-455-01', '63323-458-00', '63323-458-01', '63323-451-00', '63323-451-01']",['X3P646A2J0'],,,,,,,,,
Reverified,12/08/2020,0990-4179-05,Amino Acid Injection,1-866-829-9025 or ProductAvailability@icumed.com,Unavailable,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,['Gastroenterology'],Injection,"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)",Otsuka ICU Medical LLC,Shortage of an active ingredient,Current,['NDA019492'],['AMINOSYN-PF'],"['ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE']",['ICU Medical Inc.'],['0990-4179'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'TAURINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['800341', '800345']",['2d8f2280-bc20-45ba-bdf3-12c055684017'],['46e74ce4-cd7e-437f-bf54-ca9b98eb2663'],['0990-4179-05'],"['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '1EQV5MLY3D', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Reverified,07/24/2017,51754-5001-5,Sodium Bicarbonate Injection,828-758-5474 ext. 154,Limited Availability,Releasing weekly,11/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)","Exela Pharma Sciences, LLC",Other,Current,['ANDA211091'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Exela Pharma Sciences, LLC']","['51754-5001', '51754-5011', '51754-5002', '51754-5012']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],"['807284', '1868486', '1923484', '2198792']",['4da0ba66-756d-4b4d-8018-81ca16578ef1'],['e9698a4f-1a95-4f28-a945-e8009d1d6dd4'],"['51754-5001-5', '51754-5001-4', '51754-5011-4', '51754-5002-5', '51754-5012-4']",['8MDF5V39QO'],,,,,,,,,
Revised,07/26/2023,62037-734-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 27 mg (NDC 62037-734-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA076772'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['62037-734', '62037-725', '62037-726', '62037-727']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['89caac38-0ada-4326-8b3e-65f0d23cbb1b'],['85ef422d-af27-4126-9841-6892af1871d6'],"['62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01']",['4B3SC438HI'],,,,,,,,,
Revised,08/23/2024,66259-903-24,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-24)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
New,11/07/2025,10122-100-10,Deferiprone Tablet,888-466-6505,,Discontinuation of the manufacture of the drug.,11/07/2025,['Hematology'],Tablet,"Ferriprox, Tablet, 500 mg (NDC 10122-100-10)","Chiesi USA, Inc.",,To Be Discontinued,['NDA021825'],['FERRIPROX'],['DEFERIPRONE'],"['Chiesi USA, Inc.']","['10122-100', '10122-104', '10122-103']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DEFERIPRONE'],"['389242', '1190357', '2180997', '2180999', '2685014', '2685015']",['4253b219-ce15-4468-b5f0-2dd7e8436b08'],['946718ff-df43-1baa-74d1-e5bcfbe8ad86'],"['10122-104-01', '10122-104-05', '10122-103-05', '10122-100-11', '10122-100-10']",['2BTY8KH53L'],"['N0000000144', 'N0000175522']",['Iron Chelator [EPC]'],,11/07/2025,,,,['Iron Chelating Activity [MoA]'],
Reverified,03/23/2016,71357-007-10,Sodium Acetate Injection,833-251-8463,Available,,11/03/2025,['Total Parenteral Nutrition'],Injection,"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)",Milla Pharmaceuticals,,Current,['ANDA214805'],['SODIUM ACETATE'],['SODIUM ACETATE'],['MILLA PHARMACEUTICALS INC.'],"['71357-007', '71357-008', '71357-009']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE'],"['237371', '312965']",['2913569b-0f7e-8027-e063-6294a90aaf78'],['1ea1466d-a492-4056-e063-6394a90a80bf'],"['71357-007-01', '71357-007-10', '71357-008-01', '71357-008-10', '71357-009-01', '71357-009-10']",['4550K0SC9B'],,,,,,,,,
Reverified,07/26/2023,13811-700-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Limited Availability,Allocation to current contracted customers,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)","Trigen Laboratories, LLC",Demand increase for the drug,Current,['NDA216117'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Trigen Laboratories, LLC']","['13811-700', '13811-711']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2605796', '2605798']",['ba649db4-df0d-4587-8370-3f866e66e54b'],['dd8d7b6e-c23d-4e16-bb53-959e9127ebc6'],"['13811-711-30', '13811-700-30']",['4B3SC438HI'],,,,,,,,,
Reverified,04/10/2020,16729-432-93,Dexmedetomidine Hydrochloride Injection,"866-941-7875, option 2",Unavailable,Discontinuation of the manufacture of the drug.,11/04/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)",Accord Healthcare Inc.,Discontinuation of the manufacture of the drug,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,06/21/2018,0409-4888-20,Sodium Chloride 0.9% Injection,844-646-4398,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-20)","Hospira, Inc., a Pfizer Company",,Resolved,['NDA018803'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Hospira, Inc.']","['0409-4888', '0409-1918']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807628', '1807631', '1807637', '1807638']",['9ee88abb-024a-4a3b-9776-1777eaf2f760'],['8eb172da-dcd4-4660-4a8f-ad44a14b4af7'],"['0409-4888-02', '0409-4888-10', '0409-4888-03', '0409-4888-20', '0409-4888-06', '0409-4888-50', '0409-4888-01', '0409-4888-12', '0409-4888-90', '0409-1918-42', '0409-1918-32', '0409-1918-43', '0409-1918-33', '0409-1918-45', '0409-1918-35']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,12/15/2021,70121-1573-1,Methylprednisolone Acetate Injection,866-525-7270,Limited Availability,Next supply: week of 11/17/2025,11/07/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)",Amneal Pharmaceuticals,Other,Current,['ANDA210043'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Amneal Pharmaceuticals LLC'],"['70121-1573', '70121-1574']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743855']",['0bdaa3cf-cf32-4959-b87a-65215ac4648d'],['d944240d-2c19-46ba-ad4f-3fbee7b8629c'],"['70121-1573-1', '70121-1573-5', '70121-1574-1', '70121-1574-5']",['43502P7F0P'],,,,,,,,,
New,11/07/2025,0409-0040-10,Ketamine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,['Anesthesia'],Injection,"Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10)",Pfizer Inc.,,To Be Discontinued,['ANDA074549'],['KETAMINE HYDROCHLORIDE'],['KETAMINE HYDROCHLORIDE'],"['Hospira, Inc.']",['0409-0040'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETAMINE HYDROCHLORIDE'],['238083'],['aa1e5788-73a9-4b95-99da-17eb252f8702'],['390f2db8-0fcd-4648-b584-9effa084be27'],"['0409-0040-05', '0409-0040-10']",['O18YUO0I83'],,,,11/07/2025,,,,,
New,09/18/2025,0472-0803-02,Desonide Lotion,800-545-8800,,Discontinuation of the manufacture of the drug.,09/18/2025,['Dermatology'],Lotion,"Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-02)","Actavis Pharma, Inc.",,To Be Discontinued,['ANDA072354'],['DESONIDE'],['DESONIDE'],"['Actavis Pharma, Inc.']","['0472-0803', '0472-0804']",['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['DESONIDE'],"['197572', '349351']",['f3953b9e-138f-4d86-8eea-0fc03c3c2747'],['ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99'],"['0472-0804-15', '0472-0804-60', '0472-0803-02', '0472-0803-04']",['J280872D1O'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,09/18/2025,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
Revised,03/01/2017,0409-6625-35,Sodium Bicarbonate Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: June 2026,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA202432'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Hospira, Inc.']",['0409-6625'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],,"['55e7a069-73d0-45e3-8d36-f307f5802443', '22f08565-937c-4d4b-bd37-914abb918b14']","['8664c7ce-707b-4c6c-9ce4-7160b5f877f8', '084f5572-8c1f-4802-b179-ca0cc838fc68']","['0409-6625-30', '0409-6625-35', '0409-6625-22', '0409-6625-14']",['8MDF5V39QO'],,,,,,,,,
Revised,12/15/2021,55150-313-01,Methylprednisolone Acetate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)",Eugia US LLC,Demand increase for the drug,Current,['ANDA211930'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Eugia US LLC'],"['55150-313', '55150-314']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358610', '1358617']",['a0cbcdb5-f657-49f7-8f86-cc5959d69db0'],['a0cbcdb5-f657-49f7-8f86-cc5959d69db0'],"['55150-313-25', '55150-313-01', '55150-314-25', '55150-314-01']",['43502P7F0P'],,,,,,,,,
Reverified,04/10/2020,0409-1174-10,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1174', '0409-1454', '0409-3301', '0409-2815']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['8d48de06-361f-418b-bfec-8ef85f94d5bc'],['4419162d-81d4-49bd-96de-1729440bdb74'],"['0409-1454-01', '0409-1454-20', '0409-3301-01', '0409-3301-10', '0409-1174-01', '0409-1174-10', '0409-2815-01']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0990-7983-03,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-03)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7983', '0990-7730', '0990-7984', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,0409-2587-05,Midazolam Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA075293'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2587', '0409-2596']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['923cfac2-557d-40b4-9ee0-3e933685a5fc'],['affecd4d-1f78-4bbe-5a8d-86849bbdc520'],"['0409-2587-04', '0409-2587-05', '0409-2596-13', '0409-2596-03', '0409-2596-15', '0409-2596-05']",['W7TTW573JJ'],,,,,,,,,
Revised,01/01/2012,70436-117-80,Leucovorin Calcium Injection,888-447-0095,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 100 mg (NDC 70436-117-80)",Slate Run Pharmaceuticals,,Resolved,['ANDA217021'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Slate Run Pharmaceuticals, LLC']","['70436-117', '70436-116', '70436-118', '70436-120', '70436-119']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['2a4aaed3-885e-bc10-e063-6294a90a61af'],['d8bdd60c-9a1c-4ef4-ba6b-b911849128f1'],"['70436-116-80', '70436-116-82', '70436-117-80', '70436-118-80', '70436-120-80', '70436-119-80']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,04/10/2020,43066-557-12,Dexmedetomidine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)",Baxter Healthcare,,Current,['ANDA208532'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['Baxter Healthcare Company'],"['43066-557', '43066-555']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['949ed273-6b79-4f54-8284-a710082edd77'],['aea9a3ad-c244-42be-9cd3-5df83fe2b522'],"['43066-555-24', '43066-557-12']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0338-0049-04,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-04)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,0409-2308-02,Midazolam Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA075857'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2308', '0409-2305', '0409-0001']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['1666800', '1666814', '1666823', '1666798']","['b303a281-6633-47d5-bf29-5e9055e26da6', '8c3cf34b-901d-407a-946d-a1556bb24551']","['b95415fa-17c2-42ab-a6b0-e628d01c94ed', '1abda8b8-48a8-4995-af86-39220d1aa240']","['0409-2305-55', '0409-2305-50', '0409-2308-69', '0409-2308-49', '0409-2308-70', '0409-2308-50', '0409-2305-16', '0409-2305-17', '0409-2305-04', '0409-2305-05', '0409-2308-21', '0409-2308-01', '0409-2308-22', '0409-2308-02', '0409-0001-01', '0409-0001-25']",['W7TTW573JJ'],,,,,,,,,
Revised,12/08/2023,62135-712-42,Lidocaine Hydrochloride Solution,845-268-5000 Ext. 510,,,08/29/2025,['Anesthesia'],Solution,"Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 62135-712-42)",Chartwell Molecular Holdings LLC,,Resolved,['ANDA040708'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Chartwell RX, LLC']","['62135-712', '62135-871']",['HUMAN PRESCRIPTION DRUG'],['OROPHARYNGEAL'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],['1010739'],['1a8a5120-d592-7d82-e063-6394a90af7c1'],['c05f49a2-7512-48e7-9730-f8ee05519b9d'],"['62135-712-42', '62135-871-51', '62135-871-24']",['EC2CNF7XFP'],,,,,,,08/29/2025,,Available
Reverified,10/05/2022,67457-902-10,Etomidate Injection,800-796-9526,Available,,11/06/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)","Mylan Institutional, a Viatris Company",,Current,['ANDA201044'],['ETOMIDATE'],['ETOMIDATE'],['Mylan Institutional LLC'],"['67457-902', '67457-903']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['25fc0aef-d4b3-4b33-897c-81cc7cdae470'],['461e34d1-b862-4a02-9727-548c907aac48'],"['67457-902-00', '67457-902-10', '67457-903-00', '67457-903-20']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
New,02/26/2025,58151-103-77,"Tolterodine Tartrate Capsule, Extended Release",800-796-9526,,,02/26/2025,['Urology'],"Capsule, Extended Release","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['NDA021228'],['DETROL LA'],['TOLTERODINE TARTRATE'],['Viatris Specialty LLC'],"['58151-103', '58151-104']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOLTERODINE TARTRATE'],"['855182', '855184', '855189', '855191']",['a1e49744-9302-47ee-92af-8b19aa0b2fc1'],['d7274947-4f88-47ee-a39f-bd5ac46fcf8d'],"['58151-103-93', '58151-103-77', '58151-103-05', '58151-104-93', '58151-104-77', '58151-104-05']",['5T619TQR3R'],,,,02/26/2025,,,,,
New,10/31/2025,0603-5165-21,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5165', '0603-5166', '0603-5167', '0603-5168']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
Reverified,07/14/2023,0406-5111-01,Lisdexamfetamine Dimesylate Capsule,800-325-8888,Limited Availability,Allocation to all customers.,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA211840'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['SpecGx LLC'],"['0406-5111', '0406-5112', '0406-5113', '0406-5114', '0406-5115', '0406-5116', '0406-5117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['3ffc0695-83f7-4898-9fd7-451c0989cfe0'],['806a1c15-0842-4787-b2ad-09a21fd96b37'],"['0406-5111-01', '0406-5112-01', '0406-5113-01', '0406-5114-01', '0406-5115-01', '0406-5116-01', '0406-5117-01']",['SJT761GEGS'],,,,,,,,,
New,11/07/2025,0409-4933-10,Epinephrine Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Cardiovascular', 'Endocrinology/Metabolism']",Injection,"Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA209359'],['EPINEPHRINE'],['EPINEPHRINE'],"['Hospira, Inc.']",['0409-4933'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['EPINEPHRINE'],['727373'],['89ecdc19-31ff-40e9-93aa-a916bef2b462'],['ef18a92f-ba83-4bb0-808b-d09d736f6a81'],"['0409-4933-11', '0409-4933-01', '0409-4933-05', '0409-4933-10']",['YKH834O4BH'],"['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,11/07/2025,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
Reverified,02/20/2018,0409-1159-02,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070583'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1725078', '1725082', '1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1867594', '1867596']","['40bfa804-5f31-4bd2-b1e3-dcf428710dc1', '3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7']","['bb44c7e1-d911-4788-908f-09b7b271969b', '02a845c3-4521-4926-e397-25ab536e7cf6']","['0409-1159-09', '0409-1159-10', '0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,11/21/2023,0641-0929-25,Promethazine Hydrochloride Injection,800-631-2174,Unavailable,This presentation is temporarily on backorder.  Recovery is TBD at this time.,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['ANDA083312'],['PROMETHAZINE HYDROCHLORIDE'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-0929', '0641-0928']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992858']",['9f14d3f5-ad01-44b5-a2b7-16ed5f501f87'],['4bf3912c-8339-401e-9711-dad6acf15f11'],"['0641-0928-21', '0641-0928-25', '0641-0929-21', '0641-0929-25']",['R61ZEH7I1I'],,,,,,,,,
Revised,06/13/2018,0143-9577-10,Lidocaine Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA080407'],['LIDOCAINE'],['LIDOCAINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9577', '0143-9579', '0143-9578', '0143-9576', '0143-9575', '0143-9172', '0143-9173']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671']",['3e5c0afe-9377-4040-ab89-55a6dbb5693c'],['5523fdfe-69fd-49a5-b51f-73e2223d49a9'],"['0143-9579-01', '0143-9579-25', '0143-9578-01', '0143-9578-10', '0143-9577-01', '0143-9577-10', '0143-9576-01', '0143-9576-25', '0143-9575-01', '0143-9575-10', '0143-9172-01', '0143-9172-10', '0143-9173-01', '0143-9173-10']",['V13007Z41A'],,,,,,,,,
New,06/24/2025,0078-0405-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,888-669-6682,,Permanent discontinuation in the manufacturing of the drug,06/24/2025,['Cardiovascular'],Capsule,"Lotrel, Capsule, 5 mg; 10 mg (NDC 0078-0405-05)",Novartis Pharmaceuticals Corporation,,To Be Discontinued,['NDA020364'],['LOTREL'],['AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE'],['Novartis Pharmaceuticals Corporation'],"['0078-0405', '0078-0406', '0078-0364', '0078-0379']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898344', '898346', '898348', '898353', '898355', '898356', '898358']",['b9db75d9-9d1e-4b2d-9876-5f5520feaecc'],['94ae6054-b7ae-4212-a567-4f803af8f2c7'],"['0078-0405-05', '0078-0406-05', '0078-0364-05', '0078-0379-05']","['N1SN99T69T', '864V2Q084H']",,,,06/24/2025,,,,,
New,09/09/2025,0409-0144-11,Azithromycin Injection,844-646-4398,,Discontinuation of the manufacture of the drug,09/09/2025,['Anti-Infective'],Injection,"Azithromycin, Injection, 500 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-0144-11)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA065500'],['AZITHROMYCIN'],['AZITHROMYCIN'],"['Hospira, Inc.']",['0409-0144'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['AZITHROMYCIN MONOHYDRATE'],['1668238'],['0daee3b8-efec-4ff2-aedf-87035563373f'],['d2f4907f-b952-403b-229e-cc5b8327a773'],"['0409-0144-21', '0409-0144-11']",['JTE4MNN1MD'],,,,09/09/2025,,,,,
Reverified,10/31/2017,63323-455-01,Morphine Sulfate Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA204223'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Fresenius Kabi USA, LLC']","['63323-455', '63323-452', '63323-454', '63323-458', '63323-451']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['1731993', '1732006', '1732011', '1732136', '2003714']",['dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc'],['582f42e5-444e-4246-af8c-e7e28097c69a'],"['63323-452-00', '63323-452-01', '63323-454-00', '63323-454-01', '63323-455-00', '63323-455-01', '63323-458-00', '63323-458-01', '63323-451-00', '63323-451-01']",['X3P646A2J0'],,,,,,,,,
Revised,02/22/2012,0409-4279-02,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088329'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4279', '0409-4713', '0409-4278', '0409-4776', '0409-4282', '0409-4277', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
Reverified,03/01/2022,0990-7930-03,Dextrose Monohydrate 10% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)",Otsuka ICU Medical LLC,,Current,['NDA018080'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7930', '0990-7923', '0990-7922']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Reverified,11/23/2021,63323-185-50,Sterile Water Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Other'],Injection,"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)","Fresenius Kabi USA, LLC",,Current,['ANDA088400'],['STERILE WATER'],['WATER'],"['Fresenius Kabi USA, LLC']",['63323-185'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['42c6c812-706a-425b-b8cb-931006e40484'],['e71c6c83-d518-496c-b2ab-efd5987e4783'],"['63323-185-07', '63323-185-10', '63323-185-09', '63323-185-50', '63323-185-08', '63323-185-20', '63323-185-04', '63323-185-05']",['059QF0KO0R'],,,,,,,,,
New,10/09/2025,0781-2868-31,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-31)",Sandoz Inc.,,To Be Discontinued,['ANDA075757'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],"['0781-2868', '0781-2859']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],"['198051', '199119']",['6a54ba13-eeb3-4c8c-800b-dc9aaf961c3f'],['516170d4-4913-4577-a2d2-f5c52d1e79c6'],"['0781-2859-10', '0781-2859-01', '0781-2859-92', '0781-2859-31', '0781-2868-10', '0781-2868-01', '0781-2868-92', '0781-2868-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Revised,02/20/2018,55150-162-05,Lidocaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)",Eugia US LLC,,Current,['ANDA203082'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-162', '55150-161', '55150-163', '55150-164', '55150-165']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1737562', '1737566', '1737568', '1737757', '1737761']","['9916b09d-a116-469d-92d5-60e50ea9782b', '9b60bc92-6093-49f9-a6ba-075104ff7bb5']","['9916b09d-a116-469d-92d5-60e50ea9782b', '89701fac-7536-4f16-87fb-f4cc121e74ee']","['55150-161-09', '55150-162-09', '55150-163-00', '55150-164-09', '55150-165-09', '55150-161-02', '55150-162-05', '55150-163-30', '55150-164-02', '55150-165-05']",['V13007Z41A'],,,,,,,,,
Reverified,02/22/2012,0409-3177-01,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089635'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3177', '0409-1209', '0409-3178', '0409-3181', '0409-3182', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],12/19/2024,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
New,09/29/2025,0069-1975-40,Tafamidis Meglumine Capsule,800-879-3477,,Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.,09/29/2025,['Cardiovascular'],Capsule,"Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40)",Pfizer Inc.,,To Be Discontinued,['NDA211996'],['VYNDAQEL'],['TAFAMIDIS MEGLUMINE'],['Pfizer Laboratories Div Pfizer Inc'],"['0069-1975', '0069-8730']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TAFAMIDIS MEGLUMINE'],"['2168534', '2168540', '2168542', '2168548']",['9485b5fb-0676-4783-9668-4c076b01c497'],['1b4121ee-a733-4456-a917-be2603477839'],"['0069-1975-12', '0069-1975-40', '0069-8730-01', '0069-8730-30']","['ZU7CF08A1A', '8FG9H9D31J']",,,,09/29/2025,,,,,
New,09/30/2025,0004-0801-85,Oseltamivir Phosphate Capsule,800-551-2231,,Discontinuation of the manufacture of the drug,09/30/2025,['Antiviral'],Capsule,"Tamiflu, Capsule, 45 mg (NDC 0004-0801-85)","Genentech, Inc",,To Be Discontinued,['NDA021087'],['TAMIFLU'],['OSELTAMIVIR PHOSPHATE'],"['Genentech, Inc.']","['0004-0801', '0004-0802', '0004-0800', '0004-0822']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OSELTAMIVIR PHOSPHATE'],"['261315', '312122', '728109', '728111', '728113', '728115', '1115698', '1115700']",['7ab9f8e7-2dd7-4e79-b837-10582f2249ce'],['ee3c9555-60f2-4f82-a760-11983c86e97b'],"['0004-0802-85', '0004-0801-85', '0004-0800-85', '0004-0800-07', '0004-0800-08', '0004-0822-05']",['4A3O49NGEZ'],,,,09/30/2025,,,,,
Reverified,02/22/2012,63323-202-02,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)","Fresenius Kabi USA, LLC",,Current,['ANDA088586'],['LIDOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-202', '63323-201']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1737757']",['d19c26f4-1214-40f7-9680-43c885613306'],['cddb2b22-fce3-8967-6e54-dca3df5ac4b3'],"['63323-201-01', '63323-201-02', '63323-201-03', '63323-201-10', '63323-202-01', '63323-202-02']",['V13007Z41A'],,,,,,,,,
New,12/05/2024,57664-441-18,Digoxin Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Cardiovascular'],Tablet,"Digoxin, Tablet, 250 ug (NDC 57664-441-18)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA076363'],['DIGOXIN'],['DIGOXIN'],"['Sun Pharmaceutical Industries, Inc.']","['57664-441', '57664-437']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIGOXIN'],"['197604', '197606']",['1a3e469c-1452-3d1e-e063-6394a90ae73a'],['62795623-a2bc-4dd2-8989-3b9782bfd80e'],"['57664-437-88', '57664-437-18', '57664-441-88', '57664-441-18']",['73K4184T59'],"['N0000175568', 'M0003451']",['Cardiac Glycoside [EPC]'],,12/05/2024,,['Cardiac Glycosides [CS]'],,,
Revised,07/12/2022,0703-4636-01,"Streptozocin Powder, For Solution",800-545-8800,Unavailable,Estimated recovery: TBD,10/16/2025,['Oncology'],"Powder, For Solution","Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)","Teva Pharmaceuticals USA, Inc.",Other,Current,,,,,,,,,,,,,,,,,,,,,,
New,05/14/2025,0832-0038-10,Oxybutynin Chloride Tablet,800-654-2299,,,05/14/2025,['Renal'],Tablet,"Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-10)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA074625'],['OXYBUTYNIN CHLORIDE'],['OXYBUTYNIN CHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-0038'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXYBUTYNIN CHLORIDE'],['863664'],['2f3b30f0-e463-2de1-e063-6394a90a1b69'],['3ee6835a-7a7d-49a9-8460-2f1dd270ead3'],"['0832-0038-00', '0832-0038-50', '0832-0038-10', '0832-0038-89', '0832-0038-01']",['L9F3D9RENQ'],,,,05/14/2025,,,,,
Reverified,10/12/2022,64850-504-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",888-852-6657,Limited Availability,3 months,11/04/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)","Elite Laboratories, Inc.",Shortage of an active ingredient,Current,['ANDA211352'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Elite Laboratories, Inc.']","['64850-504', '64850-500', '64850-501', '64850-502', '64850-503', '64850-505', '64850-506']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['b65e0266-7172-4730-8f93-eb42e08fb7b8'],['e677690f-790f-4626-ad78-097cdb6ea540'],"['64850-500-01', '64850-500-05', '64850-500-30', '64850-501-01', '64850-501-05', '64850-501-30', '64850-502-01', '64850-502-05', '64850-502-30', '64850-503-01', '64850-503-05', '64850-503-30', '64850-504-01', '64850-504-05', '64850-504-30', '64850-505-01', '64850-505-05', '64850-505-30', '64850-506-01', '64850-506-05', '64850-506-30']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,10/14/2016,63323-483-57,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-483', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,01/28/2025,60505-4477-3,Teriflunomide Tablet,800-706-5575,,,01/28/2025,['Neurology'],Tablet,"Teriflunomide, Tablet, 7 mg (NDC 60505-4477-3)",Apotex Corp.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/28/2025,,,,,
New,09/11/2025,0054-0390-41,Oxycodone Hydrochloride Oral Solution,800-631-2174,,Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).,09/11/2025,['Analgesia/Addiction'],Oral Solution,"Oxycodone Hydrochloride, Oral Solution, 5 mg/5 mL (NDC 0054-0390-41)","Hikma Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA204037'],['OXYCODONE HYDROCHLORIDE'],['OXYCODONE HYDROCHLORIDE'],['Hikma Pharmceuticals USA Inc.'],['0054-0390'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXYCODONE HYDROCHLORIDE'],['1049604'],['c485af9e-af0b-4ca0-8371-dae5c6402c20'],['d8e87c66-f872-4e1d-9ade-ef11490af63b'],"['0054-0390-41', '0054-0390-63']",['C1ENJ2TE6C'],,,,09/11/2025,,,,,
Reverified,07/14/2023,0378-6854-77,Lisdexamfetamine Dimesylate Capsule,800-796-9526,Unavailable,Unavailable,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)","Mylan Pharmaceuticals Inc., a Viatris Company",Shortage of an active ingredient,Current,['ANDA202835'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Mylan Pharmaceuticals Inc.'],"['0378-6854', '0378-6855', '0378-6856', '0378-6857', '0378-6858', '0378-6859', '0378-6860']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['63cd6f7c-f976-440e-a35f-e71a9f2fd1bb'],['efbde0f6-b848-4664-b741-c6c630e66108'],"['0378-6854-77', '0378-6855-77', '0378-6856-77', '0378-6857-77', '0378-6858-77', '0378-6859-77', '0378-6860-77']",['SJT761GEGS'],,,,,,,,,
New,01/28/2025,71093-127-06,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-06)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-127', '71093-128']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
New,01/23/2025,0591-2886-01,"Verapamil Hydrochloride Capsule, Extended Release",800-545-8800,,,01/23/2025,['Cardiovascular'],"Capsule, Extended Release","Verelan, Capsule, Extended Release, 360 mg (NDC 0591-2886-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA019614'],['VERAPAMIL HYDROCHLORIDE'],['VERAPAMIL HYDROCHLORIDE'],['Teva Pharmaceuticals Inc'],"['0591-2886', '0591-2880', '0591-2882', '0591-2884']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VERAPAMIL HYDROCHLORIDE'],['897624'],['319554df-fc0d-428a-9799-a352100f1ce9'],['0742cf97-601b-4c13-a6c3-1a6a616ed292'],"['0591-2880-01', '0591-2882-01', '0591-2884-01', '0591-2886-01']",['V3888OEY5R'],,,,01/23/2025,,,,,
New,06/13/2025,0093-0771-10,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076056'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-0771', '0093-7201', '0093-7202']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],"['904458', '904467', '904475']",['72579e23-23ef-4ab7-ad64-24d5ea7997eb'],['99e0e848-f8f3-4b42-b880-8fbc42633948'],"['0093-0771-98', '0093-0771-10', '0093-7201-98', '0093-7201-10', '0093-7202-98', '0093-7202-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
New,08/29/2025,82497-022-04,Methotrexate Injection,224-441-6390,,Discontinuation of the manufacture of the drug,08/29/2025,['Rheumatology'],Injection,"Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)","Assertio Specialty Pharmaceuticals, LLC",,To Be Discontinued,['NDA204824'],['OTREXUP'],['METHOTREXATE'],"['Otter Pharmaceuticals, LLC']","['82497-022', '82497-010', '82497-012', '82497-015', '82497-017', '82497-020', '82497-025']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['METHOTREXATE'],"['1441402', '1441407', '1441411', '1441413', '1441416', '1441418', '1441422', '1441424', '1747179', '1747181', '1747185', '1747187', '1747192', '1747194']",['9aaba145-f343-4498-b754-fb7c78181bd7'],['7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f'],"['82497-010-02', '82497-010-04', '82497-012-02', '82497-012-04', '82497-015-02', '82497-015-04', '82497-017-02', '82497-017-04', '82497-020-02', '82497-020-04', '82497-022-02', '82497-022-04', '82497-025-02', '82497-025-04']",['YL5FZ2Y5U1'],"['N0000175584', 'N0000000111']",['Folate Analog Metabolic Inhibitor [EPC]'],,08/29/2025,,,,['Folic Acid Metabolism Inhibitors [MoA]'],
New,06/10/2025,0093-8035-01,Glyburide Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/10/2025,['Endocrinology/Metabolism'],Tablet,"Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA074686'],['GLYBURIDE'],['GLYBURIDE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-8035', '0093-8034', '0093-8036']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLYBURIDE'],"['310536', '310539', '314000']",['00e55b1b-81b5-4df1-8a6d-4d54ac403e76'],['e84c0dfc-a4e9-4c89-b6ea-45732eb412f5'],"['0093-8034-01', '0093-8035-01', '0093-8035-05', '0093-8036-01']",['SX6K58TVWC'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,06/10/2025,,['Sulfonylurea Compounds [CS]'],,,
Reverified,02/20/2018,63323-461-57,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Available,Check wholesaler for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)","Fresenius Kabi USA, LLC",,Current,['ANDA070967'],['SENSORCAINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-461', '63323-472', '63323-463', '63323-468']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012413', '1012417', '1724786', '1724787', '1724809', '1724810', '1867594', '1867596', '1867618', '1867620']",['cc1f6507-eb3e-4398-a1d3-0c56a2099e6b'],['bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb'],"['63323-472-03', '63323-472-17', '63323-472-01', '63323-472-37', '63323-463-01', '63323-463-57', '63323-461-01', '63323-461-57', '63323-468-02', '63323-468-37', '63323-468-01', '63323-468-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/15/2023,63323-426-05,Rocuronium Bromide Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)","Fresenius Kabi USA, LLC",,Current,['ANDA078651'],['ROCURONIUM'],['ROCURONIUM BROMIDE'],"['Fresenius Kabi USA, LLC']",['63323-426'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],"['d6e2ff8d-838d-4c27-8e73-230548b09d63', '3f4d5e11-2c14-4406-8954-04dba2fc65ff']","['f1933332-1ae0-4dc1-be4c-694849e6c9f9', 'fb9524b2-c353-4747-8954-7ca2529eabb2']","['63323-426-02', '63323-426-05', '63323-426-01', '63323-426-10', '63323-426-12', '63323-426-15']",['I65MW4OFHZ'],,,,,,,,,
Reverified,07/26/2023,68025-096-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Unavailable,Estimated recovery: TBD,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)","Vertical Pharmaceuticals, LLC",Other,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-096', '68025-088', '68025-089', '68025-095', '68025-097', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
New,09/11/2025,0409-0183-25,Gemcitabine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,09/11/2025,['Oncology'],Injection,"Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA200795'],['GEMCITABINE'],['GEMCITABINE'],"['Hospira, Inc.']","['0409-0183', '0409-0181', '0409-0182']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['GEMCITABINE HYDROCHLORIDE'],"['1720960', '1720975', '1720977']","['cc0f68d1-df16-441c-b4d7-da06b4baf1e5', '15f70b30-31dc-4c45-902b-69cad93f7308']","['dc02a23b-3ff9-4441-aa91-8e9e629a7315', 'e18ed1cb-7dd0-4001-bfda-17d1f4587fb8']","['0409-0181-01', '0409-0183-01', '0409-0182-01', '0409-0181-25', '0409-0182-25', '0409-0183-25']",['U347PV74IL'],,,,09/11/2025,,,,,
New,01/06/2025,0703-2045-03,Cisatracurium Besylate Injection,800-545-8800,,,01/06/2025,['Anesthesia'],Injection,"CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 200 mg/20 mL (NDC 0703-2045-03)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/06/2025,,,,,
Reverified,03/23/2018,63323-286-23,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-286', '63323-285', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,47781-567-01,Lisdexamfetamine Dimesylate Capsule,844-842-8672 and email: CustomerService-US@alvogen.com,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)",Alvogen,,Current,['ANDA214547'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Alvogen Inc.'],"['47781-567', '47781-562', '47781-563', '47781-564', '47781-565', '47781-566', '47781-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['567bb281-4098-07f8-9503-92299dc1c4c6'],['7f2dd6ee-3363-c87c-9693-ed838942556c'],"['47781-562-01', '47781-563-01', '47781-564-01', '47781-565-01', '47781-566-01', '47781-567-01', '47781-568-01']",['SJT761GEGS'],,,,,,,,,
Reverified,01/01/2012,0409-9094-25,Fentanyl Citrate Injection,844-646-4398,Available,,10/23/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)","Hospira, Inc., a Pfizer Company",,Current,['NDA019115'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Hospira, Inc.']","['0409-9094', '0409-9093']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735004', '1735006', '1735007', '1735008', '1735013']",['e4b31fdd-00af-416d-b14e-dbac0c83da97'],['bfa8018a-4cbc-434b-e09e-782872b0340a'],"['0409-9093-37', '0409-9093-32', '0409-9093-45', '0409-9093-35', '0409-9093-41', '0409-9093-36', '0409-9093-31', '0409-9093-38', '0409-9094-12', '0409-9094-22', '0409-9094-18', '0409-9094-25', '0409-9094-17', '0409-9094-28', '0409-9094-16', '0409-9094-31', '0409-9094-41', '0409-9094-61']",['MUN5LYG46H'],,,,,,,,,
Reverified,10/25/2022,76204-027-01,Albuterol Sulfate Solution,803-806-3300,Available,,11/03/2025,"['Pediatric', 'Pulmonary/Allergy']",Solution,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)","Ritedose Pharmaceuticals, LLC",,Current,['ANDA218386'],"['ALBUTEROL SULFATE INHALATION SOLUTION, 0.5%']",['ALBUTEROL SULFATE'],"['Ritedose Pharmaceuticals, LLC']",['76204-027'],['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],['ALBUTEROL SULFATE'],['245314'],['311a77d8-9e60-23e8-e063-6394a90a9e69'],['fdb4ac5a-bf0d-4896-89f7-1828c081b79e'],"['76204-027-11', '76204-027-01']",['021SEF3731'],,,,,,,,,
New,06/13/2025,0093-7201-10,Pravastatin Sodium Tablet,800-545-8800,,,06/13/2025,['Cardiovascular'],Tablet,"Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076056'],['PRAVASTATIN SODIUM'],['PRAVASTATIN SODIUM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-7201', '0093-0771', '0093-7202']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PRAVASTATIN SODIUM'],"['904458', '904467', '904475']",['72579e23-23ef-4ab7-ad64-24d5ea7997eb'],['99e0e848-f8f3-4b42-b880-8fbc42633948'],"['0093-0771-98', '0093-0771-10', '0093-7201-98', '0093-7201-10', '0093-7202-98', '0093-7202-10']",['3M8608UQ61'],,,,06/13/2025,,,,,
Reverified,07/14/2023,59417-120-01,"Lisdexamfetamine Dimesylate Tablet, Chewable",877-TAKEDA-7 (1-877-825-3327),Available,,08/15/2025,['Psychiatry'],"Tablet, Chewable","Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)",Takeda Pharmaceuticals USA Inc.,,Current,['NDA208510'],['VYVANSE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Takeda Pharmaceuticals America, Inc.']","['59417-120', '59417-101', '59417-102', '59417-103', '59417-104', '59417-105', '59417-106', '59417-107', '59417-115', '59417-116', '59417-117', '59417-118', '59417-119']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],,['78225b65-2133-4c6c-bfde-0f2b26e5b19f'],['704e4378-ca83-445c-8b45-3cfa51c1ecad'],"['59417-101-10', '59417-102-10', '59417-103-10', '59417-104-10', '59417-105-10', '59417-106-10', '59417-107-10', '59417-115-01', '59417-116-01', '59417-117-01', '59417-118-01', '59417-119-01', '59417-120-01']",['SJT761GEGS'],,,,,,,,,
New,06/13/2025,13668-383-05,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-05)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Reverified,02/20/2018,0409-1582-29,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1582-29)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1582', '0409-1559', '0409-1560', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,11/03/2025,0003-3641-11,Atazanavir Sulfate; Cobicistat Tablet,800-332-2056,,The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.,11/03/2025,['Antiviral'],Tablet,"Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)",Bristol Myers Squibb Co.,,To Be Discontinued,['NDA206353'],['EVOTAZ'],['ATAZANAVIR AND COBICISTAT'],"['E.R. Squibb & Sons, L.L.C.']",['0003-3641'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ATAZANAVIR SULFATE', 'COBICISTAT']","['1601654', '1601660']",['fa642c67-5a9e-4136-a141-64e1236f6a0f'],['83db29d7-5d85-49d6-8cb6-740473365cf8'],['0003-3641-11'],"['4MT4VIE29P', 'LW2E03M5PG']","['N0000190114', 'N0000191001', 'N0000185503', 'N0000182137', 'N0000190107', 'N0000190108', 'N0000190113', 'N0000191423']",['Cytochrome P450 3A Inhibitor [EPC]'],,11/03/2025,,,,"['Cytochrome P450 3A Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]', 'Cytochrome P450 2D6 Inhibitors [MoA]', 'Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]', 'Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]', 'Breast Cancer Resistance Protein Inhibitors [MoA]', 'Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]']",
Reverified,07/14/2023,65162-026-09,Lisdexamfetamine Dimesylate Capsule,866-525-7270,Unavailable,Shortage of an active ingredient,11/07/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)",Amneal Pharmaceuticals,Shortage of an active ingredient,Current,['ANDA202830'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Amneal Pharmaceuticals LLC'],"['65162-026', '65162-023', '65162-024', '65162-025', '65162-027', '65162-028']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850']",['5fde01e6-09ba-4a92-bd47-aad0d7c518e4'],['c11cb3b6-3dff-477b-a249-b4c3118edc5f'],"['65162-023-09', '65162-024-09', '65162-025-09', '65162-026-09', '65162-027-09', '65162-028-09']",['SJT761GEGS'],,,,,,,,,
New,09/18/2025,0832-6003-11,Fluphenazine Hydrochloride Tablet,763-315-2000,,Discontinuation of the manufacture of the drug.,09/18/2025,"['Neurology', 'Psychiatry']",Tablet,"Fluphenazine Hydrochloride, Tablet, 1 mg (NDC 0832-6003-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA213784'],['FLUPHENAZINE HYDROCHLORIDE'],['FLUPHENAZINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories,LLC']","['0832-6003', '0832-6004', '0832-6005', '0832-6006']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLUPHENAZINE HYDROCHLORIDE'],"['859841', '860918', '865117', '865123']",['3bb74f82-8872-9829-e063-6294a90aeace'],['f07bb3f1-c68c-441b-9de4-99a219f2500a'],"['0832-6004-11', '0832-6003-11', '0832-6005-11', '0832-6006-11']",['ZOU145W1XL'],,,,09/18/2025,,,,,
Reverified,12/13/2017,72205-101-01,Bumetanide Injection,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,Available,,09/15/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)",MSN Laboratories Private Limited,,Current,['ANDA215364'],['BUMETANIDE'],['BUMETANIDE'],['Novadoz Pharmaceuticals LLC'],"['72205-101', '72205-102']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],['387edfd4-be85-41cd-8a6d-14e6a022b5a9'],"['72205-101-01', '72205-101-07', '72205-102-01', '72205-102-07']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,11/21/2023,0641-1496-35,Promethazine Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA083312'],['PROMETHAZINE HYDROCHLORIDE'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-1496', '0641-1495']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992858']",['80a400d2-d293-4180-bfa7-7a8ce0734bc5'],['13d9e59d-eadb-41d5-9f47-9c11a6efb31c'],"['0641-1495-31', '0641-1495-35', '0641-1496-31', '0641-1496-35']",['R61ZEH7I1I'],,,,,,,,,
Revised,05/03/2018,65219-368-02,Lorazepam Injection,888-386-1300,Unavailable,Next release November 2025. Check wholesalers for inventory.,11/05/2025,['Neurology'],Injection,"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['ANDA217598'],['LORAZEPAM'],['LORAZEPAM'],"['Fresenius Kabi USA, LLC']",['65219-368'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],['1665188'],['5cd2d0d8-9639-4e96-aafd-4991ad35fabc'],['b2487467-a63f-48b5-b0de-3a6ce6672d50'],"['65219-368-01', '65219-368-02']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,08/03/2022,62135-737-30,Flurazepam Hydrochloride Capsule,845-268-5000 Ext. 510,Available,,08/19/2025,"['Neurology', 'Other']",Capsule,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)",Chartwell Molecular Holdings LLC,,Current,['ANDA072369'],['FLURAZEPAM HYDROCHLORIDE'],['FLURAZEPAM HYDROCHLORIDE'],"['Chartwell RX, LLC']","['62135-737', '62135-736']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLURAZEPAM HYDROCHLORIDE'],"['1298088', '1298091']",['25893c92-c8f1-567a-e063-6294a90a00d4'],['8f476891-1346-4e8c-ac1b-f8cbdc64f5a1'],"['62135-736-30', '62135-736-90', '62135-737-30', '62135-737-90']",['756RDM536M'],,,,,,,,,
Reverified,04/28/2023,50742-447-45,Carboplatin Injection,866-321-5031,Unavailable,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",10/15/2025,['Oncology'],Injection,"Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)",Ingenus Pharmaceuticals LLC,Other,Current,['ANDA208487'],['CARBOPLATIN'],['CARBOPLATIN'],"['Ingenus Pharmaceuticals, LLC']","['50742-447', '50742-448']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['69fafb3c-1c18-4d34-83b2-3ab9ddaa6769'],['475caee0-15a6-4f0d-bca7-f3e472b323f7'],"['50742-447-45', '50742-448-60']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,01/26/2024,70726-0306-1,Riluzole Oral Suspension,610-937-6172,Available,,11/03/2025,['Neurology'],Oral Suspension,"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)","EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",,Current,,['TEGLUTIK'],['RILUZOLE'],['EDW PHARMA'],['70726-0306'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RILUZOLE'],"['2058147', '2675565']",['1ae0e94b-14fa-9671-e063-6394a90a3d6f'],['1a3aeb59-d589-8d12-e063-6394a90a0a3a'],['70726-0306-1'],['7LJ087RS6F'],"['N0000175740', 'M0483511']",['Benzothiazole [EPC]'],,,https://www.fda.gov/media/185612/download?attachment,['Benzothiazoles [CS]'],,,
Revised,10/12/2022,13107-073-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",(866) 850-2876 or CustomerService@AurobindoUSA.com,Unavailable,Estimated availability February 2026,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)",Aurobindo Pharma USA,Shortage of an active ingredient,Current,['ANDA202424'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Aurolife Pharma, LLC']","['13107-073', '13107-068', '13107-069', '13107-070', '13107-071', '13107-072', '13107-074']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['95842af2-8d9d-4eb1-ba39-86cdbd829a79'],['a582d57f-d191-4ca5-b105-585b2d8a0e3e'],"['13107-068-50', '13107-068-01', '13107-068-25', '13107-068-05', '13107-068-99', '13107-069-50', '13107-069-01', '13107-069-25', '13107-069-05', '13107-069-99', '13107-070-50', '13107-070-01', '13107-070-25', '13107-070-05', '13107-070-99', '13107-071-50', '13107-071-01', '13107-071-25', '13107-071-05', '13107-071-99', '13107-072-50', '13107-072-01', '13107-072-25', '13107-072-05', '13107-072-99', '13107-073-50', '13107-073-01', '13107-073-25', '13107-073-05', '13107-073-99', '13107-074-50', '13107-074-01', '13107-074-25', '13107-074-05', '13107-074-99']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/07/2020,25021-311-04,Furosemide Injection,866-625-1618,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Gland Pharma Limited,Other,Current,['ANDA213902'],['FUROSEMIDE'],['FUROSEMIDE'],['Sagent Pharmaceuticals'],['25021-311'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['222ce48f-2856-4be2-b16f-6fca38c0dceb'],['d63c1277-dd7e-4d21-9e80-68143f55e2dc'],"['25021-311-02', '25021-311-04', '25021-311-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,02/20/2018,70069-752-25,Bupivacaine Hydrochloride Injection,732-554-1037,Available,,08/19/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)","Somerset Therapeutics, LLC",,Current,['ANDA217792'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-752', '70069-753']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404']",['2b24af95-6f20-4945-bf8c-742f1d6f2721'],['bcaab86f-20f0-4482-8d73-e29b36dced58'],"['70069-752-25', '70069-752-10', '70069-752-01', '70069-753-25', '70069-753-01', '70069-753-10']",['7TQO7W3VT8'],,,,,,,,,
New,11/07/2025,0409-4911-34,Atropine Sulfate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2)  (NDC 0409-4911-34)""","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA021146'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Hospira, Inc.']","['0409-4911', '0409-1630', '0409-9630', '0409-4910']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['9211a9e9-35d0-457d-ac95-4ad43ea6bf28'],['ad8916e7-206e-409e-2582-30d072845dd4'],"['0409-1630-15', '0409-1630-10', '0409-9630-15', '0409-9630-05', '0409-4910-11', '0409-4910-34', '0409-4911-11', '0409-4911-34']",['03J5ZE7KA5'],,,,11/07/2025,,,,,
New,04/28/2025,0832-1113-60,Memantine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Neurology'],Tablet,"Memantine Hydrochloride, Tablet, 10 mg (NDC 0832-1113-60)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA090043'],['MEMANTINE HYDROCHLORIDE'],['MEMANTINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-1113', '0832-1112']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEMANTINE HYDROCHLORIDE'],"['996561', '996571']",['398273bb-cd0b-d984-e063-6394a90a89ab'],['6e0ade9e-b721-4701-bcb7-de464e19e707'],"['0832-1112-60', '0832-1113-60']",['JY0WD0UA60'],,,,04/28/2025,,,,,
Reverified,04/07/2020,83634-302-10,Furosemide Injection,855-228-9470,Available,Distributed by Avenacy; Contact information: 877-283-6229,11/03/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 83634-302-10)","Avet Pharmaceuticals, Inc.",,Current,['ANDA203428'],['FUROSEMIDE'],['FUROSEMIDE'],['Avenacy Inc.'],['83634-302'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['1b3f2803-b618-4447-b5ac-cd2bdc7de3e8'],['7d0db0f7-bf4f-4b0b-9359-2a838626e04b'],"['83634-302-42', '83634-302-02', '83634-302-43', '83634-302-04', '83634-302-41', '83634-302-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,02/17/2015,0143-9930-10,"Cefotaxime Sodium Powder, for Solution",800-631-2174,Unavailable,Shortage duration is unknown at this time.,10/24/2025,"['Anti-Infective', 'Pediatric']","Powder, For Solution","Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA065072'],['CEFOTAXIME'],['CEFOTAXIME'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9930', '0143-9931', '0143-9933']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CEFOTAXIME SODIUM'],"['309068', '1656313', '1656318']",['7e0897ec-2275-4438-9cc5-4c951e52ad97'],['ed23b6bc-32c7-4c50-a53d-313ae78e5623'],"['0143-9931-01', '0143-9931-25', '0143-9933-01', '0143-9933-25', '0143-9930-01', '0143-9930-10']",['258J72S7TZ'],,,,,,,,,
Revised,02/15/2023,55150-226-10,Rocuronium Bromide Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)",Eugia US LLC,,Current,['ANDA206206'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Eugia US LLC'],"['55150-226', '55150-225']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['256e0877-720b-40a2-be71-d503e8b860ab'],['116385ea-69fc-4f44-b463-6210291032df'],"['55150-225-05', '55150-226-10']",['I65MW4OFHZ'],,,,,,,,,
New,06/03/2025,65862-062-01,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-062', '65862-063', '65862-064']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
New,11/03/2025,0002-4312-62,Lasmiditan Succinate Tablet,800-545-5979,,A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets.,11/03/2025,['Neurology'],Tablet,"Reyvow, Tablet, 50 mg (NDC 0002-4312-62)",Eli Lilly and Co.,,To Be Discontinued,['NDA211280'],['REYVOW'],['LASMIDITAN'],['Eli Lilly and Company'],"['0002-4312', '0002-4491']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LASMIDITAN'],"['2256937', '2256943', '2256945', '2256947']",['75a13e98-3736-4256-8277-6c05bcaddcf5'],['aea3358c-ff41-4490-9e6d-c7bf7b3de13f'],"['0002-4312-08', '0002-4312-61', '0002-4312-62', '0002-4491-08', '0002-4491-61', '0002-4491-62']",['760I9WM792'],,,,11/03/2025,,,,,
New,12/05/2024,62756-529-40,Desmopressin Acetate Injection,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Endocrinology/Metabolism'],Injection,"Desmopressin Acetate, Injection, 4 ug/1 mL (NDC 62756-529-40)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA091280'],['DESMOPRESSIN ACETATE'],['DESMOPRESSIN ACETATE'],"['Sun Pharmaceutical Industries, Inc.']",['62756-529'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['DESMOPRESSIN ACETATE'],['849501'],"['ec29b269-1ce9-4199-ab07-a51d3e55d604', '129770b0-b59a-4ee3-bc07-2168544c1424']","['9fd48eec-aa24-4888-b99f-d409ada958a7', '2dc2cec8-6953-4a33-9356-11534fba1fb8']","['62756-529-40', '62756-529-26']",['XB13HYU18U'],,,,12/05/2024,,,,,
Revised,12/10/2021,65219-474-10,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-474-10)","Fresenius Kabi USA, LLC",,Resolved,['ANDA207310'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']","['65219-474', '65219-466', '65219-468', '65219-470', '65219-472']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['4110390b-2806-4c92-b283-a90115f89114'],['037ac04d-f8f3-4bb8-993a-ac8f7683ff83'],"['65219-466-05', '65219-466-60', '65219-468-05', '65219-468-50', '65219-470-05', '65219-470-30', '65219-472-05', '65219-472-20', '65219-474-05', '65219-474-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,0409-2305-17,Midazolam Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)","Hospira, Inc., a Pfizer Company",,Current,['ANDA075857'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2305', '0409-2308', '0409-0001']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['1666800', '1666814', '1666823', '1666798']","['b303a281-6633-47d5-bf29-5e9055e26da6', '8c3cf34b-901d-407a-946d-a1556bb24551']","['b95415fa-17c2-42ab-a6b0-e628d01c94ed', '1abda8b8-48a8-4995-af86-39220d1aa240']","['0409-2305-55', '0409-2305-50', '0409-2308-69', '0409-2308-49', '0409-2308-70', '0409-2308-50', '0409-2305-16', '0409-2305-17', '0409-2305-04', '0409-2305-05', '0409-2308-21', '0409-2308-01', '0409-2308-22', '0409-2308-02', '0409-0001-01', '0409-0001-25']",['W7TTW573JJ'],,,,,,,,,
New,07/21/2025,73070-200-11,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,609-987-5800,,"Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",07/21/2025,['Endocrinology/Metabolism'],Injectable Suspension,"Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)","Novo Nordisk, Inc.",,To Be Discontinued,['BLA021172'],['INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30'],['INSULIN ASPART'],"['Novo Nordisk Pharma, Inc.']","['73070-200', '73070-203']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN ASPART'],"['351297', '847191']",['ec67820c-4008-4894-b933-34b28704221d'],['fc94baa4-3606-48bc-a781-9617ab6960ef'],"['73070-200-11', '73070-203-10', '73070-203-15']",['D933668QVX'],"['M0011417', 'N0000175453']",['Insulin Analog [EPC]'],,07/21/2025,,['Insulin [CS]'],,,
New,01/17/2025,16729-533-08,Cyanocobalamin Injection,866-941-7875,,Permanent discontinuation in the manufacturing of the drug.,01/17/2025,['Hematology'],Injection,"Dodex, Injection, 1000 ug/1 mL (NDC 16729-533-08)",Accord Healthcare Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/17/2025,,,,,
Revised,12/10/2021,0338-9543-06,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-9543', '0338-9657', '0338-9659', '0338-9661', '0338-9663']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['6680afa2-1474-4bc3-afee-a333a042fd3f'],['958d35f0-6834-43be-a700-fa58f38b4c19'],"['0338-9543-01', '0338-9543-02', '0338-9543-03', '0338-9543-04', '0338-9543-05', '0338-9543-06', '0338-9543-12', '0338-9657-75', '0338-9659-75', '0338-9661-60', '0338-9663-60']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,03/13/2023,63323-123-10,Methotrexate Sodium Injection,888-386-1300,Available,Check wholesaler for inventory,11/05/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['ANDA040263'],['METHOTREXATE'],['METHOTREXATE SODIUM'],"['Fresenius Kabi USA, LLC']",['63323-123'],['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRAVENOUS']",['METHOTREXATE SODIUM'],['1946772'],['880c2caa-1b11-45ce-a54e-a3733da367f0'],['b585f621-f6c9-4735-ab61-bd1b401f3df0'],['63323-123-10'],['3IG1E710ZN'],,,,,,,,,
Reverified,11/14/2017,0409-7620-03,Heparin Sodium Injection,844-646-4398,Available,,10/23/2025,['Hematology'],Injection,"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)","Hospira, Inc., a Pfizer Company",,Current,['NDA018916'],['HEPARIN SODIUM'],['HEPARIN SODIUM'],"['Hospira, Inc.']","['0409-7620', '0409-1005', '0409-2222']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['c38c96a5-ff8a-43b6-a598-dfd044719d89'],['32e34077-aff1-4ec7-f9b0-b8e240768fb8'],"['0409-7620-13', '0409-7620-03', '0409-7620-49', '0409-7620-59', '0409-1005-01', '0409-1005-20', '0409-2222-01', '0409-2222-12']",['ZZ45AB24CA'],,,,,,,01/02/2025,,
New,12/05/2024,63304-693-03,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-03)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-693', '63304-692']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
Reverified,03/23/2018,63323-288-11,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-288', '63323-286', '63323-287', '63323-285']",['HUMAN PRESCRIPTION DRUG'],['EPIDURAL'],['ROPIVACAINE HYDROCHLORIDE'],"['905189', '905191', '1734084', '1734086', '1734090', '1734091', '1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484']","['cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c', '75465ceb-e894-487d-aa80-671fa0841fce']","['23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6', '56dfabf7-f7a8-4601-b17a-cb16fb995b0f']","['63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95', '63323-288-25', '63323-288-27']",['V910P86109'],,,,,,,,,
Reverified,07/26/2023,0406-0154-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-325-8888,Limited Availability,Allocation to all customers.,11/05/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 0406-0154-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA202608'],['METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE'],['METHYLPHENIDATE HYDROCHLORIDE'],['SpecGx LLC'],"['0406-0154', '0406-0127', '0406-0136']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2001565', '2001566', '2001568']",['7a3a8731-e545-455e-83c3-888f4923e901'],['b1b0f2ff-d9df-42ab-b471-226ecf97e075'],"['0406-0127-01', '0406-0136-01', '0406-0154-01']",['4B3SC438HI'],,,,,,,,,
Reverified,10/12/2022,0527-1502-37,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)","Lannett Company, Inc.",,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,12/08/2020,0264-4500-05,Amino Acid Injection,800-227-2862,Available,,11/04/2025,['Gastroenterology'],Injection,"Plenamine, Injection, 0.15 (NDC 0264-4500-05)",B. Braun Medical Inc.,,Current,['ANDA091112'],['PLENAMINE'],"['LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE']",['B. Braun Medical Inc.'],['0264-4500'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['800584', '1601982']",['e55957d3-67af-4b6d-9232-55b654e0076f'],['a3244d1a-45b0-4e4c-bd96-f0632d761a1f'],"['0264-4500-00', '0264-4500-05']","['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Reverified,01/01/2012,16729-526-08,Atropine Sulfate Injection,"866-941-7875, option 2",Unavailable,30 days,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['NDA214652'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],['Accord Healthcare Inc.'],"['16729-526', '16729-525']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190795', '1666781']",['419aa7b6-eb26-8cb2-e063-6294a90ab8d3'],['d5e07279-48ca-4f83-9633-299e65a7f821'],"['16729-525-63', '16729-525-03', '16729-525-08', '16729-526-63', '16729-526-03', '16729-526-08']",['03J5ZE7KA5'],,,,,,,,,
Reverified,07/26/2023,43598-438-01,"Methylphenidate Hydrochloride Tablet, Extended Release",866-732-3952,Unavailable,Estimated availability TBD,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 43598-438-01)","Dr. Reddy's Laboratories, Inc.",Other,Current,,,,,,,,,,,,,,,,,,,,,,
New,12/05/2024,47335-475-13,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-13)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-475', '47335-472']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,03/21/2023,25021-115-04,Clindamycin Phosphate Injection,866-625-1618,Available,,08/26/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)",Sagent Pharmaceuticals,,Current,['ANDA090108'],['CLINDAMYCIN'],['CLINDAMYCIN PHOSPHATE'],['Sagent Pharmaceuticals'],['25021-115'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['1737244', '1737578', '1737581']",['4662502b-ce7c-4278-854d-cf8632ac9b83'],['7a6967b3-5563-4bed-9eee-d400f800e799'],"['25021-115-02', '25021-115-04', '25021-115-06']",['EH6D7113I8'],,,,,,,,,
Reverified,03/01/2017,81298-7620-3,Sodium Bicarbonate Injection,833-268-5559,Available,,09/17/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)",Long Grove Pharmaceuticals LLC,,Current,['ANDA216042'],['SODIUM BICARBONATE'],"['SODIUM BICARBONATE INJECTION,']","['Long Grove Pharmaceuticals, LLC']",['81298-7620'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],['1868486'],['1a255946-a137-4e13-8203-65dd80b34872'],['a26d709b-b294-4b02-9a88-7e840f099a33'],"['81298-7620-1', '81298-7620-3']",['8MDF5V39QO'],,,,,,,,,
Reverified,07/26/2023,13811-707-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Limited Availability,Allocation to current contracted customers,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)","Trigen Laboratories, LLC",Demand increase for the drug,Current,['ANDA205327'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Trigen Laboratories, LLC']","['13811-707', '13811-709', '13811-706', '13811-708', '13811-710']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461']",['54f7316b-8a84-4145-aecf-f380afbf261b'],['c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f'],"['13811-709-10', '13811-706-10', '13811-707-10', '13811-708-10', '13811-710-10', '13811-710-30']",['4B3SC438HI'],,,,,,,,,
New,10/01/2025,0071-5212-23,Hydrochlorothiazide; Quinapril Hydrochloride Tablet,800-533-4535,,Discontinuation of the manufacture of the drug,10/01/2025,['Cardiovascular'],Tablet,"Accuretic, Tablet, 12.5 mg; 20 mg (NDC 0071-5212-23)",Pfizer Inc.,,To Be Discontinued,['NDA020125'],['ACCURETIC'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],['Parke-Davis Div of Pfizer Inc'],"['0071-5212', '0071-0223', '0071-3112', '0071-7225']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809', '809854', '809858', '882559']",['489727cb-429e-4f04-a973-ae4dc7898519'],['80e9d61d-9674-4ac4-b84c-79a875d408dd'],"['0071-0223-23', '0071-3112-23', '0071-5212-23', '0071-7225-23']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],10/01/2025,,['Thiazides [CS]'],,,
Reverified,03/10/2023,16729-136-16,Clonazepam Tablet,"866-941-7875, option 2",Available,,11/04/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)",Accord Healthcare Inc.,,Current,['ANDA077147'],['CLONAZEPAM'],['CLONAZEPAM'],['Accord Healthcare Inc.'],"['16729-136', '16729-137', '16729-138']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['0e1e7f41-f78b-27cf-e063-6394a90a1ae0'],['ebc11109-e7bf-452d-b675-4b3236d54164'],"['16729-136-00', '16729-136-16', '16729-137-00', '16729-137-16', '16729-138-00', '16729-138-16']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,02/03/2016,69784-232-01,Sodium Acetate Injection,833-251-8463,Limited Availability,Limited Availability,11/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 69784-232-01)",Milla Pharmaceuticals,Other,Current,,,,,,,,,,,,,,,,,,,,,,
Revised,12/15/2021,70121-1574-5,Methylprednisolone Acetate Injection,866-525-7270,Available,"Currently product is under backorder as per current demand. 
Next supply: week of 11/24/2025",11/07/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)",Amneal Pharmaceuticals,Other,Current,['ANDA210043'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Amneal Pharmaceuticals LLC'],"['70121-1574', '70121-1573']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1743779', '1743855']",['0bdaa3cf-cf32-4959-b87a-65215ac4648d'],['d944240d-2c19-46ba-ad4f-3fbee7b8629c'],"['70121-1573-1', '70121-1573-5', '70121-1574-1', '70121-1574-5']",['43502P7F0P'],,,,,,,,,
New,09/26/2025,25021-230-02,Irinotecan Hydrochloride Injection,"Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals,09/26/2025,['Oncology'],Injection,"Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)","Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,To Be Discontinued,['ANDA090675'],['IRINOTECAN HYDROCHLORIDE'],['IRINOTECAN HYDROCHLORIDE'],['Sagent Pharmaceuticals'],['25021-230'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['IRINOTECAN HYDROCHLORIDE'],"['1726319', '1726324']",['6c1863de-2414-4e41-a2fa-7f2f7135af0e'],['caab50e6-0dad-4ddd-9a6c-96cc2b87aee7'],"['25021-230-02', '25021-230-05']",['042LAQ1IIS'],,,,09/26/2025,,,,,
New,11/21/2024,0173-0903-56,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 2 mg (NDC 0173-0903-56)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0903', '0173-0897', '0173-0906', '0173-0911', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
Reverified,01/01/2020,16729-484-45,Atropine Sulfate Injection,"866-941-7875, option 2",Unavailable,30 days,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA212868'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Accord Healthcare, Inc.,']","['16729-484', '16729-483']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['4082a1cf-1e1b-6f40-e063-6294a90aec06'],['c82cb295-ffce-47d6-97ad-a8aa723f4e4f'],"['16729-483-03', '16729-483-31', '16729-484-90', '16729-484-31', '16729-484-45', '16729-484-03']",['03J5ZE7KA5'],,,,,,,,,
Reverified,04/02/2020,23155-601-41,Midazolam Hydrochloride Injection,855-228-9470,Unavailable,2-4 Weeks,11/03/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)","Avet Pharmaceuticals, Inc.",Demand increase for the drug,Current,['ANDA090850'],['MIDAZOLAM HYDROCHLORIDE'],['MIDAZOLAM HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],['23155-601'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],['311702'],['e20feff9-3aca-4bc1-a5c3-44fff8a9459c'],['843cc25e-45ea-4372-ae34-843f805fa869'],"['23155-601-31', '23155-601-41', '23155-601-32', '23155-601-42']",['W7TTW573JJ'],,,,,,,,,
Revised,10/31/2017,0409-1283-37,Hydromorphone Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: April 2026; Estimated Recovery: June 2026,10/23/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA200403'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1283', '0409-1312', '0409-1380', '0409-4264', '0409-1805', '0409-2552', '0409-3356', '0409-2540', '0409-3365', '0409-1304']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1724383', '1724644', '1872271', '2675350', '897653', '897753', '897758', '1724276']","['53b6867a-0ae3-48ff-b257-9e58cc76de9c', '58ff0e68-b78f-4ebd-a91b-b53bbdefc544']","['f9ca2ef5-46d8-475a-a26e-f7c8becd6db7', 'e9c9ef18-7dfc-4322-b2fc-29b934c30f8b']","['0409-1283-17', '0409-1283-37', '0409-1312-16', '0409-1312-36', '0409-1380-11', '0409-1380-01', '0409-4264-11', '0409-4264-01', '0409-1805-10', '0409-1805-01', '0409-2552-11', '0409-2552-01', '0409-3356-11', '0409-3356-01', '0409-2540-11', '0409-2540-01', '0409-3365-11', '0409-3365-01', '0409-3365-10', '0409-1283-03', '0409-1283-31', '0409-1283-09', '0409-1283-10', '0409-1283-04', '0409-1283-05', '0409-1312-03', '0409-1312-30', '0409-1312-09', '0409-1312-10', '0409-1304-03', '0409-1304-31']",['L960UP2KRW'],,,,,,,,,
Reverified,03/10/2023,43547-408-10,Clonazepam Tablet,"For orders, Solco Healthcare 866-931-9829",Available,Marketed by Solco Healthcare,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)","Prinston Pharmaceutical, Inc.",,Current,['ANDA077856'],['CLONAZEPAM'],['CLONAZEPAM'],['Solco Healthcare LLC'],"['43547-408', '43547-406', '43547-407']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['dc17b9d4-2890-4f6c-8476-daa39d0cbc9c'],['4acbb7a9-4db5-4497-b8db-9f358b3f6fb4'],"['43547-406-10', '43547-406-50', '43547-406-11', '43547-407-10', '43547-407-50', '43547-407-11', '43547-408-10', '43547-408-50']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,12/10/2021,65219-468-50,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-468-50)","Fresenius Kabi USA, LLC",,Resolved,['ANDA207310'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']","['65219-468', '65219-466', '65219-470', '65219-472', '65219-474']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['4110390b-2806-4c92-b283-a90115f89114'],['037ac04d-f8f3-4bb8-993a-ac8f7683ff83'],"['65219-466-05', '65219-466-60', '65219-468-05', '65219-468-50', '65219-470-05', '65219-470-30', '65219-472-05', '65219-472-20', '65219-474-05', '65219-474-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,12/05/2024,62756-129-40,Pantoprazole Sodium Injection,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Gastroenterology'],Injection,"Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-40)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077674'],['PANTOPRAZOLE SODIUM'],['PANTOPRAZOLE SODIUM'],"['Sun Pharmaceutical Industries, Inc.']",['62756-129'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PANTOPRAZOLE SODIUM'],['283669'],['ef1bb9ed-b534-4698-abf5-836dcce85f45'],['d9fcf6a2-3788-4955-84d9-3c319b13267c'],"['62756-129-40', '62756-129-44', '62756-129-45']",['6871619Q5X'],,,,12/05/2024,,,,,
Reverified,11/01/2023,60505-4744-1,Lisdexamfetamine Dimesylate Capsule,800-706-5575,Available,Product currently available,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)",Apotex Corp.,,Current,['ANDA216944'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Apotex Corp.'],"['60505-4744', '60505-4739', '60505-4740', '60505-4741', '60505-4742', '60505-4743', '60505-4745']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7a3783a0-bb54-a95b-99f4-9d3aa9788649'],['ecad4442-a644-18e3-6ff2-fdbac45eec47'],"['60505-4739-1', '60505-4740-1', '60505-4741-1', '60505-4742-1', '60505-4743-1', '60505-4744-1', '60505-4745-1']",['SJT761GEGS'],,,,,,,,,
New,04/28/2025,0832-7124-01,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7124', '0832-7122', '0832-7123']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
Reverified,04/28/2023,0990-7139-36,Sterile Water Irrigant,1-866-829-9025 or ProductAvailability@icumed.com,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)",Otsuka ICU Medical LLC,Other,Current,['NDA017513'],['STERILE WATER'],['WATER'],['ICU Medical Inc.'],"['0990-7139', '0990-6139', '0990-7973']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['514c37b1-817a-4dae-a2de-3d938ea76e4e'],['e3484bc6-ed7f-43ef-9d49-c131a8dff2dd'],"['0990-6139-22', '0990-6139-03', '0990-7139-09', '0990-7139-36', '0990-7973-05', '0990-7973-07', '0990-7973-08']",['059QF0KO0R'],,,,,https://www.fda.gov/media/182619/download?attachment,,,,
New,05/19/2025,62037-560-05,"Potassium Chloride Capsule, Extended Release",800-545-8800,,,05/19/2025,"['Endocrinology/Metabolism', 'Gastroenterology']","Capsule, Extended Release","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA077419'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Actavis Pharma, Inc.']","['62037-560', '62037-559']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312504', '315183']",['b97da107-c56e-48ea-ba34-d3d64a5b9f46'],['ed5baaf6-270b-4dd3-b100-36030c0098fc'],"['62037-559-01', '62037-559-05', '62037-560-01', '62037-560-05', '62037-560-10', '62037-560-90']",['660YQ98I10'],,,,05/19/2025,,,,,
Revised,01/01/2012,63323-711-00,Leucovorin Calcium Injection,888-386-1300,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 63323-711-00)","Fresenius Kabi USA, LLC",,Resolved,['ANDA040286'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Fresenius Kabi USA, LLC']","['63323-711', '63323-710']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['1803937', '2055036']",['2497bd71-0f85-48ec-9353-d591e1c728f8'],['e3b957dc-a542-4f69-b8a0-7df401ee706f'],"['63323-710-50', '63323-711-00']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,02/14/2022,0338-0551-11,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)",Baxter Healthcare,,Current,['NDA020179'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Company'],['0338-0551'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795616']",['e702be26-651e-4d4a-9d79-4df9f53821c9'],['7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e'],"['0338-0551-11', '0338-0551-18']",['LX22YL083G'],,,,,,,,,
Revised,02/20/2018,55150-167-10,Bupivacaine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)",Eugia US LLC,,Current,['ANDA203895'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-167', '55150-168', '55150-169', '55150-170', '55150-171', '55150-172', '55150-249', '55150-250']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
New,01/22/2025,64380-156-01,Minocycline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Antiviral'],Tablet,"Minocycline Hydrochloride, Tablet, 100 mg (NDC 64380-156-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA065131'],['MINOCYCLINE HYDROCHLORIDE'],['MINOCYCLINE HYDROCHLORIDE'],['Strides Pharma Science Limited'],"['64380-156', '64380-154', '64380-155']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MINOCYCLINE HYDROCHLORIDE'],"['207362', '207364', '403840']",['73a30dc4-352b-4307-b902-07ffefc99a99'],['d6e136ba-c9b1-4846-ae2a-98a29cb4504d'],"['64380-154-01', '64380-155-01', '64380-156-01']",['0020414E5U'],,,,01/22/2025,,,,,
Revised,01/01/2012,25021-813-10,Leucovorin Calcium Injection,866-625-1618,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 25021-813-10)",Sagent Pharmaceuticals,,Resolved,['ANDA200753'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Sagent Pharmaceuticals'],"['25021-813', '25021-814', '25021-815', '25021-816']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['ff2ba160-e2f9-4ab9-9e67-2409f02c923e'],['9d0e5356-ff39-4a8e-944c-e808a21ef4b2'],"['25021-813-10', '25021-814-30', '25021-815-30', '25021-816-30']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,04/10/2020,44567-602-24,Dexmedetomidine Hydrochloride Injection,WG Critical Care 888-493-0861,Available,Marketed by WG Critical Care,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)",HQ Specialty Pharma,,Current,['NDA206628'],['DEXMEDETOMIDINE IN DEXTROSE'],['DEXMEDETOMIDINE'],"['WG Critical Care, LLC']","['44567-602', '44567-600', '44567-601', '44567-603']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909', '1788947']",['e6fa3e27-b374-49b6-a678-a5954f5beae8'],['0d2710f2-ee47-4114-ab5c-8dca74cdcb8d'],"['44567-600-04', '44567-601-04', '44567-602-24', '44567-603-24']",['1018WH7F9I'],,,,,,,,,
Revised,12/10/2021,0338-0553-11,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-11)",Baxter Healthcare,,Resolved,['NDA020178'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],['0338-0553'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632']",['aca96e4a-a57b-47ac-bd60-e65c29e19743'],['fbc01464-8885-4075-af41-911ffec5ae92'],"['0338-0553-11', '0338-0553-18']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,47781-179-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-842-8672 and email: CustomerService-US@alvogen.com,Unavailable,30 Days,11/06/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)",Alvogen,Other,Current,['ANDA207388'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 20 MG,CLL']",['Alvogen Inc.'],"['47781-179', '47781-174', '47781-175', '47781-176', '47781-177', '47781-178', '47781-180']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['0374f0f7-9297-810c-38b3-623a72709a7d'],['c907301d-e24d-9609-5529-fed14f94549f'],"['47781-174-30', '47781-174-05', '47781-174-01', '47781-175-30', '47781-175-05', '47781-175-01', '47781-176-30', '47781-176-05', '47781-176-01', '47781-177-30', '47781-177-05', '47781-177-01', '47781-178-30', '47781-178-05', '47781-178-01', '47781-179-30', '47781-179-05', '47781-179-01', '47781-180-30', '47781-180-05', '47781-180-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,04/14/2025,61314-509-64,Adalimumab-adaz Injection,800-525-8747,,,04/14/2025,['Rheumatology'],Injection,"Hyrimoz, Injection, 10 mg/.1 mL (NDC 61314-509-64)",Sandoz Inc.,,To Be Discontinued,['BLA761071'],['HYRIMOZ'],['ADALIMUMAB-ADAZ'],['Sandoz Inc'],"['61314-509', '61314-454', '61314-473', '61314-476', '61314-517', '61314-531']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['ADALIMUMAB'],"['2641644', '2641650', '2641653', '2641654', '2641655', '2641658', '2641660', '2641661', '2641662', '2641663', '2641664', '2641665', '2641666', '2641667', '2641668', '2641669', '2641670', '2641671', '2641672', '2641673']",['0d5a902f-4ca8-46d2-a790-b167842f62e4'],['1ac7d061-3380-468c-b077-c05f8dfbc829'],"['61314-454-20', '61314-454-36', '61314-454-68', '61314-473-64', '61314-473-20', '61314-473-92', '61314-476-64', '61314-509-64', '61314-517-36', '61314-531-64']",['FYS6T7F842'],"['N0000175610', 'N0000175451', 'M0001357']",['Tumor Necrosis Factor Blocker [EPC]'],,04/14/2025,,"['Antibodies, Monoclonal [CS]']",,['Tumor Necrosis Factor Receptor Blocking Activity [MoA]'],
Reverified,04/10/2020,42023-186-20,Dexmedetomidine Hydrochloride Injection,800-828-9393,Available,Please check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)","Par Pharmaceutical, Inc.",,Current,['ANDA208266'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['ENDO USA, Inc.']","['42023-186', '42023-146', '42023-187']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['309710', '1718906', '1718909']",['d518b2d2-b39c-47ac-b45f-8c6a045a8dae'],['1ee59985-4c1d-48f7-b8f9-5584c2d55e08'],"['42023-146-25', '42023-186-20', '42023-187-10']",['1018WH7F9I'],,,,,,,,,
Revised,01/06/2023,0013-2658-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 2.0 mg preservative free (NDC 0013-2658-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2658', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2654', '0013-2655', '0013-2656', '0013-2657']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Reverified,11/03/2017,0641-6020-10,Morphine Sulfate Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Duramorph (Morphine Sulfate Injection, USP), Injection, .5 mg/1 mL (NDC 0641-6020-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['NDA018565'],['DURAMORPH'],['MORPHINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6020', '0641-6019']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['892473', '892489', '1728783', '1728800']",['d8bb0ae2-68bc-40ff-ad67-867bb8b71bc7'],['ebb18761-e5c4-4238-bb84-f9549f500210'],"['0641-6020-01', '0641-6020-10', '0641-6019-01', '0641-6019-10']",['X3P646A2J0'],,,,,,,,,
Reverified,02/22/2012,63323-201-10,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)","Fresenius Kabi USA, LLC",,Current,['ANDA088586'],['LIDOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-201', '63323-202']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1737757']",['d19c26f4-1214-40f7-9680-43c885613306'],['cddb2b22-fce3-8967-6e54-dca3df5ac4b3'],"['63323-201-01', '63323-201-02', '63323-201-03', '63323-201-10', '63323-202-01', '63323-202-02']",['V13007Z41A'],,,,,,,,,
Reverified,03/01/2022,0264-7520-00,Dextrose Monohydrate 10% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)",B. Braun Medical Inc.,,Current,['NDA019626'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],"['0264-7520', '0264-7510']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE, UNSPECIFIED FORM']","['1795477', '1795480', '1795481', '1795607', '1795610', '1795612']",['c9f87749-8dd5-41fd-b393-f63d45fd00ef'],['085614c7-ada4-4e2c-87c0-c9bc2f18365a'],"['0264-7510-00', '0264-7510-10', '0264-7510-20', '0264-7520-00', '0264-7520-10', '0264-7520-20']",['IY9XDZ35W2'],,,,,,,,,
Revised,12/10/2021,0990-7984-20,Sodium Chloride 0.9% Injection,1-866-829-9025 or ProductAvailability@icumed.com,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-20)",Otsuka ICU Medical LLC,,Resolved,['NDA016366'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['ICU Medical Inc.'],"['0990-7984', '0990-7730', '0990-7983', '0990-7985']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807548', '1807549', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['beda0179-f554-4c42-b60e-68615243d312'],['5f372b75-d7a4-471e-8ac6-290040fc84b0'],"['0990-7730-36', '0990-7730-37', '0990-7983-61', '0990-7983-02', '0990-7983-03', '0990-7983-09', '0990-7983-55', '0990-7983-53', '0990-7984-37', '0990-7984-20', '0990-7984-13', '0990-7984-23', '0990-7984-36', '0990-7985-02', '0990-7985-03', '0990-7985-09']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,10/06/2023,0338-1049-02,Nitroglycerin Injection,Baxter Healthcare 888-229-0001,Unavailable,Manufacturing delay; Recovery in December 2025,10/22/2025,['Cardiovascular'],Injection,"Nitroglycerin in Dextrose 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)",Baxter Healthcare,Other,Current,['NDA019970'],['NITROGLYCERIN IN DEXTROSE'],['NITROGLYCERIN'],['Baxter Healthcare Company'],"['0338-1049', '0338-1047', '0338-1051']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['NITROGLYCERIN'],"['312004', '1868494', '1868562']",['71811937-e908-4b65-aff2-4b345fa0954b'],['457a026c-ebce-4701-9deb-2d7652759a99'],"['0338-1047-02', '0338-1049-02', '0338-1051-02']",['G59M7S0WS3'],"['N0000175415', 'M0014874', 'N0000009909']",['Nitrate Vasodilator [EPC]'],['Vasodilation [PE]'],,,['Nitrates [CS]'],,,
New,07/01/2025,64950-217-10,Isoniazid Tablet,610-782-9780,,Product expected to be available until August 2025.,07/01/2025,['Anti-Infective'],Tablet,"Isoniazid, Tablet, 300 mg (NDC 64950-217-10)",Genus Lifesciences,,To Be Discontinued,['ANDA080937'],['ISONIAZID'],['ISONIAZID'],['Genus Lifesciences'],"['64950-217', '64950-216']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ISONIAZID'],"['197832', '311166']",['6ea58bc8-a5a8-47a1-81e1-f769924e1502'],['f0b46d1d-2300-457d-a7bd-a88a3f8d2235'],"['64950-216-10', '64950-217-03', '64950-217-10']",['V83O1VOZ8L'],['N0000175483'],['Antimycobacterial [EPC]'],,07/01/2025,,,,,
Reverified,04/10/2020,0409-1638-02,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1638', '0409-1660', '0409-1434', '0409-1596', '0409-7838', '0409-7853', '0409-7875']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['284397', '309710', '1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['231f50fe-2c91-44b9-946e-33b836c07b94'],['548a88c0-afda-427e-75ac-5af0cfa2224c'],"['0409-1660-55', '0409-1660-50', '0409-1660-35', '0409-1660-10', '0409-1660-22', '0409-1660-20', '0409-1638-32', '0409-1638-02', '0409-1434-01', '0409-1596-01', '0409-1596-10', '0409-7838-01', '0409-7838-24', '0409-7853-01', '0409-7853-24', '0409-7875-01', '0409-7875-12']",['1018WH7F9I'],,,,,,,,,
Reverified,04/28/2023,0990-6139-03,Sterile Water Irrigant,1-866-829-9025 or ProductAvailability@icumed.com,Limited Availability,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)",Otsuka ICU Medical LLC,Other,Current,['NDA017513'],['STERILE WATER'],['WATER'],['ICU Medical Inc.'],"['0990-6139', '0990-7139', '0990-7973']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['514c37b1-817a-4dae-a2de-3d938ea76e4e'],['e3484bc6-ed7f-43ef-9d49-c131a8dff2dd'],"['0990-6139-22', '0990-6139-03', '0990-7139-09', '0990-7139-36', '0990-7973-05', '0990-7973-07', '0990-7973-08']",['059QF0KO0R'],,,,,https://www.fda.gov/media/182619/download?attachment,,,,
New,10/29/2025,63323-850-74,Moxifloxacin Injection,888-386-1300,,Discontinuation of the manufacture of the drug,10/29/2025,['Anti-Infective'],Injection,"Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74)","Fresenius Kabi USA, LLC",,To Be Discontinued,['NDA205572'],['MOXIFLOXACIN'],['MOXIFLOXACIN HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-850'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MOXIFLOXACIN HYDROCHLORIDE'],['351156'],['4070f637-059f-4e3d-8cf3-e5256a46ff3e'],['a4e28b09-714b-46e7-b4e6-0163cad78fc5'],"['63323-850-74', '63323-850-04']",['C53598599T'],,,,10/29/2025,,,,,
Revised,02/22/2012,0409-4903-34,Lidocaine Hydrochloride Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,['ANDA083158'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4903', '0409-4904', '0409-1323', '0409-9137']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1012066', '1012068']",['477abea3-c873-4265-82e8-5508ef54399f'],['ad1ef0a8-88db-4648-c098-d009eaeb4e5b'],"['0409-4903-11', '0409-4903-34', '0409-4904-11', '0409-4904-34', '0409-1323-15', '0409-1323-05', '0409-9137-11', '0409-9137-05']",['V13007Z41A'],,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d,,,,
New,11/07/2025,0409-4902-34,Dextrose Monohydrate 50% Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Hospira, Inc.']","['0409-4902', '0409-7517', '0409-6648', '0409-0505']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['727517', '1795514']",['0fca7d54-4d75-455b-a1d7-d25e31702264'],['4ed365da-4e62-4329-c1b9-c197ab4fb6e1'],"['0409-7517-66', '0409-7517-16', '0409-4902-64', '0409-4902-34', '0409-6648-16', '0409-6648-02', '0409-0505-15', '0409-0505-25']",['LX22YL083G'],,,,11/07/2025,,,,,
Revised,11/23/2021,0641-6147-10,Sterile Water Injection,800-631-2174,Available,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,10/24/2025,['Other'],Injection,"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA206369'],['STERILE WATER'],['WATER'],['Hikma Pharmaceuticals USA Inc.'],['0641-6147'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['081540ac-58cf-437f-ba1b-86d5264ec3dc'],['78ef7ad3-451d-43d0-a9b6-5cf0aadca003'],"['0641-6147-01', '0641-6147-10', '0641-6147-25']",['059QF0KO0R'],,,,,,,,,
New,10/09/2025,0781-2859-10,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-10)",Sandoz Inc.,,To Be Discontinued,['ANDA075757'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],"['0781-2859', '0781-2868']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],"['198051', '199119']",['6a54ba13-eeb3-4c8c-800b-dc9aaf961c3f'],['516170d4-4913-4577-a2d2-f5c52d1e79c6'],"['0781-2859-10', '0781-2859-01', '0781-2859-92', '0781-2859-31', '0781-2868-10', '0781-2868-01', '0781-2868-92', '0781-2868-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Reverified,06/06/2018,0338-0069-10,Ketorolac Tromethamine Injection,888-229-0001,Available,,10/22/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)",Baxter Healthcare,,Current,['ANDA209900'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Baxter Healthcare Corporation'],"['0338-0069', '0338-0072', '0338-0076']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['2da4dd8a-1b18-481d-b733-9c031d9ea7e3'],['4b58836d-9d58-4539-9691-9e11c505ef2a'],"['0338-0069-10', '0338-0072-25', '0338-0076-10']",['4EVE5946BQ'],,,,,,,,,
New,03/04/2025,65862-584-01,Amlodipine Besylate; Benazepril Hydrochloride Capsule,866-850-2876,,,03/04/2025,['Cardiovascular'],Capsule,"Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA202239'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-584', '65862-582', '65862-583', '65862-585', '65862-586', '65862-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898346', '898350', '898353', '898356', '898359']",['a45ec3e8-1d14-4c27-9685-976323df8cad'],['99ed4927-9a34-4e8d-8eea-60b63c867d46'],"['65862-582-01', '65862-582-05', '65862-583-01', '65862-583-05', '65862-584-01', '65862-584-05', '65862-585-01', '65862-585-05', '65862-586-01', '65862-586-05', '65862-587-01', '65862-587-05']","['N1SN99T69T', '864V2Q084H']",,,,03/04/2025,,,,,
New,09/09/2025,0409-6531-01,Vancomycin Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,09/09/2025,['Anti-Infective'],Injection,"Vancomycin Hydrochloride, Injection, 750 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-6531-01)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,"['ANDA062933', 'ANDA062912']",['VANCOMYCIN HYDROCHLORIDE'],['VANCOMYCIN HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-6531', '0409-6535', '0409-6534', '0409-6533', '0409-4332', '0409-3515']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['VANCOMYCIN HYDROCHLORIDE'],"['1807513', '1807516', '1807518', '2049890']","['771a44e0-5858-449c-be36-438a9ff52e67', '6b13ef5a-c456-4bcf-a9ec-ddc91bbd809a']","['2fd9de3f-a95f-451c-a687-d2e1306e53bf', 'f2901045-904f-47bd-74a1-c561facd7f25']","['0409-6531-11', '0409-6531-01', '0409-6535-11', '0409-6535-01', '0409-6534-11', '0409-6534-01', '0409-6531-12', '0409-6531-02', '0409-6533-11', '0409-6533-01', '0409-6533-21', '0409-4332-11', '0409-4332-01', '0409-3515-11', '0409-3515-01']",['71WO621TJD'],,,,09/09/2025,,,,,
Revised,02/15/2023,39822-4200-6,Rocuronium Bromide Injection,866-390-4411,Unavailable,Next lots scheduled for release March 2026.,10/23/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)","XGen Pharmaceuticals DJB, Inc.",Demand increase for the drug,Current,['ANDA091115'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],"['XGen Pharmaceuticals DJB, Inc.']",['39822-4200'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['eedcfb07-4e23-3152-e053-2995a90a6e6a'],['b73f192c-2912-4ec3-9b4f-05a58d9b35ba'],"['39822-4200-1', '39822-4200-2', '39822-4200-5', '39822-4200-6']",['I65MW4OFHZ'],,,,,,,,,
Reverified,02/28/2025,0574-2410-65,"Methylphenidate Film, Extended Release",800-455-8070,Available,Available. Distributed by Padagis US LLC,10/02/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)","Noven Pharmaceuticals, Inc.",,Current,['NDA021514'],['METHYLPHENIDATE TRANSDERMAL SYSTEM'],['METHYLPHENIDATE'],['PADAGIS US LLC'],"['0574-2410', '0574-2415', '0574-2420', '0574-2430']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['b743ef45-2fc0-4086-8a02-6078e6a09eaa'],['7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb'],"['0574-2410-65', '0574-2415-65', '0574-2420-65', '0574-2430-65']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
Reverified,10/05/2022,67457-903-20,Etomidate Injection,800-796-9526,Available,,11/06/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)","Mylan Institutional, a Viatris Company",,Current,['ANDA201044'],['ETOMIDATE'],['ETOMIDATE'],['Mylan Institutional LLC'],"['67457-903', '67457-902']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['25fc0aef-d4b3-4b33-897c-81cc7cdae470'],['461e34d1-b862-4a02-9727-548c907aac48'],"['67457-902-00', '67457-902-10', '67457-903-00', '67457-903-20']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Revised,02/20/2018,0409-3613-01,Bupivacaine Hydrochloride Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA071810'],['BUPIVACAINE SPINAL'],['BUPIVACAINE HYDROCHLORIDE IN DEXTROSE'],"['Hospira, Inc.']",['0409-3613'],['HUMAN PRESCRIPTION DRUG'],['SUBARACHNOID'],['BUPIVACAINE HYDROCHLORIDE'],['1724784'],['43a8f8dd-af5e-486d-bd36-a7f2956f2bc0'],['7a8d2539-4422-4312-0298-207ef1a2948e'],"['0409-3613-11', '0409-3613-01']",['7TQO7W3VT8'],,,,,,,,,
Reverified,02/17/2021,63323-351-20,Rifampin Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anti-Infective'],Injection,"Rifampin, Injection, 600 mg (NDC 63323-351-20)","Fresenius Kabi USA, LLC",,Current,['ANDA091181'],['RIFAMPIN'],['RIFAMPIN'],"['Fresenius Kabi USA, LLC']",['63323-351'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['RIFAMPIN'],['312821'],['60eb9c46-3c34-455b-a740-c03884565072'],['a1f9f1e2-dfc0-4d31-a13b-b656d897b791'],['63323-351-20'],['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,07/14/2023,0378-6860-77,Lisdexamfetamine Dimesylate Capsule,800-796-9526,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA202835'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Mylan Pharmaceuticals Inc.'],"['0378-6860', '0378-6854', '0378-6855', '0378-6856', '0378-6857', '0378-6858', '0378-6859']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['63cd6f7c-f976-440e-a35f-e71a9f2fd1bb'],['efbde0f6-b848-4664-b741-c6c630e66108'],"['0378-6854-77', '0378-6855-77', '0378-6856-77', '0378-6857-77', '0378-6858-77', '0378-6859-77', '0378-6860-77']",['SJT761GEGS'],,,,,,,,,
New,01/22/2025,64764-918-30,Febuxostat Tablet,855-268-1825,,Anticipate continued distribution to wholesalers until March 2026,01/22/2025,['Other'],Tablet,"Uloric, Tablet, 40 mg (NDC 64764-918-30)",Takeda Pharmaceuticals USA Inc.,,To Be Discontinued,['NDA021856'],['ULORIC'],['FEBUXOSTAT'],"['Takeda Pharmaceuticals America, Inc.']","['64764-918', '64764-677']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FEBUXOSTAT'],"['834235', '834239', '834241', '834243']",['fecf6101-9a35-4781-bea4-e7b92b4afb81'],['54de10ef-fe5f-4930-b91d-6bbb04c664bd'],"['64764-918-30', '64764-918-90', '64764-918-18', '64764-918-11', '64764-677-30', '64764-677-13', '64764-677-19', '64764-677-11']",['101V0R1N2E'],"['N0000175698', 'N0000000206']",['Xanthine Oxidase Inhibitor [EPC]'],,01/22/2025,,,,['Xanthine Oxidase Inhibitors [MoA]'],
Reverified,03/10/2023,72888-152-01,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-152', '72888-153', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,10/31/2025,0603-5166-32,Phenobarbital Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,10/31/2025,"['Analgesia/Addiction', 'Neurology', 'Other']",Tablet,"Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,,['PHENOBARBITAL'],['PHENOBARBITAL'],"['Endo USA, Inc.']","['0603-5166', '0603-5165', '0603-5167', '0603-5168']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['PHENOBARBITAL'],"['198086', '199164', '199167', '199168']",['670a5f53-11d3-4132-b6e5-4ad63852cfa7'],['069b92ce-0061-4724-8c25-08d8596770a2'],"['0603-5165-21', '0603-5165-32', '0603-5166-16', '0603-5166-20', '0603-5166-02', '0603-5166-21', '0603-5166-22', '0603-5166-32', '0603-5167-21', '0603-5167-32', '0603-5168-21', '0603-5168-32']",['YQE403BP4D'],,,,10/31/2025,,,,,
Reverified,07/14/2023,0378-6859-77,Lisdexamfetamine Dimesylate Capsule,800-796-9526,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA202835'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Mylan Pharmaceuticals Inc.'],"['0378-6859', '0378-6854', '0378-6855', '0378-6856', '0378-6857', '0378-6858', '0378-6860']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['63cd6f7c-f976-440e-a35f-e71a9f2fd1bb'],['efbde0f6-b848-4664-b741-c6c630e66108'],"['0378-6854-77', '0378-6855-77', '0378-6856-77', '0378-6857-77', '0378-6858-77', '0378-6859-77', '0378-6860-77']",['SJT761GEGS'],,,,,,,,,
New,06/24/2025,0409-0016-01,Docetaxel Injection,844-646-4398,,Discontinuation of the manufacture of the drug,06/24/2025,['Oncology'],Injection,"Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-0016-01)",Pfizer Inc.,,To Be Discontinued,['NDA022234'],['DOCETAXEL'],['DOCETAXEL ANHYDROUS'],"['Hospira, Inc.']","['0409-0016', '0409-2026']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOCETAXEL ANHYDROUS'],"['1093280', '1860619']",['8156a5f8-7002-479d-a08d-3c68f92c1396'],['00c61d11-d6b7-4618-b6f6-2592dbcc8af7'],"['0409-2026-01', '0409-0016-01']",['699121PHCA'],"['N0000175085', 'N0000175592']",['Microtubule Inhibitor [EPC]'],['Microtubule Inhibition [PE]'],06/24/2025,,,,,
New,11/03/2025,60951-700-70,Acetaminophen; Oxycodone Hydrochloride Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,11/03/2025,['Analgesia/Addiction'],Tablet,"Percocet, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA040330'],['ENDOCET'],['OXYCODONE AND ACETAMINOPHEN'],"['ENDO USA, Inc.']","['60951-700', '60951-602', '60951-712', '60951-701']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ACETAMINOPHEN', 'OXYCODONE HYDROCHLORIDE']","['1049214', '1049216', '1049221', '1049223', '1049225', '1049227', '1049635', '1487288']",['2a088d17-73b2-457f-99f6-efcd32f648a5'],['944d3e60-7eee-11de-a413-0002a5d5c51b'],"['60951-602-70', '60951-602-85', '60951-700-70', '60951-712-70', '60951-701-70']","['C1ENJ2TE6C', '362O9ITL9D']",,,,11/03/2025,,,,,
New,08/08/2025,57665-101-41,Amphotericin B Injection,800-447-0169,,Discontinuation of the manufacture of the drug,08/08/2025,['Anti-Infective'],Injection,"Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)","Leadiant Biosciences, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,08/08/2025,,,,,
New,07/10/2025,72305-137-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 137 ug (NDC 72305-137-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-137', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,02/14/2022,0990-7922-03,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7922', '0990-7923', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Reverified,02/20/2018,0409-1165-01,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070585'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1165', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'RETROBULBAR']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Revised,11/21/2023,0641-6082-25,Promethazine Hydrochloride Injection,800-631-2174,Available,Currently available.  Additional product will be made available as it is released.,10/24/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Pediatric', 'Pulmonary/Allergy']",Injection,"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA083312'],['PHENERGAN'],['PROMETHAZINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6082', '0641-6083']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['PROMETHAZINE HYDROCHLORIDE'],"['992460', '992462', '992858', '992876']",['a64f0625-8d56-4994-8908-13614ca7b09f'],['6f7e47cc-f823-4336-8107-f980e3049617'],"['0641-6082-01', '0641-6082-25', '0641-6083-01', '0641-6083-25']",['R61ZEH7I1I'],,,,,,,,,
Revised,07/14/2023,0480-3569-01,Lisdexamfetamine Dimesylate Capsule,800-545-8800,Limited Availability,Estimated availability: November 2025,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)","Teva Pharmaceuticals USA, Inc.",Other,Current,['ANDA202802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Teva Pharmaceuticals, Inc.']","['0480-3569', '0480-3565', '0480-3566', '0480-3567', '0480-3568', '0480-3570', '0480-3564']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['6cfe6c98-51b1-45a4-831c-33624ab129cb'],['c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc'],"['0480-3565-01', '0480-3566-01', '0480-3567-01', '0480-3568-01', '0480-3569-01', '0480-3570-01', '0480-3564-01']",['SJT761GEGS'],,,,,,,,,
Reverified,10/14/2016,63323-482-57,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-482', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,02/07/2025,65862-116-01,Benazepril Hydrochloride Tablet,866-850-2876,,,02/07/2025,['Cardiovascular'],Tablet,"Benazepril Hydrochloride, Tablet, 10 mg (NDC 65862-116-01)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA078212'],['BENAZEPRIL HYDROCHLORIDE'],['BENAZEPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-116', '65862-117', '65862-118']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BENAZEPRIL HYDROCHLORIDE'],"['898687', '898690', '898719']",['65334c7f-e49f-44d9-a6c1-6c1ce6e88fbe'],['09e383a8-e912-4cf7-8fb3-05545af80dd0'],"['65862-116-90', '65862-116-01', '65862-117-90', '65862-117-01', '65862-118-90', '65862-118-01']",['N1SN99T69T'],,,,02/07/2025,,,,,
New,07/17/2025,0591-2729-01,"Potassium Citrate Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue.,07/17/2025,['Renal'],Tablet,"Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)",Watson Pharma Private Limited,,To Be Discontinued,['ANDA209758'],['POTASSIUM CITRATE'],['POTASSIUM CITRATE'],"['Actavis Pharma, Inc.']","['0591-2729', '0591-2682', '0591-2742']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CITRATE'],"['199376', '199381', '898490']",['b81078a3-490a-4a03-a9a5-9c64acde67bf'],['ac173781-486b-461c-97ae-8b5c69e20792'],"['0591-2682-01', '0591-2729-01', '0591-2742-01']",['EE90ONI6FF'],,,,07/17/2025,,,,,
Reverified,02/22/2012,63323-485-27,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-485', '63323-492', '63323-491', '63323-495', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Revised,12/15/2022,0002-2236-80,Dulaglutide Injection,800-545-5979,,,06/13/2025,['Endocrinology/Metabolism'],Injection,"Trulicity, Injection, 3 mg/.5 mL (NDC 0002-2236-80)",Eli Lilly and Co.,,Resolved,['BLA125469'],['TRULICITY'],['DULAGLUTIDE'],['Eli Lilly and Company'],"['0002-2236', '0002-1433', '0002-1434', '0002-3182']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['DULAGLUTIDE'],"['1551295', '1551300', '1551304', '1551306', '2395777', '2395779', '2395783', '2395785']",['2a046089-7cd3-43d3-9f7f-27e3e4b49f0d'],['463050bd-2b1c-40f5-b3c3-0a04bb433309'],"['0002-1433-01', '0002-1433-80', '0002-1433-61', '0002-1434-01', '0002-1434-80', '0002-1434-61', '0002-2236-01', '0002-2236-80', '0002-2236-61', '0002-3182-01', '0002-3182-80', '0002-3182-61']",['WTT295HSY5'],"['N0000178480', 'M0160181', 'N0000020058']",['GLP-1 Receptor Agonist [EPC]'],,,,['Glucagon-Like Peptide 1 [CS]'],06/13/2025,['Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]'],Available
Revised,04/28/2023,61703-339-50,Carboplatin Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA076517'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']",['61703-339'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0ddf4411-7138-412a-908a-fadf22bdfb79'],['c3ae9880-44bb-4f4e-93d8-8a5e21708a30'],"['61703-339-18', '61703-339-22', '61703-339-50', '61703-339-56']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Reverified,01/19/2023,43547-413-09,Quinapril Hydrochloride Tablet,866-931-9829,Unavailable,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,11/05/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA205823'],['QUINAPRIL'],['QUINAPRIL'],"['Solco Healthcare US, LLC']","['43547-413', '43547-410', '43547-411', '43547-412']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['b8f1731a-cbac-4f64-a8d4-320b80b335e1'],['cd46691d-5593-4a9f-a937-999c6803e312'],"['43547-410-09', '43547-411-09', '43547-412-09', '43547-413-09']",['33067B3N2M'],,,,,,,,,
Revised,09/05/2018,0641-6000-10,Lorazepam Injection,800-631-2174,Unavailable,Unavailable,10/24/2025,['Neurology'],Injection,"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)","Hikma Pharmaceuticals USA, Inc.",Regulatory delay,Current,['NDA018140'],['ATIVAN'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6000', '0641-6003', '0641-6002', '0641-6001']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['206819', '206820', '238100', '238101', '1665188', '1665190', '1665326', '1665327']",['209b0091-c890-4f69-a693-d0594c2606fe'],['5fc0e987-61c9-40c4-b0d5-fcea07c8733e'],"['0641-6003-01', '0641-6003-25', '0641-6002-01', '0641-6002-10', '0641-6001-01', '0641-6001-25', '0641-6000-01', '0641-6000-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,02/14/2025,0378-8212-93,Erythromycin  Topical Gel,800-796-9526,,,02/14/2025,"['Anti-Infective', 'Dermatology']",Topical Gel,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-93)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,,,,,,,,,,,,,,,,,02/14/2025,,,,,
Revised,02/20/2018,55150-169-10,Bupivacaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)",Eugia US LLC,Demand increase for the drug,Current,['ANDA203895'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-169', '55150-167', '55150-168', '55150-170', '55150-171', '55150-172', '55150-249', '55150-250']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012396', '1012404', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082']",['39649703-e633-4a20-ba71-0c04dbf8ff2a'],['ffecf450-1f01-4721-8e10-251385852612'],"['55150-167-10', '55150-168-30', '55150-169-10', '55150-170-30', '55150-171-10', '55150-172-30', '55150-249-50', '55150-250-50']",['7TQO7W3VT8'],,,,,,,,,
Reverified,01/19/2023,62135-669-90,Quinapril/Hydrochlorothiazide Tablet,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,Available,,08/19/2025,['Cardiovascular'],Tablet,"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)",Chartwell Molecular Holdings LLC,,Current,['ANDA076374'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],['QUINAPRIL AND HYDROCHLOROTHIAZIDE'],"['Chartwell RX, LLC']","['62135-669', '62135-667', '62135-668']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['HYDROCHLOROTHIAZIDE', 'QUINAPRIL HYDROCHLORIDE']","['310796', '310797', '310809']",['0c3f4504-d57e-aa79-e063-6294a90ad5b8'],['2eae533f-d0af-47e8-a1f2-94bc8cc89b5a'],"['62135-667-90', '62135-668-90', '62135-669-90']","['0J48LPH2TH', '33067B3N2M']","['N0000175359', 'N0000175419', 'M0471776']",['Thiazide Diuretic [EPC]'],['Increased Diuresis [PE]'],,,['Thiazides [CS]'],,,
Revised,02/22/2012,0409-2066-05,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA040078'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']",['0409-2066'],['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],['1737761'],['7ec189f1-7357-4bc2-b1d3-57cbb695252d'],['9c18eaf1-4a0b-4916-70b2-88a827494711'],"['0409-2066-10', '0409-2066-05']",['V13007Z41A'],,,,,,,,,
Reverified,02/22/2012,0409-3181-01,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089645'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3181', '0409-1209', '0409-3177', '0409-3178', '0409-3182', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
New,08/15/2025,0591-3983-01,Celecoxib Capsule,800-545-8800,,Discontinuation of the manufacture of the drug,08/15/2025,['Analgesia/Addiction'],Capsule,"Celecoxib, Capsule, 100 mg (NDC 0591-3983-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA200562'],['CELECOXIB'],['CELECOXIB'],"['Actavis Pharma, Inc.']","['0591-3983', '0591-3982', '0591-3984', '0591-3985']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CELECOXIB'],"['205322', '205323', '349514', '686379']",['64c601bc-9b67-400f-9e30-e26de56f2f8b'],['05224473-27dc-4f6d-a52a-c40a7af2f2f4'],"['0591-3982-60', '0591-3983-01', '0591-3983-05', '0591-3984-01', '0591-3984-05', '0591-3985-60']",['JCX84Q7J1L'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,08/15/2025,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Reverified,12/18/2020,59572-102-01,Azacitidine Injection,1-888-423-5436,Available,,11/04/2025,['Oncology'],Injection,"Vidaza, Injection, 100 mg (NDC 59572-102-01)",Bristol Myers Squibb Co.,,Current,['NDA050794'],['VIDAZA'],['AZACITIDINE'],['Celgene Corporation'],['59572-102'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],"['485246', '545206']",['8cba79e2-11fa-4eb9-87e7-827ca781fbf3'],['3495a71a-cc04-4776-851f-f185956f32af'],['59572-102-01'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
Reverified,04/02/2020,63323-411-25,Midazolam Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)","Fresenius Kabi USA, LLC",,Current,['ANDA075154'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-411', '63323-412']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['9814447b-a93e-42ad-b57e-5db0a5b7f552'],['a91ce254-14a3-4cbf-8ab8-5da252aa3fdc'],"['63323-411-22', '63323-411-27', '63323-411-15', '63323-411-12', '63323-411-18', '63323-411-25', '63323-411-13', '63323-411-10', '63323-412-18', '63323-412-25', '63323-412-03', '63323-412-02', '63323-412-06', '63323-412-05', '63323-412-13', '63323-412-10']",['W7TTW573JJ'],,,,,,,,,
Reverified,03/24/2023,0009-0011-04,Hydrocortisone Sodium Succinate Injection,844-646-4398,Available,,10/23/2025,"['Pulmonary/Allergy', 'Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Pediatric', 'Renal', 'Rheumatology']",Injection,"Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)","Hospira, Inc., a Pfizer Company",,Current,['NDA009866'],['SOLU-CORTEF'],['HYDROCORTISONE SODIUM SUCCINATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0011', '0009-0825', '0009-0013', '0009-0016', '0009-0005']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['HYDROCORTISONE SODIUM SUCCINATE'],"['105398', '238755', '1738586', '1738589', '1738590', '1738592', '1738594', '1738596']",['8512044a-4a54-4634-bb97-9e20126adc61'],['65eefd58-b166-4d71-ade6-45c8fdf86922'],"['0009-0825-01', '0009-0011-03', '0009-0011-04', '0009-0013-05', '0009-0013-06', '0009-0016-12', '0009-0005-01']",['50LQB69S1Z'],,,,,https://www.fda.gov/media/187228/download,,12/19/2024,,
Reverified,12/08/2020,0990-7172-17,Amino Acid Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,['Gastroenterology'],Injection,"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Otsuka ICU Medical LLC,,Current,['NDA020015'],['AMINOSYN II'],"['ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE']",['ICU Medical Inc.'],"['0990-7172', '0990-7171']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ACETYL L-TYROSINE', 'ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'VALINE']","['800188', '800192', '800237', '800241']",['ea005122-3350-4609-83ad-9d093f25162f'],['5b426208-f090-4650-86c3-89040ba45c2d'],"['0990-7172-17', '0990-7171-17']","['8DUH1N11BX', '30KYC7MIAI', '94ZLA3W45F', 'TTL6G7LIWZ', 'HG18B9YRS7', '2ZD004190S', '04Y7590D77', '9DLQ4CIU6V', '3KX376GY7L', 'DA8G610ZO5', 'TE7660XO1C', '47E5O17Y3R', '452VLY9402', 'AE28F7PNPL', 'OF5P57N2ZX', 'GMW67QNF9C', '4QD397987E']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Revised,12/10/2021,76297-001-01,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-01)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['LABORATORIOS GRIFOLS SA'],['76297-001'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['ff5ef1ef-2a0d-476d-8483-ffd7cd47c635'],['eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf'],"['76297-001-12', '76297-001-11', '76297-001-22', '76297-001-21', '76297-001-32', '76297-001-31', '76297-001-02', '76297-001-01', '76297-001-42', '76297-001-41', '76297-001-52', '76297-001-51', '76297-001-62', '76297-001-61', '76297-001-72', '76297-001-71', '76297-001-82', '76297-001-81', '76297-001-92', '76297-001-91']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/26/2023,68025-095-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Available,,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)","Vertical Pharmaceuticals, LLC",,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-095', '68025-088', '68025-089', '68025-096', '68025-097', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
Reverified,11/04/2024,50633-310-11,Hydroxocobalamin Injection,844-293-0007,Limited Availability,"Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.",10/31/2025,['Other'],Injection,"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)",BTG International Inc.,Requirements related to complying with good manufacturing practices,Current,['NDA022041'],['CYANOKIT'],['HYDROXOCOBALAMIN'],['BTG INTERNATIONAL INC.'],['50633-310'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HYDROXOCOBALAMIN'],"['700496', '700499']",['9955075c-c059-4b63-b387-e98ef13e60dc'],['d56fcc8d-bd64-46ab-b0c0-2124bd745a6b'],['50633-310-11'],['Q40X8H422O'],['N0000175429'],['Antidote [EPC]'],,,https://www.fda.gov/media/185400/download,,,,
Reverified,04/10/2020,70121-1389-7,Dexmedetomidine Hydrochloride Injection,866-525-7270,Available,,09/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)",Amneal Pharmaceuticals,,Current,['ANDA207551'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['Amneal Pharmaceuticals LLC'],"['70121-1389', '70121-1388']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718909']",['795f643f-855c-4ba4-9bad-a96334c1a2fb'],['eb1ba463-ab42-4f49-9ebe-3ad5af108326'],"['70121-1388-1', '70121-1388-8', '70121-1389-1', '70121-1389-7']",['1018WH7F9I'],,,,,,,,,
Reverified,03/23/2018,70069-061-10,Ropivacaine Hydrochloride Injection,732-554-1019,Available,,08/19/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)","Somerset Therapeutics, LLC",,Current,['ANDA207636'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],"['Somerset Therapeutics, LLC']","['70069-061', '70069-062', '70069-063', '70069-064', '70069-065', '70069-066', '70069-067']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734203', '1734207', '1734475', '1734483']",['79b226f0-c08a-4f84-bf2b-ae5c60e01d67'],['ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64'],"['70069-061-01', '70069-061-25', '70069-061-10', '70069-062-01', '70069-062-25', '70069-062-10', '70069-063-01', '70069-063-25', '70069-064-01', '70069-064-10', '70069-064-25', '70069-065-01', '70069-065-25', '70069-066-01', '70069-066-25', '70069-066-10', '70069-067-01', '70069-067-25', '70069-067-10']",['V910P86109'],,,,,,,,,
Reverified,07/26/2023,68025-084-30,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Available,,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)","Vertical Pharmaceuticals, LLC",,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-084', '68025-088', '68025-089', '68025-095', '68025-096', '68025-097', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
New,08/19/2025,0093-7355-56,Finasteride Tablet,800-545-8800,,Discontinuation of the manufacture of the drug product,08/19/2025,['Urology'],Tablet,"Finasteride, Tablet, 5 mg (NDC 0093-7355-56)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA076511'],['FINASTERIDE'],['FINASTERIDE'],"['Teva Pharmaceuticals USA, Inc.']",['0093-7355'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FINASTERIDE'],['310346'],['ea83e229-c434-4097-81dd-e3b48814d5dc'],['77589cc3-c440-4695-800c-82a0e5128a6c'],"['0093-7355-56', '0093-7355-98', '0093-7355-05']",['57GNO57U7G'],"['N0000175836', 'N0000000126']",['5-alpha Reductase Inhibitor [EPC]'],,08/19/2025,,,,['5-alpha Reductase Inhibitors [MoA]'],
New,08/15/2025,0591-3984-01,Celecoxib Capsule,800-545-8800,,Discontinuation of the manufacture of the drug,08/15/2025,['Analgesia/Addiction'],Capsule,"Celecoxib, Capsule, 200 mg (NDC 0591-3984-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA200562'],['CELECOXIB'],['CELECOXIB'],"['Actavis Pharma, Inc.']","['0591-3984', '0591-3982', '0591-3983', '0591-3985']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CELECOXIB'],"['205322', '205323', '349514', '686379']",['64c601bc-9b67-400f-9e30-e26de56f2f8b'],['05224473-27dc-4f6d-a52a-c40a7af2f2f4'],"['0591-3982-60', '0591-3983-01', '0591-3983-05', '0591-3984-01', '0591-3984-05', '0591-3985-60']",['JCX84Q7J1L'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,08/15/2025,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Revised,03/23/2018,55150-199-20,Ropivacaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Injection, 7.5 mg/1 mL (NDC 55150-199-20)",Eugia US LLC,Demand increase for the drug,Current,['ANDA205612'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-199', '55150-195', '55150-196', '55150-197', '55150-198', '55150-200', '55150-201']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '1734084', '1734090', '1734207', '1734347', '1734475', '1734483']",['34725b26-d6e9-4d1b-95a0-da03764cc102'],['3763b7b6-da49-4658-b93d-28f5da24d09e'],"['55150-195-20', '55150-196-99', '55150-197-20', '55150-198-30', '55150-199-20', '55150-200-10', '55150-201-20']",['V910P86109'],,,,,,,,,
Revised,07/14/2023,0480-3570-01,Lisdexamfetamine Dimesylate Capsule,800-545-8800,Limited Availability,Estimated availability: December 2025,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Teva Pharmaceuticals, Inc.']","['0480-3570', '0480-3565', '0480-3566', '0480-3567', '0480-3568', '0480-3569', '0480-3564']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['6cfe6c98-51b1-45a4-831c-33624ab129cb'],['c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc'],"['0480-3565-01', '0480-3566-01', '0480-3567-01', '0480-3568-01', '0480-3569-01', '0480-3570-01', '0480-3564-01']",['SJT761GEGS'],,,,,,,,,
Revised,12/20/2023,0641-6025-10,Fentanyl Citrate Injection,800-631-2174,Unavailable,Inventory available in vial presentations.,10/24/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)","Hikma Pharmaceuticals USA, Inc.",Other,Current,['NDA019101'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6025', '0641-6024', '0641-6027', '0641-6028', '0641-6026', '0641-6029', '0641-6030', '0641-6247', '0641-6248', '0641-6249']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270', '2474269', '2629337']",['aca9742b-d890-426a-8296-14ca64748238'],['ce5db1c2-feb1-4ad2-847a-d02e865bd47e'],"['0641-6024-01', '0641-6024-10', '0641-6027-01', '0641-6027-25', '0641-6025-01', '0641-6025-10', '0641-6028-01', '0641-6028-10', '0641-6028-25', '0641-6026-01', '0641-6026-05', '0641-6029-01', '0641-6029-25', '0641-6030-01', '0641-6247-01', '0641-6247-25', '0641-6248-01', '0641-6248-10', '0641-6249-01', '0641-6249-10']",['MUN5LYG46H'],,,,,,,,,
Reverified,03/10/2023,0093-3212-05,Clonazepam Tablet,800-545-8800,Available,,10/16/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA074569'],['CLONAZEPAM'],['CLONAZEPAM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-3212', '0093-0832', '0093-3213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['d6abe4e3-7699-4ead-95f4-739a961b23ad'],['8069b1a0-7c06-4252-b44e-e2eef065d9b8'],"['0093-0832-01', '0093-0832-05', '0093-3212-01', '0093-3212-05', '0093-3213-01', '0093-3213-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,03/01/2017,0409-5555-02,Sodium Bicarbonate Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: December 2025,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA202981'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Hospira, Inc.']",['0409-5555'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],['1868469'],"['6493c4d8-9ef7-4ec3-b373-6b3ecf5db9b0', '037c4aeb-4a95-4c37-8214-a30110b1d47f']","['0c24b592-4bc8-456f-acac-9c9525844a06', 'ea9f4498-0d43-4043-8dd1-f22537841c21']","['0409-5555-11', '0409-5555-01', '0409-5555-12', '0409-5555-02']",['8MDF5V39QO'],,,,,,,,,
Reverified,10/12/2022,0406-8894-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-325-8888,Unavailable,Next release expected November 2025,11/05/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)",SpecGx LLC,Delay in shipping of the drug,Current,['ANDA040440'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'],['SpecGx LLC'],"['0406-8894', '0406-8891', '0406-8884', '0406-8892', '0406-8885', '0406-8893']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '1009145']",['b25a2f3f-ee3a-44c0-a475-f371025c767b'],['72ddd1c9-ddbd-4c95-acd9-003189a353a3'],"['0406-8891-01', '0406-8884-01', '0406-8892-01', '0406-8885-01', '0406-8893-01', '0406-8894-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/13/2025,13668-386-30,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,908-280-3333,,A business decision was made to discontinue manufacture of the product.,06/13/2025,['Cardiovascular'],Tablet,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-30)",Torrent Pharma Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,06/13/2025,,,,,
Reverified,03/10/2023,72888-153-30,Clonazepam Tablet,sales@advagenpharma.com,Available,Marketed by Advagen Pharma Ltd.,08/19/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)",Rubicon Research Private Limited,,Current,['ANDA075468'],['CLONAZEPAM'],['CLONAZEPAM'],['Advagen Pharma Ltd'],"['72888-153', '72888-152', '72888-154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['36cf156e-5980-a21b-e063-6294a90ab3a0'],['30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec'],"['72888-152-30', '72888-152-01', '72888-152-05', '72888-152-00', '72888-153-30', '72888-153-01', '72888-153-05', '72888-153-00', '72888-154-30', '72888-154-01', '72888-154-05', '72888-154-00']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,03/23/2018,63323-286-63,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-286', '63323-285', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Revised,09/05/2018,0641-6003-25,Lorazepam Injection,800-631-2174,Unavailable,Unavailable,10/24/2025,['Neurology'],Injection,"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)","Hikma Pharmaceuticals USA, Inc.",Regulatory delay,Current,['NDA018140'],['ATIVAN'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6003', '0641-6002', '0641-6001', '0641-6000']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['206819', '206820', '238100', '238101', '1665188', '1665190', '1665326', '1665327']",['209b0091-c890-4f69-a693-d0594c2606fe'],['5fc0e987-61c9-40c4-b0d5-fcea07c8733e'],"['0641-6003-01', '0641-6003-25', '0641-6002-01', '0641-6002-10', '0641-6001-01', '0641-6001-25', '0641-6000-01', '0641-6000-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,04/07/2020,23155-473-41,Furosemide Injection,855-228-9470,Available,,11/03/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)","Avet Pharmaceuticals, Inc.",,Current,['ANDA203428'],['FUROSEMIDE'],['FUROSEMIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],['23155-473'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['936eaafa-5088-4ebc-85bc-685ffb85c81f'],['1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec'],"['23155-473-31', '23155-473-41', '23155-473-32', '23155-473-42', '23155-473-43', '23155-473-33', '23155-473-44', '23155-473-45']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,12/08/2020,0264-4500-00,Amino Acid Injection,800-227-2862,Available,,11/04/2025,['Gastroenterology'],Injection,"Plenamine, Injection, 0.15 (NDC 0264-4500-00)",B. Braun Medical Inc.,,Current,['ANDA091112'],['PLENAMINE'],"['LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE']",['B. Braun Medical Inc.'],['0264-4500'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['800584', '1601982']",['e55957d3-67af-4b6d-9232-55b654e0076f'],['a3244d1a-45b0-4e4c-bd96-f0632d761a1f'],"['0264-4500-00', '0264-4500-05']","['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
New,11/07/2025,0409-5534-14,Sodium Bicarbonate Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,,,,,,,,,,,,,,,,11/07/2025,,,,,
New,06/03/2025,65862-064-99,Metoprolol Tartrate Tablet,866-850-2876,,Permanent discontinuation in the manufacturing of the drug,06/03/2025,['Cardiovascular'],Tablet,"Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-99)",Aurobindo Pharma USA,,To Be Discontinued,['ANDA077739'],['METOPROLOL TARTRATE'],['METOPROLOL TARTRATE'],['Aurobindo Pharma Limited'],"['65862-064', '65862-062', '65862-063']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METOPROLOL TARTRATE'],"['866511', '866514', '866924']",['d265c99d-8e77-4a78-b542-15e957d9d335'],['2b705cb6-cb75-4c2a-907a-4bd45d18bc2c'],"['65862-062-01', '65862-062-99', '65862-063-60', '65862-063-01', '65862-063-99', '65862-064-60', '65862-064-01', '65862-064-99']",['W5S57Y3A5L'],,,,06/03/2025,,,,,
New,06/13/2025,59310-805-06,Fluticasone Propionate; Salmeterol Xinafoate Powder,800-545-8800,,,06/13/2025,['Pulmonary/Allergy'],Powder,"AirDuo RespiClick, Powder, 55 ug; 14 ug (NDC 59310-805-06)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA208799'],['AIRDUO RESPICLICK'],['FLUTICASONE PROPIONATE AND SALMETEROL'],"['Teva Respiratory, LLC']","['59310-805', '59310-812', '59310-822']",['HUMAN PRESCRIPTION DRUG'],['RESPIRATORY (INHALATION)'],"['FLUTICASONE PROPIONATE', 'SALMETEROL XINAFOATE']","['1918194', '1918199', '1918203', '1918205', '1918209', '1918211']",['b597bc2d-bf1e-4f9b-826a-b3e39ed56545'],['9c122b91-a11f-49ca-80bb-3eec5112db87'],"['59310-805-06', '59310-805-08', '59310-812-06', '59310-812-08', '59310-822-06', '59310-822-08']","['6EW8Q962A5', 'O2GMZ0LF5W']",,,,06/13/2025,,,,,
Reverified,03/10/2023,0093-3213-05,Clonazepam Tablet,800-545-8800,Available,,10/16/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA074569'],['CLONAZEPAM'],['CLONAZEPAM'],"['Teva Pharmaceuticals USA, Inc.']","['0093-3213', '0093-0832', '0093-3212']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['d6abe4e3-7699-4ead-95f4-739a961b23ad'],['8069b1a0-7c06-4252-b44e-e2eef065d9b8'],"['0093-0832-01', '0093-0832-05', '0093-3212-01', '0093-3212-05', '0093-3213-01', '0093-3213-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,06/21/2018,65282-1510-1,Sodium Chloride 0.9% Injection,978-657-0889,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1510-1)","Spectra Medical Devices, LLC",,Resolved,['ANDA206171'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Spectra Medical Deviecs, LLC']","['65282-1510', '65282-1505']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807637', '1807646']",['0e649488-3951-382e-e063-6294a90a55c1'],['7e316d21-d6ad-4976-bd90-268fd7e51361'],"['65282-1510-1', '65282-1505-1']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,02/28/2025,0574-2415-65,"Methylphenidate Film, Extended Release",800-455-8070,Available,Available. Distributed by Padagis US LLC,10/02/2025,['Psychiatry'],"Film, Extended Release","Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)","Noven Pharmaceuticals, Inc.",,Current,['NDA021514'],['METHYLPHENIDATE TRANSDERMAL SYSTEM'],['METHYLPHENIDATE'],['PADAGIS US LLC'],"['0574-2415', '0574-2410', '0574-2420', '0574-2430']",['HUMAN PRESCRIPTION DRUG'],['TRANSDERMAL'],['METHYLPHENIDATE'],"['753436', '753438', '753440', '753441']",['b743ef45-2fc0-4086-8a02-6078e6a09eaa'],['7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb'],"['0574-2410-65', '0574-2415-65', '0574-2420-65', '0574-2430-65']",['207ZZ9QZ49'],"['N0000175739', 'N0000175729']",['Central Nervous System Stimulant [EPC]'],['Central Nervous System Stimulation [PE]'],,,,,,
New,04/07/2025,50458-253-03,Haloperidol Decanoate Injection,800-526-7736,,Last batch expiration date 5/31/2025,04/07/2025,['Psychiatry'],Injection,"Haldol, Injection, 50 mg/1 mL (NDC 50458-253-03)",Janssen Pharmaceuticals,,To Be Discontinued,['NDA018701'],['HALDOL DECANOATE'],['HALOPERIDOL DECANOATE'],"['Janssen Pharmaceuticals, Inc.']","['50458-253', '50458-254']",['HUMAN PRESCRIPTION DRUG'],['INTRAMUSCULAR'],['HALOPERIDOL DECANOATE'],"['1719803', '1719847', '1719862', '1720026']",['2cf0430f-e455-8d17-e063-6394a90a5cd3'],['af0159a8-dff5-449a-aa2b-a0c430081e21'],"['50458-253-01', '50458-253-03', '50458-254-14']",['AC20PJ4101'],,,,04/07/2025,,,,,
Reverified,02/08/2019,63323-165-30,Dexamethasone Sodium Phosphate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)","Fresenius Kabi USA, LLC",,Current,['ANDA084916'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Fresenius Kabi USA, LLC']",['63323-165'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['1116927', '1812194']","['a832bff9-0bb3-4350-abb5-d57b9417070c', '9dd90418-e564-4bc5-9077-506a1c2c1bce']","['2b626a48-c7aa-4443-9164-a08ff069ccd1', '4fedef4f-ec96-4f36-b2f0-01e243e3b89e']","['63323-165-11', '63323-165-51', '63323-165-13', '63323-165-53', '63323-165-02', '63323-165-01', '63323-165-03', '63323-165-05', '63323-165-30', '63323-165-16', '63323-165-26']",['AI9376Y64P'],,,,,,,,,
New,01/13/2025,0069-1195-30,Talazoparib Tosylate Capsule,800-533-4535,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0757-30",01/13/2025,['Oncology'],Capsule,"Talzenna, Capsule, 1 mg (NDC 0069-1195-30)",Pfizer Inc.,,To Be Discontinued,['NDA211651'],['TALZENNA'],['TALAZOPARIB'],['Pfizer Laboratories Div Pfizer Inc'],"['0069-1195', '0069-0296', '0069-1501', '0069-1751', '0069-1031', '0069-1235']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TALAZOPARIB TOSYLATE'],"['2099946', '2099952', '2099954', '2099956', '2591510', '2591512', '2591520', '2591521', '2639960', '2639962', '2639964', '2639966']",['2cb65f61-9a14-46d9-85a3-a7eea76160c5'],['f2423edd-6d24-495c-aec1-c2f457f08d9a'],"['0069-0296-30', '0069-1195-30', '0069-1501-30', '0069-1751-30', '0069-1031-30', '0069-1235-30']",['02WK9U5NZC'],,,,01/13/2025,,,,,
Reverified,04/26/2023,81284-521-01,Penicillin G Benzathine Injection,Provepharm: rahul.poria@provepharm.com,Available,,09/17/2025,['Anti-Infective'],Injection,"Extencilline, Injection, 1,200,000 units (NDC 81284-521-01)",Laboratoires Delbert,,Current,,['EXTENCILLINE'],['BENZATHINE BENZYLPENICILLIN'],['Provepharm Inc.'],"['81284-521', '81284-522', '81284-523', '81284-524']",['HUMAN PRESCRIPTION DRUG'],,,"['2671687', '2671693', '2671695', '2671697']",['5eb42da3-7f4f-4071-9a35-14565343b49c'],['5a026d0c-6f91-4ee3-b193-b2186a37e7ca'],"['81284-521-01', '81284-523-00', '81284-735-00', '81284-522-01', '81284-524-00']",['RIT82F58GK'],,,,,https://www.fda.gov/media/180283/download?attachment,,,,
Revised,03/23/2018,63323-631-50,Leucovorin Calcium Injection,888-386-1300,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-50)","Fresenius Kabi USA, LLC",,Resolved,"['ANDA207241', 'ANDA207226']",['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Fresenius Kabi USA, LLC']",['63323-631'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['2099993', '2104714']","['d1c72e5d-c25e-4b9c-b3dc-a8d0b746db3f', 'a0d41f71-6197-4c9a-8cd2-217945cb722b']","['d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee', '4b72d1fd-f389-45d9-b43b-510b45c92263']","['63323-631-10', '63323-631-50']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,02/14/2022,0338-0017-10,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
New,03/28/2025,0591-2998-01,Ursodiol Tablet,800-545-8800,,A business decision was made to discontinue manufacture of the drug.,03/28/2025,['Other'],Tablet,"Ursodiol, Tablet, 250 mg (NDC 0591-2998-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA020675'],['URSODIOL'],['URSODIOL'],"['Actavis Pharma, Inc.']","['0591-2998', '0591-3005']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['URSODIOL'],"['858733', '858751']",['3ca902a9-d8c3-4c4b-a49f-efc62cf2028a'],['0a7c1ae6-4878-43e7-9026-073f74af64c0'],"['0591-2998-01', '0591-3005-01']",['724L30Y2QR'],"['N0000175802', 'M0002475']",['Bile Acid [EPC]'],,03/28/2025,,['Bile Acids and Salts [CS]'],,,
Reverified,10/12/2022,11534-194-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",732-382-6085 Monday to Friday 9 am to 3:45 pm,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)","Sunrise Pharmaceutical, Inc.",,Current,['ANDA209799'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['SUNRISE PHARMACEUTICAL, INC.']","['11534-194', '11534-190', '11534-191', '11534-192', '11534-193', '11534-195', '11534-196']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['86a00bec-51eb-4d73-a945-b1937970b29a'],['ac102599-3a5b-4154-899e-6ff262be7ff7'],"['11534-190-01', '11534-190-03', '11534-191-01', '11534-191-03', '11534-192-01', '11534-192-03', '11534-193-01', '11534-193-03', '11534-194-01', '11534-194-03', '11534-195-01', '11534-195-03', '11534-196-01', '11534-196-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,11/07/2025,0409-4903-34,Lidocaine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only)  100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)""","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA083158'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4903', '0409-4904', '0409-1323', '0409-9137']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1012066', '1012068']",['477abea3-c873-4265-82e8-5508ef54399f'],['ad1ef0a8-88db-4648-c098-d009eaeb4e5b'],"['0409-4903-11', '0409-4903-34', '0409-4904-11', '0409-4904-34', '0409-1323-15', '0409-1323-05', '0409-9137-11', '0409-9137-05']",['V13007Z41A'],,,,11/07/2025,,,,,
Reverified,10/14/2016,63323-482-17,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-482', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Revised,12/10/2021,0338-0553-18,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-18)",Baxter Healthcare,,Resolved,['NDA020178'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],['0338-0553'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632']",['aca96e4a-a57b-47ac-bd60-e65c29e19743'],['fbc01464-8885-4075-af41-911ffec5ae92'],"['0338-0553-11', '0338-0553-18']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,02/29/2024,51224-206-30,Naltrexone Hydrochloride Tablet,888-852-6657,Available,Marketed by Tagi Pharma; Customer service: 800-397-9228,11/04/2025,['Analgesia/Addiction'],Tablet,"Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-30)","Elite Laboratories, Inc.",,Current,['ANDA075274'],['NALTREXONE HYDROCHLORIDE'],['NALTREXONE HYDROCHLORIDE'],['TAGI Pharma Inc.'],['51224-206'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['NALTREXONE HYDROCHLORIDE'],['1483744'],['c82a0ed4-3236-4166-90a8-f5e43e6dd883'],['60276f5c-657a-4b60-bcd0-44234903d7e0'],"['51224-206-30', '51224-206-50']",['Z6375YW9SF'],,,,,,,,,
Revised,08/23/2024,66259-306-23,Indocyanine Green Injection,800-624-4422,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-23)",Novadaq Technologies,,Resolved,,,,,,,,,,,,,,,,,,,,08/26/2025,,Available
Reverified,02/08/2019,63323-506-01,Dexamethasone Sodium Phosphate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)","Fresenius Kabi USA, LLC",,Current,['ANDA040491'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Fresenius Kabi USA, LLC']","['63323-506', '63323-516']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['309696', '1812079']","['5dcedfda-976c-4aa4-a3cf-909c324a09d4', '5284d2ce-44c2-4731-bf19-0cfc760265c8']","['cca2c160-9188-48e8-9505-49a52388dcb7', '7cbd9005-7df2-47ee-adb3-7244c1c69bc3']","['63323-506-00', '63323-506-01', '63323-506-03', '63323-506-13', '63323-516-01', '63323-516-10', '63323-506-41', '63323-506-16']",['AI9376Y64P'],,,,,,,,,
Revised,01/06/2023,0169-7705-21,Somatropin Injection,609-987-5800,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Norditropin, Injection, 10 mg/1.5 mL (NDC 0169-7705-21)","Novo Nordisk, Inc.",,Resolved,['BLA021148'],['NORDITROPIN'],['SOMATROPIN'],['Novo Nordisk'],"['0169-7705', '0169-7704', '0169-7708', '0169-7703']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['SOMATROPIN'],"['847243', '847245', '847247', '847348', '849850', '849851', '1736262', '1736329']",['b67c2419-4feb-4ce1-b97e-88760a8e1aee'],['1058e17c-9261-459c-a3e6-fae38d196c14'],"['0169-7704-21', '0169-7704-92', '0169-7705-21', '0169-7705-92', '0169-7708-21', '0169-7708-92', '0169-7703-11', '0169-7703-91', '0169-7703-21', '0169-7703-92']",['NQX9KB6PCL'],"['N0000175606', 'M0028842']",['Recombinant Human Growth Hormone [EPC]'],,,,['Human Growth Hormone [CS]'],08/28/2025,,Available
Reverified,07/26/2023,50458-585-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,Available,,11/04/2025,['Psychiatry'],Tablet,"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)",Janssen Pharmaceuticals,,Current,['NDA021121'],['CONCERTA'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Janssen Pharmaceuticals, Inc.']","['50458-585', '50458-588', '50458-586', '50458-587']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],,['4035a366-ebde-a1aa-e063-6294a90af4c4'],['1a88218c-5b18-4220-8f56-526de1a276cd'],"['50458-585-01', '50458-588-01', '50458-586-01', '50458-587-01']",['4B3SC438HI'],,,,,,,,,
New,12/05/2024,68001-491-04,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 400 mg (NDC 68001-491-04)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],['BluePoint Laboratories'],"['68001-491', '68001-490']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['05c9d227-d639-916a-e063-6294a90a66a6'],['be5b9047-155b-59ca-e053-2995a90ad3dc'],"['68001-490-05', '68001-491-04']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,02/14/2022,0990-7923-36,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7923', '0990-7922', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
Revised,12/10/2021,0264-7802-10,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-10)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-7802', '0264-7800']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807633', '1807634', '1807639']",['9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa'],['7f22c06b-6b4d-4b49-a4b2-d2169f2bd653'],"['0264-7800-00', '0264-7800-10', '0264-7800-20', '0264-7802-00', '0264-7802-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,10/12/2022,11534-193-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",732-382-6085 Monday to Friday 9 am to 3:45 pm,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)","Sunrise Pharmaceutical, Inc.",,Current,['ANDA209799'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['SUNRISE PHARMACEUTICAL, INC.']","['11534-193', '11534-190', '11534-191', '11534-192', '11534-194', '11534-195', '11534-196']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['86a00bec-51eb-4d73-a945-b1937970b29a'],['ac102599-3a5b-4154-899e-6ff262be7ff7'],"['11534-190-01', '11534-190-03', '11534-191-01', '11534-191-03', '11534-192-01', '11534-192-03', '11534-193-01', '11534-193-03', '11534-194-01', '11534-194-03', '11534-195-01', '11534-195-03', '11534-196-01', '11534-196-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,11/07/2025,0409-2053-10,Ketamine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,['Anesthesia'],Injection,"Ketamine Hydrochloride, Injection, 500 mg/10mL (50mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-2053-10)",Pfizer Inc.,,To Be Discontinued,['ANDA074549'],['KETAMINE HYDROCHLORIDE'],['KETAMINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2053', '0409-2051']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETAMINE HYDROCHLORIDE'],"['238083', '238084']",['37921fa5-8ef5-4af7-bf99-3a9ab24fa752'],['bb912318-2e22-4469-b0a2-774803ee1bb8'],"['0409-2051-15', '0409-2051-05', '0409-2053-20', '0409-2053-10']",['O18YUO0I83'],,,,11/07/2025,,,,,
Reverified,04/10/2020,55150-297-10,Dexmedetomidine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)",Eugia US LLC,,Current,['ANDA210321'],['DEXMEDETOMIDINE HYDROCHLORIDE'],['DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE'],['Eugia US LLC'],"['55150-297', '55150-209', '55150-296']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['309710', '1718906', '1718909']",['72d6b6e6-236e-44f8-a747-de2ee97bca87'],['8c162541-986b-4b30-866c-b2631ba2c975'],"['55150-209-02', '55150-296-10', '55150-297-10']",['1018WH7F9I'],,,,,,,,,
Revised,01/06/2023,0013-2654-02,Somatropin Injection,800-533-4535,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Genotropin, Injection, 1.2 mg preservative free (NDC 0013-2654-02)",Pfizer Inc.,,Resolved,['BLA020280'],['GENOTROPIN'],['SOMATROPIN'],['Pfizer Laboratories Div Pfizer Inc'],"['0013-2654', '0013-2626', '0013-2646', '0013-2649', '0013-2650', '0013-2651', '0013-2652', '0013-2653', '0013-2655', '0013-2656', '0013-2657', '0013-2658']",['HUMAN PRESCRIPTION DRUG'],,,"['241975', '762830', '762833', '762834', '762836', '762837', '762839', '762841', '762843', '762846', '762849', '762850', '762852', '762857', '762859', '762866', '762868', '762873', '762875', '762895', '762897', '763488', '763489', '996558', '996559']",['f09acf87-6e30-47ad-9891-8a49bf6dffbc'],['ffebf88b-d257-4542-9808-74d9b7167765'],"['0013-2626-81', '0013-2646-81', '0013-2649-02', '0013-2650-02', '0013-2651-02', '0013-2652-02', '0013-2653-02', '0013-2654-02', '0013-2655-02', '0013-2656-02', '0013-2657-02', '0013-2658-02']",,,,,,,,08/28/2025,,Available
Revised,01/13/2022,47335-993-01,Metronidazole Injection,Distributed by Sun Pharma,Unavailable,Unavailable,09/29/2025,['Anti-Infective'],Injection,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)",Gland Pharma Limited,Shortage of an active ingredient,Current,['ANDA212435'],['METRONIDAZOLE'],['METRONIDAZOLE'],"['Sun Pharmaceutical Industries, Inc.']",['47335-993'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['METRONIDAZOLE'],['311683'],['9549fa19-5d89-4ad8-82ac-5d023072b126'],['7187779a-1f4c-4607-af53-4119e324aad5'],['47335-993-01'],['140QMO216E'],"['N0000175435', 'M0014907']",['Nitroimidazole Antimicrobial [EPC]'],,,,['Nitroimidazoles [CS]'],,,
Revised,10/11/2024,0338-0125-04,Lactated Ringers Injection,888-229-0001,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-04)",Baxter Healthcare,,Resolved,['NDA016679'],['LACTATED RINGERS AND DEXTROSE'],"['SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE AND DEXTROSE MONOHYDRATE']",['Baxter Healthcare Corporation'],['0338-0125'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'DEXTROSE MONOHYDRATE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847627'],['8fc5f645-fb02-4ecf-9c07-5d515b96d7ca'],['6acc9f96-7088-45a7-b48f-1a861e3467ab'],"['0338-0125-03', '0338-0125-04']","['M4I0D6VV5M', 'LX22YL083G', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Reverified,02/14/2022,0338-0017-02,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Reverified,04/28/2023,0338-0004-04,Sterile Water Irrigant,888-229-0001,Available,,10/22/2025,"['Gastroenterology', 'Other', 'Pediatric']",Irrigant,"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)",Baxter Healthcare,,Current,['NDA017428'],['STERILE WATER'],['WATER'],['Baxter Healthcare Corporation'],"['0338-0004', '0338-0003']",['HUMAN PRESCRIPTION DRUG'],['IRRIGATION'],['WATER'],['150985'],['43dc7530-ed0a-4976-af2a-0d39a2532fb7'],['ef3e79c5-3f58-4b36-a296-64b7d9a651c1'],"['0338-0003-44', '0338-0003-46', '0338-0003-47', '0338-0004-02', '0338-0004-03', '0338-0004-04', '0338-0004-05']",['059QF0KO0R'],,,,,,,,,
New,04/28/2025,0832-0465-15,Nystatin Topical Powder,800-654-2299,,,04/28/2025,"['Anti-Infective', 'Dermatology']",Topical Powder,"Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA065183'],['NYAMYC'],['NYSTATIN'],"['Upsher-Smith Laboratories, LLC']",['0832-0465'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['NYSTATIN'],"['584414', '646456']",['3984f88f-d61f-1fa9-e063-6394a90acb11'],['01b44f91-9b68-464a-9693-b5d3e793bf3c'],"['0832-0465-15', '0832-0465-30', '0832-0465-60']",['BDF1O1C72E'],"['N0000175498', 'M0017172']",['Polyene Antifungal [EPC]'],,04/28/2025,,['Polyenes [CS]'],,,
Revised,01/01/2012,70436-118-80,Leucovorin Calcium Injection,888-447-0095,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 200 mg (NDC 70436-118-80)",Slate Run Pharmaceuticals,,Resolved,['ANDA217021'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],"['Slate Run Pharmaceuticals, LLC']","['70436-118', '70436-116', '70436-117', '70436-120', '70436-119']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['2a4aaed3-885e-bc10-e063-6294a90a61af'],['d8bdd60c-9a1c-4ef4-ba6b-b911849128f1'],"['70436-116-80', '70436-116-82', '70436-117-80', '70436-118-80', '70436-120-80', '70436-119-80']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,04/10/2020,0409-4596-20,Dexmedetomidine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)",Pfizer Inc.,,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4596', '0409-0155']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['1718906', '1718907', '1718909', '1718910']",['1fdb4815-2990-4926-ba76-25241810489e'],['92b7ddaa-e45a-4b64-a802-bb5df8771dd6'],"['0409-4596-01', '0409-4596-20', '0409-0155-01', '0409-0155-02']",['1018WH7F9I'],,,,,,,,,
New,12/09/2024,62756-224-83,Tiagabine Hydrochloride Tablet,800-818-4555,,Discontinuing for business reasons,12/09/2024,['Neurology'],Tablet,"Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-83)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA077555'],['TIAGABINE HYDROCHLORIDE'],['TIAGABINE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['62756-224', '62756-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TIAGABINE HYDROCHLORIDE'],"['1299911', '1299917']",['57975e74-e45b-4fd9-9718-bfc9690acae5'],['7eeb2d81-c5d7-46a0-aa5c-149b55df71bd'],"['62756-200-83', '62756-200-18', '62756-224-83', '62756-224-88', '62756-224-08', '62756-224-18']",['DQH6T6D8OY'],,,,12/09/2024,,,,,
Reverified,04/02/2020,63323-412-25,Midazolam Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)","Fresenius Kabi USA, LLC",,Current,"['ANDA075154', 'ANDA208878']",['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-412', '63323-411']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']","['9814447b-a93e-42ad-b57e-5db0a5b7f552', 'c2aaa2df-aa73-4ea7-96be-528010260e25']","['a91ce254-14a3-4cbf-8ab8-5da252aa3fdc', '09daf48f-1d44-4b7b-bb53-bd5635b93ca6']","['63323-411-22', '63323-411-27', '63323-411-15', '63323-411-12', '63323-411-18', '63323-411-25', '63323-411-13', '63323-411-10', '63323-412-18', '63323-412-25', '63323-412-03', '63323-412-02', '63323-412-06', '63323-412-05', '63323-412-13', '63323-412-10', '63323-412-00']",['W7TTW573JJ'],,,,,,,,,
Revised,01/01/2012,71288-160-10,Leucovorin Calcium Injection,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 71288-160-10)",Kindos Pharmaceuticals Co. Ltd.,,Resolved,['ANDA216590'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Meitheal Pharmaceuticals Inc.'],"['71288-160', '71288-161', '71288-162', '71288-163', '71288-164']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937', '2055036']",['077a459b-e884-4452-aed3-0857a38ce26f'],['9df20901-6980-4d4e-89ec-40f3c1f91852'],"['71288-160-10', '71288-161-20', '71288-162-30', '71288-163-30', '71288-164-50']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
Reverified,11/06/2017,0338-1007-03,Dopamine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)",Baxter Healthcare,,Current,['NDA019615'],['DOPAMINE HYDROCHLORIDE AND DEXTROSE'],['DOPAMINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-1007', '0338-1005', '0338-1009']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1292887', '1743869', '1743871', '1743877', '1743879']",['1b91b75f-c6e4-4425-bea8-023458ecf8f9'],['cb97d4a0-89ed-407c-a763-209386b6f75c'],"['0338-1005-02', '0338-1005-03', '0338-1007-02', '0338-1007-03', '0338-1009-02']",['7L3E358N9L'],,,,,,,,,
New,05/14/2025,0245-0036-23,Cholestyramine Powder,800-654-2299,,A business decision was made to discontinue the product.,05/14/2025,['Cardiovascular'],Powder,"Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-23)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA073263'],['PREVALITE'],['CHOLESTYRAMINE'],"['Upsher-Smith Laboratories, LLC']",['0245-0036'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CHOLESTYRAMINE'],"['848951', '1801279']",['39e73fd2-1ad0-aae8-e063-6294a90acd5a'],['dd434ef8-8af3-434c-a0a0-9a0b18459ba0'],"['0245-0036-89', '0245-0036-42', '0245-0036-60', '0245-0036-23']",['4B33BGI082'],"['N0000180292', 'N0000175365']",['Bile Acid Sequestrant [EPC]'],,05/14/2025,,,,['Bile-acid Binding Activity [MoA]'],
Reverified,12/22/2021,42806-801-30,Rifampin Capsule,(718) 276-8600 ext. 3,Available,,10/15/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 150 mg (NDC 42806-801-30)","Epic Pharma, LLC",,Current,['ANDA064150'],['RIFAMPIN'],['RIFAMPIN'],"['EPIC PHARMA, LLC']","['42806-801', '42806-799']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['a4ac02e8-68ac-4e79-8ca5-0939dd002c87'],['0391f1e1-70d4-4b15-8b58-055bb6a385b8'],"['42806-801-30', '42806-801-01', '42806-799-30', '42806-799-60', '42806-799-01', '42806-799-05']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,07/14/2018,73293-0001-2,Lidocaine Hydrochloride Injection,intbiz@huons.com,Available,,09/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)","Huons Co., Ltd. (South Korea)",,Current,['ANDA212821'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Huons Co., Ltd.']","['73293-0001', '73293-0003']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1737566', '1737761']",['14a172be-a2db-c9da-e063-6294a90ad411'],['8ec2d256-fc4f-44f6-bee2-eef2bf3bf580'],"['73293-0001-1', '73293-0001-2', '73293-0003-1', '73293-0003-2']",['V13007Z41A'],,,,,,,,,
Reverified,10/05/2022,0143-9310-10,Etomidate Injection,800-631-2174,Available,Novaplus,10/24/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA202354'],['ETOMIDATE'],['ETOMIDATE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9310', '0143-9311']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['c15bd8c1-34e3-40f2-b31a-634136fe197c'],['4312e3c3-34de-4cb3-8abd-c24d24a4bea1'],"['0143-9310-01', '0143-9310-10', '0143-9311-01', '0143-9311-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Reverified,02/20/2018,63323-462-37,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)","Fresenius Kabi USA, LLC",,Current,['NDA018304'],['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Fresenius Kabi USA, LLC']","['63323-462', '63323-464', '63323-466', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1672917', '1672919', '1673296', '1673298', '1724880', '1724881', '1724884', '1724885', '1725078', '1725082', '1725175', '1725177', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,01/19/2023,65862-620-90,Quinapril Hydrochloride Tablet,866-850-2876,Unavailable,Discontinuation of the manufacture of the drug,10/15/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)",Aurobindo Pharma USA,Discontinuation of the manufacture of the drug,Current,['ANDA202725'],['QUINAPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-620', '65862-617', '65862-618', '65862-619']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['5263abd5-ce46-4918-9bb0-9632861bcbc9'],['93e6e668-5306-4f26-81d8-cbc3a7a5e787'],"['65862-617-30', '65862-617-90', '65862-617-99', '65862-617-55', '65862-617-10', '65862-617-78', '65862-618-30', '65862-618-90', '65862-618-99', '65862-618-55', '65862-618-10', '65862-618-78', '65862-619-30', '65862-619-90', '65862-619-99', '65862-619-19', '65862-619-10', '65862-619-78', '65862-620-30', '65862-620-90', '65862-620-99', '65862-620-39', '65862-620-10', '65862-620-78']",['33067B3N2M'],,,,,,,,,
Reverified,10/12/2022,70010-113-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",877-770-3183,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)",Granules Pharmaceuticals Inc.,,Current,['ANDA215771'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Granules Pharmaceuticals Inc.'],"['70010-113', '70010-111', '70010-112', '70010-114', '70010-115', '70010-116', '70010-117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['2fab399e-2a43-5134-e063-6294a90ae09a'],['b0b4eccc-34c7-483d-966f-82d588358e1b'],"['70010-111-01', '70010-111-03', '70010-112-01', '70010-112-03', '70010-113-01', '70010-113-03', '70010-114-01', '70010-114-03', '70010-115-01', '70010-115-03', '70010-116-01', '70010-116-03', '70010-117-01', '70010-117-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/07/2020,63323-280-02,Furosemide Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)","Fresenius Kabi USA, LLC",,Current,['NDA018902'],['FUROSEMIDE'],['FUROSEMIDE'],"['Fresenius Kabi USA, LLC']",['63323-280'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['9804efac-5457-417a-8de7-a688467759c0', '64b3fb5f-3516-4e39-b74e-e0e402ed9c4d']","['3747bbcd-783d-4baa-bb5b-b6827bf390e3', 'c794c95a-654e-48fe-9596-201fc122ff75']","['63323-280-41', '63323-280-16', '63323-280-43', '63323-280-26', '63323-280-45', '63323-280-36', '63323-280-01', '63323-280-02', '63323-280-03', '63323-280-04', '63323-280-05', '63323-280-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,01/27/2025,60505-6095-0,Bendamustine Hydrochloride Injection,800-706-5575,,Discontinuation of the manufacture of the drug,01/27/2025,['Oncology'],Injection,"Bendamustine Hydrochloride, Injection, 25 mg (NDC 60505-6095-0)",Apotex Corp.,,To Be Discontinued,,,,,,,,,,,,,,,,,01/27/2025,,,,,
New,07/23/2025,0832-5323-11,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-5323', '0832-5322']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953']",['39e726b1-eab8-fcf4-e063-6394a90a950a'],['616f0de7-8843-44a1-8fa6-274d889286aa'],"['0832-5322-11', '0832-5322-10', '0832-5323-11', '0832-5323-10']",['660YQ98I10'],,,,07/23/2025,,,,,
New,07/10/2025,72305-200-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 200 ug (NDC 72305-200-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-200', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,02/14/2022,0338-0017-03,Dextrose Monohydrate 5% Injection,888-229-0001,Available,,10/22/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)",Baxter Healthcare,,Current,['NDA016673'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],['Baxter Healthcare Corporation'],"['0338-0017', '0338-0023']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618']",['31bb4a5f-733e-4354-9fbf-138dede4db0f'],['3bb406a9-f5cb-403a-b1bb-5c4facbea3d5'],"['0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04']",['LX22YL083G'],,,,,,,,,
Revised,01/31/2018,0641-6007-10,Bumetanide Injection,800-631-2174,Available,,10/24/2025,['Cardiovascular'],Injection,"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA079196'],['BUMETANIDE'],['BUMETANIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6007', '0641-6008']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['BUMETANIDE'],"['282486', '1727569']",['99d2fc38-7e1e-4209-aa57-089794eda8a6'],['681b5e9d-e2c7-4f29-aaad-e06d4a528c11'],"['0641-6007-01', '0641-6007-10', '0641-6008-01', '0641-6008-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,04/28/2025,0832-0465-30,Nystatin Topical Powder,800-654-2299,,,04/28/2025,"['Anti-Infective', 'Dermatology']",Topical Powder,"Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-30)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA065183'],['NYAMYC'],['NYSTATIN'],"['Upsher-Smith Laboratories, LLC']",['0832-0465'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['NYSTATIN'],"['584414', '646456']",['3984f88f-d61f-1fa9-e063-6394a90acb11'],['01b44f91-9b68-464a-9693-b5d3e793bf3c'],"['0832-0465-15', '0832-0465-30', '0832-0465-60']",['BDF1O1C72E'],"['N0000175498', 'M0017172']",['Polyene Antifungal [EPC]'],,04/28/2025,,['Polyenes [CS]'],,,
Reverified,10/25/2017,0338-0409-03,Lidocaine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)",Baxter Healthcare,,Current,['NDA018461'],['LIDOCAINE HYDROCHLORIDE AND DEXTROSE'],['LIDOCAINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0409', '0338-0411']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1737723', '1737742', '1737744']",['6bb9f86c-595a-47f7-b6e9-792966edb852'],['f21512ea-c7c3-4766-b976-b2c0b5616bf0'],"['0338-0409-03', '0338-0409-02', '0338-0411-02']",['V13007Z41A'],,,,,,,,,
Revised,10/05/2022,0143-9506-10,Etomidate Injection,800-631-2174,Available,Currently available.  Additional product will be made available as it is released.,10/24/2025,['Anesthesia'],Injection,"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA202354'],['ETOMIDATE'],['ETOMIDATE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9506', '0143-9507']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['98560882-bfdf-404e-ab8b-3ee2a6875830'],['75bf0494-7cb9-4e8a-8edd-af62f035d236'],"['0143-9506-01', '0143-9506-10', '0143-9507-01', '0143-9507-10']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
Revised,02/20/2018,0409-1587-50,Bupivacaine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Anesthesia'],Injection,"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1587-50)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA016964'],['MARCAINE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1587', '0409-1559', '0409-1560', '0409-1582', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,01/19/2023,65862-618-90,Quinapril Hydrochloride Tablet,866-850-2876,Unavailable,Discontinuation of the manufacture of the drug,10/15/2025,['Cardiovascular'],Tablet,"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Aurobindo Pharma USA,Discontinuation of the manufacture of the drug,Current,['ANDA202725'],['QUINAPRIL'],['QUINAPRIL HYDROCHLORIDE'],['Aurobindo Pharma Limited'],"['65862-618', '65862-617', '65862-619', '65862-620']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['QUINAPRIL HYDROCHLORIDE'],"['312748', '312749', '312750', '314203']",['5263abd5-ce46-4918-9bb0-9632861bcbc9'],['93e6e668-5306-4f26-81d8-cbc3a7a5e787'],"['65862-617-30', '65862-617-90', '65862-617-99', '65862-617-55', '65862-617-10', '65862-617-78', '65862-618-30', '65862-618-90', '65862-618-99', '65862-618-55', '65862-618-10', '65862-618-78', '65862-619-30', '65862-619-90', '65862-619-99', '65862-619-19', '65862-619-10', '65862-619-78', '65862-620-30', '65862-620-90', '65862-620-99', '65862-620-39', '65862-620-10', '65862-620-78']",['33067B3N2M'],,,,,,,,,
Revised,02/22/2012,0409-4776-01,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA080408'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4776', '0409-4713', '0409-4278', '0409-4279', '0409-4282', '0409-4277', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
New,06/24/2025,0078-0364-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,888-669-6682,,Permanent discontinuation in the manufacturing of the drug,06/24/2025,['Cardiovascular'],Capsule,"Lotrel, Capsule, 10 mg; 20 mg (NDC 0078-0364-05)",Novartis Pharmaceuticals Corporation,,To Be Discontinued,['NDA020364'],['LOTREL'],['AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE'],['Novartis Pharmaceuticals Corporation'],"['0078-0364', '0078-0405', '0078-0406', '0078-0379']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898344', '898346', '898348', '898353', '898355', '898356', '898358']",['b9db75d9-9d1e-4b2d-9876-5f5520feaecc'],['94ae6054-b7ae-4212-a567-4f803af8f2c7'],"['0078-0405-05', '0078-0406-05', '0078-0364-05', '0078-0379-05']","['N1SN99T69T', '864V2Q084H']",,,,06/24/2025,,,,,
Reverified,02/20/2018,63323-466-37,Bupivacaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Anesthesia'],Injection,"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)","Fresenius Kabi USA, LLC",,Current,"['ANDA070553', 'NDA018304']",['SENSORCAINE MPF'],['BUPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-466', '63323-464', '63323-462', '63323-465', '63323-467', '63323-460']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL', 'INFILTRATION']",['BUPIVACAINE HYDROCHLORIDE'],"['1724880', '1724881', '1725078', '1725175', '1724884', '1724885', '1725082', '1725177', '1672917', '1672919', '1673296', '1673298', '1012391', '1012396', '1012404', '1012421', '1012455', '1012457']","['b41b5dbd-7aff-4d97-ac97-f4355393ee4e', 'd3ba9fb9-63c8-4597-bb0a-cd01d31a24b6', '13a48007-3784-46f2-bd4d-da1004186b81', '2b1a1f80-cb29-4ac1-9e72-20225ed45715']","['e700eb7b-8b14-49c9-96b2-331f18776e45', 'b6bfc04a-1868-4630-9ca1-8c027af97ce3', 'dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175', 'eb6d8fee-def4-4c96-9972-695e8cea8ea8']","['63323-464-01', '63323-464-17', '63323-466-03', '63323-466-17', '63323-464-08', '63323-464-38', '63323-466-08', '63323-466-38', '63323-462-03', '63323-462-38', '63323-464-09', '63323-464-39', '63323-466-09', '63323-466-39', '63323-465-01', '63323-465-57', '63323-467-01', '63323-467-57', '63323-460-01', '63323-460-37', '63323-464-02', '63323-464-37', '63323-464-03', '63323-464-31', '63323-466-01', '63323-466-37', '63323-466-02', '63323-466-31', '63323-462-04', '63323-462-17', '63323-462-01', '63323-462-37', '63323-462-02', '63323-462-31']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,04/26/2023,81284-522-01,Penicillin G Benzathine Injection,Provepharm: rahul.poria@provepharm.com,Available,,09/17/2025,['Anti-Infective'],Injection,"Extencilline, Injection, 2,400,000 units (NDC 81284-522-01)",Laboratoires Delbert,,Current,,['EXTENCILLINE'],['BENZATHINE BENZYLPENICILLIN'],['Provepharm Inc.'],"['81284-522', '81284-521', '81284-523', '81284-524']",['HUMAN PRESCRIPTION DRUG'],,,"['2671687', '2671693', '2671695', '2671697']",['5eb42da3-7f4f-4071-9a35-14565343b49c'],['5a026d0c-6f91-4ee3-b193-b2186a37e7ca'],"['81284-521-01', '81284-523-00', '81284-735-00', '81284-522-01', '81284-524-00']",['RIT82F58GK'],,,,,https://www.fda.gov/media/180283/download?attachment,,,,
Reverified,02/22/2012,83090-002-10,Lidocaine Hydrochloride Injection,"844-425-3131, SinteticaCS@eversana.com",Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X5ML)  is Preservative free.",08/19/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)",Sintetica US,,Current,['ANDA214267'],['NA'],['LIDOCAINE HYDROCHLORIDE'],['Sintetica US LLC'],"['83090-002', '83090-001', '83090-003', '83090-004', '83090-005', '83090-006']",['HUMAN PRESCRIPTION DRUG'],['INFILTRATION'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737566', '1737568', '1737570', '1737757', '1737761', '1737763']",['0d18f291-3a92-421e-8841-6be743b1f154'],['aa3e688a-308c-4a82-a268-28ccf1677c55'],"['83090-001-01', '83090-001-10', '83090-002-01', '83090-002-10', '83090-003-01', '83090-003-10', '83090-004-01', '83090-004-10', '83090-005-01', '83090-005-10', '83090-006-01', '83090-006-10']",['EC2CNF7XFP'],,,,,,,,,
New,01/06/2025,45963-565-08,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-08)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA202968'],['EZETIMIBE AND SIMVASTATIN'],['EZETIMIBE AND SIMVASTATIN'],"['Actavis Pharma, Inc.']","['45963-565', '45963-566', '45963-567', '45963-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['EZETIMIBE', 'SIMVASTATIN']","['476345', '476349', '476350', '476351']",['bd64aee1-c95f-4767-8d31-af93dd0ab692'],['00680bea-d2fb-4362-ba67-e866b732e9ed'],"['45963-565-30', '45963-565-08', '45963-566-30', '45963-566-08', '45963-567-30', '45963-567-08', '45963-568-30', '45963-568-08']","['AGG2FN16EV', 'EOR26LQQ24']","['N0000175589', 'N0000000121', 'N0000008553', 'N0000175911']","['HMG-CoA Reductase Inhibitor [EPC]', 'Dietary Cholesterol Absorption Inhibitor [EPC]']",['Decreased Cholesterol Absorption [PE]'],01/06/2025,,,,['Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]'],
Revised,02/20/2018,0409-9042-17,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA071165'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-9042', '0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,01/08/2025,43598-741-30,Ramelteon Tablet,866-732-3952,,,01/08/2025,['Other'],Tablet,"Tablet, 8 mg (NDC 43598-741-30)","Dr. Reddy's Laboratories, Inc.",,To Be Discontinued,['ANDA091693'],['RAMELTEON'],['RAMELTEON'],['Dr.Reddys Laboratories Inc'],['43598-741'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RAMELTEON'],['577348'],['54220029-c5df-b277-af7e-2786da03bbed'],['b71cd925-1bae-5a6a-072b-941ad6d3ce65'],"['43598-741-30', '43598-741-01', '43598-741-10']",['901AS54I69'],"['N0000175743', 'N0000000250']",['Melatonin Receptor Agonist [EPC]'],,01/08/2025,,,,['Melatonin Receptor Agonists [MoA]'],
Reverified,02/22/2012,63323-493-97,Lidocaine Hydrochloride Injection,888-386-1300,Unavailable,Next release not available at this time.,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-493', '63323-492', '63323-496']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737636', '1737637', '1737640', '1737641', '1737763', '1737764']",['fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df'],['d5e0d06f-ba1e-44d4-aa89-39d6c146dc23'],"['63323-492-08', '63323-492-97', '63323-493-03', '63323-493-97', '63323-493-01', '63323-493-91', '63323-496-03', '63323-496-97']",['EC2CNF7XFP'],,,,,,,,,
Reverified,10/14/2016,63323-488-17,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],"['LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE']","['Fresenius Kabi USA, LLC']","['63323-488', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,02/12/2025,42543-493-05,Amantadine Hydrochloride Capsule,877-244-9825,,Discontinuation of manufacture of drug based on business decision,02/12/2025,"['Antiviral', 'Neurology']",Capsule,"Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-05)",Strides Pharma Inc.,,To Be Discontinued,['ANDA209047'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],['Strides Pharma Inc.'],['42543-493'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849389'],['a3230bf0-95b8-4beb-b1f5-a35614de5afa'],['e4d8f36f-d668-4728-8dca-b1c22bd9aedb'],"['42543-493-01', '42543-493-05']",['M6Q1EO9TD0'],,,,02/12/2025,,,,,
New,07/23/2025,0832-5323-10,"Potassium Chloride Tablet, Extended Release",763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology']",Tablet,"Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-10)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA019123'],['POTASSIUM CHLORIDE'],['POTASSIUM CHLORIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-5323', '0832-5322']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CHLORIDE'],"['312529', '628953']",['39e726b1-eab8-fcf4-e063-6394a90a950a'],['616f0de7-8843-44a1-8fa6-274d889286aa'],"['0832-5322-11', '0832-5322-10', '0832-5323-11', '0832-5323-10']",['660YQ98I10'],,,,07/23/2025,,,,,
Reverified,07/14/2023,42858-164-01,Lisdexamfetamine Dimesylate Capsule,888-827-0616,Available,,08/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)",Rhodes Pharmaceuticals L.P.,,Current,['ANDA215330'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Rhodes Pharmaceuticals'],"['42858-164', '42858-161', '42858-162', '42858-163', '42858-165', '42858-166', '42858-167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['047c243d-9336-4ef2-b5a8-a7cae312b1be'],['d918b40d-a461-41bc-b6c0-83dc76c28e32'],"['42858-161-01', '42858-162-01', '42858-163-01', '42858-164-01', '42858-165-01', '42858-166-01', '42858-167-01']",['SJT761GEGS'],,,,,,,,,
Revised,01/01/2012,63323-806-05,Fentanyl Citrate Injection,888-386-1300,Unavailable,Next release not available at this time. Check wholesalers for inventory.,11/05/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)","Fresenius Kabi USA, LLC",Other,Current,['ANDA210762'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Fresenius Kabi USA, LLC']",['63323-806'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735007', '1735008', '1735013', '2168270']",['341b092a-1f6f-40f1-98f2-9346bf2e1242'],['38d0c14a-a0c1-44cc-a939-0304eb8037d6'],"['63323-806-11', '63323-806-01', '63323-806-12', '63323-806-02', '63323-806-13', '63323-806-05', '63323-806-14', '63323-806-20', '63323-806-50']",['MUN5LYG46H'],,,,,,,,,
Reverified,04/10/2020,55150-209-02,Dexmedetomidine Hydrochloride Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)",Eugia US LLC,,Current,['ANDA205867'],['DEXMEDETOMIDINE'],['DEXMEDETOMIDINE'],['Eugia US LLC'],"['55150-209', '55150-296', '55150-297']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['309710', '1718906', '1718909']",['72d6b6e6-236e-44f8-a747-de2ee97bca87'],['8c162541-986b-4b30-866c-b2631ba2c975'],"['55150-209-02', '55150-296-10', '55150-297-10']",['1018WH7F9I'],,,,,,,,,
New,01/22/2025,71093-131-03,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-03)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-131', '71093-129', '71093-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Revised,05/30/2025,0409-1179-30,Meperidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Analgesia/Addiction'],Injection,"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA021171'],['DEMEROL'],['MEPERIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1179', '0409-1181', '0409-1176', '0409-1178', '0409-1180', '0409-1362', '0409-1418']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['860792', '861463', '861473', '861493', '861494', '861522', '861529', '861617', '1242106', '1242503', '2539186', '2539188', '2539191', '2539192']",['1271f15f-ccda-4892-8fb0-9bb2d38ded4a'],['b31d1308-28c3-43f4-e0a6-2f3ed76b8975'],"['0409-1181-30', '0409-1176-03', '0409-1176-30', '0409-1178-03', '0409-1178-30', '0409-1179-03', '0409-1179-30', '0409-1180-59', '0409-1180-69', '0409-1362-11', '0409-1362-01', '0409-1418-11', '0409-1418-01']",['N8E7F7Q170'],,,,,,,,,
New,03/17/2025,0049-0174-03,"Glipizide Tablet, Extended Release",800-533-4535,,Supply expected to exhaust early April 2025,03/17/2025,['Endocrinology/Metabolism'],Tablet,"Glucotrol XL, Tablet, Extended Release, 5 mg (NDC 0049-0174-03)",Pfizer Inc.,,To Be Discontinued,['NDA020329'],['GLUCOTROL XL'],['GLIPIZIDE'],['Roerig'],"['0049-0174', '0049-0170', '0049-0178']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLIPIZIDE'],"['310489', '314006', '315107', '865568', '865571', '865573']",['ce46d6b5-eab4-4630-8480-f13885be938e'],['eed99b60-d043-4249-9b2a-f05e46fb588d'],"['0049-0170-01', '0049-0174-02', '0049-0174-03', '0049-0178-07', '0049-0178-08']",['X7WDT95N5C'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,03/17/2025,,['Sulfonylurea Compounds [CS]'],,,
Reverified,12/08/2020,0338-0502-03,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Baxter Healthcare,,Current,['ANDA020512'],['CLINISOL'],"['LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE']",['Baxter Healthcare Corporation'],['0338-0502'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['800584', '800588']",['7eab93b5-5590-4381-8674-113a05edeff0'],['65ffc962-7538-41ea-9afb-4af5fbce4c5b'],"['0338-0502-03', '0338-0502-06']","['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Reverified,12/22/2020,43066-023-10,Ropivacaine Hydrochloride Injection,888-229-0001,Limited Availability,Limited supply; Check wholesalers for inventory; Marketed by Baxter,11/04/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)","Caplin Steriles, Ltd.",Other,Current,['ANDA212808'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['43066-023', '43066-015', '43066-019', '43066-027']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734084', '1734207', '1734475', '1734483']",['ef624077-2197-426c-9521-8f966f49240b'],['781d4b7f-7556-4695-8d48-7772d7a0d8e9'],"['43066-015-01', '43066-015-10', '43066-019-01', '43066-019-10', '43066-023-01', '43066-023-10', '43066-027-01', '43066-027-10']",['V910P86109'],,,,,,,,,
Revised,03/13/2023,0703-3671-01,Methotrexate Sodium Injection,800-545-8800,Limited Availability,Estimated availability: December 2025,11/06/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)","Teva Pharmaceuticals USA, Inc.",Other,Current,['ANDA040843'],['METHOTREXATE'],['METHOTREXATE'],"['Teva Parenteral Medicines, Inc.']","['0703-3671', '0703-3675', '0703-3678']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE SODIUM'],"['1655956', '1655959', '1655960']",['e81074cc-12b4-4ac9-a5bb-749188989b2c'],['346ec9ce-dc98-4a55-b55e-d3af11f2d703'],"['0703-3671-01', '0703-3675-01', '0703-3678-01']",['3IG1E710ZN'],,,,,,,,,
New,12/05/2024,47335-472-13,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-13)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-472', '47335-475']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
New,12/05/2024,63304-693-16,Clindamycin Hydrochloride Capsule,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Anti-Infective'],Capsule,"Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-16)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA065061'],['CLINDAMYCIN HYDROCHLORIDE'],['CLINDAMYCIN HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['63304-693', '63304-692']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLINDAMYCIN HYDROCHLORIDE'],"['197518', '284215']",['339366d4-2060-1c29-e063-6394a90a1cb7'],['1dbd8448-c1e5-46df-8060-50ef82380445'],"['63304-692-01', '63304-692-05', '63304-692-77', '63304-692-03', '63304-693-16', '63304-693-01', '63304-693-03', '63304-693-05', '63304-693-77', '63304-693-11', '63304-693-62']",['T20OQ1YN1W'],,,,12/05/2024,,,,,
Reverified,12/22/2020,43066-019-10,Ropivacaine Hydrochloride Injection,888-229-0001,Available,Check wholesalers for inventory; Marketed by Baxter,11/04/2025,['Anesthesia'],Injection,"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)","Caplin Steriles, Ltd.",,Current,['ANDA212808'],['ROPIVACAINE HYDROCHLORIDE'],['ROPIVACAINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['43066-019', '43066-015', '43066-023', '43066-027']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734084', '1734207', '1734475', '1734483']",['ef624077-2197-426c-9521-8f966f49240b'],['781d4b7f-7556-4695-8d48-7772d7a0d8e9'],"['43066-015-01', '43066-015-10', '43066-019-01', '43066-019-10', '43066-023-01', '43066-023-10', '43066-027-01', '43066-027-10']",['V910P86109'],,,,,,,,,
Reverified,07/14/2023,42858-162-01,Lisdexamfetamine Dimesylate Capsule,888-827-0616,Available,,08/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)",Rhodes Pharmaceuticals L.P.,,Current,['ANDA215330'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Rhodes Pharmaceuticals'],"['42858-162', '42858-161', '42858-163', '42858-164', '42858-165', '42858-166', '42858-167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['047c243d-9336-4ef2-b5a8-a7cae312b1be'],['d918b40d-a461-41bc-b6c0-83dc76c28e32'],"['42858-161-01', '42858-162-01', '42858-163-01', '42858-164-01', '42858-165-01', '42858-166-01', '42858-167-01']",['SJT761GEGS'],,,,,,,,,
Revised,01/01/2012,63323-808-11,Fentanyl Citrate Injection,888-386-1300,Unavailable,Backordered. Next release February 2026. Check wholesalers for inventory.,11/05/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)","Fresenius Kabi USA, LLC",Other,Current,['ANDA212086'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Fresenius Kabi USA, LLC']","['63323-808', '63323-810']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['2474267', '2474269']",['076a6b49-1197-4c83-a9cd-a353d9c65ebc'],['0c10e465-4117-48ba-a454-23ccb7a3fcc7'],"['63323-808-01', '63323-808-11', '63323-810-00', '63323-810-20']",['MUN5LYG46H'],,,,,,,,,
Revised,04/28/2023,61703-339-18,Carboplatin Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['ANDA076517'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']",['61703-339'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0ddf4411-7138-412a-908a-fadf22bdfb79'],['c3ae9880-44bb-4f4e-93d8-8a5e21708a30'],"['61703-339-18', '61703-339-22', '61703-339-50', '61703-339-56']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,01/08/2025,50268-708-15,Ramelteon Tablet,866-732-3952,,,01/08/2025,['Other'],Tablet,"Tablet, 8 mg (NDC 50268-708-15)","Dr. Reddy's Laboratories, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/08/2025,,,,,
Revised,07/14/2023,0527-4662-37,Lisdexamfetamine Dimesylate Capsule,844-834-0530,Limited Availability,Limited Availability,11/03/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA215802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Lannett Company, Inc.']","['0527-4662', '0527-4661', '0527-4663', '0527-4664', '0527-4665', '0527-4666', '0527-4667']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7ac942a6-689a-420b-87bf-dc59003400dc'],['2cedb4c2-1e40-4bc4-b9f4-127150c4afbd'],"['0527-4661-37', '0527-4662-37', '0527-4663-37', '0527-4664-37', '0527-4665-37', '0527-4666-37', '0527-4667-37']",['SJT761GEGS'],,,,,,,,,
Reverified,04/07/2020,0409-6102-10,Furosemide Injection,844-646-4398,Available,,10/23/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA018667'],['FUROSEMIDE'],['FUROSEMIDE'],"['Hospira, Inc.']",['0409-6102'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['c529b0df-a5cb-46ce-8131-38674ee756af', '0d4a39f2-904e-434a-9af1-83bb4febf124']","['aaced7a8-c3d7-4d66-8c07-aa407b8b3f35', '39fd32f2-6bb7-4a65-d298-e48d26bc80c7']","['0409-6102-35', '0409-6102-25', '0409-6102-36', '0409-6102-26', '0409-6102-37', '0409-6102-27', '0409-6102-19', '0409-6102-02', '0409-6102-18', '0409-6102-04', '0409-6102-20', '0409-6102-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Revised,11/03/2023,16571-600-96,Cromolyn Sodium Concentrate,(201) 961-9000 or contact@risingpharma.com,Available,,08/15/2025,['Pulmonary/Allergy'],Concentrate,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)","Rising Pharma Holdings, Inc.",,Current,['ANDA202583'],['CROMOLYN SODIUM'],['CROMOLYN SODIUM'],"['Rising Pharma Holdings, Inc.']",['16571-600'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CROMOLYN SODIUM'],['831261'],['ca2c72ae-db00-4694-9fd0-d4b6b45f8108'],['61c9cb85-129e-4490-b5f7-357307fcecbf'],['16571-600-96'],['Q2WXR1I0PK'],,,,,,,,,
Reverified,03/23/2018,63323-286-20,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)","Fresenius Kabi USA, LLC",Delay in shipping of the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-286', '63323-285', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
Reverified,10/12/2022,70010-111-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",877-770-3183,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)",Granules Pharmaceuticals Inc.,,Current,['ANDA215771'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Granules Pharmaceuticals Inc.'],"['70010-111', '70010-112', '70010-113', '70010-114', '70010-115', '70010-116', '70010-117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['2fab399e-2a43-5134-e063-6294a90ae09a'],['b0b4eccc-34c7-483d-966f-82d588358e1b'],"['70010-111-01', '70010-111-03', '70010-112-01', '70010-112-03', '70010-113-01', '70010-113-03', '70010-114-01', '70010-114-03', '70010-115-01', '70010-115-03', '70010-116-01', '70010-116-03', '70010-117-01', '70010-117-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,04/07/2020,63323-280-10,Furosemide Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)","Fresenius Kabi USA, LLC",,Current,['NDA018902'],['FUROSEMIDE'],['FUROSEMIDE'],"['Fresenius Kabi USA, LLC']",['63323-280'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['9804efac-5457-417a-8de7-a688467759c0', '64b3fb5f-3516-4e39-b74e-e0e402ed9c4d']","['3747bbcd-783d-4baa-bb5b-b6827bf390e3', 'c794c95a-654e-48fe-9596-201fc122ff75']","['63323-280-41', '63323-280-16', '63323-280-43', '63323-280-26', '63323-280-45', '63323-280-36', '63323-280-01', '63323-280-02', '63323-280-03', '63323-280-04', '63323-280-05', '63323-280-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/21/2023,0338-3410-50,Clindamycin Phosphate Injection,888-229-0001,Available,,10/22/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)",Baxter Healthcare,,Current,['ANDA208084'],['CLINDAMYCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Baxter Healthcare Company'],"['0338-3410', '0338-3612', '0338-3814']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN PHOSPHATE'],"['309335', '309336', '309339']",['9373fc85-1d70-4907-842a-ae9e2a3958b3'],['78832ac6-04c5-45e0-ae4d-f56d7920dda9'],"['0338-3410-50', '0338-3410-24', '0338-3612-50', '0338-3612-24', '0338-3814-50', '0338-3814-24']",['EH6D7113I8'],,,,,,,,,
Reverified,12/22/2021,42806-801-01,Rifampin Capsule,(718) 276-8600 ext. 3,Unavailable,Discontinuation of the manufacture of the drug.,10/15/2025,['Anti-Infective'],Capsule,"Rifampin, Capsule, 150 mg (NDC 42806-801-01)","Epic Pharma, LLC",Discontinuation of the manufacture of the drug,Current,['ANDA064150'],['RIFAMPIN'],['RIFAMPIN'],"['EPIC PHARMA, LLC']","['42806-801', '42806-799']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RIFAMPIN'],"['198201', '198202']",['a4ac02e8-68ac-4e79-8ca5-0939dd002c87'],['0391f1e1-70d4-4b15-8b58-055bb6a385b8'],"['42806-801-30', '42806-801-01', '42806-799-30', '42806-799-60', '42806-799-01', '42806-799-05']",['VJT6J7R4TR'],"['N0000175500', 'M0019113']",['Rifamycin Antibacterial [EPC]'],,,,['Rifamycins [CS]'],,,
Reverified,07/14/2023,43547-604-10,Lisdexamfetamine Dimesylate Capsule,866-931-9829,Limited Availability,On allocation,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA216266'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE CAPSULES'],"['Solco Healthcare US,LLC']","['43547-604', '43547-602', '43547-603', '43547-605', '43547-606', '43547-607', '43547-608']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7bb11568-67a4-4221-bb9b-23af37a1791c'],['68b10d9f-ca3e-493d-a309-45f1d7e08061'],"['43547-602-10', '43547-603-10', '43547-604-10', '43547-605-10', '43547-606-10', '43547-607-10', '43547-608-10']",['SJT761GEGS'],,,,,,,,,
New,02/06/2025,0591-0845-10,"Glipizide Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue manufacture of the drug.,02/06/2025,['Endocrinology/Metabolism'],Tablet,"Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-10)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,02/06/2025,,,,,
New,11/21/2024,0173-0911-13,Daprodustat Tablet,888-825-5249,,Discontinuing for Business Reasons.,11/21/2024,['Hematology'],Tablet,"Jesduvroq, Tablet, 6 mg (NDC 0173-0911-13)",GlaxoSmithKline,,To Be Discontinued,['NDA216951'],['JESDUVROQ'],['DAPRODUSTAT'],['GlaxoSmithKline LLC'],"['0173-0911', '0173-0897', '0173-0903', '0173-0906', '0173-0914']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DAPRODUSTAT'],"['2628215', '2628221', '2628223', '2628225', '2628227', '2628229', '2628231', '2628233', '2628235', '2628237']",['d52a823a-35bd-4c6a-a016-4b4f21a43d7d'],['d82aa06e-5a33-4844-99b7-4701313455a4'],"['0173-0897-13', '0173-0897-56', '0173-0903-13', '0173-0903-56', '0173-0906-13', '0173-0906-56', '0173-0911-13', '0173-0911-56', '0173-0914-13', '0173-0914-56']",['JVR38ZM64B'],"['N0000194080', 'N0000194079']",['Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]'],,11/21/2024,,,,['Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]'],
New,01/06/2025,0597-0545-66,Adalimumab-adbm Injection,800-243-0127,,,01/06/2025,['Rheumatology'],Injection,"Cyltezo, Injection, Kit (NDC 0597-0545-66)","Boehringer Ingelheim Pharmaceuticals, Inc.",,To Be Discontinued,['BLA761058'],['ADALIMUMAB-ADBM'],['ADALIMUMAB-ADBM'],"['Boehringer Ingelheim Pharmaceuticals, Inc.']","['0597-0545', '0597-0595', '0597-0555', '0597-0585', '0597-0575', '0597-0565']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2640883', '2640891', '2640893', '2640895', '2640900', '2640902', '2680743', '2680748', '2680756', '2680759']",['d6ed9087-bc5c-4c0e-843b-90b0400b0ed1'],['62f39a7c-00df-4519-a8d4-39bbd0a649ed'],"['0597-0595-20', '0597-0590-26', '0597-0555-80', '0597-0550-06', '0597-0585-89', '0597-0580-37', '0597-0545-22', '0597-0545-44', '0597-0545-66', '0597-0540-10', '0597-0575-50', '0597-0575-40', '0597-0575-60', '0597-0570-32', '0597-0565-20', '0597-0560-12']",,,,,01/06/2025,,,,,
Reverified,07/14/2023,0054-0375-25,Lisdexamfetamine Dimesylate Capsule,800-631-2174,Limited Availability,Available on allocation,10/24/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202827'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-0375', '0054-0660', '0054-0370', '0054-0371', '0054-0372', '0054-0373', '0054-0374']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['5d119550-4386-4bfa-a5d0-bb18e66191b7'],['6740a621-9bec-4178-a4fc-a3fc89f34e0a'],"['0054-0660-25', '0054-0370-25', '0054-0371-25', '0054-0372-25', '0054-0373-25', '0054-0374-25', '0054-0375-25']",['SJT761GEGS'],,,,,,,,,
Revised,04/07/2020,0409-6102-26,Furosemide Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)","Hospira, Inc., a Pfizer Company",Demand increase for the drug,Current,['NDA018667'],['FUROSEMIDE'],['FUROSEMIDE'],"['Hospira, Inc.']",['0409-6102'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['c529b0df-a5cb-46ce-8131-38674ee756af', '0d4a39f2-904e-434a-9af1-83bb4febf124']","['aaced7a8-c3d7-4d66-8c07-aa407b8b3f35', '39fd32f2-6bb7-4a65-d298-e48d26bc80c7']","['0409-6102-35', '0409-6102-25', '0409-6102-36', '0409-6102-26', '0409-6102-37', '0409-6102-27', '0409-6102-19', '0409-6102-02', '0409-6102-18', '0409-6102-04', '0409-6102-20', '0409-6102-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,03/10/2023,59651-723-99,Clonazepam Tablet,866-850-2876,Available,,10/15/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)",Aurobindo Pharma USA,,Current,['ANDA075150'],['CLONAZEPAM'],['CLONAZEPAM'],['Aurobindo Pharma Limited'],"['59651-723', '59651-722', '59651-724']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529']",['b1582eb7-af35-45d5-a52e-0e380d08527d'],['b1582eb7-af35-45d5-a52e-0e380d08527d'],"['59651-722-01', '59651-722-99', '59651-723-01', '59651-723-99', '59651-724-01', '59651-724-05']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,01/26/2024,70726-0303-2,Riluzole Oral Suspension,610-937-6172,Unavailable,Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to viscosity testing,11/03/2025,['Neurology'],Oral Suspension,"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2)","EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",Requirements related to complying with good manufacturing practices,Current,['NDA209080'],['TIGLUTIK'],['RILUZOLE'],"['EDW PHARMA, INC']",['70726-0303'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['RILUZOLE'],"['2058147', '2059266']",['2012817c-c76a-40d4-a2c8-cdb211737f3d'],['75d68f19-4208-109e-e053-2991aa0ac857'],"['70726-0303-2', '70726-0303-1']",['7LJ087RS6F'],"['N0000175740', 'M0483511']",['Benzothiazole [EPC]'],,,,['Benzothiazoles [CS]'],,,
Revised,05/30/2025,0409-1362-01,Meperidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Analgesia/Addiction'],Injection,"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA021171'],['DEMEROL'],['MEPERIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1362', '0409-1181', '0409-1176', '0409-1178', '0409-1179', '0409-1180', '0409-1418']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['860792', '861463', '861473', '861493', '861494', '861522', '861529', '861617', '1242106', '1242503', '2539186', '2539188', '2539191', '2539192']",['1271f15f-ccda-4892-8fb0-9bb2d38ded4a'],['b31d1308-28c3-43f4-e0a6-2f3ed76b8975'],"['0409-1181-30', '0409-1176-03', '0409-1176-30', '0409-1178-03', '0409-1178-30', '0409-1179-03', '0409-1179-30', '0409-1180-59', '0409-1180-69', '0409-1362-11', '0409-1362-01', '0409-1418-11', '0409-1418-01']",['N8E7F7Q170'],,,,,,,,,
Revised,10/31/2017,63323-852-25,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Next release November 2025. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-852', '63323-851', '63323-853', '63323-854']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '1724276', '1724338', '1724340', '1724341']",['9e8522c6-595c-46f9-bb25-272aa4683e0f'],['e034eb96-03e0-46e1-8b92-5e1f94555e7b'],"['63323-851-03', '63323-851-10', '63323-851-07', '63323-851-15', '63323-851-50', '63323-852-03', '63323-852-25', '63323-853-03', '63323-853-25', '63323-854-03', '63323-854-10']",['L960UP2KRW'],,,,,,,,,
Reverified,02/14/2022,0264-7510-00,Dextrose Monohydrate 5% Injection,800-227-2862,Available,,11/04/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)",B. Braun Medical Inc.,,Current,['NDA019626'],['DEXTROSE'],['DEXTROSE'],['B. Braun Medical Inc.'],"['0264-7510', '0264-7520']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['DEXTROSE, UNSPECIFIED FORM']","['1795477', '1795480', '1795481', '1795607', '1795610', '1795612']",['c9f87749-8dd5-41fd-b393-f63d45fd00ef'],['085614c7-ada4-4e2c-87c0-c9bc2f18365a'],"['0264-7510-00', '0264-7510-10', '0264-7510-20', '0264-7520-00', '0264-7520-10', '0264-7520-20']",['IY9XDZ35W2'],,,,,,,,,
New,06/13/2025,63459-920-59,Tbo-filgrastim Injection,800-545-8800,,,06/13/2025,['Hematology'],Injection,"Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)","Cephalon, LLC",,To Be Discontinued,['BLA125294'],['GRANIX'],['TBO-FILGRASTIM'],"['Cephalon, LLC']","['63459-920', '63459-910', '63459-912', '63459-918']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['FILGRASTIM'],"['1433768', '1433771', '1442681', '1442683', '2101456', '2101459', '2101464', '2101465']",['063f36a7-6f99-40fa-af02-8a5183c51e99'],['df918ec2-0907-443f-a52a-b72866959644'],"['63459-910-01', '63459-910-12', '63459-910-11', '63459-910-15', '63459-910-18', '63459-910-17', '63459-910-36', '63459-912-01', '63459-912-12', '63459-912-11', '63459-912-15', '63459-912-18', '63459-912-17', '63459-912-36', '63459-918-53', '63459-918-59', '63459-920-53', '63459-920-59']",['PVI5M0M1GW'],"['M0024696', 'N0000009451', 'N0000175666']",['Leukocyte Growth Factor [EPC]'],['Increased Myeloid Cell Production [PE]'],06/13/2025,,['Granulocyte Colony-Stimulating Factor [CS]'],,,
Revised,04/02/2020,0641-6061-25,Midazolam Hydrochloride Injection,800-631-2174,Available,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,10/24/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA075243'],['MIDAZOLAM'],['MIDAZOLAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6061', '0641-6057', '0641-6059', '0641-6056', '0641-6063', '0641-6060']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['311700', '311702']",['559c03fb-24ea-4b7b-8afd-e33cb3a2340a'],['575d8bf0-7af7-427c-a231-966e2a5e070d'],"['0641-6057-01', '0641-6057-10', '0641-6057-25', '0641-6059-01', '0641-6059-10', '0641-6056-01', '0641-6056-10', '0641-6061-01', '0641-6061-10', '0641-6061-25', '0641-6063-01', '0641-6063-10', '0641-6063-25', '0641-6060-01', '0641-6060-10']",['W7TTW573JJ'],,,,,,,,,
New,10/24/2025,0002-8235-05,Insulin Lispro-aabc Injection,800-545-5979,,A business decision was made to discontinue manufacture of the drug.,10/24/2025,['Endocrinology/Metabolism'],Injection,"Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05)",Eli Lilly and Co.,,To Be Discontinued,['BLA761109'],['LYUMJEV TEMPO PEN'],['INSULIN LISPRO-AABC'],['Eli Lilly and Company'],"['0002-8235', '0002-7728', '0002-7726', '0002-8207', '0002-8351', '0002-8228']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['INSULIN LISPRO'],"['2380231', '2380236', '2380248', '2380250', '2380254', '2380256', '2380259', '2380260', '2380265', '2380266', '2380267', '2380268']",['280961ff-5a2a-4713-a315-995e6f0b7771'],['c5a056e2-b568-4ca6-9ed8-79c010942d00'],"['0002-7728-01', '0002-7728-99', '0002-7726-01', '0002-7726-05', '0002-8207-01', '0002-8207-05', '0002-8207-61', '0002-8351-01', '0002-8351-05', '0002-8235-01', '0002-8235-05', '0002-8235-99', '0002-8228-01', '0002-8228-27']",['GFX7QIS1II'],"['N0000004931', 'N0000175453']",['Insulin Analog [EPC]'],,10/24/2025,,['Insulin [Chemical/Ingredient]'],,,
Reverified,02/14/2022,0990-7922-61,Dextrose Monohydrate 5% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)",Otsuka ICU Medical LLC,,Current,['NDA016367'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['ICU Medical, Inc.']","['0990-7922', '0990-7923', '0990-7930']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621']",['ea5b9574-2321-442f-b550-3ac4f10dcaf8'],['8b25b7e0-703e-4b43-a4eb-52863511602d'],"['0990-7923-20', '0990-7923-23', '0990-7923-36', '0990-7923-37', '0990-7923-13', '0990-7922-02', '0990-7922-03', '0990-7922-09', '0990-7922-53', '0990-7922-55', '0990-7922-61', '0990-7930-02', '0990-7930-03', '0990-7930-09']",['LX22YL083G'],,,,,,,,,
New,10/09/2025,0025-0325-01,Adalimumab-afzb Injection,800-646-4398,,Discontinuation of the manufacture of the drug,10/09/2025,['Rheumatology'],Injection,"Abrilada, Injection, Kit (NDC 0025-0325-01)",Pfizer Inc.,,To Be Discontinued,['BLA761118'],['ABRILADA'],['ADALIMUMAB-AFZB'],['Pfizer Laboratories Div Pfizer Inc'],"['0025-0325', '0025-0328', '0025-0333', '0025-0347', '0025-0319']",['HUMAN PRESCRIPTION DRUG'],,,"['797544', '2668064', '2668071', '2668074', '2668078', '2668095', '2668096', '2668105', '2668106', '2668109', '2668113']",['6dc0780f-a9b9-40ae-b3f1-a88f338ab659'],['5ef1c7cf-466f-495e-8d13-82e2ddfa7a4f'],"['0025-0325-01', '0025-0325-02', '0025-0318-01', '0069-1111-01', '0025-0328-01', '0025-0328-02', '0025-0317-01', '0025-0333-02', '0025-0329-01', '0025-0347-02', '0025-0331-01', '0025-0319-01']",,,,,10/09/2025,,,,,
Revised,10/31/2017,0409-3814-12,Morphine Sulfate Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA073509'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-3814', '0409-3815']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['1728783', '1728800']",['493a6182-2a85-4973-8a20-6bb2344d6452'],['1d181906-f3ec-4222-1883-e61577a3122e'],"['0409-3814-11', '0409-3814-12', '0409-3815-11', '0409-3815-12']",['X3P646A2J0'],,,,,,,,,
New,11/07/2025,0409-4904-34,Lidocaine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)""","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA083158'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4904', '0409-4903', '0409-1323', '0409-9137']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1012066', '1012068']",['477abea3-c873-4265-82e8-5508ef54399f'],['ad1ef0a8-88db-4648-c098-d009eaeb4e5b'],"['0409-4903-11', '0409-4903-34', '0409-4904-11', '0409-4904-34', '0409-1323-15', '0409-1323-05', '0409-9137-11', '0409-9137-05']",['V13007Z41A'],,,,11/07/2025,,,,,
Reverified,12/08/2020,0338-0502-06,Amino Acid Injection,888-229-0001,Available,,10/22/2025,['Gastroenterology'],Injection,"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Baxter Healthcare,,Current,['ANDA020512'],['CLINISOL'],"['LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE']",['Baxter Healthcare Corporation'],['0338-0502'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['ALANINE', 'ARGININE', 'ASPARTIC ACID', 'GLUTAMIC ACID', 'GLYCINE', 'HISTIDINE', 'ISOLEUCINE', 'LEUCINE', 'LYSINE ACETATE', 'METHIONINE', 'PHENYLALANINE', 'PROLINE', 'SERINE', 'THREONINE', 'TRYPTOPHAN', 'TYROSINE', 'VALINE']","['800584', '800588']",['7eab93b5-5590-4381-8674-113a05edeff0'],['65ffc962-7538-41ea-9afb-4af5fbce4c5b'],"['0338-0502-03', '0338-0502-06']","['OF5P57N2ZX', '94ZLA3W45F', '30KYC7MIAI', '3KX376GY7L', 'TE7660XO1C', '4QD397987E', '04Y7590D77', 'GMW67QNF9C', 'TTL6G7LIWZ', 'AE28F7PNPL', '47E5O17Y3R', '9DLQ4CIU6V', '452VLY9402', '2ZD004190S', '8DUH1N11BX', '42HK56048U', 'HG18B9YRS7']","['N0000175780', 'M0000922']",['Amino Acid [EPC]'],,,,['Amino Acids [CS]'],,,
Revised,06/21/2018,63323-186-20,Sodium Chloride 0.9% Injection,888-386-1300,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-20)","Fresenius Kabi USA, LLC",,Resolved,['ANDA088912'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-186'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['SODIUM CHLORIDE'],"['1807632', '1807636', '1807637', '1807638']","['debc17b5-4d24-473c-8396-e409433ce57c', '75c567e3-582b-4fff-9a72-f326f1d13c8f']","['f2a98378-9678-4738-9670-fc7a215c0606', 'f62481fd-fcdb-4be6-ac13-29c590e925c3']","['63323-186-00', '63323-186-04', '63323-186-02', '63323-186-01', '63323-186-10', '63323-186-03', '63323-186-20']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,07/26/2023,0406-0127-01,"Methylphenidate Hydrochloride Tablet, Extended Release",800-325-8888,Limited Availability,Allocation to all customers.,11/05/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 0406-0127-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA202608'],['METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE'],['METHYLPHENIDATE HYDROCHLORIDE'],['SpecGx LLC'],"['0406-0127', '0406-0136', '0406-0154']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2001565', '2001566', '2001568']",['7a3a8731-e545-455e-83c3-888f4923e901'],['b1b0f2ff-d9df-42ab-b471-226ecf97e075'],"['0406-0127-01', '0406-0136-01', '0406-0154-01']",['4B3SC438HI'],,,,,,,,,
Reverified,11/14/2017,0338-0433-04,Heparin Sodium Injection,888-229-0001,Available,,10/22/2025,['Hematology'],Injection,"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)",Baxter Healthcare,,Current,['NDA018609'],['HEPARIN SODIUM IN SODIUM CHLORIDE'],['HEPARIN SODIUM'],['Baxter Healthcare Corporation'],"['0338-0433', '0338-0431', '0338-0424', '0338-0428']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['68b37381-6db4-4ac0-ba6b-3204add02665'],['0d929726-76c3-48fc-b4e7-fd06409f9fb3'],"['0338-0431-03', '0338-0433-04', '0338-0424-18', '0338-0428-12']",['ZZ45AB24CA'],,,,,,,,,
New,05/28/2025,0472-0804-15,Desonide Cream,800-545-8800,,,05/28/2025,['Dermatology'],Cream,"Desowen, Cream, .5 mg/1 g (NDC 0472-0804-15)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA019048'],['DESONIDE'],['DESONIDE'],"['Actavis Pharma, Inc.']","['0472-0804', '0472-0803']",['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['DESONIDE'],"['197572', '349351']",['f3953b9e-138f-4d86-8eea-0fc03c3c2747'],['ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99'],"['0472-0804-15', '0472-0804-60', '0472-0803-02', '0472-0803-04']",['J280872D1O'],"['N0000175576', 'N0000175450']",['Corticosteroid [EPC]'],,05/28/2025,,,,['Corticosteroid Hormone Receptor Agonists [MoA]'],
Reverified,03/23/2018,63323-287-20,Ropivacaine Hydrochloride Injection,888-386-1300,Unavailable,Not available at this time.,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)","Fresenius Kabi USA, LLC",Demand increase for the drug,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-287', '63323-286', '63323-288', '63323-285']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'PERINEURAL']",['ROPIVACAINE HYDROCHLORIDE'],"['905189', '905191', '1734084', '1734086', '1734090', '1734091', '1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484']",['cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9'],['23d2d448-a744-4877-9f2d-7e57c198da89'],"['63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63']",['V910P86109'],,,,,,,,,
Reverified,06/16/2022,42023-240-01,Methylprednisolone Acetate Injection,800-828-9393,Available,,11/05/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)","Par Pharmaceutical, Inc.",,Current,['ANDA214297'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],"['Endo USA, Inc.']","['42023-240', '42023-239', '42023-238']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRALESIONAL', 'INTRAMUSCULAR', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358610', '1358617']",['9d6bd79b-4885-454e-b127-c5978e501024'],['631f7d3e-5620-4be3-b918-2f0d38a97890'],"['42023-240-01', '42023-239-01', '42023-238-01']",['43502P7F0P'],,,,,,,,,
Reverified,03/23/2018,63323-161-01,Ketorolac Tromethamine Injection,888-386-1300,Available,Check wholesaler inventory,11/05/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)","Fresenius Kabi USA, LLC",,Current,['ANDA075784'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],"['Fresenius Kabi USA, LLC']","['63323-161', '63323-162']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']","['2b1c6066-d9e0-40a0-ade5-776fc35a3626', '55ed7afb-db66-4b28-939b-db45b55bf058', 'ab476c4c-2c72-47b1-bf42-7a89703b0dd4']","['ccf905ca-e164-4779-9485-2d139c821bad', '950b7295-3f68-4027-ac2b-2f7d0f5f8ef9', 'd1920335-8e45-4960-b6e9-e6f1f9e6820c']","['63323-161-41', '63323-161-16', '63323-162-43', '63323-162-16', '63323-162-45', '63323-162-26', '63323-161-21', '63323-161-12', '63323-162-23', '63323-162-12', '63323-162-25', '63323-162-14', '63323-161-00', '63323-161-01', '63323-162-11', '63323-162-51', '63323-162-00', '63323-162-01', '63323-162-03', '63323-162-02']",['4EVE5946BQ'],,,,,,,,,
New,11/03/2025,63481-627-70,Acetaminophen; Oxycodone Hydrochloride Tablet,800-828-9393,,Discontinuation of the manufacture of the drug,11/03/2025,['Analgesia/Addiction'],Tablet,"Percocet, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70)","Endo Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA040330'],['PERCOCET'],['OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN'],"['Endo USA, Inc.']","['63481-627', '63481-623', '63481-628', '63481-629']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['ACETAMINOPHEN', 'OXYCODONE HYDROCHLORIDE']","['1049214', '1049221', '1049225', '1049625', '1049635', '1049637', '1049640', '1049642']",['cc85b4f2-266d-4151-91b9-077d49daeaf5'],['4dd36cf5-8f73-404a-8b1d-3bd53bd90c25'],"['63481-627-70', '63481-623-70', '63481-623-85', '63481-628-70', '63481-629-70']","['C1ENJ2TE6C', '362O9ITL9D']",,,,11/03/2025,,,,,
Revised,12/10/2021,0264-7800-09,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-09)",B. Braun Medical Inc.,,Resolved,['NDA019635'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],"['0264-7800', '0264-7802']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807639', '1807551', '1807552', '1807633', '1807634']","['318417ff-d599-47b8-8181-89c3bb3b2e8d', '9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa']","['47a0313f-36df-4fa6-a828-c9e1946ba9b0', '7f22c06b-6b4d-4b49-a4b2-d2169f2bd653']","['0264-7800-09', '0264-7800-00', '0264-7800-10', '0264-7800-20', '0264-7802-00', '0264-7802-10']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,07/26/2023,57664-608-88,"Methylphenidate Hydrochloride Tablet, Extended Release",800-818-4555,Unavailable,Currently not marketed,10/21/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)","Sun Pharmaceutical Industries, Inc.",Discontinuation of the manufacture of the drug,Current,['ANDA205135'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-608', '57664-606', '57664-607', '57664-609']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210']",['0da4b745-d498-8823-e063-6394a90a4524'],['d048e52d-7406-4fc1-9a72-c073bafc7439'],"['57664-606-88', '57664-607-88', '57664-608-88', '57664-609-88']",['4B3SC438HI'],,,,,,,,,
Reverified,11/01/2017,63323-854-10,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Backordered. Next release not available at this time. Check wholesaler for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['HYDROMORPHONE HYDROCHLORIDE'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-854', '63323-851', '63323-852', '63323-853']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897653', '897753', '1724276', '1724338', '1724340', '1724341']",['9e8522c6-595c-46f9-bb25-272aa4683e0f'],['e034eb96-03e0-46e1-8b92-5e1f94555e7b'],"['63323-851-03', '63323-851-10', '63323-851-07', '63323-851-15', '63323-851-50', '63323-852-03', '63323-852-25', '63323-853-03', '63323-853-25', '63323-854-03', '63323-854-10']",['L960UP2KRW'],,,,,,,,,
Revised,02/08/2019,55150-239-30,Dexamethasone Sodium Phosphate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-239-30)",Eugia US LLC,Demand increase for the drug,Current,['ANDA206781'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Eugia US LLC'],"['55150-239', '55150-237', '55150-238']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SOFT TISSUE']",['DEXAMETHASONE SODIUM PHOSPHATE'],"['1116927', '1812194']",['34b1362a-f970-485f-bdac-3a02217157c9'],['ce7ad5a4-a9c5-42d6-87cc-ca16556208d2'],"['55150-237-01', '55150-238-05', '55150-239-30']",['AI9376Y64P'],,,,,,,,,
New,01/22/2025,71093-131-05,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-05)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-131', '71093-129', '71093-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Revised,12/15/2021,0009-0280-52,Methylprednisolone Acetate Injection,844-646-4398,Limited Availability,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: December 2025,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)",Pfizer Inc.,Other,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0280', '0009-0274', '0009-0306']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358510', '1358512', '1358610', '1358612', '1358617', '1358619']",['4cf5a255-1360-4511-9b58-b92e3492ef12'],['823b0010-2b57-4e76-b5ac-4a8c2963438f'],"['0009-0274-01', '0009-0280-02', '0009-0280-51', '0009-0280-03', '0009-0280-52', '0009-0306-02', '0009-0306-12']",['43502P7F0P'],,,,,,,,,
Revised,10/11/2024,0264-7751-00,Lactated Ringers Injection,800-227-2862,,,10/03/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other']",Injection,"Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-00)",B. Braun Medical Inc.,,Resolved,['NDA019634'],['DEXTROSE IN LACTATED RINGERS'],"['DEXTROSE, SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE']",['B. Braun Medical Inc.'],['0264-7751'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['CALCIUM CHLORIDE', 'DEXTROSE MONOHYDRATE', 'POTASSIUM CHLORIDE', 'SODIUM CHLORIDE', 'SODIUM LACTATE']",['847627'],['63aa1cd2-fda4-4386-8d11-5d1617634ef7'],['190da07e-a616-46e6-b4e5-1c0ba39306e5'],"['0264-7751-00', '0264-7751-10']","['M4I0D6VV5M', 'LX22YL083G', '660YQ98I10', '451W47IQ8X', 'TU7HW0W0QT']",,,,,,,10/03/2025,,Available
Revised,04/10/2020,0409-1434-01,Dexmedetomidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Anesthesia'],Injection,"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)",Pfizer Inc.,Other,Current,['NDA021038'],['PRECEDEX'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1434', '0409-1660', '0409-1638', '0409-1596', '0409-7838', '0409-7853', '0409-7875']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXMEDETOMIDINE HYDROCHLORIDE'],"['284397', '309710', '1718900', '1718902', '1718906', '1718907', '1718909', '1718910', '2396891', '2396892']",['231f50fe-2c91-44b9-946e-33b836c07b94'],['548a88c0-afda-427e-75ac-5af0cfa2224c'],"['0409-1660-55', '0409-1660-50', '0409-1660-35', '0409-1660-10', '0409-1660-22', '0409-1660-20', '0409-1638-32', '0409-1638-02', '0409-1434-01', '0409-1596-01', '0409-1596-10', '0409-7838-01', '0409-7838-24', '0409-7853-01', '0409-7853-24', '0409-7875-01', '0409-7875-12']",['1018WH7F9I'],,,,,,,,,
Revised,01/06/2023,0002-8148-01,Somatropin Injection,800-545-5979,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Humatrope, Injection, 12 mg/cartridge (NDC 0002-8148-01)",Eli Lilly and Co.,,Resolved,['BLA019640'],['HUMATROPE'],['SOMATROPIN'],['Eli Lilly and Company'],"['0002-8148', '0002-8147', '0002-8149']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'SUBCUTANEOUS']",,"['582969', '582971', '582974', '582976', '729232', '729234']",['aa99e905-657f-4561-8c02-d7c0409c44e3'],['a774e1ae-3997-49ee-8b0e-99a2b315d409'],"['0002-8147-01', '0002-7554-01', '0002-7618-01', '0002-8148-01', '0002-7555-01', '0002-7619-01', '0002-8149-01', '0002-7556-01']",,,,,,,,08/28/2025,,Available
Revised,12/15/2021,0009-0280-03,Methylprednisolone Acetate Injection,844-646-4398,Unavailable,Next Delivery: October 2025; Estimated Recovery: December 2025,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)",Pfizer Inc.,Demand increase for the drug,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0280', '0009-0274', '0009-0306']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358510', '1358512', '1358610', '1358612', '1358617', '1358619']",['4cf5a255-1360-4511-9b58-b92e3492ef12'],['823b0010-2b57-4e76-b5ac-4a8c2963438f'],"['0009-0274-01', '0009-0280-02', '0009-0280-51', '0009-0280-03', '0009-0280-52', '0009-0306-02', '0009-0306-12']",['43502P7F0P'],,,,,,,,,
New,12/05/2024,47335-472-83,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-83)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-472', '47335-475']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,03/01/2022,63323-824-76,Dextrose Monohydrate 10% Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)","Fresenius Kabi USA, LLC",,Current,['ANDA209448'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Fresenius Kabi USA, LLC']",['63323-824'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795477', '1795480', '1795481']",['d4eda8d8-e374-469e-8ac0-9c9fb7a58aaf'],['3b8f2692-4371-4f1a-95af-b41842131fdd'],"['63323-824-24', '63323-824-74', '63323-824-25', '63323-824-75', '63323-824-26', '63323-824-76']",['LX22YL083G'],,,,,,,,,
Revised,12/10/2021,0264-1800-32,Sodium Chloride 0.9% Injection,800-227-2862,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-32)",B. Braun Medical Inc.,,Resolved,['NDA017464'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['B. Braun Medical Inc.'],['0264-1800'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807630', '1807631', '1807632']",['7d4ee37f-5016-422c-9f66-e675ae22c46a'],['cc14fafd-3dcd-4fc8-bdbd-6f355c375768'],"['0264-1800-36', '0264-1800-31', '0264-1800-32']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,04/28/2025,0245-0211-11,Midodrine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Cardiovascular'],Tablet,"Orvaten, Tablet, 2.5 mg (NDC 0245-0211-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076725'],['MIDODRINE HYDROCHLORIDE'],['MIDODRINE HYDROCHLORIDE'],"['Upsher-Smith laboratories, LLC']","['0245-0211', '0245-0212', '0245-0213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MIDODRINE HYDROCHLORIDE'],"['993462', '993466', '993470']",['18b0b9f5-6026-479e-af12-92b0e71a9d6b'],['4c3517f3-1c68-4ade-b5f1-c488a3a335c1'],"['0245-0211-11', '0245-0211-89', '0245-0211-01', '0245-0212-11', '0245-0212-89', '0245-0212-01', '0245-0213-11', '0245-0213-89', '0245-0213-01']",['59JV96YTXV'],,,,04/28/2025,,,,,
Revised,10/12/2022,0555-0776-02,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Unavailable,Estimated availability: December 2025,11/06/2025,['Psychiatry'],Tablet,"Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA040422'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['0555-0776', '0555-0971', '0555-0775', '0555-0972', '0555-0777', '0555-0973', '0555-0974']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['88468f3d-7d03-4cee-aabf-3abc8c9b5e38'],['cffbbb15-d776-41ae-a8a6-687f2c07bfa4'],"['0555-0971-02', '0555-0775-02', '0555-0972-02', '0555-0776-02', '0555-0777-02', '0555-0973-02', '0555-0974-02']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Reverified,10/14/2016,63323-487-37,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE MPF'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-487', '63323-492', '63323-491', '63323-495', '63323-485', '63323-486', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']","['EPINEPHRINE BITARTRATE', 'LIDOCAINE HYDROCHLORIDE ANHYDROUS']","['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']",['ea480a68-5927-4278-9deb-2956961da428'],['ba082c2f-64f4-419d-9c88-74f203316e17'],"['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
Reverified,02/20/2018,0409-1749-10,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE WITH EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Hospira, Inc.']","['0409-1749', '0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
New,04/28/2023,0069-4310-71,Prazosin Hydrochloride Capsule,800-533-4535,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023,04/28/2023,['Cardiovascular'],Capsule,"Minipress, Capsule, 1 mg (NDC 0069-4310-71)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,04/28/2023,,,04/28/2023,,
Revised,02/22/2012,0409-4276-02,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088299'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4276', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
Revised,10/05/2022,55150-221-10,Etomidate Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)",Eugia US LLC,Demand increase for the drug,Current,['ANDA206126'],['ETOMIDATE'],['ETOMIDATE'],['Eugia US LLC'],"['55150-221', '55150-222']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ETOMIDATE'],"['1654006', '1654008']",['278b160e-cdc4-451e-9405-cb001f443680'],['0820f15a-046b-4185-a2b3-2e4051ee3d82'],"['55150-221-10', '55150-222-20']",['Z22628B598'],"['N0000175975', 'N0000175681']",['General Anesthetic [EPC]'],['General Anesthesia [PE]'],,,,,,
New,02/06/2025,0378-5089-73,Varenicline Tartrate Tablet,800-796-9526,,Permanent discontinuation in the manufacturing of the drug,02/06/2025,['Analgesia/Addiction'],Tablet,"Varenicline Tartrate, Tablet, .5 mg (NDC 0378-5089-73)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['ANDA202019'],['VARENICLINE'],['VARENICLINE'],['Mylan Pharmaceuticals Inc.'],"['0378-5089', '0378-5090', '0378-5091']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VARENICLINE TARTRATE'],"['636671', '636676', '749289']",['5b7b6e3b-f427-4000-b252-968f3adbaa3b'],['4233fb78-ac6c-49f3-aad8-7e4bee18cac6'],"['0378-5089-73', '0378-5090-73', '0378-5091-85', '0378-5089-46', '0378-5090-23']",['82269ASB48'],,,,02/06/2025,,,,,
Reverified,10/31/2023,63323-604-01,Propranolol Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Cardiovascular'],Injection,"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)","Fresenius Kabi USA, LLC",,Current,['ANDA075826'],['PROPRANOLOL'],['PROPRANOLOL HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-604'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PROPRANOLOL HYDROCHLORIDE'],['856443'],['505851c4-b18c-4cd7-805c-4e923cc1fa7e'],['f14ea537-dd5c-4c78-9037-9a85e9e610ef'],['63323-604-01'],['F8A3652H1V'],,,,,,,,,
Reverified,07/14/2023,42858-166-01,Lisdexamfetamine Dimesylate Capsule,888-827-0616,Available,,08/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)",Rhodes Pharmaceuticals L.P.,,Current,['ANDA215330'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Rhodes Pharmaceuticals'],"['42858-166', '42858-161', '42858-162', '42858-163', '42858-164', '42858-165', '42858-167']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['047c243d-9336-4ef2-b5a8-a7cae312b1be'],['d918b40d-a461-41bc-b6c0-83dc76c28e32'],"['42858-161-01', '42858-162-01', '42858-163-01', '42858-164-01', '42858-165-01', '42858-166-01', '42858-167-01']",['SJT761GEGS'],,,,,,,,,
Reverified,10/11/2024,0990-7918-19,Dextrose Monohydrate 70% Injection,1-866-829-9025 or ProductAvailability@icumed.com,Available,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",11/05/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)",Otsuka ICU Medical LLC,,Current,['NDA018561'],['DEXTROSE'],['DEXTROSE'],['ICU Medical Inc.'],"['0990-7918', '0990-7935', '0990-7936', '0990-7937', '0990-8004']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['237649', '237650', '237656', '242694', '1795518']",['6785bd83-c705-41a5-a19c-906f03f380e3'],['b5cb7a5a-bbe8-4217-a82e-da818f7771c9'],"['0990-7918-19', '0990-7935-19', '0990-7936-19', '0990-7937-19', '0990-8004-15']",['LX22YL083G'],,,,,,,,,
New,04/24/2025,0245-1075-30,"Topiramate Capsule, Extended Release",716-315-2000,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,04/24/2025,['Neurology'],"Capsule, Extended Release","Qudexy XR, Capsule, Extended Release, 150 mg (NDC 0245-1075-30)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['NDA205122'],['QUDEXY XR'],['TOPIRAMATE'],"['Upsher-Smith Laboratories, LLC']","['0245-1075', '0245-1071', '0245-1072', '0245-1074', '0245-1073']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TOPIRAMATE'],"['1494766', '1494769', '1494771', '1494775', '1494778', '1494781', '1812419', '1812421', '1812425', '1812427']",['374eeb55-b017-48fd-e063-6294a90a6ad7'],['46f54677-3a22-4c38-9b92-923020164e15'],"['0245-1071-30', '0245-1071-90', '0245-1072-30', '0245-1072-90', '0245-1074-30', '0245-1074-90', '0245-1075-30', '0245-1075-90', '0245-1073-30', '0245-1073-90']",['0H73WJJ391'],"['N0000008486', 'N0000185506', 'N0000182140']",,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],04/24/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Reverified,04/02/2020,47781-588-68,Midazolam Hydrochloride Injection,Athenex: 855-273-0154; Alvogen: 973-532-7840,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 47781-588-68)",Gland Pharma Limited,Other,Current,,,,,,,,,,,,,,,,,,,,,,
New,11/03/2025,0002-4312-08,Lasmiditan Succinate Tablet,800-545-5979,,A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets.,11/03/2025,['Neurology'],Tablet,"Reyvow, Tablet, 50 mg (NDC 0002-4312-08)",Eli Lilly and Co.,,To Be Discontinued,['NDA211280'],['REYVOW'],['LASMIDITAN'],['Eli Lilly and Company'],"['0002-4312', '0002-4491']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LASMIDITAN'],"['2256937', '2256943', '2256945', '2256947']",['75a13e98-3736-4256-8277-6c05bcaddcf5'],['aea3358c-ff41-4490-9e6d-c7bf7b3de13f'],"['0002-4312-08', '0002-4312-61', '0002-4312-62', '0002-4491-08', '0002-4491-61', '0002-4491-62']",['760I9WM792'],,,,11/03/2025,,,,,
Reverified,11/06/2017,70436-203-80,Dobutamine Hydrochloride Injection,"Slate Run Pharmaceuticals, LLC: 844-529-8988",Available,"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988",10/15/2025,"['Cardiovascular', 'Pediatric', 'Renal']",Injection,"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)","Hainan Poly Pharm. Co., Ltd.",,Current,['ANDA216131'],['DOBUTAMINE'],['DOBUTAMINE'],['Slate Run Pharmaceuticals'],['70436-203'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOBUTAMINE HYDROCHLORIDE'],['1812168'],['f5cd978c-4e1d-2447-e053-2a95a90add3f'],['ee09a55f-9992-48bb-b8d6-1184bd548536'],"['70436-203-80', '70436-203-82']",['0WR771DJXV'],,,,,,,,,
Revised,01/06/2023,0002-8149-01,Somatropin Injection,800-545-5979,,,08/28/2025,['Endocrinology/Metabolism'],Injection,"Humatrope, Injection, 24 mg/cartridge (NDC 0002-8149-01)",Eli Lilly and Co.,,Resolved,['BLA019640'],['HUMATROPE'],['SOMATROPIN'],['Eli Lilly and Company'],"['0002-8149', '0002-8147', '0002-8148']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'SUBCUTANEOUS']",,"['582969', '582971', '582974', '582976', '729232', '729234']",['aa99e905-657f-4561-8c02-d7c0409c44e3'],['a774e1ae-3997-49ee-8b0e-99a2b315d409'],"['0002-8147-01', '0002-7554-01', '0002-7618-01', '0002-8148-01', '0002-7555-01', '0002-7619-01', '0002-8149-01', '0002-7556-01']",,,,,,,,08/28/2025,,Available
Revised,12/04/2024,0228-2069-10,Oxazepam Capsule,800-545-8800,,,07/03/2025,"['Neurology', 'Psychiatry']",Capsule,"Oxazepam, Capsule, 15 mg (NDC 0228-2069-10)","Teva Pharmaceuticals USA, Inc.",,Resolved,['ANDA072253'],['OXAZEPAM'],['OXAZEPAM'],"['Actavis Pharma, Inc.']","['0228-2069', '0228-2067', '0228-2073']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXAZEPAM'],"['198057', '198059', '312134']",['f191a7db-b292-4119-b144-b25c0555b050'],['a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43'],"['0228-2067-10', '0228-2069-10', '0228-2073-10']",['6GOW6DWN2A'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],07/03/2025,,Available
Reverified,10/25/2017,0338-0411-02,Lidocaine Hydrochloride Injection,888-229-0001,Available,,10/22/2025,['Cardiovascular'],Injection,"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)",Baxter Healthcare,,Current,['NDA018461'],['LIDOCAINE HYDROCHLORIDE AND DEXTROSE'],['LIDOCAINE HYDROCHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0411', '0338-0409']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1737723', '1737742', '1737744']",['6bb9f86c-595a-47f7-b6e9-792966edb852'],['f21512ea-c7c3-4766-b976-b2c0b5616bf0'],"['0338-0409-03', '0338-0409-02', '0338-0411-02']",['V13007Z41A'],,,,,,,,,
New,06/24/2025,0078-0406-05,Amlodipine Besylate; Benazepril Hydrochloride Capsule,888-669-6682,,Permanent discontinuation in the manufacturing of the drug,06/24/2025,['Cardiovascular'],Capsule,"Lotrel, Capsule, 5 mg; 20 mg (NDC 0078-0406-05)",Novartis Pharmaceuticals Corporation,,To Be Discontinued,['NDA020364'],['LOTREL'],['AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE'],['Novartis Pharmaceuticals Corporation'],"['0078-0406', '0078-0405', '0078-0364', '0078-0379']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMLODIPINE BESYLATE', 'BENAZEPRIL HYDROCHLORIDE']","['898342', '898344', '898346', '898348', '898353', '898355', '898356', '898358']",['b9db75d9-9d1e-4b2d-9876-5f5520feaecc'],['94ae6054-b7ae-4212-a567-4f803af8f2c7'],"['0078-0405-05', '0078-0406-05', '0078-0364-05', '0078-0379-05']","['N1SN99T69T', '864V2Q084H']",,,,06/24/2025,,,,,
New,04/23/2025,50090-6868-0,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 50090-6868-0)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,,,,,,,,,,,,,,,,,04/23/2025,,,,,
Revised,10/31/2017,0409-1890-01,Morphine Sulfate Injection,844-646-4398,Unavailable,Next Delivery: November 2025; Estimated Recovery: March 2026,10/23/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA202515'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-1890', '0409-1891', '0409-1892', '0409-1893', '0409-1894']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['MORPHINE SULFATE'],"['894912', '998212', '998213', '1729197', '1731995', '1732014']",['cced2ec0-6c94-4cf0-87fb-041667ee3214'],['be420e8b-bcb0-49b5-bb4d-1df8b9959809'],"['0409-1890-03', '0409-1890-01', '0409-1890-13', '0409-1890-23', '0409-1891-03', '0409-1891-01', '0409-1891-13', '0409-1891-23', '0409-1892-03', '0409-1892-01', '0409-1892-13', '0409-1892-23', '0409-1893-03', '0409-1893-01', '0409-1893-13', '0409-1893-23', '0409-1894-03', '0409-1894-01']",['X3P646A2J0'],,,,,,,,,
Revised,10/12/2022,0555-0775-02,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['0555-0775', '0555-0971', '0555-0972', '0555-0776', '0555-0777', '0555-0973', '0555-0974']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['88468f3d-7d03-4cee-aabf-3abc8c9b5e38'],['cffbbb15-d776-41ae-a8a6-687f2c07bfa4'],"['0555-0971-02', '0555-0775-02', '0555-0972-02', '0555-0776-02', '0555-0777-02', '0555-0973-02', '0555-0974-02']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,11/06/2017,0143-9252-25,Dopamine Hydrochloride Injection,800-631-2174,Unavailable,Additional lots will be available in the January 2026 timeframe.  Product will be made available as it is released.,10/24/2025,['Cardiovascular'],Injection,"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA207707'],['DOPAMINE HYDROCHLORIDE'],['DOPAMINE HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9252', '0143-9253', '0143-9254', '0143-9255']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DOPAMINE HYDROCHLORIDE'],"['1743938', '1743941', '1743950', '1743953']",['67349236-e8e3-45ec-a76d-2a0a150d8d59'],['0e499952-46c7-4172-8c70-186312e240a3'],"['0143-9252-01', '0143-9252-25', '0143-9253-01', '0143-9253-25', '0143-9254-01', '0143-9254-25', '0143-9255-01', '0143-9255-25']",['7L3E358N9L'],,,,,,,,,
Reverified,12/27/2023,69945-094-20,Technetium TC-99M Pyrophosphate Kit Injection,888-744-1414,Unavailable,Unavailable,11/03/2025,['Medical Imaging'],Injection,"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)",Curium US LLC,Shortage of an active ingredient,Current,['NDA017538'],['TECHNESCAN PYP'],['TECHNETIUM TC 99M PYROPHOSPHATE'],['Curium US LLC'],['69945-094'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],"['SODIUM PYROPHOSPHATE', 'STANNOUS CHLORIDE']",,['3635fabe-0b23-171b-e063-6394a90ae8c1'],['304b63f4-a32e-4700-805d-5bc9f27e7d6a'],['69945-094-20'],"['O352864B8Z', '1BQV3749L5']",,,,,,,,,
Reverified,09/11/2019,68875-0205-2,Parathyroid Hormone Injection,866-888-0660,Unavailable,The 100 Mcg Cartridge Is No Longer Available And Takeda Is Unable To Resupply Prior To Ceasing Of Manufacturing Of Natpara At The End Of 2024.,08/15/2025,['Endocrinology/Metabolism'],Powder,"Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Takeda Pharmaceuticals USA Inc.,Discontinuation of the manufacture of the drug,Current,['BLA125511'],['NATPARA (PARATHYROID HORMONE)'],['PARATHYROID HORMONE'],"['Takeda Pharmaceuticals America, Inc.']","['68875-0205', '68875-0202', '68875-0203', '68875-0204']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PARATHYROID HORMONE'],"['1602023', '1602028', '1602032', '1602034', '1602038', '1602040', '1602044', '1602046']",['17d2bb82-605c-43be-9918-63aeb7102d8c'],['d11fba31-0a6c-11e3-8ffd-0800200c9a66'],"['68875-0202-1', '68875-0202-2', '68875-0203-1', '68875-0203-2', '68875-0204-1', '68875-0204-2', '68875-0205-1', '68875-0205-2']",['N19A0T0E5J'],"['M0015931', 'N0000180851']",['Parathyroid Hormone [EPC]'],,,,['Parathyroid Hormone [CS]'],,,
Reverified,02/22/2012,83090-003-10,Lidocaine Hydrochloride Injection,"844-425-3131, SinteticaCS@eversana.com",Available,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X10ML) is Preservative free.",08/19/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)",Sintetica US,,Current,['ANDA214267'],['NA'],['LIDOCAINE HYDROCHLORIDE'],['Sintetica US LLC'],"['83090-003', '83090-001', '83090-002', '83090-004', '83090-005', '83090-006']",['HUMAN PRESCRIPTION DRUG'],['INFILTRATION'],['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1737566', '1737568', '1737570', '1737757', '1737761', '1737763']",['0d18f291-3a92-421e-8841-6be743b1f154'],['aa3e688a-308c-4a82-a268-28ccf1677c55'],"['83090-001-01', '83090-001-10', '83090-002-01', '83090-002-10', '83090-003-01', '83090-003-10', '83090-004-01', '83090-004-10', '83090-005-01', '83090-005-10', '83090-006-01', '83090-006-10']",['EC2CNF7XFP'],,,,,,,,,
Reverified,02/22/2012,0409-3178-01,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection",844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA089644'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],['LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE'],"['Hospira, Inc.']","['0409-3178', '0409-1209', '0409-3177', '0409-3181', '0409-3182', '0409-3183', '0409-0007', '0409-0147']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']","['EPINEPHRINE', 'LIDOCAINE HYDROCHLORIDE']","['1010688', '1010745', '1010751', '1010759', '1867996', '1867998']",['d16a4711-e663-455e-a1fe-236a41ca4e8f'],['2f94f711-14c4-48ec-c5a3-c5ec4b8e8729'],"['0409-1209-10', '0409-1209-01', '0409-1209-05', '0409-1209-70', '0409-1209-65', '0409-3177-16', '0409-3177-01', '0409-3178-16', '0409-3178-01', '0409-3178-17', '0409-3178-02', '0409-3178-18', '0409-3178-03', '0409-3181-11', '0409-3181-01', '0409-3182-11', '0409-3182-01', '0409-3182-21', '0409-3182-02', '0409-3182-31', '0409-3182-03', '0409-3183-11', '0409-3183-01', '0409-0007-01', '0409-0007-10', '0409-0147-01', '0409-0147-10']","['YKH834O4BH', 'V13007Z41A']","['N0000000209', 'N0000000245', 'N0000175552', 'N0000175555', 'N0000175570', 'M0003647']","['alpha-Adrenergic Agonist [EPC]', 'beta-Adrenergic Agonist [EPC]', 'Catecholamine [EPC]']",,,,['Catecholamines [CS]'],,"['Adrenergic alpha-Agonists [MoA]', 'Adrenergic beta-Agonists [MoA]']",
New,05/02/2025,0832-0542-11,Bumetanide Tablet,800-654-2299,,,05/02/2025,['Cardiovascular'],Tablet,"Bumetanide, Tablet, 2 mg (NDC 0832-0542-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA209916'],['BUMETANIDE'],['BUMETANIDE'],"['Upsher-Smith Laboratories, LLC']","['0832-0542', '0832-0540', '0832-0541']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['BUMETANIDE'],"['197417', '197418', '197419']",['d53166d9-64ca-4b76-81a7-b70a60c53b12'],['ff5dc8c6-b2f2-41d3-8e56-a953aa721b59'],"['0832-0540-11', '0832-0541-11', '0832-0541-10', '0832-0542-11', '0832-0542-10']",['0Y2S3XUQ5H'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],05/02/2025,,,,,
New,07/17/2025,0025-1381-31,Oxaprozin Tablet,800-533-4535,,Discontinuation of the manufacture of the drug.,07/17/2025,['Analgesia/Addiction'],Tablet,"Daypro, Tablet, 600 mg (NDC 0025-1381-31)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['NDA018841'],['DAYPRO'],['OXAPROZIN'],['Pfizer Laboratories Div Pfizer Inc'],['0025-1381'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXAPROZIN'],"['207243', '312132']",['b8c736b5-aa87-41f8-a25a-dd3c5654a4be'],['ea1de47e-3101-4414-817c-0a098af8988c'],"['0025-1381-31', '0025-1381-34', '0025-1381-51']",['MHJ80W9LRB'],"['N0000000160', 'M0001335', 'N0000175722']",['Nonsteroidal Anti-inflammatory Drug [EPC]'],,07/17/2025,,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",,['Cyclooxygenase Inhibitors [MoA]'],
Revised,10/12/2022,0555-0972-02,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Limited Availability,Estimated availability: November 2025,11/06/2025,['Psychiatry'],Tablet,"Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)","Teva Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA040422'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['0555-0972', '0555-0971', '0555-0775', '0555-0776', '0555-0777', '0555-0973', '0555-0974']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['88468f3d-7d03-4cee-aabf-3abc8c9b5e38'],['cffbbb15-d776-41ae-a8a6-687f2c07bfa4'],"['0555-0971-02', '0555-0775-02', '0555-0972-02', '0555-0776-02', '0555-0777-02', '0555-0973-02', '0555-0974-02']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/26/2025,0093-5537-56,Eszopiclone Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/26/2025,['Neurology'],Tablet,"Eszopiclone, Tablet, 1 mg (NDC 0093-5537-56)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA091169'],['ESZOPICLONE'],['ESZOPICLONE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-5537', '0093-5538', '0093-5539']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ESZOPICLONE'],"['485440', '485442', '485465']",['b7cc855f-8510-4cb2-a941-18d3c4472236'],['2435e2f1-bc52-488f-80e9-f1758e354aae'],"['0093-5537-56', '0093-5538-01', '0093-5539-01']",['UZX80K71OE'],,,,06/26/2025,,,,,
New,10/21/2025,0591-5590-01,Tranylcypromine Sulfate Tablet,800-545-8800,,Supply is expected to be depleted by 12/31/2025.,10/21/2025,['Psychiatry'],Tablet,"Parnate, Tablet, 10 mg (NDC 0591-5590-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA012342'],['TRANYLCYPROMINE SULFATE'],['TRANYLCYPROMINE SULFATE'],"['Actavis Pharma, Inc.']",['0591-5590'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['TRANYLCYPROMINE SULFATE'],['313447'],['e42c8b23-863e-4370-a3b1-b71526b12ee5'],['6a0b609b-0625-4c26-91a1-59ee3ece3ddf'],['0591-5590-01'],['7ZAT6ES870'],,,,10/21/2025,,,,,
New,04/28/2023,0069-4380-71,Prazosin Hydrochloride Capsule,800-533-4535,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,04/28/2023,['Cardiovascular'],Capsule,"Minipress, Capsule, 5 mg (NDC 0069-4380-71)",Pfizer Inc.,,To Be Discontinued,,,,,,,,,,,,,,,,,04/28/2023,,,04/28/2023,,
New,07/17/2025,0591-2679-30,Lidocaine Patch,800-545-8800,,Discontinuation is for the “NovaPlus” label product only.,07/17/2025,['Analgesia/Addiction'],Patch,"Lidocaine, Patch, 5% (NDC 0591-2679-30)","Actavis Pharma, Inc.",,To Be Discontinued,['ANDA200675'],['LIDOCAINE'],['LIDOCAINE'],"['Actavis Pharma, Inc.']",['0591-2679'],['HUMAN PRESCRIPTION DRUG'],['TOPICAL'],['LIDOCAINE'],['1745091'],['e0683309-89ba-4804-887f-12fcaf59a2ca'],['c18799cd-9e11-4196-9ab1-0a2a84585e56'],"['0591-2679-11', '0591-2679-30']",['98PI200987'],"['N0000175682', 'M0000897', 'N0000175426', 'N0000175976']","['Amide Local Anesthetic [EPC]', 'Antiarrhythmic [EPC]']",['Local Anesthesia [PE]'],07/17/2025,,['Amides [CS]'],,,
New,06/10/2025,0093-8035-05,Glyburide Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/10/2025,['Endocrinology/Metabolism'],Tablet,"Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-05)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA074686'],['GLYBURIDE'],['GLYBURIDE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-8035', '0093-8034', '0093-8036']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLYBURIDE'],"['310536', '310539', '314000']",['00e55b1b-81b5-4df1-8a6d-4d54ac403e76'],['e84c0dfc-a4e9-4c89-b6ea-45732eb412f5'],"['0093-8034-01', '0093-8035-01', '0093-8035-05', '0093-8036-01']",['SX6K58TVWC'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,06/10/2025,,['Sulfonylurea Compounds [CS]'],,,
Revised,03/21/2023,0009-0775-26,Clindamycin Phosphate Injection,800-533-4535,Unavailable,Next Delivery: December 2025; Estimated Recovery: June 2026,10/23/2025,['Anti-Infective'],Injection,"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)",Pfizer Inc.,Other,Current,['NDA050441'],['CLEOCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0775', '0009-0870', '0009-0902', '0009-0728', '0009-3124', '0009-3447', '0009-3381', '0009-3375', '0009-3382', '0009-6582']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['205964', '309335', '309336', '309339', '685574', '685576', '685578', '706461', '1737244', '1737245', '1737578', '1737579', '1737581', '1737582']",['cb513686-3220-4de2-8be6-f941273ae842'],['05a75685-0af5-407c-ac57-e380c882b49d'],"['0009-0870-21', '0009-0870-26', '0009-0775-20', '0009-0775-26', '0009-0902-11', '0009-0902-18', '0009-0728-05', '0009-0728-09', '0009-3124-01', '0009-3124-03', '0009-3447-01', '0009-3447-03', '0009-3381-01', '0009-3381-02', '0009-3375-01', '0009-3375-02', '0009-3382-01', '0009-3382-02', '0009-6582-02', '0009-6582-01']",['EH6D7113I8'],,,,,,,,,
Reverified,02/15/2023,0781-3220-95,Rocuronium Bromide Injection,800-525-8747,Available,,10/20/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)",Sandoz Inc.,,Current,['ANDA079195'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Sandoz Inc'],['0781-3220'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['eaf32464-7950-434a-e053-2a95a90aa2dc'],['cb28d869-6510-4402-9462-f6bb25fa0fa8'],"['0781-3220-70', '0781-3220-92', '0781-3220-75', '0781-3220-95']",['I65MW4OFHZ'],,,,,,,,,
Revised,07/14/2023,57664-083-88,"Lisdexamfetamine Dimesylate Tablet, Chewable",800-818-4555,Limited Availability,Available Q4 2025,10/21/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA214134'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-083', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-051', '57664-052', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
Reverified,10/12/2022,0527-0760-37,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)","Lannett Company, Inc.",,Current,['ANDA215565'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Lannett Company, Inc.']","['0527-0760', '0527-0761', '0527-0762', '0527-0763', '0527-0764', '0527-0765', '0527-0766']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['e0804f43-4685-4017-b839-3212d1167362'],['f92497b5-baea-4760-b615-45a0b6184402'],"['0527-0760-37', '0527-0761-37', '0527-0762-37', '0527-0763-37', '0527-0764-37', '0527-0765-37', '0527-0766-37']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,06/10/2025,0093-0109-01,Carbamazepine Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/10/2025,['Neurology'],Tablet,"Epitol, Tablet, 200 mg (NDC 0093-0109-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA070541'],['CARBAMAZEPINE'],['CARBAMAZEPINE'],"['Teva Pharmaceuticals USA, Inc.']","['0093-0109', '0093-0778']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CARBAMAZEPINE'],"['308973', '308979']",['042aa2c6-95ff-410a-abcf-a8ee79fa96d8'],['bfd63965-56e6-4af7-b7ef-45a5105d4d35'],"['0093-0109-01', '0093-0109-10', '0093-0778-01']",['33CM23913M'],"['N0000008486', 'N0000175751', 'N0000185506', 'N0000191266', 'N0000187064', 'N0000185507', 'N0000185607']",['Mood Stabilizer [EPC]'],['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],06/10/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]']",
New,01/22/2025,71093-129-05,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-05)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-129', '71093-130', '71093-131']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Revised,05/30/2025,0409-1418-01,Meperidine Hydrochloride Injection,844-646-4398,Unavailable,Next Delivery and Estimated Recovery: December 2027,10/23/2025,['Analgesia/Addiction'],Injection,"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)","Hospira, Inc., a Pfizer Company",Other,Current,['NDA021171'],['DEMEROL'],['MEPERIDINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1418', '0409-1181', '0409-1176', '0409-1178', '0409-1179', '0409-1180', '0409-1362']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['MEPERIDINE HYDROCHLORIDE'],"['860792', '861463', '861473', '861493', '861494', '861522', '861529', '861617', '1242106', '1242503', '2539186', '2539188', '2539191', '2539192']",['1271f15f-ccda-4892-8fb0-9bb2d38ded4a'],['b31d1308-28c3-43f4-e0a6-2f3ed76b8975'],"['0409-1181-30', '0409-1176-03', '0409-1176-30', '0409-1178-03', '0409-1178-30', '0409-1179-03', '0409-1179-30', '0409-1180-59', '0409-1180-69', '0409-1362-11', '0409-1362-01', '0409-1418-11', '0409-1418-01']",['N8E7F7Q170'],,,,,,,,,
Reverified,01/01/2012,0409-9094-28,Fentanyl Citrate Injection,844-646-4398,Available,,10/23/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)","Hospira, Inc., a Pfizer Company",,Current,['NDA019115'],['FENTANYL CITRATE'],['FENTANYL CITRATE'],"['Hospira, Inc.']","['0409-9094', '0409-9093']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FENTANYL CITRATE'],"['1735003', '1735004', '1735006', '1735007', '1735008', '1735013']",['e4b31fdd-00af-416d-b14e-dbac0c83da97'],['bfa8018a-4cbc-434b-e09e-782872b0340a'],"['0409-9093-37', '0409-9093-32', '0409-9093-45', '0409-9093-35', '0409-9093-41', '0409-9093-36', '0409-9093-31', '0409-9093-38', '0409-9094-12', '0409-9094-22', '0409-9094-18', '0409-9094-25', '0409-9094-17', '0409-9094-28', '0409-9094-16', '0409-9094-31', '0409-9094-41', '0409-9094-61']",['MUN5LYG46H'],,,,,,,01/02/2025,,
New,06/10/2025,0093-0090-01,Carbamazepine Tablet,800-545-8800,,Discontinuation of the manufacture of the drug,06/10/2025,['Neurology'],Tablet,"Epitol, Tablet, 200 mg (NDC 0093-0090-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA070541'],['EPITOL'],['CARBAMAZEPINE'],"['Teva Pharmaceuticals USA, Inc.']",['0093-0090'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CARBAMAZEPINE'],"['211817', '308979']",['5c31da75-fc21-4ab2-9487-64169767ebd0'],['32bbe864-7374-44da-8c6e-e733f0648243'],['0093-0090-01'],['33CM23913M'],"['N0000008486', 'N0000175751', 'N0000185506', 'N0000191266', 'N0000187064', 'N0000185507', 'N0000185607']",['Mood Stabilizer [EPC]'],['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],06/10/2025,,,,"['Cytochrome P450 3A4 Inducers [MoA]', 'Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]']",
Revised,06/28/2022,0143-9391-10,Remifentanil Hydrochloride Injection,800-631-2174,Available,Additional lots will be available.  Product will be made available as it is released.,10/24/2025,['Analgesia/Addiction'],Injection,"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA210594'],['REMIFENTANIL HYDROCHLORIDE'],['REMIFENTANIL HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9391', '0143-9392', '0143-9393']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['REMIFENTANIL HYDROCHLORIDE'],"['1729578', '1729584', '1729710']",['5c5e498b-d829-4f78-bcca-466631014767'],['9d289052-1eb6-4ba2-a3ca-d2e542a052ae'],"['0143-9391-01', '0143-9391-10', '0143-9392-01', '0143-9392-10', '0143-9393-01', '0143-9393-10']",['5V444H5WIC'],,,,,,,,,
Reverified,02/22/2012,63323-208-05,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)","Fresenius Kabi USA, LLC",,Current,['NDA017584'],['LIDOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']",['63323-208'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],['1737761'],['289524c2-d0be-443d-aedf-39d621f217a5'],['f1b26274-a55e-4321-b96c-ce0df830f205'],"['63323-208-01', '63323-208-05']",['V13007Z41A'],,,,,,,,,
New,11/03/2025,0378-0007-85,Everolimus Tablet,800-796-9526,,Discontinuation of the manufacture of the drug,11/03/2025,['Transplant'],Tablet,"Everolimus, Tablet, 5 mg (NDC 0378-0007-85)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,['ANDA210130'],['EVEROLIMUS'],['EVEROLIMUS'],['Mylan Pharmaceuticals Inc.'],"['0378-0007', '0378-0005', '0378-0006']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['EVEROLIMUS'],"['1308428', '1308430', '1308432']",['129ab1eb-61df-49de-953c-fca0f0a28eee'],['ca1a987e-f763-4026-93c5-c545ca95826c'],"['0378-0005-85', '0378-0006-85', '0378-0007-85']",['9HW64Q8G6G'],"['N0000175605', 'N0000175076', 'N0000182141', 'N0000182137', 'N0000175625', 'N0000175624', 'N0000175550']","['Kinase Inhibitor [EPC]', 'mTOR Inhibitor Immunosuppressant [EPC]']",['Decreased Immunologic Activity [PE]'],11/03/2025,,,,"['Protein Kinase Inhibitors [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 2D6 Inhibitors [MoA]', 'mTOR Inhibitors [MoA]']",
New,04/23/2025,50090-6868-1,Baclofen Tablet,716-315-2000,,,04/23/2025,['Neurology'],Tablet,"Baclofen, Tablet, 10 mg (NDC 50090-6868-1)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,,,,,,,,,,,,,,,,,04/23/2025,,,,,
Reverified,02/15/2023,43066-007-10,Rocuronium Bromide Injection,888-229-0001,Available,,10/22/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)",Baxter Healthcare,,Current,['ANDA091115'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Baxter Healthcare Corporation'],"['43066-007', '43066-013']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['9e0317de-2d78-4fd8-8926-4c7b476f3ed4'],['31e15c3f-aefa-4379-b684-7707744fe40d'],"['43066-007-10', '43066-013-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,10/12/2022,70010-114-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",877-770-3183,Available,,10/15/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)",Granules Pharmaceuticals Inc.,,Current,['ANDA215771'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']",['Granules Pharmaceuticals Inc.'],"['70010-114', '70010-111', '70010-112', '70010-113', '70010-115', '70010-116', '70010-117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['2fab399e-2a43-5134-e063-6294a90ae09a'],['b0b4eccc-34c7-483d-966f-82d588358e1b'],"['70010-111-01', '70010-111-03', '70010-112-01', '70010-112-03', '70010-113-01', '70010-113-03', '70010-114-01', '70010-114-03', '70010-115-01', '70010-115-03', '70010-116-01', '70010-116-03', '70010-117-01', '70010-117-03']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
New,09/18/2025,0832-6004-11,Fluphenazine Hydrochloride Tablet,763-315-2000,,Discontinuation of the manufacture of the drug.,09/18/2025,"['Neurology', 'Psychiatry']",Tablet,"Fluphenazine Hydrochloride, Tablet, 2.5 mg (NDC 0832-6004-11)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA213784'],['FLUPHENAZINE HYDROCHLORIDE'],['FLUPHENAZINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories,LLC']","['0832-6004', '0832-6003', '0832-6005', '0832-6006']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['FLUPHENAZINE HYDROCHLORIDE'],"['859841', '860918', '865117', '865123']",['3bb74f82-8872-9829-e063-6294a90aeace'],['f07bb3f1-c68c-441b-9de4-99a219f2500a'],"['0832-6004-11', '0832-6003-11', '0832-6005-11', '0832-6006-11']",['ZOU145W1XL'],,,,09/18/2025,,,,,
Reverified,04/28/2023,60505-6282-1,Carboplatin Injection,Apotex Inc.: 800-706-5575,Unavailable,Discontinuation of the manufacture of the drug.,11/05/2025,['Oncology'],Injection,"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)",Teyro Labs,Discontinuation of the manufacture of the drug,Current,['ANDA077861'],['CARBOPLATIN'],['CARBOPLATIN'],['Apotex Corp.'],['60505-6282'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0e68e276-b0df-4f03-e063-6394a90a22b9'],['1c275825-0275-4c73-b650-e4c1519f13b8'],"['60505-6282-1', '60505-6282-3', '60505-6282-6', '60505-6282-7']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection,,,,
Reverified,02/15/2023,71288-700-06,Rocuronium Bromide Injection,844-824-8426,Available,,08/19/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA213453'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Meitheal Pharmaceuticals Inc.'],"['71288-700', '71288-718']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['37295b13-65a4-40fa-8d6c-53aeb45e2939'],['b9abaf64-760d-43e0-8669-a9ca70feab11'],"['71288-700-05', '71288-700-06', '71288-718-10', '71288-718-11']",['I65MW4OFHZ'],,,,,,,,,
Reverified,07/14/2023,0378-6855-77,Lisdexamfetamine Dimesylate Capsule,800-796-9526,Available,,11/06/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)","Mylan Pharmaceuticals Inc., a Viatris Company",,Current,['ANDA202835'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE'],['Mylan Pharmaceuticals Inc.'],"['0378-6855', '0378-6854', '0378-6856', '0378-6857', '0378-6858', '0378-6859', '0378-6860']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['63cd6f7c-f976-440e-a35f-e71a9f2fd1bb'],['efbde0f6-b848-4664-b741-c6c630e66108'],"['0378-6854-77', '0378-6855-77', '0378-6856-77', '0378-6857-77', '0378-6858-77', '0378-6859-77', '0378-6860-77']",['SJT761GEGS'],,,,,,,,,
New,09/29/2025,0781-3454-95,Fondaparinux Sodium Injection,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,09/29/2025,['Hematology'],Injection,"Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95)","Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,To Be Discontinued,['ANDA206812'],['FONDAPARINUX SODIUM'],['FONDAPARINUX SODIUM'],['Sandoz Inc.'],"['0781-3454', '0781-3443', '0781-3465', '0781-3476']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['FONDAPARINUX SODIUM'],"['861356', '861360', '861363', '861365']",['3d5a4b69-462b-7e51-e063-6294a90a0721'],['baa50757-a927-4d56-a933-5d7798fe6ab0'],"['0781-3443-94', '0781-3443-12', '0781-3443-95', '0781-3454-94', '0781-3454-12', '0781-3454-95', '0781-3465-94', '0781-3465-12', '0781-3465-95', '0781-3476-94', '0781-3476-12', '0781-3476-95']",['X0Q6N9USOZ'],,,,09/29/2025,,,,,
New,01/10/2025,0409-1159-10,Bupivacaine Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug,01/10/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL); 30 mL Single Dose Glass Teartop Vial NOVAPLUS (NDC 0409-1159-10)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,['ANDA070583'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1725078', '1725082', '1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1867594', '1867596']","['40bfa804-5f31-4bd2-b1e3-dcf428710dc1', '3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7']","['bb44c7e1-d911-4788-908f-09b7b271969b', '02a845c3-4521-4926-e397-25ab536e7cf6']","['0409-1159-09', '0409-1159-10', '0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,01/10/2025,,,,,
Reverified,02/15/2023,0409-3189-10,Rocuronium Bromide Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)","Hospira, Inc., a Pfizer Company",,Current,['ANDA205656'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],"['Hospira, Inc.']","['0409-3189', '0409-7037']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['c96726ef-f1fa-4ebb-ba33-3479c3902a8e'],['c96726ef-f1fa-4ebb-ba33-3479c3902a8e'],"['0409-3189-05', '0409-3189-10', '0409-7037-01', '0409-7037-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,07/14/2023,0527-4663-37,Lisdexamfetamine Dimesylate Capsule,844-834-0530,Unavailable,Unavailable,11/03/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)","Lannett Company, Inc.",Shortage of an active ingredient,Current,['ANDA215802'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Lannett Company, Inc.']","['0527-4663', '0527-4661', '0527-4662', '0527-4664', '0527-4665', '0527-4666', '0527-4667']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7ac942a6-689a-420b-87bf-dc59003400dc'],['2cedb4c2-1e40-4bc4-b9f4-127150c4afbd'],"['0527-4661-37', '0527-4662-37', '0527-4663-37', '0527-4664-37', '0527-4665-37', '0527-4666-37', '0527-4667-37']",['SJT761GEGS'],,,,,,,,,
Reverified,04/07/2020,25021-311-10,Furosemide Injection,866-625-1918,Available,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,09/29/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Gland Pharma Limited,Other,Current,['ANDA213902'],['FUROSEMIDE'],['FUROSEMIDE'],['Sagent Pharmaceuticals'],['25021-311'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['222ce48f-2856-4be2-b16f-6fca38c0dceb'],['d63c1277-dd7e-4d21-9e80-68143f55e2dc'],"['25021-311-02', '25021-311-04', '25021-311-10']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,07/23/2025,0832-0111-50,Amantadine Hydrochloride Tablet,763-315-2000,,Discontinuation of the manufacture of the drug product,07/23/2025,"['Antiviral', 'Neurology']",Tablet,"Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-50)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076186'],['AMANTADINE HYDROCHLORIDE'],['AMANTADINE HYDROCHLORIDE'],"['Upsher-Smith Laboratories, LLC']",['0832-0111'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMANTADINE HYDROCHLORIDE'],['849395'],['395d9ef2-7ea2-c602-e063-6394a90a6ef0'],['63d9d4aa-5f92-45b0-98d0-d6ec38b727cb'],"['0832-0111-00', '0832-0111-50', '0832-0111-89', '0832-0111-03']",['M6Q1EO9TD0'],,,,07/23/2025,,,,,
Revised,01/01/2012,0409-4910-34,Atropine Sulfate Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2)  (NDC 0409-4910-34)""","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,['NDA021146'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['Hospira, Inc.']","['0409-4910', '0409-1630', '0409-9630', '0409-4911']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190546', '1190551', '1190552']",['9211a9e9-35d0-457d-ac95-4ad43ea6bf28'],['ad8916e7-206e-409e-2582-30d072845dd4'],"['0409-1630-15', '0409-1630-10', '0409-9630-15', '0409-9630-05', '0409-4910-11', '0409-4910-34', '0409-4911-11', '0409-4911-34']",['03J5ZE7KA5'],,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2,,,,
Reverified,07/14/2023,0406-5112-01,Lisdexamfetamine Dimesylate Capsule,800-325-8888,Limited Availability,Allocation to all customers.,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA211840'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['SpecGx LLC'],"['0406-5112', '0406-5111', '0406-5113', '0406-5114', '0406-5115', '0406-5116', '0406-5117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['3ffc0695-83f7-4898-9fd7-451c0989cfe0'],['806a1c15-0842-4787-b2ad-09a21fd96b37'],"['0406-5111-01', '0406-5112-01', '0406-5113-01', '0406-5114-01', '0406-5115-01', '0406-5116-01', '0406-5117-01']",['SJT761GEGS'],,,,,,,,,
Reverified,04/07/2020,71288-203-11,Furosemide Injection,844-824-8426,Available,,08/19/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)","Meitheal Pharmaceuticals, Inc.",,Current,['ANDA212803'],['FUROSEMIDE'],['FUROSEMIDE'],['Meitheal Pharmaceuticals Inc.'],['71288-203'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']","['78b32838-f75b-4aba-9b4b-9978f755fced', '53a09c30-7295-4337-89a4-93d3748d6ea3']","['a2e3c748-28ce-4c50-a182-721912919840', '3aadaca7-3661-4bfe-87f8-6368e4ab6536']","['71288-203-02', '71288-203-03', '71288-203-04', '71288-203-05', '71288-203-10', '71288-203-11', '71288-203-91', '71288-203-92', '71288-203-93', '71288-203-94']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
Reverified,02/20/2018,0409-1749-29,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection",844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)","Hospira, Inc., a Pfizer Company",,Current,['NDA016964'],['MARCAINE WITH EPINEPHRINE'],['BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'],"['Hospira, Inc.']","['0409-1749', '0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1752', '0409-1755', '0409-2510', '0409-7535', '0409-1250', '0409-5010', '0409-1530', '0409-0525', '0409-7510', '0409-2253']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRACAUDAL', 'PERINEURAL']","['BUPIVACAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE']","['1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614']",['b00b78c3-c70d-49b9-a381-6a1496f74153'],['67578b56-7540-487e-1fba-481255620e78'],"['0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50', '0409-2510-01', '0409-2510-25', '0409-7535-01', '0409-7535-25', '0409-1250-01', '0409-1250-25', '0409-5010-01', '0409-5010-25', '0409-1530-01', '0409-1530-25', '0409-0525-01', '0409-0525-25', '0409-7510-01', '0409-7510-25', '0409-2253-01', '0409-2253-25']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,01/01/2012,0517-1001-25,Atropine Sulfate Injection,800-645-1706,Available,old NDC 0517-1010-25,11/04/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)","American Regent, Inc.",,Current,['ANDA216120'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],"['American Regent, Inc.']","['0517-1001', '0517-1004']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ATROPINE SULFATE'],"['1190795', '1666781']",['1c500ed9-94a9-472c-bfb7-50e1fcfc31fb'],['6fee1727-52b7-4f73-ab45-ef47d6a1c5bb'],"['0517-1004-01', '0517-1004-25', '0517-1001-01', '0517-1001-25']",['03J5ZE7KA5'],,,,,,,,,
Reverified,07/14/2023,43547-605-10,Lisdexamfetamine Dimesylate Capsule,866-931-9829,Limited Availability,On allocation,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)","Solco Healthcare US, LLC",Shortage of an active ingredient,Current,['ANDA216266'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE CAPSULES'],"['Solco Healthcare US,LLC']","['43547-605', '43547-602', '43547-603', '43547-604', '43547-606', '43547-607', '43547-608']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['7bb11568-67a4-4221-bb9b-23af37a1791c'],['68b10d9f-ca3e-493d-a309-45f1d7e08061'],"['43547-602-10', '43547-603-10', '43547-604-10', '43547-605-10', '43547-606-10', '43547-607-10', '43547-608-10']",['SJT761GEGS'],,,,,,,,,
New,09/26/2025,25021-230-05,Irinotecan Hydrochloride Injection,"Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals,09/26/2025,['Oncology'],Injection,"Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05)","Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",,To Be Discontinued,['ANDA090675'],['IRINOTECAN HYDROCHLORIDE'],['IRINOTECAN HYDROCHLORIDE'],['Sagent Pharmaceuticals'],['25021-230'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['IRINOTECAN HYDROCHLORIDE'],"['1726319', '1726324']",['6c1863de-2414-4e41-a2fa-7f2f7135af0e'],['caab50e6-0dad-4ddd-9a6c-96cc2b87aee7'],"['25021-230-02', '25021-230-05']",['042LAQ1IIS'],,,,09/26/2025,,,,,
Reverified,02/08/2019,76045-109-10,Dexamethasone Sodium Phosphate Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10)","Fresenius Kabi USA, LLC",,Current,['ANDA209192'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],"['Fresenius Kabi USA, LLC']","['76045-109', '76045-212']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],['2099700'],['9f09143c-220b-46f8-b3ef-44bc348f7eec'],['4dd55929-fe0a-4884-ae0d-6f9435920eb7'],"['76045-109-01', '76045-109-10', '76045-212-00', '76045-212-10']",['AI9376Y64P'],,,,,,,,,
Revised,03/01/2017,0409-6625-14,Sodium Bicarbonate Injection,844-646-4398,Available,,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)","Hospira, Inc., a Pfizer Company",,Current,['ANDA202432'],['SODIUM BICARBONATE'],['SODIUM BICARBONATE'],"['Hospira, Inc.']",['0409-6625'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM BICARBONATE'],,"['55e7a069-73d0-45e3-8d36-f307f5802443', '22f08565-937c-4d4b-bd37-914abb918b14']","['8664c7ce-707b-4c6c-9ce4-7160b5f877f8', '084f5572-8c1f-4802-b179-ca0cc838fc68']","['0409-6625-30', '0409-6625-35', '0409-6625-22', '0409-6625-14']",['8MDF5V39QO'],,,,,,,,,
Reverified,07/26/2023,13811-708-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Limited Availability,Allocation to current contracted customers,11/06/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)","Trigen Laboratories, LLC",Demand increase for the drug,Current,['ANDA205327'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Trigen Laboratories, LLC']","['13811-708', '13811-709', '13811-706', '13811-707', '13811-710']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461']",['54f7316b-8a84-4145-aecf-f380afbf261b'],['c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f'],"['13811-709-10', '13811-706-10', '13811-707-10', '13811-708-10', '13811-710-10', '13811-710-30']",['4B3SC438HI'],,,,,,,,,
Revised,10/12/2022,57844-120-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Available,,11/06/2025,['Psychiatry'],Tablet,"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040422'],['ADDERALL'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['57844-120', '57844-105', '57844-117', '57844-110', '57844-112', '57844-115', '57844-130']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541365', '541878', '541879', '541892', '541894', '577957', '577960', '577961', '577962', '687043', '687045', '1009145', '1009147']",['79af1dc6-c7cf-41b1-a750-e9b47c2187ff'],['f22635fe-821d-4cde-aa12-419f8b53db81'],"['57844-105-01', '57844-117-01', '57844-110-01', '57844-112-01', '57844-115-01', '57844-120-01', '57844-130-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,03/21/2023,0009-0728-09,Clindamycin Phosphate Injection,800-533-4535,Unavailable,Next Delivery: May 2026; Estimated Recovery: June 2026,10/23/2025,['Anti-Infective'],Injection,"Cleocin Phosphate, Injection, Cleocin Phosphate 9 g/60 mL (150 mg/mL) (NDC 0009-0728-09)",Pfizer Inc.,Other,Current,['NDA050441'],['CLEOCIN PHOSPHATE'],['CLINDAMYCIN PHOSPHATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0728', '0009-0870', '0009-0775', '0009-0902', '0009-3124', '0009-3447', '0009-3381', '0009-3375', '0009-3382', '0009-6582']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CLINDAMYCIN PHOSPHATE'],"['205964', '309335', '309336', '309339', '685574', '685576', '685578', '706461', '1737244', '1737245', '1737578', '1737579', '1737581', '1737582']",['cb513686-3220-4de2-8be6-f941273ae842'],['05a75685-0af5-407c-ac57-e380c882b49d'],"['0009-0870-21', '0009-0870-26', '0009-0775-20', '0009-0775-26', '0009-0902-11', '0009-0902-18', '0009-0728-05', '0009-0728-09', '0009-3124-01', '0009-3124-03', '0009-3447-01', '0009-3447-03', '0009-3381-01', '0009-3381-02', '0009-3375-01', '0009-3375-02', '0009-3382-01', '0009-3382-02', '0009-6582-02', '0009-6582-01']",['EH6D7113I8'],,,,,,,,,
Revised,06/21/2018,0019-1188-27,Sodium Chloride 0.9% Injection,877-729-6679,,,08/08/2025,['Other'],Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-27)",Guerbet LLC,,Resolved,['NDA021569'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Liebel-Flarsheim Company LLC'],['0019-1188'],['HUMAN PRESCRIPTION DRUG'],['INTRAVASCULAR'],['SODIUM CHLORIDE'],,['cdff7813-7b00-4f61-a017-18ab8910d49d'],['e4540d03-06b4-4b4d-b859-75c13e5c20dd'],"['0019-1188-81', '0019-1188-27']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
New,04/28/2025,0245-0212-01,Midodrine Hydrochloride Tablet,800-654-2299,,,04/28/2025,['Cardiovascular'],Tablet,"Orvaten, Tablet, 5 mg (NDC 0245-0212-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA076725'],['MIDODRINE HYDROCHLORIDE'],['MIDODRINE HYDROCHLORIDE'],"['Upsher-Smith laboratories, LLC']","['0245-0212', '0245-0211', '0245-0213']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MIDODRINE HYDROCHLORIDE'],"['993462', '993466', '993470']",['18b0b9f5-6026-479e-af12-92b0e71a9d6b'],['4c3517f3-1c68-4ade-b5f1-c488a3a335c1'],"['0245-0211-11', '0245-0211-89', '0245-0211-01', '0245-0212-11', '0245-0212-89', '0245-0212-01', '0245-0213-11', '0245-0213-89', '0245-0213-01']",['59JV96YTXV'],,,,04/28/2025,,,,,
Reverified,11/14/2017,0409-7620-59,Heparin Sodium Injection,844-646-4398,Available,,10/23/2025,['Hematology'],Injection,"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)","Hospira, Inc., a Pfizer Company",,Current,['NDA018916'],['HEPARIN SODIUM'],['HEPARIN SODIUM'],"['Hospira, Inc.']","['0409-7620', '0409-1005', '0409-2222']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['HEPARIN SODIUM'],"['1658690', '1658692']",['c38c96a5-ff8a-43b6-a598-dfd044719d89'],['32e34077-aff1-4ec7-f9b0-b8e240768fb8'],"['0409-7620-13', '0409-7620-03', '0409-7620-49', '0409-7620-59', '0409-1005-01', '0409-1005-20', '0409-2222-01', '0409-2222-12']",['ZZ45AB24CA'],,,,,,,01/02/2025,,
Reverified,03/21/2023,0781-3290-09,Clindamycin Phosphate Injection,800-525-8747,Available,,11/07/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)",Sandoz Inc.,,Current,['ANDA201692'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['Sandoz Inc'],"['0781-3290', '0781-3288', '0781-3289']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN'],"['309335', '309336', '309339']",['e9ea55df-4c10-43a8-97f1-02e6fce12f2b'],['231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca'],"['0781-3288-91', '0781-3288-09', '0781-3289-91', '0781-3289-09', '0781-3290-91', '0781-3290-09']",['3U02EL437C'],"['N0000009982', 'N0000175443', 'M0515779', 'N0000175731']",['Lincosamide Antibacterial [EPC]'],"['Decreased Sebaceous Gland Activity [PE]', 'Neuromuscular Blockade [PE]']",,,['Lincosamides [CS]'],,,
Reverified,03/23/2018,63323-285-64,Ropivacaine Hydrochloride Injection,888-386-1300,Available,,11/05/2025,['Anesthesia'],Injection,"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)","Fresenius Kabi USA, LLC",,Current,['NDA020533'],['NAROPIN'],['ROPIVACAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-285', '63323-286', '63323-287', '63323-288']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION']",['ROPIVACAINE HYDROCHLORIDE'],"['1734203', '1734204', '1734207', '1734208', '1734347', '1734348', '1734355', '1734356', '1734475', '1734476', '1734479', '1734480', '1734481', '1734482', '1734483', '1734484', '905189', '905191', '1734084', '1734086', '1734090', '1734091']","['324532ac-4e54-4659-a1a2-9ade22a1ed3f', 'cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9', '73218c89-8925-468c-84bf-9960b4b3dc3c']","['dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7', '23d2d448-a744-4877-9f2d-7e57c198da89', 'c6613708-c1f7-4f5c-91a3-ebbc1d7905c6']","['63323-286-41', '63323-286-27', '63323-286-43', '63323-286-38', '63323-285-41', '63323-285-28', '63323-285-53', '63323-285-68', '63323-285-59', '63323-285-73', '63323-286-01', '63323-286-20', '63323-286-05', '63323-286-23', '63323-286-09', '63323-286-31', '63323-286-11', '63323-286-35', '63323-286-03', '63323-286-00', '63323-286-33', '63323-286-63', '63323-286-30', '63323-287-01', '63323-287-20', '63323-287-03', '63323-287-21', '63323-288-01', '63323-288-10', '63323-288-06', '63323-288-20', '63323-288-03', '63323-288-11', '63323-288-07', '63323-288-21', '63323-285-01', '63323-285-10', '63323-285-06', '63323-285-20', '63323-285-03', '63323-285-13', '63323-285-07', '63323-285-23', '63323-285-57', '63323-285-64', '63323-285-51', '63323-285-65', '63323-285-02', '63323-285-61', '63323-285-04', '63323-285-63', '63323-285-55', '63323-285-67', '63323-288-23', '63323-288-29', '63323-286-93', '63323-286-95']",['V910P86109'],,,,,,,,,
New,11/21/2024,0591-3870-44,Memantine Hydrochloride Tablet,800-545-8800,,,11/21/2024,['Neurology'],Tablet,"Namenda, Tablet, 5 mg (NDC 0591-3870-44)","Actavis Pharma, Inc.",,To Be Discontinued,['NDA021487'],['MEMANTINE HYDROCHLORIDE'],['MEMANTINE HYDROCHLORIDE'],"['Actavis Pharma, Inc.']","['0591-3870', '0591-3875', '0591-3900']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['MEMANTINE HYDROCHLORIDE'],"['996561', '996571', '996572']",['985e1190-b8a0-4775-9a20-ad1924b14fb2'],['72973b46-f307-4a9e-8fb1-ad2cbccfd736'],"['0591-3870-60', '0591-3870-45', '0591-3870-44', '0591-3875-60', '0591-3875-45', '0591-3875-44', '0591-3900-87']",['JY0WD0UA60'],,,,11/21/2024,,,,,
New,07/24/2025,0049-0178-08,"Glipizide Tablet, Extended Release",800-533-4535,,Discontinuation of the manufacture of the drug,07/24/2025,['Endocrinology/Metabolism'],Tablet,"Glucatrol XL, Tablet, Extended Release, 10 mg tablets; bottle of 500 (NDC 0049-0178-08)",Pfizer Inc.,,To Be Discontinued,['NDA020329'],['GLUCOTROL XL'],['GLIPIZIDE'],['Roerig'],"['0049-0178', '0049-0170', '0049-0174']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['GLIPIZIDE'],"['310489', '314006', '315107', '865568', '865571', '865573']",['ce46d6b5-eab4-4630-8480-f13885be938e'],['eed99b60-d043-4249-9b2a-f05e46fb588d'],"['0049-0170-01', '0049-0174-02', '0049-0174-03', '0049-0178-07', '0049-0178-08']",['X7WDT95N5C'],"['N0000175608', 'M0020795']",['Sulfonylurea [EPC]'],,07/24/2025,,['Sulfonylurea Compounds [CS]'],,,
Reverified,04/28/2023,60505-6282-3,Carboplatin Injection,Apotex Inc.: 800-706-5575,Limited Availability,Discontinuation of the manufacture of the drug.,11/05/2025,['Oncology'],Injection,"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)",Teyro Labs,Discontinuation of the manufacture of the drug,Current,['ANDA077861'],['CARBOPLATIN'],['CARBOPLATIN'],['Apotex Corp.'],['60505-6282'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0e68e276-b0df-4f03-e063-6394a90a22b9'],['1c275825-0275-4c73-b650-e4c1519f13b8'],"['60505-6282-1', '60505-6282-3', '60505-6282-6', '60505-6282-7']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection,,,,
Reverified,03/23/2016,71357-008-10,Sodium Acetate Injection,833-251-8463,Available,,11/03/2025,['Total Parenteral Nutrition'],Injection,"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)",Milla Pharmaceuticals,,Current,['ANDA214805'],['SODIUM ACETATE'],"['SODIUM ACETATE INJECTION, USP, 200 MEQ/100 ML']",['MILLA PHARMACEUTICALS INC.'],"['71357-008', '71357-007', '71357-009']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE'],"['237371', '312965']",['2913569b-0f7e-8027-e063-6294a90aaf78'],['1ea1466d-a492-4056-e063-6394a90a80bf'],"['71357-007-01', '71357-007-10', '71357-008-01', '71357-008-10', '71357-009-01', '71357-009-10']",['4550K0SC9B'],,,,,,,,,
Revised,03/13/2023,0703-3675-01,Methotrexate Sodium Injection,800-545-8800,Available,,11/06/2025,"['Rheumatology', 'Oncology']",Injection,"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)","Teva Pharmaceuticals USA, Inc.",,Current,['ANDA040843'],['METHOTREXATE'],['METHOTREXATE'],"['Teva Parenteral Medicines, Inc.']","['0703-3675', '0703-3671', '0703-3678']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS']",['METHOTREXATE SODIUM'],"['1655956', '1655959', '1655960']",['e81074cc-12b4-4ac9-a5bb-749188989b2c'],['346ec9ce-dc98-4a55-b55e-d3af11f2d703'],"['0703-3671-01', '0703-3675-01', '0703-3678-01']",['3IG1E710ZN'],,,,,,,,,
New,12/05/2024,47335-475-64,Imatinib Mesylate Tablet,800-818-4555,,Discontinuing for business reasons,12/05/2024,['Hematology'],Tablet,"Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-64)",Sun Pharmaceutical Industries Limited,,To Be Discontinued,['ANDA078340'],['IMATINIB MESYLATE'],['IMATINIB MESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['47335-475', '47335-472']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['IMATINIB MESYLATE'],"['403878', '403879']",['ad13dbca-474d-4492-9c25-e0e175143d8c'],['07764bf9-21b4-4e32-9d7e-e348f8e4291f'],"['47335-472-83', '47335-472-88', '47335-472-13', '47335-472-81', '47335-475-83', '47335-475-88', '47335-475-13', '47335-475-64']",['8A1O1M485B'],,,,12/05/2024,,,,,
Reverified,03/10/2023,61269-610-10,Clonazepam Tablet,orders@h2-pharma.com,Available,Marketed by H2-Pharma,11/05/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Klonopin, Tablet, 1 mg (NDC 61269-610-10)",Cheplapharm Arzneimittel GmbH,,Current,['NDA017533'],['KLONOPIN'],['CLONAZEPAM'],"['H2-Pharma, LLC']","['61269-610', '61269-605', '61269-620']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529', '206157', '206159', '206160']",['c8a147a4-9ebc-4c69-a5b6-bf7547dc6334'],['cfa0d79a-843c-4b88-95a1-e9511d649ca1'],"['61269-605-10', '61269-610-10', '61269-620-10']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
New,01/22/2025,71093-129-01,Sertraline Hydrochloride Tablet,877-244-9825,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,01/22/2025,['Psychiatry'],Tablet,"Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-01)",Strides Pharma Inc.,,To Be Discontinued,['ANDA076881'],['SERTRALINE HYDROCHLORIDE'],['SERTRALINE HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-129', '71093-130', '71093-131']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['SERTRALINE HYDROCHLORIDE'],"['312938', '312940', '312941']",['3f41fc19-b54a-46fd-acbf-b411816bccd5'],['1f99e897-1b70-40b0-8c19-71d0bba19422'],"['71093-129-01', '71093-129-03', '71093-129-05', '71093-130-01', '71093-130-03', '71093-130-05', '71093-131-01', '71093-131-03', '71093-131-05']",['UTI8907Y6X'],,,,01/22/2025,,,,,
Reverified,07/26/2023,68025-097-10,"Methylphenidate Hydrochloride Tablet, Extended Release",800-541-4802,Unavailable,Estimated recovery: TBD,11/06/2025,['Psychiatry'],Tablet,"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)","Vertical Pharmaceuticals, LLC",Other,Current,['NDA216117'],['RELEXXII'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Vertical Pharmaceuticals, LLC']","['68025-097', '68025-088', '68025-089', '68025-095', '68025-096', '68025-084', '68025-098']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['1091155', '1091170', '1091185', '1091210', '1995461', '2052826', '2605796', '2605798', '2605943', '2605946', '2668496', '2668499', '2668502', '2668505']",['86f477e9-07fc-466b-913e-1a4434c91df4'],['22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d'],"['68025-088-30', '68025-089-30', '68025-095-10', '68025-095-30', '68025-096-10', '68025-096-30', '68025-097-10', '68025-097-30', '68025-084-30', '68025-098-10', '68025-098-30']",['4B3SC438HI'],,,,,,,,,
Revised,10/31/2017,76045-009-06,Hydromorphone Hydrochloride Injection,888-386-1300,Unavailable,Next release November 2025. Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)","Fresenius Kabi USA, LLC",Other,Current,['NDA019034'],['DILAUDID'],['HYDROMORPHONE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['76045-009', '76045-010', '76045-121']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['HYDROMORPHONE HYDROCHLORIDE'],"['897756', '897757', '1433251', '1872265', '1872269', '1872752', '2277368', '2277370']",['97bfcafb-2037-47dc-a0ae-f7b8007c47df'],['9eebd88a-5632-460f-b7b6-26c8a180540d'],"['76045-009-96', '76045-009-06', '76045-009-01', '76045-009-11', '76045-010-01', '76045-010-11', '76045-121-01', '76045-121-11']",['L960UP2KRW'],,,,,,,,,
New,01/14/2025,60505-4552-3,Ambrisentan Tablet,800-706-5575,,,01/14/2025,['Cardiovascular'],Tablet,"Ambrisentan, Tablet, 5 mg (NDC 60505-4552-3)",Apotex Corp.,,To Be Discontinued,['ANDA210701'],['AMBRISENTAN'],['AMBRISENTAN'],['Apotex Corp.'],"['60505-4552', '60505-4553']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['AMBRISENTAN'],"['722116', '722122']",['9525d4e3-a712-40cf-a52f-9d16bc156220'],['291a782a-77e1-8a8e-e1c8-2626f305c2b7'],"['60505-4552-1', '60505-4552-0', '60505-4552-3', '60505-4553-1', '60505-4553-0', '60505-4553-3']",['HW6NV07QEC'],"['N0000175581', 'N0000175364']",['Endothelin Receptor Antagonist [EPC]'],,01/14/2025,,,,['Endothelin Receptor Antagonists [MoA]'],
Revised,03/01/2017,0409-4900-14,Sodium Bicarbonate Injection,844-646-4398,Unavailable,Discontinuation of the manufacture of the drug,11/07/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric']",Injection,"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)","Hospira, Inc., a Pfizer Company",Discontinuation of the manufacture of the drug,Current,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d,,,,
Reverified,12/15/2021,25021-820-10,Methylprednisolone Acetate Injection,866-625-1618,Available,,08/26/2025,['Rheumatology'],Injection,"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)",Sagent Pharmaceuticals,,Current,['ANDA201835'],['METHYLPREDNISOLONE ACETATE'],['METHYLPREDNISOLONE ACETATE'],['Sagent Pharmaceuticals'],"['25021-820', '25021-821']",['HUMAN PRESCRIPTION DRUG'],"['INTRA-ARTICULAR', 'INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358610', '1358617']",['13e1ca54-4fc4-4e93-a52d-c9320865e3cb'],['f98314ea-a4e4-4f78-987b-3e9b45a08bb4'],"['25021-820-05', '25021-820-10', '25021-821-05']",['43502P7F0P'],,,,,,,,,
Revised,08/23/2024,70100-825-02,Indocyanine Green Injection,888-393-3767,,,08/26/2025,"['Medical Imaging', 'Ophthalmology', 'Other']",Injection,"IC-GREEN, Injection, 25 mg (NDC 70100-825-02)",Renew Pharmaceuticals Limited,,Resolved,['NDA011525'],['IC-GREEN'],['INDOCYANINE GREEN'],['Renew Pharmaceuticals Limited'],['70100-825'],['HUMAN PRESCRIPTION DRUG'],,,,['2ecb091b-3588-4985-8223-a84825c0886a'],['ccd92843-1f0a-4ece-9978-4b300d158886'],"['70100-825-02', '70100-725-01', '0409-4887-17']",,,,,,,,08/26/2025,,Available
New,08/12/2025,23155-580-01,Desipramine Hydrochloride Tablet,855-228-9470,,Discontinuation of the manufacture of the drug,08/12/2025,['Psychiatry'],Tablet,"Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)","Avet Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA207433'],['DESIPRAMINE HYDROCHLORIDE'],['DESIPRAMINE HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],"['23155-580', '23155-578', '23155-579', '23155-581', '23155-582', '23155-583']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DESIPRAMINE HYDROCHLORIDE'],"['1099288', '1099292', '1099296', '1099300', '1099304', '1099316']",['49984729-ddde-44ed-927b-8a4ba65cefa0'],['ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0'],"['23155-578-01', '23155-579-01', '23155-580-01', '23155-581-01', '23155-582-01', '23155-583-25']",['1Y58DO4MY1'],,,,08/12/2025,,,,,
Reverified,02/03/2016,0409-7299-73,Sodium Acetate Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Pediatric', 'Total Parenteral Nutrition']",Injection,"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)","Hospira, Inc., a Pfizer Company",,Current,['NDA018893'],['SODIUM ACETATE'],['SODIUM ACETATE'],"['Hospira, Inc.']",['0409-7299'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM ACETATE ANHYDROUS'],['1859490'],"['7ed61ab6-b7ad-45ae-b660-0ed685661bc7', 'c434d6ad-d2f5-43eb-81d5-b6165b652aa7']","['ce9a7469-c4ba-4f60-8f7a-47ef0974316e', 'c91ede49-c7cc-47b7-0f93-e6841dd5916a']","['0409-7299-45', '0409-7299-25', '0409-7299-83', '0409-7299-73']",['NVG71ZZ7P0'],,,,,,,,,
Reverified,07/26/2023,62175-310-37,"Methylphenidate Hydrochloride Tablet, Extended Release",844-834-0530,Available,,11/03/2025,['Psychiatry'],Tablet,"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)","Lannett Company, Inc.",,Current,['ANDA091695'],['METHYLPHENIDATE HYDROCHLORIDE'],['METHYLPHENIDATE HYDROCHLORIDE'],"['Lannett Company, Inc.']","['62175-310', '62175-311', '62175-312', '62175-313']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['METHYLPHENIDATE HYDROCHLORIDE'],"['2001564', '2001565', '2001566', '2001568']",['fd0e4ddf-c516-4464-aeca-eb1d3bd24667'],['3d1f5aff-5d39-496c-b5ed-7f3c70ec641c'],"['62175-310-37', '62175-311-37', '62175-312-37', '62175-313-37']",['4B3SC438HI'],,,,,,,,,
Revised,11/01/2017,0409-2552-01,Hydromorphone Hydrochloride Injection,844-646-4398,,Discontinuation of the manufacture of the drug.,01/13/2025,['Analgesia/Addiction'],Injection,"Injection, 1 mg/1 mL (NDC 0409-2552-01)","Hospira, Inc., a Pfizer Company",,To Be Discontinued,,,,,,,,,,,,,,,,,01/13/2025,,,01/13/2025,,
Reverified,04/28/2023,61703-339-56,Carboplatin Injection,844-646-4398,Available,,10/23/2025,['Oncology'],Injection,"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)","Hospira, Inc., a Pfizer Company",,Current,['ANDA076517'],['CARBOPLATIN'],['CARBOPLATIN'],"['Hospira, Inc.']",['61703-339'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0ddf4411-7138-412a-908a-fadf22bdfb79'],['c3ae9880-44bb-4f4e-93d8-8a5e21708a30'],"['61703-339-18', '61703-339-22', '61703-339-50', '61703-339-56']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
Revised,12/10/2021,0338-0049-10,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-10)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,12/15/2021,0009-0306-02,Methylprednisolone Acetate Injection,844-646-4398,Available,,10/23/2025,['Rheumatology'],Injection,"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)",Pfizer Inc.,,Current,['NDA011757'],['DEPO-MEDROL'],['METHYLPREDNISOLONE ACETATE'],['Pharmacia & Upjohn Company LLC'],"['0009-0306', '0009-0274', '0009-0280']",['HUMAN PRESCRIPTION DRUG'],"['INTRALESIONAL', 'INTRAMUSCULAR', 'INTRASYNOVIAL', 'SOFT TISSUE']",['METHYLPREDNISOLONE ACETATE'],"['1358510', '1358512', '1358610', '1358612', '1358617', '1358619']",['4cf5a255-1360-4511-9b58-b92e3492ef12'],['823b0010-2b57-4e76-b5ac-4a8c2963438f'],"['0009-0274-01', '0009-0280-02', '0009-0280-51', '0009-0280-03', '0009-0280-52', '0009-0306-02', '0009-0306-12']",['43502P7F0P'],,,,,,,,,
Revised,02/22/2012,0409-1323-05,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA040302'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1323', '0409-4903', '0409-4904', '0409-9137']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['LIDOCAINE HYDROCHLORIDE'],"['1012066', '1012068']",['477abea3-c873-4265-82e8-5508ef54399f'],['ad1ef0a8-88db-4648-c098-d009eaeb4e5b'],"['0409-4903-11', '0409-4903-34', '0409-4904-11', '0409-4904-34', '0409-1323-15', '0409-1323-05', '0409-9137-11', '0409-9137-05']",['V13007Z41A'],,,,,,,,,
New,01/31/2025,0173-0857-02,Epoprostenol Sodium Injection,888-825-5249,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",01/31/2025,['Cardiovascular'],Injection,"Flolan, Injection, 1 mL/1 mL (NDC 0173-0857-02)",GlaxoSmithKline,,To Be Discontinued,['NDA020444'],['DILUENT'],['WATER'],['GlaxoSmithKline LLC'],"['0173-0857', '0173-0517', '0173-0519']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['WATER'],"['211199', '211200', '562501', '562502']",['5e54002e-7b03-46ad-ae01-c76c76967201'],['8e4b636e-ee9c-4111-779d-28c8369d283b'],"['0173-0517-00', '0173-0519-00', '0173-0857-02']","['4K04IQ1OF4', '059QF0KO0R']",,,,01/31/2025,,,,,
New,01/23/2025,0591-2884-01,"Verapamil Hydrochloride Capsule, Extended Release",800-545-8800,,,01/23/2025,['Cardiovascular'],"Capsule, Extended Release","Verelan, Capsule, Extended Release, 240 mg (NDC 0591-2884-01)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA019614'],['VERAPAMIL HYDROCHLORIDE'],['VERAPAMIL HYDROCHLORIDE'],['Teva Pharmaceuticals Inc'],"['0591-2884', '0591-2880', '0591-2882', '0591-2886']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VERAPAMIL HYDROCHLORIDE'],['897624'],['319554df-fc0d-428a-9799-a352100f1ce9'],['0742cf97-601b-4c13-a6c3-1a6a616ed292'],"['0591-2880-01', '0591-2882-01', '0591-2884-01', '0591-2886-01']",['V3888OEY5R'],,,,01/23/2025,,,,,
Revised,10/31/2017,76045-004-11,Morphine Sulfate Injection,888-386-1300,Unavailable,Next release not available at this time.  Check wholesalers for inventory.,11/05/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)","Fresenius Kabi USA, LLC",Other,Current,['NDA204223'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Fresenius Kabi, USA LLC', 'Fresenius Kabi USA, LLC']","['76045-004', '76045-005', '76045-006', '76045-007', '76045-008']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['894912', '894914', '998212', '998213', '1442790']","['286bce70-23cd-4d5b-989b-230d6cdd5a91', 'e064585d-2d2d-41cd-a0f1-43494ce4775b']","['1f53de80-efc8-4930-b3e3-fba0d026af05', 'b62ee1ef-db55-417a-a02e-b103890f9c4b']","['76045-004-01', '76045-004-11', '76045-005-01', '76045-005-11', '76045-006-01', '76045-006-11', '76045-007-01', '76045-007-11', '76045-008-01', '76045-008-11', '76045-004-02', '76045-004-12', '76045-005-02', '76045-005-12', '76045-006-02', '76045-006-12', '76045-007-00', '76045-007-10', '76045-008-00', '76045-008-10']",['X3P646A2J0'],,,,,,,,,
Revised,06/13/2018,55150-256-50,Lidocaine Hydrochloride Injection,888-238-7880,Unavailable,On backorder. Recovery: TBD. Check wholesalers for inventory,10/17/2025,['Anesthesia'],Injection,"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)",Eugia US LLC,Demand increase for the drug,Current,['ANDA207182'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],['Eugia US LLC'],"['55150-256', '55150-251', '55150-252', '55150-253', '55150-254', '55150-255']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671']",['0b1f03c2-db2f-4f90-acc0-d73abd731bf6'],['ef782e5e-e2d7-465a-99c6-b12611f3158c'],"['55150-251-10', '55150-252-20', '55150-253-50', '55150-254-10', '55150-255-20', '55150-256-50']",['V13007Z41A'],,,,,,,,,
Reverified,02/14/2022,0409-7100-67,Dextrose Monohydrate 5% Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 5 g/100mL (5%) Plastic (NDC 0409-7100-67)","Hospira, Inc., a Pfizer Company",,Current,['NDA019466'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Hospira, Inc.']",['0409-7100'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795610', '1795616']",['477c216c-7446-473a-892d-918faf1dc877'],['10e98cb0-31a5-4ad1-3eaa-aa4af387a42d'],"['0409-7100-68', '0409-7100-66', '0409-7100-69', '0409-7100-67', '0409-7100-04', '0409-7100-02']",['LX22YL083G'],,,,,,,,,
Revised,05/03/2022,0409-3382-21,Sufentanil Citrate Injection,844-646-4398,Unavailable,Next Delivery: November 2025; Estimated Recovery: December 2025,10/23/2025,"['Analgesia/Addiction', 'Pediatric']",Injection,"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)","Hospira, Inc., a Pfizer Company",Other,Current,['ANDA074534'],['SUFENTANIL CITRATE'],['SUFENTANIL CITRATE'],"['Hospira, Inc.']",['0409-3382'],['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRAVENOUS']",['SUFENTANIL CITRATE'],"['1809097', '1809102', '1809104']",['589d789c-2fbd-40ee-bbe4-8906afa2062d'],['20293943-46ff-4345-1aa4-929b4e017a25'],"['0409-3382-11', '0409-3382-21', '0409-3382-12', '0409-3382-22', '0409-3382-15', '0409-3382-25']",['S9ZFX8403R'],,,,,,,,,
Reverified,11/21/2023,39822-5525-3,Promethazine Hydrochloride Injection,866-390-4411,Limited Availability,Limited Availability,10/23/2025,"['Analgesia/Addiction', 'Gastroenterology', 'Other', 'Pulmonary/Allergy']",Injection,"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)","XGen Pharmaceuticals DJB, Inc.",Demand increase for the drug,Current,['ANDA040737'],['PROMETHAZINE HYDROCHLORIDE'],['PROMETHAZINE HYDROCHLORIDE'],"['XGen Pharmaceuticals DJB, Inc.']",['39822-5525'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['PROMETHAZINE HYDROCHLORIDE'],['992460'],['0e3526e1-38be-1d89-e063-6294a90a775d'],['1d02d52b-84bb-4e81-b352-125029eb39f6'],"['39822-5525-2', '39822-5525-3']",['R61ZEH7I1I'],,,,,,,,,
New,11/03/2025,0002-4491-08,Lasmiditan Succinate Tablet,800-545-5979,,A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets.,11/03/2025,['Neurology'],Tablet,"Reyvow, Tablet, 100 mg (NDC 0002-4491-08)",Eli Lilly and Co.,,To Be Discontinued,['NDA211280'],['REYVOW'],['LASMIDITAN'],['Eli Lilly and Company'],"['0002-4491', '0002-4312']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LASMIDITAN'],"['2256937', '2256943', '2256945', '2256947']",['75a13e98-3736-4256-8277-6c05bcaddcf5'],['aea3358c-ff41-4490-9e6d-c7bf7b3de13f'],"['0002-4312-08', '0002-4312-61', '0002-4312-62', '0002-4491-08', '0002-4491-61', '0002-4491-62']",['760I9WM792'],,,,11/03/2025,,,,,
Reverified,02/14/2022,0409-7100-66,Dextrose Monohydrate 5% Injection,844-646-4398,Available,,10/23/2025,"['Endocrinology/Metabolism', 'Gastroenterology', 'Other', 'Pediatric']",Injection,"Dextrose 5% In Plastic Container, Injection, 2.5 g/50mL (5%, 50mg/mL) (NDC 0409-7100-66)","Hospira, Inc., a Pfizer Company",,Current,['NDA019466'],['DEXTROSE'],['DEXTROSE MONOHYDRATE'],"['Hospira, Inc.']",['0409-7100'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['DEXTROSE MONOHYDRATE'],"['1795609', '1795610', '1795616']",['477c216c-7446-473a-892d-918faf1dc877'],['10e98cb0-31a5-4ad1-3eaa-aa4af387a42d'],"['0409-7100-68', '0409-7100-66', '0409-7100-69', '0409-7100-67', '0409-7100-04', '0409-7100-02']",['LX22YL083G'],,,,,,,,,
Revised,12/10/2021,0338-0049-03,Sodium Chloride 0.9% Injection,888-229-0001,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-03)",Baxter Healthcare,,Resolved,['NDA016677'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Baxter Healthcare Corporation'],"['0338-0049', '0338-0043']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639']",['6ab23768-efd2-4ff1-b336-0dda08dc56e1'],['f55bd888-5e01-474d-871b-24654c070178'],"['0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,23155-600-41,Midazolam Hydrochloride Injection,855-228-9470,Available,,11/03/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)","Avet Pharmaceuticals, Inc.",,Current,['ANDA090696'],['MIDAZOLAM HYDROCHLORIDE'],['MIDAZOLAM HYDROCHLORIDE'],['Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.'],['23155-600'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],['1666798'],['c4800842-cb3b-4907-9abe-20bac2726c0c'],['8b690f5c-2923-4c34-a8f7-11af5f546b62'],"['23155-600-31', '23155-600-41']",['W7TTW573JJ'],,,,,,,,,
Reverified,03/26/2018,25021-701-01,Ketorolac Tromethamine Injection,866-625-1618,Available,,08/26/2025,['Analgesia/Addiction'],Injection,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)",Sagent Pharmaceuticals,,Current,['ANDA204216'],['KETOROLAC TROMETHAMINE'],['KETOROLAC TROMETHAMINE'],['Sagent Pharmaceuticals'],"['25021-701', '25021-700']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['KETOROLAC TROMETHAMINE'],"['860092', '1665459', '1665461']",['ff55e1ab-2a8d-4a56-8b72-5e0a8e00d866'],['62591551-a644-4b2c-a0de-982e906fabc3'],"['25021-700-01', '25021-701-01', '25021-701-02']",['4EVE5946BQ'],,,,,,,,,
Reverified,03/21/2023,72572-074-24,Clindamycin Phosphate Injection,800-525-8747,Available,Civica Label,11/07/2025,['Anti-Infective'],Injection,"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)",Sandoz Inc.,,Current,['ANDA201692'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],['CLINDAMYCIN IN 5 PERCENT DEXTROSE'],"['Civica, Inc.']","['72572-074', '72572-076']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CLINDAMYCIN'],"['309335', '309336']",['e40b6e7f-1d37-4d0a-ace3-e5accc461e02'],['80217bd6-2bc4-401c-9345-22532b36a24f'],"['72572-074-01', '72572-074-24', '72572-076-01', '72572-076-24']",['3U02EL437C'],"['N0000009982', 'N0000175443', 'M0515779', 'N0000175731']",['Lincosamide Antibacterial [EPC]'],"['Decreased Sebaceous Gland Activity [PE]', 'Neuromuscular Blockade [PE]']",,,['Lincosamides [CS]'],,,
Revised,12/21/2020,16729-306-10,Azacitidine Injection,"866-941-7875, option 2",Limited Availability,30 days,11/04/2025,['Oncology'],Injection,"Azacitidine, Injection, 100 mg (NDC 16729-306-10)",Accord Healthcare Inc.,Regulatory delay,Current,['ANDA207475'],['AZACITIDINE'],['AZACITIDINE'],['Accord Healthcare Inc.'],['16729-306'],['HUMAN PRESCRIPTION DRUG'],"['INTRAVENOUS', 'SUBCUTANEOUS']",['AZACITIDINE'],['485246'],['28604daf-46a3-ef6c-e063-6394a90a4b27'],['70140e11-33f1-2240-e053-2991aa0a0480'],['16729-306-10'],['M801H13NRU'],"['N0000000233', 'N0000175595']",['Nucleoside Metabolic Inhibitor [EPC]'],,,,,,['Nucleic Acid Synthesis Inhibitors [MoA]'],
Reverified,10/31/2017,0409-3815-12,Morphine Sulfate Injection,844-646-4398,Available,,10/23/2025,['Analgesia/Addiction'],Injection,"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)","Hospira, Inc., a Pfizer Company",,Current,['ANDA073510'],['MORPHINE SULFATE'],['MORPHINE SULFATE'],"['Hospira, Inc.']","['0409-3815', '0409-3814']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INTRATHECAL', 'INTRAVENOUS']",['MORPHINE SULFATE'],"['1728783', '1728800']",['493a6182-2a85-4973-8a20-6bb2344d6452'],['1d181906-f3ec-4222-1883-e61577a3122e'],"['0409-3814-11', '0409-3814-12', '0409-3815-11', '0409-3815-12']",['X3P646A2J0'],,,,,,,01/03/2025,,
Revised,01/01/2012,25021-814-30,Leucovorin Calcium Injection,866-625-1618,,,07/08/2025,"['Oncology', 'Pediatric']",Injection,"Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 25021-814-30)",Sagent Pharmaceuticals,,Resolved,['ANDA200753'],['LEUCOVORIN CALCIUM'],['LEUCOVORIN CALCIUM'],['Sagent Pharmaceuticals'],"['25021-814', '25021-813', '25021-815', '25021-816']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LEUCOVORIN CALCIUM'],"['237788', '1803930', '1803932', '1803937']",['ff2ba160-e2f9-4ab9-9e67-2409f02c923e'],['9d0e5356-ff39-4a8e-944c-e808a21ef4b2'],"['25021-813-10', '25021-814-30', '25021-815-30', '25021-816-30']",['RPR1R4C0P4'],,,,,,,07/08/2025,,Available
New,04/28/2025,0832-7122-15,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-15)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7122', '0832-7123', '0832-7124']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
Revised,12/10/2021,79672-613-02,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, 100 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Nextgen Pharmaceuticals LLC'],['79672-613'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['3c545b9f-67e4-489d-bb60-c39c990d7dda'],['28f79c75-82d2-4912-81fc-a723b5ccf4c1'],"['79672-613-01', '79672-613-10', '79672-613-02', '79672-613-20', '79672-613-03', '79672-613-30', '79672-613-04', '79672-613-40', '79672-613-05', '79672-613-50']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Reverified,04/02/2020,0409-2305-05,Midazolam Hydrochloride Injection,844-646-4398,Available,,10/23/2025,"['Anesthesia', 'Neurology']",Injection,"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)","Hospira, Inc., a Pfizer Company",,Current,['ANDA075857'],['MIDAZOLAM'],['MIDAZOLAM HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-2305', '0409-2308', '0409-0001']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['MIDAZOLAM HYDROCHLORIDE'],"['1666800', '1666814', '1666823', '1666798']","['b303a281-6633-47d5-bf29-5e9055e26da6', '8c3cf34b-901d-407a-946d-a1556bb24551']","['b95415fa-17c2-42ab-a6b0-e628d01c94ed', '1abda8b8-48a8-4995-af86-39220d1aa240']","['0409-2305-55', '0409-2305-50', '0409-2308-69', '0409-2308-49', '0409-2308-70', '0409-2308-50', '0409-2305-16', '0409-2305-17', '0409-2305-04', '0409-2305-05', '0409-2308-21', '0409-2308-01', '0409-2308-22', '0409-2308-02', '0409-0001-01', '0409-0001-25']",['W7TTW573JJ'],,,,,,,,,
New,07/10/2025,72305-025-90,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 25 ug (NDC 72305-025-90)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-175', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
Reverified,03/10/2023,61269-620-10,Clonazepam Tablet,orders@h2-pharma.com,Available,Marketed by H2-Pharma,11/05/2025,"['Neurology', 'Pediatric', 'Psychiatry']",Tablet,"Klonopin, Tablet, 2 mg (NDC 61269-620-10)",Cheplapharm Arzneimittel GmbH,,Current,['NDA017533'],['KLONOPIN'],['CLONAZEPAM'],"['H2-Pharma, LLC']","['61269-620', '61269-605', '61269-610']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['CLONAZEPAM'],"['197527', '197528', '197529', '206157', '206159', '206160']",['c8a147a4-9ebc-4c69-a5b6-bf7547dc6334'],['cfa0d79a-843c-4b88-95a1-e9511d649ca1'],"['61269-605-10', '61269-610-10', '61269-620-10']",['5PE9FDE8GB'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Revised,12/10/2021,79672-613-04,Sodium Chloride 0.9% Injection,800-848-0462,,,08/08/2025,"['Gastroenterology', 'Other', 'Pediatric']",Injection,"Sodium Chloride 0.9%, 500 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)","Laboratorios Grifols, S.A.",,Resolved,['ANDA207956'],['SODIUM CHLORIDE'],['SODIUM CHLORIDE'],['Nextgen Pharmaceuticals LLC'],['79672-613'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['SODIUM CHLORIDE'],"['1807631', '1807632', '1807633', '1807634', '1807639']",['3c545b9f-67e4-489d-bb60-c39c990d7dda'],['28f79c75-82d2-4912-81fc-a723b5ccf4c1'],"['79672-613-01', '79672-613-10', '79672-613-02', '79672-613-20', '79672-613-03', '79672-613-30', '79672-613-04', '79672-613-40', '79672-613-05', '79672-613-50']",['451W47IQ8X'],,,,,,,08/08/2025,,Available
Revised,12/04/2024,0228-2073-10,Oxazepam Capsule,800-545-8800,,,07/03/2025,"['Neurology', 'Psychiatry']",Capsule,"Oxazepam, Capsule, 30 mg (NDC 0228-2073-10)","Teva Pharmaceuticals USA, Inc.",,Resolved,['ANDA072253'],['OXAZEPAM'],['OXAZEPAM'],"['Actavis Pharma, Inc.']","['0228-2073', '0228-2067', '0228-2069']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OXAZEPAM'],"['198057', '198059', '312134']",['f191a7db-b292-4119-b144-b25c0555b050'],['a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43'],"['0228-2067-10', '0228-2069-10', '0228-2073-10']",['6GOW6DWN2A'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],07/03/2025,,Available
New,07/10/2025,72305-175-30,Levothyroxine Sodium Tablet,888-899-7041,,Discontinuation of the manufacture of the drug,07/10/2025,['Endocrinology/Metabolism'],Tablet,"Euthyrox, Tablet, 175 ug (NDC 72305-175-30)","EMD Serono, Inc.",,To Be Discontinued,['NDA021292'],['EUTHYROX'],['LEVOTHYROXINE SODIUM'],"['Provell Pharmaceuticals, LLC']","['72305-175', '72305-025', '72305-050', '72305-075', '72305-088', '72305-100', '72305-112', '72305-125', '72305-137', '72305-150', '72305-200']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LEVOTHYROXINE SODIUM'],"['892246', '892251', '966153', '966160', '966166', '966173', '966177', '966182', '966187', '966196', '966202', '966207', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '2104866']",['45657074-8874-49f4-a8ef-3ca7e210c16e'],['bc3c6830-ba68-4ba3-9896-a12d0ad0b275'],"['72305-025-30', '72305-025-90', '72305-050-30', '72305-050-90', '72305-075-30', '72305-075-90', '72305-088-30', '72305-088-90', '72305-100-30', '72305-100-90', '72305-112-30', '72305-112-90', '72305-125-30', '72305-125-90', '72305-137-30', '72305-137-90', '72305-150-30', '72305-150-90', '72305-175-30', '72305-175-90', '72305-200-30', '72305-200-90']",['9J765S329G'],,,,07/10/2025,,,,,
New,01/28/2025,71093-128-05,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-05)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-128', '71093-127']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
Reverified,11/23/2021,63323-185-20,Sterile Water Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,['Other'],Injection,"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)","Fresenius Kabi USA, LLC",,Current,['ANDA088400'],['STERILE WATER'],['WATER'],"['Fresenius Kabi USA, LLC']",['63323-185'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['42c6c812-706a-425b-b8cb-931006e40484'],['e71c6c83-d518-496c-b2ab-efd5987e4783'],"['63323-185-07', '63323-185-10', '63323-185-09', '63323-185-50', '63323-185-08', '63323-185-20', '63323-185-04', '63323-185-05']",['059QF0KO0R'],,,,,,,,,
Revised,10/12/2022,47781-180-01,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",844-842-8672 and email: CustomerService-US@alvogen.com,Unavailable,30 Days,11/06/2025,['Psychiatry'],Tablet,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)",Alvogen,Other,Current,['ANDA207388'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 30 MG,CLL']",['Alvogen Inc.'],"['47781-180', '47781-174', '47781-175', '47781-176', '47781-177', '47781-178', '47781-179']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['0374f0f7-9297-810c-38b3-623a72709a7d'],['c907301d-e24d-9609-5529-fed14f94549f'],"['47781-174-30', '47781-174-05', '47781-174-01', '47781-175-30', '47781-175-05', '47781-175-01', '47781-176-30', '47781-176-05', '47781-176-01', '47781-177-30', '47781-177-05', '47781-177-01', '47781-178-30', '47781-178-05', '47781-178-01', '47781-179-30', '47781-179-05', '47781-179-01', '47781-180-30', '47781-180-05', '47781-180-01']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,10/12/2022,0555-0973-02,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",800-545-8800,Limited Availability,Estimated availability: TBD,11/06/2025,['Psychiatry'],Tablet,"Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)","Teva Pharmaceuticals USA, Inc.",Other,Current,['ANDA040422'],"['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE']","['Teva Pharmaceuticals USA, Inc.']","['0555-0973', '0555-0971', '0555-0775', '0555-0972', '0555-0776', '0555-0777', '0555-0974']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['AMPHETAMINE ASPARTATE MONOHYDRATE', 'AMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE', 'DEXTROAMPHETAMINE SULFATE']","['541363', '541878', '541892', '577957', '577961', '687043', '1009145']",['88468f3d-7d03-4cee-aabf-3abc8c9b5e38'],['cffbbb15-d776-41ae-a8a6-687f2c07bfa4'],"['0555-0971-02', '0555-0775-02', '0555-0972-02', '0555-0776-02', '0555-0777-02', '0555-0973-02', '0555-0974-02']","['G83415V073', '6DPV8NK46S', 'JJ768O327N', 'O1ZPV620O4']",,,,,,,,,
Revised,02/08/2019,55150-304-25,Dexamethasone Sodium Phosphate Injection,888-238-7880,Available,Check wholesalers for inventory,10/17/2025,"['Dermatology', 'Endocrinology/Metabolism', 'Gastroenterology', 'Hematology', 'Neurology', 'Oncology', 'Ophthalmology', 'Other', 'Pulmonary/Allergy', 'Rheumatology']",Injection,"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)",Eugia US LLC,,Current,['ANDA210966'],['DEXAMETHASONE SODIUM PHOSPHATE'],['DEXAMETHASONE SODIUM PHOSPHATE'],['Eugia US LLC'],['55150-304'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['DEXAMETHASONE SODIUM PHOSPHATE'],['1812079'],['3f5e3c7f-f1d1-431c-877f-4b9ee2cd0dff'],['29947f67-7868-40af-8ad2-a61f7149b44c'],"['55150-304-01', '55150-304-25']",['AI9376Y64P'],,,,,,,,,
Reverified,11/23/2021,64253-020-30,Sterile Water Injection,630-682-4600,Available,,11/03/2025,['Other'],Injection,"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)","Medefil, Inc.",,Current,['ANDA211188'],['STERILE WATER'],['STERILE WATER FOR INJECTION'],"['Medefil, Inc.']",['64253-020'],['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['WATER'],,['2b39b41d-419a-dab8-e063-6394a90a319a'],['99e99a50-82d5-aff6-e053-2a95a90a8c56'],"['64253-020-21', '64253-020-23', '64253-020-30', '64253-020-35', '64253-020-52', '64253-020-25', '64253-020-91']",['059QF0KO0R'],,,,,,,,,
Reverified,09/11/2019,68875-0202-2,Parathyroid Hormone Injection,866-888-0660,Limited Availability,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,08/15/2025,['Endocrinology/Metabolism'],Powder,"Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Takeda Pharmaceuticals USA Inc.,Discontinuation of the manufacture of the drug,Current,['BLA125511'],['NATPARA (PARATHYROID HORMONE)'],['PARATHYROID HORMONE'],"['Takeda Pharmaceuticals America, Inc.']","['68875-0202', '68875-0203', '68875-0204', '68875-0205']",['HUMAN PRESCRIPTION DRUG'],['SUBCUTANEOUS'],['PARATHYROID HORMONE'],"['1602023', '1602028', '1602032', '1602034', '1602038', '1602040', '1602044', '1602046']",['17d2bb82-605c-43be-9918-63aeb7102d8c'],['d11fba31-0a6c-11e3-8ffd-0800200c9a66'],"['68875-0202-1', '68875-0202-2', '68875-0203-1', '68875-0203-2', '68875-0204-1', '68875-0204-2', '68875-0205-1', '68875-0205-2']",['N19A0T0E5J'],"['M0015931', 'N0000180851']",['Parathyroid Hormone [EPC]'],,,,['Parathyroid Hormone [CS]'],,,
Revised,09/05/2018,0641-6045-25,Lorazepam Injection,800-631-2174,Unavailable,Unavailable,10/24/2025,['Neurology'],Injection,"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)","Hikma Pharmaceuticals USA, Inc.",Regulatory delay,Current,['NDA018140'],['LORAZEPAM'],['LORAZEPAM'],['Hikma Pharmaceuticals USA Inc.'],"['0641-6045', '0641-6044', '0641-6046', '0641-6047']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['LORAZEPAM'],"['238100', '238101', '1665188', '1665326']",['7c73dbc6-2623-4443-9b05-97dec7a0be2e'],['e9b54e42-04cf-4c62-90e1-36f7b31a4e81'],"['0641-6044-01', '0641-6044-25', '0641-6046-01', '0641-6046-10', '0641-6045-01', '0641-6045-25', '0641-6047-01', '0641-6047-10']",['O26FZP769L'],"['N0000175694', 'M0002356']",['Benzodiazepine [EPC]'],,,,['Benzodiazepines [CS]'],,,
Reverified,04/07/2020,16729-500-08,Furosemide Injection,866-941-7875,Unavailable,Unavailable,11/04/2025,['Cardiovascular'],Injection,"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)",Accord Healthcare Inc.,Requirements related to complying with good manufacturing practices,Current,['ANDA070017'],['FUROSEMIDE'],['FUROSEMIDE'],"['Accord Healthcare, Inc.']","['16729-500', '16729-501', '16729-502']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['FUROSEMIDE'],"['1719286', '1719290', '1719291']",['1cfab300-d796-6a68-e063-6394a90a73f9'],['f6f64972-714c-4ee9-8a5e-9ffcab41a73b'],"['16729-500-30', '16729-500-08', '16729-501-64', '16729-501-43', '16729-502-03', '16729-502-43']",['7LXU5N7ZO5'],"['N0000175366', 'N0000175590']",['Loop Diuretic [EPC]'],['Increased Diuresis at Loop of Henle [PE]'],,,,,,
New,01/06/2025,0703-2033-03,Cisatracurium Besylate Injection,800-545-8800,,,01/06/2025,['Anesthesia'],Injection,"CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 10 mg/5 mL (NDC 0703-2033-03)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,,,,,,,,,,,,,,,,,01/06/2025,,,,,
New,07/17/2025,0591-2742-01,"Potassium Citrate Tablet, Extended Release",800-545-8800,,A business decision was made to discontinue.,07/17/2025,['Renal'],Tablet,"Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)",Watson Pharma Private Limited,,To Be Discontinued,['ANDA209758'],['POTASSIUM CITRATE'],['POTASSIUM CITRATE'],"['Actavis Pharma, Inc.']","['0591-2742', '0591-2682', '0591-2729']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['POTASSIUM CITRATE'],"['199376', '199381', '898490']",['b81078a3-490a-4a03-a9a5-9c64acde67bf'],['ac173781-486b-461c-97ae-8b5c69e20792'],"['0591-2682-01', '0591-2729-01', '0591-2742-01']",['EE90ONI6FF'],,,,07/17/2025,,,,,
Revised,07/14/2023,57664-084-88,"Lisdexamfetamine Dimesylate Tablet, Chewable",800-818-4555,Limited Availability,Available Q4 2025,10/21/2025,['Psychiatry'],"Tablet, Chewable","Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)","Sun Pharmaceutical Industries, Inc.",Other,Current,['ANDA214134'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-084', '57664-047', '57664-046', '57664-048', '57664-049', '57664-050', '57664-051', '57664-052', '57664-083', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
New,02/14/2025,0378-8075-60,Erythromycin  Topical Gel,800-796-9526,,,02/14/2025,"['Anti-Infective', 'Dermatology']",Topical Gel,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-60)","Mylan Pharmaceuticals Inc., a Viatris Company",,To Be Discontinued,,,,,,,,,,,,,,,,,02/14/2025,,,,,
Revised,02/17/2015,0143-9931-25,"Cefotaxime Sodium Powder, for Solution",800-631-2174,Unavailable,Shortage duration is unknown at this time.,10/24/2025,"['Anti-Infective', 'Pediatric']","Powder, For Solution","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)","Hikma Pharmaceuticals USA, Inc.",Demand increase for the drug,Current,['ANDA065072'],['CEFOTAXIME'],['CEFOTAXIME'],['Hikma Pharmaceuticals USA Inc.'],"['0143-9931', '0143-9933', '0143-9930']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CEFOTAXIME SODIUM'],"['309068', '1656313', '1656318']",['7e0897ec-2275-4438-9cc5-4c951e52ad97'],['ed23b6bc-32c7-4c50-a53d-313ae78e5623'],"['0143-9931-01', '0143-9931-25', '0143-9933-01', '0143-9933-25', '0143-9930-01', '0143-9930-10']",['258J72S7TZ'],,,,,,,,,
Reverified,12/20/2023,0641-6251-10,Atropine Sulfate Injection,800-631-2174,Available,,10/24/2025,"['Anesthesia', 'Neurology', 'Pediatric']",Injection,"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)","Hikma Pharmaceuticals USA, Inc.",,Current,['ANDA213561'],['ATROPINE SULFATE'],['ATROPINE SULFATE'],['Hikma Pharmaceuticals USA Inc.'],['0641-6251'],['HUMAN PRESCRIPTION DRUG'],"['ENDOTRACHEAL', 'INTRAMEDULLARY', 'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS']",['ATROPINE SULFATE'],['1190776'],['f5ca4281-8c89-4efc-80b1-2fbcf61c7c55'],['4c15d3cc-7888-4c82-b3f8-a5d93c5523df'],['0641-6251-10'],['03J5ZE7KA5'],,,,,,,,,
Revised,02/22/2012,0409-4713-02,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)","Hospira, Inc., a Pfizer Company",,Current,['ANDA080408'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
New,01/10/2025,52544-064-31,"Ethinyl Estradiol; Norethindrone Tablet, Chewable",800-545-8800,,,01/10/2025,['Reproductive'],"Tablet, Chewable","Tablet, Chewable, Kit (NDC 52544-064-31)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['NDA022573'],['LAYOLIS FE'],"['NORETHINDRONE, ETHINYL ESTRADIOL, AND FERROUS FUMARATE']","['Actavis Pharma, Inc.']",['52544-064'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],,"['1095223', '1099638', '1607990', '1650201']",['82960ca4-6fe9-40c5-8688-8b3d2b65327a'],['c0db84ca-b8d4-4ed2-b2f6-19347283146e'],['52544-064-31'],,,,,01/10/2025,,,,,
Reverified,02/20/2018,0409-1159-01,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070583'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1159', '0409-1160', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1725078', '1725082', '1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1867594', '1867596']","['40bfa804-5f31-4bd2-b1e3-dcf428710dc1', '3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7']","['bb44c7e1-d911-4788-908f-09b7b271969b', '02a845c3-4521-4926-e397-25ab536e7cf6']","['0409-1159-09', '0409-1159-10', '0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,10/06/2023,0338-1051-02,Nitroglycerin Injection,Baxter Healthcare 888-229-0001,Unavailable,Manufacturing delay; Recovery in November 2025,10/22/2025,['Cardiovascular'],Injection,"Nitroglycerin in Dextrose 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)",Baxter Healthcare,Other,Current,['NDA019970'],['NITROGLYCERIN IN DEXTROSE'],['NITROGLYCERIN'],['Baxter Healthcare Company'],"['0338-1051', '0338-1047', '0338-1049']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['NITROGLYCERIN'],"['312004', '1868494', '1868562']",['71811937-e908-4b65-aff2-4b345fa0954b'],['457a026c-ebce-4701-9deb-2d7652759a99'],"['0338-1047-02', '0338-1049-02', '0338-1051-02']",['G59M7S0WS3'],"['N0000175415', 'M0014874', 'N0000009909']",['Nitrate Vasodilator [EPC]'],['Vasodilation [PE]'],,,['Nitrates [CS]'],,,
Revised,02/22/2012,0409-4282-01,Lidocaine Hydrochloride Injection,844-646-4398,Available,,11/07/2025,"['Anesthesia', 'Pediatric']",Injection,"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA088294'],['LIDOCAINE HYDROCHLORIDE'],['LIDOCAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-4282', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4277', '0409-4276', '0409-4275']",['HUMAN PRESCRIPTION DRUG'],"['EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE'],"['1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763']",['d0322a93-069a-453f-89eb-e5d5559ed075'],['3b2dd84e-cee8-4e58-d494-395a65a353a0'],"['0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01']",['V13007Z41A'],,,,,,,,,
New,04/28/2025,0832-7123-01,"Divalproex Sodium Tablet, Delayed Release",800-654-2299,,Discontinuation of manufacture of drug based on business decision.,04/28/2025,['Neurology'],Tablet,"Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-01)","Upsher-Smith Laboratories, LLC",,To Be Discontinued,['ANDA078182'],['DIVALPROEX SODIUM'],['DIVALPROEX SODIUM'],"['Upsher-Smith Laboratories, LLC']","['0832-7123', '0832-7122', '0832-7124']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DIVALPROEX SODIUM'],"['1099625', '1099678', '1099870']",['38e51a59-5802-77a6-e063-6394a90af6c6'],['02304a23-4a5f-47bc-9687-4044b43f7a20'],"['0832-7122-11', '0832-7122-15', '0832-7123-11', '0832-7123-15', '0832-7123-89', '0832-7123-01', '0832-7124-11', '0832-7124-15', '0832-7124-89', '0832-7124-01']",['644VL95AO6'],,,,04/28/2025,,,,,
New,10/16/2025,80789-117-50,Vigabatrin Oral Solution,763-315-2000,,Discontinuation of the manufacture of the drug,10/16/2025,['Neurology'],Oral Solution,"Vigpoder, Oral Solution, 50 mg/1 mL (NDC 80789-117-50)","Pyros Pharmaceuticals, Inc.",,To Be Discontinued,['ANDA214961'],['VIGPODER'],['VIGABATRIN'],"['Pyros Pharmaceuticals, Inc.']",['80789-117'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['VIGABATRIN'],"['250820', '2668482']",['05d784d4-cda0-428a-972f-d7191d86cba6'],['1859a632-e98e-4152-b91d-b8aae1107be1'],"['80789-117-01', '80789-117-50']",['GR120KRT6K'],['N0000175753'],['Anti-epileptic Agent [EPC]'],,10/16/2025,,,,,
Revised,10/31/2023,0143-9872-10,Propranolol Hydrochloride Injection,800-631-2174,Unavailable,Unavailable,10/24/2025,['Cardiovascular'],Injection,"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA077760'],['PROPRANOLOL HYDROCHLORIDE'],['PROPRANOLOL HYDROCHLORIDE'],['Hikma Pharmaceuticals USA Inc.'],['0143-9872'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['PROPRANOLOL HYDROCHLORIDE'],['856443'],['e8fc99d6-98e1-4c9f-80e7-327fb2817f08'],['91f2ff1d-68d8-4e83-a2db-618f0410ead7'],"['0143-9872-01', '0143-9872-10']",['F8A3652H1V'],,,,,,,,,
Revised,07/14/2023,57664-049-88,Lisdexamfetamine Dimesylate Capsule,800-818-4555,Limited Availability,Additional supply anticipated in Q4 2025 followed by early 2027,10/21/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)","Sun Pharmaceutical Industries, Inc.",Shortage of an active ingredient,Current,['ANDA214484'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],"['Sun Pharmaceutical Industries, Inc.']","['57664-049', '57664-047', '57664-046', '57664-048', '57664-050', '57664-051', '57664-052', '57664-083', '57664-084', '57664-085', '57664-086', '57664-087', '57664-088']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856', '1871456', '1871460', '1871462', '1871464', '1871466', '1871468']",['0b77417a-5789-8818-e063-6294a90ad2e3'],['da3148af-f9b6-4725-adae-3595b4c7dc4b'],"['57664-047-88', '57664-046-88', '57664-048-88', '57664-049-88', '57664-050-88', '57664-051-88', '57664-052-88', '57664-083-88', '57664-084-88', '57664-085-88', '57664-086-88', '57664-087-88', '57664-088-88']",['SJT761GEGS'],,,,,,,,,
New,01/06/2025,45963-565-30,Ezetimibe; Simvastatin Tablet,800-545-8800,,,01/06/2025,['Cardiovascular'],Tablet,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-30)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA202968'],['EZETIMIBE AND SIMVASTATIN'],['EZETIMIBE AND SIMVASTATIN'],"['Actavis Pharma, Inc.']","['45963-565', '45963-566', '45963-567', '45963-568']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],"['EZETIMIBE', 'SIMVASTATIN']","['476345', '476349', '476350', '476351']",['bd64aee1-c95f-4767-8d31-af93dd0ab692'],['00680bea-d2fb-4362-ba67-e866b732e9ed'],"['45963-565-30', '45963-565-08', '45963-566-30', '45963-566-08', '45963-567-30', '45963-567-08', '45963-568-30', '45963-568-08']","['AGG2FN16EV', 'EOR26LQQ24']","['N0000175589', 'N0000000121', 'N0000008553', 'N0000175911']","['HMG-CoA Reductase Inhibitor [EPC]', 'Dietary Cholesterol Absorption Inhibitor [EPC]']",['Decreased Cholesterol Absorption [PE]'],01/06/2025,,,,['Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]'],
Revised,04/28/2023,60505-6282-7,Carboplatin Injection,Apotex Inc.: 800-706-5575,"Limited Availability, Replenishment is expected 12/1/25",Wholesaler & Distributor through Marketing partner (Apotex Inc.),11/05/2025,['Oncology'],Injection,"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)",Teyro Labs,Demand increase for the drug,Current,['ANDA077861'],['CARBOPLATIN'],['CARBOPLATIN'],['Apotex Corp.'],['60505-6282'],['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['CARBOPLATIN'],['597195'],['0e68e276-b0df-4f03-e063-6394a90a22b9'],['1c275825-0275-4c73-b650-e4c1519f13b8'],"['60505-6282-1', '60505-6282-3', '60505-6282-6', '60505-6282-7']",['BG3F62OND5'],"['N0000175413', 'N0000175073']",['Platinum-based Drug [EPC]'],,,,,,,
New,10/09/2025,0781-2859-31,Omeprazole Delayed Release Capsule,800-525-8747,,Discontinuation of the manufacture of the drug,10/09/2025,['Gastroenterology'],,"Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-31)",Sandoz Inc.,,To Be Discontinued,['ANDA075757'],['OMEPRAZOLE'],['OMEPRAZOLE'],['Sandoz Inc'],"['0781-2859', '0781-2868']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['OMEPRAZOLE'],"['198051', '199119']",['6a54ba13-eeb3-4c8c-800b-dc9aaf961c3f'],['516170d4-4913-4577-a2d2-f5c52d1e79c6'],"['0781-2859-10', '0781-2859-01', '0781-2859-92', '0781-2859-31', '0781-2868-10', '0781-2868-01', '0781-2868-92', '0781-2868-31']",['KG60484QX9'],"['N0000175525', 'N0000000147', 'N0000182140']",['Proton Pump Inhibitor [EPC]'],,10/09/2025,,,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",
Reverified,02/22/2012,63323-486-17,Lidocaine Hydrochloride Injection,888-386-1300,Available,Check wholesalers for inventory,11/05/2025,"['Anesthesia', 'Pediatric']",Injection,"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)","Fresenius Kabi USA, LLC",,Current,['NDA006488'],['XYLOCAINE'],['LIDOCAINE HYDROCHLORIDE'],"['Fresenius Kabi USA, LLC']","['63323-486', '63323-492', '63323-491', '63323-495', '63323-485', '63323-484', '63323-489', '63323-488', '63323-481', '63323-483', '63323-482', '63323-487']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['LIDOCAINE HYDROCHLORIDE ANHYDROUS'],"['1010033', '1010035', '1010671', '1010673', '1010688', '1010692', '1010745', '1010749', '1010751', '1010755', '1010759', '1010763', '1010900', '1010902', '1737343', '1737345', '1737562', '1737563', '1737566', '1737567', '1737568', '1737569', '1737570', '1737571', '1737757', '1737758', '1737761', '1737762', '1867938', '1867940', '1867943', '1867944', '1867992', '1867993', '1867996', '1867997', '1868028', '1868029']","['ea480a68-5927-4278-9deb-2956961da428', '0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33']","['ba082c2f-64f4-419d-9c88-74f203316e17', '4dd52202-8eef-4136-92dd-ada573b7cf74']","['63323-492-04', '63323-492-27', '63323-492-09', '63323-492-57', '63323-492-07', '63323-492-37', '63323-492-03', '63323-492-31', '63323-491-01', '63323-491-57', '63323-495-09', '63323-495-27', '63323-495-04', '63323-495-07', '63323-485-01', '63323-485-27', '63323-485-03', '63323-485-57', '63323-486-01', '63323-486-17', '63323-486-02', '63323-486-27', '63323-486-05', '63323-486-57', '63323-484-57', '63323-489-02', '63323-489-27', '63323-489-03', '63323-489-21', '63323-489-01', '63323-489-17', '63323-488-07', '63323-488-37', '63323-488-03', '63323-488-31', '63323-488-01', '63323-488-17', '63323-481-01', '63323-481-57', '63323-483-03', '63323-483-27', '63323-483-01', '63323-483-57', '63323-482-01', '63323-482-17', '63323-482-03', '63323-482-27', '63323-482-05', '63323-482-57', '63323-487-01', '63323-487-17', '63323-487-07', '63323-487-37', '63323-487-03', '63323-487-31', '63323-492-41', '63323-492-16', '63323-492-43', '63323-492-36', '63323-492-45', '63323-492-26', '63323-485-41', '63323-485-26', '63323-486-41', '63323-486-26', '63323-482-41', '63323-482-26', '63323-495-41', '63323-495-26']","['EC2CNF7XFP', '30Q7KI53AK']",,,,,,,,,
New,01/28/2025,71093-128-06,Donepezil Hydrochloride Tablet,877-244-9825,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,01/28/2025,['Neurology'],Tablet,"Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-06)",Strides Pharma Inc.,,To Be Discontinued,['ANDA078662'],['DONEPEZIL HYDROCHLORIDE'],['DONEPEZIL HYDROCHLORIDE'],"['ACI Healthcare USA, Inc.']","['71093-128', '71093-127']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DONEPEZIL HYDROCHLORIDE'],"['997223', '997229']",['a4736add-da84-411f-8e6f-9de67bf467f8'],['297e86e8-d248-4cc9-9d9c-2ef9efb4414d'],"['71093-127-01', '71093-127-03', '71093-127-05', '71093-127-06', '71093-128-01', '71093-128-03', '71093-128-05', '71093-128-06']",['3O2T2PJ89D'],,,,01/28/2025,,,,,
Reverified,02/20/2018,0409-1160-01,Bupivacaine Hydrochloride Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)","Hospira, Inc., a Pfizer Company",,Current,['ANDA070590'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Hospira, Inc.']","['0409-1160', '0409-1159', '0409-1162', '0409-1163', '0409-1165', '0409-9043', '0409-9046', '0409-9045', '0409-9042']",['HUMAN PRESCRIPTION DRUG'],"['INFILTRATION', 'PERINEURAL']",['BUPIVACAINE HYDROCHLORIDE'],"['1012377', '1012384', '1012396', '1012404', '1672917', '1672919', '1724786', '1724787', '1724880', '1724884', '1725078', '1725082', '1867594', '1867596']",['3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7'],['02a845c3-4521-4926-e397-25ab536e7cf6'],"['0409-1159-18', '0409-1159-01', '0409-1159-19', '0409-1159-02', '0409-1160-18', '0409-1160-01', '0409-1162-18', '0409-1162-01', '0409-1162-19', '0409-1162-02', '0409-1163-18', '0409-1163-01', '0409-1165-18', '0409-1165-01', '0409-1165-19', '0409-1165-02', '0409-9043-11', '0409-9043-01', '0409-9046-11', '0409-9046-01', '0409-9045-11', '0409-9045-01', '0409-9045-16', '0409-9045-17', '0409-9042-11', '0409-9042-01', '0409-9042-16', '0409-9042-17']","['7TQO7W3VT8', '30Q7KI53AK']",,,,,,,,,
Reverified,02/15/2023,43066-013-10,Rocuronium Bromide Injection,888-229-0001,Available,,10/22/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)",Baxter Healthcare,,Current,['ANDA091115'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],['Baxter Healthcare Corporation'],"['43066-013', '43066-007']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['9e0317de-2d78-4fd8-8926-4c7b476f3ed4'],['31e15c3f-aefa-4379-b684-7707744fe40d'],"['43066-007-10', '43066-013-10']",['I65MW4OFHZ'],,,,,,,,,
Reverified,07/14/2023,0054-0373-25,Lisdexamfetamine Dimesylate Capsule,800-631-2174,Limited Availability,Available on allocation,10/24/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)","Hikma Pharmaceuticals USA, Inc.",Shortage of an active ingredient,Current,['ANDA202827'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['Hikma Pharmaceuticals USA Inc.'],"['0054-0373', '0054-0660', '0054-0370', '0054-0371', '0054-0372', '0054-0374', '0054-0375']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['5d119550-4386-4bfa-a5d0-bb18e66191b7'],['6740a621-9bec-4178-a4fc-a3fc89f34e0a'],"['0054-0660-25', '0054-0370-25', '0054-0371-25', '0054-0372-25', '0054-0373-25', '0054-0374-25', '0054-0375-25']",['SJT761GEGS'],,,,,,,,,
Reverified,08/03/2022,0378-4415-01,Flurazepam Hydrochloride Capsule,1-844-874-7464,Unavailable,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,08/19/2025,"['Neurology', 'Other']",Capsule,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)","Rising Pharma Holdings, Inc.",Regulatory delay,Current,,,,,,,,,,,,,,,,,,,,,,
Reverified,02/17/2015,21586-011-02,"Cefotaxime Sodium Powder, for Solution",800-881-3550,Available,,08/19/2025,"['Anti-Infective', 'Pediatric']","Powder, For Solution","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)","SteriMax, Inc.",,Current,,['CEFOTAXIME'],['CEFOTAXIME INJECTION'],['SteriMax Inc.'],"['21586-011', '21586-012']",['HUMAN PRESCRIPTION DRUG'],"['INTRAMUSCULAR', 'INTRAVENOUS']",['CEFOTAXIME SODIUM'],"['1656313', '1656318']",['425c90b3-5006-427e-95f6-93ee7918fb8b'],['8efe3bd0-c43a-2bd6-e053-2a95a90a92fa'],"['21586-011-01', '21586-011-02', '21586-012-01', '21586-012-02']",['258J72S7TZ'],,,,,https://www.fda.gov/media/152896/download,,,,
New,06/04/2025,0003-3631-12,Atazanavir Sulfate Capsule,1-800-332-2056; for Medical Inquiries (1-800-321-1335),,Permanent discontinuation,06/04/2025,['Antiviral'],Capsule,"Reyataz, Capsule, 200 mg (NDC 0003-3631-12)",Bristol Myers Squibb Co.,,To Be Discontinued,['NDA021567'],['REYATAZ'],['ATAZANAVIR'],"['E.R. Squibb & Sons, L.L.C.']","['0003-3631', '0003-3624', '0003-3622', '0003-3638']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['ATAZANAVIR SULFATE'],"['402093', '402094', '402246', '402247', '664741', '664743', '1598985', '1598989']",['510c2d51-4943-401c-a008-ea22f61c6938'],['165cff62-b284-4a27-a65d-9ec8a5bfcdd8'],"['0003-3624-12', '0003-3631-12', '0003-3622-12', '0003-3638-10']",['4MT4VIE29P'],,,,06/04/2025,,,,,
Reverified,07/14/2023,0406-5113-01,Lisdexamfetamine Dimesylate Capsule,800-325-8888,Limited Availability,Allocation to all customers.,11/05/2025,['Psychiatry'],Capsule,"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)",SpecGx LLC,Shortage of an active ingredient,Current,['ANDA211840'],['LISDEXAMFETAMINE DIMESYLATE'],['LISDEXAMFETAMINE DIMESYLATE'],['SpecGx LLC'],"['0406-5113', '0406-5111', '0406-5112', '0406-5114', '0406-5115', '0406-5116', '0406-5117']",['HUMAN PRESCRIPTION DRUG'],['ORAL'],['LISDEXAMFETAMINE DIMESYLATE'],"['854830', '854834', '854838', '854842', '854846', '854850', '1593856']",['3ffc0695-83f7-4898-9fd7-451c0989cfe0'],['806a1c15-0842-4787-b2ad-09a21fd96b37'],"['0406-5111-01', '0406-5112-01', '0406-5113-01', '0406-5114-01', '0406-5115-01', '0406-5116-01', '0406-5117-01']",['SJT761GEGS'],,,,,,,,,
New,05/02/2025,0591-5553-50,Doxycycline Hyclate Tablet,800-545-8800,,,05/02/2025,['Anti-Infective'],Tablet,"Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)","Teva Pharmaceuticals USA, Inc.",,To Be Discontinued,['ANDA062421'],['DOXYCYCLINE HYCLATE'],['DOXYCYCLINE HYCLATE'],"['Actavis Pharma, Inc.']",['0591-5553'],['HUMAN PRESCRIPTION DRUG'],['ORAL'],['DOXYCYCLINE HYCLATE'],['1650143'],['0fb9a3f8-9ebb-4c21-8a73-9f082b39039c'],['a569ba80-ffea-40b2-9fbe-a42810b1fccb'],"['0591-5553-50', '0591-5553-05']",['19XTS3T51U'],,,,05/02/2025,,,,,
Reverified,02/20/2018,73293-0002-2,Bupivacaine Hydrochloride Injection,+82-2-854-4700 or via email intbiz@huons.com,Available,,09/17/2025,['Anesthesia'],Injection,"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)","Huons Co., Ltd",,Current,['ANDA212822'],['BUPIVACAINE HYDROCHLORIDE'],['BUPIVACAINE HYDROCHLORIDE'],"['Huons Co., Ltd.']",['73293-0002'],['HUMAN PRESCRIPTION DRUG'],['SUBARACHNOID'],['BUPIVACAINE HYDROCHLORIDE'],['1724784'],['2e641a0d-4d42-e7cd-e063-6394a90a47d4'],['2dc693df-3218-4a90-b3f7-21e80966a851'],"['73293-0002-1', '73293-0002-2']",['7TQO7W3VT8'],,,,,,,,,
Reverified,02/15/2023,0409-1403-10,Rocuronium Bromide Injection,844-646-4398,Available,,10/23/2025,['Anesthesia'],Injection,"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)","Hospira, Inc., a Pfizer Company",,Current,['ANDA205656'],['ROCURONIUM BROMIDE'],['ROCURONIUM BROMIDE'],"['Hospira, Inc.']","['0409-1403', '0409-5160']",['HUMAN PRESCRIPTION DRUG'],['INTRAVENOUS'],['ROCURONIUM BROMIDE'],['1234995'],['f01f9986-43f9-40e8-9506-11bfe78f9242'],['f01f9986-43f9-40e8-9506-11bfe78f9242'],"['0409-1403-05', '0409-1403-10', '0409-5160-01', '0409-5160-10']",['I65MW4OFHZ'],,,,,,,,,
